[{"header": {"dataset": "BioASQ", "split": "dev"}}]
{"context": "The Philadelphia chromosome translocation (t(9;22)) results in the molecular juxtaposition of two genes, BCR and ABL, to form an aberrant BCR-ABL gene on chromosome 22. BCR-ABL is critical to the pathogenesis of chronic myelogenous leukemia and a subset of acute leukemias. The chimeric Bcr-Abl protein has constitutively elevated tyrosine phosphokinase activity. This abnormal enzymatic activation is critical to the oncogenic potential of Bcr-Abl. Initially, protein kinases were thought to be poor therapeutic targets because of their ubiquitous nature and crucial role in many normal physiologic processes. However, the advent of imatinib mesylate (Gleevec, Novartis Pharmaceuticals, Basel, Switzerland), formerly known as STI571 and CGP57148B, demonstrated that designer kinase inhibitors could be specific. This agent has shown striking activity in chronic myelogenous leukemia. It also inhibits phosphorylation of Kit (stem-cell factor receptor) and platelet-derived growth factor receptor. In addition, it has shown similar impressive responses, with little host toxicity, in gastrointestinal stromal tumors, which harbor activating Kit mutations, and in tumors with activated platelet-derived growth factor receptor. The studies of imatinib mesylate provide proof-of-principle for using aberrant kinases as a therapeutic target and are a model for the promise of molecular therapeutics. This paper reviews the current knowledge on the function of Bcr-Abl and its normal counterparts (Bcr and Abl), as well as the impact of this knowledge on the development of a remarkably successful targeted therapy approach.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "ec447381a9274cb2925d3a6a913cd81a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[33, 35], [76, 78], [54, 56], [249, 251], [25, 27]], "char_spans": [[169, 175], [441, 447], [287, 293], [1456, 1462], [138, 144]]}]}], "context_tokens": [["The", 0], ["Philadelphia", 4], ["chromosome", 17], ["translocation", 28], ["(", 42], ["t(9;22", 43], [")", 49], [")", 50], ["results", 52], ["in", 60], ["the", 63], ["molecular", 67], ["juxtaposition", 77], ["of", 91], ["two", 94], ["genes", 98], [",", 103], ["BCR", 105], ["and", 109], ["ABL", 113], [",", 116], ["to", 118], ["form", 121], ["an", 126], ["aberrant", 129], ["BCR", 138], ["-", 141], ["ABL", 142], ["gene", 146], ["on", 151], ["chromosome", 154], ["22", 165], [".", 167], ["BCR", 169], ["-", 172], ["ABL", 173], ["is", 177], ["critical", 180], ["to", 189], ["the", 192], ["pathogenesis", 196], ["of", 209], ["chronic", 212], ["myelogenous", 220], ["leukemia", 232], ["and", 241], ["a", 245], ["subset", 247], ["of", 254], ["acute", 257], ["leukemias", 263], [".", 272], ["The", 274], ["chimeric", 278], ["Bcr", 287], ["-", 290], ["Abl", 291], ["protein", 295], ["has", 303], ["constitutively", 307], ["elevated", 322], ["tyrosine", 331], ["phosphokinase", 340], ["activity", 354], [".", 362], ["This", 364], ["abnormal", 369], ["enzymatic", 378], ["activation", 388], ["is", 399], ["critical", 402], ["to", 411], ["the", 414], ["oncogenic", 418], ["potential", 428], ["of", 438], ["Bcr", 441], ["-", 444], ["Abl", 445], [".", 448], ["Initially", 450], [",", 459], ["protein", 461], ["kinases", 469], ["were", 477], ["thought", 482], ["to", 490], ["be", 493], ["poor", 496], ["therapeutic", 501], ["targets", 513], ["because", 521], ["of", 529], ["their", 532], ["ubiquitous", 538], ["nature", 549], ["and", 556], ["crucial", 560], ["role", 568], ["in", 573], ["many", 576], ["normal", 581], ["physiologic", 588], ["processes", 600], [".", 609], ["However", 611], [",", 618], ["the", 620], ["advent", 624], ["of", 631], ["imatinib", 634], ["mesylate", 643], ["(", 652], ["Gleevec", 653], [",", 660], ["Novartis", 662], ["Pharmaceuticals", 671], [",", 686], ["Basel", 688], [",", 693], ["Switzerland", 695], [")", 706], [",", 707], ["formerly", 709], ["known", 718], ["as", 724], ["STI571", 727], ["and", 734], ["CGP57148B", 738], [",", 747], ["demonstrated", 749], ["that", 762], ["designer", 767], ["kinase", 776], ["inhibitors", 783], ["could", 794], ["be", 800], ["specific", 803], [".", 811], ["This", 813], ["agent", 818], ["has", 824], ["shown", 828], ["striking", 834], ["activity", 843], ["in", 852], ["chronic", 855], ["myelogenous", 863], ["leukemia", 875], [".", 883], ["It", 885], ["also", 888], ["inhibits", 893], ["phosphorylation", 902], ["of", 918], ["Kit", 921], ["(", 925], ["stem", 926], ["-", 930], ["cell", 931], ["factor", 936], ["receptor", 943], [")", 951], ["and", 953], ["platelet", 957], ["-", 965], ["derived", 966], ["growth", 974], ["factor", 981], ["receptor", 988], [".", 996], ["In", 998], ["addition", 1001], [",", 1009], ["it", 1011], ["has", 1014], ["shown", 1018], ["similar", 1024], ["impressive", 1032], ["responses", 1043], [",", 1052], ["with", 1054], ["little", 1059], ["host", 1066], ["toxicity", 1071], [",", 1079], ["in", 1081], ["gastrointestinal", 1084], ["stromal", 1101], ["tumors", 1109], [",", 1115], ["which", 1117], ["harbor", 1123], ["activating", 1130], ["Kit", 1141], ["mutations", 1145], [",", 1154], ["and", 1156], ["in", 1160], ["tumors", 1163], ["with", 1170], ["activated", 1175], ["platelet", 1185], ["-", 1193], ["derived", 1194], ["growth", 1202], ["factor", 1209], ["receptor", 1216], [".", 1224], ["The", 1226], ["studies", 1230], ["of", 1238], ["imatinib", 1241], ["mesylate", 1250], ["provide", 1259], ["proof", 1267], ["-", 1272], ["of", 1273], ["-", 1275], ["principle", 1276], ["for", 1286], ["using", 1290], ["aberrant", 1296], ["kinases", 1305], ["as", 1313], ["a", 1316], ["therapeutic", 1318], ["target", 1330], ["and", 1337], ["are", 1341], ["a", 1345], ["model", 1347], ["for", 1353], ["the", 1357], ["promise", 1361], ["of", 1369], ["molecular", 1372], ["therapeutics", 1382], [".", 1394], ["This", 1396], ["paper", 1401], ["reviews", 1407], ["the", 1415], ["current", 1419], ["knowledge", 1427], ["on", 1437], ["the", 1440], ["function", 1444], ["of", 1453], ["Bcr", 1456], ["-", 1459], ["Abl", 1460], ["and", 1464], ["its", 1468], ["normal", 1472], ["counterparts", 1479], ["(", 1492], ["Bcr", 1493], ["and", 1497], ["Abl", 1501], [")", 1504], [",", 1505], ["as", 1507], ["well", 1510], ["as", 1515], ["the", 1518], ["impact", 1522], ["of", 1529], ["this", 1532], ["knowledge", 1537], ["on", 1547], ["the", 1550], ["development", 1554], ["of", 1566], ["a", 1569], ["remarkably", 1571], ["successful", 1582], ["targeted", 1593], ["therapy", 1602], ["approach", 1610], [".", 1618]]}
{"context": "Reported prevalence of restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), varies from country to country, and methodologic inconsistencies limit comparison of data. Impact of RLS on quality of life and health has been studied primarily in industrialized countries, particularly Europe and the United States. Many studies have relied exclusively on self-report of symptoms or have assessed only medical populations. Recently, interest has emerged on the impact of WED in rural, underserved populations globally. In a population-based survey conducted in rural Ecuador, we assessed the relationship of psychological distress to WED, evaluated with the Depression Anxiety Stress Scales-21. WED was diagnosed through a 2-phase method in which all residents were screened with the International Restless Legs Syndrome Study Group (IRLSSG) questionnaire and all suspected cases were subsequently confirmed through expert medical examination. WED severity was assessed with the IRLSSG rating scale. Of 665 persons (mean [SD] age, 59.5 [12.6] years; women, 386 [58%]), 76 had depression, 93 had anxiety, and 60 reported stress. Forty persons (6%) had WED, with 15 (38%) having severe disease. In a regression model adjusted for age and sex, the prevalence of depression, anxiety, and stress was about 3 times greater among persons with WED than the general population. Although cross-sectional data cannot establish causation, this study shows the large behavioral health burden associated with WED in an untreated, rural population.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "5dc7b7888b6a4035ae95f669a8d8cfff", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[139, 141], [3, 5]], "char_spans": [[811, 832], [23, 44]]}]}], "context_tokens": [["Reported", 0], ["prevalence", 9], ["of", 20], ["restless", 23], ["legs", 32], ["syndrome", 37], ["(", 46], ["RLS", 47], [")", 50], [",", 51], ["also", 53], ["known", 58], ["as", 64], ["Willis", 67], ["-", 73], ["Ekbom", 74], ["disease", 80], ["(", 88], ["WED", 89], [")", 92], [",", 93], ["varies", 95], ["from", 102], ["country", 107], ["to", 115], ["country", 118], [",", 125], ["and", 127], ["methodologic", 131], ["inconsistencies", 144], ["limit", 160], ["comparison", 166], ["of", 177], ["data", 180], [".", 184], ["Impact", 186], ["of", 193], ["RLS", 196], ["on", 200], ["quality", 203], ["of", 211], ["life", 214], ["and", 219], ["health", 223], ["has", 230], ["been", 234], ["studied", 239], ["primarily", 247], ["in", 257], ["industrialized", 260], ["countries", 275], [",", 284], ["particularly", 286], ["Europe", 299], ["and", 306], ["the", 310], ["United", 314], ["States", 321], [".", 327], ["Many", 329], ["studies", 334], ["have", 342], ["relied", 347], ["exclusively", 354], ["on", 366], ["self", 369], ["-", 373], ["report", 374], ["of", 381], ["symptoms", 384], ["or", 393], ["have", 396], ["assessed", 401], ["only", 410], ["medical", 415], ["populations", 423], [".", 434], ["Recently", 436], [",", 444], ["interest", 446], ["has", 455], ["emerged", 459], ["on", 467], ["the", 470], ["impact", 474], ["of", 481], ["WED", 484], ["in", 488], ["rural", 491], [",", 496], ["underserved", 498], ["populations", 510], ["globally", 522], [".", 530], ["In", 532], ["a", 535], ["population", 537], ["-", 547], ["based", 548], ["survey", 554], ["conducted", 561], ["in", 571], ["rural", 574], ["Ecuador", 580], [",", 587], ["we", 589], ["assessed", 592], ["the", 601], ["relationship", 605], ["of", 618], ["psychological", 621], ["distress", 635], ["to", 644], ["WED", 647], [",", 650], ["evaluated", 652], ["with", 662], ["the", 667], ["Depression", 671], ["Anxiety", 682], ["Stress", 690], ["Scales-21", 697], [".", 706], ["WED", 708], ["was", 712], ["diagnosed", 716], ["through", 726], ["a", 734], ["2-phase", 736], ["method", 744], ["in", 751], ["which", 754], ["all", 760], ["residents", 764], ["were", 774], ["screened", 779], ["with", 788], ["the", 793], ["International", 797], ["Restless", 811], ["Legs", 820], ["Syndrome", 825], ["Study", 834], ["Group", 840], ["(", 846], ["IRLSSG", 847], [")", 853], ["questionnaire", 855], ["and", 869], ["all", 873], ["suspected", 877], ["cases", 887], ["were", 893], ["subsequently", 898], ["confirmed", 911], ["through", 921], ["expert", 929], ["medical", 936], ["examination", 944], [".", 955], ["WED", 957], ["severity", 961], ["was", 970], ["assessed", 974], ["with", 983], ["the", 988], ["IRLSSG", 992], ["rating", 999], ["scale", 1006], [".", 1011], ["Of", 1013], ["665", 1016], ["persons", 1020], ["(", 1028], ["mean", 1029], ["[", 1034], ["SD", 1035], ["]", 1037], ["age", 1039], [",", 1042], ["59.5", 1044], ["[", 1049], ["12.6", 1050], ["]", 1054], ["years", 1056], [";", 1061], ["women", 1063], [",", 1068], ["386", 1070], ["[", 1074], ["58", 1075], ["%", 1077], ["]", 1078], [")", 1079], [",", 1080], ["76", 1082], ["had", 1085], ["depression", 1089], [",", 1099], ["93", 1101], ["had", 1104], ["anxiety", 1108], [",", 1115], ["and", 1117], ["60", 1121], ["reported", 1124], ["stress", 1133], [".", 1139], ["Forty", 1141], ["persons", 1147], ["(", 1155], ["6", 1156], ["%", 1157], [")", 1158], ["had", 1160], ["WED", 1164], [",", 1167], ["with", 1169], ["15", 1174], ["(", 1177], ["38", 1178], ["%", 1180], [")", 1181], ["having", 1183], ["severe", 1190], ["disease", 1197], [".", 1204], ["In", 1206], ["a", 1209], ["regression", 1211], ["model", 1222], ["adjusted", 1228], ["for", 1237], ["age", 1241], ["and", 1245], ["sex", 1249], [",", 1252], ["the", 1254], ["prevalence", 1258], ["of", 1269], ["depression", 1272], [",", 1282], ["anxiety", 1284], [",", 1291], ["and", 1293], ["stress", 1297], ["was", 1304], ["about", 1308], ["3", 1314], ["times", 1316], ["greater", 1322], ["among", 1330], ["persons", 1336], ["with", 1344], ["WED", 1349], ["than", 1353], ["the", 1358], ["general", 1362], ["population", 1370], [".", 1380], ["Although", 1382], ["cross", 1391], ["-", 1396], ["sectional", 1397], ["data", 1407], ["can", 1412], ["not", 1415], ["establish", 1419], ["causation", 1429], [",", 1438], ["this", 1440], ["study", 1445], ["shows", 1451], ["the", 1457], ["large", 1461], ["behavioral", 1467], ["health", 1478], ["burden", 1485], ["associated", 1492], ["with", 1503], ["WED", 1508], ["in", 1512], ["an", 1515], ["untreated", 1518], [",", 1527], ["rural", 1529], ["population", 1535], [".", 1545]]}
{"context": "The light-harvesting chlorophyll a/b-protein complex of photosystem II (LHCII) is the most abundant membrane protein in green plants, and its degradation is a crucial process for the acclimation to high light conditions and for the recovery of nitrogen (N) and carbon (C) during senescence. However, the molecular mechanism of LHCII degradation is largely unknown. Here, we report that chlorophyll b reductase, which catalyzes the first step of chlorophyll b degradation, plays a central role in LHCII degradation. When the genes for chlorophyll b reductases NOL and NYC1 were disrupted in Arabidopsis thaliana, chlorophyll b and LHCII were not degraded during senescence, whereas other pigment complexes completely disappeared. When purified trimeric LHCII was incubated with recombinant chlorophyll b reductase (NOL), expressed in Escherichia coli, the chlorophyll b in LHCII was converted to 7-hydroxymethyl chlorophyll a. Accompanying this conversion, chlorophylls were released from LHCII apoproteins until all the chlorophyll molecules in LHCII dissociated from the complexes. Chlorophyll-depleted LHCII apoproteins did not dissociate into monomeric forms but remained in the trimeric form. Based on these results, we propose the novel hypothesis that chlorophyll b reductase catalyzes the initial step of LHCII degradation, and that trimeric LHCII is a substrate of LHCII degradation.", "qas": [{"question": "Which is the most abundant membrane protein on Earth?", "answers": ["Light-harvesting pigment-protein complex of Photosystem II", "LHCII"], "qid": "e65867b72b4e4b6cab1e8ae033a60312", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["abundant", 18], ["membrane", 27], ["protein", 36], ["on", 44], ["Earth", 47], ["?", 52]], "detected_answers": [{"text": "LHCII", "token_spans": [[64, 64], [226, 226], [133, 133], [154, 154], [177, 177], [186, 186], [116, 116], [220, 220], [169, 169], [231, 231], [94, 94], [15, 15]], "char_spans": [[327, 331], [1349, 1353], [752, 756], [872, 876], [1045, 1049], [1104, 1108], [630, 634], [1312, 1316], [988, 992], [1373, 1377], [496, 500], [72, 76]]}]}], "context_tokens": [["The", 0], ["light", 4], ["-", 9], ["harvesting", 10], ["chlorophyll", 21], ["a", 33], ["/", 34], ["b", 35], ["-", 36], ["protein", 37], ["complex", 45], ["of", 53], ["photosystem", 56], ["II", 68], ["(", 71], ["LHCII", 72], [")", 77], ["is", 79], ["the", 82], ["most", 86], ["abundant", 91], ["membrane", 100], ["protein", 109], ["in", 117], ["green", 120], ["plants", 126], [",", 132], ["and", 134], ["its", 138], ["degradation", 142], ["is", 154], ["a", 157], ["crucial", 159], ["process", 167], ["for", 175], ["the", 179], ["acclimation", 183], ["to", 195], ["high", 198], ["light", 203], ["conditions", 209], ["and", 220], ["for", 224], ["the", 228], ["recovery", 232], ["of", 241], ["nitrogen", 244], ["(", 253], ["N", 254], [")", 255], ["and", 257], ["carbon", 261], ["(", 268], ["C", 269], [")", 270], ["during", 272], ["senescence", 279], [".", 289], ["However", 291], [",", 298], ["the", 300], ["molecular", 304], ["mechanism", 314], ["of", 324], ["LHCII", 327], ["degradation", 333], ["is", 345], ["largely", 348], ["unknown", 356], [".", 363], ["Here", 365], [",", 369], ["we", 371], ["report", 374], ["that", 381], ["chlorophyll", 386], ["b", 398], ["reductase", 400], [",", 409], ["which", 411], ["catalyzes", 417], ["the", 427], ["first", 431], ["step", 437], ["of", 442], ["chlorophyll", 445], ["b", 457], ["degradation", 459], [",", 470], ["plays", 472], ["a", 478], ["central", 480], ["role", 488], ["in", 493], ["LHCII", 496], ["degradation", 502], [".", 513], ["When", 515], ["the", 520], ["genes", 524], ["for", 530], ["chlorophyll", 534], ["b", 546], ["reductases", 548], ["NOL", 559], ["and", 563], ["NYC1", 567], ["were", 572], ["disrupted", 577], ["in", 587], ["Arabidopsis", 590], ["thaliana", 602], [",", 610], ["chlorophyll", 612], ["b", 624], ["and", 626], ["LHCII", 630], ["were", 636], ["not", 641], ["degraded", 645], ["during", 654], ["senescence", 661], [",", 671], ["whereas", 673], ["other", 681], ["pigment", 687], ["complexes", 695], ["completely", 705], ["disappeared", 716], [".", 727], ["When", 729], ["purified", 734], ["trimeric", 743], ["LHCII", 752], ["was", 758], ["incubated", 762], ["with", 772], ["recombinant", 777], ["chlorophyll", 789], ["b", 801], ["reductase", 803], ["(", 813], ["NOL", 814], [")", 817], [",", 818], ["expressed", 820], ["in", 830], ["Escherichia", 833], ["coli", 845], [",", 849], ["the", 851], ["chlorophyll", 855], ["b", 867], ["in", 869], ["LHCII", 872], ["was", 878], ["converted", 882], ["to", 892], ["7-hydroxymethyl", 895], ["chlorophyll", 911], ["a.", 923], ["Accompanying", 926], ["this", 939], ["conversion", 944], [",", 954], ["chlorophylls", 956], ["were", 969], ["released", 974], ["from", 983], ["LHCII", 988], ["apoproteins", 994], ["until", 1006], ["all", 1012], ["the", 1016], ["chlorophyll", 1020], ["molecules", 1032], ["in", 1042], ["LHCII", 1045], ["dissociated", 1051], ["from", 1063], ["the", 1068], ["complexes", 1072], [".", 1081], ["Chlorophyll", 1083], ["-", 1094], ["depleted", 1095], ["LHCII", 1104], ["apoproteins", 1110], ["did", 1122], ["not", 1126], ["dissociate", 1130], ["into", 1141], ["monomeric", 1146], ["forms", 1156], ["but", 1162], ["remained", 1166], ["in", 1175], ["the", 1178], ["trimeric", 1182], ["form", 1191], [".", 1195], ["Based", 1197], ["on", 1203], ["these", 1206], ["results", 1212], [",", 1219], ["we", 1221], ["propose", 1224], ["the", 1232], ["novel", 1236], ["hypothesis", 1242], ["that", 1253], ["chlorophyll", 1258], ["b", 1270], ["reductase", 1272], ["catalyzes", 1282], ["the", 1292], ["initial", 1296], ["step", 1304], ["of", 1309], ["LHCII", 1312], ["degradation", 1318], [",", 1329], ["and", 1331], ["that", 1335], ["trimeric", 1340], ["LHCII", 1349], ["is", 1355], ["a", 1358], ["substrate", 1360], ["of", 1370], ["LHCII", 1373], ["degradation", 1379], [".", 1390]]}
{"context": "Lewy bodies, neuropathological hallmarks of Parkinson's disease and dementia with Lewy bodies, comprise alpha-synuclein filaments and other less defined proteins. Characterization of Lewy body proteins that interact with alpha-synuclein may provide insight into the mechanism of Lewy body formation. Double immunofluorescence labeling and confocal microscopy revealed approximately 80% of cortical Lewy bodies contained microtubule-associated protein 1B (MAP-1B) that overlapped with alpha-synuclein. Lewy bodies were isolated using an immunomagnetic technique from brain tissue of patients dying with dementia with Lewy bodies. Lewy body proteins were resolved by polyacrylamide gel electrophoresis. Immunoblotting confirmed the presence of MAP-1B and alpha-synuclein in purified Lewy bodies. Direct binding studies revealed a high affinity interaction (IC(50) approximately 20 nm) between MAP-1B and alpha-synuclein. The MAP-1B-binding sites were mapped to the last 45 amino acids of the alpha-synuclein C terminus. MAP-1B also bound in vitro assembled alpha-synuclein fibrils. Thus, MAP-1B may be involved in the pathogenesis of Lewy bodies via its interaction with monomeric and fibrillar alpha-synuclein.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "61399ac72d9a4c4397aa7b80ee902d25", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[172, 174], [196, 198], [141, 143], [74, 76], [16, 18], [160, 162], [34, 36], [115, 117]], "char_spans": [[1055, 1069], [1193, 1207], [902, 916], [484, 498], [104, 118], [990, 1004], [221, 235], [753, 767]]}]}], "context_tokens": [["Lewy", 0], ["bodies", 5], [",", 11], ["neuropathological", 13], ["hallmarks", 31], ["of", 41], ["Parkinson", 44], ["'s", 53], ["disease", 56], ["and", 64], ["dementia", 68], ["with", 77], ["Lewy", 82], ["bodies", 87], [",", 93], ["comprise", 95], ["alpha", 104], ["-", 109], ["synuclein", 110], ["filaments", 120], ["and", 130], ["other", 134], ["less", 140], ["defined", 145], ["proteins", 153], [".", 161], ["Characterization", 163], ["of", 180], ["Lewy", 183], ["body", 188], ["proteins", 193], ["that", 202], ["interact", 207], ["with", 216], ["alpha", 221], ["-", 226], ["synuclein", 227], ["may", 237], ["provide", 241], ["insight", 249], ["into", 257], ["the", 262], ["mechanism", 266], ["of", 276], ["Lewy", 279], ["body", 284], ["formation", 289], [".", 298], ["Double", 300], ["immunofluorescence", 307], ["labeling", 326], ["and", 335], ["confocal", 339], ["microscopy", 348], ["revealed", 359], ["approximately", 368], ["80", 382], ["%", 384], ["of", 386], ["cortical", 389], ["Lewy", 398], ["bodies", 403], ["contained", 410], ["microtubule", 420], ["-", 431], ["associated", 432], ["protein", 443], ["1B", 451], ["(", 454], ["MAP-1B", 455], [")", 461], ["that", 463], ["overlapped", 468], ["with", 479], ["alpha", 484], ["-", 489], ["synuclein", 490], [".", 499], ["Lewy", 501], ["bodies", 506], ["were", 513], ["isolated", 518], ["using", 527], ["an", 533], ["immunomagnetic", 536], ["technique", 551], ["from", 561], ["brain", 566], ["tissue", 572], ["of", 579], ["patients", 582], ["dying", 591], ["with", 597], ["dementia", 602], ["with", 611], ["Lewy", 616], ["bodies", 621], [".", 627], ["Lewy", 629], ["body", 634], ["proteins", 639], ["were", 648], ["resolved", 653], ["by", 662], ["polyacrylamide", 665], ["gel", 680], ["electrophoresis", 684], [".", 699], ["Immunoblotting", 701], ["confirmed", 716], ["the", 726], ["presence", 730], ["of", 739], ["MAP-1B", 742], ["and", 749], ["alpha", 753], ["-", 758], ["synuclein", 759], ["in", 769], ["purified", 772], ["Lewy", 781], ["bodies", 786], [".", 792], ["Direct", 794], ["binding", 801], ["studies", 809], ["revealed", 817], ["a", 826], ["high", 828], ["affinity", 833], ["interaction", 842], ["(", 854], ["IC(50", 855], [")", 860], ["approximately", 862], ["20", 876], ["nm", 879], [")", 881], ["between", 883], ["MAP-1B", 891], ["and", 898], ["alpha", 902], ["-", 907], ["synuclein", 908], [".", 917], ["The", 919], ["MAP-1B", 923], ["-", 929], ["binding", 930], ["sites", 938], ["were", 944], ["mapped", 949], ["to", 956], ["the", 959], ["last", 963], ["45", 968], ["amino", 971], ["acids", 977], ["of", 983], ["the", 986], ["alpha", 990], ["-", 995], ["synuclein", 996], ["C", 1006], ["terminus", 1008], [".", 1016], ["MAP-1B", 1018], ["also", 1025], ["bound", 1030], ["in", 1036], ["vitro", 1039], ["assembled", 1045], ["alpha", 1055], ["-", 1060], ["synuclein", 1061], ["fibrils", 1071], [".", 1078], ["Thus", 1080], [",", 1084], ["MAP-1B", 1086], ["may", 1093], ["be", 1097], ["involved", 1100], ["in", 1109], ["the", 1112], ["pathogenesis", 1116], ["of", 1129], ["Lewy", 1132], ["bodies", 1137], ["via", 1144], ["its", 1148], ["interaction", 1152], ["with", 1164], ["monomeric", 1169], ["and", 1179], ["fibrillar", 1183], ["alpha", 1193], ["-", 1198], ["synuclein", 1199], [".", 1208]]}
{"context": "A proteomic study predicted that about one hundred kinds of proteins constitute a basic structure of the centrosome. Most of the core centrosomal proteins contain extensive coiled-coil domains, suggesting that the protein-protein interaction is a critical force for the core centrosome configuration. In the present study, we investigated a novel interaction between CEP135 and C-NAP1, two core centriolar proteins. Depletion of CEP135 caused a premature centrosome splitting. Reduction of the centrosomal C-NAP1 level was accompanied in a specific manner. Ectopic expression of the CEP135 mutant proteins also caused centrosome splitting in association with the reduction of the centrosomal C-NAP1 levels. Based on these results, we propose that CEP135 acts as a platform protein for C-NAP1 at the centriole.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "ed3f5c3a0167499384a5f2031c714e92", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[104, 104], [17, 17], [77, 77], [46, 46]], "char_spans": [[618, 627], [105, 114], [455, 464], [275, 284]]}]}], "context_tokens": [["A", 0], ["proteomic", 2], ["study", 12], ["predicted", 18], ["that", 28], ["about", 33], ["one", 39], ["hundred", 43], ["kinds", 51], ["of", 57], ["proteins", 60], ["constitute", 69], ["a", 80], ["basic", 82], ["structure", 88], ["of", 98], ["the", 101], ["centrosome", 105], [".", 115], ["Most", 117], ["of", 122], ["the", 125], ["core", 129], ["centrosomal", 134], ["proteins", 146], ["contain", 155], ["extensive", 163], ["coiled", 173], ["-", 179], ["coil", 180], ["domains", 185], [",", 192], ["suggesting", 194], ["that", 205], ["the", 210], ["protein", 214], ["-", 221], ["protein", 222], ["interaction", 230], ["is", 242], ["a", 245], ["critical", 247], ["force", 256], ["for", 262], ["the", 266], ["core", 270], ["centrosome", 275], ["configuration", 286], [".", 299], ["In", 301], ["the", 304], ["present", 308], ["study", 316], [",", 321], ["we", 323], ["investigated", 326], ["a", 339], ["novel", 341], ["interaction", 347], ["between", 359], ["CEP135", 367], ["and", 374], ["C", 378], ["-", 379], ["NAP1", 380], [",", 384], ["two", 386], ["core", 390], ["centriolar", 395], ["proteins", 406], [".", 414], ["Depletion", 416], ["of", 426], ["CEP135", 429], ["caused", 436], ["a", 443], ["premature", 445], ["centrosome", 455], ["splitting", 466], [".", 475], ["Reduction", 477], ["of", 487], ["the", 490], ["centrosomal", 494], ["C", 506], ["-", 507], ["NAP1", 508], ["level", 513], ["was", 519], ["accompanied", 523], ["in", 535], ["a", 538], ["specific", 540], ["manner", 549], [".", 555], ["Ectopic", 557], ["expression", 565], ["of", 576], ["the", 579], ["CEP135", 583], ["mutant", 590], ["proteins", 597], ["also", 606], ["caused", 611], ["centrosome", 618], ["splitting", 629], ["in", 639], ["association", 642], ["with", 654], ["the", 659], ["reduction", 663], ["of", 673], ["the", 676], ["centrosomal", 680], ["C", 692], ["-", 693], ["NAP1", 694], ["levels", 699], [".", 705], ["Based", 707], ["on", 713], ["these", 716], ["results", 722], [",", 729], ["we", 731], ["propose", 734], ["that", 742], ["CEP135", 747], ["acts", 754], ["as", 759], ["a", 762], ["platform", 764], ["protein", 773], ["for", 781], ["C", 785], ["-", 786], ["NAP1", 787], ["at", 792], ["the", 795], ["centriole", 799], [".", 808]]}
{"context": "Neural stem/progenitor cell (NSP) biology and neurogenesis in adult central nervous system (CNS) are important both towards potential future therapeutic applications for CNS repair, and for the fundamental function of the CNS. In the present study, we report the characterization of NSP population from subventricular zone (SVZ) of neonatal piglet brain using in vivo and in vitro systems. We show that the nestin and vimentin-positive neural progenitor cells are present in the SVZ of the lateral ventricles of neonatal piglet brain. In vitro, piglet NSPs proliferated as neurospheres, expressed the typical protein of neural progenitors, nestin and a range of well-established neurodevelopmental markers. Upon dissociation and subculture, piglet NSPs differentiated into neurons and glial cells. Clonal analysis demonstrates that piglet NSPs are multipotent and retain the capacity to generate both glia and neurons. These cells expressed VEGF, VEGFR1, VEGFR2 and Neuropilin-1 and -2 mRNAs. Real time PCR revealed that SVZ NSPs from newborn piglet expressed total VEGF and all VEGF splice variants. These findings show that piglet NSPs may be helpful to more effectively design growth factor based strategies to enhance endogenous precursor cells for cell transplantation studies potentially leading to the application of this strategy in the nervous system disease and injury.", "qas": [{"question": "Which intermediate filament (IF) protein can be used as a non-specific marker of the neuronal precursor cells of the subventricular zone?", "answers": ["Nestin"], "qid": "93550bd7ff2742e5be0946f9e56d9da7", "question_tokens": [["Which", 0], ["intermediate", 6], ["filament", 19], ["(", 28], ["IF", 29], [")", 31], ["protein", 33], ["can", 41], ["be", 45], ["used", 48], ["as", 53], ["a", 56], ["non", 58], ["-", 61], ["specific", 62], ["marker", 71], ["of", 78], ["the", 81], ["neuronal", 85], ["precursor", 94], ["cells", 104], ["of", 110], ["the", 113], ["subventricular", 117], ["zone", 132], ["?", 136]], "detected_answers": [{"text": "Nestin", "token_spans": [[113, 113], [74, 74]], "char_spans": [[640, 645], [407, 412]]}]}], "context_tokens": [["Neural", 0], ["stem", 7], ["/", 11], ["progenitor", 12], ["cell", 23], ["(", 28], ["NSP", 29], [")", 32], ["biology", 34], ["and", 42], ["neurogenesis", 46], ["in", 59], ["adult", 62], ["central", 68], ["nervous", 76], ["system", 84], ["(", 91], ["CNS", 92], [")", 95], ["are", 97], ["important", 101], ["both", 111], ["towards", 116], ["potential", 124], ["future", 134], ["therapeutic", 141], ["applications", 153], ["for", 166], ["CNS", 170], ["repair", 174], [",", 180], ["and", 182], ["for", 186], ["the", 190], ["fundamental", 194], ["function", 206], ["of", 215], ["the", 218], ["CNS", 222], [".", 225], ["In", 227], ["the", 230], ["present", 234], ["study", 242], [",", 247], ["we", 249], ["report", 252], ["the", 259], ["characterization", 263], ["of", 280], ["NSP", 283], ["population", 287], ["from", 298], ["subventricular", 303], ["zone", 318], ["(", 323], ["SVZ", 324], [")", 327], ["of", 329], ["neonatal", 332], ["piglet", 341], ["brain", 348], ["using", 354], ["in", 360], ["vivo", 363], ["and", 368], ["in", 372], ["vitro", 375], ["systems", 381], [".", 388], ["We", 390], ["show", 393], ["that", 398], ["the", 403], ["nestin", 407], ["and", 414], ["vimentin", 418], ["-", 426], ["positive", 427], ["neural", 436], ["progenitor", 443], ["cells", 454], ["are", 460], ["present", 464], ["in", 472], ["the", 475], ["SVZ", 479], ["of", 483], ["the", 486], ["lateral", 490], ["ventricles", 498], ["of", 509], ["neonatal", 512], ["piglet", 521], ["brain", 528], [".", 533], ["In", 535], ["vitro", 538], [",", 543], ["piglet", 545], ["NSPs", 552], ["proliferated", 557], ["as", 570], ["neurospheres", 573], [",", 585], ["expressed", 587], ["the", 597], ["typical", 601], ["protein", 609], ["of", 617], ["neural", 620], ["progenitors", 627], [",", 638], ["nestin", 640], ["and", 647], ["a", 651], ["range", 653], ["of", 659], ["well", 662], ["-", 666], ["established", 667], ["neurodevelopmental", 679], ["markers", 698], [".", 705], ["Upon", 707], ["dissociation", 712], ["and", 725], ["subculture", 729], [",", 739], ["piglet", 741], ["NSPs", 748], ["differentiated", 753], ["into", 768], ["neurons", 773], ["and", 781], ["glial", 785], ["cells", 791], [".", 796], ["Clonal", 798], ["analysis", 805], ["demonstrates", 814], ["that", 827], ["piglet", 832], ["NSPs", 839], ["are", 844], ["multipotent", 848], ["and", 860], ["retain", 864], ["the", 871], ["capacity", 875], ["to", 884], ["generate", 887], ["both", 896], ["glia", 901], ["and", 906], ["neurons", 910], [".", 917], ["These", 919], ["cells", 925], ["expressed", 931], ["VEGF", 941], [",", 945], ["VEGFR1", 947], [",", 953], ["VEGFR2", 955], ["and", 962], ["Neuropilin-1", 966], ["and", 979], ["-2", 983], ["mRNAs", 986], [".", 991], ["Real", 993], ["time", 998], ["PCR", 1003], ["revealed", 1007], ["that", 1016], ["SVZ", 1021], ["NSPs", 1025], ["from", 1030], ["newborn", 1035], ["piglet", 1043], ["expressed", 1050], ["total", 1060], ["VEGF", 1066], ["and", 1071], ["all", 1075], ["VEGF", 1079], ["splice", 1084], ["variants", 1091], [".", 1099], ["These", 1101], ["findings", 1107], ["show", 1116], ["that", 1121], ["piglet", 1126], ["NSPs", 1133], ["may", 1138], ["be", 1142], ["helpful", 1145], ["to", 1153], ["more", 1156], ["effectively", 1161], ["design", 1173], ["growth", 1180], ["factor", 1187], ["based", 1194], ["strategies", 1200], ["to", 1211], ["enhance", 1214], ["endogenous", 1222], ["precursor", 1233], ["cells", 1243], ["for", 1249], ["cell", 1253], ["transplantation", 1258], ["studies", 1274], ["potentially", 1282], ["leading", 1294], ["to", 1302], ["the", 1305], ["application", 1309], ["of", 1321], ["this", 1324], ["strategy", 1329], ["in", 1338], ["the", 1341], ["nervous", 1345], ["system", 1353], ["disease", 1360], ["and", 1368], ["injury", 1372], [".", 1378]]}
{"context": "Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications. Currently, there is no satisfactory pharmacotherapy for TD, which represents a major limitation to therapy with classical antipsychotics. In order to develop or optimize therapies for TD, and to develop new APDs with lower indices of motor side effects, the pathology underlying TD must first be understood. The use of animal models has been used to further this objective. Here, we review different preparations that have been used to model TD and discuss the contribution of neuroimaging studies conducted in these models. Studies in animal models have lead to several hypotheses of TD pathology, although none has yet emerged as the ultimate underlying cause of this syndrome. We discuss alterations in functional indices, neuron and synapse morphology and changes in specific neurotransmitter systems that have been described in animal models of TD, and outline how these findings have contributed to our understanding of antipsychotic-induced dyskinesias. We conclude that several non-mutually exclusive theories of TD are supported by animal studies, including increases in oxidative stress leading to structural and functional changes in specific neurotransmitter systems. Elucidating the mechanisms underlying TD neuropathology partly through the use of animal models will lead to the development of APDs with superior side effect profiles or more effective therapies for TD.", "qas": [{"question": "What is the cause of Tardive dyskinesia?", "answers": ["Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications."], "qid": "b0f3562cb2574620ba46ae33c88d65b3", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["cause", 12], ["of", 18], ["Tardive", 21], ["dyskinesia", 29], ["?", 39]], "detected_answers": [{"text": "Tardive dyskinesia (TD) is a movement disorder characterized by abnormal involuntary facial movements induced by chronic therapy with classical antipsychotic medications.", "token_spans": [[0, 22]], "char_spans": [[0, 168]]}]}], "context_tokens": [["Tardive", 0], ["dyskinesia", 8], ["(", 19], ["TD", 20], [")", 22], ["is", 24], ["a", 27], ["movement", 29], ["disorder", 38], ["characterized", 47], ["by", 61], ["abnormal", 64], ["involuntary", 73], ["facial", 85], ["movements", 92], ["induced", 102], ["by", 110], ["chronic", 113], ["therapy", 121], ["with", 129], ["classical", 134], ["antipsychotic", 144], ["medications", 158], [".", 169], ["Currently", 171], [",", 180], ["there", 182], ["is", 188], ["no", 191], ["satisfactory", 194], ["pharmacotherapy", 207], ["for", 223], ["TD", 227], [",", 229], ["which", 231], ["represents", 237], ["a", 248], ["major", 250], ["limitation", 256], ["to", 267], ["therapy", 270], ["with", 278], ["classical", 283], ["antipsychotics", 293], [".", 307], ["In", 309], ["order", 312], ["to", 318], ["develop", 321], ["or", 329], ["optimize", 332], ["therapies", 341], ["for", 351], ["TD", 355], [",", 357], ["and", 359], ["to", 363], ["develop", 366], ["new", 374], ["APDs", 378], ["with", 383], ["lower", 388], ["indices", 394], ["of", 402], ["motor", 405], ["side", 411], ["effects", 416], [",", 423], ["the", 425], ["pathology", 429], ["underlying", 439], ["TD", 450], ["must", 453], ["first", 458], ["be", 464], ["understood", 467], [".", 477], ["The", 479], ["use", 483], ["of", 487], ["animal", 490], ["models", 497], ["has", 504], ["been", 508], ["used", 513], ["to", 518], ["further", 521], ["this", 529], ["objective", 534], [".", 543], ["Here", 545], [",", 549], ["we", 551], ["review", 554], ["different", 561], ["preparations", 571], ["that", 584], ["have", 589], ["been", 594], ["used", 599], ["to", 604], ["model", 607], ["TD", 613], ["and", 616], ["discuss", 620], ["the", 628], ["contribution", 632], ["of", 645], ["neuroimaging", 648], ["studies", 661], ["conducted", 669], ["in", 679], ["these", 682], ["models", 688], [".", 694], ["Studies", 696], ["in", 704], ["animal", 707], ["models", 714], ["have", 721], ["lead", 726], ["to", 731], ["several", 734], ["hypotheses", 742], ["of", 753], ["TD", 756], ["pathology", 759], [",", 768], ["although", 770], ["none", 779], ["has", 784], ["yet", 788], ["emerged", 792], ["as", 800], ["the", 803], ["ultimate", 807], ["underlying", 816], ["cause", 827], ["of", 833], ["this", 836], ["syndrome", 841], [".", 849], ["We", 851], ["discuss", 854], ["alterations", 862], ["in", 874], ["functional", 877], ["indices", 888], [",", 895], ["neuron", 897], ["and", 904], ["synapse", 908], ["morphology", 916], ["and", 927], ["changes", 931], ["in", 939], ["specific", 942], ["neurotransmitter", 951], ["systems", 968], ["that", 976], ["have", 981], ["been", 986], ["described", 991], ["in", 1001], ["animal", 1004], ["models", 1011], ["of", 1018], ["TD", 1021], [",", 1023], ["and", 1025], ["outline", 1029], ["how", 1037], ["these", 1041], ["findings", 1047], ["have", 1056], ["contributed", 1061], ["to", 1073], ["our", 1076], ["understanding", 1080], ["of", 1094], ["antipsychotic", 1097], ["-", 1110], ["induced", 1111], ["dyskinesias", 1119], [".", 1130], ["We", 1132], ["conclude", 1135], ["that", 1144], ["several", 1149], ["non", 1157], ["-", 1160], ["mutually", 1161], ["exclusive", 1170], ["theories", 1180], ["of", 1189], ["TD", 1192], ["are", 1195], ["supported", 1199], ["by", 1209], ["animal", 1212], ["studies", 1219], [",", 1226], ["including", 1228], ["increases", 1238], ["in", 1248], ["oxidative", 1251], ["stress", 1261], ["leading", 1268], ["to", 1276], ["structural", 1279], ["and", 1290], ["functional", 1294], ["changes", 1305], ["in", 1313], ["specific", 1316], ["neurotransmitter", 1325], ["systems", 1342], [".", 1349], ["Elucidating", 1351], ["the", 1363], ["mechanisms", 1367], ["underlying", 1378], ["TD", 1389], ["neuropathology", 1392], ["partly", 1407], ["through", 1414], ["the", 1422], ["use", 1426], ["of", 1430], ["animal", 1433], ["models", 1440], ["will", 1447], ["lead", 1452], ["to", 1457], ["the", 1460], ["development", 1464], ["of", 1476], ["APDs", 1479], ["with", 1484], ["superior", 1489], ["side", 1498], ["effect", 1503], ["profiles", 1510], ["or", 1519], ["more", 1522], ["effective", 1527], ["therapies", 1537], ["for", 1547], ["TD", 1551], [".", 1553]]}
{"context": "Chaperone-mediated autophagy is one of several lysosomal pathways of proteolysis. This pathway is activated by physiological stresses such as prolonged starvation. Cytosolic proteins with particular peptide sequence motifs are recognized by a complex of molecular chaperones and delivered to lysosomes. No vesicular traffic is required for this protein degradation pathway, so it differs from microautophagy and macroautophagy. Protein substrates bind to a receptor in the lysosomal membrane, the lysosome-associated membrane protein (lamp) type 2a. Levels of lamp2a in the lysosomal membrane are controlled by alterations in the lamp2a half-life as well as by the dynamic distribution of the protein between the lysosomal membrane and the lumen. Substrate proteins are unfolded before transport into the lysosome lumen, and the transport of substrate proteins requires a molecular chaperone within the lysosomal lumen. The exact roles of this lysosomal chaperone remain to be defined. The mechanisms of chaperone-mediated autophagy are similar to mechanisms of protein import into mitochondria, chloroplasts, and the endoplasmic reticulum.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "2af13c4b405e44c8820036a07143c462", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[100, 100], [89, 89]], "char_spans": [[630, 635], [560, 565]]}]}], "context_tokens": [["Chaperone", 0], ["-", 9], ["mediated", 10], ["autophagy", 19], ["is", 29], ["one", 32], ["of", 36], ["several", 39], ["lysosomal", 47], ["pathways", 57], ["of", 66], ["proteolysis", 69], [".", 80], ["This", 82], ["pathway", 87], ["is", 95], ["activated", 98], ["by", 108], ["physiological", 111], ["stresses", 125], ["such", 134], ["as", 139], ["prolonged", 142], ["starvation", 152], [".", 162], ["Cytosolic", 164], ["proteins", 174], ["with", 183], ["particular", 188], ["peptide", 199], ["sequence", 207], ["motifs", 216], ["are", 223], ["recognized", 227], ["by", 238], ["a", 241], ["complex", 243], ["of", 251], ["molecular", 254], ["chaperones", 264], ["and", 275], ["delivered", 279], ["to", 289], ["lysosomes", 292], [".", 301], ["No", 303], ["vesicular", 306], ["traffic", 316], ["is", 324], ["required", 327], ["for", 336], ["this", 340], ["protein", 345], ["degradation", 353], ["pathway", 365], [",", 372], ["so", 374], ["it", 377], ["differs", 380], ["from", 388], ["microautophagy", 393], ["and", 408], ["macroautophagy", 412], [".", 426], ["Protein", 428], ["substrates", 436], ["bind", 447], ["to", 452], ["a", 455], ["receptor", 457], ["in", 466], ["the", 469], ["lysosomal", 473], ["membrane", 483], [",", 491], ["the", 493], ["lysosome", 497], ["-", 505], ["associated", 506], ["membrane", 517], ["protein", 526], ["(", 534], ["lamp", 535], [")", 539], ["type", 541], ["2a", 546], [".", 548], ["Levels", 550], ["of", 557], ["lamp2a", 560], ["in", 567], ["the", 570], ["lysosomal", 574], ["membrane", 584], ["are", 593], ["controlled", 597], ["by", 608], ["alterations", 611], ["in", 623], ["the", 626], ["lamp2a", 630], ["half", 637], ["-", 641], ["life", 642], ["as", 647], ["well", 650], ["as", 655], ["by", 658], ["the", 661], ["dynamic", 665], ["distribution", 673], ["of", 686], ["the", 689], ["protein", 693], ["between", 701], ["the", 709], ["lysosomal", 713], ["membrane", 723], ["and", 732], ["the", 736], ["lumen", 740], [".", 745], ["Substrate", 747], ["proteins", 757], ["are", 766], ["unfolded", 770], ["before", 779], ["transport", 786], ["into", 796], ["the", 801], ["lysosome", 805], ["lumen", 814], [",", 819], ["and", 821], ["the", 825], ["transport", 829], ["of", 839], ["substrate", 842], ["proteins", 852], ["requires", 861], ["a", 870], ["molecular", 872], ["chaperone", 882], ["within", 892], ["the", 899], ["lysosomal", 903], ["lumen", 913], [".", 918], ["The", 920], ["exact", 924], ["roles", 930], ["of", 936], ["this", 939], ["lysosomal", 944], ["chaperone", 954], ["remain", 964], ["to", 971], ["be", 974], ["defined", 977], [".", 984], ["The", 986], ["mechanisms", 990], ["of", 1001], ["chaperone", 1004], ["-", 1013], ["mediated", 1014], ["autophagy", 1023], ["are", 1033], ["similar", 1037], ["to", 1045], ["mechanisms", 1048], ["of", 1059], ["protein", 1062], ["import", 1070], ["into", 1077], ["mitochondria", 1082], [",", 1094], ["chloroplasts", 1096], [",", 1108], ["and", 1110], ["the", 1114], ["endoplasmic", 1118], ["reticulum", 1130], [".", 1139]]}
{"context": "The Web site for the Anxiety Disorders Association of America (ADAA) receives more than 5 million visits per month and thus represents a unique medium for the study of anxiety disorders. ADAA Web site users from October 2002 to January 2003 were invited to complete a survey oriented toward trauma history and psychiatric sequelae. A diagnostic approximation of posttraumatic stress disorder (PTSD) was based on responses to the Trauma Questionnaire, the Davidson Trauma Scale, and questions about impairment. The Connor-Davidson Resilience Scale was also used. Variables were tested for their association with PTSD. Among 1558 participants, 87% had a history of trauma, and 38% had current PTSD. The population was comprised predominantly of white middle-class women, half of whom were married. More than 90% were first-time users of the site. Factors associated with PTSD included death of, or harm to, a loved one; personal history of incest, rape, or physical abuse; lower age; lower income; unemployment; missed work; increased medical care; dissatisfaction with psychotropic medication; depressive symptoms; and lower resilience. In this selective convenience sample, there were high rates of traumatization and PTSD. The demographics of this group are similar to those seen in previously studied populations that had contacted the ADAA. Furthermore, the factors associated with PTSD were like those in many community surveys. The ADAA Web site has the opportunity to benefit large numbers of highly distressed individuals.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "7b813fb8fbe444c2b8ed096bcfc51ca6", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[123, 123], [251, 251], [104, 104], [159, 159], [66, 66], [223, 223]], "char_spans": [[691, 694], [1385, 1388], [611, 614], [869, 872], [393, 396], [1218, 1221]]}]}], "context_tokens": [["The", 0], ["Web", 4], ["site", 8], ["for", 13], ["the", 17], ["Anxiety", 21], ["Disorders", 29], ["Association", 39], ["of", 51], ["America", 54], ["(", 62], ["ADAA", 63], [")", 67], ["receives", 69], ["more", 78], ["than", 83], ["5", 88], ["million", 90], ["visits", 98], ["per", 105], ["month", 109], ["and", 115], ["thus", 119], ["represents", 124], ["a", 135], ["unique", 137], ["medium", 144], ["for", 151], ["the", 155], ["study", 159], ["of", 165], ["anxiety", 168], ["disorders", 176], [".", 185], ["ADAA", 187], ["Web", 192], ["site", 196], ["users", 201], ["from", 207], ["October", 212], ["2002", 220], ["to", 225], ["January", 228], ["2003", 236], ["were", 241], ["invited", 246], ["to", 254], ["complete", 257], ["a", 266], ["survey", 268], ["oriented", 275], ["toward", 284], ["trauma", 291], ["history", 298], ["and", 306], ["psychiatric", 310], ["sequelae", 322], [".", 330], ["A", 332], ["diagnostic", 334], ["approximation", 345], ["of", 359], ["posttraumatic", 362], ["stress", 376], ["disorder", 383], ["(", 392], ["PTSD", 393], [")", 397], ["was", 399], ["based", 403], ["on", 409], ["responses", 412], ["to", 422], ["the", 425], ["Trauma", 429], ["Questionnaire", 436], [",", 449], ["the", 451], ["Davidson", 455], ["Trauma", 464], ["Scale", 471], [",", 476], ["and", 478], ["questions", 482], ["about", 492], ["impairment", 498], [".", 508], ["The", 510], ["Connor", 514], ["-", 520], ["Davidson", 521], ["Resilience", 530], ["Scale", 541], ["was", 547], ["also", 551], ["used", 556], [".", 560], ["Variables", 562], ["were", 572], ["tested", 577], ["for", 584], ["their", 588], ["association", 594], ["with", 606], ["PTSD", 611], [".", 615], ["Among", 617], ["1558", 623], ["participants", 628], [",", 640], ["87", 642], ["%", 644], ["had", 646], ["a", 650], ["history", 652], ["of", 660], ["trauma", 663], [",", 669], ["and", 671], ["38", 675], ["%", 677], ["had", 679], ["current", 683], ["PTSD", 691], [".", 695], ["The", 697], ["population", 701], ["was", 712], ["comprised", 716], ["predominantly", 726], ["of", 740], ["white", 743], ["middle", 749], ["-", 755], ["class", 756], ["women", 762], [",", 767], ["half", 769], ["of", 774], ["whom", 777], ["were", 782], ["married", 787], [".", 794], ["More", 796], ["than", 801], ["90", 806], ["%", 808], ["were", 810], ["first", 815], ["-", 820], ["time", 821], ["users", 826], ["of", 832], ["the", 835], ["site", 839], [".", 843], ["Factors", 845], ["associated", 853], ["with", 864], ["PTSD", 869], ["included", 874], ["death", 883], ["of", 889], [",", 891], ["or", 893], ["harm", 896], ["to", 901], [",", 903], ["a", 905], ["loved", 907], ["one", 913], [";", 916], ["personal", 918], ["history", 927], ["of", 935], ["incest", 938], [",", 944], ["rape", 946], [",", 950], ["or", 952], ["physical", 955], ["abuse", 964], [";", 969], ["lower", 971], ["age", 977], [";", 980], ["lower", 982], ["income", 988], [";", 994], ["unemployment", 996], [";", 1008], ["missed", 1010], ["work", 1017], [";", 1021], ["increased", 1023], ["medical", 1033], ["care", 1041], [";", 1045], ["dissatisfaction", 1047], ["with", 1063], ["psychotropic", 1068], ["medication", 1081], [";", 1091], ["depressive", 1093], ["symptoms", 1104], [";", 1112], ["and", 1114], ["lower", 1118], ["resilience", 1124], [".", 1134], ["In", 1136], ["this", 1139], ["selective", 1144], ["convenience", 1154], ["sample", 1166], [",", 1172], ["there", 1174], ["were", 1180], ["high", 1185], ["rates", 1190], ["of", 1196], ["traumatization", 1199], ["and", 1214], ["PTSD", 1218], [".", 1222], ["The", 1224], ["demographics", 1228], ["of", 1241], ["this", 1244], ["group", 1249], ["are", 1255], ["similar", 1259], ["to", 1267], ["those", 1270], ["seen", 1276], ["in", 1281], ["previously", 1284], ["studied", 1295], ["populations", 1303], ["that", 1315], ["had", 1320], ["contacted", 1324], ["the", 1334], ["ADAA", 1338], [".", 1342], ["Furthermore", 1344], [",", 1355], ["the", 1357], ["factors", 1361], ["associated", 1369], ["with", 1380], ["PTSD", 1385], ["were", 1390], ["like", 1395], ["those", 1400], ["in", 1406], ["many", 1409], ["community", 1414], ["surveys", 1424], [".", 1431], ["The", 1433], ["ADAA", 1437], ["Web", 1442], ["site", 1446], ["has", 1451], ["the", 1455], ["opportunity", 1459], ["to", 1471], ["benefit", 1474], ["large", 1482], ["numbers", 1488], ["of", 1496], ["highly", 1499], ["distressed", 1506], ["individuals", 1517], [".", 1528]]}
{"context": "Chronic myeloid leukemia (CML) is the first human malignancy for which the promise of targeted therapy has come true. CML is invariably associated with a specific genetic lesion--the t(9;22) chromosomal translocation. As a consequence of this translocation, a BCR-ABL fusion gene is formed on the 22q- derivative (traditionally known as the Philadelphia chromosome) and the deregulated tyrosine kinase activity of the protein encoded by this gene has been shown to be both necessary and sufficient for initiation and maintenance of the disease. Imatinib mesylate, an orally available tyrosine kinase inhibitor that targets Bcr-Abl, entered clinical evaluation in 1998. Its efficacy surpassed almost everyone's predictions, and the observation of high response rates and favorable toxicity profile associated with imatinib therapy led to its approval as first-line treatment for all newly diagnosed CML patients over an exceptionally short period of time. The 6-year results of the Phase III trial have recently been reported and confirm durability of responses and declining incidence of adverse events over time, although, at present, occurrence of unexpected side effects in the long term cannot be excluded. Although imatinib does not 'cure' CML and has to be administered chronically to patients, it has revolutionized both outcome and quality of life of CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "b84adc8ad62e42e3b5cd84477d1d0750", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[46, 48], [106, 108]], "char_spans": [[260, 266], [623, 629]]}]}], "context_tokens": [["Chronic", 0], ["myeloid", 8], ["leukemia", 16], ["(", 25], ["CML", 26], [")", 29], ["is", 31], ["the", 34], ["first", 38], ["human", 44], ["malignancy", 50], ["for", 61], ["which", 65], ["the", 71], ["promise", 75], ["of", 83], ["targeted", 86], ["therapy", 95], ["has", 103], ["come", 107], ["true", 112], [".", 116], ["CML", 118], ["is", 122], ["invariably", 125], ["associated", 136], ["with", 147], ["a", 152], ["specific", 154], ["genetic", 163], ["lesion", 171], ["--", 177], ["the", 179], ["t(9;22", 183], [")", 189], ["chromosomal", 191], ["translocation", 203], [".", 216], ["As", 218], ["a", 221], ["consequence", 223], ["of", 235], ["this", 238], ["translocation", 243], [",", 256], ["a", 258], ["BCR", 260], ["-", 263], ["ABL", 264], ["fusion", 268], ["gene", 275], ["is", 280], ["formed", 283], ["on", 290], ["the", 293], ["22q-", 297], ["derivative", 302], ["(", 313], ["traditionally", 314], ["known", 328], ["as", 334], ["the", 337], ["Philadelphia", 341], ["chromosome", 354], [")", 364], ["and", 366], ["the", 370], ["deregulated", 374], ["tyrosine", 386], ["kinase", 395], ["activity", 402], ["of", 411], ["the", 414], ["protein", 418], ["encoded", 426], ["by", 434], ["this", 437], ["gene", 442], ["has", 447], ["been", 451], ["shown", 456], ["to", 462], ["be", 465], ["both", 468], ["necessary", 473], ["and", 483], ["sufficient", 487], ["for", 498], ["initiation", 502], ["and", 513], ["maintenance", 517], ["of", 529], ["the", 532], ["disease", 536], [".", 543], ["Imatinib", 545], ["mesylate", 554], [",", 562], ["an", 564], ["orally", 567], ["available", 574], ["tyrosine", 584], ["kinase", 593], ["inhibitor", 600], ["that", 610], ["targets", 615], ["Bcr", 623], ["-", 626], ["Abl", 627], [",", 630], ["entered", 632], ["clinical", 640], ["evaluation", 649], ["in", 660], ["1998", 663], [".", 667], ["Its", 669], ["efficacy", 673], ["surpassed", 682], ["almost", 692], ["everyone", 699], ["'s", 707], ["predictions", 710], [",", 721], ["and", 723], ["the", 727], ["observation", 731], ["of", 743], ["high", 746], ["response", 751], ["rates", 760], ["and", 766], ["favorable", 770], ["toxicity", 780], ["profile", 789], ["associated", 797], ["with", 808], ["imatinib", 813], ["therapy", 822], ["led", 830], ["to", 834], ["its", 837], ["approval", 841], ["as", 850], ["first", 853], ["-", 858], ["line", 859], ["treatment", 864], ["for", 874], ["all", 878], ["newly", 882], ["diagnosed", 888], ["CML", 898], ["patients", 902], ["over", 911], ["an", 916], ["exceptionally", 919], ["short", 933], ["period", 939], ["of", 946], ["time", 949], [".", 953], ["The", 955], ["6-year", 959], ["results", 966], ["of", 974], ["the", 977], ["Phase", 981], ["III", 987], ["trial", 991], ["have", 997], ["recently", 1002], ["been", 1011], ["reported", 1016], ["and", 1025], ["confirm", 1029], ["durability", 1037], ["of", 1048], ["responses", 1051], ["and", 1061], ["declining", 1065], ["incidence", 1075], ["of", 1085], ["adverse", 1088], ["events", 1096], ["over", 1103], ["time", 1108], [",", 1112], ["although", 1114], [",", 1122], ["at", 1124], ["present", 1127], [",", 1134], ["occurrence", 1136], ["of", 1147], ["unexpected", 1150], ["side", 1161], ["effects", 1166], ["in", 1174], ["the", 1177], ["long", 1181], ["term", 1186], ["can", 1191], ["not", 1194], ["be", 1198], ["excluded", 1201], [".", 1209], ["Although", 1211], ["imatinib", 1220], ["does", 1229], ["not", 1234], ["'", 1238], ["cure", 1239], ["'", 1243], ["CML", 1245], ["and", 1249], ["has", 1253], ["to", 1257], ["be", 1260], ["administered", 1263], ["chronically", 1276], ["to", 1288], ["patients", 1291], [",", 1299], ["it", 1301], ["has", 1304], ["revolutionized", 1308], ["both", 1323], ["outcome", 1328], ["and", 1336], ["quality", 1340], ["of", 1348], ["life", 1351], ["of", 1356], ["CML", 1359], ["patients", 1363], [".", 1371]]}
{"context": "The Ehlers-Danlos syndromes (EDS) comprise a heterogenous group of heritable disorders of connective tissue, characterized by joint hypermobility, skin hyperextensibility and tissue fragility. Most EDS types are caused by mutations in genes encoding different types of collagen or enzymes, essential for normal processing of collagen. Oral health was assessed in 31 subjects with EDS (16 with hypermobility EDS, nine with classical EDS and six with vascular EDS), including signs and symptoms of temporomandibular disorders (TMD), alterations of dental hard tissues, oral mucosa and periodontium, and was compared with matched controls. All EDS subjects were symptomatic for TMD and reported recurrent temporomandibular joint (TMJ) dislocations. Abnormal pulp shape (13%) and pulp calcification (78%) were observed in subjects affected with classical EDS. Caries experience was higher in EDS compared with controls and was related to poor oral hygiene, influenced by increased mucosal fragility and restraint of (wrist) joint mobility. The overall periodontal status in EDS was poor, with 62% of EDS subjects presenting high periodontal treatment needs (community periodontal index for treatment need, CPITN = II). Oral health may be severely compromised in EDS as a result of specific alterations of collagen in orofacial structures. When considering dental treatment in EDS, a number of tissue responses (mucosa, periodontium, pulp) and precautions (TMJ dislocation) should be anticipated.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "e43d93e0fc3b425690165278b7db59e3", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[16, 17]], "char_spans": [[90, 106]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndromes", 18], ["(", 28], ["EDS", 29], [")", 32], ["comprise", 34], ["a", 43], ["heterogenous", 45], ["group", 58], ["of", 64], ["heritable", 67], ["disorders", 77], ["of", 87], ["connective", 90], ["tissue", 101], [",", 107], ["characterized", 109], ["by", 123], ["joint", 126], ["hypermobility", 132], [",", 145], ["skin", 147], ["hyperextensibility", 152], ["and", 171], ["tissue", 175], ["fragility", 182], [".", 191], ["Most", 193], ["EDS", 198], ["types", 202], ["are", 208], ["caused", 212], ["by", 219], ["mutations", 222], ["in", 232], ["genes", 235], ["encoding", 241], ["different", 250], ["types", 260], ["of", 266], ["collagen", 269], ["or", 278], ["enzymes", 281], [",", 288], ["essential", 290], ["for", 300], ["normal", 304], ["processing", 311], ["of", 322], ["collagen", 325], [".", 333], ["Oral", 335], ["health", 340], ["was", 347], ["assessed", 351], ["in", 360], ["31", 363], ["subjects", 366], ["with", 375], ["EDS", 380], ["(", 384], ["16", 385], ["with", 388], ["hypermobility", 393], ["EDS", 407], [",", 410], ["nine", 412], ["with", 417], ["classical", 422], ["EDS", 432], ["and", 436], ["six", 440], ["with", 444], ["vascular", 449], ["EDS", 458], [")", 461], [",", 462], ["including", 464], ["signs", 474], ["and", 480], ["symptoms", 484], ["of", 493], ["temporomandibular", 496], ["disorders", 514], ["(", 524], ["TMD", 525], [")", 528], [",", 529], ["alterations", 531], ["of", 543], ["dental", 546], ["hard", 553], ["tissues", 558], [",", 565], ["oral", 567], ["mucosa", 572], ["and", 579], ["periodontium", 583], [",", 595], ["and", 597], ["was", 601], ["compared", 605], ["with", 614], ["matched", 619], ["controls", 627], [".", 635], ["All", 637], ["EDS", 641], ["subjects", 645], ["were", 654], ["symptomatic", 659], ["for", 671], ["TMD", 675], ["and", 679], ["reported", 683], ["recurrent", 692], ["temporomandibular", 702], ["joint", 720], ["(", 726], ["TMJ", 727], [")", 730], ["dislocations", 732], [".", 744], ["Abnormal", 746], ["pulp", 755], ["shape", 760], ["(", 766], ["13", 767], ["%", 769], [")", 770], ["and", 772], ["pulp", 776], ["calcification", 781], ["(", 795], ["78", 796], ["%", 798], [")", 799], ["were", 801], ["observed", 806], ["in", 815], ["subjects", 818], ["affected", 827], ["with", 836], ["classical", 841], ["EDS", 851], [".", 854], ["Caries", 856], ["experience", 863], ["was", 874], ["higher", 878], ["in", 885], ["EDS", 888], ["compared", 892], ["with", 901], ["controls", 906], ["and", 915], ["was", 919], ["related", 923], ["to", 931], ["poor", 934], ["oral", 939], ["hygiene", 944], [",", 951], ["influenced", 953], ["by", 964], ["increased", 967], ["mucosal", 977], ["fragility", 985], ["and", 995], ["restraint", 999], ["of", 1009], ["(", 1012], ["wrist", 1013], [")", 1018], ["joint", 1020], ["mobility", 1026], [".", 1034], ["The", 1036], ["overall", 1040], ["periodontal", 1048], ["status", 1060], ["in", 1067], ["EDS", 1070], ["was", 1074], ["poor", 1078], [",", 1082], ["with", 1084], ["62", 1089], ["%", 1091], ["of", 1093], ["EDS", 1096], ["subjects", 1100], ["presenting", 1109], ["high", 1120], ["periodontal", 1125], ["treatment", 1137], ["needs", 1147], ["(", 1153], ["community", 1154], ["periodontal", 1164], ["index", 1176], ["for", 1182], ["treatment", 1186], ["need", 1196], [",", 1200], ["CPITN", 1202], ["=", 1208], ["II", 1210], [")", 1212], [".", 1213], ["Oral", 1215], ["health", 1220], ["may", 1227], ["be", 1231], ["severely", 1234], ["compromised", 1243], ["in", 1255], ["EDS", 1258], ["as", 1262], ["a", 1265], ["result", 1267], ["of", 1274], ["specific", 1277], ["alterations", 1286], ["of", 1298], ["collagen", 1301], ["in", 1310], ["orofacial", 1313], ["structures", 1323], [".", 1333], ["When", 1335], ["considering", 1340], ["dental", 1352], ["treatment", 1359], ["in", 1369], ["EDS", 1372], [",", 1375], ["a", 1377], ["number", 1379], ["of", 1386], ["tissue", 1389], ["responses", 1396], ["(", 1406], ["mucosa", 1407], [",", 1413], ["periodontium", 1415], [",", 1427], ["pulp", 1429], [")", 1433], ["and", 1435], ["precautions", 1439], ["(", 1451], ["TMJ", 1452], ["dislocation", 1456], [")", 1467], ["should", 1469], ["be", 1476], ["anticipated", 1479], [".", 1490]]}
{"context": "Cells respond to stresses such as osmotic shock and heat shock by activating stress-activated protein kinases (SAPKs), including c-Jun N-terminal kinase (JNK) [1]. Activation of JNK requires phosphorylation of threonine and tyrosine residues in the TPY activation loop motif [2, 3] and can be reversed by the removal of either phosphate group. Numerous JNK phosphatases including dual-specificity phosphatases [4, 5], have been identified. Many stimuli activate JNK by increasing its rate of phosphorylation; however, JNK dephosphorylation is inhibited in cells after heat shock [6], suggesting that a JNK phosphatase(s) is inactivated. M3/6 is a dual-specificity phosphatase selective for JNK [7, 8]. We have previously expressed M3/6 in the mouse bone marrow cell line BAF3 in order to show that JNK activation by IL-3 is necessary for cell survival and proliferation [9]. Here we report that M3/6 dissociates from JNK and appears in an insoluble fraction after heat shock. These data identify M3/6 as a JNK phosphatase that is inactivated by heat shock and provide a molecular mechanism for the activation of JNK by heat shock.", "qas": [{"question": "Which protein is affected by dusp8 activation?", "answers": ["JNK"], "qid": "902996f009de41b18ed94ad607438522", "question_tokens": [["Which", 0], ["protein", 6], ["is", 14], ["affected", 17], ["by", 26], ["dusp8", 29], ["activation", 35], ["?", 45]], "detected_answers": [{"text": "JNK", "token_spans": [[37, 37], [69, 69], [99, 99], [115, 115], [173, 173], [89, 89], [153, 153], [190, 190], [130, 130], [31, 31], [207, 207]], "char_spans": [[178, 180], [353, 355], [518, 520], [602, 604], [917, 919], [462, 464], [798, 800], [1006, 1008], [690, 692], [154, 156], [1112, 1114]]}]}], "context_tokens": [["Cells", 0], ["respond", 6], ["to", 14], ["stresses", 17], ["such", 26], ["as", 31], ["osmotic", 34], ["shock", 42], ["and", 48], ["heat", 52], ["shock", 57], ["by", 63], ["activating", 66], ["stress", 77], ["-", 83], ["activated", 84], ["protein", 94], ["kinases", 102], ["(", 110], ["SAPKs", 111], [")", 116], [",", 117], ["including", 119], ["c", 129], ["-", 130], ["Jun", 131], ["N", 135], ["-", 136], ["terminal", 137], ["kinase", 146], ["(", 153], ["JNK", 154], [")", 157], ["[", 159], ["1].", 160], ["Activation", 164], ["of", 175], ["JNK", 178], ["requires", 182], ["phosphorylation", 191], ["of", 207], ["threonine", 210], ["and", 220], ["tyrosine", 224], ["residues", 233], ["in", 242], ["the", 245], ["TPY", 249], ["activation", 253], ["loop", 264], ["motif", 269], ["[", 275], ["2", 276], [",", 277], ["3", 279], ["]", 280], ["and", 282], ["can", 286], ["be", 290], ["reversed", 293], ["by", 302], ["the", 305], ["removal", 309], ["of", 317], ["either", 320], ["phosphate", 327], ["group", 337], [".", 342], ["Numerous", 344], ["JNK", 353], ["phosphatases", 357], ["including", 370], ["dual", 380], ["-", 384], ["specificity", 385], ["phosphatases", 397], ["[", 410], ["4", 411], [",", 412], ["5", 414], ["]", 415], [",", 416], ["have", 418], ["been", 423], ["identified", 428], [".", 438], ["Many", 440], ["stimuli", 445], ["activate", 453], ["JNK", 462], ["by", 466], ["increasing", 469], ["its", 480], ["rate", 484], ["of", 489], ["phosphorylation", 492], [";", 507], ["however", 509], [",", 516], ["JNK", 518], ["dephosphorylation", 522], ["is", 540], ["inhibited", 543], ["in", 553], ["cells", 556], ["after", 562], ["heat", 568], ["shock", 573], ["[", 579], ["6", 580], ["]", 581], [",", 582], ["suggesting", 584], ["that", 595], ["a", 600], ["JNK", 602], ["phosphatase(s", 606], [")", 619], ["is", 621], ["inactivated", 624], [".", 635], ["M3/6", 637], ["is", 642], ["a", 645], ["dual", 647], ["-", 651], ["specificity", 652], ["phosphatase", 664], ["selective", 676], ["for", 686], ["JNK", 690], ["[", 694], ["7", 695], [",", 696], ["8].", 698], ["We", 702], ["have", 705], ["previously", 710], ["expressed", 721], ["M3/6", 731], ["in", 736], ["the", 739], ["mouse", 743], ["bone", 749], ["marrow", 754], ["cell", 761], ["line", 766], ["BAF3", 771], ["in", 776], ["order", 779], ["to", 785], ["show", 788], ["that", 793], ["JNK", 798], ["activation", 802], ["by", 813], ["IL-3", 816], ["is", 821], ["necessary", 824], ["for", 834], ["cell", 838], ["survival", 843], ["and", 852], ["proliferation", 856], ["[", 870], ["9].", 871], ["Here", 875], ["we", 880], ["report", 883], ["that", 890], ["M3/6", 895], ["dissociates", 900], ["from", 912], ["JNK", 917], ["and", 921], ["appears", 925], ["in", 933], ["an", 936], ["insoluble", 939], ["fraction", 949], ["after", 958], ["heat", 964], ["shock", 969], [".", 974], ["These", 976], ["data", 982], ["identify", 987], ["M3/6", 996], ["as", 1001], ["a", 1004], ["JNK", 1006], ["phosphatase", 1010], ["that", 1022], ["is", 1027], ["inactivated", 1030], ["by", 1042], ["heat", 1045], ["shock", 1050], ["and", 1056], ["provide", 1060], ["a", 1068], ["molecular", 1070], ["mechanism", 1080], ["for", 1090], ["the", 1094], ["activation", 1098], ["of", 1109], ["JNK", 1112], ["by", 1116], ["heat", 1119], ["shock", 1124], [".", 1129]]}
{"context": "Lung cancer is the leading cause of death worldwide. Adenocarcinomas, the most common histologic subtype of non-small cell lung cancer (NSCLC), are frequently associated with activating mutations in the epidermal growth factor receptor (EGFR) gene. Although these patients often respond clinically to the EGFR tyrosine kinase inhibitors erlotinib and gefitinib, relapse inevitably occurs, suggesting the development of escape mechanisms that promote cell survival. Using a loss-of-function, whole genome short hairpin RNA (shRNA) screen, we identified that the canonical Wnt pathway contributes to the maintenance of NSCLC cells during EGFR inhibition, particularly the poly-ADP-ribosylating enzymes tankyrase 1 and 2 that positively regulate canonical Wnt signaling. Inhibition of tankyrase and various other components of the Wnt pathway with shRNAs or small molecules significantly increased the efficacy of EGFR inhibitors both in vitro and in vivo. Our findings therefore reveal a critical role for tankyrase and the canonical Wnt pathway in maintaining lung cancer cells during EGFR inhibition. Targeting the Wnt-tankyrase-\u03b2-catenin pathway together with EGFR inhibition may improve clinical outcome in patients with NSCLC.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "5cfd33dc4aa142d6ae71e5954d750d83", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[36, 43]], "char_spans": [[203, 246]]}]}], "context_tokens": [["Lung", 0], ["cancer", 5], ["is", 12], ["the", 15], ["leading", 19], ["cause", 27], ["of", 33], ["death", 36], ["worldwide", 42], [".", 51], ["Adenocarcinomas", 53], [",", 68], ["the", 70], ["most", 74], ["common", 79], ["histologic", 86], ["subtype", 97], ["of", 105], ["non", 108], ["-", 111], ["small", 112], ["cell", 118], ["lung", 123], ["cancer", 128], ["(", 135], ["NSCLC", 136], [")", 141], [",", 142], ["are", 144], ["frequently", 148], ["associated", 159], ["with", 170], ["activating", 175], ["mutations", 186], ["in", 196], ["the", 199], ["epidermal", 203], ["growth", 213], ["factor", 220], ["receptor", 227], ["(", 236], ["EGFR", 237], [")", 241], ["gene", 243], [".", 247], ["Although", 249], ["these", 258], ["patients", 264], ["often", 273], ["respond", 279], ["clinically", 287], ["to", 298], ["the", 301], ["EGFR", 305], ["tyrosine", 310], ["kinase", 319], ["inhibitors", 326], ["erlotinib", 337], ["and", 347], ["gefitinib", 351], [",", 360], ["relapse", 362], ["inevitably", 370], ["occurs", 381], [",", 387], ["suggesting", 389], ["the", 400], ["development", 404], ["of", 416], ["escape", 419], ["mechanisms", 426], ["that", 437], ["promote", 442], ["cell", 450], ["survival", 455], [".", 463], ["Using", 465], ["a", 471], ["loss", 473], ["-", 477], ["of", 478], ["-", 480], ["function", 481], [",", 489], ["whole", 491], ["genome", 497], ["short", 504], ["hairpin", 510], ["RNA", 518], ["(", 522], ["shRNA", 523], [")", 528], ["screen", 530], [",", 536], ["we", 538], ["identified", 541], ["that", 552], ["the", 557], ["canonical", 561], ["Wnt", 571], ["pathway", 575], ["contributes", 583], ["to", 595], ["the", 598], ["maintenance", 602], ["of", 614], ["NSCLC", 617], ["cells", 623], ["during", 629], ["EGFR", 636], ["inhibition", 641], [",", 651], ["particularly", 653], ["the", 666], ["poly", 670], ["-", 674], ["ADP", 675], ["-", 678], ["ribosylating", 679], ["enzymes", 692], ["tankyrase", 700], ["1", 710], ["and", 712], ["2", 716], ["that", 718], ["positively", 723], ["regulate", 734], ["canonical", 743], ["Wnt", 753], ["signaling", 757], [".", 766], ["Inhibition", 768], ["of", 779], ["tankyrase", 782], ["and", 792], ["various", 796], ["other", 804], ["components", 810], ["of", 821], ["the", 824], ["Wnt", 828], ["pathway", 832], ["with", 840], ["shRNAs", 845], ["or", 852], ["small", 855], ["molecules", 861], ["significantly", 871], ["increased", 885], ["the", 895], ["efficacy", 899], ["of", 908], ["EGFR", 911], ["inhibitors", 916], ["both", 927], ["in", 932], ["vitro", 935], ["and", 941], ["in", 945], ["vivo", 948], [".", 952], ["Our", 954], ["findings", 958], ["therefore", 967], ["reveal", 977], ["a", 984], ["critical", 986], ["role", 995], ["for", 1000], ["tankyrase", 1004], ["and", 1014], ["the", 1018], ["canonical", 1022], ["Wnt", 1032], ["pathway", 1036], ["in", 1044], ["maintaining", 1047], ["lung", 1059], ["cancer", 1064], ["cells", 1071], ["during", 1077], ["EGFR", 1084], ["inhibition", 1089], [".", 1099], ["Targeting", 1101], ["the", 1111], ["Wnt", 1115], ["-", 1118], ["tankyrase", 1119], ["-", 1128], ["\u03b2", 1129], ["-", 1130], ["catenin", 1131], ["pathway", 1139], ["together", 1147], ["with", 1156], ["EGFR", 1161], ["inhibition", 1166], ["may", 1177], ["improve", 1181], ["clinical", 1189], ["outcome", 1198], ["in", 1206], ["patients", 1209], ["with", 1218], ["NSCLC", 1223], [".", 1228]]}
{"context": "Mgm1 is a member of the dynamin family of GTP-binding proteins. Mgm1 was first identified in yeast, where it affects mitochondrial morphology. The human homologue of Mgm1 is called OPA1. Mutations in the OPA1 gene are the prevailing cause of dominant optic atrophy, a hereditary disease in which progressive degeneration of the optic nerve can lead to blindness. Here we investigate the properties of the Mgm1/OPA1 protein in mammalian cells. We find that Mgm1/OPA1 is localized to the mitochondrial intermembrane space, where it is tightly bound to the outer surface of the inner membrane. Overexpression of wild type or mutant forms of the Mgm1/OPA1 protein cause mitochondria to fragment and, in some cases, cluster near the nucleus, whereas the loss of protein caused by small interfering RNA (siRNA) leads to dispersal of mitochondrial fragments throughout the cytosol. The cristae of these fragmented mitochondria are disorganized. At early time points after transfection with Mgm1/OPA1 siRNA, the mitochondria are not yet fragmented. Instead, the mitochondria swell and stretch, after which they form localized constrictions similar to the mitochondrial abnormalities observed during the early stages of apoptosis. These abnormalities might be the earliest effects of losing Mgm1/OPA1 protein.", "qas": [{"question": "Which is the cellular localization of the protein Opa1?", "answers": ["mitochondrial intermembrane space"], "qid": "da99a2b47daf44bb94a87ccf477bf308", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["localization", 22], ["of", 35], ["the", 38], ["protein", 42], ["Opa1", 50], ["?", 54]], "detected_answers": [{"text": "mitochondrial intermembrane space", "token_spans": [[87, 89]], "char_spans": [[486, 518]]}]}], "context_tokens": [["Mgm1", 0], ["is", 5], ["a", 8], ["member", 10], ["of", 17], ["the", 20], ["dynamin", 24], ["family", 32], ["of", 39], ["GTP", 42], ["-", 45], ["binding", 46], ["proteins", 54], [".", 62], ["Mgm1", 64], ["was", 69], ["first", 73], ["identified", 79], ["in", 90], ["yeast", 93], [",", 98], ["where", 100], ["it", 106], ["affects", 109], ["mitochondrial", 117], ["morphology", 131], [".", 141], ["The", 143], ["human", 147], ["homologue", 153], ["of", 163], ["Mgm1", 166], ["is", 171], ["called", 174], ["OPA1", 181], [".", 185], ["Mutations", 187], ["in", 197], ["the", 200], ["OPA1", 204], ["gene", 209], ["are", 214], ["the", 218], ["prevailing", 222], ["cause", 233], ["of", 239], ["dominant", 242], ["optic", 251], ["atrophy", 257], [",", 264], ["a", 266], ["hereditary", 268], ["disease", 279], ["in", 287], ["which", 290], ["progressive", 296], ["degeneration", 308], ["of", 321], ["the", 324], ["optic", 328], ["nerve", 334], ["can", 340], ["lead", 344], ["to", 349], ["blindness", 352], [".", 361], ["Here", 363], ["we", 368], ["investigate", 371], ["the", 383], ["properties", 387], ["of", 398], ["the", 401], ["Mgm1/OPA1", 405], ["protein", 415], ["in", 423], ["mammalian", 426], ["cells", 436], [".", 441], ["We", 443], ["find", 446], ["that", 451], ["Mgm1/OPA1", 456], ["is", 466], ["localized", 469], ["to", 479], ["the", 482], ["mitochondrial", 486], ["intermembrane", 500], ["space", 514], [",", 519], ["where", 521], ["it", 527], ["is", 530], ["tightly", 533], ["bound", 541], ["to", 547], ["the", 550], ["outer", 554], ["surface", 560], ["of", 568], ["the", 571], ["inner", 575], ["membrane", 581], [".", 589], ["Overexpression", 591], ["of", 606], ["wild", 609], ["type", 614], ["or", 619], ["mutant", 622], ["forms", 629], ["of", 635], ["the", 638], ["Mgm1/OPA1", 642], ["protein", 652], ["cause", 660], ["mitochondria", 666], ["to", 679], ["fragment", 682], ["and", 691], [",", 694], ["in", 696], ["some", 699], ["cases", 704], [",", 709], ["cluster", 711], ["near", 719], ["the", 724], ["nucleus", 728], [",", 735], ["whereas", 737], ["the", 745], ["loss", 749], ["of", 754], ["protein", 757], ["caused", 765], ["by", 772], ["small", 775], ["interfering", 781], ["RNA", 793], ["(", 797], ["siRNA", 798], [")", 803], ["leads", 805], ["to", 811], ["dispersal", 814], ["of", 824], ["mitochondrial", 827], ["fragments", 841], ["throughout", 851], ["the", 862], ["cytosol", 866], [".", 873], ["The", 875], ["cristae", 879], ["of", 887], ["these", 890], ["fragmented", 896], ["mitochondria", 907], ["are", 920], ["disorganized", 924], [".", 936], ["At", 938], ["early", 941], ["time", 947], ["points", 952], ["after", 959], ["transfection", 965], ["with", 978], ["Mgm1/OPA1", 983], ["siRNA", 993], [",", 998], ["the", 1000], ["mitochondria", 1004], ["are", 1017], ["not", 1021], ["yet", 1025], ["fragmented", 1029], [".", 1039], ["Instead", 1041], [",", 1048], ["the", 1050], ["mitochondria", 1054], ["swell", 1067], ["and", 1073], ["stretch", 1077], [",", 1084], ["after", 1086], ["which", 1092], ["they", 1098], ["form", 1103], ["localized", 1108], ["constrictions", 1118], ["similar", 1132], ["to", 1140], ["the", 1143], ["mitochondrial", 1147], ["abnormalities", 1161], ["observed", 1175], ["during", 1184], ["the", 1191], ["early", 1195], ["stages", 1201], ["of", 1208], ["apoptosis", 1211], [".", 1220], ["These", 1222], ["abnormalities", 1228], ["might", 1242], ["be", 1248], ["the", 1251], ["earliest", 1255], ["effects", 1264], ["of", 1272], ["losing", 1275], ["Mgm1/OPA1", 1282], ["protein", 1292], [".", 1299]]}
{"context": "Objective. A study to determine if addition of palatal petechiae to Centor criteria adds more value for clinical diagnosis of acute strep pharyngitis in children. Hypothesis. In children, Centor Criteria does not cover all the symptoms and signs of acute strep pharyngitis. We hypothesize that addition of palatal petechiae to Centor Criteria will increase the possibility of clinical diagnosis of group A streptococcal pharyngitis in children. Methods. One hundred patients with a complaint of sore throat were enrolled in the study. All the patients were examined clinically using the Centor Criteria. They were also examined for other signs and symptoms like petechial lesions over the palate, abdominal pain, and skin rash. All the patients were given rapid strep tests, and throat cultures were sent. No antibiotics were given until culture results were obtained. Results. The sample size was 100 patients. All 100 had fever, sore throat, and erythema of tonsils. Twenty of the 100 patients had tonsillar exudates, 85/100 had tender anterior cervical lymph nodes, and 86/100 had no cough. In total, 9 out of the 100 patients had positive throat cultures. We observed that petechiae over the palate, a very significant sign, is not included in the Centor Criteria. Palatal petechiae were present in 8 out of the 100 patients. Six out of these 8 with palatal petechiae had positive throat culture for strep (75%). Only 7 out of 20 with exudates had positive strep culture. Sixteen out of the 100 patients had rapid strep test positive. Those 84/100 who had negative rapid strep also had negative throat culture. Statistics. We used Fisher's exact test, comparing throat culture positive and negative versus presence of exudates and palatal hemorrhages with positive and negative throat cultures and the resultant P value <.0001. Conclusion. Our study concludes that addition of petechiae over the palate to Centor Criteria will increase the possibility of diagnosing acute group A streptococcal pharyngitis in children.", "qas": [{"question": "Centor criteria are used for which disease?", "answers": ["streptococcal pharyngitis"], "qid": "345cc6f39eb0472ebb37229e6f4e34b1", "question_tokens": [["Centor", 0], ["criteria", 7], ["are", 16], ["used", 20], ["for", 25], ["which", 29], ["disease", 35], ["?", 42]], "detected_answers": [{"text": "streptococcal pharyngitis", "token_spans": [[356, 357], [67, 68]], "char_spans": [[1984, 2008], [406, 430]]}]}], "context_tokens": [["Objective", 0], [".", 9], ["A", 11], ["study", 13], ["to", 19], ["determine", 22], ["if", 32], ["addition", 35], ["of", 44], ["palatal", 47], ["petechiae", 55], ["to", 65], ["Centor", 68], ["criteria", 75], ["adds", 84], ["more", 89], ["value", 94], ["for", 100], ["clinical", 104], ["diagnosis", 113], ["of", 123], ["acute", 126], ["strep", 132], ["pharyngitis", 138], ["in", 150], ["children", 153], [".", 161], ["Hypothesis", 163], [".", 173], ["In", 175], ["children", 178], [",", 186], ["Centor", 188], ["Criteria", 195], ["does", 204], ["not", 209], ["cover", 213], ["all", 219], ["the", 223], ["symptoms", 227], ["and", 236], ["signs", 240], ["of", 246], ["acute", 249], ["strep", 255], ["pharyngitis", 261], [".", 272], ["We", 274], ["hypothesize", 277], ["that", 289], ["addition", 294], ["of", 303], ["palatal", 306], ["petechiae", 314], ["to", 324], ["Centor", 327], ["Criteria", 334], ["will", 343], ["increase", 348], ["the", 357], ["possibility", 361], ["of", 373], ["clinical", 376], ["diagnosis", 385], ["of", 395], ["group", 398], ["A", 404], ["streptococcal", 406], ["pharyngitis", 420], ["in", 432], ["children", 435], [".", 443], ["Methods", 445], [".", 452], ["One", 454], ["hundred", 458], ["patients", 466], ["with", 475], ["a", 480], ["complaint", 482], ["of", 492], ["sore", 495], ["throat", 500], ["were", 507], ["enrolled", 512], ["in", 521], ["the", 524], ["study", 528], [".", 533], ["All", 535], ["the", 539], ["patients", 543], ["were", 552], ["examined", 557], ["clinically", 566], ["using", 577], ["the", 583], ["Centor", 587], ["Criteria", 594], [".", 602], ["They", 604], ["were", 609], ["also", 614], ["examined", 619], ["for", 628], ["other", 632], ["signs", 638], ["and", 644], ["symptoms", 648], ["like", 657], ["petechial", 662], ["lesions", 672], ["over", 680], ["the", 685], ["palate", 689], [",", 695], ["abdominal", 697], ["pain", 707], [",", 711], ["and", 713], ["skin", 717], ["rash", 722], [".", 726], ["All", 728], ["the", 732], ["patients", 736], ["were", 745], ["given", 750], ["rapid", 756], ["strep", 762], ["tests", 768], [",", 773], ["and", 775], ["throat", 779], ["cultures", 786], ["were", 795], ["sent", 800], [".", 804], ["No", 806], ["antibiotics", 809], ["were", 821], ["given", 826], ["until", 832], ["culture", 838], ["results", 846], ["were", 854], ["obtained", 859], [".", 867], ["Results", 869], [".", 876], ["The", 878], ["sample", 882], ["size", 889], ["was", 894], ["100", 898], ["patients", 902], [".", 910], ["All", 912], ["100", 916], ["had", 920], ["fever", 924], [",", 929], ["sore", 931], ["throat", 936], [",", 942], ["and", 944], ["erythema", 948], ["of", 957], ["tonsils", 960], [".", 967], ["Twenty", 969], ["of", 976], ["the", 979], ["100", 983], ["patients", 987], ["had", 996], ["tonsillar", 1000], ["exudates", 1010], [",", 1018], ["85/100", 1020], ["had", 1027], ["tender", 1031], ["anterior", 1038], ["cervical", 1047], ["lymph", 1056], ["nodes", 1062], [",", 1067], ["and", 1069], ["86/100", 1073], ["had", 1080], ["no", 1084], ["cough", 1087], [".", 1092], ["In", 1094], ["total", 1097], [",", 1102], ["9", 1104], ["out", 1106], ["of", 1110], ["the", 1113], ["100", 1117], ["patients", 1121], ["had", 1130], ["positive", 1134], ["throat", 1143], ["cultures", 1150], [".", 1158], ["We", 1160], ["observed", 1163], ["that", 1172], ["petechiae", 1177], ["over", 1187], ["the", 1192], ["palate", 1196], [",", 1202], ["a", 1204], ["very", 1206], ["significant", 1211], ["sign", 1223], [",", 1227], ["is", 1229], ["not", 1232], ["included", 1236], ["in", 1245], ["the", 1248], ["Centor", 1252], ["Criteria", 1259], [".", 1267], ["Palatal", 1269], ["petechiae", 1277], ["were", 1287], ["present", 1292], ["in", 1300], ["8", 1303], ["out", 1305], ["of", 1309], ["the", 1312], ["100", 1316], ["patients", 1320], [".", 1328], ["Six", 1330], ["out", 1334], ["of", 1338], ["these", 1341], ["8", 1347], ["with", 1349], ["palatal", 1354], ["petechiae", 1362], ["had", 1372], ["positive", 1376], ["throat", 1385], ["culture", 1392], ["for", 1400], ["strep", 1404], ["(", 1410], ["75", 1411], ["%", 1413], [")", 1414], [".", 1415], ["Only", 1417], ["7", 1422], ["out", 1424], ["of", 1428], ["20", 1431], ["with", 1434], ["exudates", 1439], ["had", 1448], ["positive", 1452], ["strep", 1461], ["culture", 1467], [".", 1474], ["Sixteen", 1476], ["out", 1484], ["of", 1488], ["the", 1491], ["100", 1495], ["patients", 1499], ["had", 1508], ["rapid", 1512], ["strep", 1518], ["test", 1524], ["positive", 1529], [".", 1537], ["Those", 1539], ["84/100", 1545], ["who", 1552], ["had", 1556], ["negative", 1560], ["rapid", 1569], ["strep", 1575], ["also", 1581], ["had", 1586], ["negative", 1590], ["throat", 1599], ["culture", 1606], [".", 1613], ["Statistics", 1615], [".", 1625], ["We", 1627], ["used", 1630], ["Fisher", 1635], ["'s", 1641], ["exact", 1644], ["test", 1650], [",", 1654], ["comparing", 1656], ["throat", 1666], ["culture", 1673], ["positive", 1681], ["and", 1690], ["negative", 1694], ["versus", 1703], ["presence", 1710], ["of", 1719], ["exudates", 1722], ["and", 1731], ["palatal", 1735], ["hemorrhages", 1743], ["with", 1755], ["positive", 1760], ["and", 1769], ["negative", 1773], ["throat", 1782], ["cultures", 1789], ["and", 1798], ["the", 1802], ["resultant", 1806], ["P", 1816], ["value", 1818], ["<", 1824], [".0001", 1825], [".", 1830], ["Conclusion", 1832], [".", 1842], ["Our", 1844], ["study", 1848], ["concludes", 1854], ["that", 1864], ["addition", 1869], ["of", 1878], ["petechiae", 1881], ["over", 1891], ["the", 1896], ["palate", 1900], ["to", 1907], ["Centor", 1910], ["Criteria", 1917], ["will", 1926], ["increase", 1931], ["the", 1940], ["possibility", 1944], ["of", 1956], ["diagnosing", 1959], ["acute", 1970], ["group", 1976], ["A", 1982], ["streptococcal", 1984], ["pharyngitis", 1998], ["in", 2010], ["children", 2013], [".", 2021]]}
{"context": "The aim of this study was to evaluate the efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder (PTSD). This 12-week, multicenter, double-blind study randomized patients to receive either tiagabine or placebo. Tiagabine (administered in divided doses) was initiated at 4 mg/d (2 mg BID) and individually titrated of up to 4 mg/d weekly to a maximum dose of 16 mg/d. Assessments included the Clinician-Administered PTSD Scale, Clinical Global Impressions of Change, Treatment Outcome PTSD Scale, Davidson Trauma Scale, Connor-Davidson Resilience Scale, Sheehan Disability Scale, Massachusetts General Hospital Sexual Functioning Questionnaire, and Montgomery-Asberg Depression Rating Scale. A total of 232 patients (tiagabine, n = 116; placebo, n = 116) were randomized. There were no significant differences in change from baseline in the Clinician-Administered PTSD Scale total score at final visit for tiagabine compared with placebo (P = 0.85). Similarly, no significant differences were observed with tiagabine on the other efficacy outcome measures (described above) compared with placebo. Tiagabine was generally well tolerated and not associated with weight gain, changes in sexual function, or worsening of depressive symptoms. Tiagabine was not significantly different from placebo in the treatment of symptoms of PTSD. Additional studies are needed to assess the role of drugs that target the gamma-aminobutyric acid system in the treatment of PTSD.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "b5c03080f08845128cbb48af0b93fc6d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "post-traumatic stress disorder", "token_spans": [[18, 22]], "char_spans": [[104, 133]]}, {"text": "PTSD", "token_spans": [[91, 91], [246, 246], [102, 102], [169, 169], [24, 24], [270, 270]], "char_spans": [[453, 456], [1362, 1365], [522, 525], [901, 904], [136, 139], [1493, 1496]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["this", 11], ["study", 16], ["was", 22], ["to", 26], ["evaluate", 29], ["the", 38], ["efficacy", 42], ["and", 51], ["tolerability", 55], ["of", 68], ["tiagabine", 71], ["in", 81], ["adult", 84], ["patients", 90], ["with", 99], ["post", 104], ["-", 108], ["traumatic", 109], ["stress", 119], ["disorder", 126], ["(", 135], ["PTSD", 136], [")", 140], [".", 141], ["This", 143], ["12-week", 148], [",", 155], ["multicenter", 157], [",", 168], ["double", 170], ["-", 176], ["blind", 177], ["study", 183], ["randomized", 189], ["patients", 200], ["to", 209], ["receive", 212], ["either", 220], ["tiagabine", 227], ["or", 237], ["placebo", 240], [".", 247], ["Tiagabine", 249], ["(", 259], ["administered", 260], ["in", 273], ["divided", 276], ["doses", 284], [")", 289], ["was", 291], ["initiated", 295], ["at", 305], ["4", 308], ["mg", 310], ["/", 312], ["d", 313], ["(", 315], ["2", 316], ["mg", 318], ["BID", 321], [")", 324], ["and", 326], ["individually", 330], ["titrated", 343], ["of", 352], ["up", 355], ["to", 358], ["4", 361], ["mg", 363], ["/", 365], ["d", 366], ["weekly", 368], ["to", 375], ["a", 378], ["maximum", 380], ["dose", 388], ["of", 393], ["16", 396], ["mg", 399], ["/", 401], ["d", 402], [".", 403], ["Assessments", 405], ["included", 417], ["the", 426], ["Clinician", 430], ["-", 439], ["Administered", 440], ["PTSD", 453], ["Scale", 458], [",", 463], ["Clinical", 465], ["Global", 474], ["Impressions", 481], ["of", 493], ["Change", 496], [",", 502], ["Treatment", 504], ["Outcome", 514], ["PTSD", 522], ["Scale", 527], [",", 532], ["Davidson", 534], ["Trauma", 543], ["Scale", 550], [",", 555], ["Connor", 557], ["-", 563], ["Davidson", 564], ["Resilience", 573], ["Scale", 584], [",", 589], ["Sheehan", 591], ["Disability", 599], ["Scale", 610], [",", 615], ["Massachusetts", 617], ["General", 631], ["Hospital", 639], ["Sexual", 648], ["Functioning", 655], ["Questionnaire", 667], [",", 680], ["and", 682], ["Montgomery", 686], ["-", 696], ["Asberg", 697], ["Depression", 704], ["Rating", 715], ["Scale", 722], [".", 727], ["A", 729], ["total", 731], ["of", 737], ["232", 740], ["patients", 744], ["(", 753], ["tiagabine", 754], [",", 763], ["n", 765], ["=", 767], ["116", 769], [";", 772], ["placebo", 774], [",", 781], ["n", 783], ["=", 785], ["116", 787], [")", 790], ["were", 792], ["randomized", 797], [".", 807], ["There", 809], ["were", 815], ["no", 820], ["significant", 823], ["differences", 835], ["in", 847], ["change", 850], ["from", 857], ["baseline", 862], ["in", 871], ["the", 874], ["Clinician", 878], ["-", 887], ["Administered", 888], ["PTSD", 901], ["Scale", 906], ["total", 912], ["score", 918], ["at", 924], ["final", 927], ["visit", 933], ["for", 939], ["tiagabine", 943], ["compared", 953], ["with", 962], ["placebo", 967], ["(", 975], ["P", 976], ["=", 978], ["0.85", 980], [")", 984], [".", 985], ["Similarly", 987], [",", 996], ["no", 998], ["significant", 1001], ["differences", 1013], ["were", 1025], ["observed", 1030], ["with", 1039], ["tiagabine", 1044], ["on", 1054], ["the", 1057], ["other", 1061], ["efficacy", 1067], ["outcome", 1076], ["measures", 1084], ["(", 1093], ["described", 1094], ["above", 1104], [")", 1109], ["compared", 1111], ["with", 1120], ["placebo", 1125], [".", 1132], ["Tiagabine", 1134], ["was", 1144], ["generally", 1148], ["well", 1158], ["tolerated", 1163], ["and", 1173], ["not", 1177], ["associated", 1181], ["with", 1192], ["weight", 1197], ["gain", 1204], [",", 1208], ["changes", 1210], ["in", 1218], ["sexual", 1221], ["function", 1228], [",", 1236], ["or", 1238], ["worsening", 1241], ["of", 1251], ["depressive", 1254], ["symptoms", 1265], [".", 1273], ["Tiagabine", 1275], ["was", 1285], ["not", 1289], ["significantly", 1293], ["different", 1307], ["from", 1317], ["placebo", 1322], ["in", 1330], ["the", 1333], ["treatment", 1337], ["of", 1347], ["symptoms", 1350], ["of", 1359], ["PTSD", 1362], [".", 1366], ["Additional", 1368], ["studies", 1379], ["are", 1387], ["needed", 1391], ["to", 1398], ["assess", 1401], ["the", 1408], ["role", 1412], ["of", 1417], ["drugs", 1420], ["that", 1426], ["target", 1431], ["the", 1438], ["gamma", 1442], ["-", 1447], ["aminobutyric", 1448], ["acid", 1461], ["system", 1466], ["in", 1473], ["the", 1476], ["treatment", 1480], ["of", 1490], ["PTSD", 1493], [".", 1497]]}
{"context": "During mitosis, Promyelocytic leukemia nuclear bodies (PML NBs) change dramatically in morphology and composition, but little is known about function of PML in mitosis. Here, we show that PML is phosphorylated at T409 (PML p409) in a mitosis-specific manner. More importantly, PML p409 contributes to maintain the duration of pro-metaphase and regulates spindle checkpoint. Deficient PML p409 caused a shortening of pro-metaphase and challenged the nocodazole-triggered mitotic arrest. T409A mutation led to a higher frequency of misaligned chromosomes on metaphase plate, and subsequently death in late mitosis. In addition, inhibition of PML p409 repressed growth of tumor cells, suggesting that PML p409 is a potential target for cancer therapy. Collectively, our study demonstrated an important phosphorylated site of PML, which contributed to explore the role of PML in mitosis.", "qas": [{"question": "What is the effect of nocodazole cell treatment?", "answers": ["Mitotic arrest"], "qid": "fb1932c2568743f8a7e02da6141a50f9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["effect", 12], ["of", 19], ["nocodazole", 22], ["cell", 33], ["treatment", 38], ["?", 47]], "detected_answers": [{"text": "Mitotic arrest", "token_spans": [[85, 86]], "char_spans": [[470, 483]]}]}], "context_tokens": [["During", 0], ["mitosis", 7], [",", 14], ["Promyelocytic", 16], ["leukemia", 30], ["nuclear", 39], ["bodies", 47], ["(", 54], ["PML", 55], ["NBs", 59], [")", 62], ["change", 64], ["dramatically", 71], ["in", 84], ["morphology", 87], ["and", 98], ["composition", 102], [",", 113], ["but", 115], ["little", 119], ["is", 126], ["known", 129], ["about", 135], ["function", 141], ["of", 150], ["PML", 153], ["in", 157], ["mitosis", 160], [".", 167], ["Here", 169], [",", 173], ["we", 175], ["show", 178], ["that", 183], ["PML", 188], ["is", 192], ["phosphorylated", 195], ["at", 210], ["T409", 213], ["(", 218], ["PML", 219], ["p409", 223], [")", 227], ["in", 229], ["a", 232], ["mitosis", 234], ["-", 241], ["specific", 242], ["manner", 251], [".", 257], ["More", 259], ["importantly", 264], [",", 275], ["PML", 277], ["p409", 281], ["contributes", 286], ["to", 298], ["maintain", 301], ["the", 310], ["duration", 314], ["of", 323], ["pro", 326], ["-", 329], ["metaphase", 330], ["and", 340], ["regulates", 344], ["spindle", 354], ["checkpoint", 362], [".", 372], ["Deficient", 374], ["PML", 384], ["p409", 388], ["caused", 393], ["a", 400], ["shortening", 402], ["of", 413], ["pro", 416], ["-", 419], ["metaphase", 420], ["and", 430], ["challenged", 434], ["the", 445], ["nocodazole", 449], ["-", 459], ["triggered", 460], ["mitotic", 470], ["arrest", 478], [".", 484], ["T409A", 486], ["mutation", 492], ["led", 501], ["to", 505], ["a", 508], ["higher", 510], ["frequency", 517], ["of", 527], ["misaligned", 530], ["chromosomes", 541], ["on", 553], ["metaphase", 556], ["plate", 566], [",", 571], ["and", 573], ["subsequently", 577], ["death", 590], ["in", 596], ["late", 599], ["mitosis", 604], [".", 611], ["In", 613], ["addition", 616], [",", 624], ["inhibition", 626], ["of", 637], ["PML", 640], ["p409", 644], ["repressed", 649], ["growth", 659], ["of", 666], ["tumor", 669], ["cells", 675], [",", 680], ["suggesting", 682], ["that", 693], ["PML", 698], ["p409", 702], ["is", 707], ["a", 710], ["potential", 712], ["target", 722], ["for", 729], ["cancer", 733], ["therapy", 740], [".", 747], ["Collectively", 749], [",", 761], ["our", 763], ["study", 767], ["demonstrated", 773], ["an", 786], ["important", 789], ["phosphorylated", 799], ["site", 814], ["of", 819], ["PML", 822], [",", 825], ["which", 827], ["contributed", 833], ["to", 845], ["explore", 848], ["the", 856], ["role", 860], ["of", 865], ["PML", 868], ["in", 872], ["mitosis", 875], [".", 882]]}
{"context": "Ehlers-Danlos syndrome denotes a group of inherited connective tissue diseases comprising nine types. Type IV Ehlers-Danlos syndrome is the most life-threatening form. It is characterized by a type III collagen deficiency resulting in arterial fragility and death from vascular rupture or bowel perforation. This disease involves a col 3A1 gene mutation. We report the case of a 44 year-old woman with type IV Ehlers-Danlos syndrome. The medical history of our patient included bowel necrosis and two vascular ruptures. We indicate data required to establish Ehlers-Danlos syndrome diagnosis and guidelines for patient management.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "549476d728754e0e979168d1b056eae7", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[9, 10]], "char_spans": [[52, 68]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndrome", 14], ["denotes", 23], ["a", 31], ["group", 33], ["of", 39], ["inherited", 42], ["connective", 52], ["tissue", 63], ["diseases", 70], ["comprising", 79], ["nine", 90], ["types", 95], [".", 100], ["Type", 102], ["IV", 107], ["Ehlers", 110], ["-", 116], ["Danlos", 117], ["syndrome", 124], ["is", 133], ["the", 136], ["most", 140], ["life", 145], ["-", 149], ["threatening", 150], ["form", 162], [".", 166], ["It", 168], ["is", 171], ["characterized", 174], ["by", 188], ["a", 191], ["type", 193], ["III", 198], ["collagen", 202], ["deficiency", 211], ["resulting", 222], ["in", 232], ["arterial", 235], ["fragility", 244], ["and", 254], ["death", 258], ["from", 264], ["vascular", 269], ["rupture", 278], ["or", 286], ["bowel", 289], ["perforation", 295], [".", 306], ["This", 308], ["disease", 313], ["involves", 321], ["a", 330], ["col", 332], ["3A1", 336], ["gene", 340], ["mutation", 345], [".", 353], ["We", 355], ["report", 358], ["the", 365], ["case", 369], ["of", 374], ["a", 377], ["44", 379], ["year", 382], ["-", 386], ["old", 387], ["woman", 391], ["with", 397], ["type", 402], ["IV", 407], ["Ehlers", 410], ["-", 416], ["Danlos", 417], ["syndrome", 424], [".", 432], ["The", 434], ["medical", 438], ["history", 446], ["of", 454], ["our", 457], ["patient", 461], ["included", 469], ["bowel", 478], ["necrosis", 484], ["and", 493], ["two", 497], ["vascular", 501], ["ruptures", 510], [".", 518], ["We", 520], ["indicate", 523], ["data", 532], ["required", 537], ["to", 546], ["establish", 549], ["Ehlers", 559], ["-", 565], ["Danlos", 566], ["syndrome", 573], ["diagnosis", 582], ["and", 592], ["guidelines", 596], ["for", 607], ["patient", 611], ["management", 619], [".", 629]]}
{"context": "Hereditary long QT syndrome (LQTS) is a genetically heterogeneous disease characterized by prolonged QT intervals and an increased risk for ventricular arrhythmias and sudden cardiac death. Mutations in the voltage-gated potassium channel subunit KCNQ1 induce the most common form of LQTS. KCNQ1 is associated with two different entities of LQTS, the autosomal-dominant Romano-Ward syndrome (RWS), and the autosomal-recessive Jervell and Lange-Nielsen syndrome (JLNS) characterized by bilateral deafness in addition to cardiac arrhythmias. In this study, we investigate and discuss dominant-negative I(Ks) current reduction by a KCNQ1 deletion mutation identified in a RWS family. Single-strand conformation polymorphism analysis and direct sequencing were used to screen LQTS genes for mutations. Mutant KCNQ1 channels were heterologously expressed in Xenopus oocytes, and potassium currents were recorded using the two-microelectrode voltage clamp technique. A heterozygous deletion of three nucleotides (CTT) identified in the KCNQ1 gene caused the loss of a single phenylalanine residue at position 339 (KCNQ1-deltaF339). Electrophysiological measurements in the presence and absence of the regulatory beta-subunit KCNE1 revealed that mutant and wild type forms of an N-terminal truncated KCNQ1 subunit (isoform 2) caused much stronger dominant-negative current reduction than the mutant form of the full-length KCNQ1 subunit (isoform 1). This study highlights the functional relevance of the truncated KCNQ1 splice variant (isoform 2) in establishment and mode of inheritance in long QT syndrome. In the RWS family presented here, the autosomal-dominant trait is caused by multiple dominant-negative effects provoked by heteromultimeric channels formed by wild type and mutant KCNQ1-isoforms in combination with KCNE1.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "3c809ea1a7604eca9f5319c8cf28554b", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[282, 284], [58, 60]], "char_spans": [[1640, 1657], [351, 368]]}]}], "context_tokens": [["Hereditary", 0], ["long", 11], ["QT", 16], ["syndrome", 19], ["(", 28], ["LQTS", 29], [")", 33], ["is", 35], ["a", 38], ["genetically", 40], ["heterogeneous", 52], ["disease", 66], ["characterized", 74], ["by", 88], ["prolonged", 91], ["QT", 101], ["intervals", 104], ["and", 114], ["an", 118], ["increased", 121], ["risk", 131], ["for", 136], ["ventricular", 140], ["arrhythmias", 152], ["and", 164], ["sudden", 168], ["cardiac", 175], ["death", 183], [".", 188], ["Mutations", 190], ["in", 200], ["the", 203], ["voltage", 207], ["-", 214], ["gated", 215], ["potassium", 221], ["channel", 231], ["subunit", 239], ["KCNQ1", 247], ["induce", 253], ["the", 260], ["most", 264], ["common", 269], ["form", 276], ["of", 281], ["LQTS", 284], [".", 288], ["KCNQ1", 290], ["is", 296], ["associated", 299], ["with", 310], ["two", 315], ["different", 319], ["entities", 329], ["of", 338], ["LQTS", 341], [",", 345], ["the", 347], ["autosomal", 351], ["-", 360], ["dominant", 361], ["Romano", 370], ["-", 376], ["Ward", 377], ["syndrome", 382], ["(", 391], ["RWS", 392], [")", 395], [",", 396], ["and", 398], ["the", 402], ["autosomal", 406], ["-", 415], ["recessive", 416], ["Jervell", 426], ["and", 434], ["Lange", 438], ["-", 443], ["Nielsen", 444], ["syndrome", 452], ["(", 461], ["JLNS", 462], [")", 466], ["characterized", 468], ["by", 482], ["bilateral", 485], ["deafness", 495], ["in", 504], ["addition", 507], ["to", 516], ["cardiac", 519], ["arrhythmias", 527], [".", 538], ["In", 540], ["this", 543], ["study", 548], [",", 553], ["we", 555], ["investigate", 558], ["and", 570], ["discuss", 574], ["dominant", 582], ["-", 590], ["negative", 591], ["I(Ks", 600], [")", 604], ["current", 606], ["reduction", 614], ["by", 624], ["a", 627], ["KCNQ1", 629], ["deletion", 635], ["mutation", 644], ["identified", 653], ["in", 664], ["a", 667], ["RWS", 669], ["family", 673], [".", 679], ["Single", 681], ["-", 687], ["strand", 688], ["conformation", 695], ["polymorphism", 708], ["analysis", 721], ["and", 730], ["direct", 734], ["sequencing", 741], ["were", 752], ["used", 757], ["to", 762], ["screen", 765], ["LQTS", 772], ["genes", 777], ["for", 783], ["mutations", 787], [".", 796], ["Mutant", 798], ["KCNQ1", 805], ["channels", 811], ["were", 820], ["heterologously", 825], ["expressed", 840], ["in", 850], ["Xenopus", 853], ["oocytes", 861], [",", 868], ["and", 870], ["potassium", 874], ["currents", 884], ["were", 893], ["recorded", 898], ["using", 907], ["the", 913], ["two", 917], ["-", 920], ["microelectrode", 921], ["voltage", 936], ["clamp", 944], ["technique", 950], [".", 959], ["A", 961], ["heterozygous", 963], ["deletion", 976], ["of", 985], ["three", 988], ["nucleotides", 994], ["(", 1006], ["CTT", 1007], [")", 1010], ["identified", 1012], ["in", 1023], ["the", 1026], ["KCNQ1", 1030], ["gene", 1036], ["caused", 1041], ["the", 1048], ["loss", 1052], ["of", 1057], ["a", 1060], ["single", 1062], ["phenylalanine", 1069], ["residue", 1083], ["at", 1091], ["position", 1094], ["339", 1103], ["(", 1107], ["KCNQ1-deltaF339", 1108], [")", 1123], [".", 1124], ["Electrophysiological", 1126], ["measurements", 1147], ["in", 1160], ["the", 1163], ["presence", 1167], ["and", 1176], ["absence", 1180], ["of", 1188], ["the", 1191], ["regulatory", 1195], ["beta", 1206], ["-", 1210], ["subunit", 1211], ["KCNE1", 1219], ["revealed", 1225], ["that", 1234], ["mutant", 1239], ["and", 1246], ["wild", 1250], ["type", 1255], ["forms", 1260], ["of", 1266], ["an", 1269], ["N", 1272], ["-", 1273], ["terminal", 1274], ["truncated", 1283], ["KCNQ1", 1293], ["subunit", 1299], ["(", 1307], ["isoform", 1308], ["2", 1316], [")", 1317], ["caused", 1319], ["much", 1326], ["stronger", 1331], ["dominant", 1340], ["-", 1348], ["negative", 1349], ["current", 1358], ["reduction", 1366], ["than", 1376], ["the", 1381], ["mutant", 1385], ["form", 1392], ["of", 1397], ["the", 1400], ["full", 1404], ["-", 1408], ["length", 1409], ["KCNQ1", 1416], ["subunit", 1422], ["(", 1430], ["isoform", 1431], ["1", 1439], [")", 1440], [".", 1441], ["This", 1443], ["study", 1448], ["highlights", 1454], ["the", 1465], ["functional", 1469], ["relevance", 1480], ["of", 1490], ["the", 1493], ["truncated", 1497], ["KCNQ1", 1507], ["splice", 1513], ["variant", 1520], ["(", 1528], ["isoform", 1529], ["2", 1537], [")", 1538], ["in", 1540], ["establishment", 1543], ["and", 1557], ["mode", 1561], ["of", 1566], ["inheritance", 1569], ["in", 1581], ["long", 1584], ["QT", 1589], ["syndrome", 1592], [".", 1600], ["In", 1602], ["the", 1605], ["RWS", 1609], ["family", 1613], ["presented", 1620], ["here", 1630], [",", 1634], ["the", 1636], ["autosomal", 1640], ["-", 1649], ["dominant", 1650], ["trait", 1659], ["is", 1665], ["caused", 1668], ["by", 1675], ["multiple", 1678], ["dominant", 1687], ["-", 1695], ["negative", 1696], ["effects", 1705], ["provoked", 1713], ["by", 1722], ["heteromultimeric", 1725], ["channels", 1742], ["formed", 1751], ["by", 1758], ["wild", 1761], ["type", 1766], ["and", 1771], ["mutant", 1775], ["KCNQ1-isoforms", 1782], ["in", 1797], ["combination", 1800], ["with", 1812], ["KCNE1", 1817], [".", 1822]]}
{"context": "Members of the signal transducer and activator of transcription (STAT) family of transcription factors are potential targets for the treatment and prevention of cancers including non-small-cell lung cancer. STAT proteins can be phosphorylated and activated by diverse upstream kinases including cytokine receptors and tyrosine kinases. We examined STAT protein activation in lung cancer cell lines including those with activating mutations in the EGFR and examined upstream kinases responsible for STAT3 phosphorylation and activation using small molecules, antibodies, and RNA interference. We found more pronounced STAT3 activation in cells with activating EGFR mutations, yet inhibition of EGFR activity had no effect on STAT3 activation. Inhibition of JAK1 with small molecules or RNA interference resulted in loss of STAT3 tyrosine phosphorylation and inhibition of cell growth. An interleukin-6 neutralizing antibody, siltuximab (CNTO 328) could inhibit STAT3 tyrosine phosphorylation in a cell-dependent manner. Siltuximab could completely inhibit STAT3 tyrosine phosphorylation in H1650 cells, and this resulted in inhibition of lung cancer cell growth in vivo. Combined EGFR inhibition with erlotinib and siltuximab resulted in dual inhibition of both tyrosine and serine STAT3 phosphorylation, more pronounced inhibition of STAT3 transcriptional activity, and translated into combined effects on lung cancer growth in a mouse model. Our results suggest that JAK1 is responsible for STAT3 activation in lung cancer cells and that indirect attacks on JAK1-STAT3 using an IL-6 neutralizing antibody with or without EGFR inhibition can inhibit lung cancer growth in lung cancer subsets.", "qas": [{"question": "Which interleukin is blocked by Siltuximab?", "answers": ["interleukin-6"], "qid": "fc6f88c8ca2e451284d7c33fa8b5071a", "question_tokens": [["Which", 0], ["interleukin", 6], ["is", 18], ["blocked", 21], ["by", 29], ["Siltuximab", 32], ["?", 42]], "detected_answers": [{"text": "interleukin-6", "token_spans": [[139, 139]], "char_spans": [[887, 899]]}]}], "context_tokens": [["Members", 0], ["of", 8], ["the", 11], ["signal", 15], ["transducer", 22], ["and", 33], ["activator", 37], ["of", 47], ["transcription", 50], ["(", 64], ["STAT", 65], [")", 69], ["family", 71], ["of", 78], ["transcription", 81], ["factors", 95], ["are", 103], ["potential", 107], ["targets", 117], ["for", 125], ["the", 129], ["treatment", 133], ["and", 143], ["prevention", 147], ["of", 158], ["cancers", 161], ["including", 169], ["non", 179], ["-", 182], ["small", 183], ["-", 188], ["cell", 189], ["lung", 194], ["cancer", 199], [".", 205], ["STAT", 207], ["proteins", 212], ["can", 221], ["be", 225], ["phosphorylated", 228], ["and", 243], ["activated", 247], ["by", 257], ["diverse", 260], ["upstream", 268], ["kinases", 277], ["including", 285], ["cytokine", 295], ["receptors", 304], ["and", 314], ["tyrosine", 318], ["kinases", 327], [".", 334], ["We", 336], ["examined", 339], ["STAT", 348], ["protein", 353], ["activation", 361], ["in", 372], ["lung", 375], ["cancer", 380], ["cell", 387], ["lines", 392], ["including", 398], ["those", 408], ["with", 414], ["activating", 419], ["mutations", 430], ["in", 440], ["the", 443], ["EGFR", 447], ["and", 452], ["examined", 456], ["upstream", 465], ["kinases", 474], ["responsible", 482], ["for", 494], ["STAT3", 498], ["phosphorylation", 504], ["and", 520], ["activation", 524], ["using", 535], ["small", 541], ["molecules", 547], [",", 556], ["antibodies", 558], [",", 568], ["and", 570], ["RNA", 574], ["interference", 578], [".", 590], ["We", 592], ["found", 595], ["more", 601], ["pronounced", 606], ["STAT3", 617], ["activation", 623], ["in", 634], ["cells", 637], ["with", 643], ["activating", 648], ["EGFR", 659], ["mutations", 664], [",", 673], ["yet", 675], ["inhibition", 679], ["of", 690], ["EGFR", 693], ["activity", 698], ["had", 707], ["no", 711], ["effect", 714], ["on", 721], ["STAT3", 724], ["activation", 730], [".", 740], ["Inhibition", 742], ["of", 753], ["JAK1", 756], ["with", 761], ["small", 766], ["molecules", 772], ["or", 782], ["RNA", 785], ["interference", 789], ["resulted", 802], ["in", 811], ["loss", 814], ["of", 819], ["STAT3", 822], ["tyrosine", 828], ["phosphorylation", 837], ["and", 853], ["inhibition", 857], ["of", 868], ["cell", 871], ["growth", 876], [".", 882], ["An", 884], ["interleukin-6", 887], ["neutralizing", 901], ["antibody", 914], [",", 922], ["siltuximab", 924], ["(", 935], ["CNTO", 936], ["328", 941], [")", 944], ["could", 946], ["inhibit", 952], ["STAT3", 960], ["tyrosine", 966], ["phosphorylation", 975], ["in", 991], ["a", 994], ["cell", 996], ["-", 1000], ["dependent", 1001], ["manner", 1011], [".", 1017], ["Siltuximab", 1019], ["could", 1030], ["completely", 1036], ["inhibit", 1047], ["STAT3", 1055], ["tyrosine", 1061], ["phosphorylation", 1070], ["in", 1086], ["H1650", 1089], ["cells", 1095], [",", 1100], ["and", 1102], ["this", 1106], ["resulted", 1111], ["in", 1120], ["inhibition", 1123], ["of", 1134], ["lung", 1137], ["cancer", 1142], ["cell", 1149], ["growth", 1154], ["in", 1161], ["vivo", 1164], [".", 1168], ["Combined", 1170], ["EGFR", 1179], ["inhibition", 1184], ["with", 1195], ["erlotinib", 1200], ["and", 1210], ["siltuximab", 1214], ["resulted", 1225], ["in", 1234], ["dual", 1237], ["inhibition", 1242], ["of", 1253], ["both", 1256], ["tyrosine", 1261], ["and", 1270], ["serine", 1274], ["STAT3", 1281], ["phosphorylation", 1287], [",", 1302], ["more", 1304], ["pronounced", 1309], ["inhibition", 1320], ["of", 1331], ["STAT3", 1334], ["transcriptional", 1340], ["activity", 1356], [",", 1364], ["and", 1366], ["translated", 1370], ["into", 1381], ["combined", 1386], ["effects", 1395], ["on", 1403], ["lung", 1406], ["cancer", 1411], ["growth", 1418], ["in", 1425], ["a", 1428], ["mouse", 1430], ["model", 1436], [".", 1441], ["Our", 1443], ["results", 1447], ["suggest", 1455], ["that", 1463], ["JAK1", 1468], ["is", 1473], ["responsible", 1476], ["for", 1488], ["STAT3", 1492], ["activation", 1498], ["in", 1509], ["lung", 1512], ["cancer", 1517], ["cells", 1524], ["and", 1530], ["that", 1534], ["indirect", 1539], ["attacks", 1548], ["on", 1556], ["JAK1-STAT3", 1559], ["using", 1570], ["an", 1576], ["IL-6", 1579], ["neutralizing", 1584], ["antibody", 1597], ["with", 1606], ["or", 1611], ["without", 1614], ["EGFR", 1622], ["inhibition", 1627], ["can", 1638], ["inhibit", 1642], ["lung", 1650], ["cancer", 1655], ["growth", 1662], ["in", 1669], ["lung", 1672], ["cancer", 1677], ["subsets", 1684], [".", 1691]]}
{"context": "Ataxin-3 is a ubiquitously expressed deubiqutinating enzyme with important functions in the proteasomal protein degradation pathway and regulation of transcription. The C-terminus of the ataxin-3 protein contains a polyglutamine (PolyQ) region that, when mutationally expanded to over 52 glutamines, causes the neurodegenerative disease spinocerebellar ataxia 3 (SCA3). In spite of extensive research, the molecular mechanisms underlying the cellular toxicity resulting from mutant ataxin-3 remain elusive and no preventive treatment is currently available. It has become clear over the last decade that the hallmark intracellular ataxin-3 aggregates are likely not the main toxic entity in SCA3. Instead, the soluble PolyQ containing fragments arising from proteolytic cleavage of ataxin-3 by caspases and calpains are now regarded to be of greater influence in pathogenesis. In addition, recent evidence suggests potential involvement of a RNA toxicity component in SCA3 and other PolyQ expansion disorders, increasing the pathogenic complexity. Herein, we review the functioning of ataxin-3 and the involvement of known protein and RNA toxicity mechanisms of mutant ataxin-3 that have been discovered, as well as future opportunities for therapeutic intervention.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "5196d6a345bb4a5db1019bc0c286be72", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[0, 0], [96, 96], [27, 27], [182, 182], [73, 73], [169, 169], [120, 120]], "char_spans": [[0, 7], [631, 638], [187, 194], [1169, 1176], [482, 489], [1085, 1092], [782, 789]]}]}], "context_tokens": [["Ataxin-3", 0], ["is", 9], ["a", 12], ["ubiquitously", 14], ["expressed", 27], ["deubiqutinating", 37], ["enzyme", 53], ["with", 60], ["important", 65], ["functions", 75], ["in", 85], ["the", 88], ["proteasomal", 92], ["protein", 104], ["degradation", 112], ["pathway", 124], ["and", 132], ["regulation", 136], ["of", 147], ["transcription", 150], [".", 163], ["The", 165], ["C", 169], ["-", 170], ["terminus", 171], ["of", 180], ["the", 183], ["ataxin-3", 187], ["protein", 196], ["contains", 204], ["a", 213], ["polyglutamine", 215], ["(", 229], ["PolyQ", 230], [")", 235], ["region", 237], ["that", 244], [",", 248], ["when", 250], ["mutationally", 255], ["expanded", 268], ["to", 277], ["over", 280], ["52", 285], ["glutamines", 288], [",", 298], ["causes", 300], ["the", 307], ["neurodegenerative", 311], ["disease", 329], ["spinocerebellar", 337], ["ataxia", 353], ["3", 360], ["(", 362], ["SCA3", 363], [")", 367], [".", 368], ["In", 370], ["spite", 373], ["of", 379], ["extensive", 382], ["research", 392], [",", 400], ["the", 402], ["molecular", 406], ["mechanisms", 416], ["underlying", 427], ["the", 438], ["cellular", 442], ["toxicity", 451], ["resulting", 460], ["from", 470], ["mutant", 475], ["ataxin-3", 482], ["remain", 491], ["elusive", 498], ["and", 506], ["no", 510], ["preventive", 513], ["treatment", 524], ["is", 534], ["currently", 537], ["available", 547], [".", 556], ["It", 558], ["has", 561], ["become", 565], ["clear", 572], ["over", 578], ["the", 583], ["last", 587], ["decade", 592], ["that", 599], ["the", 604], ["hallmark", 608], ["intracellular", 617], ["ataxin-3", 631], ["aggregates", 640], ["are", 651], ["likely", 655], ["not", 662], ["the", 666], ["main", 670], ["toxic", 675], ["entity", 681], ["in", 688], ["SCA3", 691], [".", 695], ["Instead", 697], [",", 704], ["the", 706], ["soluble", 710], ["PolyQ", 718], ["containing", 724], ["fragments", 735], ["arising", 745], ["from", 753], ["proteolytic", 758], ["cleavage", 770], ["of", 779], ["ataxin-3", 782], ["by", 791], ["caspases", 794], ["and", 803], ["calpains", 807], ["are", 816], ["now", 820], ["regarded", 824], ["to", 833], ["be", 836], ["of", 839], ["greater", 842], ["influence", 850], ["in", 860], ["pathogenesis", 863], [".", 875], ["In", 877], ["addition", 880], [",", 888], ["recent", 890], ["evidence", 897], ["suggests", 906], ["potential", 915], ["involvement", 925], ["of", 937], ["a", 940], ["RNA", 942], ["toxicity", 946], ["component", 955], ["in", 965], ["SCA3", 968], ["and", 973], ["other", 977], ["PolyQ", 983], ["expansion", 989], ["disorders", 999], [",", 1008], ["increasing", 1010], ["the", 1021], ["pathogenic", 1025], ["complexity", 1036], [".", 1046], ["Herein", 1048], [",", 1054], ["we", 1056], ["review", 1059], ["the", 1066], ["functioning", 1070], ["of", 1082], ["ataxin-3", 1085], ["and", 1094], ["the", 1098], ["involvement", 1102], ["of", 1114], ["known", 1117], ["protein", 1123], ["and", 1131], ["RNA", 1135], ["toxicity", 1139], ["mechanisms", 1148], ["of", 1159], ["mutant", 1162], ["ataxin-3", 1169], ["that", 1178], ["have", 1183], ["been", 1188], ["discovered", 1193], [",", 1203], ["as", 1205], ["well", 1208], ["as", 1213], ["future", 1216], ["opportunities", 1223], ["for", 1237], ["therapeutic", 1241], ["intervention", 1253], [".", 1265]]}
{"context": "A specialized nucleotide excision repair pathway known as transcription-coupled repair (TCR) counteracts the toxic effects of DNA damage in transcriptionally active genes. The clustering of active genes into gene-rich chromosomal domains predicts that the sites of TCR are unevenly distributed through the genome. To elucidate the genomic organization and chromosomal localization of TCR, we isolated DNA fragments encompassing TCR-mediated repair sites from UV-C irradiated xeroderma pigmentosum group C cells, which can only repair the transcribed strand of active genes. This DNA was used as a molecular probe to visualize TCR in normal metaphase spreads by reverse fluorescence in situ hybridization. Whereas DNA repair sites in normal human cells are evenly distributed through the genome, TCR is highly localized at specific chromosomal domains. Particularly, clusters of TCR sites were identified at early-replicating gene-rich bands and telomeric regions of several chromosomes. High gene-density chromosomes such as chromosome 19 and the GC-rich domains of several chromosomes (T bands) are preferential locations of TCR. Our results demonstrate that the intragenomic localization of TCR resembles the uneven distribution of the human transcriptome, CpG islands, and hyperacetylated histones, enforcing the basic link between DNA repair, transcription, and nuclear organization in a complex genome.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "a279fbb04c944d8dbfb90dbe26a570cd", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[88, 89]], "char_spans": [[538, 555]]}]}], "context_tokens": [["A", 0], ["specialized", 2], ["nucleotide", 14], ["excision", 25], ["repair", 34], ["pathway", 41], ["known", 49], ["as", 55], ["transcription", 58], ["-", 71], ["coupled", 72], ["repair", 80], ["(", 87], ["TCR", 88], [")", 91], ["counteracts", 93], ["the", 105], ["toxic", 109], ["effects", 115], ["of", 123], ["DNA", 126], ["damage", 130], ["in", 137], ["transcriptionally", 140], ["active", 158], ["genes", 165], [".", 170], ["The", 172], ["clustering", 176], ["of", 187], ["active", 190], ["genes", 197], ["into", 203], ["gene", 208], ["-", 212], ["rich", 213], ["chromosomal", 218], ["domains", 230], ["predicts", 238], ["that", 247], ["the", 252], ["sites", 256], ["of", 262], ["TCR", 265], ["are", 269], ["unevenly", 273], ["distributed", 282], ["through", 294], ["the", 302], ["genome", 306], [".", 312], ["To", 314], ["elucidate", 317], ["the", 327], ["genomic", 331], ["organization", 339], ["and", 352], ["chromosomal", 356], ["localization", 368], ["of", 381], ["TCR", 384], [",", 387], ["we", 389], ["isolated", 392], ["DNA", 401], ["fragments", 405], ["encompassing", 415], ["TCR", 428], ["-", 431], ["mediated", 432], ["repair", 441], ["sites", 448], ["from", 454], ["UV", 459], ["-", 461], ["C", 462], ["irradiated", 464], ["xeroderma", 475], ["pigmentosum", 485], ["group", 497], ["C", 503], ["cells", 505], [",", 510], ["which", 512], ["can", 518], ["only", 522], ["repair", 527], ["the", 534], ["transcribed", 538], ["strand", 550], ["of", 557], ["active", 560], ["genes", 567], [".", 572], ["This", 574], ["DNA", 579], ["was", 583], ["used", 587], ["as", 592], ["a", 595], ["molecular", 597], ["probe", 607], ["to", 613], ["visualize", 616], ["TCR", 626], ["in", 630], ["normal", 633], ["metaphase", 640], ["spreads", 650], ["by", 658], ["reverse", 661], ["fluorescence", 669], ["in", 682], ["situ", 685], ["hybridization", 690], [".", 703], ["Whereas", 705], ["DNA", 713], ["repair", 717], ["sites", 724], ["in", 730], ["normal", 733], ["human", 740], ["cells", 746], ["are", 752], ["evenly", 756], ["distributed", 763], ["through", 775], ["the", 783], ["genome", 787], [",", 793], ["TCR", 795], ["is", 799], ["highly", 802], ["localized", 809], ["at", 819], ["specific", 822], ["chromosomal", 831], ["domains", 843], [".", 850], ["Particularly", 852], [",", 864], ["clusters", 866], ["of", 875], ["TCR", 878], ["sites", 882], ["were", 888], ["identified", 893], ["at", 904], ["early", 907], ["-", 912], ["replicating", 913], ["gene", 925], ["-", 929], ["rich", 930], ["bands", 935], ["and", 941], ["telomeric", 945], ["regions", 955], ["of", 963], ["several", 966], ["chromosomes", 974], [".", 985], ["High", 987], ["gene", 992], ["-", 996], ["density", 997], ["chromosomes", 1005], ["such", 1017], ["as", 1022], ["chromosome", 1025], ["19", 1036], ["and", 1039], ["the", 1043], ["GC", 1047], ["-", 1049], ["rich", 1050], ["domains", 1055], ["of", 1063], ["several", 1066], ["chromosomes", 1074], ["(", 1086], ["T", 1087], ["bands", 1089], [")", 1094], ["are", 1096], ["preferential", 1100], ["locations", 1113], ["of", 1123], ["TCR", 1126], [".", 1129], ["Our", 1131], ["results", 1135], ["demonstrate", 1143], ["that", 1155], ["the", 1160], ["intragenomic", 1164], ["localization", 1177], ["of", 1190], ["TCR", 1193], ["resembles", 1197], ["the", 1207], ["uneven", 1211], ["distribution", 1218], ["of", 1231], ["the", 1234], ["human", 1238], ["transcriptome", 1244], [",", 1257], ["CpG", 1259], ["islands", 1263], [",", 1270], ["and", 1272], ["hyperacetylated", 1276], ["histones", 1292], [",", 1300], ["enforcing", 1302], ["the", 1312], ["basic", 1316], ["link", 1322], ["between", 1327], ["DNA", 1335], ["repair", 1339], [",", 1345], ["transcription", 1347], [",", 1360], ["and", 1362], ["nuclear", 1366], ["organization", 1374], ["in", 1387], ["a", 1390], ["complex", 1392], ["genome", 1400], [".", 1406]]}
{"context": "Viliuisk encephalomyelitis (VE) is an endemic neurological disease in Northeast Siberia and generally considered to be a chronic encephalomyelitis of unknown origin actually spreading in the Sakha (Yakutian) Republic. In search for the pathophysiology and causative agent of VE, we performed a cross-sectional study on clinical, serological and neuroimaging data on chronic VE patients during two medical expeditions to three villages within the Viliuiski river basin in the Republic of Sakha in 2000 and to the capital Yakutsk in 2006. The severity of the core clinical picture with predominant sensory ataxia, gait apraxia, lower limb spasticity, cognitive impairment and bladder dysfunction correlated with the degree of MRI findings showing enlargement of inner ventricular spaces as in communicating hydrocephalus. Laboratory studies revealed transient eosinophilia during the preceding acute meningitis-like phase, but no ongoing inflammatory process in the CSF. We found immune reactions against Toxocara canis in the majority of chronic VE patients but rarely in controls (P = 0.025; Fisher's exact test). Histological analysis of subacute to subchronic VE brain samples showed eosinophilic infiltrations with no signs of persistent Toxocara canis infection. Our data showed that pressure by the communicating hydrocephalus as a mechanical factor is the major pathogenic mechanism in chronic VE, most likely triggered by eosinophilic meningitis. There are no signs for an ongoing inflammatory process in chronic VE. The past eosinophilic reaction in VE might be caused by Toxocara ssp. infection and might therefore represent the first hint for an initial cause leading to the development of chronic VE. Our data provide a framework for future studies and potential therapeutic interventions for this enigmatic epidemic neurological disease potentially spreading in Sakha Republic.", "qas": [{"question": "Viliuisk encephalomyelitis is diagnosed in which geographical area?", "answers": ["Northeast Siberia"], "qid": "15bd193287ec4c43b761c54699d4ca55", "question_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["is", 27], ["diagnosed", 30], ["in", 40], ["which", 43], ["geographical", 49], ["area", 62], ["?", 66]], "detected_answers": [{"text": "Northeast Siberia", "token_spans": [[11, 12]], "char_spans": [[70, 86]]}]}], "context_tokens": [["Viliuisk", 0], ["encephalomyelitis", 9], ["(", 27], ["VE", 28], [")", 30], ["is", 32], ["an", 35], ["endemic", 38], ["neurological", 46], ["disease", 59], ["in", 67], ["Northeast", 70], ["Siberia", 80], ["and", 88], ["generally", 92], ["considered", 102], ["to", 113], ["be", 116], ["a", 119], ["chronic", 121], ["encephalomyelitis", 129], ["of", 147], ["unknown", 150], ["origin", 158], ["actually", 165], ["spreading", 174], ["in", 184], ["the", 187], ["Sakha", 191], ["(", 197], ["Yakutian", 198], [")", 206], ["Republic", 208], [".", 216], ["In", 218], ["search", 221], ["for", 228], ["the", 232], ["pathophysiology", 236], ["and", 252], ["causative", 256], ["agent", 266], ["of", 272], ["VE", 275], [",", 277], ["we", 279], ["performed", 282], ["a", 292], ["cross", 294], ["-", 299], ["sectional", 300], ["study", 310], ["on", 316], ["clinical", 319], [",", 327], ["serological", 329], ["and", 341], ["neuroimaging", 345], ["data", 358], ["on", 363], ["chronic", 366], ["VE", 374], ["patients", 377], ["during", 386], ["two", 393], ["medical", 397], ["expeditions", 405], ["to", 417], ["three", 420], ["villages", 426], ["within", 435], ["the", 442], ["Viliuiski", 446], ["river", 456], ["basin", 462], ["in", 468], ["the", 471], ["Republic", 475], ["of", 484], ["Sakha", 487], ["in", 493], ["2000", 496], ["and", 501], ["to", 505], ["the", 508], ["capital", 512], ["Yakutsk", 520], ["in", 528], ["2006", 531], [".", 535], ["The", 537], ["severity", 541], ["of", 550], ["the", 553], ["core", 557], ["clinical", 562], ["picture", 571], ["with", 579], ["predominant", 584], ["sensory", 596], ["ataxia", 604], [",", 610], ["gait", 612], ["apraxia", 617], [",", 624], ["lower", 626], ["limb", 632], ["spasticity", 637], [",", 647], ["cognitive", 649], ["impairment", 659], ["and", 670], ["bladder", 674], ["dysfunction", 682], ["correlated", 694], ["with", 705], ["the", 710], ["degree", 714], ["of", 721], ["MRI", 724], ["findings", 728], ["showing", 737], ["enlargement", 745], ["of", 757], ["inner", 760], ["ventricular", 766], ["spaces", 778], ["as", 785], ["in", 788], ["communicating", 791], ["hydrocephalus", 805], [".", 818], ["Laboratory", 820], ["studies", 831], ["revealed", 839], ["transient", 848], ["eosinophilia", 858], ["during", 871], ["the", 878], ["preceding", 882], ["acute", 892], ["meningitis", 898], ["-", 908], ["like", 909], ["phase", 914], [",", 919], ["but", 921], ["no", 925], ["ongoing", 928], ["inflammatory", 936], ["process", 949], ["in", 957], ["the", 960], ["CSF", 964], [".", 967], ["We", 969], ["found", 972], ["immune", 978], ["reactions", 985], ["against", 995], ["Toxocara", 1003], ["canis", 1012], ["in", 1018], ["the", 1021], ["majority", 1025], ["of", 1034], ["chronic", 1037], ["VE", 1045], ["patients", 1048], ["but", 1057], ["rarely", 1061], ["in", 1068], ["controls", 1071], ["(", 1080], ["P", 1081], ["=", 1083], ["0.025", 1085], [";", 1090], ["Fisher", 1092], ["'s", 1098], ["exact", 1101], ["test", 1107], [")", 1111], [".", 1112], ["Histological", 1114], ["analysis", 1127], ["of", 1136], ["subacute", 1139], ["to", 1148], ["subchronic", 1151], ["VE", 1162], ["brain", 1165], ["samples", 1171], ["showed", 1179], ["eosinophilic", 1186], ["infiltrations", 1199], ["with", 1213], ["no", 1218], ["signs", 1221], ["of", 1227], ["persistent", 1230], ["Toxocara", 1241], ["canis", 1250], ["infection", 1256], [".", 1265], ["Our", 1267], ["data", 1271], ["showed", 1276], ["that", 1283], ["pressure", 1288], ["by", 1297], ["the", 1300], ["communicating", 1304], ["hydrocephalus", 1318], ["as", 1332], ["a", 1335], ["mechanical", 1337], ["factor", 1348], ["is", 1355], ["the", 1358], ["major", 1362], ["pathogenic", 1368], ["mechanism", 1379], ["in", 1389], ["chronic", 1392], ["VE", 1400], [",", 1402], ["most", 1404], ["likely", 1409], ["triggered", 1416], ["by", 1426], ["eosinophilic", 1429], ["meningitis", 1442], [".", 1452], ["There", 1454], ["are", 1460], ["no", 1464], ["signs", 1467], ["for", 1473], ["an", 1477], ["ongoing", 1480], ["inflammatory", 1488], ["process", 1501], ["in", 1509], ["chronic", 1512], ["VE", 1520], [".", 1522], ["The", 1524], ["past", 1528], ["eosinophilic", 1533], ["reaction", 1546], ["in", 1555], ["VE", 1558], ["might", 1561], ["be", 1567], ["caused", 1570], ["by", 1577], ["Toxocara", 1580], ["ssp", 1589], [".", 1592], ["infection", 1594], ["and", 1604], ["might", 1608], ["therefore", 1614], ["represent", 1624], ["the", 1634], ["first", 1638], ["hint", 1644], ["for", 1649], ["an", 1653], ["initial", 1656], ["cause", 1664], ["leading", 1670], ["to", 1678], ["the", 1681], ["development", 1685], ["of", 1697], ["chronic", 1700], ["VE", 1708], [".", 1710], ["Our", 1712], ["data", 1716], ["provide", 1721], ["a", 1729], ["framework", 1731], ["for", 1741], ["future", 1745], ["studies", 1752], ["and", 1760], ["potential", 1764], ["therapeutic", 1774], ["interventions", 1786], ["for", 1800], ["this", 1804], ["enigmatic", 1809], ["epidemic", 1819], ["neurological", 1828], ["disease", 1841], ["potentially", 1849], ["spreading", 1861], ["in", 1871], ["Sakha", 1874], ["Republic", 1880], [".", 1888]]}
{"context": "Tanezumab, a monoclonal antibody, inhibits nerve growth factor and reduces chronic pain. This randomised, double-blind, controlled multicentre study was conducted to evaluate the efficacy and safety of tanezumab added to oral diclofenac sustained release (DSR) in patients with hip or knee osteoarthritis (OA) pain. Patients (N=604) with moderate to severe knee or hip OA tolerating stable DSR were randomised and treated with DSR 75\u2005mg twice daily combined with intravenous tanezumab 10, 5 or 2.5\u2005mg or placebo at weeks 0, 8 and 16. Co-primary efficacy endpoints (Western Ontario and McMaster Universities OA Index (WOMAC) Pain and Physical Function subscales and patient's global assessment of OA) were assessed at week 16. All co-primary endpoints were significantly improved for all tanezumab+DSR groups versus placebo+DSR (p\u22640.039). The incidence of adverse events of abnormal peripheral sensation was lower than in previous tanezumab trials. No new safety signals emerged. Overall incidence of adverse events was higher with tanezumab+DSR (45.2%-49.7%) than with placebo+DSR (34.9%); serious adverse event rates were similar across treatments (5.3%-7.6%). Osteonecrosis was reported in six of 452 patients with tanezumab+DSR (1.3%), but an external adjudication committee did not confirm osteonecrosis in any patient. Addition of tanezumab to DSR resulted in significant improvements in pain, function and global assessments in patients with OA. Although no new safety signals were observed, the higher incidence of adverse events in the tanezumab+diclofenac group suggests that combination therapy is unfavourable. Further investigations of tanezumab monotherapy for OA pain treatment are required. NCT00864097.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "24a13e3726da44deb5ad15627d9c04f8", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[7, 9]], "char_spans": [[43, 61]]}]}], "context_tokens": [["Tanezumab", 0], [",", 9], ["a", 11], ["monoclonal", 13], ["antibody", 24], [",", 32], ["inhibits", 34], ["nerve", 43], ["growth", 49], ["factor", 56], ["and", 63], ["reduces", 67], ["chronic", 75], ["pain", 83], [".", 87], ["This", 89], ["randomised", 94], [",", 104], ["double", 106], ["-", 112], ["blind", 113], [",", 118], ["controlled", 120], ["multicentre", 131], ["study", 143], ["was", 149], ["conducted", 153], ["to", 163], ["evaluate", 166], ["the", 175], ["efficacy", 179], ["and", 188], ["safety", 192], ["of", 199], ["tanezumab", 202], ["added", 212], ["to", 218], ["oral", 221], ["diclofenac", 226], ["sustained", 237], ["release", 247], ["(", 255], ["DSR", 256], [")", 259], ["in", 261], ["patients", 264], ["with", 273], ["hip", 278], ["or", 282], ["knee", 285], ["osteoarthritis", 290], ["(", 305], ["OA", 306], [")", 308], ["pain", 310], [".", 314], ["Patients", 316], ["(", 325], ["N=604", 326], [")", 331], ["with", 333], ["moderate", 338], ["to", 347], ["severe", 350], ["knee", 357], ["or", 362], ["hip", 365], ["OA", 369], ["tolerating", 372], ["stable", 383], ["DSR", 390], ["were", 394], ["randomised", 399], ["and", 410], ["treated", 414], ["with", 422], ["DSR", 427], ["75", 431], ["mg", 434], ["twice", 437], ["daily", 443], ["combined", 449], ["with", 458], ["intravenous", 463], ["tanezumab", 475], ["10", 485], [",", 487], ["5", 489], ["or", 491], ["2.5", 494], ["mg", 498], ["or", 501], ["placebo", 504], ["at", 512], ["weeks", 515], ["0", 521], [",", 522], ["8", 524], ["and", 526], ["16", 530], [".", 532], ["Co", 534], ["-", 536], ["primary", 537], ["efficacy", 545], ["endpoints", 554], ["(", 564], ["Western", 565], ["Ontario", 573], ["and", 581], ["McMaster", 585], ["Universities", 594], ["OA", 607], ["Index", 610], ["(", 616], ["WOMAC", 617], [")", 622], ["Pain", 624], ["and", 629], ["Physical", 633], ["Function", 642], ["subscales", 651], ["and", 661], ["patient", 665], ["'s", 672], ["global", 675], ["assessment", 682], ["of", 693], ["OA", 696], [")", 698], ["were", 700], ["assessed", 705], ["at", 714], ["week", 717], ["16", 722], [".", 724], ["All", 726], ["co", 730], ["-", 732], ["primary", 733], ["endpoints", 741], ["were", 751], ["significantly", 756], ["improved", 770], ["for", 779], ["all", 783], ["tanezumab+DSR", 787], ["groups", 801], ["versus", 808], ["placebo+DSR", 815], ["(", 827], ["p\u22640.039", 828], [")", 835], [".", 836], ["The", 838], ["incidence", 842], ["of", 852], ["adverse", 855], ["events", 863], ["of", 870], ["abnormal", 873], ["peripheral", 882], ["sensation", 893], ["was", 903], ["lower", 907], ["than", 913], ["in", 918], ["previous", 921], ["tanezumab", 930], ["trials", 940], [".", 946], ["No", 948], ["new", 951], ["safety", 955], ["signals", 962], ["emerged", 970], [".", 977], ["Overall", 979], ["incidence", 987], ["of", 997], ["adverse", 1000], ["events", 1008], ["was", 1015], ["higher", 1019], ["with", 1026], ["tanezumab+DSR", 1031], ["(", 1045], ["45.2%-49.7", 1046], ["%", 1056], [")", 1057], ["than", 1059], ["with", 1064], ["placebo+DSR", 1069], ["(", 1081], ["34.9", 1082], ["%", 1086], [")", 1087], [";", 1088], ["serious", 1090], ["adverse", 1098], ["event", 1106], ["rates", 1112], ["were", 1118], ["similar", 1123], ["across", 1131], ["treatments", 1138], ["(", 1149], ["5.3%-7.6", 1150], ["%", 1158], [")", 1159], [".", 1160], ["Osteonecrosis", 1162], ["was", 1176], ["reported", 1180], ["in", 1189], ["six", 1192], ["of", 1196], ["452", 1199], ["patients", 1203], ["with", 1212], ["tanezumab+DSR", 1217], ["(", 1231], ["1.3", 1232], ["%", 1235], [")", 1236], [",", 1237], ["but", 1239], ["an", 1243], ["external", 1246], ["adjudication", 1255], ["committee", 1268], ["did", 1278], ["not", 1282], ["confirm", 1286], ["osteonecrosis", 1294], ["in", 1308], ["any", 1311], ["patient", 1315], [".", 1322], ["Addition", 1324], ["of", 1333], ["tanezumab", 1336], ["to", 1346], ["DSR", 1349], ["resulted", 1353], ["in", 1362], ["significant", 1365], ["improvements", 1377], ["in", 1390], ["pain", 1393], [",", 1397], ["function", 1399], ["and", 1408], ["global", 1412], ["assessments", 1419], ["in", 1431], ["patients", 1434], ["with", 1443], ["OA", 1448], [".", 1450], ["Although", 1452], ["no", 1461], ["new", 1464], ["safety", 1468], ["signals", 1475], ["were", 1483], ["observed", 1488], [",", 1496], ["the", 1498], ["higher", 1502], ["incidence", 1509], ["of", 1519], ["adverse", 1522], ["events", 1530], ["in", 1537], ["the", 1540], ["tanezumab+diclofenac", 1544], ["group", 1565], ["suggests", 1571], ["that", 1580], ["combination", 1585], ["therapy", 1597], ["is", 1605], ["unfavourable", 1608], [".", 1620], ["Further", 1622], ["investigations", 1630], ["of", 1645], ["tanezumab", 1648], ["monotherapy", 1658], ["for", 1670], ["OA", 1674], ["pain", 1677], ["treatment", 1682], ["are", 1692], ["required", 1696], [".", 1704], ["NCT00864097", 1706], [".", 1717]]}
{"context": "Transgenic mice over-expressing a mutated form of the human amyloid precursor protein (APP, 695 isoform) bearing a mutation associated with Alzheimer's disease (V642I, so-called London mutation, hereafter APPLd2) and wild-type controls were studied at age periods (3 and 10 months) prior to the overt development of neuritic amyloid plaques. Both 3- and 10-month-old APPLd2 mice had reflex eyelid responses like those of controls, but only younger mice were able to acquire a classical conditioning of eyelid responses in a trace paradigm. In vitro studies on hippocampal slices showed that 10-month-old APPLd2 mice also presented deficits in paired-pulse facilitation and long-term potentiation, but presented a normal synaptic activation of CA1 pyramidal cells by the stimulation of Schaffer collaterals. It is proposed that definite functional changes may appear well in advance of noticeable structural alterations in this animal model of Alzheimer's disease, and that specific learning tasks could have a relevant diagnostic value.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "b8293e4bcc944de3949762790d040d05", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[25, 27], [167, 169]], "char_spans": [[140, 158], [943, 961]]}]}], "context_tokens": [["Transgenic", 0], ["mice", 11], ["over", 16], ["-", 20], ["expressing", 21], ["a", 32], ["mutated", 34], ["form", 42], ["of", 47], ["the", 50], ["human", 54], ["amyloid", 60], ["precursor", 68], ["protein", 78], ["(", 86], ["APP", 87], [",", 90], ["695", 92], ["isoform", 96], [")", 103], ["bearing", 105], ["a", 113], ["mutation", 115], ["associated", 124], ["with", 135], ["Alzheimer", 140], ["'s", 149], ["disease", 152], ["(", 160], ["V642I", 161], [",", 166], ["so", 168], ["-", 170], ["called", 171], ["London", 178], ["mutation", 185], [",", 193], ["hereafter", 195], ["APPLd2", 205], [")", 211], ["and", 213], ["wild", 217], ["-", 221], ["type", 222], ["controls", 227], ["were", 236], ["studied", 241], ["at", 249], ["age", 252], ["periods", 256], ["(", 264], ["3", 265], ["and", 267], ["10", 271], ["months", 274], [")", 280], ["prior", 282], ["to", 288], ["the", 291], ["overt", 295], ["development", 301], ["of", 313], ["neuritic", 316], ["amyloid", 325], ["plaques", 333], [".", 340], ["Both", 342], ["3-", 347], ["and", 350], ["10-month", 354], ["-", 362], ["old", 363], ["APPLd2", 367], ["mice", 374], ["had", 379], ["reflex", 383], ["eyelid", 390], ["responses", 397], ["like", 407], ["those", 412], ["of", 418], ["controls", 421], [",", 429], ["but", 431], ["only", 435], ["younger", 440], ["mice", 448], ["were", 453], ["able", 458], ["to", 463], ["acquire", 466], ["a", 474], ["classical", 476], ["conditioning", 486], ["of", 499], ["eyelid", 502], ["responses", 509], ["in", 519], ["a", 522], ["trace", 524], ["paradigm", 530], [".", 538], ["In", 540], ["vitro", 543], ["studies", 549], ["on", 557], ["hippocampal", 560], ["slices", 572], ["showed", 579], ["that", 586], ["10-month", 591], ["-", 599], ["old", 600], ["APPLd2", 604], ["mice", 611], ["also", 616], ["presented", 621], ["deficits", 631], ["in", 640], ["paired", 643], ["-", 649], ["pulse", 650], ["facilitation", 656], ["and", 669], ["long", 673], ["-", 677], ["term", 678], ["potentiation", 683], [",", 695], ["but", 697], ["presented", 701], ["a", 711], ["normal", 713], ["synaptic", 720], ["activation", 729], ["of", 740], ["CA1", 743], ["pyramidal", 747], ["cells", 757], ["by", 763], ["the", 766], ["stimulation", 770], ["of", 782], ["Schaffer", 785], ["collaterals", 794], [".", 805], ["It", 807], ["is", 810], ["proposed", 813], ["that", 822], ["definite", 827], ["functional", 836], ["changes", 847], ["may", 855], ["appear", 859], ["well", 866], ["in", 871], ["advance", 874], ["of", 882], ["noticeable", 885], ["structural", 896], ["alterations", 907], ["in", 919], ["this", 922], ["animal", 927], ["model", 934], ["of", 940], ["Alzheimer", 943], ["'s", 952], ["disease", 955], [",", 962], ["and", 964], ["that", 968], ["specific", 973], ["learning", 982], ["tasks", 991], ["could", 997], ["have", 1003], ["a", 1008], ["relevant", 1010], ["diagnostic", 1019], ["value", 1030], [".", 1035]]}
{"context": "Epigenetic modifications of histones regulate gene expression and chromatin structure. Here we show that Meisetz (meiosis-induced factor containing a PR/SET domain and zinc-finger motif) is a histone methyltransferase that is important for the progression of early meiotic prophase. Meisetz transcripts are detected only in germ cells entering meiotic prophase in female fetal gonads and in postnatal testis. Notably, Meisetz has catalytic activity for trimethylation, but not mono- or dimethylation, of lysine 4 of histone H3, and a transactivation activity that depends on its methylation activity. Mice in which the Meisetz gene is disrupted show sterility in both sexes due to severe impairment of the double-stranded break repair pathway, deficient pairing of homologous chromosomes and impaired sex body formation. In Meisetz-deficient testis, trimethylation of lysine 4 of histone H3 is attenuated and meiotic gene transcription is altered. These findings indicate that meiosis-specific epigenetic events in mammals are crucial for proper meiotic progression.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "549167c35b584704bfc6c93fb4bb55e9", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[25, 26]], "char_spans": [[153, 162]]}]}], "context_tokens": [["Epigenetic", 0], ["modifications", 11], ["of", 25], ["histones", 28], ["regulate", 37], ["gene", 46], ["expression", 51], ["and", 62], ["chromatin", 66], ["structure", 76], [".", 85], ["Here", 87], ["we", 92], ["show", 95], ["that", 100], ["Meisetz", 105], ["(", 113], ["meiosis", 114], ["-", 121], ["induced", 122], ["factor", 130], ["containing", 137], ["a", 148], ["PR", 150], ["/", 152], ["SET", 153], ["domain", 157], ["and", 164], ["zinc", 168], ["-", 172], ["finger", 173], ["motif", 180], [")", 185], ["is", 187], ["a", 190], ["histone", 192], ["methyltransferase", 200], ["that", 218], ["is", 223], ["important", 226], ["for", 236], ["the", 240], ["progression", 244], ["of", 256], ["early", 259], ["meiotic", 265], ["prophase", 273], [".", 281], ["Meisetz", 283], ["transcripts", 291], ["are", 303], ["detected", 307], ["only", 316], ["in", 321], ["germ", 324], ["cells", 329], ["entering", 335], ["meiotic", 344], ["prophase", 352], ["in", 361], ["female", 364], ["fetal", 371], ["gonads", 377], ["and", 384], ["in", 388], ["postnatal", 391], ["testis", 401], [".", 407], ["Notably", 409], [",", 416], ["Meisetz", 418], ["has", 426], ["catalytic", 430], ["activity", 440], ["for", 449], ["trimethylation", 453], [",", 467], ["but", 469], ["not", 473], ["mono-", 477], ["or", 483], ["dimethylation", 486], [",", 499], ["of", 501], ["lysine", 504], ["4", 511], ["of", 513], ["histone", 516], ["H3", 524], [",", 526], ["and", 528], ["a", 532], ["transactivation", 534], ["activity", 550], ["that", 559], ["depends", 564], ["on", 572], ["its", 575], ["methylation", 579], ["activity", 591], [".", 599], ["Mice", 601], ["in", 606], ["which", 609], ["the", 615], ["Meisetz", 619], ["gene", 627], ["is", 632], ["disrupted", 635], ["show", 645], ["sterility", 650], ["in", 660], ["both", 663], ["sexes", 668], ["due", 674], ["to", 678], ["severe", 681], ["impairment", 688], ["of", 699], ["the", 702], ["double", 706], ["-", 712], ["stranded", 713], ["break", 722], ["repair", 728], ["pathway", 735], [",", 742], ["deficient", 744], ["pairing", 754], ["of", 762], ["homologous", 765], ["chromosomes", 776], ["and", 788], ["impaired", 792], ["sex", 801], ["body", 805], ["formation", 810], [".", 819], ["In", 821], ["Meisetz", 824], ["-", 831], ["deficient", 832], ["testis", 842], [",", 848], ["trimethylation", 850], ["of", 865], ["lysine", 868], ["4", 875], ["of", 877], ["histone", 880], ["H3", 888], ["is", 891], ["attenuated", 894], ["and", 905], ["meiotic", 909], ["gene", 917], ["transcription", 922], ["is", 936], ["altered", 939], [".", 946], ["These", 948], ["findings", 954], ["indicate", 963], ["that", 972], ["meiosis", 977], ["-", 984], ["specific", 985], ["epigenetic", 994], ["events", 1005], ["in", 1012], ["mammals", 1015], ["are", 1023], ["crucial", 1027], ["for", 1035], ["proper", 1039], ["meiotic", 1046], ["progression", 1054], [".", 1065]]}
{"context": "Allelic polymorphism of the apolipoprotein E (ApoE) gene (ApoE \u03b52, ApoE \u03b53 and ApoE \u03b54 alleles) gives rise to three protein isoforms (ApoE2, ApoE3 and ApoE4) that differ by 1 or 2 amino acids. Inheritance of the ApoE \u03b54 allele is a risk factor for developing Alzheimer's disease (AD). The potential diagnostic value of ApoE protein levels in biological fluids (i.e. cerebrospinal fluid, plasma and serum) for distinguishing between AD patients and healthy elderly subjects is subject to great controversy. Although a recent study reported subnormal total ApoE and ApoE4 levels in the plasma of AD patients, other studies have found normal or even elevated protein levels (versus controls). Because all previously reported assays were based on immunoenzymatic techniques, we decided to develop an orthogonal assay based on targeted mass spectrometry by tracking (i) a proteotypic peptide common to all ApoE isoforms and (ii) a peptide that is specific for the \u03b54 allele. After trypsin digestion, the ApoE4-specific peptide contains an oxidation-prone methionine residue. The endogenous methionine oxidation level was evaluated in a small cohort (n=68) of heterozygous \u03b53\u03b54 carriers containing both healthy controls and AD patients. As expected, the proportion of oxidized residues varied from 0 to 10%, with an average of 5%. We therefore developed a standardized strategy for the unbiased, absolute quantification of ApoE4, based on performic acid oxidization of methionine. Once the sample workflow had been thoroughly validated, it was applied to the concomitant quantification of total ApoE and ApoE4 isoform in a large case-control study (n=669). The final measurements were consistent with most previously reported ApoE concentration values and confirm the influence of the different alleles on the protein expression level. Our results illustrate (i) the reliability of selected reaction monitoring-based assays and (ii) the value of the oxidization step for unbiased monitoring of methionine-containing proteotypic peptides. Furthermore, a statistical analysis indicated that neither total ApoE and ApoE4 levels nor the ApoE/ApoE4 ratio correlated with the diagnosis of AD. These findings reinforce the conclusions of previous studies in which plasma ApoE levels had no obvious clinical significance.", "qas": [{"question": "Which ApoE isoform is associated with atherosclerosis and Alzheimer's disease?", "answers": ["ApoE4 isoform", "Apolipoprotein E4 isoform"], "qid": "2594b3b5c34d4b7f830baf5eb3094b4c", "question_tokens": [["Which", 0], ["ApoE", 6], ["isoform", 11], ["is", 19], ["associated", 22], ["with", 33], ["atherosclerosis", 38], ["and", 54], ["Alzheimer", 58], ["'s", 67], ["disease", 70], ["?", 77]], "detected_answers": [{"text": "ApoE4 isoform", "token_spans": [[286, 287]], "char_spans": [[1598, 1610]]}]}], "context_tokens": [["Allelic", 0], ["polymorphism", 8], ["of", 21], ["the", 24], ["apolipoprotein", 28], ["E", 43], ["(", 45], ["ApoE", 46], [")", 50], ["gene", 52], ["(", 57], ["ApoE", 58], ["\u03b52", 63], [",", 65], ["ApoE", 67], ["\u03b53", 72], ["and", 75], ["ApoE", 79], ["\u03b54", 84], ["alleles", 87], [")", 94], ["gives", 96], ["rise", 102], ["to", 107], ["three", 110], ["protein", 116], ["isoforms", 124], ["(", 133], ["ApoE2", 134], [",", 139], ["ApoE3", 141], ["and", 147], ["ApoE4", 151], [")", 156], ["that", 158], ["differ", 163], ["by", 170], ["1", 173], ["or", 175], ["2", 178], ["amino", 180], ["acids", 186], [".", 191], ["Inheritance", 193], ["of", 205], ["the", 208], ["ApoE", 212], ["\u03b54", 217], ["allele", 220], ["is", 227], ["a", 230], ["risk", 232], ["factor", 237], ["for", 244], ["developing", 248], ["Alzheimer", 259], ["'s", 268], ["disease", 271], ["(", 279], ["AD", 280], [")", 282], [".", 283], ["The", 285], ["potential", 289], ["diagnostic", 299], ["value", 310], ["of", 316], ["ApoE", 319], ["protein", 324], ["levels", 332], ["in", 339], ["biological", 342], ["fluids", 353], ["(", 360], ["i.e.", 361], ["cerebrospinal", 366], ["fluid", 380], [",", 385], ["plasma", 387], ["and", 394], ["serum", 398], [")", 403], ["for", 405], ["distinguishing", 409], ["between", 424], ["AD", 432], ["patients", 435], ["and", 444], ["healthy", 448], ["elderly", 456], ["subjects", 464], ["is", 473], ["subject", 476], ["to", 484], ["great", 487], ["controversy", 493], [".", 504], ["Although", 506], ["a", 515], ["recent", 517], ["study", 524], ["reported", 530], ["subnormal", 539], ["total", 549], ["ApoE", 555], ["and", 560], ["ApoE4", 564], ["levels", 570], ["in", 577], ["the", 580], ["plasma", 584], ["of", 591], ["AD", 594], ["patients", 597], [",", 605], ["other", 607], ["studies", 613], ["have", 621], ["found", 626], ["normal", 632], ["or", 639], ["even", 642], ["elevated", 647], ["protein", 656], ["levels", 664], ["(", 671], ["versus", 672], ["controls", 679], [")", 687], [".", 688], ["Because", 690], ["all", 698], ["previously", 702], ["reported", 713], ["assays", 722], ["were", 729], ["based", 734], ["on", 740], ["immunoenzymatic", 743], ["techniques", 759], [",", 769], ["we", 771], ["decided", 774], ["to", 782], ["develop", 785], ["an", 793], ["orthogonal", 796], ["assay", 807], ["based", 813], ["on", 819], ["targeted", 822], ["mass", 831], ["spectrometry", 836], ["by", 849], ["tracking", 852], ["(", 861], ["i", 862], [")", 863], ["a", 865], ["proteotypic", 867], ["peptide", 879], ["common", 887], ["to", 894], ["all", 897], ["ApoE", 901], ["isoforms", 906], ["and", 915], ["(", 919], ["ii", 920], [")", 922], ["a", 924], ["peptide", 926], ["that", 934], ["is", 939], ["specific", 942], ["for", 951], ["the", 955], ["\u03b54", 959], ["allele", 962], [".", 968], ["After", 970], ["trypsin", 976], ["digestion", 984], [",", 993], ["the", 995], ["ApoE4-specific", 999], ["peptide", 1014], ["contains", 1022], ["an", 1031], ["oxidation", 1034], ["-", 1043], ["prone", 1044], ["methionine", 1050], ["residue", 1061], [".", 1068], ["The", 1070], ["endogenous", 1074], ["methionine", 1085], ["oxidation", 1096], ["level", 1106], ["was", 1112], ["evaluated", 1116], ["in", 1126], ["a", 1129], ["small", 1131], ["cohort", 1137], ["(", 1144], ["n=68", 1145], [")", 1149], ["of", 1151], ["heterozygous", 1154], ["\u03b53\u03b54", 1167], ["carriers", 1172], ["containing", 1181], ["both", 1192], ["healthy", 1197], ["controls", 1205], ["and", 1214], ["AD", 1218], ["patients", 1221], [".", 1229], ["As", 1231], ["expected", 1234], [",", 1242], ["the", 1244], ["proportion", 1248], ["of", 1259], ["oxidized", 1262], ["residues", 1271], ["varied", 1280], ["from", 1287], ["0", 1292], ["to", 1294], ["10", 1297], ["%", 1299], [",", 1300], ["with", 1302], ["an", 1307], ["average", 1310], ["of", 1318], ["5", 1321], ["%", 1322], [".", 1323], ["We", 1325], ["therefore", 1328], ["developed", 1338], ["a", 1348], ["standardized", 1350], ["strategy", 1363], ["for", 1372], ["the", 1376], ["unbiased", 1380], [",", 1388], ["absolute", 1390], ["quantification", 1399], ["of", 1414], ["ApoE4", 1417], [",", 1422], ["based", 1424], ["on", 1430], ["performic", 1433], ["acid", 1443], ["oxidization", 1448], ["of", 1460], ["methionine", 1463], [".", 1473], ["Once", 1475], ["the", 1480], ["sample", 1484], ["workflow", 1491], ["had", 1500], ["been", 1504], ["thoroughly", 1509], ["validated", 1520], [",", 1529], ["it", 1531], ["was", 1534], ["applied", 1538], ["to", 1546], ["the", 1549], ["concomitant", 1553], ["quantification", 1565], ["of", 1580], ["total", 1583], ["ApoE", 1589], ["and", 1594], ["ApoE4", 1598], ["isoform", 1604], ["in", 1612], ["a", 1615], ["large", 1617], ["case", 1623], ["-", 1627], ["control", 1628], ["study", 1636], ["(", 1642], ["n=669", 1643], [")", 1648], [".", 1649], ["The", 1651], ["final", 1655], ["measurements", 1661], ["were", 1674], ["consistent", 1679], ["with", 1690], ["most", 1695], ["previously", 1700], ["reported", 1711], ["ApoE", 1720], ["concentration", 1725], ["values", 1739], ["and", 1746], ["confirm", 1750], ["the", 1758], ["influence", 1762], ["of", 1772], ["the", 1775], ["different", 1779], ["alleles", 1789], ["on", 1797], ["the", 1800], ["protein", 1804], ["expression", 1812], ["level", 1823], [".", 1828], ["Our", 1830], ["results", 1834], ["illustrate", 1842], ["(", 1853], ["i", 1854], [")", 1855], ["the", 1857], ["reliability", 1861], ["of", 1873], ["selected", 1876], ["reaction", 1885], ["monitoring", 1894], ["-", 1904], ["based", 1905], ["assays", 1911], ["and", 1918], ["(", 1922], ["ii", 1923], [")", 1925], ["the", 1927], ["value", 1931], ["of", 1937], ["the", 1940], ["oxidization", 1944], ["step", 1956], ["for", 1961], ["unbiased", 1965], ["monitoring", 1974], ["of", 1985], ["methionine", 1988], ["-", 1998], ["containing", 1999], ["proteotypic", 2010], ["peptides", 2022], [".", 2030], ["Furthermore", 2032], [",", 2043], ["a", 2045], ["statistical", 2047], ["analysis", 2059], ["indicated", 2068], ["that", 2078], ["neither", 2083], ["total", 2091], ["ApoE", 2097], ["and", 2102], ["ApoE4", 2106], ["levels", 2112], ["nor", 2119], ["the", 2123], ["ApoE", 2127], ["/", 2131], ["ApoE4", 2132], ["ratio", 2138], ["correlated", 2144], ["with", 2155], ["the", 2160], ["diagnosis", 2164], ["of", 2174], ["AD", 2177], [".", 2179], ["These", 2181], ["findings", 2187], ["reinforce", 2196], ["the", 2206], ["conclusions", 2210], ["of", 2222], ["previous", 2225], ["studies", 2234], ["in", 2242], ["which", 2245], ["plasma", 2251], ["ApoE", 2258], ["levels", 2263], ["had", 2270], ["no", 2274], ["obvious", 2277], ["clinical", 2285], ["significance", 2294], [".", 2306]]}
{"context": "The generation of reactive oxygen species (ROS) is required for proper cell signaling, but must be tightly regulated to minimize deleterious oxidizing effects. Activation of the NADPH oxidases (Nox) triggers ROS production and, thus, regulatory mechanisms exist to properly control Nox activity. In this study, we report a novel mechanism in which Nox1 activity is regulated through the proteasomal degradation of Nox organizer 1 (NoxO1). We found that through the interaction between NoxO1 and growth receptor-bound protein 2 (Grb2), the Casitas B-lineage lymphoma (Cbl) E3 ligase was recruited, leading to decreased NoxO1 stability and a subsequent reduction in ROS generation upon epidermal growth factor (EGF) stimulation. Additionally, we show that EGF-mediated phosphorylation of NoxO1 induced its release from Grb2 and facilitated its association with Nox activator 1 (NoxA1) to stimulate ROS production. Consistently, overexpression of Grb2 resulted in decreased Nox1 activity, whereas knockdown of Grb2 led to increased Nox1 activity in response to EGF. CRISPR/Cas9-mediated NoxO1 knockout in human colon cancer cells abrogated anchorage-independent growth on soft agar and tumor-forming ability in athymic nude mice. Moreover, the expression and stability of NoxO1 were significantly increased in human colon cancer tissues compared with normal colon. Taken together, these results support a model whereby Nox1 activity and ROS generation are regulated by Grb2/Cbl-mediated proteolysis of NoxO1 in response to EGF, providing new insight into the processes by which excessive ROS production may promote oncogenic signaling to drive colorectal tumorigenesis.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "9017897d71c2434d90f474f17544eebd", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NOX1", "token_spans": [[172, 172], [247, 247], [182, 182], [62, 62]], "char_spans": [[971, 974], [1416, 1419], [1029, 1032], [348, 351]]}]}], "context_tokens": [["The", 0], ["generation", 4], ["of", 15], ["reactive", 18], ["oxygen", 27], ["species", 34], ["(", 42], ["ROS", 43], [")", 46], ["is", 48], ["required", 51], ["for", 60], ["proper", 64], ["cell", 71], ["signaling", 76], [",", 85], ["but", 87], ["must", 91], ["be", 96], ["tightly", 99], ["regulated", 107], ["to", 117], ["minimize", 120], ["deleterious", 129], ["oxidizing", 141], ["effects", 151], [".", 158], ["Activation", 160], ["of", 171], ["the", 174], ["NADPH", 178], ["oxidases", 184], ["(", 193], ["Nox", 194], [")", 197], ["triggers", 199], ["ROS", 208], ["production", 212], ["and", 223], [",", 226], ["thus", 228], [",", 232], ["regulatory", 234], ["mechanisms", 245], ["exist", 256], ["to", 262], ["properly", 265], ["control", 274], ["Nox", 282], ["activity", 286], [".", 294], ["In", 296], ["this", 299], ["study", 304], [",", 309], ["we", 311], ["report", 314], ["a", 321], ["novel", 323], ["mechanism", 329], ["in", 339], ["which", 342], ["Nox1", 348], ["activity", 353], ["is", 362], ["regulated", 365], ["through", 375], ["the", 383], ["proteasomal", 387], ["degradation", 399], ["of", 411], ["Nox", 414], ["organizer", 418], ["1", 428], ["(", 430], ["NoxO1", 431], [")", 436], [".", 437], ["We", 439], ["found", 442], ["that", 448], ["through", 453], ["the", 461], ["interaction", 465], ["between", 477], ["NoxO1", 485], ["and", 491], ["growth", 495], ["receptor", 502], ["-", 510], ["bound", 511], ["protein", 517], ["2", 525], ["(", 527], ["Grb2", 528], [")", 532], [",", 533], ["the", 535], ["Casitas", 539], ["B", 547], ["-", 548], ["lineage", 549], ["lymphoma", 557], ["(", 566], ["Cbl", 567], [")", 570], ["E3", 572], ["ligase", 575], ["was", 582], ["recruited", 586], [",", 595], ["leading", 597], ["to", 605], ["decreased", 608], ["NoxO1", 618], ["stability", 624], ["and", 634], ["a", 638], ["subsequent", 640], ["reduction", 651], ["in", 661], ["ROS", 664], ["generation", 668], ["upon", 679], ["epidermal", 684], ["growth", 694], ["factor", 701], ["(", 708], ["EGF", 709], [")", 712], ["stimulation", 714], [".", 725], ["Additionally", 727], [",", 739], ["we", 741], ["show", 744], ["that", 749], ["EGF", 754], ["-", 757], ["mediated", 758], ["phosphorylation", 767], ["of", 783], ["NoxO1", 786], ["induced", 792], ["its", 800], ["release", 804], ["from", 812], ["Grb2", 817], ["and", 822], ["facilitated", 826], ["its", 838], ["association", 842], ["with", 854], ["Nox", 859], ["activator", 863], ["1", 873], ["(", 875], ["NoxA1", 876], [")", 881], ["to", 883], ["stimulate", 886], ["ROS", 896], ["production", 900], [".", 910], ["Consistently", 912], [",", 924], ["overexpression", 926], ["of", 941], ["Grb2", 944], ["resulted", 949], ["in", 958], ["decreased", 961], ["Nox1", 971], ["activity", 976], [",", 984], ["whereas", 986], ["knockdown", 994], ["of", 1004], ["Grb2", 1007], ["led", 1012], ["to", 1016], ["increased", 1019], ["Nox1", 1029], ["activity", 1034], ["in", 1043], ["response", 1046], ["to", 1055], ["EGF", 1058], [".", 1061], ["CRISPR", 1063], ["/", 1069], ["Cas9-mediated", 1070], ["NoxO1", 1084], ["knockout", 1090], ["in", 1099], ["human", 1102], ["colon", 1108], ["cancer", 1114], ["cells", 1121], ["abrogated", 1127], ["anchorage", 1137], ["-", 1146], ["independent", 1147], ["growth", 1159], ["on", 1166], ["soft", 1169], ["agar", 1174], ["and", 1179], ["tumor", 1183], ["-", 1188], ["forming", 1189], ["ability", 1197], ["in", 1205], ["athymic", 1208], ["nude", 1216], ["mice", 1221], [".", 1225], ["Moreover", 1227], [",", 1235], ["the", 1237], ["expression", 1241], ["and", 1252], ["stability", 1256], ["of", 1266], ["NoxO1", 1269], ["were", 1275], ["significantly", 1280], ["increased", 1294], ["in", 1304], ["human", 1307], ["colon", 1313], ["cancer", 1319], ["tissues", 1326], ["compared", 1334], ["with", 1343], ["normal", 1348], ["colon", 1355], [".", 1360], ["Taken", 1362], ["together", 1368], [",", 1376], ["these", 1378], ["results", 1384], ["support", 1392], ["a", 1400], ["model", 1402], ["whereby", 1408], ["Nox1", 1416], ["activity", 1421], ["and", 1430], ["ROS", 1434], ["generation", 1438], ["are", 1449], ["regulated", 1453], ["by", 1463], ["Grb2/Cbl", 1466], ["-", 1474], ["mediated", 1475], ["proteolysis", 1484], ["of", 1496], ["NoxO1", 1499], ["in", 1505], ["response", 1508], ["to", 1517], ["EGF", 1520], [",", 1523], ["providing", 1525], ["new", 1535], ["insight", 1539], ["into", 1547], ["the", 1552], ["processes", 1556], ["by", 1566], ["which", 1569], ["excessive", 1575], ["ROS", 1585], ["production", 1589], ["may", 1600], ["promote", 1604], ["oncogenic", 1612], ["signaling", 1622], ["to", 1632], ["drive", 1635], ["colorectal", 1641], ["tumorigenesis", 1652], [".", 1665]]}
{"context": "Methylation of lysine residues in the N-terminal tails of histones is thought to represent an important component of the mechanism that regulates chromatin structure. The evolutionarily conserved SET domain occurs in most proteins known to possess histone lysine methyltransferase activity. We present here the crystal structure of a large fragment of human SET7/9 that contains a N-terminal beta-sheet domain as well as the conserved SET domain. Mutagenesis identifies two residues in the C terminus of the protein that appear essential for catalytic activity toward lysine-4 of histone H3. Furthermore, we show how the cofactor AdoMet binds to this domain and present biochemical data supporting the role of invariant residues in catalysis, binding of AdoMet, and interactions with the peptide substrate.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "3f7b340bb0f840e98a015f2346104288", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[72, 73], [30, 31]], "char_spans": [[435, 444], [196, 205]]}]}], "context_tokens": [["Methylation", 0], ["of", 12], ["lysine", 15], ["residues", 22], ["in", 31], ["the", 34], ["N", 38], ["-", 39], ["terminal", 40], ["tails", 49], ["of", 55], ["histones", 58], ["is", 67], ["thought", 70], ["to", 78], ["represent", 81], ["an", 91], ["important", 94], ["component", 104], ["of", 114], ["the", 117], ["mechanism", 121], ["that", 131], ["regulates", 136], ["chromatin", 146], ["structure", 156], [".", 165], ["The", 167], ["evolutionarily", 171], ["conserved", 186], ["SET", 196], ["domain", 200], ["occurs", 207], ["in", 214], ["most", 217], ["proteins", 222], ["known", 231], ["to", 237], ["possess", 240], ["histone", 248], ["lysine", 256], ["methyltransferase", 263], ["activity", 281], [".", 289], ["We", 291], ["present", 294], ["here", 302], ["the", 307], ["crystal", 311], ["structure", 319], ["of", 329], ["a", 332], ["large", 334], ["fragment", 340], ["of", 349], ["human", 352], ["SET7/9", 358], ["that", 365], ["contains", 370], ["a", 379], ["N", 381], ["-", 382], ["terminal", 383], ["beta", 392], ["-", 396], ["sheet", 397], ["domain", 403], ["as", 410], ["well", 413], ["as", 418], ["the", 421], ["conserved", 425], ["SET", 435], ["domain", 439], [".", 445], ["Mutagenesis", 447], ["identifies", 459], ["two", 470], ["residues", 474], ["in", 483], ["the", 486], ["C", 490], ["terminus", 492], ["of", 501], ["the", 504], ["protein", 508], ["that", 516], ["appear", 521], ["essential", 528], ["for", 538], ["catalytic", 542], ["activity", 552], ["toward", 561], ["lysine-4", 568], ["of", 577], ["histone", 580], ["H3", 588], [".", 590], ["Furthermore", 592], [",", 603], ["we", 605], ["show", 608], ["how", 613], ["the", 617], ["cofactor", 621], ["AdoMet", 630], ["binds", 637], ["to", 643], ["this", 646], ["domain", 651], ["and", 658], ["present", 662], ["biochemical", 670], ["data", 682], ["supporting", 687], ["the", 698], ["role", 702], ["of", 707], ["invariant", 710], ["residues", 720], ["in", 729], ["catalysis", 732], [",", 741], ["binding", 743], ["of", 751], ["AdoMet", 754], [",", 760], ["and", 762], ["interactions", 766], ["with", 779], ["the", 784], ["peptide", 788], ["substrate", 796], [".", 805]]}
{"context": "We have determined sequences of PCR-amplified B1 elements from hamster and rat (Myomorpha), chipmunk (Sciuromorpha), and guinea pig (Caviomorpha). Between three and six B1 subfamilies were found in these species. In the phylogenetic analysis B1 sequences of hamster, mouse, and rat clustered separately from those of chipmunk and those of guinea pig. This is consistent with an independent evolution of B1 elements in separate rodent lineages. We exclude the possibility of convergent mutations to explain certain diagnostic characters within the modern B1 quasi-dimers and view these elements as mosaic structures assembling preexisting mutations. Furthermore, the presence of Alu-like structural motifs supports the hypothesis of the monophyletic origin of Alu and B1 repeats, i.e., from a common 7SL RNA-derived retroposing monomeric element.", "qas": [{"question": "From which sequence does the Alu repeat originate from?", "answers": ["7SL RNA"], "qid": "e4f9aab09e074c42b56d239bd1ea6bf9", "question_tokens": [["From", 0], ["which", 5], ["sequence", 11], ["does", 20], ["the", 25], ["Alu", 29], ["repeat", 33], ["originate", 40], ["from", 50], ["?", 54]], "detected_answers": [{"text": "7SL RNA", "token_spans": [[140, 141]], "char_spans": [[799, 805]]}]}], "context_tokens": [["We", 0], ["have", 3], ["determined", 8], ["sequences", 19], ["of", 29], ["PCR", 32], ["-", 35], ["amplified", 36], ["B1", 46], ["elements", 49], ["from", 58], ["hamster", 63], ["and", 71], ["rat", 75], ["(", 79], ["Myomorpha", 80], [")", 89], [",", 90], ["chipmunk", 92], ["(", 101], ["Sciuromorpha", 102], [")", 114], [",", 115], ["and", 117], ["guinea", 121], ["pig", 128], ["(", 132], ["Caviomorpha", 133], [")", 144], [".", 145], ["Between", 147], ["three", 155], ["and", 161], ["six", 165], ["B1", 169], ["subfamilies", 172], ["were", 184], ["found", 189], ["in", 195], ["these", 198], ["species", 204], [".", 211], ["In", 213], ["the", 216], ["phylogenetic", 220], ["analysis", 233], ["B1", 242], ["sequences", 245], ["of", 255], ["hamster", 258], [",", 265], ["mouse", 267], [",", 272], ["and", 274], ["rat", 278], ["clustered", 282], ["separately", 292], ["from", 303], ["those", 308], ["of", 314], ["chipmunk", 317], ["and", 326], ["those", 330], ["of", 336], ["guinea", 339], ["pig", 346], [".", 349], ["This", 351], ["is", 356], ["consistent", 359], ["with", 370], ["an", 375], ["independent", 378], ["evolution", 390], ["of", 400], ["B1", 403], ["elements", 406], ["in", 415], ["separate", 418], ["rodent", 427], ["lineages", 434], [".", 442], ["We", 444], ["exclude", 447], ["the", 455], ["possibility", 459], ["of", 471], ["convergent", 474], ["mutations", 485], ["to", 495], ["explain", 498], ["certain", 506], ["diagnostic", 514], ["characters", 525], ["within", 536], ["the", 543], ["modern", 547], ["B1", 554], ["quasi", 557], ["-", 562], ["dimers", 563], ["and", 570], ["view", 574], ["these", 579], ["elements", 585], ["as", 594], ["mosaic", 597], ["structures", 604], ["assembling", 615], ["preexisting", 626], ["mutations", 638], [".", 647], ["Furthermore", 649], [",", 660], ["the", 662], ["presence", 666], ["of", 675], ["Alu", 678], ["-", 681], ["like", 682], ["structural", 687], ["motifs", 698], ["supports", 705], ["the", 714], ["hypothesis", 718], ["of", 729], ["the", 732], ["monophyletic", 736], ["origin", 749], ["of", 756], ["Alu", 759], ["and", 763], ["B1", 767], ["repeats", 770], [",", 777], ["i.e.", 779], [",", 783], ["from", 785], ["a", 790], ["common", 792], ["7SL", 799], ["RNA", 803], ["-", 806], ["derived", 807], ["retroposing", 815], ["monomeric", 827], ["element", 837], [".", 844]]}
{"context": "Fluorescence in situ hybridization (FISH) technique has been successfully used to detect the BCR-ABL gene fusion in chronic myeloid leukemia (CML) with the classic form of the Philadelphia chromosome (Ph). We applied FISH to study three CML patients showing variant Ph chromosome (either complex or simple type). The results demonstrate that the use of a yeast artificial chromosome (YAC)-derived probe (D107F9) and a cosmid probe (cos-abl 8), specific for BCR and ABL genes respectively, allows also the detection of the BCR-ABL fusion in CML patients with variant Ph.", "qas": [{"question": "Which gene fusion is the result of the \"philadelphia translocation\" or the \"philadelphia chromosome\" mutation?", "answers": ["The BCR/ABL gene fusion", "ABL/BCR fusion"], "qid": "97cb4d97afcb4eb2952fd63b3de90dbf", "question_tokens": [["Which", 0], ["gene", 6], ["fusion", 11], ["is", 18], ["the", 21], ["result", 25], ["of", 32], ["the", 35], ["\"", 39], ["philadelphia", 40], ["translocation", 53], ["\"", 66], ["or", 68], ["the", 71], ["\"", 75], ["philadelphia", 76], ["chromosome", 89], ["\"", 99], ["mutation", 101], ["?", 109]], "detected_answers": [{"text": "The BCR/ABL gene fusion", "token_spans": [[15, 19]], "char_spans": [[93, 111]]}]}], "context_tokens": [["Fluorescence", 0], ["in", 13], ["situ", 16], ["hybridization", 21], ["(", 35], ["FISH", 36], [")", 40], ["technique", 42], ["has", 52], ["been", 56], ["successfully", 61], ["used", 74], ["to", 79], ["detect", 82], ["the", 89], ["BCR", 93], ["-", 96], ["ABL", 97], ["gene", 101], ["fusion", 106], ["in", 113], ["chronic", 116], ["myeloid", 124], ["leukemia", 132], ["(", 141], ["CML", 142], [")", 145], ["with", 147], ["the", 152], ["classic", 156], ["form", 164], ["of", 169], ["the", 172], ["Philadelphia", 176], ["chromosome", 189], ["(", 200], ["Ph", 201], [")", 203], [".", 204], ["We", 206], ["applied", 209], ["FISH", 217], ["to", 222], ["study", 225], ["three", 231], ["CML", 237], ["patients", 241], ["showing", 250], ["variant", 258], ["Ph", 266], ["chromosome", 269], ["(", 280], ["either", 281], ["complex", 288], ["or", 296], ["simple", 299], ["type", 306], [")", 310], [".", 311], ["The", 313], ["results", 317], ["demonstrate", 325], ["that", 337], ["the", 342], ["use", 346], ["of", 350], ["a", 353], ["yeast", 355], ["artificial", 361], ["chromosome", 372], ["(", 383], ["YAC)-derived", 384], ["probe", 397], ["(", 403], ["D107F9", 404], [")", 410], ["and", 412], ["a", 416], ["cosmid", 418], ["probe", 425], ["(", 431], ["cos", 432], ["-", 435], ["abl", 436], ["8)", 440], [",", 442], ["specific", 444], ["for", 453], ["BCR", 457], ["and", 461], ["ABL", 465], ["genes", 469], ["respectively", 475], [",", 487], ["allows", 489], ["also", 496], ["the", 501], ["detection", 505], ["of", 515], ["the", 518], ["BCR", 522], ["-", 525], ["ABL", 526], ["fusion", 530], ["in", 537], ["CML", 540], ["patients", 544], ["with", 553], ["variant", 558], ["Ph", 566], [".", 568]]}
{"context": "The Malaria Policy Advisory Committee to the World Health Organization met in Geneva, Switzerland from 13 to 15 March, 2013. This article provides a summary of the discussions, conclusions and recommendations from that meeting.Meeting sessions included: a review of the efficacy of artemisinin-based combination therapy in Guyana and Suriname; the outcomes from a consultation on non-malaria febrile illness; the outcomes from the second meeting of the Evidence Review Group on malaria burden estimation; an update on the review of the WHO Guidelines for the Treatment of Malaria; an update regarding progress on the constitution of the vector control Technical Expert Group; updates on the RTS, S/AS01 vaccine and the malaria vaccine technology roadmap; financing and resource allocation for malaria control; malaria surveillance and the need for a surveillance, monitoring and evaluation Technical Expert Group; criteria and classification related to malaria elimination; the next meeting of the Evidence Review Group on Intermittent Preventive Treatment in pregnancy; an update on the soon-to-be launched Elimination Scenario Planning Tool; and an update on the process for the Global Technical Strategy for Malaria Control and Elimination (2016-2025).Policy statements, position statements, and guidelines that arise from the MPAC meeting conclusions and recommendations will be formally issued and disseminated to World Health Organization Member States by the World Health Organization Global Malaria Programme.", "qas": [{"question": "RTS S AS01 vaccine was developed to prevent which disease?", "answers": ["malaria"], "qid": "08c2300228d848599dbb36a771fdc904", "question_tokens": [["RTS", 0], ["S", 4], ["AS01", 6], ["vaccine", 11], ["was", 19], ["developed", 23], ["to", 33], ["prevent", 36], ["which", 44], ["disease", 50], ["?", 57]], "detected_answers": [{"text": "malaria", "token_spans": [[128, 128], [83, 83], [67, 67], [138, 138], [141, 141], [100, 100], [249, 249], [162, 162], [1, 1], [207, 207]], "char_spans": [[719, 725], [478, 484], [384, 390], [793, 799], [810, 816], [572, 578], [1499, 1505], [953, 959], [4, 10], [1211, 1217]]}]}], "context_tokens": [["The", 0], ["Malaria", 4], ["Policy", 12], ["Advisory", 19], ["Committee", 28], ["to", 38], ["the", 41], ["World", 45], ["Health", 51], ["Organization", 58], ["met", 71], ["in", 75], ["Geneva", 78], [",", 84], ["Switzerland", 86], ["from", 98], ["13", 103], ["to", 106], ["15", 109], ["March", 112], [",", 117], ["2013", 119], [".", 123], ["This", 125], ["article", 130], ["provides", 138], ["a", 147], ["summary", 149], ["of", 157], ["the", 160], ["discussions", 164], [",", 175], ["conclusions", 177], ["and", 189], ["recommendations", 193], ["from", 209], ["that", 214], ["meeting", 219], [".", 226], ["Meeting", 227], ["sessions", 235], ["included", 244], [":", 252], ["a", 254], ["review", 256], ["of", 263], ["the", 266], ["efficacy", 270], ["of", 279], ["artemisinin", 282], ["-", 293], ["based", 294], ["combination", 300], ["therapy", 312], ["in", 320], ["Guyana", 323], ["and", 330], ["Suriname", 334], [";", 342], ["the", 344], ["outcomes", 348], ["from", 357], ["a", 362], ["consultation", 364], ["on", 377], ["non", 380], ["-", 383], ["malaria", 384], ["febrile", 392], ["illness", 400], [";", 407], ["the", 409], ["outcomes", 413], ["from", 422], ["the", 427], ["second", 431], ["meeting", 438], ["of", 446], ["the", 449], ["Evidence", 453], ["Review", 462], ["Group", 469], ["on", 475], ["malaria", 478], ["burden", 486], ["estimation", 493], [";", 503], ["an", 505], ["update", 508], ["on", 515], ["the", 518], ["review", 522], ["of", 529], ["the", 532], ["WHO", 536], ["Guidelines", 540], ["for", 551], ["the", 555], ["Treatment", 559], ["of", 569], ["Malaria", 572], [";", 579], ["an", 581], ["update", 584], ["regarding", 591], ["progress", 601], ["on", 610], ["the", 613], ["constitution", 617], ["of", 630], ["the", 633], ["vector", 637], ["control", 644], ["Technical", 652], ["Expert", 662], ["Group", 669], [";", 674], ["updates", 676], ["on", 684], ["the", 687], ["RTS", 691], [",", 694], ["S", 696], ["/", 697], ["AS01", 698], ["vaccine", 703], ["and", 711], ["the", 715], ["malaria", 719], ["vaccine", 727], ["technology", 735], ["roadmap", 746], [";", 753], ["financing", 755], ["and", 765], ["resource", 769], ["allocation", 778], ["for", 789], ["malaria", 793], ["control", 801], [";", 808], ["malaria", 810], ["surveillance", 818], ["and", 831], ["the", 835], ["need", 839], ["for", 844], ["a", 848], ["surveillance", 850], [",", 862], ["monitoring", 864], ["and", 875], ["evaluation", 879], ["Technical", 890], ["Expert", 900], ["Group", 907], [";", 912], ["criteria", 914], ["and", 923], ["classification", 927], ["related", 942], ["to", 950], ["malaria", 953], ["elimination", 961], [";", 972], ["the", 974], ["next", 978], ["meeting", 983], ["of", 991], ["the", 994], ["Evidence", 998], ["Review", 1007], ["Group", 1014], ["on", 1020], ["Intermittent", 1023], ["Preventive", 1036], ["Treatment", 1047], ["in", 1057], ["pregnancy", 1060], [";", 1069], ["an", 1071], ["update", 1074], ["on", 1081], ["the", 1084], ["soon", 1088], ["-", 1092], ["to", 1093], ["-", 1095], ["be", 1096], ["launched", 1099], ["Elimination", 1108], ["Scenario", 1120], ["Planning", 1129], ["Tool", 1138], [";", 1142], ["and", 1144], ["an", 1148], ["update", 1151], ["on", 1158], ["the", 1161], ["process", 1165], ["for", 1173], ["the", 1177], ["Global", 1181], ["Technical", 1188], ["Strategy", 1198], ["for", 1207], ["Malaria", 1211], ["Control", 1219], ["and", 1227], ["Elimination", 1231], ["(", 1243], ["2016", 1244], ["-", 1248], ["2025).Policy", 1249], ["statements", 1262], [",", 1272], ["position", 1274], ["statements", 1283], [",", 1293], ["and", 1295], ["guidelines", 1299], ["that", 1310], ["arise", 1315], ["from", 1321], ["the", 1326], ["MPAC", 1330], ["meeting", 1335], ["conclusions", 1343], ["and", 1355], ["recommendations", 1359], ["will", 1375], ["be", 1380], ["formally", 1383], ["issued", 1392], ["and", 1399], ["disseminated", 1403], ["to", 1416], ["World", 1419], ["Health", 1425], ["Organization", 1432], ["Member", 1445], ["States", 1452], ["by", 1459], ["the", 1462], ["World", 1466], ["Health", 1472], ["Organization", 1479], ["Global", 1492], ["Malaria", 1499], ["Programme", 1507], [".", 1516]]}
{"context": "The organization of chromatin into higher-order structures influences chromosome function and epigenetic gene regulation. Higher-order chromatin has been proposed to be nucleated by the covalent modification of histone tails and the subsequent establishment of chromosomal subdomains by non-histone modifier factors. Here we show that human SUV39H1 and murine Suv39h1--mammalian homologues of Drosophila Su(var)3-9 and of Schizosaccharomyces pombe clr4--encode histone H3-specific methyltransferases that selectively methylate lysine 9 of the amino terminus of histone H3 in vitro. We mapped the catalytic motif to the evolutionarily conserved SET domain, which requires adjacent cysteine-rich regions to confer histone methyltransferase activity. Methylation of lysine 9 interferes with phosphorylation of serine 10, but is also influenced by pre-existing modifications in the amino terminus of H3. In vivo, deregulated SUV39H1 or disrupted Suv39h activity modulate H3 serine 10 phosphorylation in native chromatin and induce aberrant mitotic divisions. Our data reveal a functional interdependence of site-specific H3 tail modifications and suggest a dynamic mechanism for the regulation of higher-order chromatin.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "d2b96659e02a4db4a080036e2a0c4128", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[99, 100]], "char_spans": [[644, 653]]}]}], "context_tokens": [["The", 0], ["organization", 4], ["of", 17], ["chromatin", 20], ["into", 30], ["higher", 35], ["-", 41], ["order", 42], ["structures", 48], ["influences", 59], ["chromosome", 70], ["function", 81], ["and", 90], ["epigenetic", 94], ["gene", 105], ["regulation", 110], [".", 120], ["Higher", 122], ["-", 128], ["order", 129], ["chromatin", 135], ["has", 145], ["been", 149], ["proposed", 154], ["to", 163], ["be", 166], ["nucleated", 169], ["by", 179], ["the", 182], ["covalent", 186], ["modification", 195], ["of", 208], ["histone", 211], ["tails", 219], ["and", 225], ["the", 229], ["subsequent", 233], ["establishment", 244], ["of", 258], ["chromosomal", 261], ["subdomains", 273], ["by", 284], ["non", 287], ["-", 290], ["histone", 291], ["modifier", 299], ["factors", 308], [".", 315], ["Here", 317], ["we", 322], ["show", 325], ["that", 330], ["human", 335], ["SUV39H1", 341], ["and", 349], ["murine", 353], ["Suv39h1", 360], ["-", 367], ["-mammalian", 368], ["homologues", 379], ["of", 390], ["Drosophila", 393], ["Su(var)3", 404], ["-", 412], ["9", 413], ["and", 415], ["of", 419], ["Schizosaccharomyces", 422], ["pombe", 442], ["clr4", 448], ["-", 452], ["-encode", 453], ["histone", 461], ["H3-specific", 469], ["methyltransferases", 481], ["that", 500], ["selectively", 505], ["methylate", 517], ["lysine", 527], ["9", 534], ["of", 536], ["the", 539], ["amino", 543], ["terminus", 549], ["of", 558], ["histone", 561], ["H3", 569], ["in", 572], ["vitro", 575], [".", 580], ["We", 582], ["mapped", 585], ["the", 592], ["catalytic", 596], ["motif", 606], ["to", 612], ["the", 615], ["evolutionarily", 619], ["conserved", 634], ["SET", 644], ["domain", 648], [",", 654], ["which", 656], ["requires", 662], ["adjacent", 671], ["cysteine", 680], ["-", 688], ["rich", 689], ["regions", 694], ["to", 702], ["confer", 705], ["histone", 712], ["methyltransferase", 720], ["activity", 738], [".", 746], ["Methylation", 748], ["of", 760], ["lysine", 763], ["9", 770], ["interferes", 772], ["with", 783], ["phosphorylation", 788], ["of", 804], ["serine", 807], ["10", 814], [",", 816], ["but", 818], ["is", 822], ["also", 825], ["influenced", 830], ["by", 841], ["pre", 844], ["-", 847], ["existing", 848], ["modifications", 857], ["in", 871], ["the", 874], ["amino", 878], ["terminus", 884], ["of", 893], ["H3", 896], [".", 898], ["In", 900], ["vivo", 903], [",", 907], ["deregulated", 909], ["SUV39H1", 921], ["or", 929], ["disrupted", 932], ["Suv39h", 942], ["activity", 949], ["modulate", 958], ["H3", 967], ["serine", 970], ["10", 977], ["phosphorylation", 980], ["in", 996], ["native", 999], ["chromatin", 1006], ["and", 1016], ["induce", 1020], ["aberrant", 1027], ["mitotic", 1036], ["divisions", 1044], [".", 1053], ["Our", 1055], ["data", 1059], ["reveal", 1064], ["a", 1071], ["functional", 1073], ["interdependence", 1084], ["of", 1100], ["site", 1103], ["-", 1107], ["specific", 1108], ["H3", 1117], ["tail", 1120], ["modifications", 1125], ["and", 1139], ["suggest", 1143], ["a", 1151], ["dynamic", 1153], ["mechanism", 1161], ["for", 1171], ["the", 1175], ["regulation", 1179], ["of", 1190], ["higher", 1193], ["-", 1199], ["order", 1200], ["chromatin", 1206], [".", 1215]]}
{"context": "Haploinsufficiency of the NSD1 gene due to 5q35 microdeletions or intragenic mutations is the major cause of Sotos syndrome characterized by generalized overgrowth, large hands and feet with advanced bone age, craniofacial dysmorphic features, learning disability, and possible susceptibility to tumors. Here, we report on a 14-month-old boy with a reverse phenotype of Sotos syndrome due to the reciprocal duplication of the 5q35.3 region, including the NSD1 gene, detected by array CGH. The phenotype includes delayed bone age, microcephaly, seizures, and failure to thrive. Our case suggests that the gene dosage effect of the NSD1 gene is the likely cause for the reversed phenotype of Sotos syndrome in this patient.", "qas": [{"question": "Which gene is responsible for the development of Sotos syndrome?", "answers": ["NSD1 gene"], "qid": "4dacfcd587cf4e6f8eed4e508e7a454e", "question_tokens": [["Which", 0], ["gene", 6], ["is", 11], ["responsible", 14], ["for", 26], ["the", 30], ["development", 34], ["of", 46], ["Sotos", 49], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "NSD1 gene", "token_spans": [[109, 110], [75, 76], [3, 4]], "char_spans": [[630, 638], [455, 463], [26, 34]]}]}], "context_tokens": [["Haploinsufficiency", 0], ["of", 19], ["the", 22], ["NSD1", 26], ["gene", 31], ["due", 36], ["to", 40], ["5q35", 43], ["microdeletions", 48], ["or", 63], ["intragenic", 66], ["mutations", 77], ["is", 87], ["the", 90], ["major", 94], ["cause", 100], ["of", 106], ["Sotos", 109], ["syndrome", 115], ["characterized", 124], ["by", 138], ["generalized", 141], ["overgrowth", 153], [",", 163], ["large", 165], ["hands", 171], ["and", 177], ["feet", 181], ["with", 186], ["advanced", 191], ["bone", 200], ["age", 205], [",", 208], ["craniofacial", 210], ["dysmorphic", 223], ["features", 234], [",", 242], ["learning", 244], ["disability", 253], [",", 263], ["and", 265], ["possible", 269], ["susceptibility", 278], ["to", 293], ["tumors", 296], [".", 302], ["Here", 304], [",", 308], ["we", 310], ["report", 313], ["on", 320], ["a", 323], ["14-month", 325], ["-", 333], ["old", 334], ["boy", 338], ["with", 342], ["a", 347], ["reverse", 349], ["phenotype", 357], ["of", 367], ["Sotos", 370], ["syndrome", 376], ["due", 385], ["to", 389], ["the", 392], ["reciprocal", 396], ["duplication", 407], ["of", 419], ["the", 422], ["5q35.3", 426], ["region", 433], [",", 439], ["including", 441], ["the", 451], ["NSD1", 455], ["gene", 460], [",", 464], ["detected", 466], ["by", 475], ["array", 478], ["CGH", 484], [".", 487], ["The", 489], ["phenotype", 493], ["includes", 503], ["delayed", 512], ["bone", 520], ["age", 525], [",", 528], ["microcephaly", 530], [",", 542], ["seizures", 544], [",", 552], ["and", 554], ["failure", 558], ["to", 566], ["thrive", 569], [".", 575], ["Our", 577], ["case", 581], ["suggests", 586], ["that", 595], ["the", 600], ["gene", 604], ["dosage", 609], ["effect", 616], ["of", 623], ["the", 626], ["NSD1", 630], ["gene", 635], ["is", 640], ["the", 643], ["likely", 647], ["cause", 654], ["for", 660], ["the", 664], ["reversed", 668], ["phenotype", 677], ["of", 687], ["Sotos", 690], ["syndrome", 696], ["in", 705], ["this", 708], ["patient", 713], [".", 720]]}
{"context": "Romano-Ward syndrome is an autosomal dominant long-QT syndrome (LQTS) that predisposes affected individuals to sudden death from tachyarrhythmias. We investigated the molecular basis of LQTS in a Taiwanese kindred. Clinical and genetic analyses revealed that a mutation was linked to the human ether-a-go-go-related gene (HERG). The coding sequences and exon-intron borders of HERG were amplified by means of polymerase chain reaction and subjected to single-strand conformation polymorphism (SSCP) analysis. An exon with an aberrant SSCP pattern was cloned and sequenced to study the molecular lesion. A C-->T transition in codon 614, leading to substitution of a valine for an alanine residue in the pore region of the HERG protein, was identified. Analysis with Bsp12861 endonuclease digestion showed the mutation to be present in all affected family members. Given that an unaffected paternal uncle had inherited the same allele from the grandfather as the proband's father, a de novo mutation had apparently occurred in the father and was transmitted to his offspring. In addition to offering presymptomatic genetic diagnosis, identification of the disease-causing mutation may suggest new therapeutic approaches for treatment and prevention of this cardiovascular disease.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "d838cda896684309ac3a07c8d28d403e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[6, 7]], "char_spans": [[27, 44]]}]}], "context_tokens": [["Romano", 0], ["-", 6], ["Ward", 7], ["syndrome", 12], ["is", 21], ["an", 24], ["autosomal", 27], ["dominant", 37], ["long", 46], ["-", 50], ["QT", 51], ["syndrome", 54], ["(", 63], ["LQTS", 64], [")", 68], ["that", 70], ["predisposes", 75], ["affected", 87], ["individuals", 96], ["to", 108], ["sudden", 111], ["death", 118], ["from", 124], ["tachyarrhythmias", 129], [".", 145], ["We", 147], ["investigated", 150], ["the", 163], ["molecular", 167], ["basis", 177], ["of", 183], ["LQTS", 186], ["in", 191], ["a", 194], ["Taiwanese", 196], ["kindred", 206], [".", 213], ["Clinical", 215], ["and", 224], ["genetic", 228], ["analyses", 236], ["revealed", 245], ["that", 254], ["a", 259], ["mutation", 261], ["was", 270], ["linked", 274], ["to", 281], ["the", 284], ["human", 288], ["ether", 294], ["-", 299], ["a", 300], ["-", 301], ["go", 302], ["-", 304], ["go", 305], ["-", 307], ["related", 308], ["gene", 316], ["(", 321], ["HERG", 322], [")", 326], [".", 327], ["The", 329], ["coding", 333], ["sequences", 340], ["and", 350], ["exon", 354], ["-", 358], ["intron", 359], ["borders", 366], ["of", 374], ["HERG", 377], ["were", 382], ["amplified", 387], ["by", 397], ["means", 400], ["of", 406], ["polymerase", 409], ["chain", 420], ["reaction", 426], ["and", 435], ["subjected", 439], ["to", 449], ["single", 452], ["-", 458], ["strand", 459], ["conformation", 466], ["polymorphism", 479], ["(", 492], ["SSCP", 493], [")", 497], ["analysis", 499], [".", 507], ["An", 509], ["exon", 512], ["with", 517], ["an", 522], ["aberrant", 525], ["SSCP", 534], ["pattern", 539], ["was", 547], ["cloned", 551], ["and", 558], ["sequenced", 562], ["to", 572], ["study", 575], ["the", 581], ["molecular", 585], ["lesion", 595], [".", 601], ["A", 603], ["C-->T", 605], ["transition", 611], ["in", 622], ["codon", 625], ["614", 631], [",", 634], ["leading", 636], ["to", 644], ["substitution", 647], ["of", 660], ["a", 663], ["valine", 665], ["for", 672], ["an", 676], ["alanine", 679], ["residue", 687], ["in", 695], ["the", 698], ["pore", 702], ["region", 707], ["of", 714], ["the", 717], ["HERG", 721], ["protein", 726], [",", 733], ["was", 735], ["identified", 739], [".", 749], ["Analysis", 751], ["with", 760], ["Bsp12861", 765], ["endonuclease", 774], ["digestion", 787], ["showed", 797], ["the", 804], ["mutation", 808], ["to", 817], ["be", 820], ["present", 823], ["in", 831], ["all", 834], ["affected", 838], ["family", 847], ["members", 854], [".", 861], ["Given", 863], ["that", 869], ["an", 874], ["unaffected", 877], ["paternal", 888], ["uncle", 897], ["had", 903], ["inherited", 907], ["the", 917], ["same", 921], ["allele", 926], ["from", 933], ["the", 938], ["grandfather", 942], ["as", 954], ["the", 957], ["proband", 961], ["'s", 968], ["father", 971], [",", 977], ["a", 979], ["de", 981], ["novo", 984], ["mutation", 989], ["had", 998], ["apparently", 1002], ["occurred", 1013], ["in", 1022], ["the", 1025], ["father", 1029], ["and", 1036], ["was", 1040], ["transmitted", 1044], ["to", 1056], ["his", 1059], ["offspring", 1063], [".", 1072], ["In", 1074], ["addition", 1077], ["to", 1086], ["offering", 1089], ["presymptomatic", 1098], ["genetic", 1113], ["diagnosis", 1121], [",", 1130], ["identification", 1132], ["of", 1147], ["the", 1150], ["disease", 1154], ["-", 1161], ["causing", 1162], ["mutation", 1170], ["may", 1179], ["suggest", 1183], ["new", 1191], ["therapeutic", 1195], ["approaches", 1207], ["for", 1218], ["treatment", 1222], ["and", 1232], ["prevention", 1236], ["of", 1247], ["this", 1250], ["cardiovascular", 1255], ["disease", 1270], [".", 1277]]}
{"context": "Facioscapulohumeral dystrophy (FSHD) is an autosomal-dominant disorder characterized by weakness of the face, upper arm, shoulder, and lower limb musculature, with an onset between the first and third decades. Coats disease is a congenital disorder of retinal vascular development characterized by unilateral peripheral retinal telangiectasia and progressive subretinal and intraretinal exudation. This condition has a predilection for children and is usually isolated. Retinal vascular changes similar to those seen in Coats disease have been demonstrated by fluorescein angiography in 40% to 75% of patients with FSHD. Most patients have asymptomatic retinal telangiectasia found at ocular screening in adulthood after diagnosis of FSHD. We report a 7-month-old infant with bilateral Coats-like retinopathy in which the eye disease was discovered before findings of FSHD were clinically evident. To our knowledge, this patient represents the youngest reported case of preclinical FSHD with ocular disease.", "qas": [{"question": "What is the mode of inheritance of Facioscapulohumeral muscular dystrophy (FSHD)?", "answers": ["autosomal-dominant", "autosomal dominant"], "qid": "a40ec3c2b8dd4fa4a955eb489be36aa0", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Facioscapulohumeral", 35], ["muscular", 55], ["dystrophy", 64], ["(", 74], ["FSHD", 75], [")", 79], ["?", 80]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[7, 9]], "char_spans": [[43, 60]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["dystrophy", 20], ["(", 30], ["FSHD", 31], [")", 35], ["is", 37], ["an", 40], ["autosomal", 43], ["-", 52], ["dominant", 53], ["disorder", 62], ["characterized", 71], ["by", 85], ["weakness", 88], ["of", 97], ["the", 100], ["face", 104], [",", 108], ["upper", 110], ["arm", 116], [",", 119], ["shoulder", 121], [",", 129], ["and", 131], ["lower", 135], ["limb", 141], ["musculature", 146], [",", 157], ["with", 159], ["an", 164], ["onset", 167], ["between", 173], ["the", 181], ["first", 185], ["and", 191], ["third", 195], ["decades", 201], [".", 208], ["Coats", 210], ["disease", 216], ["is", 224], ["a", 227], ["congenital", 229], ["disorder", 240], ["of", 249], ["retinal", 252], ["vascular", 260], ["development", 269], ["characterized", 281], ["by", 295], ["unilateral", 298], ["peripheral", 309], ["retinal", 320], ["telangiectasia", 328], ["and", 343], ["progressive", 347], ["subretinal", 359], ["and", 370], ["intraretinal", 374], ["exudation", 387], [".", 396], ["This", 398], ["condition", 403], ["has", 413], ["a", 417], ["predilection", 419], ["for", 432], ["children", 436], ["and", 445], ["is", 449], ["usually", 452], ["isolated", 460], [".", 468], ["Retinal", 470], ["vascular", 478], ["changes", 487], ["similar", 495], ["to", 503], ["those", 506], ["seen", 512], ["in", 517], ["Coats", 520], ["disease", 526], ["have", 534], ["been", 539], ["demonstrated", 544], ["by", 557], ["fluorescein", 560], ["angiography", 572], ["in", 584], ["40", 587], ["%", 589], ["to", 591], ["75", 594], ["%", 596], ["of", 598], ["patients", 601], ["with", 610], ["FSHD", 615], [".", 619], ["Most", 621], ["patients", 626], ["have", 635], ["asymptomatic", 640], ["retinal", 653], ["telangiectasia", 661], ["found", 676], ["at", 682], ["ocular", 685], ["screening", 692], ["in", 702], ["adulthood", 705], ["after", 715], ["diagnosis", 721], ["of", 731], ["FSHD", 734], [".", 738], ["We", 740], ["report", 743], ["a", 750], ["7-month", 752], ["-", 759], ["old", 760], ["infant", 764], ["with", 771], ["bilateral", 776], ["Coats", 786], ["-", 791], ["like", 792], ["retinopathy", 797], ["in", 809], ["which", 812], ["the", 818], ["eye", 822], ["disease", 826], ["was", 834], ["discovered", 838], ["before", 849], ["findings", 856], ["of", 865], ["FSHD", 868], ["were", 873], ["clinically", 878], ["evident", 889], [".", 896], ["To", 898], ["our", 901], ["knowledge", 905], [",", 914], ["this", 916], ["patient", 921], ["represents", 929], ["the", 940], ["youngest", 944], ["reported", 953], ["case", 962], ["of", 967], ["preclinical", 970], ["FSHD", 982], ["with", 987], ["ocular", 992], ["disease", 999], [".", 1006]]}
{"context": "To investigate whether gender is an independent factor associated with disease expression in early rheumatoid arthritis (RA) patients. 438 patients with early RA (disease duration less than one year) were studied. They all were patients with early RA who presented at the Rheumatology Clinic of the University Hospital of Ioannina during the period 1991-2000. All patients fulfilled the American College of Rheumatology criteria for RA. The demographic, clinical, laboratory, radiological and therapeutic characteristics of the disease at diagnosis, and at the last follow-up were analyzed according to gender. We studied 312 women and 126 men with early RA. The female to male ratio was 2.5:1 and the mean age at diagnosis was 49.4 +/- 14.9 years for women and 55.3 +/-15.6 years for men (P < 0.0003). Women had a longer duration of follow-up (P < 0.0003). There were no differences between genders in the general symptoms or the simmetricity of joint involvement at at disease onset. However at disease onset women had a higher erythrocyte sedimentation rate (ESR) (> 30 mm/1st hour), although there were no significant differences between the two groups concerninig the rest of the clinical, laboratory and radiological findings. At the last follow-up women still had a higher ESR (>30 min/1st hour), but no significant differences were found between the two groups concerning the rest of the parameters investigated independently of the follow-up duration. Finally, women and men showed the same degree of radiological changes and functional ability and were treated similarly except for the more frequent use of hydroxychloroquine in women. It seems that gender does not signficantly influence the expression of RA.", "qas": [{"question": "Is Rheumatoid Arthritis more common in men or women?", "answers": ["Women"], "qid": "b3aff0ff72834de8bbd3a3ca13a60532", "question_tokens": [["Is", 0], ["Rheumatoid", 3], ["Arthritis", 14], ["more", 24], ["common", 29], ["in", 36], ["men", 39], ["or", 43], ["women", 46], ["?", 51]], "detected_answers": [{"text": "Women", "token_spans": [[235, 235], [275, 275], [150, 150], [301, 301], [108, 108], [136, 136], [190, 190]], "char_spans": [[1255, 1259], [1470, 1474], [803, 807], [1639, 1643], [626, 630], [752, 756], [1011, 1015]]}]}], "context_tokens": [["To", 0], ["investigate", 3], ["whether", 15], ["gender", 23], ["is", 30], ["an", 33], ["independent", 36], ["factor", 48], ["associated", 55], ["with", 66], ["disease", 71], ["expression", 79], ["in", 90], ["early", 93], ["rheumatoid", 99], ["arthritis", 110], ["(", 120], ["RA", 121], [")", 123], ["patients", 125], [".", 133], ["438", 135], ["patients", 139], ["with", 148], ["early", 153], ["RA", 159], ["(", 162], ["disease", 163], ["duration", 171], ["less", 180], ["than", 185], ["one", 190], ["year", 194], [")", 198], ["were", 200], ["studied", 205], [".", 212], ["They", 214], ["all", 219], ["were", 223], ["patients", 228], ["with", 237], ["early", 242], ["RA", 248], ["who", 251], ["presented", 255], ["at", 265], ["the", 268], ["Rheumatology", 272], ["Clinic", 285], ["of", 292], ["the", 295], ["University", 299], ["Hospital", 310], ["of", 319], ["Ioannina", 322], ["during", 331], ["the", 338], ["period", 342], ["1991", 349], ["-", 353], ["2000", 354], [".", 358], ["All", 360], ["patients", 364], ["fulfilled", 373], ["the", 383], ["American", 387], ["College", 396], ["of", 404], ["Rheumatology", 407], ["criteria", 420], ["for", 429], ["RA", 433], [".", 435], ["The", 437], ["demographic", 441], [",", 452], ["clinical", 454], [",", 462], ["laboratory", 464], [",", 474], ["radiological", 476], ["and", 489], ["therapeutic", 493], ["characteristics", 505], ["of", 521], ["the", 524], ["disease", 528], ["at", 536], ["diagnosis", 539], [",", 548], ["and", 550], ["at", 554], ["the", 557], ["last", 561], ["follow", 566], ["-", 572], ["up", 573], ["were", 576], ["analyzed", 581], ["according", 590], ["to", 600], ["gender", 603], [".", 609], ["We", 611], ["studied", 614], ["312", 622], ["women", 626], ["and", 632], ["126", 636], ["men", 640], ["with", 644], ["early", 649], ["RA", 655], [".", 657], ["The", 659], ["female", 663], ["to", 670], ["male", 673], ["ratio", 678], ["was", 684], ["2.5:1", 688], ["and", 694], ["the", 698], ["mean", 702], ["age", 707], ["at", 711], ["diagnosis", 714], ["was", 724], ["49.4", 728], ["+", 733], ["/-", 734], ["14.9", 737], ["years", 742], ["for", 748], ["women", 752], ["and", 758], ["55.3", 762], ["+", 767], ["/-15.6", 768], ["years", 775], ["for", 781], ["men", 785], ["(", 789], ["P", 790], ["<", 792], ["0.0003", 794], [")", 800], [".", 801], ["Women", 803], ["had", 809], ["a", 813], ["longer", 815], ["duration", 822], ["of", 831], ["follow", 834], ["-", 840], ["up", 841], ["(", 844], ["P", 845], ["<", 847], ["0.0003", 849], [")", 855], [".", 856], ["There", 858], ["were", 864], ["no", 869], ["differences", 872], ["between", 884], ["genders", 892], ["in", 900], ["the", 903], ["general", 907], ["symptoms", 915], ["or", 924], ["the", 927], ["simmetricity", 931], ["of", 944], ["joint", 947], ["involvement", 953], ["at", 965], ["at", 968], ["disease", 971], ["onset", 979], [".", 984], ["However", 986], ["at", 994], ["disease", 997], ["onset", 1005], ["women", 1011], ["had", 1017], ["a", 1021], ["higher", 1023], ["erythrocyte", 1030], ["sedimentation", 1042], ["rate", 1056], ["(", 1061], ["ESR", 1062], [")", 1065], ["(", 1067], [">", 1068], ["30", 1070], ["mm/1st", 1073], ["hour", 1080], [")", 1084], [",", 1085], ["although", 1087], ["there", 1096], ["were", 1102], ["no", 1107], ["significant", 1110], ["differences", 1122], ["between", 1134], ["the", 1142], ["two", 1146], ["groups", 1150], ["concerninig", 1157], ["the", 1169], ["rest", 1173], ["of", 1178], ["the", 1181], ["clinical", 1185], [",", 1193], ["laboratory", 1195], ["and", 1206], ["radiological", 1210], ["findings", 1223], [".", 1231], ["At", 1233], ["the", 1236], ["last", 1240], ["follow", 1245], ["-", 1251], ["up", 1252], ["women", 1255], ["still", 1261], ["had", 1267], ["a", 1271], ["higher", 1273], ["ESR", 1280], ["(", 1284], [">", 1285], ["30", 1286], ["min/1st", 1289], ["hour", 1297], [")", 1301], [",", 1302], ["but", 1304], ["no", 1308], ["significant", 1311], ["differences", 1323], ["were", 1335], ["found", 1340], ["between", 1346], ["the", 1354], ["two", 1358], ["groups", 1362], ["concerning", 1369], ["the", 1380], ["rest", 1384], ["of", 1389], ["the", 1392], ["parameters", 1396], ["investigated", 1407], ["independently", 1420], ["of", 1434], ["the", 1437], ["follow", 1441], ["-", 1447], ["up", 1448], ["duration", 1451], [".", 1459], ["Finally", 1461], [",", 1468], ["women", 1470], ["and", 1476], ["men", 1480], ["showed", 1484], ["the", 1491], ["same", 1495], ["degree", 1500], ["of", 1507], ["radiological", 1510], ["changes", 1523], ["and", 1531], ["functional", 1535], ["ability", 1546], ["and", 1554], ["were", 1558], ["treated", 1563], ["similarly", 1571], ["except", 1581], ["for", 1588], ["the", 1592], ["more", 1596], ["frequent", 1601], ["use", 1610], ["of", 1614], ["hydroxychloroquine", 1617], ["in", 1636], ["women", 1639], [".", 1644], ["It", 1646], ["seems", 1649], ["that", 1655], ["gender", 1660], ["does", 1667], ["not", 1672], ["signficantly", 1676], ["influence", 1689], ["the", 1699], ["expression", 1703], ["of", 1714], ["RA", 1717], [".", 1719]]}
{"context": "Sleep disorders are frequent comorbidities in neurologic patients. This review focuses on clinical aspects and prognosis of 3 neurologic sleep disorders: narcolepsy, restless legs syndrome/Willis-Ekbom disease (RLS/WED), and REM sleep behavior disorder (RBD). Narcolepsy causes pervasive, enduring excessive daytime sleepiness, adversely affecting patients' daily functioning. RLS/WED is characterized by an uncomfortable urge to move the legs before sleep, often evolving toward augmentation and resulting in daylong bothersome symptoms. RBD causes potentially injurious dream enactment behaviors that often signify future evolution of overt synucleinopathy neurodegeneration in as many as 81% of patients. Timely recognition, referral for polysomnography, and longitudinal follow-up of narcolepsy, RLS/WED, and RBD patients are imperatives for neurologists in providing quality comprehensive patient care.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "2e85dc045cba4859af5eff8296aecc96", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[25, 27]], "char_spans": [[166, 187]]}]}], "context_tokens": [["Sleep", 0], ["disorders", 6], ["are", 16], ["frequent", 20], ["comorbidities", 29], ["in", 43], ["neurologic", 46], ["patients", 57], [".", 65], ["This", 67], ["review", 72], ["focuses", 79], ["on", 87], ["clinical", 90], ["aspects", 99], ["and", 107], ["prognosis", 111], ["of", 121], ["3", 124], ["neurologic", 126], ["sleep", 137], ["disorders", 143], [":", 152], ["narcolepsy", 154], [",", 164], ["restless", 166], ["legs", 175], ["syndrome", 180], ["/", 188], ["Willis", 189], ["-", 195], ["Ekbom", 196], ["disease", 202], ["(", 210], ["RLS", 211], ["/", 214], ["WED", 215], [")", 218], [",", 219], ["and", 221], ["REM", 225], ["sleep", 229], ["behavior", 235], ["disorder", 244], ["(", 253], ["RBD", 254], [")", 257], [".", 258], ["Narcolepsy", 260], ["causes", 271], ["pervasive", 278], [",", 287], ["enduring", 289], ["excessive", 298], ["daytime", 308], ["sleepiness", 316], [",", 326], ["adversely", 328], ["affecting", 338], ["patients", 348], ["'", 356], ["daily", 358], ["functioning", 364], [".", 375], ["RLS", 377], ["/", 380], ["WED", 381], ["is", 385], ["characterized", 388], ["by", 402], ["an", 405], ["uncomfortable", 408], ["urge", 422], ["to", 427], ["move", 430], ["the", 435], ["legs", 439], ["before", 444], ["sleep", 451], [",", 456], ["often", 458], ["evolving", 464], ["toward", 473], ["augmentation", 480], ["and", 493], ["resulting", 497], ["in", 507], ["daylong", 510], ["bothersome", 518], ["symptoms", 529], [".", 537], ["RBD", 539], ["causes", 543], ["potentially", 550], ["injurious", 562], ["dream", 572], ["enactment", 578], ["behaviors", 588], ["that", 598], ["often", 603], ["signify", 609], ["future", 617], ["evolution", 624], ["of", 634], ["overt", 637], ["synucleinopathy", 643], ["neurodegeneration", 659], ["in", 677], ["as", 680], ["many", 683], ["as", 688], ["81", 691], ["%", 693], ["of", 695], ["patients", 698], [".", 706], ["Timely", 708], ["recognition", 715], [",", 726], ["referral", 728], ["for", 737], ["polysomnography", 741], [",", 756], ["and", 758], ["longitudinal", 762], ["follow", 775], ["-", 781], ["up", 782], ["of", 785], ["narcolepsy", 788], [",", 798], ["RLS", 800], ["/", 803], ["WED", 804], [",", 807], ["and", 809], ["RBD", 813], ["patients", 817], ["are", 826], ["imperatives", 830], ["for", 842], ["neurologists", 846], ["in", 859], ["providing", 862], ["quality", 872], ["comprehensive", 880], ["patient", 894], ["care", 902], [".", 906]]}
{"context": "The amino acid selenocysteine is encoded by UGA, usually a stop codon, thus requiring a specialized machinery to enable its incorporation into selenoproteins. The machinery comprises the tRNA(Sec), a 3'-UTR mRNA stem-loop termed SElenoCysteine Insertion Sequence (SECIS), which is mandatory for recoding UGA as a Sec codon, the SECIS Binding Protein 2 (SBP2), and other proteins. Little is known about the molecular mechanism and, in particular, when, where, and how the SECIS and SBP2 contact the ribosome. Previous work by others used the isolated SECIS RNA to address this question. Here, we developed a novel approach using instead engineered minimal selenoprotein mRNAs containing SECIS elements derivatized with photoreactive groups. By cross-linking experiments in rabbit reticulocyte lysate, new information could be gained about the SBP2 and SECIS contacts with components of the translation machinery at various translation steps. In particular, we found that SBP2 was bound only to the SECIS in 48S pre-initiation and 80S pretranslocation complexes. In the complex where the Sec-tRNA(Sec) was accommodated to the A site but transpeptidation was blocked, SBP2 bound the ribosome and possibly the SECIS element as well, and the SECIS had flexible contacts with the 60S ribosomal subunit involving several ribosomal proteins. Altogether, our findings led to broadening our understanding about the unique mechanism of selenocysteine incorporation in mammals.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "00475180d274498e9dad745b5ff8c048", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[176, 176], [59, 59], [125, 125], [90, 90], [214, 214], [221, 221], [44, 44], [151, 151], [104, 104]], "char_spans": [[997, 1001], [328, 332], [686, 690], [471, 475], [1206, 1210], [1237, 1241], [264, 268], [851, 855], [550, 554]]}]}], "context_tokens": [["The", 0], ["amino", 4], ["acid", 10], ["selenocysteine", 15], ["is", 30], ["encoded", 33], ["by", 41], ["UGA", 44], [",", 47], ["usually", 49], ["a", 57], ["stop", 59], ["codon", 64], [",", 69], ["thus", 71], ["requiring", 76], ["a", 86], ["specialized", 88], ["machinery", 100], ["to", 110], ["enable", 113], ["its", 120], ["incorporation", 124], ["into", 138], ["selenoproteins", 143], [".", 157], ["The", 159], ["machinery", 163], ["comprises", 173], ["the", 183], ["tRNA(Sec", 187], [")", 195], [",", 196], ["a", 198], ["3'-UTR", 200], ["mRNA", 207], ["stem", 212], ["-", 216], ["loop", 217], ["termed", 222], ["SElenoCysteine", 229], ["Insertion", 244], ["Sequence", 254], ["(", 263], ["SECIS", 264], [")", 269], [",", 270], ["which", 272], ["is", 278], ["mandatory", 281], ["for", 291], ["recoding", 295], ["UGA", 304], ["as", 308], ["a", 311], ["Sec", 313], ["codon", 317], [",", 322], ["the", 324], ["SECIS", 328], ["Binding", 334], ["Protein", 342], ["2", 350], ["(", 352], ["SBP2", 353], [")", 357], [",", 358], ["and", 360], ["other", 364], ["proteins", 370], [".", 378], ["Little", 380], ["is", 387], ["known", 390], ["about", 396], ["the", 402], ["molecular", 406], ["mechanism", 416], ["and", 426], [",", 429], ["in", 431], ["particular", 434], [",", 444], ["when", 446], [",", 450], ["where", 452], [",", 457], ["and", 459], ["how", 463], ["the", 467], ["SECIS", 471], ["and", 477], ["SBP2", 481], ["contact", 486], ["the", 494], ["ribosome", 498], [".", 506], ["Previous", 508], ["work", 517], ["by", 522], ["others", 525], ["used", 532], ["the", 537], ["isolated", 541], ["SECIS", 550], ["RNA", 556], ["to", 560], ["address", 563], ["this", 571], ["question", 576], [".", 584], ["Here", 586], [",", 590], ["we", 592], ["developed", 595], ["a", 605], ["novel", 607], ["approach", 613], ["using", 622], ["instead", 628], ["engineered", 636], ["minimal", 647], ["selenoprotein", 655], ["mRNAs", 669], ["containing", 675], ["SECIS", 686], ["elements", 692], ["derivatized", 701], ["with", 713], ["photoreactive", 718], ["groups", 732], [".", 738], ["By", 740], ["cross", 743], ["-", 748], ["linking", 749], ["experiments", 757], ["in", 769], ["rabbit", 772], ["reticulocyte", 779], ["lysate", 792], [",", 798], ["new", 800], ["information", 804], ["could", 816], ["be", 822], ["gained", 825], ["about", 832], ["the", 838], ["SBP2", 842], ["and", 847], ["SECIS", 851], ["contacts", 857], ["with", 866], ["components", 871], ["of", 882], ["the", 885], ["translation", 889], ["machinery", 901], ["at", 911], ["various", 914], ["translation", 922], ["steps", 934], [".", 939], ["In", 941], ["particular", 944], [",", 954], ["we", 956], ["found", 959], ["that", 965], ["SBP2", 970], ["was", 975], ["bound", 979], ["only", 985], ["to", 990], ["the", 993], ["SECIS", 997], ["in", 1003], ["48S", 1006], ["pre", 1010], ["-", 1013], ["initiation", 1014], ["and", 1025], ["80S", 1029], ["pretranslocation", 1033], ["complexes", 1050], [".", 1059], ["In", 1061], ["the", 1064], ["complex", 1068], ["where", 1076], ["the", 1082], ["Sec", 1086], ["-", 1089], ["tRNA(Sec", 1090], [")", 1098], ["was", 1100], ["accommodated", 1104], ["to", 1117], ["the", 1120], ["A", 1124], ["site", 1126], ["but", 1131], ["transpeptidation", 1135], ["was", 1152], ["blocked", 1156], [",", 1163], ["SBP2", 1165], ["bound", 1170], ["the", 1176], ["ribosome", 1180], ["and", 1189], ["possibly", 1193], ["the", 1202], ["SECIS", 1206], ["element", 1212], ["as", 1220], ["well", 1223], [",", 1227], ["and", 1229], ["the", 1233], ["SECIS", 1237], ["had", 1243], ["flexible", 1247], ["contacts", 1256], ["with", 1265], ["the", 1270], ["60S", 1274], ["ribosomal", 1278], ["subunit", 1288], ["involving", 1296], ["several", 1306], ["ribosomal", 1314], ["proteins", 1324], [".", 1332], ["Altogether", 1334], [",", 1344], ["our", 1346], ["findings", 1350], ["led", 1359], ["to", 1363], ["broadening", 1366], ["our", 1377], ["understanding", 1381], ["about", 1395], ["the", 1401], ["unique", 1405], ["mechanism", 1412], ["of", 1422], ["selenocysteine", 1425], ["incorporation", 1440], ["in", 1454], ["mammals", 1457], [".", 1464]]}
{"context": "The mixed-lineage leukemia protein MLL1 is a transcriptional regulator with an essential role in early development and hematopoiesis. The biological function of MLL1 is mediated by the histone H3K4 methyltransferase activity of the carboxyl-terminal SET domain. We have determined the crystal structure of the MLL1 SET domain in complex with cofactor product AdoHcy and a histone H3 peptide. This structure indicates that, in order to form a well-ordered active site, a highly variable but essential component of the SET domain must be repositioned. To test this idea, we compared the effect of the addition of MLL complex members on methyltransferase activity and show that both RbBP5 and Ash2L but not Wdr5 stimulate activity. Additionally, we have determined the effect of posttranslational modifications on histone H3 residues downstream and upstream from the target lysine and provide a structural explanation for why H3T3 phosphorylation and H3K9 acetylation regulate activity.", "qas": [{"question": "What is the characteristic domain of histone methyltransferases?", "answers": ["SET domain"], "qid": "f7e5563396b64495a72b3ad4feedde3e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["characteristic", 12], ["domain", 27], ["of", 34], ["histone", 37], ["methyltransferases", 45], ["?", 63]], "detected_answers": [{"text": "SET domain", "token_spans": [[89, 90], [39, 40], [51, 52]], "char_spans": [[517, 526], [250, 259], [315, 324]]}]}], "context_tokens": [["The", 0], ["mixed", 4], ["-", 9], ["lineage", 10], ["leukemia", 18], ["protein", 27], ["MLL1", 35], ["is", 40], ["a", 43], ["transcriptional", 45], ["regulator", 61], ["with", 71], ["an", 76], ["essential", 79], ["role", 89], ["in", 94], ["early", 97], ["development", 103], ["and", 115], ["hematopoiesis", 119], [".", 132], ["The", 134], ["biological", 138], ["function", 149], ["of", 158], ["MLL1", 161], ["is", 166], ["mediated", 169], ["by", 178], ["the", 181], ["histone", 185], ["H3K4", 193], ["methyltransferase", 198], ["activity", 216], ["of", 225], ["the", 228], ["carboxyl", 232], ["-", 240], ["terminal", 241], ["SET", 250], ["domain", 254], [".", 260], ["We", 262], ["have", 265], ["determined", 270], ["the", 281], ["crystal", 285], ["structure", 293], ["of", 303], ["the", 306], ["MLL1", 310], ["SET", 315], ["domain", 319], ["in", 326], ["complex", 329], ["with", 337], ["cofactor", 342], ["product", 351], ["AdoHcy", 359], ["and", 366], ["a", 370], ["histone", 372], ["H3", 380], ["peptide", 383], [".", 390], ["This", 392], ["structure", 397], ["indicates", 407], ["that", 417], [",", 421], ["in", 423], ["order", 426], ["to", 432], ["form", 435], ["a", 440], ["well", 442], ["-", 446], ["ordered", 447], ["active", 455], ["site", 462], [",", 466], ["a", 468], ["highly", 470], ["variable", 477], ["but", 486], ["essential", 490], ["component", 500], ["of", 510], ["the", 513], ["SET", 517], ["domain", 521], ["must", 528], ["be", 533], ["repositioned", 536], [".", 548], ["To", 550], ["test", 553], ["this", 558], ["idea", 563], [",", 567], ["we", 569], ["compared", 572], ["the", 581], ["effect", 585], ["of", 592], ["the", 595], ["addition", 599], ["of", 608], ["MLL", 611], ["complex", 615], ["members", 623], ["on", 631], ["methyltransferase", 634], ["activity", 652], ["and", 661], ["show", 665], ["that", 670], ["both", 675], ["RbBP5", 680], ["and", 686], ["Ash2L", 690], ["but", 696], ["not", 700], ["Wdr5", 704], ["stimulate", 709], ["activity", 719], [".", 727], ["Additionally", 729], [",", 741], ["we", 743], ["have", 746], ["determined", 751], ["the", 762], ["effect", 766], ["of", 773], ["posttranslational", 776], ["modifications", 794], ["on", 808], ["histone", 811], ["H3", 819], ["residues", 822], ["downstream", 831], ["and", 842], ["upstream", 846], ["from", 855], ["the", 860], ["target", 864], ["lysine", 871], ["and", 878], ["provide", 882], ["a", 890], ["structural", 892], ["explanation", 903], ["for", 915], ["why", 919], ["H3T3", 923], ["phosphorylation", 928], ["and", 944], ["H3K9", 948], ["acetylation", 953], ["regulate", 965], ["activity", 974], [".", 982]]}
{"context": "The nationwide prevalence of latent tuberculosis infection (LTBI) in Italian patients with psoriasis has never been investigated. To estimate the nationwide prevalence of LTBI in Italian patients with psoriasis who are candidates for systemic treatment. Data were obtained from the Psocare Registry on those patients (n\u00a0=\u00a04946) with age >\u00a018\u00a0years, systemic treatment at entry specified and tuberculin skin test (TST) performed according to the Mantoux method. LTBI diagnosis was based on a positive TST result in the absence of any clinical, radiological or microbiological evidence of active tuberculosis. Latent tuberculosis infection was diagnosed in 8\u00b73% of patients with psoriasis (409 of 4946). The prevalence of LTBI was lower in patients on biologics than in those on conventional systemic treatments, ranging from 4\u00b73% (19 of 444) of patients on adalimumab to 31% (eight of 26) of those on psoralen-ultraviolet A (P\u00a0<\u00a00\u00b705). Independent factors associated with LTBI were male sex [odds ratio (OR) 1\u00b730, 95% confidence interval (CI) 1\u00b704-1\u00b762; P\u00a0=\u00a00\u00b702], age over 55\u00a0years (OR 2\u00b793, 95% CI 2\u00b718-3\u00b793; P\u00a0<\u00a00\u00b7001) and being entered into a conventional treatment (OR 3\u00b783, 95% CI 3\u00b710-4\u00b774; P\u00a0<\u00a00\u00b7001). Positive history of tuberculosis was seen in 1% of patients (n\u00a0=\u00a049). The nationwide prevalence of LTBI in Italian patients with psoriasis candidate to systemic treatment is high, and screening is recommended prior to biological treatment.", "qas": [{"question": "The Mantoux test detects what latent infection/disease?", "answers": ["tuberculosis"], "qid": "4edb95a363144efdb21977cc7f1912a8", "question_tokens": [["The", 0], ["Mantoux", 4], ["test", 12], ["detects", 17], ["what", 25], ["latent", 30], ["infection", 37], ["/", 46], ["disease", 47], ["?", 54]], "detected_answers": [{"text": "tuberculosis", "token_spans": [[104, 104], [5, 5], [101, 101], [250, 250]], "char_spans": [[615, 626], [36, 47], [594, 605], [1229, 1240]]}]}], "context_tokens": [["The", 0], ["nationwide", 4], ["prevalence", 15], ["of", 26], ["latent", 29], ["tuberculosis", 36], ["infection", 49], ["(", 59], ["LTBI", 60], [")", 64], ["in", 66], ["Italian", 69], ["patients", 77], ["with", 86], ["psoriasis", 91], ["has", 101], ["never", 105], ["been", 111], ["investigated", 116], [".", 128], ["To", 130], ["estimate", 133], ["the", 142], ["nationwide", 146], ["prevalence", 157], ["of", 168], ["LTBI", 171], ["in", 176], ["Italian", 179], ["patients", 187], ["with", 196], ["psoriasis", 201], ["who", 211], ["are", 215], ["candidates", 219], ["for", 230], ["systemic", 234], ["treatment", 243], [".", 252], ["Data", 254], ["were", 259], ["obtained", 264], ["from", 273], ["the", 278], ["Psocare", 282], ["Registry", 290], ["on", 299], ["those", 302], ["patients", 308], ["(", 317], ["n", 318], ["=", 320], ["4946", 322], [")", 326], ["with", 328], ["age", 333], [">", 337], ["18", 339], ["years", 342], [",", 347], ["systemic", 349], ["treatment", 358], ["at", 368], ["entry", 371], ["specified", 377], ["and", 387], ["tuberculin", 391], ["skin", 402], ["test", 407], ["(", 412], ["TST", 413], [")", 416], ["performed", 418], ["according", 428], ["to", 438], ["the", 441], ["Mantoux", 445], ["method", 453], [".", 459], ["LTBI", 461], ["diagnosis", 466], ["was", 476], ["based", 480], ["on", 486], ["a", 489], ["positive", 491], ["TST", 500], ["result", 504], ["in", 511], ["the", 514], ["absence", 518], ["of", 526], ["any", 529], ["clinical", 533], [",", 541], ["radiological", 543], ["or", 556], ["microbiological", 559], ["evidence", 575], ["of", 584], ["active", 587], ["tuberculosis", 594], [".", 606], ["Latent", 608], ["tuberculosis", 615], ["infection", 628], ["was", 638], ["diagnosed", 642], ["in", 652], ["8\u00b73", 655], ["%", 658], ["of", 660], ["patients", 663], ["with", 672], ["psoriasis", 677], ["(", 687], ["409", 688], ["of", 692], ["4946", 695], [")", 699], [".", 700], ["The", 702], ["prevalence", 706], ["of", 717], ["LTBI", 720], ["was", 725], ["lower", 729], ["in", 735], ["patients", 738], ["on", 747], ["biologics", 750], ["than", 760], ["in", 765], ["those", 768], ["on", 774], ["conventional", 777], ["systemic", 790], ["treatments", 799], [",", 809], ["ranging", 811], ["from", 819], ["4\u00b73", 824], ["%", 827], ["(", 829], ["19", 830], ["of", 833], ["444", 836], [")", 839], ["of", 841], ["patients", 844], ["on", 853], ["adalimumab", 856], ["to", 867], ["31", 870], ["%", 872], ["(", 874], ["eight", 875], ["of", 881], ["26", 884], [")", 886], ["of", 888], ["those", 891], ["on", 897], ["psoralen", 900], ["-", 908], ["ultraviolet", 909], ["A", 921], ["(", 923], ["P", 924], ["<", 926], ["0\u00b705", 928], [")", 932], [".", 933], ["Independent", 935], ["factors", 947], ["associated", 955], ["with", 966], ["LTBI", 971], ["were", 976], ["male", 981], ["sex", 986], ["[", 990], ["odds", 991], ["ratio", 996], ["(", 1002], ["OR", 1003], [")", 1005], ["1\u00b730", 1007], [",", 1011], ["95", 1013], ["%", 1015], ["confidence", 1017], ["interval", 1028], ["(", 1037], ["CI", 1038], [")", 1040], ["1\u00b704", 1042], ["-", 1046], ["1\u00b762", 1047], [";", 1051], ["P", 1053], ["=", 1055], ["0\u00b702", 1057], ["]", 1061], [",", 1062], ["age", 1064], ["over", 1068], ["55", 1073], ["years", 1076], ["(", 1082], ["OR", 1083], ["2\u00b793", 1086], [",", 1090], ["95", 1092], ["%", 1094], ["CI", 1096], ["2\u00b718", 1099], ["-", 1103], ["3\u00b793", 1104], [";", 1108], ["P", 1110], ["<", 1112], ["0\u00b7001", 1114], [")", 1119], ["and", 1121], ["being", 1125], ["entered", 1131], ["into", 1139], ["a", 1144], ["conventional", 1146], ["treatment", 1159], ["(", 1169], ["OR", 1170], ["3\u00b783", 1173], [",", 1177], ["95", 1179], ["%", 1181], ["CI", 1183], ["3\u00b710", 1186], ["-", 1190], ["4\u00b774", 1191], [";", 1195], ["P", 1197], ["<", 1199], ["0\u00b7001", 1201], [")", 1206], [".", 1207], ["Positive", 1209], ["history", 1218], ["of", 1226], ["tuberculosis", 1229], ["was", 1242], ["seen", 1246], ["in", 1251], ["1", 1254], ["%", 1255], ["of", 1257], ["patients", 1260], ["(", 1269], ["n", 1270], ["=", 1272], ["49", 1274], [")", 1276], [".", 1277], ["The", 1279], ["nationwide", 1283], ["prevalence", 1294], ["of", 1305], ["LTBI", 1308], ["in", 1313], ["Italian", 1316], ["patients", 1324], ["with", 1333], ["psoriasis", 1338], ["candidate", 1348], ["to", 1358], ["systemic", 1361], ["treatment", 1370], ["is", 1380], ["high", 1383], [",", 1387], ["and", 1389], ["screening", 1393], ["is", 1403], ["recommended", 1406], ["prior", 1418], ["to", 1424], ["biological", 1427], ["treatment", 1438], [".", 1447]]}
{"context": "The McLeod syndrome is a rare X-linked recessive disorder characterized by blood group, neuromuscular and haematopoietic abnormalities. It is caused by XK gene defects and may include large deletions in the Xp21 region. Analysis of three unrelated McLeod patients for the presence of the XK, DMD, CYBB, ETX1, RPGR and OTC loci, as well as for the DXS709 marker, revealed deletions from the 39th exon of DMD to the ETX1 locus (patient Be), from the XK to RPGR loci (patient Bi) and from the XK to CYBB loci (patient Lh). All three patients normally expressed the Lutheran (Lu) red cell antigens, thus excluding the interval between the RPGR and DMD genes as site of the XS locus, previously mapped to the Xp21.2-Xq21.1 region and thought to regulate the expression of the LU blood group gene on chromosome 19.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "e6169de72a8e46a8bfd4b79a1daa5dc7", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[100, 100], [89, 89], [25, 25], [49, 49]], "char_spans": [[490, 491], [448, 449], [152, 153], [288, 289]]}]}], "context_tokens": [["The", 0], ["McLeod", 4], ["syndrome", 11], ["is", 20], ["a", 23], ["rare", 25], ["X", 30], ["-", 31], ["linked", 32], ["recessive", 39], ["disorder", 49], ["characterized", 58], ["by", 72], ["blood", 75], ["group", 81], [",", 86], ["neuromuscular", 88], ["and", 102], ["haematopoietic", 106], ["abnormalities", 121], [".", 134], ["It", 136], ["is", 139], ["caused", 142], ["by", 149], ["XK", 152], ["gene", 155], ["defects", 160], ["and", 168], ["may", 172], ["include", 176], ["large", 184], ["deletions", 190], ["in", 200], ["the", 203], ["Xp21", 207], ["region", 212], [".", 218], ["Analysis", 220], ["of", 229], ["three", 232], ["unrelated", 238], ["McLeod", 248], ["patients", 255], ["for", 264], ["the", 268], ["presence", 272], ["of", 281], ["the", 284], ["XK", 288], [",", 290], ["DMD", 292], [",", 295], ["CYBB", 297], [",", 301], ["ETX1", 303], [",", 307], ["RPGR", 309], ["and", 314], ["OTC", 318], ["loci", 322], [",", 326], ["as", 328], ["well", 331], ["as", 336], ["for", 339], ["the", 343], ["DXS709", 347], ["marker", 354], [",", 360], ["revealed", 362], ["deletions", 371], ["from", 381], ["the", 386], ["39th", 390], ["exon", 395], ["of", 400], ["DMD", 403], ["to", 407], ["the", 410], ["ETX1", 414], ["locus", 419], ["(", 425], ["patient", 426], ["Be", 434], [")", 436], [",", 437], ["from", 439], ["the", 444], ["XK", 448], ["to", 451], ["RPGR", 454], ["loci", 459], ["(", 464], ["patient", 465], ["Bi", 473], [")", 475], ["and", 477], ["from", 481], ["the", 486], ["XK", 490], ["to", 493], ["CYBB", 496], ["loci", 501], ["(", 506], ["patient", 507], ["Lh", 515], [")", 517], [".", 518], ["All", 520], ["three", 524], ["patients", 530], ["normally", 539], ["expressed", 548], ["the", 558], ["Lutheran", 562], ["(", 571], ["Lu", 572], [")", 574], ["red", 576], ["cell", 580], ["antigens", 585], [",", 593], ["thus", 595], ["excluding", 600], ["the", 610], ["interval", 614], ["between", 623], ["the", 631], ["RPGR", 635], ["and", 640], ["DMD", 644], ["genes", 648], ["as", 654], ["site", 657], ["of", 662], ["the", 665], ["XS", 669], ["locus", 672], [",", 677], ["previously", 679], ["mapped", 690], ["to", 697], ["the", 700], ["Xp21.2-Xq21.1", 704], ["region", 718], ["and", 725], ["thought", 729], ["to", 737], ["regulate", 740], ["the", 749], ["expression", 753], ["of", 764], ["the", 767], ["LU", 771], ["blood", 774], ["group", 780], ["gene", 786], ["on", 791], ["chromosome", 794], ["19", 805], [".", 807]]}
{"context": "To determine the change in prevalence of posttraumatic stress disorder (PTSD) symptoms in victims of the March 11 attacks and their relatives, 1 and 6 months after the attacks. Evaluation of PTSD symptoms using the Davidson Trauma Scale (DTS) and General Health Questionnaire (GHQ) in a sample of 56 patients admitted to an emergency room of a general hospital, and assessment of PTSD symptoms in relatives of the patients. At Month 1, 41.1% of patients (31.3% of males and 54.2% of females) presented with PTSD. At Month 6, this figure was 40.9% (30.4% of males and 52.4% of females). There was a significant improvement in perception of health among females between Month 1 and Month 6. Relatives presented similar DTS scores at baseline and at 6 months. We verified that rates of PTSD did not vary substantively between the two evaluations. PTSD symptoms positively correlated with psychological health involvement. This correlation points out that both PTSD symptoms and subjective general health involvement are part of the psychological response to trauma. The prevalence of PTSD symptoms was high and remained stable between Month 1 and Month 6, while subjective perception of health improved significantly.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "c35f27d4167846e1adc3aadd2981e4dc", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[35, 35], [11, 11], [202, 202], [100, 100], [71, 71], [183, 183], [168, 168], [158, 158]], "char_spans": [[191, 194], [72, 75], [1081, 1084], [507, 510], [380, 383], [957, 960], [844, 847], [783, 786]]}]}], "context_tokens": [["To", 0], ["determine", 3], ["the", 13], ["change", 17], ["in", 24], ["prevalence", 27], ["of", 38], ["posttraumatic", 41], ["stress", 55], ["disorder", 62], ["(", 71], ["PTSD", 72], [")", 76], ["symptoms", 78], ["in", 87], ["victims", 90], ["of", 98], ["the", 101], ["March", 105], ["11", 111], ["attacks", 114], ["and", 122], ["their", 126], ["relatives", 132], [",", 141], ["1", 143], ["and", 145], ["6", 149], ["months", 151], ["after", 158], ["the", 164], ["attacks", 168], [".", 175], ["Evaluation", 177], ["of", 188], ["PTSD", 191], ["symptoms", 196], ["using", 205], ["the", 211], ["Davidson", 215], ["Trauma", 224], ["Scale", 231], ["(", 237], ["DTS", 238], [")", 241], ["and", 243], ["General", 247], ["Health", 255], ["Questionnaire", 262], ["(", 276], ["GHQ", 277], [")", 280], ["in", 282], ["a", 285], ["sample", 287], ["of", 294], ["56", 297], ["patients", 300], ["admitted", 309], ["to", 318], ["an", 321], ["emergency", 324], ["room", 334], ["of", 339], ["a", 342], ["general", 344], ["hospital", 352], [",", 360], ["and", 362], ["assessment", 366], ["of", 377], ["PTSD", 380], ["symptoms", 385], ["in", 394], ["relatives", 397], ["of", 407], ["the", 410], ["patients", 414], [".", 422], ["At", 424], ["Month", 427], ["1", 433], [",", 434], ["41.1", 436], ["%", 440], ["of", 442], ["patients", 445], ["(", 454], ["31.3", 455], ["%", 459], ["of", 461], ["males", 464], ["and", 470], ["54.2", 474], ["%", 478], ["of", 480], ["females", 483], [")", 490], ["presented", 492], ["with", 502], ["PTSD", 507], [".", 511], ["At", 513], ["Month", 516], ["6", 522], [",", 523], ["this", 525], ["figure", 530], ["was", 537], ["40.9", 541], ["%", 545], ["(", 547], ["30.4", 548], ["%", 552], ["of", 554], ["males", 557], ["and", 563], ["52.4", 567], ["%", 571], ["of", 573], ["females", 576], [")", 583], [".", 584], ["There", 586], ["was", 592], ["a", 596], ["significant", 598], ["improvement", 610], ["in", 622], ["perception", 625], ["of", 636], ["health", 639], ["among", 646], ["females", 652], ["between", 660], ["Month", 668], ["1", 674], ["and", 676], ["Month", 680], ["6", 686], [".", 687], ["Relatives", 689], ["presented", 699], ["similar", 709], ["DTS", 717], ["scores", 721], ["at", 728], ["baseline", 731], ["and", 740], ["at", 744], ["6", 747], ["months", 749], [".", 755], ["We", 757], ["verified", 760], ["that", 769], ["rates", 774], ["of", 780], ["PTSD", 783], ["did", 788], ["not", 792], ["vary", 796], ["substantively", 801], ["between", 815], ["the", 823], ["two", 827], ["evaluations", 831], [".", 842], ["PTSD", 844], ["symptoms", 849], ["positively", 858], ["correlated", 869], ["with", 880], ["psychological", 885], ["health", 899], ["involvement", 906], [".", 917], ["This", 919], ["correlation", 924], ["points", 936], ["out", 943], ["that", 947], ["both", 952], ["PTSD", 957], ["symptoms", 962], ["and", 971], ["subjective", 975], ["general", 986], ["health", 994], ["involvement", 1001], ["are", 1013], ["part", 1017], ["of", 1022], ["the", 1025], ["psychological", 1029], ["response", 1043], ["to", 1052], ["trauma", 1055], [".", 1061], ["The", 1063], ["prevalence", 1067], ["of", 1078], ["PTSD", 1081], ["symptoms", 1086], ["was", 1095], ["high", 1099], ["and", 1104], ["remained", 1108], ["stable", 1117], ["between", 1124], ["Month", 1132], ["1", 1138], ["and", 1140], ["Month", 1144], ["6", 1150], [",", 1151], ["while", 1153], ["subjective", 1159], ["perception", 1170], ["of", 1181], ["health", 1184], ["improved", 1191], ["significantly", 1200], [".", 1213]]}
{"context": "With the recent introduction of inhibitors of mammalian target of rapamycin (mTOR) in oncology, distinct cutaneous and oral adverse events have been identified. In fact, stomatitis and rash are documented as the most frequent and potentially dose-limiting side effects. Clinically, mTOR inhibitor-associated stomatitis (mIAS) more closely resembles aphthous stomatitis than oral mucositis due to conventional anticancer therapies. While most cases of mIAS are mild to moderate and self-limiting, more severe and persistent mIAS can become a dose-limiting toxicity. Small ulcerations may cause significant pain and mucosal sensitivity may occur in the absence of clinical changes. Use of clinical assessment tools that are primarily driven by ulceration size may underestimate mIAS, and assessment should include patient-reported outcomes. This article provides an up-to-date review of the clinical presentation, terminology, pathogenesis, assessment and management of mIAS and other mTOR inhibitor-associated oral adverse events. In addition, areas of future research are considered.", "qas": [{"question": "What does mTOR stands for?", "answers": ["mammalian target of rapamycin"], "qid": "51c0f6328c564f34adfee63c41eda084", "question_tokens": [["What", 0], ["does", 5], ["mTOR", 10], ["stands", 15], ["for", 22], ["?", 25]], "detected_answers": [{"text": "mammalian target of rapamycin", "token_spans": [[7, 10]], "char_spans": [[46, 74]]}]}], "context_tokens": [["With", 0], ["the", 5], ["recent", 9], ["introduction", 16], ["of", 29], ["inhibitors", 32], ["of", 43], ["mammalian", 46], ["target", 56], ["of", 63], ["rapamycin", 66], ["(", 76], ["mTOR", 77], [")", 81], ["in", 83], ["oncology", 86], [",", 94], ["distinct", 96], ["cutaneous", 105], ["and", 115], ["oral", 119], ["adverse", 124], ["events", 132], ["have", 139], ["been", 144], ["identified", 149], [".", 159], ["In", 161], ["fact", 164], [",", 168], ["stomatitis", 170], ["and", 181], ["rash", 185], ["are", 190], ["documented", 194], ["as", 205], ["the", 208], ["most", 212], ["frequent", 217], ["and", 226], ["potentially", 230], ["dose", 242], ["-", 246], ["limiting", 247], ["side", 256], ["effects", 261], [".", 268], ["Clinically", 270], [",", 280], ["mTOR", 282], ["inhibitor", 287], ["-", 296], ["associated", 297], ["stomatitis", 308], ["(", 319], ["mIAS", 320], [")", 324], ["more", 326], ["closely", 331], ["resembles", 339], ["aphthous", 349], ["stomatitis", 358], ["than", 369], ["oral", 374], ["mucositis", 379], ["due", 389], ["to", 393], ["conventional", 396], ["anticancer", 409], ["therapies", 420], [".", 429], ["While", 431], ["most", 437], ["cases", 442], ["of", 448], ["mIAS", 451], ["are", 456], ["mild", 460], ["to", 465], ["moderate", 468], ["and", 477], ["self", 481], ["-", 485], ["limiting", 486], [",", 494], ["more", 496], ["severe", 501], ["and", 508], ["persistent", 512], ["mIAS", 523], ["can", 528], ["become", 532], ["a", 539], ["dose", 541], ["-", 545], ["limiting", 546], ["toxicity", 555], [".", 563], ["Small", 565], ["ulcerations", 571], ["may", 583], ["cause", 587], ["significant", 593], ["pain", 605], ["and", 610], ["mucosal", 614], ["sensitivity", 622], ["may", 634], ["occur", 638], ["in", 644], ["the", 647], ["absence", 651], ["of", 659], ["clinical", 662], ["changes", 671], [".", 678], ["Use", 680], ["of", 684], ["clinical", 687], ["assessment", 696], ["tools", 707], ["that", 713], ["are", 718], ["primarily", 722], ["driven", 732], ["by", 739], ["ulceration", 742], ["size", 753], ["may", 758], ["underestimate", 762], ["mIAS", 776], [",", 780], ["and", 782], ["assessment", 786], ["should", 797], ["include", 804], ["patient", 812], ["-", 819], ["reported", 820], ["outcomes", 829], [".", 837], ["This", 839], ["article", 844], ["provides", 852], ["an", 861], ["up", 864], ["-", 866], ["to", 867], ["-", 869], ["date", 870], ["review", 875], ["of", 882], ["the", 885], ["clinical", 889], ["presentation", 898], [",", 910], ["terminology", 912], [",", 923], ["pathogenesis", 925], [",", 937], ["assessment", 939], ["and", 950], ["management", 954], ["of", 965], ["mIAS", 968], ["and", 973], ["other", 977], ["mTOR", 983], ["inhibitor", 988], ["-", 997], ["associated", 998], ["oral", 1009], ["adverse", 1014], ["events", 1022], [".", 1028], ["In", 1030], ["addition", 1033], [",", 1041], ["areas", 1043], ["of", 1049], ["future", 1052], ["research", 1059], ["are", 1068], ["considered", 1072], [".", 1082]]}
{"context": "Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are characterized by abnormal deposition of \u03b1-synuclein aggregates in many regions of the central and peripheral nervous systems. Accumulating evidence suggests that the \u03b1-synuclein pathology initiates in a few discrete regions and spreads to larger areas in the nervous system. Recent pathological studies of PD patients have raised the possibility that the enteric nervous system is one of the initial sites of \u03b1-synuclein aggregation and propagation. Here, we evaluated the induction and propagation of \u03b1-synuclein aggregates in the enteric nervous system of the A53T \u03b1-synuclein transgenic mice after injection of human brain tissue extracts into the gastric walls of the mice. Western analysis of the brain extracts showed that the DLB extract contained detergent-stable \u03b1-synuclein aggregates, but the normal brain extract did not. Injection of the DLB extract resulted in an increased deposition of \u03b1-synuclein in the myenteric neurons, in which \u03b1-synuclein formed punctate aggregates over time up to 4 months. In these mice, inflammatory responses were increased transiently at early time points. None of these changes were observed in the A53T mice injected with saline or the normal brain extract, nor were these found in the wild type mice injected with the DLB extract. These results demonstrate that pathological \u03b1-synuclein aggregates present in the brain of DLB patient can induce the aggregation of endogenous \u03b1-synuclein in the myenteric neurons in A53T mice, suggesting the transmission of synucleinopathy lesions in the enteric nervous system.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "9a225d6aa2034d27a58fc2dea42dbe40", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["and", 25], ["dementia", 29], ["with", 38], ["Lewy", 43], ["bodies", 48], ["(", 55], ["DLB", 56], [")", 59], ["are", 61], ["characterized", 65], ["by", 79], ["abnormal", 82], ["deposition", 91], ["of", 102], ["\u03b1", 105], ["-", 106], ["synuclein", 107], ["aggregates", 117], ["in", 128], ["many", 131], ["regions", 136], ["of", 144], ["the", 147], ["central", 151], ["and", 159], ["peripheral", 163], ["nervous", 174], ["systems", 182], [".", 189], ["Accumulating", 191], ["evidence", 204], ["suggests", 213], ["that", 222], ["the", 227], ["\u03b1", 231], ["-", 232], ["synuclein", 233], ["pathology", 243], ["initiates", 253], ["in", 263], ["a", 266], ["few", 268], ["discrete", 272], ["regions", 281], ["and", 289], ["spreads", 293], ["to", 301], ["larger", 304], ["areas", 311], ["in", 317], ["the", 320], ["nervous", 324], ["system", 332], [".", 338], ["Recent", 340], ["pathological", 347], ["studies", 360], ["of", 368], ["PD", 371], ["patients", 374], ["have", 383], ["raised", 388], ["the", 395], ["possibility", 399], ["that", 411], ["the", 416], ["enteric", 420], ["nervous", 428], ["system", 436], ["is", 443], ["one", 446], ["of", 450], ["the", 453], ["initial", 457], ["sites", 465], ["of", 471], ["\u03b1", 474], ["-", 475], ["synuclein", 476], ["aggregation", 486], ["and", 498], ["propagation", 502], [".", 513], ["Here", 515], [",", 519], ["we", 521], ["evaluated", 524], ["the", 534], ["induction", 538], ["and", 548], ["propagation", 552], ["of", 564], ["\u03b1", 567], ["-", 568], ["synuclein", 569], ["aggregates", 579], ["in", 590], ["the", 593], ["enteric", 597], ["nervous", 605], ["system", 613], ["of", 620], ["the", 623], ["A53", 627], ["T", 630], ["\u03b1", 632], ["-", 633], ["synuclein", 634], ["transgenic", 644], ["mice", 655], ["after", 660], ["injection", 666], ["of", 676], ["human", 679], ["brain", 685], ["tissue", 691], ["extracts", 698], ["into", 707], ["the", 712], ["gastric", 716], ["walls", 724], ["of", 730], ["the", 733], ["mice", 737], [".", 741], ["Western", 743], ["analysis", 751], ["of", 760], ["the", 763], ["brain", 767], ["extracts", 773], ["showed", 782], ["that", 789], ["the", 794], ["DLB", 798], ["extract", 802], ["contained", 810], ["detergent", 820], ["-", 829], ["stable", 830], ["\u03b1", 837], ["-", 838], ["synuclein", 839], ["aggregates", 849], [",", 859], ["but", 861], ["the", 865], ["normal", 869], ["brain", 876], ["extract", 882], ["did", 890], ["not", 894], [".", 897], ["Injection", 899], ["of", 909], ["the", 912], ["DLB", 916], ["extract", 920], ["resulted", 928], ["in", 937], ["an", 940], ["increased", 943], ["deposition", 953], ["of", 964], ["\u03b1", 967], ["-", 968], ["synuclein", 969], ["in", 979], ["the", 982], ["myenteric", 986], ["neurons", 996], [",", 1003], ["in", 1005], ["which", 1008], ["\u03b1", 1014], ["-", 1015], ["synuclein", 1016], ["formed", 1026], ["punctate", 1033], ["aggregates", 1042], ["over", 1053], ["time", 1058], ["up", 1063], ["to", 1066], ["4", 1069], ["months", 1071], [".", 1077], ["In", 1079], ["these", 1082], ["mice", 1088], [",", 1092], ["inflammatory", 1094], ["responses", 1107], ["were", 1117], ["increased", 1122], ["transiently", 1132], ["at", 1144], ["early", 1147], ["time", 1153], ["points", 1158], [".", 1164], ["None", 1166], ["of", 1171], ["these", 1174], ["changes", 1180], ["were", 1188], ["observed", 1193], ["in", 1202], ["the", 1205], ["A53", 1209], ["T", 1212], ["mice", 1214], ["injected", 1219], ["with", 1228], ["saline", 1233], ["or", 1240], ["the", 1243], ["normal", 1247], ["brain", 1254], ["extract", 1260], [",", 1267], ["nor", 1269], ["were", 1273], ["these", 1278], ["found", 1284], ["in", 1290], ["the", 1293], ["wild", 1297], ["type", 1302], ["mice", 1307], ["injected", 1312], ["with", 1321], ["the", 1326], ["DLB", 1330], ["extract", 1334], [".", 1341], ["These", 1343], ["results", 1349], ["demonstrate", 1357], ["that", 1369], ["pathological", 1374], ["\u03b1", 1387], ["-", 1388], ["synuclein", 1389], ["aggregates", 1399], ["present", 1410], ["in", 1418], ["the", 1421], ["brain", 1425], ["of", 1431], ["DLB", 1434], ["patient", 1438], ["can", 1446], ["induce", 1450], ["the", 1457], ["aggregation", 1461], ["of", 1473], ["endogenous", 1476], ["\u03b1", 1487], ["-", 1488], ["synuclein", 1489], ["in", 1499], ["the", 1502], ["myenteric", 1506], ["neurons", 1516], ["in", 1524], ["A53", 1527], ["T", 1530], ["mice", 1532], [",", 1536], ["suggesting", 1538], ["the", 1549], ["transmission", 1553], ["of", 1566], ["synucleinopathy", 1569], ["lesions", 1585], ["in", 1593], ["the", 1596], ["enteric", 1600], ["nervous", 1608], ["system", 1616], [".", 1622]]}
{"context": "Amyloid precursor protein (APP) is strongly related to the onset of Alzheimer's disease. It possesses cleavage sites for beta- and gamma-secretases, and the resulting cleaved products (amyloid-beta peptides) are capable of causing neurotoxicity. Such cleavage is promoted by the Swedish and London mutations (APPSwe/Lon) inside the APP gene. Here, we characterized APPSL transgenic mice (APPSL-Tg) to determine the effects of this mutation. We observed that both the amount of insoluble amyloid-beta and the ratio of amyloid-beta 42/40 increased promptly in the brain during 6-16 months of age. Amyloid-beta plaques were observed in whole brain sections at 12 months. In contrast, the spatial memory assessed by the Morris water maze task was already impaired at 3 months, which suggested that the APPSL-Tg mice may represent an early-onset model of familial Alzheimer's disease. Furthermore, the levels of LAMP-1, a marker protein of lysosome, increased in the brain at 28 months. Such LAMP-1 protein was detected around the amyloid-beta plaques at the hippocampal regions of the APPSL-Tg mice. Our results suggested that the increase in LAMP-1 was enhanced by the accumulation of amyloid-beta occurring during aging. Our findings coincided with the pathological hallmarks of Alzheimer's disease.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "d8237f9d763b42d483bb971b70dd1706", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[13, 15], [244, 246], [168, 170]], "char_spans": [[68, 86], [1277, 1295], [859, 877]]}]}], "context_tokens": [["Amyloid", 0], ["precursor", 8], ["protein", 18], ["(", 26], ["APP", 27], [")", 30], ["is", 32], ["strongly", 35], ["related", 44], ["to", 52], ["the", 55], ["onset", 59], ["of", 65], ["Alzheimer", 68], ["'s", 77], ["disease", 80], [".", 87], ["It", 89], ["possesses", 92], ["cleavage", 102], ["sites", 111], ["for", 117], ["beta-", 121], ["and", 127], ["gamma", 131], ["-", 136], ["secretases", 137], [",", 147], ["and", 149], ["the", 153], ["resulting", 157], ["cleaved", 167], ["products", 175], ["(", 184], ["amyloid", 185], ["-", 192], ["beta", 193], ["peptides", 198], [")", 206], ["are", 208], ["capable", 212], ["of", 220], ["causing", 223], ["neurotoxicity", 231], [".", 244], ["Such", 246], ["cleavage", 251], ["is", 260], ["promoted", 263], ["by", 272], ["the", 275], ["Swedish", 279], ["and", 287], ["London", 291], ["mutations", 298], ["(", 308], ["APPSwe", 309], ["/", 315], ["Lon", 316], [")", 319], ["inside", 321], ["the", 328], ["APP", 332], ["gene", 336], [".", 340], ["Here", 342], [",", 346], ["we", 348], ["characterized", 351], ["APPSL", 365], ["transgenic", 371], ["mice", 382], ["(", 387], ["APPSL", 388], ["-", 393], ["Tg", 394], [")", 396], ["to", 398], ["determine", 401], ["the", 411], ["effects", 415], ["of", 423], ["this", 426], ["mutation", 431], [".", 439], ["We", 441], ["observed", 444], ["that", 453], ["both", 458], ["the", 463], ["amount", 467], ["of", 474], ["insoluble", 477], ["amyloid", 487], ["-", 494], ["beta", 495], ["and", 500], ["the", 504], ["ratio", 508], ["of", 514], ["amyloid", 517], ["-", 524], ["beta", 525], ["42/40", 530], ["increased", 536], ["promptly", 546], ["in", 555], ["the", 558], ["brain", 562], ["during", 568], ["6", 575], ["-", 576], ["16", 577], ["months", 580], ["of", 587], ["age", 590], [".", 593], ["Amyloid", 595], ["-", 602], ["beta", 603], ["plaques", 608], ["were", 616], ["observed", 621], ["in", 630], ["whole", 633], ["brain", 639], ["sections", 645], ["at", 654], ["12", 657], ["months", 660], [".", 666], ["In", 668], ["contrast", 671], [",", 679], ["the", 681], ["spatial", 685], ["memory", 693], ["assessed", 700], ["by", 709], ["the", 712], ["Morris", 716], ["water", 723], ["maze", 729], ["task", 734], ["was", 739], ["already", 743], ["impaired", 751], ["at", 760], ["3", 763], ["months", 765], [",", 771], ["which", 773], ["suggested", 779], ["that", 789], ["the", 794], ["APPSL", 798], ["-", 803], ["Tg", 804], ["mice", 807], ["may", 812], ["represent", 816], ["an", 826], ["early", 829], ["-", 834], ["onset", 835], ["model", 841], ["of", 847], ["familial", 850], ["Alzheimer", 859], ["'s", 868], ["disease", 871], [".", 878], ["Furthermore", 880], [",", 891], ["the", 893], ["levels", 897], ["of", 904], ["LAMP-1", 907], [",", 913], ["a", 915], ["marker", 917], ["protein", 924], ["of", 932], ["lysosome", 935], [",", 943], ["increased", 945], ["in", 955], ["the", 958], ["brain", 962], ["at", 968], ["28", 971], ["months", 974], [".", 980], ["Such", 982], ["LAMP-1", 987], ["protein", 994], ["was", 1002], ["detected", 1006], ["around", 1015], ["the", 1022], ["amyloid", 1026], ["-", 1033], ["beta", 1034], ["plaques", 1039], ["at", 1047], ["the", 1050], ["hippocampal", 1054], ["regions", 1066], ["of", 1074], ["the", 1077], ["APPSL", 1081], ["-", 1086], ["Tg", 1087], ["mice", 1090], [".", 1094], ["Our", 1096], ["results", 1100], ["suggested", 1108], ["that", 1118], ["the", 1123], ["increase", 1127], ["in", 1136], ["LAMP-1", 1139], ["was", 1146], ["enhanced", 1150], ["by", 1159], ["the", 1162], ["accumulation", 1166], ["of", 1179], ["amyloid", 1182], ["-", 1189], ["beta", 1190], ["occurring", 1195], ["during", 1205], ["aging", 1212], [".", 1217], ["Our", 1219], ["findings", 1223], ["coincided", 1232], ["with", 1242], ["the", 1247], ["pathological", 1251], ["hallmarks", 1264], ["of", 1274], ["Alzheimer", 1277], ["'s", 1286], ["disease", 1289], [".", 1296]]}
{"context": "\u03b1-Synuclein (\u03b1Syn), which forms amyloid fibrils, is linked to the neuronal pathology of Parkinson's disease, as it is the major fibrillar component of Lewy bodies, the inclusions that are characteristic of the disease. Oligomeric structures, common to many neurodegenerative disease-related proteins, may in fact be the primary toxic species, while the amyloid fibrils exist either as a less toxic dead-end species or even as a beneficial mechanism for clearing damaged proteins. To alter the progression of the aggregation and gain insights into the prefibrillar structures, we determined the effect of heme on \u03b1Syn oligomerization by several different techniques, including native (nondenaturing) polyacrylamide gel electrophoresis, thioflavin T fluorescence, transmission electron microscopy, atomic force microscopy, circular dichroism, and membrane permeation using a calcein release assay. During aggregation, heme is able to bind the \u03b1Syn in a specific fashion, stabilizing distinct oligomeric conformations and promoting the formation of \u03b1Syn into annular structures, thereby delaying and/or inhibiting the fibrillation process. These results indicate that heme may play a regulatory role in the progression of Parkinson's disease; in addition, they provide insights into how the aggregation process may be altered, which may be applicable to the understanding of many neurodegenerative diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "bbcdadd974b7443eae14570e28207e80", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[0, 2]], "char_spans": [[0, 10]]}, {"text": "\u03b1Syn", "token_spans": [[175, 175], [4, 4], [160, 160], [111, 111]], "char_spans": [[1046, 1049], [13, 16], [941, 944], [612, 615]]}]}], "context_tokens": [["\u03b1", 0], ["-", 1], ["Synuclein", 2], ["(", 12], ["\u03b1Syn", 13], [")", 17], [",", 18], ["which", 20], ["forms", 26], ["amyloid", 32], ["fibrils", 40], [",", 47], ["is", 49], ["linked", 52], ["to", 59], ["the", 62], ["neuronal", 66], ["pathology", 75], ["of", 85], ["Parkinson", 88], ["'s", 97], ["disease", 100], [",", 107], ["as", 109], ["it", 112], ["is", 115], ["the", 118], ["major", 122], ["fibrillar", 128], ["component", 138], ["of", 148], ["Lewy", 151], ["bodies", 156], [",", 162], ["the", 164], ["inclusions", 168], ["that", 179], ["are", 184], ["characteristic", 188], ["of", 203], ["the", 206], ["disease", 210], [".", 217], ["Oligomeric", 219], ["structures", 230], [",", 240], ["common", 242], ["to", 249], ["many", 252], ["neurodegenerative", 257], ["disease", 275], ["-", 282], ["related", 283], ["proteins", 291], [",", 299], ["may", 301], ["in", 305], ["fact", 308], ["be", 313], ["the", 316], ["primary", 320], ["toxic", 328], ["species", 334], [",", 341], ["while", 343], ["the", 349], ["amyloid", 353], ["fibrils", 361], ["exist", 369], ["either", 375], ["as", 382], ["a", 385], ["less", 387], ["toxic", 392], ["dead", 398], ["-", 402], ["end", 403], ["species", 407], ["or", 415], ["even", 418], ["as", 423], ["a", 426], ["beneficial", 428], ["mechanism", 439], ["for", 449], ["clearing", 453], ["damaged", 462], ["proteins", 470], [".", 478], ["To", 480], ["alter", 483], ["the", 489], ["progression", 493], ["of", 505], ["the", 508], ["aggregation", 512], ["and", 524], ["gain", 528], ["insights", 533], ["into", 542], ["the", 547], ["prefibrillar", 551], ["structures", 564], [",", 574], ["we", 576], ["determined", 579], ["the", 590], ["effect", 594], ["of", 601], ["heme", 604], ["on", 609], ["\u03b1Syn", 612], ["oligomerization", 617], ["by", 633], ["several", 636], ["different", 644], ["techniques", 654], [",", 664], ["including", 666], ["native", 676], ["(", 683], ["nondenaturing", 684], [")", 697], ["polyacrylamide", 699], ["gel", 714], ["electrophoresis", 718], [",", 733], ["thioflavin", 735], ["T", 746], ["fluorescence", 748], [",", 760], ["transmission", 762], ["electron", 775], ["microscopy", 784], [",", 794], ["atomic", 796], ["force", 803], ["microscopy", 809], [",", 819], ["circular", 821], ["dichroism", 830], [",", 839], ["and", 841], ["membrane", 845], ["permeation", 854], ["using", 865], ["a", 871], ["calcein", 873], ["release", 881], ["assay", 889], [".", 894], ["During", 896], ["aggregation", 903], [",", 914], ["heme", 916], ["is", 921], ["able", 924], ["to", 929], ["bind", 932], ["the", 937], ["\u03b1Syn", 941], ["in", 946], ["a", 949], ["specific", 951], ["fashion", 960], [",", 967], ["stabilizing", 969], ["distinct", 981], ["oligomeric", 990], ["conformations", 1001], ["and", 1015], ["promoting", 1019], ["the", 1029], ["formation", 1033], ["of", 1043], ["\u03b1Syn", 1046], ["into", 1051], ["annular", 1056], ["structures", 1064], [",", 1074], ["thereby", 1076], ["delaying", 1084], ["and/or", 1093], ["inhibiting", 1100], ["the", 1111], ["fibrillation", 1115], ["process", 1128], [".", 1135], ["These", 1137], ["results", 1143], ["indicate", 1151], ["that", 1160], ["heme", 1165], ["may", 1170], ["play", 1174], ["a", 1179], ["regulatory", 1181], ["role", 1192], ["in", 1197], ["the", 1200], ["progression", 1204], ["of", 1216], ["Parkinson", 1219], ["'s", 1228], ["disease", 1231], [";", 1238], ["in", 1240], ["addition", 1243], [",", 1251], ["they", 1253], ["provide", 1258], ["insights", 1266], ["into", 1275], ["how", 1280], ["the", 1284], ["aggregation", 1288], ["process", 1300], ["may", 1308], ["be", 1312], ["altered", 1315], [",", 1322], ["which", 1324], ["may", 1330], ["be", 1334], ["applicable", 1337], ["to", 1348], ["the", 1351], ["understanding", 1355], ["of", 1369], ["many", 1372], ["neurodegenerative", 1377], ["diseases", 1395], [".", 1403]]}
{"context": "Low back pain with or without radiculopathy is an important cause of disability and economic expenditure. However, many patients are not meeting optimal pain control through existing treatments. Recent studies have linked nerve growth factor (NGF) and the pathophysiology of persistent pain. Anti-NGF could be an alternative drug treatment for low back pain. Systematically review the efficacy and safety of anti-NGF in the treatment of low back pain. A systematic review of the literature with no language, date or publication status restriction, using Medline, EMBASE, Cochrane Library, and the clinicaltrials.gov database. Additional literature was retrieved by conferring with experts in the field or reviewing bibliographies and annals of meetings and congresses. Search terms included \"monoclonal antibodies,\" \"nerve growth factor,\" \"anti-ngf,\" \"fulranumab,\" \"tanezumab,\" \"sciatica,\" \"back pain,\" and \"spine.\" Inclusion criteria were observational studies with safety as an outcome and randomized or nonrandomized controlled trials studying the efficacy and/or the safety of anti-NGF drugs on low back pain. Exclusion criteria included patients with autoimmune conditions or osteoporosis. Studies were assessed independently by 2 authors regarding inclusion/exclusion criteria, risk of bias, clinical relevance, and quality of evidence (GRADE approach). 1,168 studies were retrieved. After excluding duplicates and applying the inclusion/exclusion criteria, 4 RCTs remained (n = 2,109): 2 for tanezumab, one for REGN475, and one for fulranumab. Only the tanezumab studies showed any significant difference over placebo (n = 1,563) for both pain relief and functional improvement. There is very low evidence that systemically administered anti-NGF therapy has a small positive effect compared to placebo for both pain relief (standarized mean difference [SMD] = -0.29, 95% confidence interval [CI] -0.58 to 0.00) and functional improvement (SMD = -0.21, 95%CI -0.37 to -0.05 ) of low back pain. There was low evidence of adverse effects (AEs) compared to placebo and low evidence of neurological AEs than placebo (relative risk = 1.93, 95%CI 1.41 to 2.64).Tanezumab, as a specific anti-NGF treatment, showed low evidence of a small to moderate effect for pain relief of low back pain (SMD = -0.44, 95%CI -0.81 to -0.07); and low evidence of a small effect for functional improvement (SMD = -0.26, 95%CI -0.40 to -0.12) with systemic administration, although not clinically significant. Tanezumab and anti-NGFs overall had, respectively, moderate and low evidence of overall AEs and serious AEs and a higher risk of developing neurological AEs when compared with placebo. Although anti-NGF, specifically tanezumab, showed a low-to-moderate effect on pain relief and functional improvement, it cannot be recommended for low back pain treatment. Without more research on the pathophysiology of anti-NGFs and adverse effects, its use is not safe in the overall population. However, as corroborated by the US Food and Drug Administration, this meta-analysis underscores a role for greater insight into anti-NGF therapy for painful conditions that are refractory to current drugs, such as oncologic pain, chronic pancreatitis, and phantom-limb pain. Given the pathophysiology of axial pain involving inflammatory mediators and the adverse effects of systemic anti-NGF use, consideration of local therapies may warrant further exploration.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "2ab00371c0644e0ca45158c35d6dbf8e", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[139, 141], [35, 37]], "char_spans": [[817, 835], [222, 240]]}, {"text": "NGF", "token_spans": [[147, 147], [197, 197], [314, 314], [499, 499], [579, 579], [404, 404], [39, 39], [71, 71], [50, 50], [622, 622]], "char_spans": [[845, 847], [1086, 1088], [1749, 1751], [2690, 2692], [3107, 3109], [2191, 2193], [243, 245], [413, 415], [297, 299], [3363, 3365]]}]}], "context_tokens": [["Low", 0], ["back", 4], ["pain", 9], ["with", 14], ["or", 19], ["without", 22], ["radiculopathy", 30], ["is", 44], ["an", 47], ["important", 50], ["cause", 60], ["of", 66], ["disability", 69], ["and", 80], ["economic", 84], ["expenditure", 93], [".", 104], ["However", 106], [",", 113], ["many", 115], ["patients", 120], ["are", 129], ["not", 133], ["meeting", 137], ["optimal", 145], ["pain", 153], ["control", 158], ["through", 166], ["existing", 174], ["treatments", 183], [".", 193], ["Recent", 195], ["studies", 202], ["have", 210], ["linked", 215], ["nerve", 222], ["growth", 228], ["factor", 235], ["(", 242], ["NGF", 243], [")", 246], ["and", 248], ["the", 252], ["pathophysiology", 256], ["of", 272], ["persistent", 275], ["pain", 286], [".", 290], ["Anti", 292], ["-", 296], ["NGF", 297], ["could", 301], ["be", 307], ["an", 310], ["alternative", 313], ["drug", 325], ["treatment", 330], ["for", 340], ["low", 344], ["back", 348], ["pain", 353], [".", 357], ["Systematically", 359], ["review", 374], ["the", 381], ["efficacy", 385], ["and", 394], ["safety", 398], ["of", 405], ["anti", 408], ["-", 412], ["NGF", 413], ["in", 417], ["the", 420], ["treatment", 424], ["of", 434], ["low", 437], ["back", 441], ["pain", 446], [".", 450], ["A", 452], ["systematic", 454], ["review", 465], ["of", 472], ["the", 475], ["literature", 479], ["with", 490], ["no", 495], ["language", 498], [",", 506], ["date", 508], ["or", 513], ["publication", 516], ["status", 528], ["restriction", 535], [",", 546], ["using", 548], ["Medline", 554], [",", 561], ["EMBASE", 563], [",", 569], ["Cochrane", 571], ["Library", 580], [",", 587], ["and", 589], ["the", 593], ["clinicaltrials.gov", 597], ["database", 616], [".", 624], ["Additional", 626], ["literature", 637], ["was", 648], ["retrieved", 652], ["by", 662], ["conferring", 665], ["with", 676], ["experts", 681], ["in", 689], ["the", 692], ["field", 696], ["or", 702], ["reviewing", 705], ["bibliographies", 715], ["and", 730], ["annals", 734], ["of", 741], ["meetings", 744], ["and", 753], ["congresses", 757], [".", 767], ["Search", 769], ["terms", 776], ["included", 782], ["\"", 791], ["monoclonal", 792], ["antibodies", 803], [",", 813], ["\"", 814], ["\"", 816], ["nerve", 817], ["growth", 823], ["factor", 830], [",", 836], ["\"", 837], ["\"", 839], ["anti", 840], ["-", 844], ["ngf", 845], [",", 848], ["\"", 849], ["\"", 851], ["fulranumab", 852], [",", 862], ["\"", 863], ["\"", 865], ["tanezumab", 866], [",", 875], ["\"", 876], ["\"", 878], ["sciatica", 879], [",", 887], ["\"", 888], ["\"", 890], ["back", 891], ["pain", 896], [",", 900], ["\"", 901], ["and", 903], ["\"", 907], ["spine", 908], [".", 913], ["\"", 914], ["Inclusion", 916], ["criteria", 926], ["were", 935], ["observational", 940], ["studies", 954], ["with", 962], ["safety", 967], ["as", 974], ["an", 977], ["outcome", 980], ["and", 988], ["randomized", 992], ["or", 1003], ["nonrandomized", 1006], ["controlled", 1020], ["trials", 1031], ["studying", 1038], ["the", 1047], ["efficacy", 1051], ["and/or", 1060], ["the", 1067], ["safety", 1071], ["of", 1078], ["anti", 1081], ["-", 1085], ["NGF", 1086], ["drugs", 1090], ["on", 1096], ["low", 1099], ["back", 1103], ["pain", 1108], [".", 1112], ["Exclusion", 1114], ["criteria", 1124], ["included", 1133], ["patients", 1142], ["with", 1151], ["autoimmune", 1156], ["conditions", 1167], ["or", 1178], ["osteoporosis", 1181], [".", 1193], ["Studies", 1195], ["were", 1203], ["assessed", 1208], ["independently", 1217], ["by", 1231], ["2", 1234], ["authors", 1236], ["regarding", 1244], ["inclusion", 1254], ["/", 1263], ["exclusion", 1264], ["criteria", 1274], [",", 1282], ["risk", 1284], ["of", 1289], ["bias", 1292], [",", 1296], ["clinical", 1298], ["relevance", 1307], [",", 1316], ["and", 1318], ["quality", 1322], ["of", 1330], ["evidence", 1333], ["(", 1342], ["GRADE", 1343], ["approach", 1349], [")", 1357], [".", 1358], ["1,168", 1360], ["studies", 1366], ["were", 1374], ["retrieved", 1379], [".", 1388], ["After", 1390], ["excluding", 1396], ["duplicates", 1406], ["and", 1417], ["applying", 1421], ["the", 1430], ["inclusion", 1434], ["/", 1443], ["exclusion", 1444], ["criteria", 1454], [",", 1462], ["4", 1464], ["RCTs", 1466], ["remained", 1471], ["(", 1480], ["n", 1481], ["=", 1483], ["2,109", 1485], [")", 1490], [":", 1491], ["2", 1493], ["for", 1495], ["tanezumab", 1499], [",", 1508], ["one", 1510], ["for", 1514], ["REGN475", 1518], [",", 1525], ["and", 1527], ["one", 1531], ["for", 1535], ["fulranumab", 1539], [".", 1549], ["Only", 1551], ["the", 1556], ["tanezumab", 1560], ["studies", 1570], ["showed", 1578], ["any", 1585], ["significant", 1589], ["difference", 1601], ["over", 1612], ["placebo", 1617], ["(", 1625], ["n", 1626], ["=", 1628], ["1,563", 1630], [")", 1635], ["for", 1637], ["both", 1641], ["pain", 1646], ["relief", 1651], ["and", 1658], ["functional", 1662], ["improvement", 1673], [".", 1684], ["There", 1686], ["is", 1692], ["very", 1695], ["low", 1700], ["evidence", 1704], ["that", 1713], ["systemically", 1718], ["administered", 1731], ["anti", 1744], ["-", 1748], ["NGF", 1749], ["therapy", 1753], ["has", 1761], ["a", 1765], ["small", 1767], ["positive", 1773], ["effect", 1782], ["compared", 1789], ["to", 1798], ["placebo", 1801], ["for", 1809], ["both", 1813], ["pain", 1818], ["relief", 1823], ["(", 1830], ["standarized", 1831], ["mean", 1843], ["difference", 1848], ["[", 1859], ["SMD", 1860], ["]", 1863], ["=", 1865], ["-0.29", 1867], [",", 1872], ["95", 1874], ["%", 1876], ["confidence", 1878], ["interval", 1889], ["[", 1898], ["CI", 1899], ["]", 1901], ["-0.58", 1903], ["to", 1909], ["0.00", 1912], [")", 1916], ["and", 1918], ["functional", 1922], ["improvement", 1933], ["(", 1945], ["SMD", 1946], ["=", 1950], ["-0.21", 1952], [",", 1957], ["95%CI", 1959], ["-0.37", 1965], ["to", 1971], ["-0.05", 1974], [")", 1980], ["of", 1982], ["low", 1985], ["back", 1989], ["pain", 1994], [".", 1998], ["There", 2000], ["was", 2006], ["low", 2010], ["evidence", 2014], ["of", 2023], ["adverse", 2026], ["effects", 2034], ["(", 2042], ["AEs", 2043], [")", 2046], ["compared", 2048], ["to", 2057], ["placebo", 2060], ["and", 2068], ["low", 2072], ["evidence", 2076], ["of", 2085], ["neurological", 2088], ["AEs", 2101], ["than", 2105], ["placebo", 2110], ["(", 2118], ["relative", 2119], ["risk", 2128], ["=", 2133], ["1.93", 2135], [",", 2139], ["95%CI", 2141], ["1.41", 2147], ["to", 2152], ["2.64).Tanezumab", 2155], [",", 2170], ["as", 2172], ["a", 2175], ["specific", 2177], ["anti", 2186], ["-", 2190], ["NGF", 2191], ["treatment", 2195], [",", 2204], ["showed", 2206], ["low", 2213], ["evidence", 2217], ["of", 2226], ["a", 2229], ["small", 2231], ["to", 2237], ["moderate", 2240], ["effect", 2249], ["for", 2256], ["pain", 2260], ["relief", 2265], ["of", 2272], ["low", 2275], ["back", 2279], ["pain", 2284], ["(", 2289], ["SMD", 2290], ["=", 2294], ["-0.44", 2296], [",", 2301], ["95%CI", 2303], ["-0.81", 2309], ["to", 2315], ["-0.07", 2318], [")", 2323], [";", 2324], ["and", 2326], ["low", 2330], ["evidence", 2334], ["of", 2343], ["a", 2346], ["small", 2348], ["effect", 2354], ["for", 2361], ["functional", 2365], ["improvement", 2376], ["(", 2388], ["SMD", 2389], ["=", 2393], ["-0.26", 2395], [",", 2400], ["95%CI", 2402], ["-0.40", 2408], ["to", 2414], ["-0.12", 2417], [")", 2422], ["with", 2424], ["systemic", 2429], ["administration", 2438], [",", 2452], ["although", 2454], ["not", 2463], ["clinically", 2467], ["significant", 2478], [".", 2489], ["Tanezumab", 2491], ["and", 2501], ["anti", 2505], ["-", 2509], ["NGFs", 2510], ["overall", 2515], ["had", 2523], [",", 2526], ["respectively", 2528], [",", 2540], ["moderate", 2542], ["and", 2551], ["low", 2555], ["evidence", 2559], ["of", 2568], ["overall", 2571], ["AEs", 2579], ["and", 2583], ["serious", 2587], ["AEs", 2595], ["and", 2599], ["a", 2603], ["higher", 2605], ["risk", 2612], ["of", 2617], ["developing", 2620], ["neurological", 2631], ["AEs", 2644], ["when", 2648], ["compared", 2653], ["with", 2662], ["placebo", 2667], [".", 2674], ["Although", 2676], ["anti", 2685], ["-", 2689], ["NGF", 2690], [",", 2693], ["specifically", 2695], ["tanezumab", 2708], [",", 2717], ["showed", 2719], ["a", 2726], ["low", 2728], ["-", 2731], ["to", 2732], ["-", 2734], ["moderate", 2735], ["effect", 2744], ["on", 2751], ["pain", 2754], ["relief", 2759], ["and", 2766], ["functional", 2770], ["improvement", 2781], [",", 2792], ["it", 2794], ["can", 2797], ["not", 2800], ["be", 2804], ["recommended", 2807], ["for", 2819], ["low", 2823], ["back", 2827], ["pain", 2832], ["treatment", 2837], [".", 2846], ["Without", 2848], ["more", 2856], ["research", 2861], ["on", 2870], ["the", 2873], ["pathophysiology", 2877], ["of", 2893], ["anti", 2896], ["-", 2900], ["NGFs", 2901], ["and", 2906], ["adverse", 2910], ["effects", 2918], [",", 2925], ["its", 2927], ["use", 2931], ["is", 2935], ["not", 2938], ["safe", 2942], ["in", 2947], ["the", 2950], ["overall", 2954], ["population", 2962], [".", 2972], ["However", 2974], [",", 2981], ["as", 2983], ["corroborated", 2986], ["by", 2999], ["the", 3002], ["US", 3006], ["Food", 3009], ["and", 3014], ["Drug", 3018], ["Administration", 3023], [",", 3037], ["this", 3039], ["meta", 3044], ["-", 3048], ["analysis", 3049], ["underscores", 3058], ["a", 3070], ["role", 3072], ["for", 3077], ["greater", 3081], ["insight", 3089], ["into", 3097], ["anti", 3102], ["-", 3106], ["NGF", 3107], ["therapy", 3111], ["for", 3119], ["painful", 3123], ["conditions", 3131], ["that", 3142], ["are", 3147], ["refractory", 3151], ["to", 3162], ["current", 3165], ["drugs", 3173], [",", 3178], ["such", 3180], ["as", 3185], ["oncologic", 3188], ["pain", 3198], [",", 3202], ["chronic", 3204], ["pancreatitis", 3212], [",", 3224], ["and", 3226], ["phantom", 3230], ["-", 3237], ["limb", 3238], ["pain", 3243], [".", 3247], ["Given", 3249], ["the", 3255], ["pathophysiology", 3259], ["of", 3275], ["axial", 3278], ["pain", 3284], ["involving", 3289], ["inflammatory", 3299], ["mediators", 3312], ["and", 3322], ["the", 3326], ["adverse", 3330], ["effects", 3338], ["of", 3346], ["systemic", 3349], ["anti", 3358], ["-", 3362], ["NGF", 3363], ["use", 3367], [",", 3370], ["consideration", 3372], ["of", 3386], ["local", 3389], ["therapies", 3395], ["may", 3405], ["warrant", 3409], ["further", 3417], ["exploration", 3425], [".", 3436]]}
{"context": "Direct oral anticoagulants (DOACs) offer noninferior efficacy and improved safety compared to vitamin K antagonists (VKAs) for the prevention and treatment of venous thromboembolism and for the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Unlike VKAs, DOACs do not require routine laboratory monitoring of anticoagulant effect and dose adjustment. In certain situations, however, laboratory assessment of anticoagulant effect may be desirable. Here we review the utility of currently available assays for assessment of DOAC effect and recommend an optimal assessment strategy for each drug, including calibrated dilute thrombin time or ecarin-based assays for dabigatran and calibrated anti-Xa activity assays for the factor Xa inhibitors. We also discuss reversal strategies, both specific and nonspecific, for each drug, including the preferential use of idarucizumab for the reversal of dabigatran and two agents, andexanet and ciraparantag, currently under development for the reversal of rivaroxaban, apixaban, and edoxaban.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "e6ccf71d79284970a5d7adfff0807ec8", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[148, 148], [109, 109]], "char_spans": [[924, 933], [694, 703]]}]}], "context_tokens": [["Direct", 0], ["oral", 7], ["anticoagulants", 12], ["(", 27], ["DOACs", 28], [")", 33], ["offer", 35], ["noninferior", 41], ["efficacy", 53], ["and", 62], ["improved", 66], ["safety", 75], ["compared", 82], ["to", 91], ["vitamin", 94], ["K", 102], ["antagonists", 104], ["(", 116], ["VKAs", 117], [")", 121], ["for", 123], ["the", 127], ["prevention", 131], ["and", 142], ["treatment", 146], ["of", 156], ["venous", 159], ["thromboembolism", 166], ["and", 182], ["for", 186], ["the", 190], ["prevention", 194], ["of", 205], ["stroke", 208], ["and", 215], ["systemic", 219], ["embolism", 228], ["in", 237], ["nonvalvular", 240], ["atrial", 252], ["fibrillation", 259], [".", 271], ["Unlike", 273], ["VKAs", 280], [",", 284], ["DOACs", 286], ["do", 292], ["not", 295], ["require", 299], ["routine", 307], ["laboratory", 315], ["monitoring", 326], ["of", 337], ["anticoagulant", 340], ["effect", 354], ["and", 361], ["dose", 365], ["adjustment", 370], [".", 380], ["In", 382], ["certain", 385], ["situations", 393], [",", 403], ["however", 405], [",", 412], ["laboratory", 414], ["assessment", 425], ["of", 436], ["anticoagulant", 439], ["effect", 453], ["may", 460], ["be", 464], ["desirable", 467], [".", 476], ["Here", 478], ["we", 483], ["review", 486], ["the", 493], ["utility", 497], ["of", 505], ["currently", 508], ["available", 518], ["assays", 528], ["for", 535], ["assessment", 539], ["of", 550], ["DOAC", 553], ["effect", 558], ["and", 565], ["recommend", 569], ["an", 579], ["optimal", 582], ["assessment", 590], ["strategy", 601], ["for", 610], ["each", 614], ["drug", 619], [",", 623], ["including", 625], ["calibrated", 635], ["dilute", 646], ["thrombin", 653], ["time", 662], ["or", 667], ["ecarin", 670], ["-", 676], ["based", 677], ["assays", 683], ["for", 690], ["dabigatran", 694], ["and", 705], ["calibrated", 709], ["anti", 720], ["-", 724], ["Xa", 725], ["activity", 728], ["assays", 737], ["for", 744], ["the", 748], ["factor", 752], ["Xa", 759], ["inhibitors", 762], [".", 772], ["We", 774], ["also", 777], ["discuss", 782], ["reversal", 790], ["strategies", 799], [",", 809], ["both", 811], ["specific", 816], ["and", 825], ["nonspecific", 829], [",", 840], ["for", 842], ["each", 846], ["drug", 851], [",", 855], ["including", 857], ["the", 867], ["preferential", 871], ["use", 884], ["of", 888], ["idarucizumab", 891], ["for", 904], ["the", 908], ["reversal", 912], ["of", 921], ["dabigatran", 924], ["and", 935], ["two", 939], ["agents", 943], [",", 949], ["andexanet", 951], ["and", 961], ["ciraparantag", 965], [",", 977], ["currently", 979], ["under", 989], ["development", 995], ["for", 1007], ["the", 1011], ["reversal", 1015], ["of", 1024], ["rivaroxaban", 1027], [",", 1038], ["apixaban", 1040], [",", 1048], ["and", 1050], ["edoxaban", 1054], [".", 1062]]}
{"context": "A novel approach to design selective spleen tyrosine kinase (Syk) inhibitors is described. Inhibition of spleen tyrosine kinase has attracted much attention as a mechanism for the treatment of autoimmune diseases such as asthma, rheumatoid arthritis, and SLE. Fostamatinib, a Syk inhibitor that successfully completed phase II clinical trials, also exhibits some undesirable side effects. More selective Syk inhibitors could offer safer, alternative treatments. Through a systematic evaluation of the kinome, we identified Pro455 and Asn457 in the Syk ATP binding site as a rare combination among sequence aligned kinases and hypothesized that optimizing the interaction between them and a Syk inhibitor molecule would impart high selectivity for Syk over other kinases. We report the structure-guided identification of three series of selective spleen tyrosine kinase inhibitors that support our hypothesis and offer useful guidance to other researchers in the field.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "a684e2797a984c48b274c3513981d491", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[137, 139], [18, 20], [6, 8]], "char_spans": [[846, 867], [105, 126], [37, 58]]}]}], "context_tokens": [["A", 0], ["novel", 2], ["approach", 8], ["to", 17], ["design", 20], ["selective", 27], ["spleen", 37], ["tyrosine", 44], ["kinase", 53], ["(", 60], ["Syk", 61], [")", 64], ["inhibitors", 66], ["is", 77], ["described", 80], [".", 89], ["Inhibition", 91], ["of", 102], ["spleen", 105], ["tyrosine", 112], ["kinase", 121], ["has", 128], ["attracted", 132], ["much", 142], ["attention", 147], ["as", 157], ["a", 160], ["mechanism", 162], ["for", 172], ["the", 176], ["treatment", 180], ["of", 190], ["autoimmune", 193], ["diseases", 204], ["such", 213], ["as", 218], ["asthma", 221], [",", 227], ["rheumatoid", 229], ["arthritis", 240], [",", 249], ["and", 251], ["SLE", 255], [".", 258], ["Fostamatinib", 260], [",", 272], ["a", 274], ["Syk", 276], ["inhibitor", 280], ["that", 290], ["successfully", 295], ["completed", 308], ["phase", 318], ["II", 324], ["clinical", 327], ["trials", 336], [",", 342], ["also", 344], ["exhibits", 349], ["some", 358], ["undesirable", 363], ["side", 375], ["effects", 380], [".", 387], ["More", 389], ["selective", 394], ["Syk", 404], ["inhibitors", 408], ["could", 419], ["offer", 425], ["safer", 431], [",", 436], ["alternative", 438], ["treatments", 450], [".", 460], ["Through", 462], ["a", 470], ["systematic", 472], ["evaluation", 483], ["of", 494], ["the", 497], ["kinome", 501], [",", 507], ["we", 509], ["identified", 512], ["Pro455", 523], ["and", 530], ["Asn457", 534], ["in", 541], ["the", 544], ["Syk", 548], ["ATP", 552], ["binding", 556], ["site", 564], ["as", 569], ["a", 572], ["rare", 574], ["combination", 579], ["among", 591], ["sequence", 597], ["aligned", 606], ["kinases", 614], ["and", 622], ["hypothesized", 626], ["that", 639], ["optimizing", 644], ["the", 655], ["interaction", 659], ["between", 671], ["them", 679], ["and", 684], ["a", 688], ["Syk", 690], ["inhibitor", 694], ["molecule", 704], ["would", 713], ["impart", 719], ["high", 726], ["selectivity", 731], ["for", 743], ["Syk", 747], ["over", 751], ["other", 756], ["kinases", 762], [".", 769], ["We", 771], ["report", 774], ["the", 781], ["structure", 785], ["-", 794], ["guided", 795], ["identification", 802], ["of", 817], ["three", 820], ["series", 826], ["of", 833], ["selective", 836], ["spleen", 846], ["tyrosine", 853], ["kinase", 862], ["inhibitors", 869], ["that", 880], ["support", 885], ["our", 893], ["hypothesis", 897], ["and", 908], ["offer", 912], ["useful", 918], ["guidance", 925], ["to", 934], ["other", 937], ["researchers", 943], ["in", 955], ["the", 958], ["field", 962], [".", 967]]}
{"context": "In chronic myelogenous leukemia (CML), the development of chromosomal abnormalities in addition to the Philadelphia chromosome (clonal evolution) is considered by many to be a feature of accelerated phase (AP). Imatinib mesylate (STI571), a selective inhibitor of the Bcr-Abl tyrosine kinase, has significant activity in AP CML. As clonal evolution could allow Bcr-Abl independent proliferation, we analyzed its impact on the outcome of 71 AP patients treated with 600 mg of imatinib mesylate. Fifteen patients had clonal evolution alone (AP-CE), 32 had AP features but no evidence of clonal evolution (HEM-AP), and 24 had AP features plus clonal evolution (HEM-AP + CE). Of the AP-CE patients, 73% had a major cytogenetic response, compared with 31% of the HEM-AP patients (P =.043) and 12.5% of the HEM-AP + CE patients (P =.007). Complete cytogenetic responses were seen in 60% of AP-CE patients, compared with 31% of HEM-AP patients (P =.19) and 8% of HEM-AP + CE patients (P <.001). With mean follow-up of 11.2 months, 35% of all patients failed treatment. The lowest estimated rate of treatment failure at 1 year, 0%, was seen in AP-CE patients, compared with rates of 31% for HEM-AP patients and 69% for HEM-AP + CE patients (P =.0004). After 1 year, 100% of AP-CE patients were still alive, compared with 85% of HEM-AP patients and 67.5% of HEM-AP + CE patients (P =.01). In conclusion, in patients with clonal evolution as the sole criterion of disease acceleration, good responses to imatinib are still possible. Once patients have other signs of acceleration, clonal evolution predicts lower response rates and a shorter time to treatment failure.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "3cc897405a194e8f95127a9560586a7a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[49, 51], [67, 69]], "char_spans": [[268, 274], [361, 367]]}]}], "context_tokens": [["In", 0], ["chronic", 3], ["myelogenous", 11], ["leukemia", 23], ["(", 32], ["CML", 33], [")", 36], [",", 37], ["the", 39], ["development", 43], ["of", 55], ["chromosomal", 58], ["abnormalities", 70], ["in", 84], ["addition", 87], ["to", 96], ["the", 99], ["Philadelphia", 103], ["chromosome", 116], ["(", 127], ["clonal", 128], ["evolution", 135], [")", 144], ["is", 146], ["considered", 149], ["by", 160], ["many", 163], ["to", 168], ["be", 171], ["a", 174], ["feature", 176], ["of", 184], ["accelerated", 187], ["phase", 199], ["(", 205], ["AP", 206], [")", 208], [".", 209], ["Imatinib", 211], ["mesylate", 220], ["(", 229], ["STI571", 230], [")", 236], [",", 237], ["a", 239], ["selective", 241], ["inhibitor", 251], ["of", 261], ["the", 264], ["Bcr", 268], ["-", 271], ["Abl", 272], ["tyrosine", 276], ["kinase", 285], [",", 291], ["has", 293], ["significant", 297], ["activity", 309], ["in", 318], ["AP", 321], ["CML", 324], [".", 327], ["As", 329], ["clonal", 332], ["evolution", 339], ["could", 349], ["allow", 355], ["Bcr", 361], ["-", 364], ["Abl", 365], ["independent", 369], ["proliferation", 381], [",", 394], ["we", 396], ["analyzed", 399], ["its", 408], ["impact", 412], ["on", 419], ["the", 422], ["outcome", 426], ["of", 434], ["71", 437], ["AP", 440], ["patients", 443], ["treated", 452], ["with", 460], ["600", 465], ["mg", 469], ["of", 472], ["imatinib", 475], ["mesylate", 484], [".", 492], ["Fifteen", 494], ["patients", 502], ["had", 511], ["clonal", 515], ["evolution", 522], ["alone", 532], ["(", 538], ["AP", 539], ["-", 541], ["CE", 542], [")", 544], [",", 545], ["32", 547], ["had", 550], ["AP", 554], ["features", 557], ["but", 566], ["no", 570], ["evidence", 573], ["of", 582], ["clonal", 585], ["evolution", 592], ["(", 602], ["HEM", 603], ["-", 606], ["AP", 607], [")", 609], [",", 610], ["and", 612], ["24", 616], ["had", 619], ["AP", 623], ["features", 626], ["plus", 635], ["clonal", 640], ["evolution", 647], ["(", 657], ["HEM", 658], ["-", 661], ["AP", 662], ["+", 665], ["CE", 667], [")", 669], [".", 670], ["Of", 672], ["the", 675], ["AP", 679], ["-", 681], ["CE", 682], ["patients", 685], [",", 693], ["73", 695], ["%", 697], ["had", 699], ["a", 703], ["major", 705], ["cytogenetic", 711], ["response", 723], [",", 731], ["compared", 733], ["with", 742], ["31", 747], ["%", 749], ["of", 751], ["the", 754], ["HEM", 758], ["-", 761], ["AP", 762], ["patients", 765], ["(", 774], ["P", 775], ["=", 777], [".043", 778], [")", 782], ["and", 784], ["12.5", 788], ["%", 792], ["of", 794], ["the", 797], ["HEM", 801], ["-", 804], ["AP", 805], ["+", 808], ["CE", 810], ["patients", 813], ["(", 822], ["P", 823], ["=", 825], [".007", 826], [")", 830], [".", 831], ["Complete", 833], ["cytogenetic", 842], ["responses", 854], ["were", 864], ["seen", 869], ["in", 874], ["60", 877], ["%", 879], ["of", 881], ["AP", 884], ["-", 886], ["CE", 887], ["patients", 890], [",", 898], ["compared", 900], ["with", 909], ["31", 914], ["%", 916], ["of", 918], ["HEM", 921], ["-", 924], ["AP", 925], ["patients", 928], ["(", 937], ["P", 938], ["=", 940], [".19", 941], [")", 944], ["and", 946], ["8", 950], ["%", 951], ["of", 953], ["HEM", 956], ["-", 959], ["AP", 960], ["+", 963], ["CE", 965], ["patients", 968], ["(", 977], ["P", 978], ["<", 980], [".001", 981], [")", 985], [".", 986], ["With", 988], ["mean", 993], ["follow", 998], ["-", 1004], ["up", 1005], ["of", 1008], ["11.2", 1011], ["months", 1016], [",", 1022], ["35", 1024], ["%", 1026], ["of", 1028], ["all", 1031], ["patients", 1035], ["failed", 1044], ["treatment", 1051], [".", 1060], ["The", 1062], ["lowest", 1066], ["estimated", 1073], ["rate", 1083], ["of", 1088], ["treatment", 1091], ["failure", 1101], ["at", 1109], ["1", 1112], ["year", 1114], [",", 1118], ["0", 1120], ["%", 1121], [",", 1122], ["was", 1124], ["seen", 1128], ["in", 1133], ["AP", 1136], ["-", 1138], ["CE", 1139], ["patients", 1142], [",", 1150], ["compared", 1152], ["with", 1161], ["rates", 1166], ["of", 1172], ["31", 1175], ["%", 1177], ["for", 1179], ["HEM", 1183], ["-", 1186], ["AP", 1187], ["patients", 1190], ["and", 1199], ["69", 1203], ["%", 1205], ["for", 1207], ["HEM", 1211], ["-", 1214], ["AP", 1215], ["+", 1218], ["CE", 1220], ["patients", 1223], ["(", 1232], ["P", 1233], ["=", 1235], [".0004", 1236], [")", 1241], [".", 1242], ["After", 1244], ["1", 1250], ["year", 1252], [",", 1256], ["100", 1258], ["%", 1261], ["of", 1263], ["AP", 1266], ["-", 1268], ["CE", 1269], ["patients", 1272], ["were", 1281], ["still", 1286], ["alive", 1292], [",", 1297], ["compared", 1299], ["with", 1308], ["85", 1313], ["%", 1315], ["of", 1317], ["HEM", 1320], ["-", 1323], ["AP", 1324], ["patients", 1327], ["and", 1336], ["67.5", 1340], ["%", 1344], ["of", 1346], ["HEM", 1349], ["-", 1352], ["AP", 1353], ["+", 1356], ["CE", 1358], ["patients", 1361], ["(", 1370], ["P", 1371], ["=", 1373], [".01", 1374], [")", 1377], [".", 1378], ["In", 1380], ["conclusion", 1383], [",", 1393], ["in", 1395], ["patients", 1398], ["with", 1407], ["clonal", 1412], ["evolution", 1419], ["as", 1429], ["the", 1432], ["sole", 1436], ["criterion", 1441], ["of", 1451], ["disease", 1454], ["acceleration", 1462], [",", 1474], ["good", 1476], ["responses", 1481], ["to", 1491], ["imatinib", 1494], ["are", 1503], ["still", 1507], ["possible", 1513], [".", 1521], ["Once", 1523], ["patients", 1528], ["have", 1537], ["other", 1542], ["signs", 1548], ["of", 1554], ["acceleration", 1557], [",", 1569], ["clonal", 1571], ["evolution", 1578], ["predicts", 1588], ["lower", 1597], ["response", 1603], ["rates", 1612], ["and", 1618], ["a", 1622], ["shorter", 1624], ["time", 1632], ["to", 1637], ["treatment", 1640], ["failure", 1650], [".", 1657]]}
{"context": "Allele-specific gene silencing by RNA interference (RNAi) is therapeutically useful for specifically suppressing the expression of alleles associated with disease. To realize such allele-specific RNAi (ASPRNAi), the design and assessment of small interfering RNA (siRNA) duplexes conferring ASP-RNAi is vital, but is also difficult. Here, we show ASP-RNAi against the Swedish- and London-type amyloid precursor protein (APP) variants related to familial Alzheimer's disease using two reporter alleles encoding the Photinus and Renilla luciferase genes and carrying mutant and wild-type allelic sequences in their 3'-untranslated regions. We examined the effects of siRNA duplexes against the mutant alleles in allele-specific gene silencing and off-target silencing against the wild-type allele under heterozygous conditions, which were generated by cotransfecting the reporter alleles and siRNA duplexes into cultured human cells. Consistently, the siRNA duplexes determined to confer ASP-RNAi also inhibited the expression of the bona fide mutant APP and the production of either amyloid beta 40- or 42-peptide in Cos-7 cells expressing both the full-length Swedish- and wild-type APP alleles. The present data suggest that the system with reporter alleles may permit the preclinical assessment of siRNA duplexes conferring ASP-RNAi, and thus contribute to the design and selection of the most suitable of such siRNA duplexes.", "qas": [{"question": "Which disease the London mutation involved in?", "answers": ["Alzheimer's Disease", "AD"], "qid": "32973e8f67554664bd82736f4b992923", "question_tokens": [["Which", 0], ["disease", 6], ["the", 14], ["London", 18], ["mutation", 25], ["involved", 34], ["in", 43], ["?", 45]], "detected_answers": [{"text": "Alzheimer's Disease", "token_spans": [[84, 86]], "char_spans": [[454, 472]]}]}], "context_tokens": [["Allele", 0], ["-", 6], ["specific", 7], ["gene", 16], ["silencing", 21], ["by", 31], ["RNA", 34], ["interference", 38], ["(", 51], ["RNAi", 52], [")", 56], ["is", 58], ["therapeutically", 61], ["useful", 77], ["for", 84], ["specifically", 88], ["suppressing", 101], ["the", 113], ["expression", 117], ["of", 128], ["alleles", 131], ["associated", 139], ["with", 150], ["disease", 155], [".", 162], ["To", 164], ["realize", 167], ["such", 175], ["allele", 180], ["-", 186], ["specific", 187], ["RNAi", 196], ["(", 201], ["ASPRNAi", 202], [")", 209], [",", 210], ["the", 212], ["design", 216], ["and", 223], ["assessment", 227], ["of", 238], ["small", 241], ["interfering", 247], ["RNA", 259], ["(", 263], ["siRNA", 264], [")", 269], ["duplexes", 271], ["conferring", 280], ["ASP", 291], ["-", 294], ["RNAi", 295], ["is", 300], ["vital", 303], [",", 308], ["but", 310], ["is", 314], ["also", 317], ["difficult", 322], [".", 331], ["Here", 333], [",", 337], ["we", 339], ["show", 342], ["ASP", 347], ["-", 350], ["RNAi", 351], ["against", 356], ["the", 364], ["Swedish-", 368], ["and", 377], ["London", 381], ["-", 387], ["type", 388], ["amyloid", 393], ["precursor", 401], ["protein", 411], ["(", 419], ["APP", 420], [")", 423], ["variants", 425], ["related", 434], ["to", 442], ["familial", 445], ["Alzheimer", 454], ["'s", 463], ["disease", 466], ["using", 474], ["two", 480], ["reporter", 484], ["alleles", 493], ["encoding", 501], ["the", 510], ["Photinus", 514], ["and", 523], ["Renilla", 527], ["luciferase", 535], ["genes", 546], ["and", 552], ["carrying", 556], ["mutant", 565], ["and", 572], ["wild", 576], ["-", 580], ["type", 581], ["allelic", 586], ["sequences", 594], ["in", 604], ["their", 607], ["3'-untranslated", 613], ["regions", 629], [".", 636], ["We", 638], ["examined", 641], ["the", 650], ["effects", 654], ["of", 662], ["siRNA", 665], ["duplexes", 671], ["against", 680], ["the", 688], ["mutant", 692], ["alleles", 699], ["in", 707], ["allele", 710], ["-", 716], ["specific", 717], ["gene", 726], ["silencing", 731], ["and", 741], ["off", 745], ["-", 748], ["target", 749], ["silencing", 756], ["against", 766], ["the", 774], ["wild", 778], ["-", 782], ["type", 783], ["allele", 788], ["under", 795], ["heterozygous", 801], ["conditions", 814], [",", 824], ["which", 826], ["were", 832], ["generated", 837], ["by", 847], ["cotransfecting", 850], ["the", 865], ["reporter", 869], ["alleles", 878], ["and", 886], ["siRNA", 890], ["duplexes", 896], ["into", 905], ["cultured", 910], ["human", 919], ["cells", 925], [".", 930], ["Consistently", 932], [",", 944], ["the", 946], ["siRNA", 950], ["duplexes", 956], ["determined", 965], ["to", 976], ["confer", 979], ["ASP", 986], ["-", 989], ["RNAi", 990], ["also", 995], ["inhibited", 1000], ["the", 1010], ["expression", 1014], ["of", 1025], ["the", 1028], ["bona", 1032], ["fide", 1037], ["mutant", 1042], ["APP", 1049], ["and", 1053], ["the", 1057], ["production", 1061], ["of", 1072], ["either", 1075], ["amyloid", 1082], ["beta", 1090], ["40-", 1095], ["or", 1099], ["42-peptide", 1102], ["in", 1113], ["Cos-7", 1116], ["cells", 1122], ["expressing", 1128], ["both", 1139], ["the", 1144], ["full", 1148], ["-", 1152], ["length", 1153], ["Swedish-", 1160], ["and", 1169], ["wild", 1173], ["-", 1177], ["type", 1178], ["APP", 1183], ["alleles", 1187], [".", 1194], ["The", 1196], ["present", 1200], ["data", 1208], ["suggest", 1213], ["that", 1221], ["the", 1226], ["system", 1230], ["with", 1237], ["reporter", 1242], ["alleles", 1251], ["may", 1259], ["permit", 1263], ["the", 1270], ["preclinical", 1274], ["assessment", 1286], ["of", 1297], ["siRNA", 1300], ["duplexes", 1306], ["conferring", 1315], ["ASP", 1326], ["-", 1329], ["RNAi", 1330], [",", 1334], ["and", 1336], ["thus", 1340], ["contribute", 1345], ["to", 1356], ["the", 1359], ["design", 1363], ["and", 1370], ["selection", 1374], ["of", 1384], ["the", 1387], ["most", 1391], ["suitable", 1396], ["of", 1405], ["such", 1408], ["siRNA", 1413], ["duplexes", 1419], [".", 1427]]}
{"context": "NADPH oxidase 1 (Nox1) is a multicomponent enzyme consisting of p22(phox), Nox organizer 1 (NOXO1), Nox1 activator 1, and Rac1. Interleukin-1beta, flagellin, interferon-gamma, and tumor necrosis factor alpha (TNF-alpha) similarly induced Nox1 in a colon cancer cell line (T84), whereas only TNF-alpha fully induced NOXO1 and upregulated superoxide-producing activity by ninefold. This upregulation was canceled by knockdown of NOXO1 with small interfering RNAs. TNF-alpha rapidly phosphorylated p38 mitogen-activated protein kinase and c-Jun N-terminal kinase 1/2, followed by phosphorylation of c-Jun and c-Fos and appearance of an AP-1 binding activity within 30 min. We cloned the 5' flank of the human NOXO1 gene (-3888 to +263 bp), and found that the region between -585 and -452 bp, which contains consensus elements of YY-1, AP-1, and Ets, and the GC-rich region encoding three putative binding sites for SP-1, was crucial for TNF-alpha-dependent promoter activity. Serial mutation analysis of the elements identified an AP-1 binding site (from -561 to -551 bp, agtAAGtcatg) as a crucial element for TNF-alpha-stimulated transcription of the human NOXO1 gene, which was also confirmed by the AP-1 decoy experiments. Thus, TNF-alpha acts as a potent activator of Nox1-based oxidase in colon epithelial cells, suggesting a potential role of this oxidase in inflammation of the colon.", "qas": [{"question": "Which NADPH oxidase family member requires interaction with NOXO1 for function?", "answers": ["NADPH oxidase 1", "NOX1", "nicotinamide adenine dinucleotide phosphate-oxidase 1"], "qid": "6779bef390824d269a423840772240f6", "question_tokens": [["Which", 0], ["NADPH", 6], ["oxidase", 12], ["family", 20], ["member", 27], ["requires", 34], ["interaction", 43], ["with", 55], ["NOXO1", 60], ["for", 66], ["function", 70], ["?", 78]], "detected_answers": [{"text": "NADPH oxidase 1", "token_spans": [[0, 2]], "char_spans": [[0, 14]]}, {"text": "NOX1", "token_spans": [[4, 4], [49, 49], [22, 22]], "char_spans": [[17, 20], [238, 241], [100, 103]]}]}], "context_tokens": [["NADPH", 0], ["oxidase", 6], ["1", 14], ["(", 16], ["Nox1", 17], [")", 21], ["is", 23], ["a", 26], ["multicomponent", 28], ["enzyme", 43], ["consisting", 50], ["of", 61], ["p22(phox", 64], [")", 72], [",", 73], ["Nox", 75], ["organizer", 79], ["1", 89], ["(", 91], ["NOXO1", 92], [")", 97], [",", 98], ["Nox1", 100], ["activator", 105], ["1", 115], [",", 116], ["and", 118], ["Rac1", 122], [".", 126], ["Interleukin-1beta", 128], [",", 145], ["flagellin", 147], [",", 156], ["interferon", 158], ["-", 168], ["gamma", 169], [",", 174], ["and", 176], ["tumor", 180], ["necrosis", 186], ["factor", 195], ["alpha", 202], ["(", 208], ["TNF", 209], ["-", 212], ["alpha", 213], [")", 218], ["similarly", 220], ["induced", 230], ["Nox1", 238], ["in", 243], ["a", 246], ["colon", 248], ["cancer", 254], ["cell", 261], ["line", 266], ["(", 271], ["T84", 272], [")", 275], [",", 276], ["whereas", 278], ["only", 286], ["TNF", 291], ["-", 294], ["alpha", 295], ["fully", 301], ["induced", 307], ["NOXO1", 315], ["and", 321], ["upregulated", 325], ["superoxide", 337], ["-", 347], ["producing", 348], ["activity", 358], ["by", 367], ["ninefold", 370], [".", 378], ["This", 380], ["upregulation", 385], ["was", 398], ["canceled", 402], ["by", 411], ["knockdown", 414], ["of", 424], ["NOXO1", 427], ["with", 433], ["small", 438], ["interfering", 444], ["RNAs", 456], [".", 460], ["TNF", 462], ["-", 465], ["alpha", 466], ["rapidly", 472], ["phosphorylated", 480], ["p38", 495], ["mitogen", 499], ["-", 506], ["activated", 507], ["protein", 517], ["kinase", 525], ["and", 532], ["c", 536], ["-", 537], ["Jun", 538], ["N", 542], ["-", 543], ["terminal", 544], ["kinase", 553], ["1/2", 560], [",", 563], ["followed", 565], ["by", 574], ["phosphorylation", 577], ["of", 593], ["c", 596], ["-", 597], ["Jun", 598], ["and", 602], ["c", 606], ["-", 607], ["Fos", 608], ["and", 612], ["appearance", 616], ["of", 627], ["an", 630], ["AP-1", 633], ["binding", 638], ["activity", 646], ["within", 655], ["30", 662], ["min", 665], [".", 668], ["We", 670], ["cloned", 673], ["the", 680], ["5", 684], ["'", 685], ["flank", 687], ["of", 693], ["the", 696], ["human", 700], ["NOXO1", 706], ["gene", 712], ["(", 717], ["-3888", 718], ["to", 724], ["+263", 727], ["bp", 732], [")", 734], [",", 735], ["and", 737], ["found", 741], ["that", 747], ["the", 752], ["region", 756], ["between", 763], ["-585", 771], ["and", 776], ["-452", 780], ["bp", 785], [",", 787], ["which", 789], ["contains", 795], ["consensus", 804], ["elements", 814], ["of", 823], ["YY-1", 826], [",", 830], ["AP-1", 832], [",", 836], ["and", 838], ["Ets", 842], [",", 845], ["and", 847], ["the", 851], ["GC", 855], ["-", 857], ["rich", 858], ["region", 863], ["encoding", 870], ["three", 879], ["putative", 885], ["binding", 894], ["sites", 902], ["for", 908], ["SP-1", 912], [",", 916], ["was", 918], ["crucial", 922], ["for", 930], ["TNF", 934], ["-", 937], ["alpha", 938], ["-", 943], ["dependent", 944], ["promoter", 954], ["activity", 963], [".", 971], ["Serial", 973], ["mutation", 980], ["analysis", 989], ["of", 998], ["the", 1001], ["elements", 1005], ["identified", 1014], ["an", 1025], ["AP-1", 1028], ["binding", 1033], ["site", 1041], ["(", 1046], ["from", 1047], ["-561", 1052], ["to", 1057], ["-551", 1060], ["bp", 1065], [",", 1067], ["agtAAGtcatg", 1069], [")", 1080], ["as", 1082], ["a", 1085], ["crucial", 1087], ["element", 1095], ["for", 1103], ["TNF", 1107], ["-", 1110], ["alpha", 1111], ["-", 1116], ["stimulated", 1117], ["transcription", 1128], ["of", 1142], ["the", 1145], ["human", 1149], ["NOXO1", 1155], ["gene", 1161], [",", 1165], ["which", 1167], ["was", 1173], ["also", 1177], ["confirmed", 1182], ["by", 1192], ["the", 1195], ["AP-1", 1199], ["decoy", 1204], ["experiments", 1210], [".", 1221], ["Thus", 1223], [",", 1227], ["TNF", 1229], ["-", 1232], ["alpha", 1233], ["acts", 1239], ["as", 1244], ["a", 1247], ["potent", 1249], ["activator", 1256], ["of", 1266], ["Nox1-based", 1269], ["oxidase", 1280], ["in", 1288], ["colon", 1291], ["epithelial", 1297], ["cells", 1308], [",", 1313], ["suggesting", 1315], ["a", 1326], ["potential", 1328], ["role", 1338], ["of", 1343], ["this", 1346], ["oxidase", 1351], ["in", 1359], ["inflammation", 1362], ["of", 1375], ["the", 1378], ["colon", 1382], [".", 1387]]}
{"context": "Machado-Joseph disease (MJD), also called spinocerebellar ataxia type 3, is caused by mutant ataxin-3 with a polyglutamine expansion. Although there is no treatment available at present to cure or delay the onset of MJD, mouse models have been generated to facilitate the development of a therapy. In this review, the published reports on mouse models of MJD and other polyglutamine spinocerebellar ataxias are compared. Based on these studies, the following approaches will be discussed as candidate treatments for MJD: 1) interfering with the formation of the mutant ataxin-3 cleavage fragment and possibly aggregate or inclusions, 2) reducing the disease protein nuclear localization, and 3) decreasing mutant ataxin-3 expression in neurons.", "qas": [{"question": "Which is the protein implicated in Spinocerebellar ataxia type 3?", "answers": ["Ataxin-3"], "qid": "e0187e9fdece45e5bba46192786ac6b4", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["protein", 13], ["implicated", 21], ["in", 32], ["Spinocerebellar", 35], ["ataxia", 51], ["type", 58], ["3", 63], ["?", 64]], "detected_answers": [{"text": "Ataxin-3", "token_spans": [[124, 124], [19, 19], [101, 101]], "char_spans": [[713, 720], [93, 100], [569, 576]]}]}], "context_tokens": [["Machado", 0], ["-", 7], ["Joseph", 8], ["disease", 15], ["(", 23], ["MJD", 24], [")", 27], [",", 28], ["also", 30], ["called", 35], ["spinocerebellar", 42], ["ataxia", 58], ["type", 65], ["3", 70], [",", 71], ["is", 73], ["caused", 76], ["by", 83], ["mutant", 86], ["ataxin-3", 93], ["with", 102], ["a", 107], ["polyglutamine", 109], ["expansion", 123], [".", 132], ["Although", 134], ["there", 143], ["is", 149], ["no", 152], ["treatment", 155], ["available", 165], ["at", 175], ["present", 178], ["to", 186], ["cure", 189], ["or", 194], ["delay", 197], ["the", 203], ["onset", 207], ["of", 213], ["MJD", 216], [",", 219], ["mouse", 221], ["models", 227], ["have", 234], ["been", 239], ["generated", 244], ["to", 254], ["facilitate", 257], ["the", 268], ["development", 272], ["of", 284], ["a", 287], ["therapy", 289], [".", 296], ["In", 298], ["this", 301], ["review", 306], [",", 312], ["the", 314], ["published", 318], ["reports", 328], ["on", 336], ["mouse", 339], ["models", 345], ["of", 352], ["MJD", 355], ["and", 359], ["other", 363], ["polyglutamine", 369], ["spinocerebellar", 383], ["ataxias", 399], ["are", 407], ["compared", 411], [".", 419], ["Based", 421], ["on", 427], ["these", 430], ["studies", 436], [",", 443], ["the", 445], ["following", 449], ["approaches", 459], ["will", 470], ["be", 475], ["discussed", 478], ["as", 488], ["candidate", 491], ["treatments", 501], ["for", 512], ["MJD", 516], [":", 519], ["1", 521], [")", 522], ["interfering", 524], ["with", 536], ["the", 541], ["formation", 545], ["of", 555], ["the", 558], ["mutant", 562], ["ataxin-3", 569], ["cleavage", 578], ["fragment", 587], ["and", 596], ["possibly", 600], ["aggregate", 609], ["or", 619], ["inclusions", 622], [",", 632], ["2", 634], [")", 635], ["reducing", 637], ["the", 646], ["disease", 650], ["protein", 658], ["nuclear", 666], ["localization", 674], [",", 686], ["and", 688], ["3", 692], [")", 693], ["decreasing", 695], ["mutant", 706], ["ataxin-3", 713], ["expression", 722], ["in", 733], ["neurons", 736], [".", 743]]}
{"context": "The acromelic dysplasia group includes three rare disorders: Weill-Marchesani syndrome (WMS), Geleophysic dysplasia (GD) and Acromicric dysplasia (AD) all characterized by short stature, short hands and stiff joints. The clinical overlap between the three disorders is striking. Indeed, in addition to the diagnostic criteria, they all share common features including delayed bone age, cone shaped epiphyses, thick skin and heart disease. In contrast, a microspherophakic lens seems to be a characteristic feature of WMS whereas hepatomegaly and a severe outcome are encountered only in the most severe forms of GD. Finally, WMS is transmitted either by an autosomal dominant or an autosomal recessive (AR) mode of inheritance, GD by an autosomal recessive mode of inheritance and AD by an autosomal dominant mode of inheritance. Using genetic approaches, we have identified the molecular basis of WMS and GD which both involved the same superfamily of proteins, the ADAMTS [A Disintegrin-like And Metalloproteinase domain (reprolysin type) with ThromboSpondin type 1 repeats (TSR)]. We have found ADAMTS10 mutations in the recessive form of WMS and Fibrillin 1 mutations in the dominant form of WMS. More recently, we have identified ADAMTSL2 mutations in GD. The function of ADAMTS1 0 and AD AMTSL 2 are unknown. But the findings of FBN1 and ADAMTS10 mutations in WMS suggest a direct link between the two proteins. Using a yeast double hybrid screen, we have identified LTBP1 (Latent TGFbeta Binding protein 1) as a partner of ADAMTSL2. The combination of these findings suggests that ADAMTS10 and ADAMTSL2 are both involved in the microfibrillar network.", "qas": [{"question": "What is the mode of inheritance of Acromicric dysplasia?", "answers": ["autosomal dominant"], "qid": "30fd38ce62fe459b88937446ee06bcbb", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Acromicric", 35], ["dysplasia", 46], ["?", 55]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[143, 144], [118, 119]], "char_spans": [[790, 807], [657, 674]]}]}], "context_tokens": [["The", 0], ["acromelic", 4], ["dysplasia", 14], ["group", 24], ["includes", 30], ["three", 39], ["rare", 45], ["disorders", 50], [":", 59], ["Weill", 61], ["-", 66], ["Marchesani", 67], ["syndrome", 78], ["(", 87], ["WMS", 88], [")", 91], [",", 92], ["Geleophysic", 94], ["dysplasia", 106], ["(", 116], ["GD", 117], [")", 119], ["and", 121], ["Acromicric", 125], ["dysplasia", 136], ["(", 146], ["AD", 147], [")", 149], ["all", 151], ["characterized", 155], ["by", 169], ["short", 172], ["stature", 178], [",", 185], ["short", 187], ["hands", 193], ["and", 199], ["stiff", 203], ["joints", 209], [".", 215], ["The", 217], ["clinical", 221], ["overlap", 230], ["between", 238], ["the", 246], ["three", 250], ["disorders", 256], ["is", 266], ["striking", 269], [".", 277], ["Indeed", 279], [",", 285], ["in", 287], ["addition", 290], ["to", 299], ["the", 302], ["diagnostic", 306], ["criteria", 317], [",", 325], ["they", 327], ["all", 332], ["share", 336], ["common", 342], ["features", 349], ["including", 358], ["delayed", 368], ["bone", 376], ["age", 381], [",", 384], ["cone", 386], ["shaped", 391], ["epiphyses", 398], [",", 407], ["thick", 409], ["skin", 415], ["and", 420], ["heart", 424], ["disease", 430], [".", 437], ["In", 439], ["contrast", 442], [",", 450], ["a", 452], ["microspherophakic", 454], ["lens", 472], ["seems", 477], ["to", 483], ["be", 486], ["a", 489], ["characteristic", 491], ["feature", 506], ["of", 514], ["WMS", 517], ["whereas", 521], ["hepatomegaly", 529], ["and", 542], ["a", 546], ["severe", 548], ["outcome", 555], ["are", 563], ["encountered", 567], ["only", 579], ["in", 584], ["the", 587], ["most", 591], ["severe", 596], ["forms", 603], ["of", 609], ["GD", 612], [".", 614], ["Finally", 616], [",", 623], ["WMS", 625], ["is", 629], ["transmitted", 632], ["either", 644], ["by", 651], ["an", 654], ["autosomal", 657], ["dominant", 667], ["or", 676], ["an", 679], ["autosomal", 682], ["recessive", 692], ["(", 702], ["AR", 703], [")", 705], ["mode", 707], ["of", 712], ["inheritance", 715], [",", 726], ["GD", 728], ["by", 731], ["an", 734], ["autosomal", 737], ["recessive", 747], ["mode", 757], ["of", 762], ["inheritance", 765], ["and", 777], ["AD", 781], ["by", 784], ["an", 787], ["autosomal", 790], ["dominant", 800], ["mode", 809], ["of", 814], ["inheritance", 817], [".", 828], ["Using", 830], ["genetic", 836], ["approaches", 844], [",", 854], ["we", 856], ["have", 859], ["identified", 864], ["the", 875], ["molecular", 879], ["basis", 889], ["of", 895], ["WMS", 898], ["and", 902], ["GD", 906], ["which", 909], ["both", 915], ["involved", 920], ["the", 929], ["same", 933], ["superfamily", 938], ["of", 950], ["proteins", 953], [",", 961], ["the", 963], ["ADAMTS", 967], ["[", 974], ["A", 975], ["Disintegrin", 977], ["-", 988], ["like", 989], ["And", 994], ["Metalloproteinase", 998], ["domain", 1016], ["(", 1023], ["reprolysin", 1024], ["type", 1035], [")", 1039], ["with", 1041], ["ThromboSpondin", 1046], ["type", 1061], ["1", 1066], ["repeats", 1068], ["(", 1076], ["TSR)].", 1077], ["We", 1084], ["have", 1087], ["found", 1092], ["ADAMTS10", 1098], ["mutations", 1107], ["in", 1117], ["the", 1120], ["recessive", 1124], ["form", 1134], ["of", 1139], ["WMS", 1142], ["and", 1146], ["Fibrillin", 1150], ["1", 1160], ["mutations", 1162], ["in", 1172], ["the", 1175], ["dominant", 1179], ["form", 1188], ["of", 1193], ["WMS", 1196], [".", 1199], ["More", 1201], ["recently", 1206], [",", 1214], ["we", 1216], ["have", 1219], ["identified", 1224], ["ADAMTSL2", 1235], ["mutations", 1244], ["in", 1254], ["GD", 1257], [".", 1259], ["The", 1261], ["function", 1265], ["of", 1274], ["ADAMTS1", 1277], ["0", 1285], ["and", 1287], ["AD", 1291], ["AMTSL", 1294], ["2", 1300], ["are", 1302], ["unknown", 1306], [".", 1313], ["But", 1315], ["the", 1319], ["findings", 1323], ["of", 1332], ["FBN1", 1335], ["and", 1340], ["ADAMTS10", 1344], ["mutations", 1353], ["in", 1363], ["WMS", 1366], ["suggest", 1370], ["a", 1378], ["direct", 1380], ["link", 1387], ["between", 1392], ["the", 1400], ["two", 1404], ["proteins", 1408], [".", 1416], ["Using", 1418], ["a", 1424], ["yeast", 1426], ["double", 1432], ["hybrid", 1439], ["screen", 1446], [",", 1452], ["we", 1454], ["have", 1457], ["identified", 1462], ["LTBP1", 1473], ["(", 1479], ["Latent", 1480], ["TGFbeta", 1487], ["Binding", 1495], ["protein", 1503], ["1", 1511], [")", 1512], ["as", 1514], ["a", 1517], ["partner", 1519], ["of", 1527], ["ADAMTSL2", 1530], [".", 1538], ["The", 1540], ["combination", 1544], ["of", 1556], ["these", 1559], ["findings", 1565], ["suggests", 1574], ["that", 1583], ["ADAMTS10", 1588], ["and", 1597], ["ADAMTSL2", 1601], ["are", 1610], ["both", 1614], ["involved", 1619], ["in", 1628], ["the", 1631], ["microfibrillar", 1635], ["network", 1650], [".", 1657]]}
{"context": "Mutations in the SLC9A6 gene cause Christianson syndrome in boys. This X-linked syndrome is characterized by profound mental retardation with autistic behavior, microcephaly, epilepsy, ophthalmoplegia, and ataxia. Progressive cerebellar atrophy with motor regression is a remarkable feature in some patients. We report on a 22year-old male patient with Christianson syndrome carrying the novel p.Gln306X mutation. The infantile phenotype suggested pervasive developmental disorder, then profound mental retardation ensued. In later childhood, progressive cerebellar atrophy was diagnosed on serial brain MRIs and motor regression occurred. Furthermore, ophthalmological evaluations showed a retinitis pigmentosum previously unreported in this condition. We conclude that the natural history of the disease in this patient tends to confirm the degenerative nature of Christianson syndrome, and that retinal degeneration may be part of the condition. Before the onset of degeneration, the syndromic association of severe mental retardation, autistic behavior, external ophthalmoplegia, and facial dysmorphism in male patients is a clue to the diagnosis.", "qas": [{"question": "Mutation of which gene is implicated in the Christianson syndrome?", "answers": ["SLC9A6"], "qid": "1c8d376fd6a5424aa7f69d6d2222e256", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["implicated", 26], ["in", 37], ["the", 40], ["Christianson", 44], ["syndrome", 57], ["?", 65]], "detected_answers": [{"text": "SLC9A6", "token_spans": [[3, 3]], "char_spans": [[17, 22]]}]}], "context_tokens": [["Mutations", 0], ["in", 10], ["the", 13], ["SLC9A6", 17], ["gene", 24], ["cause", 29], ["Christianson", 35], ["syndrome", 48], ["in", 57], ["boys", 60], [".", 64], ["This", 66], ["X", 71], ["-", 72], ["linked", 73], ["syndrome", 80], ["is", 89], ["characterized", 92], ["by", 106], ["profound", 109], ["mental", 118], ["retardation", 125], ["with", 137], ["autistic", 142], ["behavior", 151], [",", 159], ["microcephaly", 161], [",", 173], ["epilepsy", 175], [",", 183], ["ophthalmoplegia", 185], [",", 200], ["and", 202], ["ataxia", 206], [".", 212], ["Progressive", 214], ["cerebellar", 226], ["atrophy", 237], ["with", 245], ["motor", 250], ["regression", 256], ["is", 267], ["a", 270], ["remarkable", 272], ["feature", 283], ["in", 291], ["some", 294], ["patients", 299], [".", 307], ["We", 309], ["report", 312], ["on", 319], ["a", 322], ["22year", 324], ["-", 330], ["old", 331], ["male", 335], ["patient", 340], ["with", 348], ["Christianson", 353], ["syndrome", 366], ["carrying", 375], ["the", 384], ["novel", 388], ["p", 394], [".", 395], ["Gln306X", 396], ["mutation", 404], [".", 412], ["The", 414], ["infantile", 418], ["phenotype", 428], ["suggested", 438], ["pervasive", 448], ["developmental", 458], ["disorder", 472], [",", 480], ["then", 482], ["profound", 487], ["mental", 496], ["retardation", 503], ["ensued", 515], [".", 521], ["In", 523], ["later", 526], ["childhood", 532], [",", 541], ["progressive", 543], ["cerebellar", 555], ["atrophy", 566], ["was", 574], ["diagnosed", 578], ["on", 588], ["serial", 591], ["brain", 598], ["MRIs", 604], ["and", 609], ["motor", 613], ["regression", 619], ["occurred", 630], [".", 638], ["Furthermore", 640], [",", 651], ["ophthalmological", 653], ["evaluations", 670], ["showed", 682], ["a", 689], ["retinitis", 691], ["pigmentosum", 701], ["previously", 713], ["unreported", 724], ["in", 735], ["this", 738], ["condition", 743], [".", 752], ["We", 754], ["conclude", 757], ["that", 766], ["the", 771], ["natural", 775], ["history", 783], ["of", 791], ["the", 794], ["disease", 798], ["in", 806], ["this", 809], ["patient", 814], ["tends", 822], ["to", 828], ["confirm", 831], ["the", 839], ["degenerative", 843], ["nature", 856], ["of", 863], ["Christianson", 866], ["syndrome", 879], [",", 887], ["and", 889], ["that", 893], ["retinal", 898], ["degeneration", 906], ["may", 919], ["be", 923], ["part", 926], ["of", 931], ["the", 934], ["condition", 938], [".", 947], ["Before", 949], ["the", 956], ["onset", 960], ["of", 966], ["degeneration", 969], [",", 981], ["the", 983], ["syndromic", 987], ["association", 997], ["of", 1009], ["severe", 1012], ["mental", 1019], ["retardation", 1026], [",", 1037], ["autistic", 1039], ["behavior", 1048], [",", 1056], ["external", 1058], ["ophthalmoplegia", 1067], [",", 1082], ["and", 1084], ["facial", 1088], ["dysmorphism", 1095], ["in", 1107], ["male", 1110], ["patients", 1115], ["is", 1124], ["a", 1127], ["clue", 1129], ["to", 1134], ["the", 1137], ["diagnosis", 1141], [".", 1150]]}
{"context": "Erythrasma is a superficial infection caused by Corynebacterium minutissimum and affects the major skin folds and the interdigital regions of the feet. It is characterized by erythematous, brown, scaly patches and maceration, and exhibits coral-red fluorescence under Wood light. The aim of this study was to determine the frequency of erythrasma in patients with interdigital lesions. An open, prospective, longitudinal, observational study was performed in a hospital in Mexico City between March and December, 2006. All patients with interdigital lesions were examined with a Wood lamp and direct examination was performed with 20 % potassium hydroxide. Cultures were done in Sabouraud dextrose agar and brain heart infusion agar, and smears were analyzed. General characteristics and concomitant diseases were recorded. We examined 73 patients, of whom 24 (32.8 %) were diagnosed with erythrasma based on coral-red fluorescence under Wood light and identification of corynebacteria by Gram staining. The disease was more common in women (83.33 %) and the mean age of the patients was 43.5 years. The main clinical findings were scaling and maceration, and the fourth interdigital web was the most commonly affected. Corynebacterium could not be isolated in any of the cases. Mycology was positive in 15 cases (62.5 %) and the following microorganisms were isolated: Candida (16.6 %), dermatophytes (12.5 %), and Trichosporon (4.1 %). Interdigital erythrasma is a common condition and can be easily confused with interdigital tinea. It persists if not treated appropriately. Rapid diagnosis is easily obtained by examination with a Wood lamp, while culture is difficult and unnecessary for diagnosis. The coexistence of erythrasma with dermatophytes and Candida should be considered when the interdigital webs are affected.", "qas": [{"question": "Which bacteria causes erythrasma?", "answers": ["Corynebacterium minutissimum"], "qid": "c5a3515ce38440f0bf803e4cbe2c9b10", "question_tokens": [["Which", 0], ["bacteria", 6], ["causes", 15], ["erythrasma", 22], ["?", 32]], "detected_answers": [{"text": "Corynebacterium minutissimum", "token_spans": [[7, 8]], "char_spans": [[48, 75]]}]}], "context_tokens": [["Erythrasma", 0], ["is", 11], ["a", 14], ["superficial", 16], ["infection", 28], ["caused", 38], ["by", 45], ["Corynebacterium", 48], ["minutissimum", 64], ["and", 77], ["affects", 81], ["the", 89], ["major", 93], ["skin", 99], ["folds", 104], ["and", 110], ["the", 114], ["interdigital", 118], ["regions", 131], ["of", 139], ["the", 142], ["feet", 146], [".", 150], ["It", 152], ["is", 155], ["characterized", 158], ["by", 172], ["erythematous", 175], [",", 187], ["brown", 189], [",", 194], ["scaly", 196], ["patches", 202], ["and", 210], ["maceration", 214], [",", 224], ["and", 226], ["exhibits", 230], ["coral", 239], ["-", 244], ["red", 245], ["fluorescence", 249], ["under", 262], ["Wood", 268], ["light", 273], [".", 278], ["The", 280], ["aim", 284], ["of", 288], ["this", 291], ["study", 296], ["was", 302], ["to", 306], ["determine", 309], ["the", 319], ["frequency", 323], ["of", 333], ["erythrasma", 336], ["in", 347], ["patients", 350], ["with", 359], ["interdigital", 364], ["lesions", 377], [".", 384], ["An", 386], ["open", 389], [",", 393], ["prospective", 395], [",", 406], ["longitudinal", 408], [",", 420], ["observational", 422], ["study", 436], ["was", 442], ["performed", 446], ["in", 456], ["a", 459], ["hospital", 461], ["in", 470], ["Mexico", 473], ["City", 480], ["between", 485], ["March", 493], ["and", 499], ["December", 503], [",", 511], ["2006", 513], [".", 517], ["All", 519], ["patients", 523], ["with", 532], ["interdigital", 537], ["lesions", 550], ["were", 558], ["examined", 563], ["with", 572], ["a", 577], ["Wood", 579], ["lamp", 584], ["and", 589], ["direct", 593], ["examination", 600], ["was", 612], ["performed", 616], ["with", 626], ["20", 631], ["%", 634], ["potassium", 636], ["hydroxide", 646], [".", 655], ["Cultures", 657], ["were", 666], ["done", 671], ["in", 676], ["Sabouraud", 679], ["dextrose", 689], ["agar", 698], ["and", 703], ["brain", 707], ["heart", 713], ["infusion", 719], ["agar", 728], [",", 732], ["and", 734], ["smears", 738], ["were", 745], ["analyzed", 750], [".", 758], ["General", 760], ["characteristics", 768], ["and", 784], ["concomitant", 788], ["diseases", 800], ["were", 809], ["recorded", 814], [".", 822], ["We", 824], ["examined", 827], ["73", 836], ["patients", 839], [",", 847], ["of", 849], ["whom", 852], ["24", 857], ["(", 860], ["32.8", 861], ["%", 866], [")", 867], ["were", 869], ["diagnosed", 874], ["with", 884], ["erythrasma", 889], ["based", 900], ["on", 906], ["coral", 909], ["-", 914], ["red", 915], ["fluorescence", 919], ["under", 932], ["Wood", 938], ["light", 943], ["and", 949], ["identification", 953], ["of", 968], ["corynebacteria", 971], ["by", 986], ["Gram", 989], ["staining", 994], [".", 1002], ["The", 1004], ["disease", 1008], ["was", 1016], ["more", 1020], ["common", 1025], ["in", 1032], ["women", 1035], ["(", 1041], ["83.33", 1042], ["%", 1048], [")", 1049], ["and", 1051], ["the", 1055], ["mean", 1059], ["age", 1064], ["of", 1068], ["the", 1071], ["patients", 1075], ["was", 1084], ["43.5", 1088], ["years", 1093], [".", 1098], ["The", 1100], ["main", 1104], ["clinical", 1109], ["findings", 1118], ["were", 1127], ["scaling", 1132], ["and", 1140], ["maceration", 1144], [",", 1154], ["and", 1156], ["the", 1160], ["fourth", 1164], ["interdigital", 1171], ["web", 1184], ["was", 1188], ["the", 1192], ["most", 1196], ["commonly", 1201], ["affected", 1210], [".", 1218], ["Corynebacterium", 1220], ["could", 1236], ["not", 1242], ["be", 1246], ["isolated", 1249], ["in", 1258], ["any", 1261], ["of", 1265], ["the", 1268], ["cases", 1272], [".", 1277], ["Mycology", 1279], ["was", 1288], ["positive", 1292], ["in", 1301], ["15", 1304], ["cases", 1307], ["(", 1313], ["62.5", 1314], ["%", 1319], [")", 1320], ["and", 1322], ["the", 1326], ["following", 1330], ["microorganisms", 1340], ["were", 1355], ["isolated", 1360], [":", 1368], ["Candida", 1370], ["(", 1378], ["16.6", 1379], ["%", 1384], [")", 1385], [",", 1386], ["dermatophytes", 1388], ["(", 1402], ["12.5", 1403], ["%", 1408], [")", 1409], [",", 1410], ["and", 1412], ["Trichosporon", 1416], ["(", 1429], ["4.1", 1430], ["%", 1434], [")", 1435], [".", 1436], ["Interdigital", 1438], ["erythrasma", 1451], ["is", 1462], ["a", 1465], ["common", 1467], ["condition", 1474], ["and", 1484], ["can", 1488], ["be", 1492], ["easily", 1495], ["confused", 1502], ["with", 1511], ["interdigital", 1516], ["tinea", 1529], [".", 1534], ["It", 1536], ["persists", 1539], ["if", 1548], ["not", 1551], ["treated", 1555], ["appropriately", 1563], [".", 1576], ["Rapid", 1578], ["diagnosis", 1584], ["is", 1594], ["easily", 1597], ["obtained", 1604], ["by", 1613], ["examination", 1616], ["with", 1628], ["a", 1633], ["Wood", 1635], ["lamp", 1640], [",", 1644], ["while", 1646], ["culture", 1652], ["is", 1660], ["difficult", 1663], ["and", 1673], ["unnecessary", 1677], ["for", 1689], ["diagnosis", 1693], [".", 1702], ["The", 1704], ["coexistence", 1708], ["of", 1720], ["erythrasma", 1723], ["with", 1734], ["dermatophytes", 1739], ["and", 1753], ["Candida", 1757], ["should", 1765], ["be", 1772], ["considered", 1775], ["when", 1786], ["the", 1791], ["interdigital", 1795], ["webs", 1808], ["are", 1813], ["affected", 1817], [".", 1825]]}
{"context": "Empirical data have challenged chronic posttraumatic stress disorder (PTSD) consisting of three dimensions. In the present study we aimed to determine the factor structure of acute posttraumatic symptoms in two recently traumatized samples. In sample 1, 203 civilian trauma survivors were administered the Davidson Trauma Scale (DTS) approximately 1 week posttrauma. In sample 2, 182 civilian treatment seeking trauma survivors completed the DTS at an average of 41.4 days posttrauma. Our confirmatory factor analyses indicated that a 4-factor intercorrelated model provided the best representation of the data in both samples. The four factors are best described as reexperiencing, active avoidance, dysphoria, and hyperarousal. For acute posttraumatic symptoms, the empirical data suggest to split the avoidance cluster into 'Active avoidance' and 'Dysphoria'-confirming findings in studies on chronic PTSD. In future revisions of the DSM, the diagnostic criteria for PTSD may need to be adapted to fit the research findings.", "qas": [{"question": "Symptoms of which disorder are evaluated with the Davidson Trauma Scale?", "answers": ["post-traumatic stress disorder", "PTSD"], "qid": "154d75312f834698b4172f50c831682d", "question_tokens": [["Symptoms", 0], ["of", 9], ["which", 12], ["disorder", 18], ["are", 27], ["evaluated", 31], ["with", 41], ["the", 46], ["Davidson", 50], ["Trauma", 59], ["Scale", 66], ["?", 71]], "detected_answers": [{"text": "PTSD", "token_spans": [[145, 145], [9, 9], [158, 158]], "char_spans": [[904, 907], [70, 73], [970, 973]]}]}], "context_tokens": [["Empirical", 0], ["data", 10], ["have", 15], ["challenged", 20], ["chronic", 31], ["posttraumatic", 39], ["stress", 53], ["disorder", 60], ["(", 69], ["PTSD", 70], [")", 74], ["consisting", 76], ["of", 87], ["three", 90], ["dimensions", 96], [".", 106], ["In", 108], ["the", 111], ["present", 115], ["study", 123], ["we", 129], ["aimed", 132], ["to", 138], ["determine", 141], ["the", 151], ["factor", 155], ["structure", 162], ["of", 172], ["acute", 175], ["posttraumatic", 181], ["symptoms", 195], ["in", 204], ["two", 207], ["recently", 211], ["traumatized", 220], ["samples", 232], [".", 239], ["In", 241], ["sample", 244], ["1", 251], [",", 252], ["203", 254], ["civilian", 258], ["trauma", 267], ["survivors", 274], ["were", 284], ["administered", 289], ["the", 302], ["Davidson", 306], ["Trauma", 315], ["Scale", 322], ["(", 328], ["DTS", 329], [")", 332], ["approximately", 334], ["1", 348], ["week", 350], ["posttrauma", 355], [".", 365], ["In", 367], ["sample", 370], ["2", 377], [",", 378], ["182", 380], ["civilian", 384], ["treatment", 393], ["seeking", 403], ["trauma", 411], ["survivors", 418], ["completed", 428], ["the", 438], ["DTS", 442], ["at", 446], ["an", 449], ["average", 452], ["of", 460], ["41.4", 463], ["days", 468], ["posttrauma", 473], [".", 483], ["Our", 485], ["confirmatory", 489], ["factor", 502], ["analyses", 509], ["indicated", 518], ["that", 528], ["a", 533], ["4-factor", 535], ["intercorrelated", 544], ["model", 560], ["provided", 566], ["the", 575], ["best", 579], ["representation", 584], ["of", 599], ["the", 602], ["data", 606], ["in", 611], ["both", 614], ["samples", 619], [".", 626], ["The", 628], ["four", 632], ["factors", 637], ["are", 645], ["best", 649], ["described", 654], ["as", 664], ["reexperiencing", 667], [",", 681], ["active", 683], ["avoidance", 690], [",", 699], ["dysphoria", 701], [",", 710], ["and", 712], ["hyperarousal", 716], [".", 728], ["For", 730], ["acute", 734], ["posttraumatic", 740], ["symptoms", 754], [",", 762], ["the", 764], ["empirical", 768], ["data", 778], ["suggest", 783], ["to", 791], ["split", 794], ["the", 800], ["avoidance", 804], ["cluster", 814], ["into", 822], ["'", 827], ["Active", 828], ["avoidance", 835], ["'", 844], ["and", 846], ["'", 850], ["Dysphoria'-confirming", 851], ["findings", 873], ["in", 882], ["studies", 885], ["on", 893], ["chronic", 896], ["PTSD", 904], [".", 908], ["In", 910], ["future", 913], ["revisions", 920], ["of", 930], ["the", 933], ["DSM", 937], [",", 940], ["the", 942], ["diagnostic", 946], ["criteria", 957], ["for", 966], ["PTSD", 970], ["may", 975], ["need", 979], ["to", 984], ["be", 987], ["adapted", 990], ["to", 998], ["fit", 1001], ["the", 1005], ["research", 1009], ["findings", 1018], [".", 1026]]}
{"context": "Non-vitamin K anticoagulants (NOAC) such as dabigatran have become important therapeutic options for the prevention of stroke. Until recently, there were only nonspecific agents to reverse their anticoagulant effects in a case of emergency. Idarucizumab, an antibody fragment targeting dabigatran, is the first specific antidote for a NOAC to be approved, but real-world experience is limited. We report two cases of patients on dabigatran with acute intracerebral hemorrhage who received idarucizumab. In both cases, idarucizumab promptly reversed the anticoagulant effect of dabigatran and there was no hematoma expansion in follow-up imaging. In addition to clinical and preclinical studies, our cases add to the experience regarding the safety and efficacy of idarucizumab. They show that idarucizumab may be an important safety option for patients on dabigatran in emergency situations.", "qas": [{"question": "Which drug can be reversed with idarucizumab?", "answers": ["dabigatran"], "qid": "0f0142c6d85345b6ad31f47e1f7b98d4", "question_tokens": [["Which", 0], ["drug", 6], ["can", 11], ["be", 15], ["reversed", 18], ["with", 27], ["idarucizumab", 32], ["?", 44]], "detected_answers": [{"text": "dabigatran", "token_spans": [[144, 144], [96, 96], [10, 10], [76, 76], [47, 47]], "char_spans": [[856, 865], [577, 586], [44, 53], [429, 438], [286, 295]]}]}], "context_tokens": [["Non", 0], ["-", 3], ["vitamin", 4], ["K", 12], ["anticoagulants", 14], ["(", 29], ["NOAC", 30], [")", 34], ["such", 36], ["as", 41], ["dabigatran", 44], ["have", 55], ["become", 60], ["important", 67], ["therapeutic", 77], ["options", 89], ["for", 97], ["the", 101], ["prevention", 105], ["of", 116], ["stroke", 119], [".", 125], ["Until", 127], ["recently", 133], [",", 141], ["there", 143], ["were", 149], ["only", 154], ["nonspecific", 159], ["agents", 171], ["to", 178], ["reverse", 181], ["their", 189], ["anticoagulant", 195], ["effects", 209], ["in", 217], ["a", 220], ["case", 222], ["of", 227], ["emergency", 230], [".", 239], ["Idarucizumab", 241], [",", 253], ["an", 255], ["antibody", 258], ["fragment", 267], ["targeting", 276], ["dabigatran", 286], [",", 296], ["is", 298], ["the", 301], ["first", 305], ["specific", 311], ["antidote", 320], ["for", 329], ["a", 333], ["NOAC", 335], ["to", 340], ["be", 343], ["approved", 346], [",", 354], ["but", 356], ["real", 360], ["-", 364], ["world", 365], ["experience", 371], ["is", 382], ["limited", 385], [".", 392], ["We", 394], ["report", 397], ["two", 404], ["cases", 408], ["of", 414], ["patients", 417], ["on", 426], ["dabigatran", 429], ["with", 440], ["acute", 445], ["intracerebral", 451], ["hemorrhage", 465], ["who", 476], ["received", 480], ["idarucizumab", 489], [".", 501], ["In", 503], ["both", 506], ["cases", 511], [",", 516], ["idarucizumab", 518], ["promptly", 531], ["reversed", 540], ["the", 549], ["anticoagulant", 553], ["effect", 567], ["of", 574], ["dabigatran", 577], ["and", 588], ["there", 592], ["was", 598], ["no", 602], ["hematoma", 605], ["expansion", 614], ["in", 624], ["follow", 627], ["-", 633], ["up", 634], ["imaging", 637], [".", 644], ["In", 646], ["addition", 649], ["to", 658], ["clinical", 661], ["and", 670], ["preclinical", 674], ["studies", 686], [",", 693], ["our", 695], ["cases", 699], ["add", 705], ["to", 709], ["the", 712], ["experience", 716], ["regarding", 727], ["the", 737], ["safety", 741], ["and", 748], ["efficacy", 752], ["of", 761], ["idarucizumab", 764], [".", 776], ["They", 778], ["show", 783], ["that", 788], ["idarucizumab", 793], ["may", 806], ["be", 810], ["an", 813], ["important", 816], ["safety", 826], ["option", 833], ["for", 840], ["patients", 844], ["on", 853], ["dabigatran", 856], ["in", 867], ["emergency", 870], ["situations", 880], [".", 890]]}
{"context": "Facioscapulohumeral muscular dystrophy (FSHD) is a common form of muscular dystrophy characterized by an asymmetric progressive weakness and wasting of the facial, shoulder and upper arm muscles, frequently accompanied by hearing loss and retinal vasculopathy. FSHD is an autosomal dominant disease linked to chromosome 4q35, but the causative gene remains controversial. DUX4 is a leading candidate gene as causative of FSHD. However, DUX4 expression is extremely low in FSHD muscle, and there is no DUX4 animal model that mirrors the pathology in human FSHD. Here, we show that the misexpression of very low levels of human DUX4 in zebrafish development recapitulates the phenotypes seen in human FSHD patients. Microinjection of small amounts of human full-length DUX4 (DUX4-fl) mRNA into fertilized zebrafish eggs caused asymmetric abnormalities such as less pigmentation of the eyes, altered morphology of ears, developmental abnormality of fin muscle, disorganization of facial musculature and/or degeneration of trunk muscle later in development. Moreover, DUX4-fl expression caused aberrant localization of myogenic cells marked with \u03b1-actin promoter-driven enhanced green fluorescent protein outside somite boundary, especially in head region. These abnormalities were rescued by coinjection of the short form of DUX4 (DUX4-s). Our results suggest that the misexpression of DUX4-fl, even at extremely low level, can recapitulate the phenotype observed in FSHD patients in a vertebrate model. These results strongly support the current hypothesis for a role of DUX4 in FSHD pathogenesis. We also propose that DUX4 expression during development is important for the pathogenesis of FSHD.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "69c2179d41c04582949a39853d960dbb", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[93, 93], [67, 67], [77, 77], [118, 118], [262, 262], [4, 4], [279, 279], [40, 40], [242, 242]], "char_spans": [[555, 558], [421, 424], [472, 475], [699, 702], [1577, 1580], [40, 43], [1689, 1692], [261, 264], [1464, 1467]]}]}], "context_tokens": [["Facioscapulohumeral", 0], ["muscular", 20], ["dystrophy", 29], ["(", 39], ["FSHD", 40], [")", 44], ["is", 46], ["a", 49], ["common", 51], ["form", 58], ["of", 63], ["muscular", 66], ["dystrophy", 75], ["characterized", 85], ["by", 99], ["an", 102], ["asymmetric", 105], ["progressive", 116], ["weakness", 128], ["and", 137], ["wasting", 141], ["of", 149], ["the", 152], ["facial", 156], [",", 162], ["shoulder", 164], ["and", 173], ["upper", 177], ["arm", 183], ["muscles", 187], [",", 194], ["frequently", 196], ["accompanied", 207], ["by", 219], ["hearing", 222], ["loss", 230], ["and", 235], ["retinal", 239], ["vasculopathy", 247], [".", 259], ["FSHD", 261], ["is", 266], ["an", 269], ["autosomal", 272], ["dominant", 282], ["disease", 291], ["linked", 299], ["to", 306], ["chromosome", 309], ["4q35", 320], [",", 324], ["but", 326], ["the", 330], ["causative", 334], ["gene", 344], ["remains", 349], ["controversial", 357], [".", 370], ["DUX4", 372], ["is", 377], ["a", 380], ["leading", 382], ["candidate", 390], ["gene", 400], ["as", 405], ["causative", 408], ["of", 418], ["FSHD", 421], [".", 425], ["However", 427], [",", 434], ["DUX4", 436], ["expression", 441], ["is", 452], ["extremely", 455], ["low", 465], ["in", 469], ["FSHD", 472], ["muscle", 477], [",", 483], ["and", 485], ["there", 489], ["is", 495], ["no", 498], ["DUX4", 501], ["animal", 506], ["model", 513], ["that", 519], ["mirrors", 524], ["the", 532], ["pathology", 536], ["in", 546], ["human", 549], ["FSHD", 555], [".", 559], ["Here", 561], [",", 565], ["we", 567], ["show", 570], ["that", 575], ["the", 580], ["misexpression", 584], ["of", 598], ["very", 601], ["low", 606], ["levels", 610], ["of", 617], ["human", 620], ["DUX4", 626], ["in", 631], ["zebrafish", 634], ["development", 644], ["recapitulates", 656], ["the", 670], ["phenotypes", 674], ["seen", 685], ["in", 690], ["human", 693], ["FSHD", 699], ["patients", 704], [".", 712], ["Microinjection", 714], ["of", 729], ["small", 732], ["amounts", 738], ["of", 746], ["human", 749], ["full", 755], ["-", 759], ["length", 760], ["DUX4", 767], ["(", 772], ["DUX4-fl", 773], [")", 780], ["mRNA", 782], ["into", 787], ["fertilized", 792], ["zebrafish", 803], ["eggs", 813], ["caused", 818], ["asymmetric", 825], ["abnormalities", 836], ["such", 850], ["as", 855], ["less", 858], ["pigmentation", 863], ["of", 876], ["the", 879], ["eyes", 883], [",", 887], ["altered", 889], ["morphology", 897], ["of", 908], ["ears", 911], [",", 915], ["developmental", 917], ["abnormality", 931], ["of", 943], ["fin", 946], ["muscle", 950], [",", 956], ["disorganization", 958], ["of", 974], ["facial", 977], ["musculature", 984], ["and/or", 996], ["degeneration", 1003], ["of", 1016], ["trunk", 1019], ["muscle", 1025], ["later", 1032], ["in", 1038], ["development", 1041], [".", 1052], ["Moreover", 1054], [",", 1062], ["DUX4-fl", 1064], ["expression", 1072], ["caused", 1083], ["aberrant", 1090], ["localization", 1099], ["of", 1112], ["myogenic", 1115], ["cells", 1124], ["marked", 1130], ["with", 1137], ["\u03b1", 1142], ["-", 1143], ["actin", 1144], ["promoter", 1150], ["-", 1158], ["driven", 1159], ["enhanced", 1166], ["green", 1175], ["fluorescent", 1181], ["protein", 1193], ["outside", 1201], ["somite", 1209], ["boundary", 1216], [",", 1224], ["especially", 1226], ["in", 1237], ["head", 1240], ["region", 1245], [".", 1251], ["These", 1253], ["abnormalities", 1259], ["were", 1273], ["rescued", 1278], ["by", 1286], ["coinjection", 1289], ["of", 1301], ["the", 1304], ["short", 1308], ["form", 1314], ["of", 1319], ["DUX4", 1322], ["(", 1327], ["DUX4-s", 1328], [")", 1334], [".", 1335], ["Our", 1337], ["results", 1341], ["suggest", 1349], ["that", 1357], ["the", 1362], ["misexpression", 1366], ["of", 1380], ["DUX4-fl", 1383], [",", 1390], ["even", 1392], ["at", 1397], ["extremely", 1400], ["low", 1410], ["level", 1414], [",", 1419], ["can", 1421], ["recapitulate", 1425], ["the", 1438], ["phenotype", 1442], ["observed", 1452], ["in", 1461], ["FSHD", 1464], ["patients", 1469], ["in", 1478], ["a", 1481], ["vertebrate", 1483], ["model", 1494], [".", 1499], ["These", 1501], ["results", 1507], ["strongly", 1515], ["support", 1524], ["the", 1532], ["current", 1536], ["hypothesis", 1544], ["for", 1555], ["a", 1559], ["role", 1561], ["of", 1566], ["DUX4", 1569], ["in", 1574], ["FSHD", 1577], ["pathogenesis", 1582], [".", 1594], ["We", 1596], ["also", 1599], ["propose", 1604], ["that", 1612], ["DUX4", 1617], ["expression", 1622], ["during", 1633], ["development", 1640], ["is", 1652], ["important", 1655], ["for", 1665], ["the", 1669], ["pathogenesis", 1673], ["of", 1686], ["FSHD", 1689], [".", 1693]]}
{"context": "To compare tumor control rates after surgical resection or stereotactic radiosurgery for patients with small- to medium-size intracranial meningiomas. Between 1990 and 1997, 198 adult meningioma patients treated at our center underwent either surgical resection (n = 136) or radiosurgery (n = 62) as primary management for benign meningiomas <35 mm in average diameter. Tumor recurrence or progression rates were calculated by the Kaplan-Meier method according to an independent radiographic review. The mean follow-up was 64 months. The tumor resections were Simpson Grade 1 in 57 (42%), Grade 2 in 57 (42%), and Grade 3-4 in 22 (16%). The mean margin and maximal radiation dose at radiosurgery was 17.7 Gy and 34.9 Gy, respectively. Tumor recurrence/progression was more frequent in the surgical resection group (12%) than in the radiosurgical group (2%; p = 0.04). No statistically significant difference was detected in the 3- and 7-year actuarial progression-free survival (PFS) rate between patients with Simpson Grade 1 resections (100% and 96%, respectively) and patients who underwent radiosurgery (100% and 95%, respectively; p = 0.94). Radiosurgery provided a higher PFS rate compared with patients with Simpson Grade 2 (3- and 7-year PFS rate, 91% and 82%, respectively; p <0.05) and Grade 3-4 (3- and 7-year PFS rate, 68% and 34%, respectively; p <0.001) resections. Subsequent tumor treatments were more common after surgical resection (15% vs. 3%, p = 0.02). Complications occurred in 10% of patients after radiosurgery compared with 22% of patients after surgical resection (p = 0.06). The PFS rate after radiosurgery was equivalent to that after resection of a Simpson Grade 1 tumor and was superior to Grade 2 and 3-4 resections in our study. If long-term follow-up confirms the high tumor control rate and low morbidity of radiosurgery, this technique will likely become the preferred treatment for most patients with small- to moderate-size meningiomas without symptomatic mass effect.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "df74d144994648f89a2af1ac7f36e432", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[29, 29]], "char_spans": [[184, 193]]}]}], "context_tokens": [["To", 0], ["compare", 3], ["tumor", 11], ["control", 17], ["rates", 25], ["after", 31], ["surgical", 37], ["resection", 46], ["or", 56], ["stereotactic", 59], ["radiosurgery", 72], ["for", 85], ["patients", 89], ["with", 98], ["small-", 103], ["to", 110], ["medium", 113], ["-", 119], ["size", 120], ["intracranial", 125], ["meningiomas", 138], [".", 149], ["Between", 151], ["1990", 159], ["and", 164], ["1997", 168], [",", 172], ["198", 174], ["adult", 178], ["meningioma", 184], ["patients", 195], ["treated", 204], ["at", 212], ["our", 215], ["center", 219], ["underwent", 226], ["either", 236], ["surgical", 243], ["resection", 252], ["(", 262], ["n", 263], ["=", 265], ["136", 267], [")", 270], ["or", 272], ["radiosurgery", 275], ["(", 288], ["n", 289], ["=", 291], ["62", 293], [")", 295], ["as", 297], ["primary", 300], ["management", 308], ["for", 319], ["benign", 323], ["meningiomas", 330], ["<", 342], ["35", 343], ["mm", 346], ["in", 349], ["average", 352], ["diameter", 360], [".", 368], ["Tumor", 370], ["recurrence", 376], ["or", 387], ["progression", 390], ["rates", 402], ["were", 408], ["calculated", 413], ["by", 424], ["the", 427], ["Kaplan", 431], ["-", 437], ["Meier", 438], ["method", 444], ["according", 451], ["to", 461], ["an", 464], ["independent", 467], ["radiographic", 479], ["review", 492], [".", 498], ["The", 500], ["mean", 504], ["follow", 509], ["-", 515], ["up", 516], ["was", 519], ["64", 523], ["months", 526], [".", 532], ["The", 534], ["tumor", 538], ["resections", 544], ["were", 555], ["Simpson", 560], ["Grade", 568], ["1", 574], ["in", 576], ["57", 579], ["(", 582], ["42", 583], ["%", 585], [")", 586], [",", 587], ["Grade", 589], ["2", 595], ["in", 597], ["57", 600], ["(", 603], ["42", 604], ["%", 606], [")", 607], [",", 608], ["and", 610], ["Grade", 614], ["3", 620], ["-", 621], ["4", 622], ["in", 624], ["22", 627], ["(", 630], ["16", 631], ["%", 633], [")", 634], [".", 635], ["The", 637], ["mean", 641], ["margin", 646], ["and", 653], ["maximal", 657], ["radiation", 665], ["dose", 675], ["at", 680], ["radiosurgery", 683], ["was", 696], ["17.7", 700], ["Gy", 705], ["and", 708], ["34.9", 712], ["Gy", 717], [",", 719], ["respectively", 721], [".", 733], ["Tumor", 735], ["recurrence", 741], ["/", 751], ["progression", 752], ["was", 764], ["more", 768], ["frequent", 773], ["in", 782], ["the", 785], ["surgical", 789], ["resection", 798], ["group", 808], ["(", 814], ["12", 815], ["%", 817], [")", 818], ["than", 820], ["in", 825], ["the", 828], ["radiosurgical", 832], ["group", 846], ["(", 852], ["2", 853], ["%", 854], [";", 855], ["p", 857], ["=", 859], ["0.04", 861], [")", 865], [".", 866], ["No", 868], ["statistically", 871], ["significant", 885], ["difference", 897], ["was", 908], ["detected", 912], ["in", 921], ["the", 924], ["3-", 928], ["and", 931], ["7-year", 935], ["actuarial", 942], ["progression", 952], ["-", 963], ["free", 964], ["survival", 969], ["(", 978], ["PFS", 979], [")", 982], ["rate", 984], ["between", 989], ["patients", 997], ["with", 1006], ["Simpson", 1011], ["Grade", 1019], ["1", 1025], ["resections", 1027], ["(", 1038], ["100", 1039], ["%", 1042], ["and", 1044], ["96", 1048], ["%", 1050], [",", 1051], ["respectively", 1053], [")", 1065], ["and", 1067], ["patients", 1071], ["who", 1080], ["underwent", 1084], ["radiosurgery", 1094], ["(", 1107], ["100", 1108], ["%", 1111], ["and", 1113], ["95", 1117], ["%", 1119], [",", 1120], ["respectively", 1122], [";", 1134], ["p", 1136], ["=", 1138], ["0.94", 1140], [")", 1144], [".", 1145], ["Radiosurgery", 1147], ["provided", 1160], ["a", 1169], ["higher", 1171], ["PFS", 1178], ["rate", 1182], ["compared", 1187], ["with", 1196], ["patients", 1201], ["with", 1210], ["Simpson", 1215], ["Grade", 1223], ["2", 1229], ["(", 1231], ["3-", 1232], ["and", 1235], ["7-year", 1239], ["PFS", 1246], ["rate", 1250], [",", 1254], ["91", 1256], ["%", 1258], ["and", 1260], ["82", 1264], ["%", 1266], [",", 1267], ["respectively", 1269], [";", 1281], ["p", 1283], ["<", 1285], ["0.05", 1286], [")", 1290], ["and", 1292], ["Grade", 1296], ["3", 1302], ["-", 1303], ["4", 1304], ["(", 1306], ["3-", 1307], ["and", 1310], ["7-year", 1314], ["PFS", 1321], ["rate", 1325], [",", 1329], ["68", 1331], ["%", 1333], ["and", 1335], ["34", 1339], ["%", 1341], [",", 1342], ["respectively", 1344], [";", 1356], ["p", 1358], ["<", 1360], ["0.001", 1361], [")", 1366], ["resections", 1368], [".", 1378], ["Subsequent", 1380], ["tumor", 1391], ["treatments", 1397], ["were", 1408], ["more", 1413], ["common", 1418], ["after", 1425], ["surgical", 1431], ["resection", 1440], ["(", 1450], ["15", 1451], ["%", 1453], ["vs.", 1455], ["3", 1459], ["%", 1460], [",", 1461], ["p", 1463], ["=", 1465], ["0.02", 1467], [")", 1471], [".", 1472], ["Complications", 1474], ["occurred", 1488], ["in", 1497], ["10", 1500], ["%", 1502], ["of", 1504], ["patients", 1507], ["after", 1516], ["radiosurgery", 1522], ["compared", 1535], ["with", 1544], ["22", 1549], ["%", 1551], ["of", 1553], ["patients", 1556], ["after", 1565], ["surgical", 1571], ["resection", 1580], ["(", 1590], ["p", 1591], ["=", 1593], ["0.06", 1595], [")", 1599], [".", 1600], ["The", 1602], ["PFS", 1606], ["rate", 1610], ["after", 1615], ["radiosurgery", 1621], ["was", 1634], ["equivalent", 1638], ["to", 1649], ["that", 1652], ["after", 1657], ["resection", 1663], ["of", 1673], ["a", 1676], ["Simpson", 1678], ["Grade", 1686], ["1", 1692], ["tumor", 1694], ["and", 1700], ["was", 1704], ["superior", 1708], ["to", 1717], ["Grade", 1720], ["2", 1726], ["and", 1728], ["3", 1732], ["-", 1733], ["4", 1734], ["resections", 1736], ["in", 1747], ["our", 1750], ["study", 1754], [".", 1759], ["If", 1761], ["long", 1764], ["-", 1768], ["term", 1769], ["follow", 1774], ["-", 1780], ["up", 1781], ["confirms", 1784], ["the", 1793], ["high", 1797], ["tumor", 1802], ["control", 1808], ["rate", 1816], ["and", 1821], ["low", 1825], ["morbidity", 1829], ["of", 1839], ["radiosurgery", 1842], [",", 1854], ["this", 1856], ["technique", 1861], ["will", 1871], ["likely", 1876], ["become", 1883], ["the", 1890], ["preferred", 1894], ["treatment", 1904], ["for", 1914], ["most", 1918], ["patients", 1923], ["with", 1932], ["small-", 1937], ["to", 1944], ["moderate", 1947], ["-", 1955], ["size", 1956], ["meningiomas", 1961], ["without", 1973], ["symptomatic", 1981], ["mass", 1993], ["effect", 1998], [".", 2004]]}
{"context": "Selenoprotein P (Sepp1) is a secreted protein that is made up of 2 domains. The larger N-terminal domain contains 1 selenocysteine residue in a redox motif and the smaller C-terminal domain contains the other 9 selenocysteines. Sepp1 isoforms of varying lengths occur but quantitation of them has not been achieved. Hepatic synthesis of Sepp1 affects whole-body selenium content and the liver is the source of most plasma Sepp1. ApoER2, a member of the lipoprotein receptor family, binds Sepp1 and facilitates its uptake into the testis and retention of its selenium by the brain. Megalin, another lipoprotein receptor, facilitates uptake of filtered Sepp1 into proximal tubule cells of the kidney. Thus, Sepp1 serves in homeostasis and distribution of selenium. Mice with deletion of Sepp1 suffer greater morbidity and mortality from infection with Trypanosoma congolense than do wild-type mice. Mice that express only the N-terminal domain of Sepp1 have the same severity of illness as wild-type mice, indicating that the protective function of Sepp1 against the infection resides in the N-terminal (redox) domain. Thus, Sepp1 has several functions. In addition, plasma Sepp1 concentration falls in selenium deficiency and, therefore, it can be used as an index of selenium nutritional status.", "qas": [{"question": "Which is the human selenoprotein that contains several Se-Cys residues?", "answers": ["Selenoprotein P"], "qid": "109aecf700c048eb8d16d5d20b654c22", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["human", 13], ["selenoprotein", 19], ["that", 33], ["contains", 38], ["several", 47], ["Se", 55], ["-", 57], ["Cys", 58], ["residues", 62], ["?", 70]], "detected_answers": [{"text": "Selenoprotein P", "token_spans": [[0, 1]], "char_spans": [[0, 14]]}]}], "context_tokens": [["Selenoprotein", 0], ["P", 14], ["(", 16], ["Sepp1", 17], [")", 22], ["is", 24], ["a", 27], ["secreted", 29], ["protein", 38], ["that", 46], ["is", 51], ["made", 54], ["up", 59], ["of", 62], ["2", 65], ["domains", 67], [".", 74], ["The", 76], ["larger", 80], ["N", 87], ["-", 88], ["terminal", 89], ["domain", 98], ["contains", 105], ["1", 114], ["selenocysteine", 116], ["residue", 131], ["in", 139], ["a", 142], ["redox", 144], ["motif", 150], ["and", 156], ["the", 160], ["smaller", 164], ["C", 172], ["-", 173], ["terminal", 174], ["domain", 183], ["contains", 190], ["the", 199], ["other", 203], ["9", 209], ["selenocysteines", 211], [".", 226], ["Sepp1", 228], ["isoforms", 234], ["of", 243], ["varying", 246], ["lengths", 254], ["occur", 262], ["but", 268], ["quantitation", 272], ["of", 285], ["them", 288], ["has", 293], ["not", 297], ["been", 301], ["achieved", 306], [".", 314], ["Hepatic", 316], ["synthesis", 324], ["of", 334], ["Sepp1", 337], ["affects", 343], ["whole", 351], ["-", 356], ["body", 357], ["selenium", 362], ["content", 371], ["and", 379], ["the", 383], ["liver", 387], ["is", 393], ["the", 396], ["source", 400], ["of", 407], ["most", 410], ["plasma", 415], ["Sepp1", 422], [".", 427], ["ApoER2", 429], [",", 435], ["a", 437], ["member", 439], ["of", 446], ["the", 449], ["lipoprotein", 453], ["receptor", 465], ["family", 474], [",", 480], ["binds", 482], ["Sepp1", 488], ["and", 494], ["facilitates", 498], ["its", 510], ["uptake", 514], ["into", 521], ["the", 526], ["testis", 530], ["and", 537], ["retention", 541], ["of", 551], ["its", 554], ["selenium", 558], ["by", 567], ["the", 570], ["brain", 574], [".", 579], ["Megalin", 581], [",", 588], ["another", 590], ["lipoprotein", 598], ["receptor", 610], [",", 618], ["facilitates", 620], ["uptake", 632], ["of", 639], ["filtered", 642], ["Sepp1", 651], ["into", 657], ["proximal", 662], ["tubule", 671], ["cells", 678], ["of", 684], ["the", 687], ["kidney", 691], [".", 697], ["Thus", 699], [",", 703], ["Sepp1", 705], ["serves", 711], ["in", 718], ["homeostasis", 721], ["and", 733], ["distribution", 737], ["of", 750], ["selenium", 753], [".", 761], ["Mice", 763], ["with", 768], ["deletion", 773], ["of", 782], ["Sepp1", 785], ["suffer", 791], ["greater", 798], ["morbidity", 806], ["and", 816], ["mortality", 820], ["from", 830], ["infection", 835], ["with", 845], ["Trypanosoma", 850], ["congolense", 862], ["than", 873], ["do", 878], ["wild", 881], ["-", 885], ["type", 886], ["mice", 891], [".", 895], ["Mice", 897], ["that", 902], ["express", 907], ["only", 915], ["the", 920], ["N", 924], ["-", 925], ["terminal", 926], ["domain", 935], ["of", 942], ["Sepp1", 945], ["have", 951], ["the", 956], ["same", 960], ["severity", 965], ["of", 974], ["illness", 977], ["as", 985], ["wild", 988], ["-", 992], ["type", 993], ["mice", 998], [",", 1002], ["indicating", 1004], ["that", 1015], ["the", 1020], ["protective", 1024], ["function", 1035], ["of", 1044], ["Sepp1", 1047], ["against", 1053], ["the", 1061], ["infection", 1065], ["resides", 1075], ["in", 1083], ["the", 1086], ["N", 1090], ["-", 1091], ["terminal", 1092], ["(", 1101], ["redox", 1102], [")", 1107], ["domain", 1109], [".", 1115], ["Thus", 1117], [",", 1121], ["Sepp1", 1123], ["has", 1129], ["several", 1133], ["functions", 1141], [".", 1150], ["In", 1152], ["addition", 1155], [",", 1163], ["plasma", 1165], ["Sepp1", 1172], ["concentration", 1178], ["falls", 1192], ["in", 1198], ["selenium", 1201], ["deficiency", 1210], ["and", 1221], [",", 1224], ["therefore", 1226], [",", 1235], ["it", 1237], ["can", 1240], ["be", 1244], ["used", 1247], ["as", 1252], ["an", 1255], ["index", 1258], ["of", 1264], ["selenium", 1267], ["nutritional", 1276], ["status", 1288], [".", 1294]]}
{"context": "The McLeod syndrome is an X-linked neuroacanthocytosis manifesting with myopathy and progressive chorea. It is caused by mutations of the XK gene encoding the XK protein, a putative membrane transport protein of yet unknown function. In erythroid tissues, XK forms a functional complex with the Kell glycoprotein. Here, we present an immunohistochemical study in skeletal muscle of normal controls and a McLeod patient with a XK gene point mutation (C977T) using affinity-purified antibodies against XK and Kell proteins. Histological examination of the affected muscle revealed the typical pattern of McLeod myopathy including type 2 fiber atrophy. In control muscles, Kell immunohistochemistry stained sarcoplasmic membranes. XK immunohistochemistry resulted in a type 2 fiber-specific intracellular staining that was most probably confined to the sarcoplasmic reticulum. In contrast, there was only a weak background signal without a specific staining pattern for XK and Kell in the McLeod muscle. Our results demonstrate that the lack of physiological XK expression correlates to the type 2 fiber atrophy in McLeod myopathy, and suggest that the XK protein represents a crucial factor for the maintenance of normal muscle structure and function.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "f252703de7194f1983547f4bf860ba40", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[192, 192], [27, 27], [44, 44], [87, 87], [23, 23], [73, 73], [121, 121], [175, 175], [159, 159]], "char_spans": [[1150, 1151], [159, 160], [256, 257], [500, 501], [138, 139], [426, 427], [728, 729], [1056, 1057], [967, 968]]}]}], "context_tokens": [["The", 0], ["McLeod", 4], ["syndrome", 11], ["is", 20], ["an", 23], ["X", 26], ["-", 27], ["linked", 28], ["neuroacanthocytosis", 35], ["manifesting", 55], ["with", 67], ["myopathy", 72], ["and", 81], ["progressive", 85], ["chorea", 97], [".", 103], ["It", 105], ["is", 108], ["caused", 111], ["by", 118], ["mutations", 121], ["of", 131], ["the", 134], ["XK", 138], ["gene", 141], ["encoding", 146], ["the", 155], ["XK", 159], ["protein", 162], [",", 169], ["a", 171], ["putative", 173], ["membrane", 182], ["transport", 191], ["protein", 201], ["of", 209], ["yet", 212], ["unknown", 216], ["function", 224], [".", 232], ["In", 234], ["erythroid", 237], ["tissues", 247], [",", 254], ["XK", 256], ["forms", 259], ["a", 265], ["functional", 267], ["complex", 278], ["with", 286], ["the", 291], ["Kell", 295], ["glycoprotein", 300], [".", 312], ["Here", 314], [",", 318], ["we", 320], ["present", 323], ["an", 331], ["immunohistochemical", 334], ["study", 354], ["in", 360], ["skeletal", 363], ["muscle", 372], ["of", 379], ["normal", 382], ["controls", 389], ["and", 398], ["a", 402], ["McLeod", 404], ["patient", 411], ["with", 419], ["a", 424], ["XK", 426], ["gene", 429], ["point", 434], ["mutation", 440], ["(", 449], ["C977", 450], ["T", 454], [")", 455], ["using", 457], ["affinity", 463], ["-", 471], ["purified", 472], ["antibodies", 481], ["against", 492], ["XK", 500], ["and", 503], ["Kell", 507], ["proteins", 512], [".", 520], ["Histological", 522], ["examination", 535], ["of", 547], ["the", 550], ["affected", 554], ["muscle", 563], ["revealed", 570], ["the", 579], ["typical", 583], ["pattern", 591], ["of", 599], ["McLeod", 602], ["myopathy", 609], ["including", 618], ["type", 628], ["2", 633], ["fiber", 635], ["atrophy", 641], [".", 648], ["In", 650], ["control", 653], ["muscles", 661], [",", 668], ["Kell", 670], ["immunohistochemistry", 675], ["stained", 696], ["sarcoplasmic", 704], ["membranes", 717], [".", 726], ["XK", 728], ["immunohistochemistry", 731], ["resulted", 752], ["in", 761], ["a", 764], ["type", 766], ["2", 771], ["fiber", 773], ["-", 778], ["specific", 779], ["intracellular", 788], ["staining", 802], ["that", 811], ["was", 816], ["most", 820], ["probably", 825], ["confined", 834], ["to", 843], ["the", 846], ["sarcoplasmic", 850], ["reticulum", 863], [".", 872], ["In", 874], ["contrast", 877], [",", 885], ["there", 887], ["was", 893], ["only", 897], ["a", 902], ["weak", 904], ["background", 909], ["signal", 920], ["without", 927], ["a", 935], ["specific", 937], ["staining", 946], ["pattern", 955], ["for", 963], ["XK", 967], ["and", 970], ["Kell", 974], ["in", 979], ["the", 982], ["McLeod", 986], ["muscle", 993], [".", 999], ["Our", 1001], ["results", 1005], ["demonstrate", 1013], ["that", 1025], ["the", 1030], ["lack", 1034], ["of", 1039], ["physiological", 1042], ["XK", 1056], ["expression", 1059], ["correlates", 1070], ["to", 1081], ["the", 1084], ["type", 1088], ["2", 1093], ["fiber", 1095], ["atrophy", 1101], ["in", 1109], ["McLeod", 1112], ["myopathy", 1119], [",", 1127], ["and", 1129], ["suggest", 1133], ["that", 1141], ["the", 1146], ["XK", 1150], ["protein", 1153], ["represents", 1161], ["a", 1172], ["crucial", 1174], ["factor", 1182], ["for", 1189], ["the", 1193], ["maintenance", 1197], ["of", 1209], ["normal", 1212], ["muscle", 1219], ["structure", 1226], ["and", 1236], ["function", 1240], [".", 1248]]}
{"context": "Gefitinib, the specific inhibitor of the epidermal growth factor receptor (EGFR), may cause growth delay in cancer cell lines. Thorough understanding of the downstream cellular signaling of gefitinib will facilitate the discovery of biomarkers for predicting outcomes and monitoring anti-EGFR therapies, and provide information for key targets for therapeutic intervention. In this study, we investigated the role of transducer of erbB2.1 (TOB1) in gefitinib therapy. Using the lung carcinoma cell lines A549 and NCI-H1975, the results suggested that gefitinib might mediate cell cycle arrest in lung cancer cells at least by targeting TOB1 expression. Gefitinib treatment caused cell cycle arrest predominantly at the G1 phase, which is associated with TOB1 nuclear translocation and its interaction with cyclin D1. We also showed that knockdown of TOB1 expression by RNAi rescued lung cancer cells from gefitinib-induced cell-proliferative arrest. These results suggest that TOB1 interaction with cyclin D1 and nuclear translocation is directly involved in the gefitinib-induced anti-proliferative cell cycle arrest.", "qas": [{"question": "Which is the cellular target of gefitinib?", "answers": ["Epidermal growth factor receptor (EGFR)"], "qid": "69bb73c08e1848e080576cacd9b2c307", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["target", 22], ["of", 29], ["gefitinib", 32], ["?", 41]], "detected_answers": [{"text": "Epidermal growth factor receptor (EGFR)", "token_spans": [[7, 12]], "char_spans": [[41, 78]]}]}], "context_tokens": [["Gefitinib", 0], [",", 9], ["the", 11], ["specific", 15], ["inhibitor", 24], ["of", 34], ["the", 37], ["epidermal", 41], ["growth", 51], ["factor", 58], ["receptor", 65], ["(", 74], ["EGFR", 75], [")", 79], [",", 80], ["may", 82], ["cause", 86], ["growth", 92], ["delay", 99], ["in", 105], ["cancer", 108], ["cell", 115], ["lines", 120], [".", 125], ["Thorough", 127], ["understanding", 136], ["of", 150], ["the", 153], ["downstream", 157], ["cellular", 168], ["signaling", 177], ["of", 187], ["gefitinib", 190], ["will", 200], ["facilitate", 205], ["the", 216], ["discovery", 220], ["of", 230], ["biomarkers", 233], ["for", 244], ["predicting", 248], ["outcomes", 259], ["and", 268], ["monitoring", 272], ["anti", 283], ["-", 287], ["EGFR", 288], ["therapies", 293], [",", 302], ["and", 304], ["provide", 308], ["information", 316], ["for", 328], ["key", 332], ["targets", 336], ["for", 344], ["therapeutic", 348], ["intervention", 360], [".", 372], ["In", 374], ["this", 377], ["study", 382], [",", 387], ["we", 389], ["investigated", 392], ["the", 405], ["role", 409], ["of", 414], ["transducer", 417], ["of", 428], ["erbB2.1", 431], ["(", 439], ["TOB1", 440], [")", 444], ["in", 446], ["gefitinib", 449], ["therapy", 459], [".", 466], ["Using", 468], ["the", 474], ["lung", 478], ["carcinoma", 483], ["cell", 493], ["lines", 498], ["A549", 504], ["and", 509], ["NCI", 513], ["-", 516], ["H1975", 517], [",", 522], ["the", 524], ["results", 528], ["suggested", 536], ["that", 546], ["gefitinib", 551], ["might", 561], ["mediate", 567], ["cell", 575], ["cycle", 580], ["arrest", 586], ["in", 593], ["lung", 596], ["cancer", 601], ["cells", 608], ["at", 614], ["least", 617], ["by", 623], ["targeting", 626], ["TOB1", 636], ["expression", 641], [".", 651], ["Gefitinib", 653], ["treatment", 663], ["caused", 673], ["cell", 680], ["cycle", 685], ["arrest", 691], ["predominantly", 698], ["at", 712], ["the", 715], ["G1", 719], ["phase", 722], [",", 727], ["which", 729], ["is", 735], ["associated", 738], ["with", 749], ["TOB1", 754], ["nuclear", 759], ["translocation", 767], ["and", 781], ["its", 785], ["interaction", 789], ["with", 801], ["cyclin", 806], ["D1", 813], [".", 815], ["We", 817], ["also", 820], ["showed", 825], ["that", 832], ["knockdown", 837], ["of", 847], ["TOB1", 850], ["expression", 855], ["by", 866], ["RNAi", 869], ["rescued", 874], ["lung", 882], ["cancer", 887], ["cells", 894], ["from", 900], ["gefitinib", 905], ["-", 914], ["induced", 915], ["cell", 923], ["-", 927], ["proliferative", 928], ["arrest", 942], [".", 948], ["These", 950], ["results", 956], ["suggest", 964], ["that", 972], ["TOB1", 977], ["interaction", 982], ["with", 994], ["cyclin", 999], ["D1", 1006], ["and", 1009], ["nuclear", 1013], ["translocation", 1021], ["is", 1035], ["directly", 1038], ["involved", 1047], ["in", 1056], ["the", 1059], ["gefitinib", 1063], ["-", 1072], ["induced", 1073], ["anti", 1081], ["-", 1085], ["proliferative", 1086], ["cell", 1100], ["cycle", 1105], ["arrest", 1111], [".", 1117]]}
{"context": "Mutations of the alpha-synuclein gene have shown to be relevant in some rare families with autosomal dominant Parkinson's disease (PD). Furthermore, alpha-synuclein protein is a major component of the Lewy bodies also in sporadic PD patients. Increased levels of wildtype alpha-synuclein in the cell leads to increased intracellular hydrogen peroxide levels and causes death of dopaminergic neurons in rat primary culture. Subsequently, oxidative stress has been directly linked with alpha-synuclein aggregation in vitro. This raises the question whether increased alpha-synuclein expression might be linked to higher susceptibility to PD and whether alpha-synuclein promoter polymorphisms are associated with PD. Here, two polymorphisms (-116C>G and -668T>C) of the alpha-synuclein promoter defining four haplotypes have been characterized in 315 German PD patients. The influence of the four haplotypes on gene expression was studied by CAT reporter gene assays in neuronal SK-N-AS cells. The -668C/-116G haplotype revealed significant higher CAT expression than the -668T/-116G or the -668T/-116C haplotype, respectively. Although the -668C/-116G haplotype was more common in PD patients, this difference was not significant.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "25ed7d746b414134b9454c0b72df2885", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[3, 5], [28, 30], [110, 112], [96, 98], [135, 137], [50, 52], [83, 85]], "char_spans": [[17, 31], [149, 163], [651, 665], [565, 579], [767, 781], [272, 286], [484, 498]]}]}], "context_tokens": [["Mutations", 0], ["of", 10], ["the", 13], ["alpha", 17], ["-", 22], ["synuclein", 23], ["gene", 33], ["have", 38], ["shown", 43], ["to", 49], ["be", 52], ["relevant", 55], ["in", 64], ["some", 67], ["rare", 72], ["families", 77], ["with", 86], ["autosomal", 91], ["dominant", 101], ["Parkinson", 110], ["'s", 119], ["disease", 122], ["(", 130], ["PD", 131], [")", 133], [".", 134], ["Furthermore", 136], [",", 147], ["alpha", 149], ["-", 154], ["synuclein", 155], ["protein", 165], ["is", 173], ["a", 176], ["major", 178], ["component", 184], ["of", 194], ["the", 197], ["Lewy", 201], ["bodies", 206], ["also", 213], ["in", 218], ["sporadic", 221], ["PD", 230], ["patients", 233], [".", 241], ["Increased", 243], ["levels", 253], ["of", 260], ["wildtype", 263], ["alpha", 272], ["-", 277], ["synuclein", 278], ["in", 288], ["the", 291], ["cell", 295], ["leads", 300], ["to", 306], ["increased", 309], ["intracellular", 319], ["hydrogen", 333], ["peroxide", 342], ["levels", 351], ["and", 358], ["causes", 362], ["death", 369], ["of", 375], ["dopaminergic", 378], ["neurons", 391], ["in", 399], ["rat", 402], ["primary", 406], ["culture", 414], [".", 421], ["Subsequently", 423], [",", 435], ["oxidative", 437], ["stress", 447], ["has", 454], ["been", 458], ["directly", 463], ["linked", 472], ["with", 479], ["alpha", 484], ["-", 489], ["synuclein", 490], ["aggregation", 500], ["in", 512], ["vitro", 515], [".", 520], ["This", 522], ["raises", 527], ["the", 534], ["question", 538], ["whether", 547], ["increased", 555], ["alpha", 565], ["-", 570], ["synuclein", 571], ["expression", 581], ["might", 592], ["be", 598], ["linked", 601], ["to", 608], ["higher", 611], ["susceptibility", 618], ["to", 633], ["PD", 636], ["and", 639], ["whether", 643], ["alpha", 651], ["-", 656], ["synuclein", 657], ["promoter", 667], ["polymorphisms", 676], ["are", 690], ["associated", 694], ["with", 705], ["PD", 710], [".", 712], ["Here", 714], [",", 718], ["two", 720], ["polymorphisms", 724], ["(", 738], ["-116C", 739], [">", 744], ["G", 745], ["and", 747], ["-668T", 751], [">", 756], ["C", 757], [")", 758], ["of", 760], ["the", 763], ["alpha", 767], ["-", 772], ["synuclein", 773], ["promoter", 783], ["defining", 792], ["four", 801], ["haplotypes", 806], ["have", 817], ["been", 822], ["characterized", 827], ["in", 841], ["315", 844], ["German", 848], ["PD", 855], ["patients", 858], [".", 866], ["The", 868], ["influence", 872], ["of", 882], ["the", 885], ["four", 889], ["haplotypes", 894], ["on", 905], ["gene", 908], ["expression", 913], ["was", 924], ["studied", 928], ["by", 936], ["CAT", 939], ["reporter", 943], ["gene", 952], ["assays", 957], ["in", 964], ["neuronal", 967], ["SK", 976], ["-", 978], ["N", 979], ["-", 980], ["AS", 981], ["cells", 984], [".", 989], ["The", 991], ["-668C/-116", 995], ["G", 1005], ["haplotype", 1007], ["revealed", 1017], ["significant", 1026], ["higher", 1038], ["CAT", 1045], ["expression", 1049], ["than", 1060], ["the", 1065], ["-668T/-116", 1069], ["G", 1079], ["or", 1081], ["the", 1084], ["-668T/-116C", 1088], ["haplotype", 1100], [",", 1109], ["respectively", 1111], [".", 1123], ["Although", 1125], ["the", 1134], ["-668C/-116", 1138], ["G", 1148], ["haplotype", 1150], ["was", 1160], ["more", 1164], ["common", 1169], ["in", 1176], ["PD", 1179], ["patients", 1182], [",", 1190], ["this", 1192], ["difference", 1197], ["was", 1208], ["not", 1212], ["significant", 1216], [".", 1227]]}
{"context": "Primary sinonasal intestinal-type adenocarcinomas (ITAC) are defined on the basis of their morphological similarities to colorectal adenocarcinomas (CRA). Thus, differential diagnosis with sinonasal metastasis of CRA could be a real challenge. Neuroendocrine differentiation has been variably described in several types of adenocarcinomas and notably in ITACs and CRAs. In a series of 25 ITACs and 25 lymph node metastasis of CRAs (nmCRA), we analysed neuroendocrine differentiation by immunohistochemistry with anti-chromogranin A and synaptophysin antibodies. Neuroendocrine differentiation (chromogranin A and/or synaptophysin positivity) was significantly different (p=0.0002) in ITACs (72%) and in nmCRAs (20%). In conclusion, presence of neuroendocrine cells seems more in favour of a sinonasal intestinal-type adenocarcinoma, than metastatic CRA. This immunohistochemical study could be useful in difficult cases and should be an interesting complement in a clinical discussion.", "qas": [{"question": "Which cell type has the protein Chromogranin A as marker?", "answers": ["neuroendocrine cells"], "qid": "ec272621cd3149a5b39e759406ab8844", "question_tokens": [["Which", 0], ["cell", 6], ["type", 11], ["has", 16], ["the", 20], ["protein", 24], ["Chromogranin", 32], ["A", 45], ["as", 47], ["marker", 50], ["?", 56]], "detected_answers": [{"text": "neuroendocrine cells", "token_spans": [[124, 125]], "char_spans": [[744, 763]]}]}], "context_tokens": [["Primary", 0], ["sinonasal", 8], ["intestinal", 18], ["-", 28], ["type", 29], ["adenocarcinomas", 34], ["(", 50], ["ITAC", 51], [")", 55], ["are", 57], ["defined", 61], ["on", 69], ["the", 72], ["basis", 76], ["of", 82], ["their", 85], ["morphological", 91], ["similarities", 105], ["to", 118], ["colorectal", 121], ["adenocarcinomas", 132], ["(", 148], ["CRA", 149], [")", 152], [".", 153], ["Thus", 155], [",", 159], ["differential", 161], ["diagnosis", 174], ["with", 184], ["sinonasal", 189], ["metastasis", 199], ["of", 210], ["CRA", 213], ["could", 217], ["be", 223], ["a", 226], ["real", 228], ["challenge", 233], [".", 242], ["Neuroendocrine", 244], ["differentiation", 259], ["has", 275], ["been", 279], ["variably", 284], ["described", 293], ["in", 303], ["several", 306], ["types", 314], ["of", 320], ["adenocarcinomas", 323], ["and", 339], ["notably", 343], ["in", 351], ["ITACs", 354], ["and", 360], ["CRAs", 364], [".", 368], ["In", 370], ["a", 373], ["series", 375], ["of", 382], ["25", 385], ["ITACs", 388], ["and", 394], ["25", 398], ["lymph", 401], ["node", 407], ["metastasis", 412], ["of", 423], ["CRAs", 426], ["(", 431], ["nmCRA", 432], [")", 437], [",", 438], ["we", 440], ["analysed", 443], ["neuroendocrine", 452], ["differentiation", 467], ["by", 483], ["immunohistochemistry", 486], ["with", 507], ["anti", 512], ["-", 516], ["chromogranin", 517], ["A", 530], ["and", 532], ["synaptophysin", 536], ["antibodies", 550], [".", 560], ["Neuroendocrine", 562], ["differentiation", 577], ["(", 593], ["chromogranin", 594], ["A", 607], ["and/or", 609], ["synaptophysin", 616], ["positivity", 630], [")", 640], ["was", 642], ["significantly", 646], ["different", 660], ["(", 670], ["p=0.0002", 671], [")", 679], ["in", 681], ["ITACs", 684], ["(", 690], ["72", 691], ["%", 693], [")", 694], ["and", 696], ["in", 700], ["nmCRAs", 703], ["(", 710], ["20", 711], ["%", 713], [")", 714], [".", 715], ["In", 717], ["conclusion", 720], [",", 730], ["presence", 732], ["of", 741], ["neuroendocrine", 744], ["cells", 759], ["seems", 765], ["more", 771], ["in", 776], ["favour", 779], ["of", 786], ["a", 789], ["sinonasal", 791], ["intestinal", 801], ["-", 811], ["type", 812], ["adenocarcinoma", 817], [",", 831], ["than", 833], ["metastatic", 838], ["CRA", 849], [".", 852], ["This", 854], ["immunohistochemical", 859], ["study", 879], ["could", 885], ["be", 891], ["useful", 894], ["in", 901], ["difficult", 904], ["cases", 914], ["and", 920], ["should", 924], ["be", 931], ["an", 934], ["interesting", 937], ["complement", 949], ["in", 960], ["a", 963], ["clinical", 965], ["discussion", 974], [".", 984]]}
{"context": "Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide. Despite significant progresses in the last decades, the origin of this cancer remains unclear and no efficient therapy exists. PDAC does not arise de novo: three remarkable different types of pancreatic lesions can evolve towards pancreatic cancer. These precursor lesions include: Pancreatic intraepithelial neoplasia (PanIN) that are microscopic lesions of the pancreas, Intraductal Papillary Mucinous Neoplasms (IPMN) and Mucinous Cystic Neoplasms (MCN) that are both macroscopic lesions. However, the cellular origin of these lesions is still a matter of debate. Classically, neoplasm initiation or progression is driven by several genetic and epigenetic alterations. The aim of this review is to assemble the current information on genetic mutations and epigenetic disorders that affect genes during pancreatic carcinogenesis. We will further discuss the interest of the genetic and epigenetic alterations for the diagnosis and prognosis of PDAC. Large genetic alterations (chromosomal deletion/amplification) and single point mutations are well described for carcinogenesis inducers. Mutations classically occur within key regions of the genome. Consequences are various and include activation of mitogenic pathways or silencing of apoptotic processes. Alterations of K-RAS, P16 and DPC4 genes are frequently observed in PDAC samples and have been described to arise gradually during carcinogenesis. DNA methylation is an epigenetic process involved in imprinting and X chromosome inactivation. Alteration of DNA methylation patterns leads to deregulation of gene expression, in the absence of mutation. Both genetic and epigenetic events influence genes and non-coding RNA expression, with dramatic effects on proliferation, survival and invasion. Besides improvement in our fundamental understanding of PDAC development, highlighting the molecular alterations that occur in pancreatic carcinogenesis could provide new clinical tools for early diagnosis of PDAC and the molecular basis for the development of new effective therapies.", "qas": [{"question": "Which is the molecular mechanism underlying K-ras alterations in carcinomas?", "answers": ["Point mutations"], "qid": "2729af5d87194532a74ffb452dcb9886", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["molecular", 13], ["mechanism", 23], ["underlying", 33], ["K", 44], ["-", 45], ["ras", 46], ["alterations", 50], ["in", 62], ["carcinomas", 65], ["?", 75]], "detected_answers": [{"text": "Point mutations", "token_spans": [[180, 181]], "char_spans": [[1111, 1125]]}]}], "context_tokens": [["Pancreatic", 0], ["ductal", 11], ["adenocarcinoma", 18], ["(", 33], ["PDAC", 34], [")", 38], ["is", 40], ["one", 43], ["of", 47], ["the", 50], ["most", 54], ["lethal", 59], ["cancers", 66], ["worldwide", 74], [".", 83], ["Despite", 85], ["significant", 93], ["progresses", 105], ["in", 116], ["the", 119], ["last", 123], ["decades", 128], [",", 135], ["the", 137], ["origin", 141], ["of", 148], ["this", 151], ["cancer", 156], ["remains", 163], ["unclear", 171], ["and", 179], ["no", 183], ["efficient", 186], ["therapy", 196], ["exists", 204], [".", 210], ["PDAC", 212], ["does", 217], ["not", 222], ["arise", 226], ["de", 232], ["novo", 235], [":", 239], ["three", 241], ["remarkable", 247], ["different", 258], ["types", 268], ["of", 274], ["pancreatic", 277], ["lesions", 288], ["can", 296], ["evolve", 300], ["towards", 307], ["pancreatic", 315], ["cancer", 326], [".", 332], ["These", 334], ["precursor", 340], ["lesions", 350], ["include", 358], [":", 365], ["Pancreatic", 367], ["intraepithelial", 378], ["neoplasia", 394], ["(", 404], ["PanIN", 405], [")", 410], ["that", 412], ["are", 417], ["microscopic", 421], ["lesions", 433], ["of", 441], ["the", 444], ["pancreas", 448], [",", 456], ["Intraductal", 458], ["Papillary", 470], ["Mucinous", 480], ["Neoplasms", 489], ["(", 499], ["IPMN", 500], [")", 504], ["and", 506], ["Mucinous", 510], ["Cystic", 519], ["Neoplasms", 526], ["(", 536], ["MCN", 537], [")", 540], ["that", 542], ["are", 547], ["both", 551], ["macroscopic", 556], ["lesions", 568], [".", 575], ["However", 577], [",", 584], ["the", 586], ["cellular", 590], ["origin", 599], ["of", 606], ["these", 609], ["lesions", 615], ["is", 623], ["still", 626], ["a", 632], ["matter", 634], ["of", 641], ["debate", 644], [".", 650], ["Classically", 652], [",", 663], ["neoplasm", 665], ["initiation", 674], ["or", 685], ["progression", 688], ["is", 700], ["driven", 703], ["by", 710], ["several", 713], ["genetic", 721], ["and", 729], ["epigenetic", 733], ["alterations", 744], [".", 755], ["The", 757], ["aim", 761], ["of", 765], ["this", 768], ["review", 773], ["is", 780], ["to", 783], ["assemble", 786], ["the", 795], ["current", 799], ["information", 807], ["on", 819], ["genetic", 822], ["mutations", 830], ["and", 840], ["epigenetic", 844], ["disorders", 855], ["that", 865], ["affect", 870], ["genes", 877], ["during", 883], ["pancreatic", 890], ["carcinogenesis", 901], [".", 915], ["We", 917], ["will", 920], ["further", 925], ["discuss", 933], ["the", 941], ["interest", 945], ["of", 954], ["the", 957], ["genetic", 961], ["and", 969], ["epigenetic", 973], ["alterations", 984], ["for", 996], ["the", 1000], ["diagnosis", 1004], ["and", 1014], ["prognosis", 1018], ["of", 1028], ["PDAC", 1031], [".", 1035], ["Large", 1037], ["genetic", 1043], ["alterations", 1051], ["(", 1063], ["chromosomal", 1064], ["deletion", 1076], ["/", 1084], ["amplification", 1085], [")", 1098], ["and", 1100], ["single", 1104], ["point", 1111], ["mutations", 1117], ["are", 1127], ["well", 1131], ["described", 1136], ["for", 1146], ["carcinogenesis", 1150], ["inducers", 1165], [".", 1173], ["Mutations", 1175], ["classically", 1185], ["occur", 1197], ["within", 1203], ["key", 1210], ["regions", 1214], ["of", 1222], ["the", 1225], ["genome", 1229], [".", 1235], ["Consequences", 1237], ["are", 1250], ["various", 1254], ["and", 1262], ["include", 1266], ["activation", 1274], ["of", 1285], ["mitogenic", 1288], ["pathways", 1298], ["or", 1307], ["silencing", 1310], ["of", 1320], ["apoptotic", 1323], ["processes", 1333], [".", 1342], ["Alterations", 1344], ["of", 1356], ["K", 1359], ["-", 1360], ["RAS", 1361], [",", 1364], ["P16", 1366], ["and", 1370], ["DPC4", 1374], ["genes", 1379], ["are", 1385], ["frequently", 1389], ["observed", 1400], ["in", 1409], ["PDAC", 1412], ["samples", 1417], ["and", 1425], ["have", 1429], ["been", 1434], ["described", 1439], ["to", 1449], ["arise", 1452], ["gradually", 1458], ["during", 1468], ["carcinogenesis", 1475], [".", 1489], ["DNA", 1491], ["methylation", 1495], ["is", 1507], ["an", 1510], ["epigenetic", 1513], ["process", 1524], ["involved", 1532], ["in", 1541], ["imprinting", 1544], ["and", 1555], ["X", 1559], ["chromosome", 1561], ["inactivation", 1572], [".", 1584], ["Alteration", 1586], ["of", 1597], ["DNA", 1600], ["methylation", 1604], ["patterns", 1616], ["leads", 1625], ["to", 1631], ["deregulation", 1634], ["of", 1647], ["gene", 1650], ["expression", 1655], [",", 1665], ["in", 1667], ["the", 1670], ["absence", 1674], ["of", 1682], ["mutation", 1685], [".", 1693], ["Both", 1695], ["genetic", 1700], ["and", 1708], ["epigenetic", 1712], ["events", 1723], ["influence", 1730], ["genes", 1740], ["and", 1746], ["non", 1750], ["-", 1753], ["coding", 1754], ["RNA", 1761], ["expression", 1765], [",", 1775], ["with", 1777], ["dramatic", 1782], ["effects", 1791], ["on", 1799], ["proliferation", 1802], [",", 1815], ["survival", 1817], ["and", 1826], ["invasion", 1830], [".", 1838], ["Besides", 1840], ["improvement", 1848], ["in", 1860], ["our", 1863], ["fundamental", 1867], ["understanding", 1879], ["of", 1893], ["PDAC", 1896], ["development", 1901], [",", 1912], ["highlighting", 1914], ["the", 1927], ["molecular", 1931], ["alterations", 1941], ["that", 1953], ["occur", 1958], ["in", 1964], ["pancreatic", 1967], ["carcinogenesis", 1978], ["could", 1993], ["provide", 1999], ["new", 2007], ["clinical", 2011], ["tools", 2020], ["for", 2026], ["early", 2030], ["diagnosis", 2036], ["of", 2046], ["PDAC", 2049], ["and", 2054], ["the", 2058], ["molecular", 2062], ["basis", 2072], ["for", 2078], ["the", 2082], ["development", 2086], ["of", 2098], ["new", 2101], ["effective", 2105], ["therapies", 2115], [".", 2124]]}
{"context": "Women in sub-Saharan Africa are a priority population for evaluation of new biomedical HIV-1 prevention strategies. Antiretroviral pre-exposure prophylaxis is a promising prevention approach; however, clinical trials among young women using daily or coitally-dependent products have found low adherence. Antiretroviral-containing vaginal microbicide rings, which release medication over a month or longer, may reduce these adherence challenges. ASPIRE (A Study to Prevent Infection with a Ring for Extended Use) is a phase III, randomized, double-blind, placebo-controlled trial testing the safety and effectiveness of a vaginal ring containing the non-nucleoside reverse transcriptase inhibitor dapivirine for prevention of HIV-1 infection. We describe the baseline characteristics of African women enrolled in the ASPIRE trial. Between August 2012 and June 2014, 5516 women were screened and 2629 HIV-1 seronegative women between 18-45 years of age were enrolled from 15 research sites in Malawi, South Africa, Uganda, and Zimbabwe. The median age was 26 years (IQR 22-31) and the majority (59%) were unmarried. Nearly 100% of participants reported having a primary sex partner in the prior three months but 43% did not know the HIV-1 status of their primary partner; 17% reported additional concurrent partners. Nearly two-thirds (64%) reported having disclosed to primary partners about planned vaginal ring use in the trial. Sexually transmitted infections were prevalent: 12% had Chlamydia trachomatis, 7% Trichomonas vaginalis, 4% Neisseria gonorrhoeae, and 1% syphilis. African HIV-1 seronegative women at risk of HIV -1 infection were successfully enrolled into a phase III trial of dapivirine vaginal ring for HIV-1 prevention.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "5c077ce1a2b84aa199040b93309cc5b6", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[294, 294]], "char_spans": [[1622, 1624]]}]}], "context_tokens": [["Women", 0], ["in", 6], ["sub", 9], ["-", 12], ["Saharan", 13], ["Africa", 21], ["are", 28], ["a", 32], ["priority", 34], ["population", 43], ["for", 54], ["evaluation", 58], ["of", 69], ["new", 72], ["biomedical", 76], ["HIV-1", 87], ["prevention", 93], ["strategies", 104], [".", 114], ["Antiretroviral", 116], ["pre", 131], ["-", 134], ["exposure", 135], ["prophylaxis", 144], ["is", 156], ["a", 159], ["promising", 161], ["prevention", 171], ["approach", 182], [";", 190], ["however", 192], [",", 199], ["clinical", 201], ["trials", 210], ["among", 217], ["young", 223], ["women", 229], ["using", 235], ["daily", 241], ["or", 247], ["coitally", 250], ["-", 258], ["dependent", 259], ["products", 269], ["have", 278], ["found", 283], ["low", 289], ["adherence", 293], [".", 302], ["Antiretroviral", 304], ["-", 318], ["containing", 319], ["vaginal", 330], ["microbicide", 338], ["rings", 350], [",", 355], ["which", 357], ["release", 363], ["medication", 371], ["over", 382], ["a", 387], ["month", 389], ["or", 395], ["longer", 398], [",", 404], ["may", 406], ["reduce", 410], ["these", 417], ["adherence", 423], ["challenges", 433], [".", 443], ["ASPIRE", 445], ["(", 452], ["A", 453], ["Study", 455], ["to", 461], ["Prevent", 464], ["Infection", 472], ["with", 482], ["a", 487], ["Ring", 489], ["for", 494], ["Extended", 498], ["Use", 507], [")", 510], ["is", 512], ["a", 515], ["phase", 517], ["III", 523], [",", 526], ["randomized", 528], [",", 538], ["double", 540], ["-", 546], ["blind", 547], [",", 552], ["placebo", 554], ["-", 561], ["controlled", 562], ["trial", 573], ["testing", 579], ["the", 587], ["safety", 591], ["and", 598], ["effectiveness", 602], ["of", 616], ["a", 619], ["vaginal", 621], ["ring", 629], ["containing", 634], ["the", 645], ["non", 649], ["-", 652], ["nucleoside", 653], ["reverse", 664], ["transcriptase", 672], ["inhibitor", 686], ["dapivirine", 696], ["for", 707], ["prevention", 711], ["of", 722], ["HIV-1", 725], ["infection", 731], [".", 740], ["We", 742], ["describe", 745], ["the", 754], ["baseline", 758], ["characteristics", 767], ["of", 783], ["African", 786], ["women", 794], ["enrolled", 800], ["in", 809], ["the", 812], ["ASPIRE", 816], ["trial", 823], [".", 828], ["Between", 830], ["August", 838], ["2012", 845], ["and", 850], ["June", 854], ["2014", 859], [",", 863], ["5516", 865], ["women", 870], ["were", 876], ["screened", 881], ["and", 890], ["2629", 894], ["HIV-1", 899], ["seronegative", 905], ["women", 918], ["between", 924], ["18", 932], ["-", 934], ["45", 935], ["years", 938], ["of", 944], ["age", 947], ["were", 951], ["enrolled", 956], ["from", 965], ["15", 970], ["research", 973], ["sites", 982], ["in", 988], ["Malawi", 991], [",", 997], ["South", 999], ["Africa", 1005], [",", 1011], ["Uganda", 1013], [",", 1019], ["and", 1021], ["Zimbabwe", 1025], [".", 1033], ["The", 1035], ["median", 1039], ["age", 1046], ["was", 1050], ["26", 1054], ["years", 1057], ["(", 1063], ["IQR", 1064], ["22", 1068], ["-", 1070], ["31", 1071], [")", 1073], ["and", 1075], ["the", 1079], ["majority", 1083], ["(", 1092], ["59", 1093], ["%", 1095], [")", 1096], ["were", 1098], ["unmarried", 1103], [".", 1112], ["Nearly", 1114], ["100", 1121], ["%", 1124], ["of", 1126], ["participants", 1129], ["reported", 1142], ["having", 1151], ["a", 1158], ["primary", 1160], ["sex", 1168], ["partner", 1172], ["in", 1180], ["the", 1183], ["prior", 1187], ["three", 1193], ["months", 1199], ["but", 1206], ["43", 1210], ["%", 1212], ["did", 1214], ["not", 1218], ["know", 1222], ["the", 1227], ["HIV-1", 1231], ["status", 1237], ["of", 1244], ["their", 1247], ["primary", 1253], ["partner", 1261], [";", 1268], ["17", 1270], ["%", 1272], ["reported", 1274], ["additional", 1283], ["concurrent", 1294], ["partners", 1305], [".", 1313], ["Nearly", 1315], ["two", 1322], ["-", 1325], ["thirds", 1326], ["(", 1333], ["64", 1334], ["%", 1336], [")", 1337], ["reported", 1339], ["having", 1348], ["disclosed", 1355], ["to", 1365], ["primary", 1368], ["partners", 1376], ["about", 1385], ["planned", 1391], ["vaginal", 1399], ["ring", 1407], ["use", 1412], ["in", 1416], ["the", 1419], ["trial", 1423], [".", 1428], ["Sexually", 1430], ["transmitted", 1439], ["infections", 1451], ["were", 1462], ["prevalent", 1467], [":", 1476], ["12", 1478], ["%", 1480], ["had", 1482], ["Chlamydia", 1486], ["trachomatis", 1496], [",", 1507], ["7", 1509], ["%", 1510], ["Trichomonas", 1512], ["vaginalis", 1524], [",", 1533], ["4", 1535], ["%", 1536], ["Neisseria", 1538], ["gonorrhoeae", 1548], [",", 1559], ["and", 1561], ["1", 1565], ["%", 1566], ["syphilis", 1568], [".", 1576], ["African", 1578], ["HIV-1", 1586], ["seronegative", 1592], ["women", 1605], ["at", 1611], ["risk", 1614], ["of", 1619], ["HIV", 1622], ["-1", 1626], ["infection", 1629], ["were", 1639], ["successfully", 1644], ["enrolled", 1657], ["into", 1666], ["a", 1671], ["phase", 1673], ["III", 1679], ["trial", 1683], ["of", 1689], ["dapivirine", 1692], ["vaginal", 1703], ["ring", 1711], ["for", 1716], ["HIV-1", 1720], ["prevention", 1726], [".", 1736]]}
{"context": "Facio-scapulo-humeral dystrophy (FSHD) results from deletions in the subtelomeric macrosatellite D4Z4 array on the 4q35 region. Upregulation of the DUX4 retrogene from the last D4Z4 repeated unit is thought to underlie FSHD pathophysiology. However, no one knows what triggers muscle defect and when alteration arises. To gain further insights into the molecular mechanisms of the disease, we evaluated at the molecular level, the perturbation linked to the FSHD genotype with no a priori on disease onset, severity or penetrance and prior to any infiltration by fibrotic or adipose tissue in biopsies from fetuses carrying a short pathogenic D4Z4 array (n = 6) compared with fetuses with a non-pathogenic D4Z4 array (n = 21). By measuring expression of several muscle-specific markers and 4q35 genes including the DUX4 retrogene by an RT-PCR and western blotting, we observed a global dysregulation of genes involved in myogenesis including MYOD1 in samples with <11 D4Z4. The DUX4-fl pathogenic transcript was detected in FSHD biopsies but also in controls. Importantly, in FSHD fetuses, we mainly detected the non-spliced DUX4-fl isoform. In addition, several other genes clustered at the 4q35 locus are upregulated in FSHD fetuses. Our study is the first to examine fetuses carrying an FSHD-linked genotype and reveals an extensive dysregulation of several muscle-specific and 4q35 genes at early development stage at a distance from any muscle defect. Overall, our work suggests that even if FSHD is an adult-onset muscular dystrophy, the disease might also involve early molecular defects arising during myogenesis or early differentiation.", "qas": [{"question": "Which disease is associated with the ectopic expression of the protein encoded by the gene DUX4?", "answers": ["Facioscapulohumeral dystrophy", "FSHD"], "qid": "4fc29c2642a542c698f2e6a566dc9c37", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["associated", 17], ["with", 28], ["the", 33], ["ectopic", 37], ["expression", 45], ["of", 56], ["the", 59], ["protein", 63], ["encoded", 71], ["by", 79], ["the", 82], ["gene", 86], ["DUX4", 91], ["?", 95]], "detected_answers": [{"text": "FSHD", "token_spans": [[221, 221], [38, 38], [234, 234], [7, 7], [184, 184], [194, 194], [79, 79], [271, 271]], "char_spans": [[1222, 1225], [219, 222], [1290, 1293], [33, 36], [1024, 1027], [1076, 1079], [458, 461], [1497, 1500]]}]}], "context_tokens": [["Facio", 0], ["-", 5], ["scapulo", 6], ["-", 13], ["humeral", 14], ["dystrophy", 22], ["(", 32], ["FSHD", 33], [")", 37], ["results", 39], ["from", 47], ["deletions", 52], ["in", 62], ["the", 65], ["subtelomeric", 69], ["macrosatellite", 82], ["D4Z4", 97], ["array", 102], ["on", 108], ["the", 111], ["4q35", 115], ["region", 120], [".", 126], ["Upregulation", 128], ["of", 141], ["the", 144], ["DUX4", 148], ["retrogene", 153], ["from", 163], ["the", 168], ["last", 172], ["D4Z4", 177], ["repeated", 182], ["unit", 191], ["is", 196], ["thought", 199], ["to", 207], ["underlie", 210], ["FSHD", 219], ["pathophysiology", 224], [".", 239], ["However", 241], [",", 248], ["no", 250], ["one", 253], ["knows", 257], ["what", 263], ["triggers", 268], ["muscle", 277], ["defect", 284], ["and", 291], ["when", 295], ["alteration", 300], ["arises", 311], [".", 317], ["To", 319], ["gain", 322], ["further", 327], ["insights", 335], ["into", 344], ["the", 349], ["molecular", 353], ["mechanisms", 363], ["of", 374], ["the", 377], ["disease", 381], [",", 388], ["we", 390], ["evaluated", 393], ["at", 403], ["the", 406], ["molecular", 410], ["level", 420], [",", 425], ["the", 427], ["perturbation", 431], ["linked", 444], ["to", 451], ["the", 454], ["FSHD", 458], ["genotype", 463], ["with", 472], ["no", 477], ["a", 480], ["priori", 482], ["on", 489], ["disease", 492], ["onset", 500], [",", 505], ["severity", 507], ["or", 516], ["penetrance", 519], ["and", 530], ["prior", 534], ["to", 540], ["any", 543], ["infiltration", 547], ["by", 560], ["fibrotic", 563], ["or", 572], ["adipose", 575], ["tissue", 583], ["in", 590], ["biopsies", 593], ["from", 602], ["fetuses", 607], ["carrying", 615], ["a", 624], ["short", 626], ["pathogenic", 632], ["D4Z4", 643], ["array", 648], ["(", 654], ["n", 655], ["=", 657], ["6", 659], [")", 660], ["compared", 662], ["with", 671], ["fetuses", 676], ["with", 684], ["a", 689], ["non", 691], ["-", 694], ["pathogenic", 695], ["D4Z4", 706], ["array", 711], ["(", 717], ["n", 718], ["=", 720], ["21", 722], [")", 724], [".", 725], ["By", 727], ["measuring", 730], ["expression", 740], ["of", 751], ["several", 754], ["muscle", 762], ["-", 768], ["specific", 769], ["markers", 778], ["and", 786], ["4q35", 790], ["genes", 795], ["including", 801], ["the", 811], ["DUX4", 815], ["retrogene", 820], ["by", 830], ["an", 833], ["RT", 836], ["-", 838], ["PCR", 839], ["and", 843], ["western", 847], ["blotting", 855], [",", 863], ["we", 865], ["observed", 868], ["a", 877], ["global", 879], ["dysregulation", 886], ["of", 900], ["genes", 903], ["involved", 909], ["in", 918], ["myogenesis", 921], ["including", 932], ["MYOD1", 942], ["in", 948], ["samples", 951], ["with", 959], ["<", 964], ["11", 965], ["D4Z4", 968], [".", 972], ["The", 974], ["DUX4-fl", 978], ["pathogenic", 986], ["transcript", 997], ["was", 1008], ["detected", 1012], ["in", 1021], ["FSHD", 1024], ["biopsies", 1029], ["but", 1038], ["also", 1042], ["in", 1047], ["controls", 1050], [".", 1058], ["Importantly", 1060], [",", 1071], ["in", 1073], ["FSHD", 1076], ["fetuses", 1081], [",", 1088], ["we", 1090], ["mainly", 1093], ["detected", 1100], ["the", 1109], ["non", 1113], ["-", 1116], ["spliced", 1117], ["DUX4-fl", 1125], ["isoform", 1133], [".", 1140], ["In", 1142], ["addition", 1145], [",", 1153], ["several", 1155], ["other", 1163], ["genes", 1169], ["clustered", 1175], ["at", 1185], ["the", 1188], ["4q35", 1192], ["locus", 1197], ["are", 1203], ["upregulated", 1207], ["in", 1219], ["FSHD", 1222], ["fetuses", 1227], [".", 1234], ["Our", 1236], ["study", 1240], ["is", 1246], ["the", 1249], ["first", 1253], ["to", 1259], ["examine", 1262], ["fetuses", 1270], ["carrying", 1278], ["an", 1287], ["FSHD", 1290], ["-", 1294], ["linked", 1295], ["genotype", 1302], ["and", 1311], ["reveals", 1315], ["an", 1323], ["extensive", 1326], ["dysregulation", 1336], ["of", 1350], ["several", 1353], ["muscle", 1361], ["-", 1367], ["specific", 1368], ["and", 1377], ["4q35", 1381], ["genes", 1386], ["at", 1392], ["early", 1395], ["development", 1401], ["stage", 1413], ["at", 1419], ["a", 1422], ["distance", 1424], ["from", 1433], ["any", 1438], ["muscle", 1442], ["defect", 1449], [".", 1455], ["Overall", 1457], [",", 1464], ["our", 1466], ["work", 1470], ["suggests", 1475], ["that", 1484], ["even", 1489], ["if", 1494], ["FSHD", 1497], ["is", 1502], ["an", 1505], ["adult", 1508], ["-", 1513], ["onset", 1514], ["muscular", 1520], ["dystrophy", 1529], [",", 1538], ["the", 1540], ["disease", 1544], ["might", 1552], ["also", 1558], ["involve", 1563], ["early", 1571], ["molecular", 1577], ["defects", 1587], ["arising", 1595], ["during", 1603], ["myogenesis", 1610], ["or", 1621], ["early", 1624], ["differentiation", 1630], [".", 1645]]}
{"context": "Restless legs syndrome, now called Willis-Ekbom Disease (RLS/WED), is a sensorimotor-related sleep disorder. Little is known of the effect of RLS/WED on motor function. The current study investigated upper limb function in RLS/WED patients. We hypothesised that RLS/WED patients exhibit subtle changes in tremor amplitude but normal dexterity and movement speed and rhythmicity compared to healthy controls. RLS/WED patients (n=17, 59 \u00b1 7 years) with moderate disease and healthy controls (n=17, 58 \u00b1 6 years) completed screening tests and five tasks including object manipulation, maximal pinch grip, flexion and extension of the index finger (tremor assessment), maximal finger tapping (movement speed and rhythmicity assessment), and the grooved pegboard test. Force, acceleration, and/or first dorsal interosseus EMG were recorded during four of the tasks. Task performance did not differ between groups. Learning was evident on tasks with repeated trials and the magnitude of learning did not differ between groups. Hand function, tremor, and task learning were unaffected in RLS/WED patients. Patients manipulated objects in a normal manner and exhibited normal movement speed, rhythmicity, and tremor. Further research is needed to assess other types of movement in RLS/WED patients to gain insight into the motor circuitry affected and the underlying pathophysiology.", "qas": [{"question": "Willis-Ekbom disease is also known as?", "answers": ["Restless legs syndrome"], "qid": "3e5986f118e1472abdf00781a69c02a0", "question_tokens": [["Willis", 0], ["-", 6], ["Ekbom", 7], ["disease", 13], ["is", 21], ["also", 24], ["known", 29], ["as", 35], ["?", 37]], "detected_answers": [{"text": "Restless legs syndrome", "token_spans": [[0, 2]], "char_spans": [[0, 21]]}]}], "context_tokens": [["Restless", 0], ["legs", 9], ["syndrome", 14], [",", 22], ["now", 24], ["called", 28], ["Willis", 35], ["-", 41], ["Ekbom", 42], ["Disease", 48], ["(", 56], ["RLS", 57], ["/", 60], ["WED", 61], [")", 64], [",", 65], ["is", 67], ["a", 70], ["sensorimotor", 72], ["-", 84], ["related", 85], ["sleep", 93], ["disorder", 99], [".", 107], ["Little", 109], ["is", 116], ["known", 119], ["of", 125], ["the", 128], ["effect", 132], ["of", 139], ["RLS", 142], ["/", 145], ["WED", 146], ["on", 150], ["motor", 153], ["function", 159], [".", 167], ["The", 169], ["current", 173], ["study", 181], ["investigated", 187], ["upper", 200], ["limb", 206], ["function", 211], ["in", 220], ["RLS", 223], ["/", 226], ["WED", 227], ["patients", 231], [".", 239], ["We", 241], ["hypothesised", 244], ["that", 257], ["RLS", 262], ["/", 265], ["WED", 266], ["patients", 270], ["exhibit", 279], ["subtle", 287], ["changes", 294], ["in", 302], ["tremor", 305], ["amplitude", 312], ["but", 322], ["normal", 326], ["dexterity", 333], ["and", 343], ["movement", 347], ["speed", 356], ["and", 362], ["rhythmicity", 366], ["compared", 378], ["to", 387], ["healthy", 390], ["controls", 398], [".", 406], ["RLS", 408], ["/", 411], ["WED", 412], ["patients", 416], ["(", 425], ["n=17", 426], [",", 430], ["59", 432], ["\u00b1", 435], ["7", 437], ["years", 439], [")", 444], ["with", 446], ["moderate", 451], ["disease", 460], ["and", 468], ["healthy", 472], ["controls", 480], ["(", 489], ["n=17", 490], [",", 494], ["58", 496], ["\u00b1", 499], ["6", 501], ["years", 503], [")", 508], ["completed", 510], ["screening", 520], ["tests", 530], ["and", 536], ["five", 540], ["tasks", 545], ["including", 551], ["object", 561], ["manipulation", 568], [",", 580], ["maximal", 582], ["pinch", 590], ["grip", 596], [",", 600], ["flexion", 602], ["and", 610], ["extension", 614], ["of", 624], ["the", 627], ["index", 631], ["finger", 637], ["(", 644], ["tremor", 645], ["assessment", 652], [")", 662], [",", 663], ["maximal", 665], ["finger", 673], ["tapping", 680], ["(", 688], ["movement", 689], ["speed", 698], ["and", 704], ["rhythmicity", 708], ["assessment", 720], [")", 730], [",", 731], ["and", 733], ["the", 737], ["grooved", 741], ["pegboard", 749], ["test", 758], [".", 762], ["Force", 764], [",", 769], ["acceleration", 771], [",", 783], ["and/or", 785], ["first", 792], ["dorsal", 798], ["interosseus", 805], ["EMG", 817], ["were", 821], ["recorded", 826], ["during", 835], ["four", 842], ["of", 847], ["the", 850], ["tasks", 854], [".", 859], ["Task", 861], ["performance", 866], ["did", 878], ["not", 882], ["differ", 886], ["between", 893], ["groups", 901], [".", 907], ["Learning", 909], ["was", 918], ["evident", 922], ["on", 930], ["tasks", 933], ["with", 939], ["repeated", 944], ["trials", 953], ["and", 960], ["the", 964], ["magnitude", 968], ["of", 978], ["learning", 981], ["did", 990], ["not", 994], ["differ", 998], ["between", 1005], ["groups", 1013], [".", 1019], ["Hand", 1021], ["function", 1026], [",", 1034], ["tremor", 1036], [",", 1042], ["and", 1044], ["task", 1048], ["learning", 1053], ["were", 1062], ["unaffected", 1067], ["in", 1078], ["RLS", 1081], ["/", 1084], ["WED", 1085], ["patients", 1089], [".", 1097], ["Patients", 1099], ["manipulated", 1108], ["objects", 1120], ["in", 1128], ["a", 1131], ["normal", 1133], ["manner", 1140], ["and", 1147], ["exhibited", 1151], ["normal", 1161], ["movement", 1168], ["speed", 1177], [",", 1182], ["rhythmicity", 1184], [",", 1195], ["and", 1197], ["tremor", 1201], [".", 1207], ["Further", 1209], ["research", 1217], ["is", 1226], ["needed", 1229], ["to", 1236], ["assess", 1239], ["other", 1246], ["types", 1252], ["of", 1258], ["movement", 1261], ["in", 1270], ["RLS", 1273], ["/", 1276], ["WED", 1277], ["patients", 1281], ["to", 1290], ["gain", 1293], ["insight", 1298], ["into", 1306], ["the", 1311], ["motor", 1315], ["circuitry", 1321], ["affected", 1331], ["and", 1340], ["the", 1344], ["underlying", 1348], ["pathophysiology", 1359], [".", 1374]]}
{"context": "Several gene products are involved in co-translational insertion of selenocysteine by the tRNA(Sec). In addition, a stem-loop structure in the mRNAs coding for selenoproteins is essential to mediate the selection of the proper selenocysteine UGA codon. Interestingly, in eukaryotic selenoprotein mRNAs, this stem-loop structure, the selenocysteine insertion sequence (SECIS) element, resides in the 3'-untranslated region, far downstream of the UGA codon. In view of unravelling the underlying complex mechanism, we have attempted to detect RNA-binding proteins with specificity for the SECIS element. Using mobility shift assays, we could show that a protein, present in different types of mammalian cell extracts, possesses the capacity of binding the SECIS element of the selenoprotein glutathione peroxidase (GPx) mRNA. We have termed this protein SBP, for Secis Binding Protein. Competition experiments attested that the binding is highly specific and UV cross-linking indicated that the protein has an apparent molecular weight in the range of 60-65 kDa. Finally, some data suggest that the SECIS elements in the mRNAs of GPx and another selenoprotein, type I iodothyronine 5' deiodinase, recognize the same SBP protein. This constitutes the first report of the existence of a 3' UTR binding protein possibly involved in the eukaryotic selenocysteine insertion mechanism.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "22db25e825ff4bcfb783e89d2d7a8162", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[131, 131], [101, 101], [151, 151], [62, 62], [194, 194]], "char_spans": [[754, 758], [587, 591], [861, 865], [368, 372], [1097, 1101]]}]}], "context_tokens": [["Several", 0], ["gene", 8], ["products", 13], ["are", 22], ["involved", 26], ["in", 35], ["co", 38], ["-", 40], ["translational", 41], ["insertion", 55], ["of", 65], ["selenocysteine", 68], ["by", 83], ["the", 86], ["tRNA(Sec", 90], [")", 98], [".", 99], ["In", 101], ["addition", 104], [",", 112], ["a", 114], ["stem", 116], ["-", 120], ["loop", 121], ["structure", 126], ["in", 136], ["the", 139], ["mRNAs", 143], ["coding", 149], ["for", 156], ["selenoproteins", 160], ["is", 175], ["essential", 178], ["to", 188], ["mediate", 191], ["the", 199], ["selection", 203], ["of", 213], ["the", 216], ["proper", 220], ["selenocysteine", 227], ["UGA", 242], ["codon", 246], [".", 251], ["Interestingly", 253], [",", 266], ["in", 268], ["eukaryotic", 271], ["selenoprotein", 282], ["mRNAs", 296], [",", 301], ["this", 303], ["stem", 308], ["-", 312], ["loop", 313], ["structure", 318], [",", 327], ["the", 329], ["selenocysteine", 333], ["insertion", 348], ["sequence", 358], ["(", 367], ["SECIS", 368], [")", 373], ["element", 375], [",", 382], ["resides", 384], ["in", 392], ["the", 395], ["3'-untranslated", 399], ["region", 415], [",", 421], ["far", 423], ["downstream", 427], ["of", 438], ["the", 441], ["UGA", 445], ["codon", 449], [".", 454], ["In", 456], ["view", 459], ["of", 464], ["unravelling", 467], ["the", 479], ["underlying", 483], ["complex", 494], ["mechanism", 502], [",", 511], ["we", 513], ["have", 516], ["attempted", 521], ["to", 531], ["detect", 534], ["RNA", 541], ["-", 544], ["binding", 545], ["proteins", 553], ["with", 562], ["specificity", 567], ["for", 579], ["the", 583], ["SECIS", 587], ["element", 593], [".", 600], ["Using", 602], ["mobility", 608], ["shift", 617], ["assays", 623], [",", 629], ["we", 631], ["could", 634], ["show", 640], ["that", 645], ["a", 650], ["protein", 652], [",", 659], ["present", 661], ["in", 669], ["different", 672], ["types", 682], ["of", 688], ["mammalian", 691], ["cell", 701], ["extracts", 706], [",", 714], ["possesses", 716], ["the", 726], ["capacity", 730], ["of", 739], ["binding", 742], ["the", 750], ["SECIS", 754], ["element", 760], ["of", 768], ["the", 771], ["selenoprotein", 775], ["glutathione", 789], ["peroxidase", 801], ["(", 812], ["GPx", 813], [")", 816], ["mRNA", 818], [".", 822], ["We", 824], ["have", 827], ["termed", 832], ["this", 839], ["protein", 844], ["SBP", 852], [",", 855], ["for", 857], ["Secis", 861], ["Binding", 867], ["Protein", 875], [".", 882], ["Competition", 884], ["experiments", 896], ["attested", 908], ["that", 917], ["the", 922], ["binding", 926], ["is", 934], ["highly", 937], ["specific", 944], ["and", 953], ["UV", 957], ["cross", 960], ["-", 965], ["linking", 966], ["indicated", 974], ["that", 984], ["the", 989], ["protein", 993], ["has", 1001], ["an", 1005], ["apparent", 1008], ["molecular", 1017], ["weight", 1027], ["in", 1034], ["the", 1037], ["range", 1041], ["of", 1047], ["60", 1050], ["-", 1052], ["65", 1053], ["kDa", 1056], [".", 1059], ["Finally", 1061], [",", 1068], ["some", 1070], ["data", 1075], ["suggest", 1080], ["that", 1088], ["the", 1093], ["SECIS", 1097], ["elements", 1103], ["in", 1112], ["the", 1115], ["mRNAs", 1119], ["of", 1125], ["GPx", 1128], ["and", 1132], ["another", 1136], ["selenoprotein", 1144], [",", 1157], ["type", 1159], ["I", 1164], ["iodothyronine", 1166], ["5", 1180], ["'", 1181], ["deiodinase", 1183], [",", 1193], ["recognize", 1195], ["the", 1205], ["same", 1209], ["SBP", 1214], ["protein", 1218], [".", 1225], ["This", 1227], ["constitutes", 1232], ["the", 1244], ["first", 1248], ["report", 1254], ["of", 1261], ["the", 1264], ["existence", 1268], ["of", 1278], ["a", 1281], ["3", 1283], ["'", 1284], ["UTR", 1286], ["binding", 1290], ["protein", 1298], ["possibly", 1306], ["involved", 1315], ["in", 1324], ["the", 1327], ["eukaryotic", 1331], ["selenocysteine", 1342], ["insertion", 1357], ["mechanism", 1367], [".", 1376]]}
{"context": "alpha-Synuclein and ubiquitin are two Lewy body protein components that may play antagonistic roles in the pathogenesis of Lewy bodies. We examined the relationship between alpha-synuclein, ubiquitin, and lipids in Lewy bodies of fixed brain sections or isolated from cortical tissues of dementia with Lewy bodies. Lewy bodies exhibited a range of labeling patterns for alpha-synuclein and ubiquitin, from a homogeneous pattern in which alpha-synuclein and ubiquitin were evenly distributed and overlapped across the inclusion body to a concentric pattern in which alpha-synuclein and ubiquitin were partially segregated, with alpha-synuclein labeling concentrated in the peripheral domain and ubiquitin in the central domain of the Lewy body. Lipids represented a significant component in both homogeneous and concentric Lewy bodies. These results suggest that Lewy bodies are heterogeneous in their subregional composition. The segregation of alpha-synuclein to Lewy body peripheral domain is consistent with the hypothesis that alpha-synuclein is continually deposited onto Lewy bodies.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "84268ced61744024a40b6f8d2316d275", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[63, 65], [28, 30], [154, 156], [168, 170], [95, 97], [105, 107], [0, 2], [75, 77]], "char_spans": [[370, 384], [173, 187], [945, 959], [1031, 1045], [565, 579], [627, 641], [0, 14], [437, 451]]}]}], "context_tokens": [["alpha", 0], ["-", 5], ["Synuclein", 6], ["and", 16], ["ubiquitin", 20], ["are", 30], ["two", 34], ["Lewy", 38], ["body", 43], ["protein", 48], ["components", 56], ["that", 67], ["may", 72], ["play", 76], ["antagonistic", 81], ["roles", 94], ["in", 100], ["the", 103], ["pathogenesis", 107], ["of", 120], ["Lewy", 123], ["bodies", 128], [".", 134], ["We", 136], ["examined", 139], ["the", 148], ["relationship", 152], ["between", 165], ["alpha", 173], ["-", 178], ["synuclein", 179], [",", 188], ["ubiquitin", 190], [",", 199], ["and", 201], ["lipids", 205], ["in", 212], ["Lewy", 215], ["bodies", 220], ["of", 227], ["fixed", 230], ["brain", 236], ["sections", 242], ["or", 251], ["isolated", 254], ["from", 263], ["cortical", 268], ["tissues", 277], ["of", 285], ["dementia", 288], ["with", 297], ["Lewy", 302], ["bodies", 307], [".", 313], ["Lewy", 315], ["bodies", 320], ["exhibited", 327], ["a", 337], ["range", 339], ["of", 345], ["labeling", 348], ["patterns", 357], ["for", 366], ["alpha", 370], ["-", 375], ["synuclein", 376], ["and", 386], ["ubiquitin", 390], [",", 399], ["from", 401], ["a", 406], ["homogeneous", 408], ["pattern", 420], ["in", 428], ["which", 431], ["alpha", 437], ["-", 442], ["synuclein", 443], ["and", 453], ["ubiquitin", 457], ["were", 467], ["evenly", 472], ["distributed", 479], ["and", 491], ["overlapped", 495], ["across", 506], ["the", 513], ["inclusion", 517], ["body", 527], ["to", 532], ["a", 535], ["concentric", 537], ["pattern", 548], ["in", 556], ["which", 559], ["alpha", 565], ["-", 570], ["synuclein", 571], ["and", 581], ["ubiquitin", 585], ["were", 595], ["partially", 600], ["segregated", 610], [",", 620], ["with", 622], ["alpha", 627], ["-", 632], ["synuclein", 633], ["labeling", 643], ["concentrated", 652], ["in", 665], ["the", 668], ["peripheral", 672], ["domain", 683], ["and", 690], ["ubiquitin", 694], ["in", 704], ["the", 707], ["central", 711], ["domain", 719], ["of", 726], ["the", 729], ["Lewy", 733], ["body", 738], [".", 742], ["Lipids", 744], ["represented", 751], ["a", 763], ["significant", 765], ["component", 777], ["in", 787], ["both", 790], ["homogeneous", 795], ["and", 807], ["concentric", 811], ["Lewy", 822], ["bodies", 827], [".", 833], ["These", 835], ["results", 841], ["suggest", 849], ["that", 857], ["Lewy", 862], ["bodies", 867], ["are", 874], ["heterogeneous", 878], ["in", 892], ["their", 895], ["subregional", 901], ["composition", 913], [".", 924], ["The", 926], ["segregation", 930], ["of", 942], ["alpha", 945], ["-", 950], ["synuclein", 951], ["to", 961], ["Lewy", 964], ["body", 969], ["peripheral", 974], ["domain", 985], ["is", 992], ["consistent", 995], ["with", 1006], ["the", 1011], ["hypothesis", 1015], ["that", 1026], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], ["is", 1047], ["continually", 1050], ["deposited", 1062], ["onto", 1072], ["Lewy", 1077], ["bodies", 1082], [".", 1088]]}
{"context": "Research during the last 15 years has conclusively shown that viroids are not only fundamentally different from viruses at the molecular level, but that they are most likely not directly related to viruses in an evolutionary sense. Today, viroids are among the most thoroughly studied biological macromolecules. Their molecular structures have been elucidated to a large extent, but much needs to be learned regarding the correlation between molecular structure and biological function. The availability of the tools of recombinant DNA technology in viroid research promises rapid progress in these areas of inquiry.", "qas": [{"question": "Which are the smallest known subviral pathogens of plants?", "answers": ["Viroids"], "qid": "e33fefebc3a946c4b17c7aaf7f33de2e", "question_tokens": [["Which", 0], ["are", 6], ["the", 10], ["smallest", 14], ["known", 23], ["subviral", 29], ["pathogens", 38], ["of", 48], ["plants", 51], ["?", 57]], "detected_answers": [{"text": "Viroids", "token_spans": [[41, 41], [10, 10]], "char_spans": [[239, 245], [62, 68]]}]}], "context_tokens": [["Research", 0], ["during", 9], ["the", 16], ["last", 20], ["15", 25], ["years", 28], ["has", 34], ["conclusively", 38], ["shown", 51], ["that", 57], ["viroids", 62], ["are", 70], ["not", 74], ["only", 78], ["fundamentally", 83], ["different", 97], ["from", 107], ["viruses", 112], ["at", 120], ["the", 123], ["molecular", 127], ["level", 137], [",", 142], ["but", 144], ["that", 148], ["they", 153], ["are", 158], ["most", 162], ["likely", 167], ["not", 174], ["directly", 178], ["related", 187], ["to", 195], ["viruses", 198], ["in", 206], ["an", 209], ["evolutionary", 212], ["sense", 225], [".", 230], ["Today", 232], [",", 237], ["viroids", 239], ["are", 247], ["among", 251], ["the", 257], ["most", 261], ["thoroughly", 266], ["studied", 277], ["biological", 285], ["macromolecules", 296], [".", 310], ["Their", 312], ["molecular", 318], ["structures", 328], ["have", 339], ["been", 344], ["elucidated", 349], ["to", 360], ["a", 363], ["large", 365], ["extent", 371], [",", 377], ["but", 379], ["much", 383], ["needs", 388], ["to", 394], ["be", 397], ["learned", 400], ["regarding", 408], ["the", 418], ["correlation", 422], ["between", 434], ["molecular", 442], ["structure", 452], ["and", 462], ["biological", 466], ["function", 477], [".", 485], ["The", 487], ["availability", 491], ["of", 504], ["the", 507], ["tools", 511], ["of", 517], ["recombinant", 520], ["DNA", 532], ["technology", 536], ["in", 547], ["viroid", 550], ["research", 557], ["promises", 566], ["rapid", 575], ["progress", 581], ["in", 590], ["these", 593], ["areas", 599], ["of", 605], ["inquiry", 608], [".", 615]]}
{"context": "Ten years after Fire and Melo's Nobel Prize for discovery of gene silencing by double-stranded RNA, a remarkable progress was achieved in RNA interference (RNAi). Changes in the chemical structure of synthetic oligonucleotides make them more stable and specific, and new delivery strategies became progressively available. The attention of pharmaceutical industry rapidly turned to RNAi, as an opportunity to explore new drug targets. This review addresses nine small-interfering RNAs (siRNAs) and one unique microRNA (miRNA) inhibitor, which entered the phase 2-3 clinical trials. The siRNAs in focus are PF-04523655, TKM-080301, Atu027, SYL040012, SYL1001, siG12D-LODER (phase 2), QPI-1002, QPI-1007, and patisiran (phase 3). Regarding miRNAs, their content can be down- or up-regulated, by using miRNA inhibitors (AntimiRs) or miRNA mimics. Miravirsen is an AntimiR-122 for hepatitis C virus infection. The flexibility of RNAi technology is easily understood taking into account: (i) the different drug targets (i.e. p53, caspase 2, PKN3, \u03b22-adrenergic receptor, mutated KRAS, microRNAs); (ii) therapeutic conditions, including ophthalmic diseases, kidney injury, amyloidosis, pancreatic cancer, viral hepatitis; and (iii) routes of administration (ocular, intravenous, subcutaneous, intratumoral). Although some issues are still matters of concern (delivery, toxicity, cost, and biological barriers), RNAi definitively opens a wide avenue for drug development.", "qas": [{"question": "In November 2017,  in what phase  was  the clinical trial for the drug SYL040012?", "answers": ["Phase 3"], "qid": "d2fdd08c60094d70a63f61dde1ded606", "question_tokens": [["In", 0], ["November", 3], ["2017", 12], [",", 16], [" ", 18], ["in", 19], ["what", 22], ["phase", 27], [" ", 33], ["was", 34], [" ", 38], ["the", 39], ["clinical", 43], ["trial", 52], ["for", 58], ["the", 62], ["drug", 66], ["SYL040012", 71], ["?", 80]], "detected_answers": [{"text": "Phase 3", "token_spans": [[134, 135]], "char_spans": [[718, 724]]}]}], "context_tokens": [["Ten", 0], ["years", 4], ["after", 10], ["Fire", 16], ["and", 21], ["Melo", 25], ["'s", 29], ["Nobel", 32], ["Prize", 38], ["for", 44], ["discovery", 48], ["of", 58], ["gene", 61], ["silencing", 66], ["by", 76], ["double", 79], ["-", 85], ["stranded", 86], ["RNA", 95], [",", 98], ["a", 100], ["remarkable", 102], ["progress", 113], ["was", 122], ["achieved", 126], ["in", 135], ["RNA", 138], ["interference", 142], ["(", 155], ["RNAi", 156], [")", 160], [".", 161], ["Changes", 163], ["in", 171], ["the", 174], ["chemical", 178], ["structure", 187], ["of", 197], ["synthetic", 200], ["oligonucleotides", 210], ["make", 227], ["them", 232], ["more", 237], ["stable", 242], ["and", 249], ["specific", 253], [",", 261], ["and", 263], ["new", 267], ["delivery", 271], ["strategies", 280], ["became", 291], ["progressively", 298], ["available", 312], [".", 321], ["The", 323], ["attention", 327], ["of", 337], ["pharmaceutical", 340], ["industry", 355], ["rapidly", 364], ["turned", 372], ["to", 379], ["RNAi", 382], [",", 386], ["as", 388], ["an", 391], ["opportunity", 394], ["to", 406], ["explore", 409], ["new", 417], ["drug", 421], ["targets", 426], [".", 433], ["This", 435], ["review", 440], ["addresses", 447], ["nine", 457], ["small", 462], ["-", 467], ["interfering", 468], ["RNAs", 480], ["(", 485], ["siRNAs", 486], [")", 492], ["and", 494], ["one", 498], ["unique", 502], ["microRNA", 509], ["(", 518], ["miRNA", 519], [")", 524], ["inhibitor", 526], [",", 535], ["which", 537], ["entered", 543], ["the", 551], ["phase", 555], ["2", 561], ["-", 562], ["3", 563], ["clinical", 565], ["trials", 574], [".", 580], ["The", 582], ["siRNAs", 586], ["in", 593], ["focus", 596], ["are", 602], ["PF-04523655", 606], [",", 617], ["TKM-080301", 619], [",", 629], ["Atu027", 631], [",", 637], ["SYL040012", 639], [",", 648], ["SYL1001", 650], [",", 657], ["siG12D", 659], ["-", 665], ["LODER", 666], ["(", 672], ["phase", 673], ["2", 679], [")", 680], [",", 681], ["QPI-1002", 683], [",", 691], ["QPI-1007", 693], [",", 701], ["and", 703], ["patisiran", 707], ["(", 717], ["phase", 718], ["3", 724], [")", 725], [".", 726], ["Regarding", 728], ["miRNAs", 738], [",", 744], ["their", 746], ["content", 752], ["can", 760], ["be", 764], ["down-", 767], ["or", 773], ["up", 776], ["-", 778], ["regulated", 779], [",", 788], ["by", 790], ["using", 793], ["miRNA", 799], ["inhibitors", 805], ["(", 816], ["AntimiRs", 817], [")", 825], ["or", 827], ["miRNA", 830], ["mimics", 836], [".", 842], ["Miravirsen", 844], ["is", 855], ["an", 858], ["AntimiR-122", 861], ["for", 873], ["hepatitis", 877], ["C", 887], ["virus", 889], ["infection", 895], [".", 904], ["The", 906], ["flexibility", 910], ["of", 922], ["RNAi", 925], ["technology", 930], ["is", 941], ["easily", 944], ["understood", 951], ["taking", 962], ["into", 969], ["account", 974], [":", 981], ["(", 983], ["i", 984], [")", 985], ["the", 987], ["different", 991], ["drug", 1001], ["targets", 1006], ["(", 1014], ["i.e.", 1015], ["p53", 1020], [",", 1023], ["caspase", 1025], ["2", 1033], [",", 1034], ["PKN3", 1036], [",", 1040], ["\u03b22-adrenergic", 1042], ["receptor", 1056], [",", 1064], ["mutated", 1066], ["KRAS", 1074], [",", 1078], ["microRNAs", 1080], [")", 1089], [";", 1090], ["(", 1092], ["ii", 1093], [")", 1095], ["therapeutic", 1097], ["conditions", 1109], [",", 1119], ["including", 1121], ["ophthalmic", 1131], ["diseases", 1142], [",", 1150], ["kidney", 1152], ["injury", 1159], [",", 1165], ["amyloidosis", 1167], [",", 1178], ["pancreatic", 1180], ["cancer", 1191], [",", 1197], ["viral", 1199], ["hepatitis", 1205], [";", 1214], ["and", 1216], ["(", 1220], ["iii", 1221], [")", 1224], ["routes", 1226], ["of", 1233], ["administration", 1236], ["(", 1251], ["ocular", 1252], [",", 1258], ["intravenous", 1260], [",", 1271], ["subcutaneous", 1273], [",", 1285], ["intratumoral", 1287], [")", 1299], [".", 1300], ["Although", 1302], ["some", 1311], ["issues", 1316], ["are", 1323], ["still", 1327], ["matters", 1333], ["of", 1341], ["concern", 1344], ["(", 1352], ["delivery", 1353], [",", 1361], ["toxicity", 1363], [",", 1371], ["cost", 1373], [",", 1377], ["and", 1379], ["biological", 1383], ["barriers", 1394], [")", 1402], [",", 1403], ["RNAi", 1405], ["definitively", 1410], ["opens", 1423], ["a", 1429], ["wide", 1431], ["avenue", 1436], ["for", 1443], ["drug", 1447], ["development", 1452], [".", 1463]]}
{"context": "The Ca2+ overload by Ca2+ influx via Na+/Ca2+ exchanger (NCX) is a critical mechanism in myocardial ischemia/reperfusion injury. We investigated protective effects of a novel selective inhibitor of NCX, SEA0400, on cardiac function and energy metabolism during ischemia and reperfusion. Langendorff-perfused rat hearts were exposed to 35 minutes global ischemia and 40 minutes reperfusion. Using 31P nuclear magnetic resonance spectroscopy, cardiac phosphocreatine (PCr), ATP, and pHi were monitored. SEA0400 did not change the basic cardiac function, but improved the recovery of left ventricular developed pressure (LVDP) after reperfusion (27.6 +/- 4.9 mm Hg in control, 101.2 +/- 19.3 mm Hg in 0.1 microM, and 115.5 +/- 13.3 mm Hg in 1 microM SEA0400, means +/- SE, n = 6, P < 0.05). SEA0400 reduced left ventricular end-diastolic pressure and increased coronary flow after reperfusion. SEA0400 improved the recoveries of cardiac phosphocreatine and ATP after reperfusion, but did not affect pHi. There were significant linear correlations between left ventricular developed pressure and cardiac phosphocreatine (r = 0.79, P < 0.05), and left ventricular developed pressure and ATP (r = 0.80, P < 0.05). However, SEA0400 increased the incidence and duration of reperfusion ventricular arrhythmias. SEA0400 added only after reperfusion also improved both the contractile function and energy metabolism. It is concluded that the selective inhibition of NCX may be effective to preserve high-energy phosphates and to improve cardiac function after reperfusion, but may not be able to prevent fatal arrhythmias.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "e732552a8ada436c980aa2d6f437c42b", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "NCX", "token_spans": [[36, 36], [13, 13], [266, 266]], "char_spans": [[198, 200], [57, 59], [1455, 1457]]}]}], "context_tokens": [["The", 0], ["Ca2", 4], ["+", 7], ["overload", 9], ["by", 18], ["Ca2", 21], ["+", 24], ["influx", 26], ["via", 33], ["Na+/Ca2", 37], ["+", 44], ["exchanger", 46], ["(", 56], ["NCX", 57], [")", 60], ["is", 62], ["a", 65], ["critical", 67], ["mechanism", 76], ["in", 86], ["myocardial", 89], ["ischemia", 100], ["/", 108], ["reperfusion", 109], ["injury", 121], [".", 127], ["We", 129], ["investigated", 132], ["protective", 145], ["effects", 156], ["of", 164], ["a", 167], ["novel", 169], ["selective", 175], ["inhibitor", 185], ["of", 195], ["NCX", 198], [",", 201], ["SEA0400", 203], [",", 210], ["on", 212], ["cardiac", 215], ["function", 223], ["and", 232], ["energy", 236], ["metabolism", 243], ["during", 254], ["ischemia", 261], ["and", 270], ["reperfusion", 274], [".", 285], ["Langendorff", 287], ["-", 298], ["perfused", 299], ["rat", 308], ["hearts", 312], ["were", 319], ["exposed", 324], ["to", 332], ["35", 335], ["minutes", 338], ["global", 346], ["ischemia", 353], ["and", 362], ["40", 366], ["minutes", 369], ["reperfusion", 377], [".", 388], ["Using", 390], ["31P", 396], ["nuclear", 400], ["magnetic", 408], ["resonance", 417], ["spectroscopy", 427], [",", 439], ["cardiac", 441], ["phosphocreatine", 449], ["(", 465], ["PCr", 466], [")", 469], [",", 470], ["ATP", 472], [",", 475], ["and", 477], ["pHi", 481], ["were", 485], ["monitored", 490], [".", 499], ["SEA0400", 501], ["did", 509], ["not", 513], ["change", 517], ["the", 524], ["basic", 528], ["cardiac", 534], ["function", 542], [",", 550], ["but", 552], ["improved", 556], ["the", 565], ["recovery", 569], ["of", 578], ["left", 581], ["ventricular", 586], ["developed", 598], ["pressure", 608], ["(", 617], ["LVDP", 618], [")", 622], ["after", 624], ["reperfusion", 630], ["(", 642], ["27.6", 643], ["+", 648], ["/-", 649], ["4.9", 652], ["mm", 656], ["Hg", 659], ["in", 662], ["control", 665], [",", 672], ["101.2", 674], ["+", 680], ["/-", 681], ["19.3", 684], ["mm", 689], ["Hg", 692], ["in", 695], ["0.1", 698], ["microM", 702], [",", 708], ["and", 710], ["115.5", 714], ["+", 720], ["/-", 721], ["13.3", 724], ["mm", 729], ["Hg", 732], ["in", 735], ["1", 738], ["microM", 740], ["SEA0400", 747], [",", 754], ["means", 756], ["+", 762], ["/-", 763], ["SE", 766], [",", 768], ["n", 770], ["=", 772], ["6", 774], [",", 775], ["P", 777], ["<", 779], ["0.05", 781], [")", 785], [".", 786], ["SEA0400", 788], ["reduced", 796], ["left", 804], ["ventricular", 809], ["end", 821], ["-", 824], ["diastolic", 825], ["pressure", 835], ["and", 844], ["increased", 848], ["coronary", 858], ["flow", 867], ["after", 872], ["reperfusion", 878], [".", 889], ["SEA0400", 891], ["improved", 899], ["the", 908], ["recoveries", 912], ["of", 923], ["cardiac", 926], ["phosphocreatine", 934], ["and", 950], ["ATP", 954], ["after", 958], ["reperfusion", 964], [",", 975], ["but", 977], ["did", 981], ["not", 985], ["affect", 989], ["pHi", 996], [".", 999], ["There", 1001], ["were", 1007], ["significant", 1012], ["linear", 1024], ["correlations", 1031], ["between", 1044], ["left", 1052], ["ventricular", 1057], ["developed", 1069], ["pressure", 1079], ["and", 1088], ["cardiac", 1092], ["phosphocreatine", 1100], ["(", 1116], ["r", 1117], ["=", 1119], ["0.79", 1121], [",", 1125], ["P", 1127], ["<", 1129], ["0.05", 1131], [")", 1135], [",", 1136], ["and", 1138], ["left", 1142], ["ventricular", 1147], ["developed", 1159], ["pressure", 1169], ["and", 1178], ["ATP", 1182], ["(", 1186], ["r", 1187], ["=", 1189], ["0.80", 1191], [",", 1195], ["P", 1197], ["<", 1199], ["0.05", 1201], [")", 1205], [".", 1206], ["However", 1208], [",", 1215], ["SEA0400", 1217], ["increased", 1225], ["the", 1235], ["incidence", 1239], ["and", 1249], ["duration", 1253], ["of", 1262], ["reperfusion", 1265], ["ventricular", 1277], ["arrhythmias", 1289], [".", 1300], ["SEA0400", 1302], ["added", 1310], ["only", 1316], ["after", 1321], ["reperfusion", 1327], ["also", 1339], ["improved", 1344], ["both", 1353], ["the", 1358], ["contractile", 1362], ["function", 1374], ["and", 1383], ["energy", 1387], ["metabolism", 1394], [".", 1404], ["It", 1406], ["is", 1409], ["concluded", 1412], ["that", 1422], ["the", 1427], ["selective", 1431], ["inhibition", 1441], ["of", 1452], ["NCX", 1455], ["may", 1459], ["be", 1463], ["effective", 1466], ["to", 1476], ["preserve", 1479], ["high", 1488], ["-", 1492], ["energy", 1493], ["phosphates", 1500], ["and", 1511], ["to", 1515], ["improve", 1518], ["cardiac", 1526], ["function", 1534], ["after", 1543], ["reperfusion", 1549], [",", 1560], ["but", 1562], ["may", 1566], ["not", 1570], ["be", 1574], ["able", 1577], ["to", 1582], ["prevent", 1585], ["fatal", 1593], ["arrhythmias", 1599], [".", 1610]]}
{"context": "SEA0400 is a selective inhibitor of the Na(+)/Ca(2+) exchanger having equal potencies to suppress both the forward and reverse mode operation of the Na(+)/Ca(2+) exchanger. Present experiments were designed to study the effect of partial blockade of Na(+)/Ca(2+) exchanger on Ca(2+) handling in isolated rat ventricular myocytes. Intracellular Ca(2+) transient and cell shortening were measured in ventricular myocytes loaded with Fura-2-AM fluorescent dye. Partial blockade of Na(+)/Ca(2+) exchanger was induced by superfusion of the cells with SEA0400 at a concentration of 0.3 microM. Amplitude of the intracellular Ca(2+) transient and cell shortening was significantly increased by SEA0400 in both field stimulated and voltage clamped myocytes, without significant elevation of diastolic Ca(2+) level and the decay time constant of the Ca(2+) transient. In patch clamped myocytes the SEA0400 induced increase in the Ca(2+) transient and cell shortening was accompanied by significant reduction of peak L-type Ca(2+) current. These effects can be explained by the autoregulative nature of cardiac Ca(2+) handling, as the reduced Ca(2+) efflux from the cell results in an increased Ca(2+) load to the sarcoplasmic reticulum leading to increased Ca(2+) release, which in turn may decrease the L-type Ca(2+) current by accelaration of Ca(2+) dependent inactivation of L-type Ca(2+) current. Our results suggest that complex changes in the Ca(2+) cycling can occur after selective pharmacological inhibition of the Na(+)/Ca(2+) exchanger.", "qas": [{"question": "The small molecule SEA0400 is an inhibitor of which ion antiporter/exchanger?", "answers": ["Na(+)/Ca(2+) exchanger", "NCX"], "qid": "4fe2e279a8224262a6918b198e8b0ed1", "question_tokens": [["The", 0], ["small", 4], ["molecule", 10], ["SEA0400", 19], ["is", 27], ["an", 30], ["inhibitor", 33], ["of", 43], ["which", 46], ["ion", 52], ["antiporter", 56], ["/", 66], ["exchanger", 67], ["?", 76]], "detected_answers": [{"text": "Na(+)/Ca(2+) exchanger", "token_spans": [[42, 45], [79, 82], [7, 10], [272, 275], [25, 28]], "char_spans": [[250, 271], [478, 499], [40, 61], [1515, 1536], [149, 170]]}]}], "context_tokens": [["SEA0400", 0], ["is", 8], ["a", 11], ["selective", 13], ["inhibitor", 23], ["of", 33], ["the", 36], ["Na(+)/Ca(2", 40], ["+", 50], [")", 51], ["exchanger", 53], ["having", 63], ["equal", 70], ["potencies", 76], ["to", 86], ["suppress", 89], ["both", 98], ["the", 103], ["forward", 107], ["and", 115], ["reverse", 119], ["mode", 127], ["operation", 132], ["of", 142], ["the", 145], ["Na(+)/Ca(2", 149], ["+", 159], [")", 160], ["exchanger", 162], [".", 171], ["Present", 173], ["experiments", 181], ["were", 193], ["designed", 198], ["to", 207], ["study", 210], ["the", 216], ["effect", 220], ["of", 227], ["partial", 230], ["blockade", 238], ["of", 247], ["Na(+)/Ca(2", 250], ["+", 260], [")", 261], ["exchanger", 263], ["on", 273], ["Ca(2", 276], ["+", 280], [")", 281], ["handling", 283], ["in", 292], ["isolated", 295], ["rat", 304], ["ventricular", 308], ["myocytes", 320], [".", 328], ["Intracellular", 330], ["Ca(2", 344], ["+", 348], [")", 349], ["transient", 351], ["and", 361], ["cell", 365], ["shortening", 370], ["were", 381], ["measured", 386], ["in", 395], ["ventricular", 398], ["myocytes", 410], ["loaded", 419], ["with", 426], ["Fura-2-AM", 431], ["fluorescent", 441], ["dye", 453], [".", 456], ["Partial", 458], ["blockade", 466], ["of", 475], ["Na(+)/Ca(2", 478], ["+", 488], [")", 489], ["exchanger", 491], ["was", 501], ["induced", 505], ["by", 513], ["superfusion", 516], ["of", 528], ["the", 531], ["cells", 535], ["with", 541], ["SEA0400", 546], ["at", 554], ["a", 557], ["concentration", 559], ["of", 573], ["0.3", 576], ["microM.", 580], ["Amplitude", 588], ["of", 598], ["the", 601], ["intracellular", 605], ["Ca(2", 619], ["+", 623], [")", 624], ["transient", 626], ["and", 636], ["cell", 640], ["shortening", 645], ["was", 656], ["significantly", 660], ["increased", 674], ["by", 684], ["SEA0400", 687], ["in", 695], ["both", 698], ["field", 703], ["stimulated", 709], ["and", 720], ["voltage", 724], ["clamped", 732], ["myocytes", 740], [",", 748], ["without", 750], ["significant", 758], ["elevation", 770], ["of", 780], ["diastolic", 783], ["Ca(2", 793], ["+", 797], [")", 798], ["level", 800], ["and", 806], ["the", 810], ["decay", 814], ["time", 820], ["constant", 825], ["of", 834], ["the", 837], ["Ca(2", 841], ["+", 845], [")", 846], ["transient", 848], [".", 857], ["In", 859], ["patch", 862], ["clamped", 868], ["myocytes", 876], ["the", 885], ["SEA0400", 889], ["induced", 897], ["increase", 905], ["in", 914], ["the", 917], ["Ca(2", 921], ["+", 925], [")", 926], ["transient", 928], ["and", 938], ["cell", 942], ["shortening", 947], ["was", 958], ["accompanied", 962], ["by", 974], ["significant", 977], ["reduction", 989], ["of", 999], ["peak", 1002], ["L", 1007], ["-", 1008], ["type", 1009], ["Ca(2", 1014], ["+", 1018], [")", 1019], ["current", 1021], [".", 1028], ["These", 1030], ["effects", 1036], ["can", 1044], ["be", 1048], ["explained", 1051], ["by", 1061], ["the", 1064], ["autoregulative", 1068], ["nature", 1083], ["of", 1090], ["cardiac", 1093], ["Ca(2", 1101], ["+", 1105], [")", 1106], ["handling", 1108], [",", 1116], ["as", 1118], ["the", 1121], ["reduced", 1125], ["Ca(2", 1133], ["+", 1137], [")", 1138], ["efflux", 1140], ["from", 1147], ["the", 1152], ["cell", 1156], ["results", 1161], ["in", 1169], ["an", 1172], ["increased", 1175], ["Ca(2", 1185], ["+", 1189], [")", 1190], ["load", 1192], ["to", 1197], ["the", 1200], ["sarcoplasmic", 1204], ["reticulum", 1217], ["leading", 1227], ["to", 1235], ["increased", 1238], ["Ca(2", 1248], ["+", 1252], [")", 1253], ["release", 1255], [",", 1262], ["which", 1264], ["in", 1270], ["turn", 1273], ["may", 1278], ["decrease", 1282], ["the", 1291], ["L", 1295], ["-", 1296], ["type", 1297], ["Ca(2", 1302], ["+", 1306], [")", 1307], ["current", 1309], ["by", 1317], ["accelaration", 1320], ["of", 1333], ["Ca(2", 1336], ["+", 1340], [")", 1341], ["dependent", 1343], ["inactivation", 1353], ["of", 1366], ["L", 1369], ["-", 1370], ["type", 1371], ["Ca(2", 1376], ["+", 1380], [")", 1381], ["current", 1383], [".", 1390], ["Our", 1392], ["results", 1396], ["suggest", 1404], ["that", 1412], ["complex", 1417], ["changes", 1425], ["in", 1433], ["the", 1436], ["Ca(2", 1440], ["+", 1444], [")", 1445], ["cycling", 1447], ["can", 1455], ["occur", 1459], ["after", 1465], ["selective", 1471], ["pharmacological", 1481], ["inhibition", 1497], ["of", 1508], ["the", 1511], ["Na(+)/Ca(2", 1515], ["+", 1525], [")", 1526], ["exchanger", 1528], [".", 1537]]}
{"context": "Centrioles are essential for the formation of cilia and flagella. They also form the core of the centrosome, which organizes microtubule arrays important for cell shape, polarity, motility and division. Here, we have used super-resolution 3D-structured illumination microscopy to analyse the spatial relationship of 18 centriole and pericentriolar matrix (PCM) components of human centrosomes at different cell cycle stages. During mitosis, PCM proteins formed extended networks with interspersed \u03b3-Tubulin. During interphase, most proteins were arranged at specific distances from the walls of centrioles, resulting in ring staining, often with discernible density masses. Through use of site-specific antibodies, we found the C-terminus of Cep152 to be closer to centrioles than the N-terminus, illustrating the power of 3D-SIM to study protein disposition. Appendage proteins showed rings with multiple density masses, and the number of these masses was strongly reduced during mitosis. At the proximal end of centrioles, Sas-6 formed a dot at the site of daughter centriole assembly, consistent with its role in cartwheel formation. Plk4 and STIL co-localized with Sas-6, but Cep135 was associated mostly with mother centrioles. Remarkably, Plk4 formed a dot on the surface of the mother centriole before Sas-6 staining became detectable, indicating that Plk4 constitutes an early marker for the site of nascent centriole formation. Our study provides novel insights into the architecture of human centrosomes and illustrates the power of super-resolution microscopy in revealing the relative localization of centriole and PCM proteins in unprecedented detail.", "qas": [{"question": "Where in the cell do we find the protein Cep135?", "answers": ["centrosome"], "qid": "9ac493dfeaa446d1b53b353bcedbf4eb", "question_tokens": [["Where", 0], ["in", 6], ["the", 9], ["cell", 13], ["do", 18], ["we", 21], ["find", 24], ["the", 29], ["protein", 33], ["Cep135", 41], ["?", 47]], "detected_answers": [{"text": "centrosome", "token_spans": [[18, 18]], "char_spans": [[97, 106]]}]}], "context_tokens": [["Centrioles", 0], ["are", 11], ["essential", 15], ["for", 25], ["the", 29], ["formation", 33], ["of", 43], ["cilia", 46], ["and", 52], ["flagella", 56], [".", 64], ["They", 66], ["also", 71], ["form", 76], ["the", 81], ["core", 85], ["of", 90], ["the", 93], ["centrosome", 97], [",", 107], ["which", 109], ["organizes", 115], ["microtubule", 125], ["arrays", 137], ["important", 144], ["for", 154], ["cell", 158], ["shape", 163], [",", 168], ["polarity", 170], [",", 178], ["motility", 180], ["and", 189], ["division", 193], [".", 201], ["Here", 203], [",", 207], ["we", 209], ["have", 212], ["used", 217], ["super", 222], ["-", 227], ["resolution", 228], ["3D", 239], ["-", 241], ["structured", 242], ["illumination", 253], ["microscopy", 266], ["to", 277], ["analyse", 280], ["the", 288], ["spatial", 292], ["relationship", 300], ["of", 313], ["18", 316], ["centriole", 319], ["and", 329], ["pericentriolar", 333], ["matrix", 348], ["(", 355], ["PCM", 356], [")", 359], ["components", 361], ["of", 372], ["human", 375], ["centrosomes", 381], ["at", 393], ["different", 396], ["cell", 406], ["cycle", 411], ["stages", 417], [".", 423], ["During", 425], ["mitosis", 432], [",", 439], ["PCM", 441], ["proteins", 445], ["formed", 454], ["extended", 461], ["networks", 470], ["with", 479], ["interspersed", 484], ["\u03b3", 497], ["-", 498], ["Tubulin", 499], [".", 506], ["During", 508], ["interphase", 515], [",", 525], ["most", 527], ["proteins", 532], ["were", 541], ["arranged", 546], ["at", 555], ["specific", 558], ["distances", 567], ["from", 577], ["the", 582], ["walls", 586], ["of", 592], ["centrioles", 595], [",", 605], ["resulting", 607], ["in", 617], ["ring", 620], ["staining", 625], [",", 633], ["often", 635], ["with", 641], ["discernible", 646], ["density", 658], ["masses", 666], [".", 672], ["Through", 674], ["use", 682], ["of", 686], ["site", 689], ["-", 693], ["specific", 694], ["antibodies", 703], [",", 713], ["we", 715], ["found", 718], ["the", 724], ["C", 728], ["-", 729], ["terminus", 730], ["of", 739], ["Cep152", 742], ["to", 749], ["be", 752], ["closer", 755], ["to", 762], ["centrioles", 765], ["than", 776], ["the", 781], ["N", 785], ["-", 786], ["terminus", 787], [",", 795], ["illustrating", 797], ["the", 810], ["power", 814], ["of", 820], ["3D", 823], ["-", 825], ["SIM", 826], ["to", 830], ["study", 833], ["protein", 839], ["disposition", 847], [".", 858], ["Appendage", 860], ["proteins", 870], ["showed", 879], ["rings", 886], ["with", 892], ["multiple", 897], ["density", 906], ["masses", 914], [",", 920], ["and", 922], ["the", 926], ["number", 930], ["of", 937], ["these", 940], ["masses", 946], ["was", 953], ["strongly", 957], ["reduced", 966], ["during", 974], ["mitosis", 981], [".", 988], ["At", 990], ["the", 993], ["proximal", 997], ["end", 1006], ["of", 1010], ["centrioles", 1013], [",", 1023], ["Sas-6", 1025], ["formed", 1031], ["a", 1038], ["dot", 1040], ["at", 1044], ["the", 1047], ["site", 1051], ["of", 1056], ["daughter", 1059], ["centriole", 1068], ["assembly", 1078], [",", 1086], ["consistent", 1088], ["with", 1099], ["its", 1104], ["role", 1108], ["in", 1113], ["cartwheel", 1116], ["formation", 1126], [".", 1135], ["Plk4", 1137], ["and", 1142], ["STIL", 1146], ["co", 1151], ["-", 1153], ["localized", 1154], ["with", 1164], ["Sas-6", 1169], [",", 1174], ["but", 1176], ["Cep135", 1180], ["was", 1187], ["associated", 1191], ["mostly", 1202], ["with", 1209], ["mother", 1214], ["centrioles", 1221], [".", 1231], ["Remarkably", 1233], [",", 1243], ["Plk4", 1245], ["formed", 1250], ["a", 1257], ["dot", 1259], ["on", 1263], ["the", 1266], ["surface", 1270], ["of", 1278], ["the", 1281], ["mother", 1285], ["centriole", 1292], ["before", 1302], ["Sas-6", 1309], ["staining", 1315], ["became", 1324], ["detectable", 1331], [",", 1341], ["indicating", 1343], ["that", 1354], ["Plk4", 1359], ["constitutes", 1364], ["an", 1376], ["early", 1379], ["marker", 1385], ["for", 1392], ["the", 1396], ["site", 1400], ["of", 1405], ["nascent", 1408], ["centriole", 1416], ["formation", 1426], [".", 1435], ["Our", 1437], ["study", 1441], ["provides", 1447], ["novel", 1456], ["insights", 1462], ["into", 1471], ["the", 1476], ["architecture", 1480], ["of", 1493], ["human", 1496], ["centrosomes", 1502], ["and", 1514], ["illustrates", 1518], ["the", 1530], ["power", 1534], ["of", 1540], ["super", 1543], ["-", 1548], ["resolution", 1549], ["microscopy", 1560], ["in", 1571], ["revealing", 1574], ["the", 1584], ["relative", 1588], ["localization", 1597], ["of", 1610], ["centriole", 1613], ["and", 1623], ["PCM", 1627], ["proteins", 1631], ["in", 1640], ["unprecedented", 1643], ["detail", 1657], [".", 1663]]}
{"context": "U.K ambulance services assess patients with suspected stroke using the Face Arm Speech Test (FAST). The Recognition Of Stroke In the Emergency Room (ROSIER) tool has been shown superior to the FAST in identifying strokes in emergency departments but has not previously been tested in the ambulance setting. We investigated whether ROSIER use by ambulance clinicians can improve stroke recognition. Ambulance clinicians used the ROSIER in place of the FAST to assess patients with suspected stroke. As the ROSIER includes all FAST elements, we calculated a FAST score from the ROSIER to enable comparisons between the two tools. Ambulance clinicians' provisional stroke diagnoses using the ROSIER and calculated FAST were compared with stroke consultants' diagnosis. We used stepwise logistic regression to compare the contribution of individual ROSIER and FAST items and patient demographics to the prediction of consultants' diagnoses. Sixty-four percent of strokes and 78% of nonstrokes identified by ambulance clinicians using the ROSIER were subsequently confirmed by a stroke consultant. There was no difference in the proportion of strokes correctly detected by the ROSIER or FAST with both displaying excellent levels of sensitivity. The ROSIER detected marginally more nonstroke cases than the FAST, but both demonstrated poor specificity. Facial weakness, arm weakness, seizure activity, age, and sex predicted consultants' diagnosis of stroke. The ROSIER was not better than the FAST for prehospital recognition of stroke. A revised version of the FAST incorporating assessment of seizure activity may improve stroke identification and decision making by ambulance clinicians.", "qas": [{"question": "ROSIER scale is used for which disorder?", "answers": ["stroke"], "qid": "14137672ed6a4876bd365f25ca43ab63", "question_tokens": [["ROSIER", 0], ["scale", 7], ["is", 13], ["used", 16], ["for", 21], ["which", 25], ["disorder", 31], ["?", 39]], "detected_answers": [{"text": "stroke", "token_spans": [[112, 112], [64, 64], [21, 21], [123, 123], [253, 253], [268, 268], [7, 7], [82, 82], [239, 239], [177, 177]], "char_spans": [[662, 667], [378, 383], [119, 124], [735, 740], [1525, 1530], [1620, 1625], [54, 59], [490, 495], [1446, 1451], [1074, 1079]]}]}], "context_tokens": [["U.K", 0], ["ambulance", 4], ["services", 14], ["assess", 23], ["patients", 30], ["with", 39], ["suspected", 44], ["stroke", 54], ["using", 61], ["the", 67], ["Face", 71], ["Arm", 76], ["Speech", 80], ["Test", 87], ["(", 92], ["FAST", 93], [")", 97], [".", 98], ["The", 100], ["Recognition", 104], ["Of", 116], ["Stroke", 119], ["In", 126], ["the", 129], ["Emergency", 133], ["Room", 143], ["(", 148], ["ROSIER", 149], [")", 155], ["tool", 157], ["has", 162], ["been", 166], ["shown", 171], ["superior", 177], ["to", 186], ["the", 189], ["FAST", 193], ["in", 198], ["identifying", 201], ["strokes", 213], ["in", 221], ["emergency", 224], ["departments", 234], ["but", 246], ["has", 250], ["not", 254], ["previously", 258], ["been", 269], ["tested", 274], ["in", 281], ["the", 284], ["ambulance", 288], ["setting", 298], [".", 305], ["We", 307], ["investigated", 310], ["whether", 323], ["ROSIER", 331], ["use", 338], ["by", 342], ["ambulance", 345], ["clinicians", 355], ["can", 366], ["improve", 370], ["stroke", 378], ["recognition", 385], [".", 396], ["Ambulance", 398], ["clinicians", 408], ["used", 419], ["the", 424], ["ROSIER", 428], ["in", 435], ["place", 438], ["of", 444], ["the", 447], ["FAST", 451], ["to", 456], ["assess", 459], ["patients", 466], ["with", 475], ["suspected", 480], ["stroke", 490], [".", 496], ["As", 498], ["the", 501], ["ROSIER", 505], ["includes", 512], ["all", 521], ["FAST", 525], ["elements", 530], [",", 538], ["we", 540], ["calculated", 543], ["a", 554], ["FAST", 556], ["score", 561], ["from", 567], ["the", 572], ["ROSIER", 576], ["to", 583], ["enable", 586], ["comparisons", 593], ["between", 605], ["the", 613], ["two", 617], ["tools", 621], [".", 626], ["Ambulance", 628], ["clinicians", 638], ["'", 648], ["provisional", 650], ["stroke", 662], ["diagnoses", 669], ["using", 679], ["the", 685], ["ROSIER", 689], ["and", 696], ["calculated", 700], ["FAST", 711], ["were", 716], ["compared", 721], ["with", 730], ["stroke", 735], ["consultants", 742], ["'", 753], ["diagnosis", 755], [".", 764], ["We", 766], ["used", 769], ["stepwise", 774], ["logistic", 783], ["regression", 792], ["to", 803], ["compare", 806], ["the", 814], ["contribution", 818], ["of", 831], ["individual", 834], ["ROSIER", 845], ["and", 852], ["FAST", 856], ["items", 861], ["and", 867], ["patient", 871], ["demographics", 879], ["to", 892], ["the", 895], ["prediction", 899], ["of", 910], ["consultants", 913], ["'", 924], ["diagnoses", 926], [".", 935], ["Sixty", 937], ["-", 942], ["four", 943], ["percent", 948], ["of", 956], ["strokes", 959], ["and", 967], ["78", 971], ["%", 973], ["of", 975], ["nonstrokes", 978], ["identified", 989], ["by", 1000], ["ambulance", 1003], ["clinicians", 1013], ["using", 1024], ["the", 1030], ["ROSIER", 1034], ["were", 1041], ["subsequently", 1046], ["confirmed", 1059], ["by", 1069], ["a", 1072], ["stroke", 1074], ["consultant", 1081], [".", 1091], ["There", 1093], ["was", 1099], ["no", 1103], ["difference", 1106], ["in", 1117], ["the", 1120], ["proportion", 1124], ["of", 1135], ["strokes", 1138], ["correctly", 1146], ["detected", 1156], ["by", 1165], ["the", 1168], ["ROSIER", 1172], ["or", 1179], ["FAST", 1182], ["with", 1187], ["both", 1192], ["displaying", 1197], ["excellent", 1208], ["levels", 1218], ["of", 1225], ["sensitivity", 1228], [".", 1239], ["The", 1241], ["ROSIER", 1245], ["detected", 1252], ["marginally", 1261], ["more", 1272], ["nonstroke", 1277], ["cases", 1287], ["than", 1293], ["the", 1298], ["FAST", 1302], [",", 1306], ["but", 1308], ["both", 1312], ["demonstrated", 1317], ["poor", 1330], ["specificity", 1335], [".", 1346], ["Facial", 1348], ["weakness", 1355], [",", 1363], ["arm", 1365], ["weakness", 1369], [",", 1377], ["seizure", 1379], ["activity", 1387], [",", 1395], ["age", 1397], [",", 1400], ["and", 1402], ["sex", 1406], ["predicted", 1410], ["consultants", 1420], ["'", 1431], ["diagnosis", 1433], ["of", 1443], ["stroke", 1446], [".", 1452], ["The", 1454], ["ROSIER", 1458], ["was", 1465], ["not", 1469], ["better", 1473], ["than", 1480], ["the", 1485], ["FAST", 1489], ["for", 1494], ["prehospital", 1498], ["recognition", 1510], ["of", 1522], ["stroke", 1525], [".", 1531], ["A", 1533], ["revised", 1535], ["version", 1543], ["of", 1551], ["the", 1554], ["FAST", 1558], ["incorporating", 1563], ["assessment", 1577], ["of", 1588], ["seizure", 1591], ["activity", 1599], ["may", 1608], ["improve", 1612], ["stroke", 1620], ["identification", 1627], ["and", 1642], ["decision", 1646], ["making", 1655], ["by", 1662], ["ambulance", 1665], ["clinicians", 1675], [".", 1685]]}
{"context": "Somatic mutations in exons encoding the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are found in human lung adenocarcinomas and are associated with sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib. Nearly 90% of the EGFR mutations are either short, in-frame deletions in exon 19 or point mutations that result in substitution of arginine for leucine at amino acid 858 (L858R). To study further the role of these mutations in the initiation and maintenance of lung cancer, we have developed transgenic mice that express an exon 19 deletion mutant (EGFR(DeltaL747-S752)) or the L858R mutant (EGFR(L858R)) in type II pneumocytes under the control of doxycycline. Expression of either EGFR mutant leads to the development of lung adenocarcinomas. Two weeks after induction with doxycycline, mice that express the EGFR(L858R) allele show diffuse lung cancer highly reminiscent of human bronchioloalveolar carcinoma and later develop interspersed multifocal adenocarcinomas. In contrast, mice expressing EGFR(DeltaL747-S752) develop multifocal tumors embedded in normal lung parenchyma with a longer latency. With mice carrying either EGFR allele, withdrawal of doxycycline (to reduce expression of the transgene) or treatment with erlotinib (to inhibit kinase activity) causes rapid tumor regression, as assessed by magnetic resonance imaging and histopathology, demonstrating that mutant EGFR is required for tumor maintenance. These models may be useful for developing improved therapies for patients with lung cancers bearing EGFR mutations.", "qas": [{"question": "Mutations in which gene determine response to both erlotinib and gefitinib?", "answers": ["epidermal growth factor receptor (EGFR) gene"], "qid": "c1fed25571dd435caf919c7770d931d8", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["determine", 24], ["response", 34], ["to", 43], ["both", 46], ["erlotinib", 51], ["and", 61], ["gefitinib", 65], ["?", 74]], "detected_answers": [{"text": "epidermal growth factor receptor (EGFR) gene", "token_spans": [[11, 18]], "char_spans": [[70, 113]]}]}], "context_tokens": [["Somatic", 0], ["mutations", 8], ["in", 18], ["exons", 21], ["encoding", 27], ["the", 36], ["tyrosine", 40], ["kinase", 49], ["domain", 56], ["of", 63], ["the", 66], ["epidermal", 70], ["growth", 80], ["factor", 87], ["receptor", 94], ["(", 103], ["EGFR", 104], [")", 108], ["gene", 110], ["are", 115], ["found", 119], ["in", 125], ["human", 128], ["lung", 134], ["adenocarcinomas", 139], ["and", 155], ["are", 159], ["associated", 163], ["with", 174], ["sensitivity", 179], ["to", 191], ["the", 194], ["tyrosine", 198], ["kinase", 207], ["inhibitors", 214], ["gefitinib", 225], ["and", 235], ["erlotinib", 239], [".", 248], ["Nearly", 250], ["90", 257], ["%", 259], ["of", 261], ["the", 264], ["EGFR", 268], ["mutations", 273], ["are", 283], ["either", 287], ["short", 294], [",", 299], ["in", 301], ["-", 303], ["frame", 304], ["deletions", 310], ["in", 320], ["exon", 323], ["19", 328], ["or", 331], ["point", 334], ["mutations", 340], ["that", 350], ["result", 355], ["in", 362], ["substitution", 365], ["of", 378], ["arginine", 381], ["for", 390], ["leucine", 394], ["at", 402], ["amino", 405], ["acid", 411], ["858", 416], ["(", 420], ["L858R", 421], [")", 426], [".", 427], ["To", 429], ["study", 432], ["further", 438], ["the", 446], ["role", 450], ["of", 455], ["these", 458], ["mutations", 464], ["in", 474], ["the", 477], ["initiation", 481], ["and", 492], ["maintenance", 496], ["of", 508], ["lung", 511], ["cancer", 516], [",", 522], ["we", 524], ["have", 527], ["developed", 532], ["transgenic", 542], ["mice", 553], ["that", 558], ["express", 563], ["an", 571], ["exon", 574], ["19", 579], ["deletion", 582], ["mutant", 591], ["(", 598], ["EGFR(DeltaL747-S752", 599], [")", 618], [")", 619], ["or", 621], ["the", 624], ["L858R", 628], ["mutant", 634], ["(", 641], ["EGFR(L858R", 642], [")", 652], [")", 653], ["in", 655], ["type", 658], ["II", 663], ["pneumocytes", 666], ["under", 678], ["the", 684], ["control", 688], ["of", 696], ["doxycycline", 699], [".", 710], ["Expression", 712], ["of", 723], ["either", 726], ["EGFR", 733], ["mutant", 738], ["leads", 745], ["to", 751], ["the", 754], ["development", 758], ["of", 770], ["lung", 773], ["adenocarcinomas", 778], [".", 793], ["Two", 795], ["weeks", 799], ["after", 805], ["induction", 811], ["with", 821], ["doxycycline", 826], [",", 837], ["mice", 839], ["that", 844], ["express", 849], ["the", 857], ["EGFR(L858R", 861], [")", 871], ["allele", 873], ["show", 880], ["diffuse", 885], ["lung", 893], ["cancer", 898], ["highly", 905], ["reminiscent", 912], ["of", 924], ["human", 927], ["bronchioloalveolar", 933], ["carcinoma", 952], ["and", 962], ["later", 966], ["develop", 972], ["interspersed", 980], ["multifocal", 993], ["adenocarcinomas", 1004], [".", 1019], ["In", 1021], ["contrast", 1024], [",", 1032], ["mice", 1034], ["expressing", 1039], ["EGFR(DeltaL747-S752", 1050], [")", 1069], ["develop", 1071], ["multifocal", 1079], ["tumors", 1090], ["embedded", 1097], ["in", 1106], ["normal", 1109], ["lung", 1116], ["parenchyma", 1121], ["with", 1132], ["a", 1137], ["longer", 1139], ["latency", 1146], [".", 1153], ["With", 1155], ["mice", 1160], ["carrying", 1165], ["either", 1174], ["EGFR", 1181], ["allele", 1186], [",", 1192], ["withdrawal", 1194], ["of", 1205], ["doxycycline", 1208], ["(", 1220], ["to", 1221], ["reduce", 1224], ["expression", 1231], ["of", 1242], ["the", 1245], ["transgene", 1249], [")", 1258], ["or", 1260], ["treatment", 1263], ["with", 1273], ["erlotinib", 1278], ["(", 1288], ["to", 1289], ["inhibit", 1292], ["kinase", 1300], ["activity", 1307], [")", 1315], ["causes", 1317], ["rapid", 1324], ["tumor", 1330], ["regression", 1336], [",", 1346], ["as", 1348], ["assessed", 1351], ["by", 1360], ["magnetic", 1363], ["resonance", 1372], ["imaging", 1382], ["and", 1390], ["histopathology", 1394], [",", 1408], ["demonstrating", 1410], ["that", 1424], ["mutant", 1429], ["EGFR", 1436], ["is", 1441], ["required", 1444], ["for", 1453], ["tumor", 1457], ["maintenance", 1463], [".", 1474], ["These", 1476], ["models", 1482], ["may", 1489], ["be", 1493], ["useful", 1496], ["for", 1503], ["developing", 1507], ["improved", 1518], ["therapies", 1527], ["for", 1537], ["patients", 1541], ["with", 1550], ["lung", 1555], ["cancers", 1560], ["bearing", 1568], ["EGFR", 1576], ["mutations", 1581], [".", 1590]]}
{"context": "Rigel Pharmaceuticals Inc is developing fostamatinib, a prodrug of the spleen tyrosine kinase (Syk) inhibitor R-406, for the potential treatment of autoimmune diseases such as rheumatoid arthritis (RA), idiopathic thrombocytopenic purpura (ITP) and B-cell lymphomas. Syk is a key mediator of Fc and B-cell receptor signaling in inflammatory cells, such as B-cells, mast cells, macrophages and neutrophils. Preclinical studies of R-406 or fostamatinib demonstrated a significant reduction in major inflammatory mediators such as TNFalpha, IL-1, IL-6 and IL-18, leading to reduced inflammation and bone degradation in models of RA. In a phase II clinical trial, fostamatinib treatment effectively improved American College of Rheumatology response rates in patients with RA. Preclinical studies and phase II trials also suggested the potential of using fostamatinib for the treatment of ITP and B-cell lymphomas, by increasing platelet counts and inducing response rates, respectively. Fostamatinib is orally bioavailable and was well tolerated in phase I and II trials, with the most common side effect being gastrointestinal symptoms. At the time of publication, phase II trials for fostamatinib were ongoing in patients with RA, ITP and B-cell lymphomas. The Syk inhibitor appears to be a promising therapeutic for immunological diseases, but further data are required to establish the efficacy and long-term safety of the drug in humans.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "7a4fa67d3e7042d388d3a34034a61556", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[11, 13]], "char_spans": [[71, 92]]}]}], "context_tokens": [["Rigel", 0], ["Pharmaceuticals", 6], ["Inc", 22], ["is", 26], ["developing", 29], ["fostamatinib", 40], [",", 52], ["a", 54], ["prodrug", 56], ["of", 64], ["the", 67], ["spleen", 71], ["tyrosine", 78], ["kinase", 87], ["(", 94], ["Syk", 95], [")", 98], ["inhibitor", 100], ["R-406", 110], [",", 115], ["for", 117], ["the", 121], ["potential", 125], ["treatment", 135], ["of", 145], ["autoimmune", 148], ["diseases", 159], ["such", 168], ["as", 173], ["rheumatoid", 176], ["arthritis", 187], ["(", 197], ["RA", 198], [")", 200], [",", 201], ["idiopathic", 203], ["thrombocytopenic", 214], ["purpura", 231], ["(", 239], ["ITP", 240], [")", 243], ["and", 245], ["B", 249], ["-", 250], ["cell", 251], ["lymphomas", 256], [".", 265], ["Syk", 267], ["is", 271], ["a", 274], ["key", 276], ["mediator", 280], ["of", 289], ["Fc", 292], ["and", 295], ["B", 299], ["-", 300], ["cell", 301], ["receptor", 306], ["signaling", 315], ["in", 325], ["inflammatory", 328], ["cells", 341], [",", 346], ["such", 348], ["as", 353], ["B", 356], ["-", 357], ["cells", 358], [",", 363], ["mast", 365], ["cells", 370], [",", 375], ["macrophages", 377], ["and", 389], ["neutrophils", 393], [".", 404], ["Preclinical", 406], ["studies", 418], ["of", 426], ["R-406", 429], ["or", 435], ["fostamatinib", 438], ["demonstrated", 451], ["a", 464], ["significant", 466], ["reduction", 478], ["in", 488], ["major", 491], ["inflammatory", 497], ["mediators", 510], ["such", 520], ["as", 525], ["TNFalpha", 528], [",", 536], ["IL-1", 538], [",", 542], ["IL-6", 544], ["and", 549], ["IL-18", 553], [",", 558], ["leading", 560], ["to", 568], ["reduced", 571], ["inflammation", 579], ["and", 592], ["bone", 596], ["degradation", 601], ["in", 613], ["models", 616], ["of", 623], ["RA", 626], [".", 628], ["In", 630], ["a", 633], ["phase", 635], ["II", 641], ["clinical", 644], ["trial", 653], [",", 658], ["fostamatinib", 660], ["treatment", 673], ["effectively", 683], ["improved", 695], ["American", 704], ["College", 713], ["of", 721], ["Rheumatology", 724], ["response", 737], ["rates", 746], ["in", 752], ["patients", 755], ["with", 764], ["RA", 769], [".", 771], ["Preclinical", 773], ["studies", 785], ["and", 793], ["phase", 797], ["II", 803], ["trials", 806], ["also", 813], ["suggested", 818], ["the", 828], ["potential", 832], ["of", 842], ["using", 845], ["fostamatinib", 851], ["for", 864], ["the", 868], ["treatment", 872], ["of", 882], ["ITP", 885], ["and", 889], ["B", 893], ["-", 894], ["cell", 895], ["lymphomas", 900], [",", 909], ["by", 911], ["increasing", 914], ["platelet", 925], ["counts", 934], ["and", 941], ["inducing", 945], ["response", 954], ["rates", 963], [",", 968], ["respectively", 970], [".", 982], ["Fostamatinib", 984], ["is", 997], ["orally", 1000], ["bioavailable", 1007], ["and", 1020], ["was", 1024], ["well", 1028], ["tolerated", 1033], ["in", 1043], ["phase", 1046], ["I", 1052], ["and", 1054], ["II", 1058], ["trials", 1061], [",", 1067], ["with", 1069], ["the", 1074], ["most", 1078], ["common", 1083], ["side", 1090], ["effect", 1095], ["being", 1102], ["gastrointestinal", 1108], ["symptoms", 1125], [".", 1133], ["At", 1135], ["the", 1138], ["time", 1142], ["of", 1147], ["publication", 1150], [",", 1161], ["phase", 1163], ["II", 1169], ["trials", 1172], ["for", 1179], ["fostamatinib", 1183], ["were", 1196], ["ongoing", 1201], ["in", 1209], ["patients", 1212], ["with", 1221], ["RA", 1226], [",", 1228], ["ITP", 1230], ["and", 1234], ["B", 1238], ["-", 1239], ["cell", 1240], ["lymphomas", 1245], [".", 1254], ["The", 1256], ["Syk", 1260], ["inhibitor", 1264], ["appears", 1274], ["to", 1282], ["be", 1285], ["a", 1288], ["promising", 1290], ["therapeutic", 1300], ["for", 1312], ["immunological", 1316], ["diseases", 1330], [",", 1338], ["but", 1340], ["further", 1344], ["data", 1352], ["are", 1357], ["required", 1361], ["to", 1370], ["establish", 1373], ["the", 1383], ["efficacy", 1387], ["and", 1396], ["long", 1400], ["-", 1404], ["term", 1405], ["safety", 1410], ["of", 1417], ["the", 1420], ["drug", 1424], ["in", 1429], ["humans", 1432], [".", 1438]]}
{"context": "The spectrin heterodimer is formed by the antiparallel lateral association of an alpha and a beta subunit, each of which comprises largely a series of homologous triple-helical motifs. Initiation of dimer assembly involves strong binding between complementary motifs near the actin-binding end of the dimer. In this study, the mechanism of lateral spectrin association at this dimer nucleation site was investigated using the analytical ultracentrifuge to analyze heterodimers formed from recombinant peptides containing two or four homologous motifs from each subunit (alpha20-21/beta1-2; alpha18-21/beta1-4). Both the two-motif and four-motif dimer associations were weakened substantially with increasing salt concentration, indicating that electrostatic interactions are important for the dimer initiation process. Modeling of the electrostatic potential on the surface of the alpha20 and beta2 motifs showed that the side of the motifs comprising the A and B helices is the most favorable for association, with an area of positive electrostatic potential on the AB face of the beta2 motif opposite negative potential on the AB face of the alpha20 motif and vise versa. Protease protection analysis of the alpha20-21/beta1-2 dimer showed that multiple trypsin and proteinase K sites in the A helices of the beta2 and alpha21 motifs become buried upon dimer formation. Together, these data support a model where complementary long range electrostatic interactions on the AB faces of the triple-helical motifs in the dimer nucleation site initiate the correct pairing of motifs, i.e. alpha21-beta1 and alpha20-beta2. After initial docking of these complementary triple-helical motifs, this association is probably stabilized by subsequent formation of stronger hydrophobic interactions in a complex involving the A helices of both subunits and possibly most of the AB faces. The beta subunit A helix in particular appears to be buried in the dimer interface.", "qas": [{"question": "Alpha-spectrin and beta-spectrin subunits form parallel or antiparallel heterodimers?", "answers": ["antiparallel"], "qid": "341b721c73f64225b0bb8a8e9b4fdbef", "question_tokens": [["Alpha", 0], ["-", 5], ["spectrin", 6], ["and", 15], ["beta", 19], ["-", 23], ["spectrin", 24], ["subunits", 33], ["form", 42], ["parallel", 47], ["or", 56], ["antiparallel", 59], ["heterodimers", 72], ["?", 84]], "detected_answers": [{"text": "antiparallel", "token_spans": [[7, 7]], "char_spans": [[42, 53]]}]}], "context_tokens": [["The", 0], ["spectrin", 4], ["heterodimer", 13], ["is", 25], ["formed", 28], ["by", 35], ["the", 38], ["antiparallel", 42], ["lateral", 55], ["association", 63], ["of", 75], ["an", 78], ["alpha", 81], ["and", 87], ["a", 91], ["beta", 93], ["subunit", 98], [",", 105], ["each", 107], ["of", 112], ["which", 115], ["comprises", 121], ["largely", 131], ["a", 139], ["series", 141], ["of", 148], ["homologous", 151], ["triple", 162], ["-", 168], ["helical", 169], ["motifs", 177], [".", 183], ["Initiation", 185], ["of", 196], ["dimer", 199], ["assembly", 205], ["involves", 214], ["strong", 223], ["binding", 230], ["between", 238], ["complementary", 246], ["motifs", 260], ["near", 267], ["the", 272], ["actin", 276], ["-", 281], ["binding", 282], ["end", 290], ["of", 294], ["the", 297], ["dimer", 301], [".", 306], ["In", 308], ["this", 311], ["study", 316], [",", 321], ["the", 323], ["mechanism", 327], ["of", 337], ["lateral", 340], ["spectrin", 348], ["association", 357], ["at", 369], ["this", 372], ["dimer", 377], ["nucleation", 383], ["site", 394], ["was", 399], ["investigated", 403], ["using", 416], ["the", 422], ["analytical", 426], ["ultracentrifuge", 437], ["to", 453], ["analyze", 456], ["heterodimers", 464], ["formed", 477], ["from", 484], ["recombinant", 489], ["peptides", 501], ["containing", 510], ["two", 521], ["or", 525], ["four", 528], ["homologous", 533], ["motifs", 544], ["from", 551], ["each", 556], ["subunit", 561], ["(", 569], ["alpha20", 570], ["-", 577], ["21/beta1", 578], ["-", 586], ["2", 587], [";", 588], ["alpha18", 590], ["-", 597], ["21/beta1", 598], ["-", 606], ["4", 607], [")", 608], [".", 609], ["Both", 611], ["the", 616], ["two", 620], ["-", 623], ["motif", 624], ["and", 630], ["four", 634], ["-", 638], ["motif", 639], ["dimer", 645], ["associations", 651], ["were", 664], ["weakened", 669], ["substantially", 678], ["with", 692], ["increasing", 697], ["salt", 708], ["concentration", 713], [",", 726], ["indicating", 728], ["that", 739], ["electrostatic", 744], ["interactions", 758], ["are", 771], ["important", 775], ["for", 785], ["the", 789], ["dimer", 793], ["initiation", 799], ["process", 810], [".", 817], ["Modeling", 819], ["of", 828], ["the", 831], ["electrostatic", 835], ["potential", 849], ["on", 859], ["the", 862], ["surface", 866], ["of", 874], ["the", 877], ["alpha20", 881], ["and", 889], ["beta2", 893], ["motifs", 899], ["showed", 906], ["that", 913], ["the", 918], ["side", 922], ["of", 927], ["the", 930], ["motifs", 934], ["comprising", 941], ["the", 952], ["A", 956], ["and", 958], ["B", 962], ["helices", 964], ["is", 972], ["the", 975], ["most", 979], ["favorable", 984], ["for", 994], ["association", 998], [",", 1009], ["with", 1011], ["an", 1016], ["area", 1019], ["of", 1024], ["positive", 1027], ["electrostatic", 1036], ["potential", 1050], ["on", 1060], ["the", 1063], ["AB", 1067], ["face", 1070], ["of", 1075], ["the", 1078], ["beta2", 1082], ["motif", 1088], ["opposite", 1094], ["negative", 1103], ["potential", 1112], ["on", 1122], ["the", 1125], ["AB", 1129], ["face", 1132], ["of", 1137], ["the", 1140], ["alpha20", 1144], ["motif", 1152], ["and", 1158], ["vise", 1162], ["versa", 1167], [".", 1172], ["Protease", 1174], ["protection", 1183], ["analysis", 1194], ["of", 1203], ["the", 1206], ["alpha20", 1210], ["-", 1217], ["21/beta1", 1218], ["-", 1226], ["2", 1227], ["dimer", 1229], ["showed", 1235], ["that", 1242], ["multiple", 1247], ["trypsin", 1256], ["and", 1264], ["proteinase", 1268], ["K", 1279], ["sites", 1281], ["in", 1287], ["the", 1290], ["A", 1294], ["helices", 1296], ["of", 1304], ["the", 1307], ["beta2", 1311], ["and", 1317], ["alpha21", 1321], ["motifs", 1329], ["become", 1336], ["buried", 1343], ["upon", 1350], ["dimer", 1355], ["formation", 1361], [".", 1370], ["Together", 1372], [",", 1380], ["these", 1382], ["data", 1388], ["support", 1393], ["a", 1401], ["model", 1403], ["where", 1409], ["complementary", 1415], ["long", 1429], ["range", 1434], ["electrostatic", 1440], ["interactions", 1454], ["on", 1467], ["the", 1470], ["AB", 1474], ["faces", 1477], ["of", 1483], ["the", 1486], ["triple", 1490], ["-", 1496], ["helical", 1497], ["motifs", 1505], ["in", 1512], ["the", 1515], ["dimer", 1519], ["nucleation", 1525], ["site", 1536], ["initiate", 1541], ["the", 1550], ["correct", 1554], ["pairing", 1562], ["of", 1570], ["motifs", 1573], [",", 1579], ["i.e.", 1581], ["alpha21-beta1", 1586], ["and", 1600], ["alpha20-beta2", 1604], [".", 1617], ["After", 1619], ["initial", 1625], ["docking", 1633], ["of", 1641], ["these", 1644], ["complementary", 1650], ["triple", 1664], ["-", 1670], ["helical", 1671], ["motifs", 1679], [",", 1685], ["this", 1687], ["association", 1692], ["is", 1704], ["probably", 1707], ["stabilized", 1716], ["by", 1727], ["subsequent", 1730], ["formation", 1741], ["of", 1751], ["stronger", 1754], ["hydrophobic", 1763], ["interactions", 1775], ["in", 1788], ["a", 1791], ["complex", 1793], ["involving", 1801], ["the", 1811], ["A", 1815], ["helices", 1817], ["of", 1825], ["both", 1828], ["subunits", 1833], ["and", 1842], ["possibly", 1846], ["most", 1855], ["of", 1860], ["the", 1863], ["AB", 1867], ["faces", 1870], [".", 1875], ["The", 1877], ["beta", 1881], ["subunit", 1886], ["A", 1894], ["helix", 1896], ["in", 1902], ["particular", 1905], ["appears", 1916], ["to", 1924], ["be", 1927], ["buried", 1930], ["in", 1937], ["the", 1940], ["dimer", 1944], ["interface", 1950], [".", 1959]]}
{"context": "Neurofibromatosis type 1 (NF1) gene is a tumor suppressor gene, and the NF1 gene product, neurofibromin, can downregulate the N-ras gene. Because the N-ras gene is often mutated in acute myelogenous leukemia (AML), we wondered if the NF1 gene might be mutated in those AML samples not having N-ras mutations. We investigated the mutational status of the N-ras gene and the FLR exon of codons 1371-1423 of the open reading frame of the full-length NF1 cDNA, which has a strong homology with the mammalian ras GTPase-activating protein (GAP), especially for a stretch of three consecutive amino acids (F, L, R), by single-strand conformation polymorphism analysis and direct sequencing in samples from patients with AML. Of 48 AML patients, 10 (21%) had point (missense) mutations of the N-ras gene involving codons 12, 13 and 61. However, mutations in the FLR exon of the NF1 gene were not detected in any of the AML samples. We also examined the difference of clinical response to induction therapy between AML patients with and without N-ras mutation. A significantly lower rate of complete remission was noted in individuals with N-ras gene mutations. These results suggest that mutation of the NF1 gene, at least in the FLR exon, is very rare in AML and the NF1 gene probably is not a functional complement of the N-ras gene mutation. The presence of N-ras gene mutation may be associated with a lower clinical response to antileukemic therapy.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "fb9d60b81eed4b7e93174fdf341800eb", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[96, 96], [189, 189], [4, 4], [265, 265], [248, 248], [50, 50], [15, 15]], "char_spans": [[447, 449], [871, 873], [26, 28], [1261, 1263], [1197, 1199], [234, 236], [72, 74]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["gene", 31], ["is", 36], ["a", 39], ["tumor", 41], ["suppressor", 47], ["gene", 58], [",", 62], ["and", 64], ["the", 68], ["NF1", 72], ["gene", 76], ["product", 81], [",", 88], ["neurofibromin", 90], [",", 103], ["can", 105], ["downregulate", 109], ["the", 122], ["N", 126], ["-", 127], ["ras", 128], ["gene", 132], [".", 136], ["Because", 138], ["the", 146], ["N", 150], ["-", 151], ["ras", 152], ["gene", 156], ["is", 161], ["often", 164], ["mutated", 170], ["in", 178], ["acute", 181], ["myelogenous", 187], ["leukemia", 199], ["(", 208], ["AML", 209], [")", 212], [",", 213], ["we", 215], ["wondered", 218], ["if", 227], ["the", 230], ["NF1", 234], ["gene", 238], ["might", 243], ["be", 249], ["mutated", 252], ["in", 260], ["those", 263], ["AML", 269], ["samples", 273], ["not", 281], ["having", 285], ["N", 292], ["-", 293], ["ras", 294], ["mutations", 298], [".", 307], ["We", 309], ["investigated", 312], ["the", 325], ["mutational", 329], ["status", 340], ["of", 347], ["the", 350], ["N", 354], ["-", 355], ["ras", 356], ["gene", 360], ["and", 365], ["the", 369], ["FLR", 373], ["exon", 377], ["of", 382], ["codons", 385], ["1371", 392], ["-", 396], ["1423", 397], ["of", 402], ["the", 405], ["open", 409], ["reading", 414], ["frame", 422], ["of", 428], ["the", 431], ["full", 435], ["-", 439], ["length", 440], ["NF1", 447], ["cDNA", 451], [",", 455], ["which", 457], ["has", 463], ["a", 467], ["strong", 469], ["homology", 476], ["with", 485], ["the", 490], ["mammalian", 494], ["ras", 504], ["GTPase", 508], ["-", 514], ["activating", 515], ["protein", 526], ["(", 534], ["GAP", 535], [")", 538], [",", 539], ["especially", 541], ["for", 552], ["a", 556], ["stretch", 558], ["of", 566], ["three", 569], ["consecutive", 575], ["amino", 587], ["acids", 593], ["(", 599], ["F", 600], [",", 601], ["L", 603], [",", 604], ["R", 606], [")", 607], [",", 608], ["by", 610], ["single", 613], ["-", 619], ["strand", 620], ["conformation", 627], ["polymorphism", 640], ["analysis", 653], ["and", 662], ["direct", 666], ["sequencing", 673], ["in", 684], ["samples", 687], ["from", 695], ["patients", 700], ["with", 709], ["AML", 714], [".", 717], ["Of", 719], ["48", 722], ["AML", 725], ["patients", 729], [",", 737], ["10", 739], ["(", 742], ["21", 743], ["%", 745], [")", 746], ["had", 748], ["point", 752], ["(", 758], ["missense", 759], [")", 767], ["mutations", 769], ["of", 779], ["the", 782], ["N", 786], ["-", 787], ["ras", 788], ["gene", 792], ["involving", 797], ["codons", 807], ["12", 814], [",", 816], ["13", 818], ["and", 821], ["61", 825], [".", 827], ["However", 829], [",", 836], ["mutations", 838], ["in", 848], ["the", 851], ["FLR", 855], ["exon", 859], ["of", 864], ["the", 867], ["NF1", 871], ["gene", 875], ["were", 880], ["not", 885], ["detected", 889], ["in", 898], ["any", 901], ["of", 905], ["the", 908], ["AML", 912], ["samples", 916], [".", 923], ["We", 925], ["also", 928], ["examined", 933], ["the", 942], ["difference", 946], ["of", 957], ["clinical", 960], ["response", 969], ["to", 978], ["induction", 981], ["therapy", 991], ["between", 999], ["AML", 1007], ["patients", 1011], ["with", 1020], ["and", 1025], ["without", 1029], ["N", 1037], ["-", 1038], ["ras", 1039], ["mutation", 1043], [".", 1051], ["A", 1053], ["significantly", 1055], ["lower", 1069], ["rate", 1075], ["of", 1080], ["complete", 1083], ["remission", 1092], ["was", 1102], ["noted", 1106], ["in", 1112], ["individuals", 1115], ["with", 1127], ["N", 1132], ["-", 1133], ["ras", 1134], ["gene", 1138], ["mutations", 1143], [".", 1152], ["These", 1154], ["results", 1160], ["suggest", 1168], ["that", 1176], ["mutation", 1181], ["of", 1190], ["the", 1193], ["NF1", 1197], ["gene", 1201], [",", 1205], ["at", 1207], ["least", 1210], ["in", 1216], ["the", 1219], ["FLR", 1223], ["exon", 1227], [",", 1231], ["is", 1233], ["very", 1236], ["rare", 1241], ["in", 1246], ["AML", 1249], ["and", 1253], ["the", 1257], ["NF1", 1261], ["gene", 1265], ["probably", 1270], ["is", 1279], ["not", 1282], ["a", 1286], ["functional", 1288], ["complement", 1299], ["of", 1310], ["the", 1313], ["N", 1317], ["-", 1318], ["ras", 1319], ["gene", 1323], ["mutation", 1328], [".", 1336], ["The", 1338], ["presence", 1342], ["of", 1351], ["N", 1354], ["-", 1355], ["ras", 1356], ["gene", 1360], ["mutation", 1365], ["may", 1374], ["be", 1378], ["associated", 1381], ["with", 1392], ["a", 1397], ["lower", 1399], ["clinical", 1405], ["response", 1414], ["to", 1423], ["antileukemic", 1426], ["therapy", 1439], [".", 1446]]}
{"context": "Increased nerve growth factor levels are associated with chronic pain conditions, including chronic low back pain (LBP). This study examined safety and analgesic efficacy of tanezumab, a humanized anti-nerve growth factor antibody, in adults with chronic LBP. Patients received intravenous tanezumab 200 \u03bcg/kg plus oral placebo (n=88), intravenous placebo plus oral naproxen 500 mg twice a day (n=88), or intravenous placebo plus oral placebo (n=41). Primary outcome was average LBP intensity (aLBPI) at Week 6. Secondary outcomes were proportion of patients with \u226530% or \u226550% reduction in aLBPI, Roland-Morris Disability Questionnaire and Brief Pain Inventory-short form scores, Patients' Global Assessment of LBP, Patients' Global Evaluation of study medication, and rescue medication use. Mean aLBPI change from baseline to Week 6 was greater with tanezumab vs naproxen (P=0.004) and placebo (P<0.001). Greater proportions of patients reported \u226530% and \u226550% reduction in aLBPI with tanezumab vs naproxen (P\u22640.013) and placebo (P<0.001), and greater improvements in Roland-Morris Disability Questionnaire (P<0.001) and other secondary outcomes except rescue medication use. Tanezumab was associated with adverse events (AEs) of abnormal peripheral sensation that were generally mild and resolved before study completion; however, there were no serious AEs. Nine patients (4 of whom were tanezumab-treated) discontinued due to AEs. In conclusion, tanezumab resulted in analgesic efficacy that was clinically and statistically superior to placebo and naproxen in patients with chronic LBP. Tanezumab clinical development is on regulatory hold due to AEs in osteoarthritis patients.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "b57cadd16f7a4c1795c6018b46b69e57", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[1, 3], [35, 37]], "char_spans": [[10, 28], [202, 220]]}]}], "context_tokens": [["Increased", 0], ["nerve", 10], ["growth", 16], ["factor", 23], ["levels", 30], ["are", 37], ["associated", 41], ["with", 52], ["chronic", 57], ["pain", 65], ["conditions", 70], [",", 80], ["including", 82], ["chronic", 92], ["low", 100], ["back", 104], ["pain", 109], ["(", 114], ["LBP", 115], [")", 118], [".", 119], ["This", 121], ["study", 126], ["examined", 132], ["safety", 141], ["and", 148], ["analgesic", 152], ["efficacy", 162], ["of", 171], ["tanezumab", 174], [",", 183], ["a", 185], ["humanized", 187], ["anti", 197], ["-", 201], ["nerve", 202], ["growth", 208], ["factor", 215], ["antibody", 222], [",", 230], ["in", 232], ["adults", 235], ["with", 242], ["chronic", 247], ["LBP", 255], [".", 258], ["Patients", 260], ["received", 269], ["intravenous", 278], ["tanezumab", 290], ["200", 300], ["\u03bcg", 304], ["/", 306], ["kg", 307], ["plus", 310], ["oral", 315], ["placebo", 320], ["(", 328], ["n=88", 329], [")", 333], [",", 334], ["intravenous", 336], ["placebo", 348], ["plus", 356], ["oral", 361], ["naproxen", 366], ["500", 375], ["mg", 379], ["twice", 382], ["a", 388], ["day", 390], ["(", 394], ["n=88", 395], [")", 399], [",", 400], ["or", 402], ["intravenous", 405], ["placebo", 417], ["plus", 425], ["oral", 430], ["placebo", 435], ["(", 443], ["n=41", 444], [")", 448], [".", 449], ["Primary", 451], ["outcome", 459], ["was", 467], ["average", 471], ["LBP", 479], ["intensity", 483], ["(", 493], ["aLBPI", 494], [")", 499], ["at", 501], ["Week", 504], ["6", 509], [".", 510], ["Secondary", 512], ["outcomes", 522], ["were", 531], ["proportion", 536], ["of", 547], ["patients", 550], ["with", 559], ["\u226530", 564], ["%", 567], ["or", 569], ["\u226550", 572], ["%", 575], ["reduction", 577], ["in", 587], ["aLBPI", 590], [",", 595], ["Roland", 597], ["-", 603], ["Morris", 604], ["Disability", 611], ["Questionnaire", 622], ["and", 636], ["Brief", 640], ["Pain", 646], ["Inventory", 651], ["-", 660], ["short", 661], ["form", 667], ["scores", 672], [",", 678], ["Patients", 680], ["'", 688], ["Global", 690], ["Assessment", 697], ["of", 708], ["LBP", 711], [",", 714], ["Patients", 716], ["'", 724], ["Global", 726], ["Evaluation", 733], ["of", 744], ["study", 747], ["medication", 753], [",", 763], ["and", 765], ["rescue", 769], ["medication", 776], ["use", 787], [".", 790], ["Mean", 792], ["aLBPI", 797], ["change", 803], ["from", 810], ["baseline", 815], ["to", 824], ["Week", 827], ["6", 832], ["was", 834], ["greater", 838], ["with", 846], ["tanezumab", 851], ["vs", 861], ["naproxen", 864], ["(", 873], ["P=0.004", 874], [")", 881], ["and", 883], ["placebo", 887], ["(", 895], ["P<0.001", 896], [")", 903], [".", 904], ["Greater", 906], ["proportions", 914], ["of", 926], ["patients", 929], ["reported", 938], ["\u226530", 947], ["%", 950], ["and", 952], ["\u226550", 956], ["%", 959], ["reduction", 961], ["in", 971], ["aLBPI", 974], ["with", 980], ["tanezumab", 985], ["vs", 995], ["naproxen", 998], ["(", 1007], ["P\u22640.013", 1008], [")", 1015], ["and", 1017], ["placebo", 1021], ["(", 1029], ["P<0.001", 1030], [")", 1037], [",", 1038], ["and", 1040], ["greater", 1044], ["improvements", 1052], ["in", 1065], ["Roland", 1068], ["-", 1074], ["Morris", 1075], ["Disability", 1082], ["Questionnaire", 1093], ["(", 1107], ["P<0.001", 1108], [")", 1115], ["and", 1117], ["other", 1121], ["secondary", 1127], ["outcomes", 1137], ["except", 1146], ["rescue", 1153], ["medication", 1160], ["use", 1171], [".", 1174], ["Tanezumab", 1176], ["was", 1186], ["associated", 1190], ["with", 1201], ["adverse", 1206], ["events", 1214], ["(", 1221], ["AEs", 1222], [")", 1225], ["of", 1227], ["abnormal", 1230], ["peripheral", 1239], ["sensation", 1250], ["that", 1260], ["were", 1265], ["generally", 1270], ["mild", 1280], ["and", 1285], ["resolved", 1289], ["before", 1298], ["study", 1305], ["completion", 1311], [";", 1321], ["however", 1323], [",", 1330], ["there", 1332], ["were", 1338], ["no", 1343], ["serious", 1346], ["AEs", 1354], [".", 1357], ["Nine", 1359], ["patients", 1364], ["(", 1373], ["4", 1374], ["of", 1376], ["whom", 1379], ["were", 1384], ["tanezumab", 1389], ["-", 1398], ["treated", 1399], [")", 1406], ["discontinued", 1408], ["due", 1421], ["to", 1425], ["AEs", 1428], [".", 1431], ["In", 1433], ["conclusion", 1436], [",", 1446], ["tanezumab", 1448], ["resulted", 1458], ["in", 1467], ["analgesic", 1470], ["efficacy", 1480], ["that", 1489], ["was", 1494], ["clinically", 1498], ["and", 1509], ["statistically", 1513], ["superior", 1527], ["to", 1536], ["placebo", 1539], ["and", 1547], ["naproxen", 1551], ["in", 1560], ["patients", 1563], ["with", 1572], ["chronic", 1577], ["LBP", 1585], [".", 1588], ["Tanezumab", 1590], ["clinical", 1600], ["development", 1609], ["is", 1621], ["on", 1624], ["regulatory", 1627], ["hold", 1638], ["due", 1643], ["to", 1647], ["AEs", 1650], ["in", 1654], ["osteoarthritis", 1657], ["patients", 1672], [".", 1680]]}
{"context": "Neuronal loss in specific brain regions and neurons with intracellular inclusions termed Lewy bodies are the pathologic hallmark in both Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Lewy bodies comprise of aggregated intracellular vesicles and proteins and \u03b1-synuclein is reported to be a major protein component. Using human brain tissue from control, PD and DLB and light and confocal immunohistochemistry with antibodies to superoxide dismutase 2 as a marker for mitochondria, \u03b1-synuclein for Lewy bodies and \u03b2III Tubulin for microtubules we have examined the relationship between Lewy bodies and mitochondrial loss. We have shown microtubule regression and mitochondrial and nuclear degradation in neurons with developing Lewy bodies. In PD, multiple Lewy bodies were often observed with \u03b1-synuclein interacting with DNA to cause marked nuclear degradation. In DLB, the mitochondria are drawn into the Lewy body and the mitochondrial integrity is lost. This work suggests that Lewy bodies are cytotoxic. In DLB, we suggest that microtubule regression and mitochondrial loss results in decreased cellular energy and axonal transport that leads to cell death. In PD, \u03b1-synuclein aggregations are associated with intact mitochondria but interacts with and causes nuclear degradation which may be the major cause of cell death.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "a26bb24d46114aeaa1d54858c6340119", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "\u03b1-synuclein", "token_spans": [[134, 136], [201, 203], [45, 47], [84, 86]], "char_spans": [[809, 819], [1186, 1196], [274, 284], [497, 507]]}]}], "context_tokens": [["Neuronal", 0], ["loss", 9], ["in", 14], ["specific", 17], ["brain", 26], ["regions", 32], ["and", 40], ["neurons", 44], ["with", 52], ["intracellular", 57], ["inclusions", 71], ["termed", 82], ["Lewy", 89], ["bodies", 94], ["are", 101], ["the", 105], ["pathologic", 109], ["hallmark", 120], ["in", 129], ["both", 132], ["Parkinson", 137], ["'s", 146], ["disease", 149], ["(", 157], ["PD", 158], [")", 160], ["and", 162], ["dementia", 166], ["with", 175], ["Lewy", 180], ["bodies", 185], ["(", 192], ["DLB", 193], [")", 196], [".", 197], ["Lewy", 199], ["bodies", 204], ["comprise", 211], ["of", 220], ["aggregated", 223], ["intracellular", 234], ["vesicles", 248], ["and", 257], ["proteins", 261], ["and", 270], ["\u03b1", 274], ["-", 275], ["synuclein", 276], ["is", 286], ["reported", 289], ["to", 298], ["be", 301], ["a", 304], ["major", 306], ["protein", 312], ["component", 320], [".", 329], ["Using", 331], ["human", 337], ["brain", 343], ["tissue", 349], ["from", 356], ["control", 361], [",", 368], ["PD", 370], ["and", 373], ["DLB", 377], ["and", 381], ["light", 385], ["and", 391], ["confocal", 395], ["immunohistochemistry", 404], ["with", 425], ["antibodies", 430], ["to", 441], ["superoxide", 444], ["dismutase", 455], ["2", 465], ["as", 467], ["a", 470], ["marker", 472], ["for", 479], ["mitochondria", 483], [",", 495], ["\u03b1", 497], ["-", 498], ["synuclein", 499], ["for", 509], ["Lewy", 513], ["bodies", 518], ["and", 525], ["\u03b2III", 529], ["Tubulin", 534], ["for", 542], ["microtubules", 546], ["we", 559], ["have", 562], ["examined", 567], ["the", 576], ["relationship", 580], ["between", 593], ["Lewy", 601], ["bodies", 606], ["and", 613], ["mitochondrial", 617], ["loss", 631], [".", 635], ["We", 637], ["have", 640], ["shown", 645], ["microtubule", 651], ["regression", 663], ["and", 674], ["mitochondrial", 678], ["and", 692], ["nuclear", 696], ["degradation", 704], ["in", 716], ["neurons", 719], ["with", 727], ["developing", 732], ["Lewy", 743], ["bodies", 748], [".", 754], ["In", 756], ["PD", 759], [",", 761], ["multiple", 763], ["Lewy", 772], ["bodies", 777], ["were", 784], ["often", 789], ["observed", 795], ["with", 804], ["\u03b1", 809], ["-", 810], ["synuclein", 811], ["interacting", 821], ["with", 833], ["DNA", 838], ["to", 842], ["cause", 845], ["marked", 851], ["nuclear", 858], ["degradation", 866], [".", 877], ["In", 879], ["DLB", 882], [",", 885], ["the", 887], ["mitochondria", 891], ["are", 904], ["drawn", 908], ["into", 914], ["the", 919], ["Lewy", 923], ["body", 928], ["and", 933], ["the", 937], ["mitochondrial", 941], ["integrity", 955], ["is", 965], ["lost", 968], [".", 972], ["This", 974], ["work", 979], ["suggests", 984], ["that", 993], ["Lewy", 998], ["bodies", 1003], ["are", 1010], ["cytotoxic", 1014], [".", 1023], ["In", 1025], ["DLB", 1028], [",", 1031], ["we", 1033], ["suggest", 1036], ["that", 1044], ["microtubule", 1049], ["regression", 1061], ["and", 1072], ["mitochondrial", 1076], ["loss", 1090], ["results", 1095], ["in", 1103], ["decreased", 1106], ["cellular", 1116], ["energy", 1125], ["and", 1132], ["axonal", 1136], ["transport", 1143], ["that", 1153], ["leads", 1158], ["to", 1164], ["cell", 1167], ["death", 1172], [".", 1177], ["In", 1179], ["PD", 1182], [",", 1184], ["\u03b1", 1186], ["-", 1187], ["synuclein", 1188], ["aggregations", 1198], ["are", 1211], ["associated", 1215], ["with", 1226], ["intact", 1231], ["mitochondria", 1238], ["but", 1251], ["interacts", 1255], ["with", 1265], ["and", 1270], ["causes", 1274], ["nuclear", 1281], ["degradation", 1289], ["which", 1301], ["may", 1307], ["be", 1311], ["the", 1314], ["major", 1318], ["cause", 1324], ["of", 1330], ["cell", 1333], ["death", 1338], [".", 1343]]}
{"context": "Schimke immuno-osseous dysplasia (OMIM 242900) is an uncommon autosomal-recessive multisystem disease caused by mutations in SMARCAL1 (swi/snf-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1), a gene encoding a putative chromatin remodeling protein. Neurologic manifestations identified to date relate to enhanced atherosclerosis and cerebrovascular disease. Based on a clinical survey, we determined that half of Schimke immuno-osseous dysplasia patients have a small head circumference, and 15% have social, language, motor, or cognitive abnormalities. Postmortem examination of 2 Schimke immuno-osseous dysplasia patients showed low brain weights and subtle brain histologic abnormalities suggestive of perturbed neuron-glial migration such as heterotopia, irregular cortical thickness, incomplete gyral formation, and poor definition of cortical layers. We found that SMARCAL1 is highly expressed in the developing and adult mouse and human brain, including neural precursors and neuronal lineage cells. These observations suggest that SMARCAL1 deficiency may influence brain development and function in addition to its previously recognized effect on cerebral circulation.", "qas": [{"question": "Mutations in which gene cause Schimke immune-osseous dysplasia?", "answers": ["HARP", "SMARCAL1 (swi/snf-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1", "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)"], "qid": "86b60944892d4aba80de48bd155dcdcb", "question_tokens": [["Mutations", 0], ["in", 10], ["which", 13], ["gene", 19], ["cause", 24], ["Schimke", 30], ["immune", 38], ["-", 44], ["osseous", 45], ["dysplasia", 53], ["?", 62]], "detected_answers": [{"text": "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1)", "token_spans": [[21, 44]], "char_spans": [[125, 228]]}]}], "context_tokens": [["Schimke", 0], ["immuno", 8], ["-", 14], ["osseous", 15], ["dysplasia", 23], ["(", 33], ["OMIM", 34], ["242900", 39], [")", 45], ["is", 47], ["an", 50], ["uncommon", 53], ["autosomal", 62], ["-", 71], ["recessive", 72], ["multisystem", 82], ["disease", 94], ["caused", 102], ["by", 109], ["mutations", 112], ["in", 122], ["SMARCAL1", 125], ["(", 134], ["swi", 135], ["/", 138], ["snf", 139], ["-", 142], ["related", 143], [",", 150], ["matrix", 152], ["-", 158], ["associated", 159], [",", 169], ["actin", 171], ["-", 176], ["dependent", 177], ["regulator", 187], ["of", 197], ["chromatin", 200], [",", 209], ["subfamily", 211], ["a", 221], ["-", 222], ["like", 223], ["1", 228], [")", 229], [",", 230], ["a", 232], ["gene", 234], ["encoding", 239], ["a", 248], ["putative", 250], ["chromatin", 259], ["remodeling", 269], ["protein", 280], [".", 287], ["Neurologic", 289], ["manifestations", 300], ["identified", 315], ["to", 326], ["date", 329], ["relate", 334], ["to", 341], ["enhanced", 344], ["atherosclerosis", 353], ["and", 369], ["cerebrovascular", 373], ["disease", 389], [".", 396], ["Based", 398], ["on", 404], ["a", 407], ["clinical", 409], ["survey", 418], [",", 424], ["we", 426], ["determined", 429], ["that", 440], ["half", 445], ["of", 450], ["Schimke", 453], ["immuno", 461], ["-", 467], ["osseous", 468], ["dysplasia", 476], ["patients", 486], ["have", 495], ["a", 500], ["small", 502], ["head", 508], ["circumference", 513], [",", 526], ["and", 528], ["15", 532], ["%", 534], ["have", 536], ["social", 541], [",", 547], ["language", 549], [",", 557], ["motor", 559], [",", 564], ["or", 566], ["cognitive", 569], ["abnormalities", 579], [".", 592], ["Postmortem", 594], ["examination", 605], ["of", 617], ["2", 620], ["Schimke", 622], ["immuno", 630], ["-", 636], ["osseous", 637], ["dysplasia", 645], ["patients", 655], ["showed", 664], ["low", 671], ["brain", 675], ["weights", 681], ["and", 689], ["subtle", 693], ["brain", 700], ["histologic", 706], ["abnormalities", 717], ["suggestive", 731], ["of", 742], ["perturbed", 745], ["neuron", 755], ["-", 761], ["glial", 762], ["migration", 768], ["such", 778], ["as", 783], ["heterotopia", 786], [",", 797], ["irregular", 799], ["cortical", 809], ["thickness", 818], [",", 827], ["incomplete", 829], ["gyral", 840], ["formation", 846], [",", 855], ["and", 857], ["poor", 861], ["definition", 866], ["of", 877], ["cortical", 880], ["layers", 889], [".", 895], ["We", 897], ["found", 900], ["that", 906], ["SMARCAL1", 911], ["is", 920], ["highly", 923], ["expressed", 930], ["in", 940], ["the", 943], ["developing", 947], ["and", 958], ["adult", 962], ["mouse", 968], ["and", 974], ["human", 978], ["brain", 984], [",", 989], ["including", 991], ["neural", 1001], ["precursors", 1008], ["and", 1019], ["neuronal", 1023], ["lineage", 1032], ["cells", 1040], [".", 1045], ["These", 1047], ["observations", 1053], ["suggest", 1066], ["that", 1074], ["SMARCAL1", 1079], ["deficiency", 1088], ["may", 1099], ["influence", 1103], ["brain", 1113], ["development", 1119], ["and", 1131], ["function", 1135], ["in", 1144], ["addition", 1147], ["to", 1156], ["its", 1159], ["previously", 1163], ["recognized", 1174], ["effect", 1185], ["on", 1192], ["cerebral", 1195], ["circulation", 1204], [".", 1215]]}
{"context": "To review available studies of empagliflozin, a sodium glucose co-transporter-2 (SGLT2) inhibitor approved in 2014 by the European Commission and the United States Food and Drug Administration for the treatment of type 2 diabetes mellitus (T2DM). PubMed was searched using the search terms empagliflozin, BI 10773, and BI10773, for entries between January 1, 2000, and December 1, 2014. Reference lists from retrieved articles were searched manually for additional peer-reviewed publications. All publications reporting clinical trials of empagliflozin were eligible for inclusion. Empagliflozin is a new once-daily oral SGLT2 inhibitor with a mechanism of action that is independent of \u03b2-cell function and the insulin pathway. Data from a comprehensive phase III clinical trial program have demonstrated its efficacy as monotherapy, as add-on to other glucose-lowering agents, and in different patient populations. In these studies, empagliflozin resulted in improvements in blood glucose levels as well as reductions in body weight and blood pressure. Empagliflozin was well tolerated and was not associated with an increased risk of hypoglycemia versus placebo. The oral antidiabetes agent, empagliflozin, can be used as monotherapy or alongside other glucose-lowering treatments, including insulin, to treat T2DM.", "qas": [{"question": "Which protein does empagliflozin inhibit?", "answers": ["SGLT2"], "qid": "8e4362d962304849af0e9a9cf344f780", "question_tokens": [["Which", 0], ["protein", 6], ["does", 14], ["empagliflozin", 19], ["inhibit", 33], ["?", 40]], "detected_answers": [{"text": "SGLT2", "token_spans": [[108, 108], [14, 14]], "char_spans": [[621, 625], [81, 85]]}]}], "context_tokens": [["To", 0], ["review", 3], ["available", 10], ["studies", 20], ["of", 28], ["empagliflozin", 31], [",", 44], ["a", 46], ["sodium", 48], ["glucose", 55], ["co", 63], ["-", 65], ["transporter-2", 66], ["(", 80], ["SGLT2", 81], [")", 86], ["inhibitor", 88], ["approved", 98], ["in", 107], ["2014", 110], ["by", 115], ["the", 118], ["European", 122], ["Commission", 131], ["and", 142], ["the", 146], ["United", 150], ["States", 157], ["Food", 164], ["and", 169], ["Drug", 173], ["Administration", 178], ["for", 193], ["the", 197], ["treatment", 201], ["of", 211], ["type", 214], ["2", 219], ["diabetes", 221], ["mellitus", 230], ["(", 239], ["T2DM", 240], [")", 244], [".", 245], ["PubMed", 247], ["was", 254], ["searched", 258], ["using", 267], ["the", 273], ["search", 277], ["terms", 284], ["empagliflozin", 290], [",", 303], ["BI", 305], ["10773", 308], [",", 313], ["and", 315], ["BI10773", 319], [",", 326], ["for", 328], ["entries", 332], ["between", 340], ["January", 348], ["1", 356], [",", 357], ["2000", 359], [",", 363], ["and", 365], ["December", 369], ["1", 378], [",", 379], ["2014", 381], [".", 385], ["Reference", 387], ["lists", 397], ["from", 403], ["retrieved", 408], ["articles", 418], ["were", 427], ["searched", 432], ["manually", 441], ["for", 450], ["additional", 454], ["peer", 465], ["-", 469], ["reviewed", 470], ["publications", 479], [".", 491], ["All", 493], ["publications", 497], ["reporting", 510], ["clinical", 520], ["trials", 529], ["of", 536], ["empagliflozin", 539], ["were", 553], ["eligible", 558], ["for", 567], ["inclusion", 571], [".", 580], ["Empagliflozin", 582], ["is", 596], ["a", 599], ["new", 601], ["once", 605], ["-", 609], ["daily", 610], ["oral", 616], ["SGLT2", 621], ["inhibitor", 627], ["with", 637], ["a", 642], ["mechanism", 644], ["of", 654], ["action", 657], ["that", 664], ["is", 669], ["independent", 672], ["of", 684], ["\u03b2", 687], ["-", 688], ["cell", 689], ["function", 694], ["and", 703], ["the", 707], ["insulin", 711], ["pathway", 719], [".", 726], ["Data", 728], ["from", 733], ["a", 738], ["comprehensive", 740], ["phase", 754], ["III", 760], ["clinical", 764], ["trial", 773], ["program", 779], ["have", 787], ["demonstrated", 792], ["its", 805], ["efficacy", 809], ["as", 818], ["monotherapy", 821], [",", 832], ["as", 834], ["add", 837], ["-", 840], ["on", 841], ["to", 844], ["other", 847], ["glucose", 853], ["-", 860], ["lowering", 861], ["agents", 870], [",", 876], ["and", 878], ["in", 882], ["different", 885], ["patient", 895], ["populations", 903], [".", 914], ["In", 916], ["these", 919], ["studies", 925], [",", 932], ["empagliflozin", 934], ["resulted", 948], ["in", 957], ["improvements", 960], ["in", 973], ["blood", 976], ["glucose", 982], ["levels", 990], ["as", 997], ["well", 1000], ["as", 1005], ["reductions", 1008], ["in", 1019], ["body", 1022], ["weight", 1027], ["and", 1034], ["blood", 1038], ["pressure", 1044], [".", 1052], ["Empagliflozin", 1054], ["was", 1068], ["well", 1072], ["tolerated", 1077], ["and", 1087], ["was", 1091], ["not", 1095], ["associated", 1099], ["with", 1110], ["an", 1115], ["increased", 1118], ["risk", 1128], ["of", 1133], ["hypoglycemia", 1136], ["versus", 1149], ["placebo", 1156], [".", 1163], ["The", 1165], ["oral", 1169], ["antidiabetes", 1174], ["agent", 1187], [",", 1192], ["empagliflozin", 1194], [",", 1207], ["can", 1209], ["be", 1213], ["used", 1216], ["as", 1221], ["monotherapy", 1224], ["or", 1236], ["alongside", 1239], ["other", 1249], ["glucose", 1255], ["-", 1262], ["lowering", 1263], ["treatments", 1272], [",", 1282], ["including", 1284], ["insulin", 1294], [",", 1301], ["to", 1303], ["treat", 1306], ["T2DM", 1312], [".", 1316]]}
{"context": "Plasmids are ubiquitous mobile elements that serve as a pool of many host beneficial traits such as antibiotic resistance in bacterial communities. To understand the importance of plasmids in horizontal gene transfer, we need to gain insight into the 'evolutionary history' of these plasmids, i.e. the range of hosts in which they have evolved. Since extensive data support the proposal that foreign DNA acquires the host's nucleotide composition during long-term residence, comparison of nucleotide composition of plasmids and chromosomes could shed light on a plasmid's evolutionary history. The average absolute dinucleotide relative abundance difference, termed delta-distance, has been commonly used to measure differences in dinucleotide composition, or 'genomic signature', between bacterial chromosomes and plasmids. Here, we introduce the Mahalanobis distance, which takes into account the variance-covariance structure of the chromosome signatures. We demonstrate that the Mahalanobis distance is better than the delta-distance at measuring genomic signature differences between plasmids and chromosomes of potential hosts. We illustrate the usefulness of this metric for proposing candidate long-term hosts for plasmids, focusing on the virulence plasmids pXO1 from Bacillus anthracis, and pO157 from Escherichia coli O157:H7, as well as the broad host range multi-drug resistance plasmid pB10 from an unknown host.", "qas": [{"question": "Which is the most common measure of differences between dinucleotide relative abundance \"genomic signatures\"", "answers": ["delta-distance"], "qid": "082b7ea2976047d8b572fd00bfddec04", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["most", 13], ["common", 18], ["measure", 25], ["of", 33], ["differences", 36], ["between", 48], ["dinucleotide", 56], ["relative", 69], ["abundance", 78], ["\"", 88], ["genomic", 89], ["signatures", 97], ["\"", 107]], "detected_answers": [{"text": "delta-distance", "token_spans": [[108, 110], [167, 169]], "char_spans": [[666, 679], [1023, 1036]]}]}], "context_tokens": [["Plasmids", 0], ["are", 9], ["ubiquitous", 13], ["mobile", 24], ["elements", 31], ["that", 40], ["serve", 45], ["as", 51], ["a", 54], ["pool", 56], ["of", 61], ["many", 64], ["host", 69], ["beneficial", 74], ["traits", 85], ["such", 92], ["as", 97], ["antibiotic", 100], ["resistance", 111], ["in", 122], ["bacterial", 125], ["communities", 135], [".", 146], ["To", 148], ["understand", 151], ["the", 162], ["importance", 166], ["of", 177], ["plasmids", 180], ["in", 189], ["horizontal", 192], ["gene", 203], ["transfer", 208], [",", 216], ["we", 218], ["need", 221], ["to", 226], ["gain", 229], ["insight", 234], ["into", 242], ["the", 247], ["'", 251], ["evolutionary", 252], ["history", 265], ["'", 272], ["of", 274], ["these", 277], ["plasmids", 283], [",", 291], ["i.e.", 293], ["the", 298], ["range", 302], ["of", 308], ["hosts", 311], ["in", 317], ["which", 320], ["they", 326], ["have", 331], ["evolved", 336], [".", 343], ["Since", 345], ["extensive", 351], ["data", 361], ["support", 366], ["the", 374], ["proposal", 378], ["that", 387], ["foreign", 392], ["DNA", 400], ["acquires", 404], ["the", 413], ["host", 417], ["'s", 421], ["nucleotide", 424], ["composition", 435], ["during", 447], ["long", 454], ["-", 458], ["term", 459], ["residence", 464], [",", 473], ["comparison", 475], ["of", 486], ["nucleotide", 489], ["composition", 500], ["of", 512], ["plasmids", 515], ["and", 524], ["chromosomes", 528], ["could", 540], ["shed", 546], ["light", 551], ["on", 557], ["a", 560], ["plasmid", 562], ["'s", 569], ["evolutionary", 572], ["history", 585], [".", 592], ["The", 594], ["average", 598], ["absolute", 606], ["dinucleotide", 615], ["relative", 628], ["abundance", 637], ["difference", 647], [",", 657], ["termed", 659], ["delta", 666], ["-", 671], ["distance", 672], [",", 680], ["has", 682], ["been", 686], ["commonly", 691], ["used", 700], ["to", 705], ["measure", 708], ["differences", 716], ["in", 728], ["dinucleotide", 731], ["composition", 744], [",", 755], ["or", 757], ["'", 760], ["genomic", 761], ["signature", 769], ["'", 778], [",", 779], ["between", 781], ["bacterial", 789], ["chromosomes", 799], ["and", 811], ["plasmids", 815], [".", 823], ["Here", 825], [",", 829], ["we", 831], ["introduce", 834], ["the", 844], ["Mahalanobis", 848], ["distance", 860], [",", 868], ["which", 870], ["takes", 876], ["into", 882], ["account", 887], ["the", 895], ["variance", 899], ["-", 907], ["covariance", 908], ["structure", 919], ["of", 929], ["the", 932], ["chromosome", 936], ["signatures", 947], [".", 957], ["We", 959], ["demonstrate", 962], ["that", 974], ["the", 979], ["Mahalanobis", 983], ["distance", 995], ["is", 1004], ["better", 1007], ["than", 1014], ["the", 1019], ["delta", 1023], ["-", 1028], ["distance", 1029], ["at", 1038], ["measuring", 1041], ["genomic", 1051], ["signature", 1059], ["differences", 1069], ["between", 1081], ["plasmids", 1089], ["and", 1098], ["chromosomes", 1102], ["of", 1114], ["potential", 1117], ["hosts", 1127], [".", 1132], ["We", 1134], ["illustrate", 1137], ["the", 1148], ["usefulness", 1152], ["of", 1163], ["this", 1166], ["metric", 1171], ["for", 1178], ["proposing", 1182], ["candidate", 1192], ["long", 1202], ["-", 1206], ["term", 1207], ["hosts", 1212], ["for", 1218], ["plasmids", 1222], [",", 1230], ["focusing", 1232], ["on", 1241], ["the", 1244], ["virulence", 1248], ["plasmids", 1258], ["pXO1", 1267], ["from", 1272], ["Bacillus", 1277], ["anthracis", 1286], [",", 1295], ["and", 1297], ["pO157", 1301], ["from", 1307], ["Escherichia", 1312], ["coli", 1324], ["O157:H7", 1329], [",", 1336], ["as", 1338], ["well", 1341], ["as", 1346], ["the", 1349], ["broad", 1353], ["host", 1359], ["range", 1364], ["multi", 1370], ["-", 1375], ["drug", 1376], ["resistance", 1381], ["plasmid", 1392], ["pB10", 1400], ["from", 1405], ["an", 1410], ["unknown", 1413], ["host", 1421], [".", 1425]]}
{"context": "Chronic inflammation contributes to a wide variety of human disorders. In the stomach, longstanding gastritis often results in structural alterations in the gastric mucosa, including metaplastic changes and gastric cancers. Therefore, it is important to elucidate factors that are involved in gastric inflammation. Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins. Here, we have demonstrated that Nrdc crucially regulates gastric inflammation caused by Helicobacter felis infection or forced expression of prostaglandin E", "qas": [{"question": "Which is the enzymatic activity of nardilysin?", "answers": ["Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins."], "qid": "133771e8d5b9448681074f5d120771a8", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["enzymatic", 13], ["activity", 23], ["of", 32], ["nardilysin", 35], ["?", 45]], "detected_answers": [{"text": "Nardilysin (N-arginine dibasic convertase; Nrdc) is a metalloendopeptidase of the M16 family that promotes ectodomain shedding of the precursor forms of various growth factors and cytokines by enhancing the protease activities of a disintegrin and metalloproteinase (ADAM) proteins.", "token_spans": [[49, 93]], "char_spans": [[315, 595]]}]}], "context_tokens": [["Chronic", 0], ["inflammation", 8], ["contributes", 21], ["to", 33], ["a", 36], ["wide", 38], ["variety", 43], ["of", 51], ["human", 54], ["disorders", 60], [".", 69], ["In", 71], ["the", 74], ["stomach", 78], [",", 85], ["longstanding", 87], ["gastritis", 100], ["often", 110], ["results", 116], ["in", 124], ["structural", 127], ["alterations", 138], ["in", 150], ["the", 153], ["gastric", 157], ["mucosa", 165], [",", 171], ["including", 173], ["metaplastic", 183], ["changes", 195], ["and", 203], ["gastric", 207], ["cancers", 215], [".", 222], ["Therefore", 224], [",", 233], ["it", 235], ["is", 238], ["important", 241], ["to", 251], ["elucidate", 254], ["factors", 264], ["that", 272], ["are", 277], ["involved", 281], ["in", 290], ["gastric", 293], ["inflammation", 301], [".", 313], ["Nardilysin", 315], ["(", 326], ["N", 327], ["-", 328], ["arginine", 329], ["dibasic", 338], ["convertase", 346], [";", 356], ["Nrdc", 358], [")", 362], ["is", 364], ["a", 367], ["metalloendopeptidase", 369], ["of", 390], ["the", 393], ["M16", 397], ["family", 401], ["that", 408], ["promotes", 413], ["ectodomain", 422], ["shedding", 433], ["of", 442], ["the", 445], ["precursor", 449], ["forms", 459], ["of", 465], ["various", 468], ["growth", 476], ["factors", 483], ["and", 491], ["cytokines", 495], ["by", 505], ["enhancing", 508], ["the", 518], ["protease", 522], ["activities", 531], ["of", 542], ["a", 545], ["disintegrin", 547], ["and", 559], ["metalloproteinase", 563], ["(", 581], ["ADAM", 582], [")", 586], ["proteins", 588], [".", 596], ["Here", 598], [",", 602], ["we", 604], ["have", 607], ["demonstrated", 612], ["that", 625], ["Nrdc", 630], ["crucially", 635], ["regulates", 645], ["gastric", 655], ["inflammation", 663], ["caused", 676], ["by", 683], ["Helicobacter", 686], ["felis", 699], ["infection", 705], ["or", 715], ["forced", 718], ["expression", 725], ["of", 736], ["prostaglandin", 739], ["E", 753]]}
{"context": "Chronic myelogenous leukemia (CML) is a clonal hematopoietic disorder caused by the reciprocal translocation between chromosome 9 and 22. As a result of this translocation, a novel fusion gene, BCR-ABL, is created on Philadelphia (Ph) chromosome, and the constitutive activity of the BCR-ABL protein tyrosine kinase plays a critical role in the disease pathogenesis. Imatinib mesylate, a selective BCR-ABL tyrosine kinase inhibitor, was first given to a patient with CML in June 1998. Since then, it has continued to demonstrate remarkable efficacy in treating patients with CML. Based upon the results of early phase I and II studies, a phase III study (IRIS Study) that was randomized to first-line imatinib (400 mg/day) or to standard treatment with interferon+low-dose Ara-C, was conducted on 1,106 patients newly diagnosed (within 6 months) with chronic-phase CML. After median follow-up of 30 months, imatinib showed significantly superior tolerability, hematologic and cytogenetic responses (major cytogenetic response, 90%; complete cytogenetic response, 82%), and overall survival (95% without censoring allo-HSCT). Although imatinib is the first-line therapy and has changed the paradigm of CML treatment strategy, questions remain as to the meaning of cytogenetic and molecular response, curability, optimal dose, and relation with allo-HSCT.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "90bd5d6d1bbd4a51af5bf2328d5aebb7", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[73, 75], [53, 55], [34, 36]], "char_spans": [[398, 404], [284, 290], [194, 200]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["a", 38], ["clonal", 40], ["hematopoietic", 47], ["disorder", 61], ["caused", 70], ["by", 77], ["the", 80], ["reciprocal", 84], ["translocation", 95], ["between", 109], ["chromosome", 117], ["9", 128], ["and", 130], ["22", 134], [".", 136], ["As", 138], ["a", 141], ["result", 143], ["of", 150], ["this", 153], ["translocation", 158], [",", 171], ["a", 173], ["novel", 175], ["fusion", 181], ["gene", 188], [",", 192], ["BCR", 194], ["-", 197], ["ABL", 198], [",", 201], ["is", 203], ["created", 206], ["on", 214], ["Philadelphia", 217], ["(", 230], ["Ph", 231], [")", 233], ["chromosome", 235], [",", 245], ["and", 247], ["the", 251], ["constitutive", 255], ["activity", 268], ["of", 277], ["the", 280], ["BCR", 284], ["-", 287], ["ABL", 288], ["protein", 292], ["tyrosine", 300], ["kinase", 309], ["plays", 316], ["a", 322], ["critical", 324], ["role", 333], ["in", 338], ["the", 341], ["disease", 345], ["pathogenesis", 353], [".", 365], ["Imatinib", 367], ["mesylate", 376], [",", 384], ["a", 386], ["selective", 388], ["BCR", 398], ["-", 401], ["ABL", 402], ["tyrosine", 406], ["kinase", 415], ["inhibitor", 422], [",", 431], ["was", 433], ["first", 437], ["given", 443], ["to", 449], ["a", 452], ["patient", 454], ["with", 462], ["CML", 467], ["in", 471], ["June", 474], ["1998", 479], [".", 483], ["Since", 485], ["then", 491], [",", 495], ["it", 497], ["has", 500], ["continued", 504], ["to", 514], ["demonstrate", 517], ["remarkable", 529], ["efficacy", 540], ["in", 549], ["treating", 552], ["patients", 561], ["with", 570], ["CML", 575], [".", 578], ["Based", 580], ["upon", 586], ["the", 591], ["results", 595], ["of", 603], ["early", 606], ["phase", 612], ["I", 618], ["and", 620], ["II", 624], ["studies", 627], [",", 634], ["a", 636], ["phase", 638], ["III", 644], ["study", 648], ["(", 654], ["IRIS", 655], ["Study", 660], [")", 665], ["that", 667], ["was", 672], ["randomized", 676], ["to", 687], ["first", 690], ["-", 695], ["line", 696], ["imatinib", 701], ["(", 710], ["400", 711], ["mg", 715], ["/", 717], ["day", 718], [")", 721], ["or", 723], ["to", 726], ["standard", 729], ["treatment", 738], ["with", 748], ["interferon+low", 753], ["-", 767], ["dose", 768], ["Ara", 773], ["-", 776], ["C", 777], [",", 778], ["was", 780], ["conducted", 784], ["on", 794], ["1,106", 797], ["patients", 803], ["newly", 812], ["diagnosed", 818], ["(", 828], ["within", 829], ["6", 836], ["months", 838], [")", 844], ["with", 846], ["chronic", 851], ["-", 858], ["phase", 859], ["CML", 865], [".", 868], ["After", 870], ["median", 876], ["follow", 883], ["-", 889], ["up", 890], ["of", 893], ["30", 896], ["months", 899], [",", 905], ["imatinib", 907], ["showed", 916], ["significantly", 923], ["superior", 937], ["tolerability", 946], [",", 958], ["hematologic", 960], ["and", 972], ["cytogenetic", 976], ["responses", 988], ["(", 998], ["major", 999], ["cytogenetic", 1005], ["response", 1017], [",", 1025], ["90", 1027], ["%", 1029], [";", 1030], ["complete", 1032], ["cytogenetic", 1041], ["response", 1053], [",", 1061], ["82", 1063], ["%", 1065], [")", 1066], [",", 1067], ["and", 1069], ["overall", 1073], ["survival", 1081], ["(", 1090], ["95", 1091], ["%", 1093], ["without", 1095], ["censoring", 1103], ["allo", 1113], ["-", 1117], ["HSCT", 1118], [")", 1122], [".", 1123], ["Although", 1125], ["imatinib", 1134], ["is", 1143], ["the", 1146], ["first", 1150], ["-", 1155], ["line", 1156], ["therapy", 1161], ["and", 1169], ["has", 1173], ["changed", 1177], ["the", 1185], ["paradigm", 1189], ["of", 1198], ["CML", 1201], ["treatment", 1205], ["strategy", 1215], [",", 1223], ["questions", 1225], ["remain", 1235], ["as", 1242], ["to", 1245], ["the", 1248], ["meaning", 1252], ["of", 1260], ["cytogenetic", 1263], ["and", 1275], ["molecular", 1279], ["response", 1289], [",", 1297], ["curability", 1299], [",", 1309], ["optimal", 1311], ["dose", 1319], [",", 1323], ["and", 1325], ["relation", 1329], ["with", 1338], ["allo", 1343], ["-", 1347], ["HSCT", 1348], [".", 1352]]}
{"context": "The Ehlers-Danlos syndrome is a heritable connective-tissue disorder caused by defects in fibrillar-collagen metabolism. Mutations in the type V collagen genes account for up to 50 percent of cases of classic Ehlers-Danlos syndrome, but many other cases are unexplained. We investigated whether the deficiency of the tenascins, extracellular-matrix proteins that are highly expressed in connective tissues, was associated with the Ehlers-Danlos syndrome. We screened serum samples from 151 patients with the classic, hypermobility, or vascular types of the Ehlers-Danlos syndrome; 75 patients with psoriasis; 93 patients with rheumatoid arthritis; and 21 healthy persons for the presence of tenascin-X and tenascin-C by enzyme-linked immunosorbent assay. We examined the expression of tenascins and type V collagen in skin by immunohistochemical methods and sequenced the tenascin-X gene. Tenascin-X was present in serum from all normal subjects, all patients with psoriasis, all patients with rheumatoid arthritis, and 146 of 151 patients with the Ehlers-Danlos syndrome. Tenascin-X was absent from the serum of the 5 remaining patients with Ehlers-Danlos syndrome, who were unrelated. Tenascin-X deficiency was confirmed in these patients by analysis of skin fibroblasts and by immunostaining of skin. The expression of tenascin-C and type V collagen was normal in these patients. All five of these patients had hypermobile joints, hyperelastic skin, and easy bruising, without atrophic scarring. Tenascin-X mutations were identified in all tenascin-X-deficient patients; one patient had a homozygous tenascin-X gene deletion, one was heterozygous for the deletion, and three others had homozygous truncating point mutations, confirming a causative role for tenascin-X and a recessive pattern of inheritance. Tenascin-X deficiency causes a clinically distinct, recessive form of the Ehlers-Danlos syndrome. This finding indicates that factors other than the collagens or collagen-processing enzymes can cause the syndrome and suggests a central role for tenascin-X in maintaining the integrity of collagenous matrix.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective-tissue", "connective tissue"], "qid": "84ecb54e06cc44c78c9482f8b29d119c", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[8, 10]], "char_spans": [[42, 58]]}]}], "context_tokens": [["The", 0], ["Ehlers", 4], ["-", 10], ["Danlos", 11], ["syndrome", 18], ["is", 27], ["a", 30], ["heritable", 32], ["connective", 42], ["-", 52], ["tissue", 53], ["disorder", 60], ["caused", 69], ["by", 76], ["defects", 79], ["in", 87], ["fibrillar", 90], ["-", 99], ["collagen", 100], ["metabolism", 109], [".", 119], ["Mutations", 121], ["in", 131], ["the", 134], ["type", 138], ["V", 143], ["collagen", 145], ["genes", 154], ["account", 160], ["for", 168], ["up", 172], ["to", 175], ["50", 178], ["percent", 181], ["of", 189], ["cases", 192], ["of", 198], ["classic", 201], ["Ehlers", 209], ["-", 215], ["Danlos", 216], ["syndrome", 223], [",", 231], ["but", 233], ["many", 237], ["other", 242], ["cases", 248], ["are", 254], ["unexplained", 258], [".", 269], ["We", 271], ["investigated", 274], ["whether", 287], ["the", 295], ["deficiency", 299], ["of", 310], ["the", 313], ["tenascins", 317], [",", 326], ["extracellular", 328], ["-", 341], ["matrix", 342], ["proteins", 349], ["that", 358], ["are", 363], ["highly", 367], ["expressed", 374], ["in", 384], ["connective", 387], ["tissues", 398], [",", 405], ["was", 407], ["associated", 411], ["with", 422], ["the", 427], ["Ehlers", 431], ["-", 437], ["Danlos", 438], ["syndrome", 445], [".", 453], ["We", 455], ["screened", 458], ["serum", 467], ["samples", 473], ["from", 481], ["151", 486], ["patients", 490], ["with", 499], ["the", 504], ["classic", 508], [",", 515], ["hypermobility", 517], [",", 530], ["or", 532], ["vascular", 535], ["types", 544], ["of", 550], ["the", 553], ["Ehlers", 557], ["-", 563], ["Danlos", 564], ["syndrome", 571], [";", 579], ["75", 581], ["patients", 584], ["with", 593], ["psoriasis", 598], [";", 607], ["93", 609], ["patients", 612], ["with", 621], ["rheumatoid", 626], ["arthritis", 637], [";", 646], ["and", 648], ["21", 652], ["healthy", 655], ["persons", 663], ["for", 671], ["the", 675], ["presence", 679], ["of", 688], ["tenascin", 691], ["-", 699], ["X", 700], ["and", 702], ["tenascin", 706], ["-", 714], ["C", 715], ["by", 717], ["enzyme", 720], ["-", 726], ["linked", 727], ["immunosorbent", 734], ["assay", 748], [".", 753], ["We", 755], ["examined", 758], ["the", 767], ["expression", 771], ["of", 782], ["tenascins", 785], ["and", 795], ["type", 799], ["V", 804], ["collagen", 806], ["in", 815], ["skin", 818], ["by", 823], ["immunohistochemical", 826], ["methods", 846], ["and", 854], ["sequenced", 858], ["the", 868], ["tenascin", 872], ["-", 880], ["X", 881], ["gene", 883], [".", 887], ["Tenascin", 889], ["-", 897], ["X", 898], ["was", 900], ["present", 904], ["in", 912], ["serum", 915], ["from", 921], ["all", 926], ["normal", 930], ["subjects", 937], [",", 945], ["all", 947], ["patients", 951], ["with", 960], ["psoriasis", 965], [",", 974], ["all", 976], ["patients", 980], ["with", 989], ["rheumatoid", 994], ["arthritis", 1005], [",", 1014], ["and", 1016], ["146", 1020], ["of", 1024], ["151", 1027], ["patients", 1031], ["with", 1040], ["the", 1045], ["Ehlers", 1049], ["-", 1055], ["Danlos", 1056], ["syndrome", 1063], [".", 1071], ["Tenascin", 1073], ["-", 1081], ["X", 1082], ["was", 1084], ["absent", 1088], ["from", 1095], ["the", 1100], ["serum", 1104], ["of", 1110], ["the", 1113], ["5", 1117], ["remaining", 1119], ["patients", 1129], ["with", 1138], ["Ehlers", 1143], ["-", 1149], ["Danlos", 1150], ["syndrome", 1157], [",", 1165], ["who", 1167], ["were", 1171], ["unrelated", 1176], [".", 1185], ["Tenascin", 1187], ["-", 1195], ["X", 1196], ["deficiency", 1198], ["was", 1209], ["confirmed", 1213], ["in", 1223], ["these", 1226], ["patients", 1232], ["by", 1241], ["analysis", 1244], ["of", 1253], ["skin", 1256], ["fibroblasts", 1261], ["and", 1273], ["by", 1277], ["immunostaining", 1280], ["of", 1295], ["skin", 1298], [".", 1302], ["The", 1304], ["expression", 1308], ["of", 1319], ["tenascin", 1322], ["-", 1330], ["C", 1331], ["and", 1333], ["type", 1337], ["V", 1342], ["collagen", 1344], ["was", 1353], ["normal", 1357], ["in", 1364], ["these", 1367], ["patients", 1373], [".", 1381], ["All", 1383], ["five", 1387], ["of", 1392], ["these", 1395], ["patients", 1401], ["had", 1410], ["hypermobile", 1414], ["joints", 1426], [",", 1432], ["hyperelastic", 1434], ["skin", 1447], [",", 1451], ["and", 1453], ["easy", 1457], ["bruising", 1462], [",", 1470], ["without", 1472], ["atrophic", 1480], ["scarring", 1489], [".", 1497], ["Tenascin", 1499], ["-", 1507], ["X", 1508], ["mutations", 1510], ["were", 1520], ["identified", 1525], ["in", 1536], ["all", 1539], ["tenascin", 1543], ["-", 1551], ["X", 1552], ["-", 1553], ["deficient", 1554], ["patients", 1564], [";", 1572], ["one", 1574], ["patient", 1578], ["had", 1586], ["a", 1590], ["homozygous", 1592], ["tenascin", 1603], ["-", 1611], ["X", 1612], ["gene", 1614], ["deletion", 1619], [",", 1627], ["one", 1629], ["was", 1633], ["heterozygous", 1637], ["for", 1650], ["the", 1654], ["deletion", 1658], [",", 1666], ["and", 1668], ["three", 1672], ["others", 1678], ["had", 1685], ["homozygous", 1689], ["truncating", 1700], ["point", 1711], ["mutations", 1717], [",", 1726], ["confirming", 1728], ["a", 1739], ["causative", 1741], ["role", 1751], ["for", 1756], ["tenascin", 1760], ["-", 1768], ["X", 1769], ["and", 1771], ["a", 1775], ["recessive", 1777], ["pattern", 1787], ["of", 1795], ["inheritance", 1798], [".", 1809], ["Tenascin", 1811], ["-", 1819], ["X", 1820], ["deficiency", 1822], ["causes", 1833], ["a", 1840], ["clinically", 1842], ["distinct", 1853], [",", 1861], ["recessive", 1863], ["form", 1873], ["of", 1878], ["the", 1881], ["Ehlers", 1885], ["-", 1891], ["Danlos", 1892], ["syndrome", 1899], [".", 1907], ["This", 1909], ["finding", 1914], ["indicates", 1922], ["that", 1932], ["factors", 1937], ["other", 1945], ["than", 1951], ["the", 1956], ["collagens", 1960], ["or", 1970], ["collagen", 1973], ["-", 1981], ["processing", 1982], ["enzymes", 1993], ["can", 2001], ["cause", 2005], ["the", 2011], ["syndrome", 2015], ["and", 2024], ["suggests", 2028], ["a", 2037], ["central", 2039], ["role", 2047], ["for", 2052], ["tenascin", 2056], ["-", 2064], ["X", 2065], ["in", 2067], ["maintaining", 2070], ["the", 2082], ["integrity", 2086], ["of", 2096], ["collagenous", 2099], ["matrix", 2111], [".", 2117]]}
{"context": "Parkinson's disease (PD) and related Lewy body diseases are characterized by deposition of \u03b1-synuclein aggregates in both the central nervous system and peripheral nervous system. Synucleinopathy lesions spread to larger brain areas as the disease progresses, and prion-like cell-to-cell transmission of aggregated \u03b1-synuclein is thought to be the underlying mechanism for this pathological spreading. LRRK2 is another protein linked to the pathogenesis of PD, and its presence in Lewy bodies has attracted much attention as to whether LRRK2 and \u03b1-synuclein interplay during the pathogenesis of PD. However, the relationship between these two crucial proteins still remains unclear. In this review article, we will discuss the current state of knowledge in terms of how these proteins cause the disease and provide the hypothetical mechanisms by which LRRK2 might modify the generation and progression of synucleinopathy.", "qas": [{"question": "Which disease of the central nervous system is characterized by the presence of Lewy bodies?", "answers": ["Parkinson's disease (PD)"], "qid": "ab5ce079faa34a7b97b77449fa304a3f", "question_tokens": [["Which", 0], ["disease", 6], ["of", 14], ["the", 17], ["central", 21], ["nervous", 29], ["system", 37], ["is", 44], ["characterized", 47], ["by", 61], ["the", 64], ["presence", 68], ["of", 77], ["Lewy", 80], ["bodies", 85], ["?", 91]], "detected_answers": [{"text": "Parkinson's disease (PD)", "token_spans": [[0, 4]], "char_spans": [[0, 22]]}]}], "context_tokens": [["Parkinson", 0], ["'s", 9], ["disease", 12], ["(", 20], ["PD", 21], [")", 23], ["and", 25], ["related", 29], ["Lewy", 37], ["body", 42], ["diseases", 47], ["are", 56], ["characterized", 60], ["by", 74], ["deposition", 77], ["of", 88], ["\u03b1", 91], ["-", 92], ["synuclein", 93], ["aggregates", 103], ["in", 114], ["both", 117], ["the", 122], ["central", 126], ["nervous", 134], ["system", 142], ["and", 149], ["peripheral", 153], ["nervous", 164], ["system", 172], [".", 178], ["Synucleinopathy", 180], ["lesions", 196], ["spread", 204], ["to", 211], ["larger", 214], ["brain", 221], ["areas", 227], ["as", 233], ["the", 236], ["disease", 240], ["progresses", 248], [",", 258], ["and", 260], ["prion", 264], ["-", 269], ["like", 270], ["cell", 275], ["-", 279], ["to", 280], ["-", 282], ["cell", 283], ["transmission", 288], ["of", 301], ["aggregated", 304], ["\u03b1", 315], ["-", 316], ["synuclein", 317], ["is", 327], ["thought", 330], ["to", 338], ["be", 341], ["the", 344], ["underlying", 348], ["mechanism", 359], ["for", 369], ["this", 373], ["pathological", 378], ["spreading", 391], [".", 400], ["LRRK2", 402], ["is", 408], ["another", 411], ["protein", 419], ["linked", 427], ["to", 434], ["the", 437], ["pathogenesis", 441], ["of", 454], ["PD", 457], [",", 459], ["and", 461], ["its", 465], ["presence", 469], ["in", 478], ["Lewy", 481], ["bodies", 486], ["has", 493], ["attracted", 497], ["much", 507], ["attention", 512], ["as", 522], ["to", 525], ["whether", 528], ["LRRK2", 536], ["and", 542], ["\u03b1", 546], ["-", 547], ["synuclein", 548], ["interplay", 558], ["during", 568], ["the", 575], ["pathogenesis", 579], ["of", 592], ["PD", 595], [".", 597], ["However", 599], [",", 606], ["the", 608], ["relationship", 612], ["between", 625], ["these", 633], ["two", 639], ["crucial", 643], ["proteins", 651], ["still", 660], ["remains", 666], ["unclear", 674], [".", 681], ["In", 683], ["this", 686], ["review", 691], ["article", 698], [",", 705], ["we", 707], ["will", 710], ["discuss", 715], ["the", 723], ["current", 727], ["state", 735], ["of", 741], ["knowledge", 744], ["in", 754], ["terms", 757], ["of", 763], ["how", 766], ["these", 770], ["proteins", 776], ["cause", 785], ["the", 791], ["disease", 795], ["and", 803], ["provide", 807], ["the", 815], ["hypothetical", 819], ["mechanisms", 832], ["by", 843], ["which", 846], ["LRRK2", 852], ["might", 858], ["modify", 864], ["the", 871], ["generation", 875], ["and", 886], ["progression", 890], ["of", 902], ["synucleinopathy", 905], [".", 920]]}
{"context": "One of the primary criticismes of vestibular schwannoma (VS) radiosurgery is that the risk of surgical morbidity is increased for patients whose tumor progresses after the procedures. We reviewed the French experience of operated patients after failed Gamma Knife radiosurgery. From July 1992 to January 2002, 25 out of the 1000 treated patients underwent another treatment procedure for a gamma knife failure. Excluding the NF2 patients, 21 patients have been operated and the present study shows the data collected for 20 of them. In order to analyze the difficulties observed during the surgery, a questionnaire was filled by the surgeons. The mean interval between radiosurgery and removal was 36 Months, from 10 to 83 Months. The mean increase in Volume was 559% (37 to 3036%, median 160%). Evolution of the Koos grading was found from 8 grade II, 10 grade III et 2 grade IV to 10 grade III and 10 grade IV. Patients have been operated for radiological tumor growth in 7 cases and for clinico-radiological evolution in 13 cases. In 9 cases, the surgeon considered that he had to face unusual difficulties mainly because of adhesion of the tumor to neurovascular structures. Tumor removal was total in 14 cases, near total in 4 cases and subtotal in 2 cases. One case of venous infarction was noticed at the second day following surgery responsible of hemiparesis and aphasia that gradually recovered. At last follow-up examination, facial nerve was normal (House and Brackmann grade I and II) in 10 cases while it was a grade III in 7 cases and grade IV and V in 3 cases. We recommend that the decision for surgical removal of growing vestibular schwannoma after Gamma Knife treatment should be done after a sufficiently long follow-up period. Our results show that the quality of removal and of facial nerve preservation might be impaired by radiosurgery in half of cases. However these results do not support a change in our policy of radiosurgical treatment of small to medium size vestibular schwannoma.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "82b7ad0ac3da45f8850154988038abc3", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[312, 313], [6, 7], [372, 373]], "char_spans": [[1640, 1660], [34, 54], [1990, 2010]]}]}], "context_tokens": [["One", 0], ["of", 4], ["the", 7], ["primary", 11], ["criticismes", 19], ["of", 31], ["vestibular", 34], ["schwannoma", 45], ["(", 56], ["VS", 57], [")", 59], ["radiosurgery", 61], ["is", 74], ["that", 77], ["the", 82], ["risk", 86], ["of", 91], ["surgical", 94], ["morbidity", 103], ["is", 113], ["increased", 116], ["for", 126], ["patients", 130], ["whose", 139], ["tumor", 145], ["progresses", 151], ["after", 162], ["the", 168], ["procedures", 172], [".", 182], ["We", 184], ["reviewed", 187], ["the", 196], ["French", 200], ["experience", 207], ["of", 218], ["operated", 221], ["patients", 230], ["after", 239], ["failed", 245], ["Gamma", 252], ["Knife", 258], ["radiosurgery", 264], [".", 276], ["From", 278], ["July", 283], ["1992", 288], ["to", 293], ["January", 296], ["2002", 304], [",", 308], ["25", 310], ["out", 313], ["of", 317], ["the", 320], ["1000", 324], ["treated", 329], ["patients", 337], ["underwent", 346], ["another", 356], ["treatment", 364], ["procedure", 374], ["for", 384], ["a", 388], ["gamma", 390], ["knife", 396], ["failure", 402], [".", 409], ["Excluding", 411], ["the", 421], ["NF2", 425], ["patients", 429], [",", 437], ["21", 439], ["patients", 442], ["have", 451], ["been", 456], ["operated", 461], ["and", 470], ["the", 474], ["present", 478], ["study", 486], ["shows", 492], ["the", 498], ["data", 502], ["collected", 507], ["for", 517], ["20", 521], ["of", 524], ["them", 527], [".", 531], ["In", 533], ["order", 536], ["to", 542], ["analyze", 545], ["the", 553], ["difficulties", 557], ["observed", 570], ["during", 579], ["the", 586], ["surgery", 590], [",", 597], ["a", 599], ["questionnaire", 601], ["was", 615], ["filled", 619], ["by", 626], ["the", 629], ["surgeons", 633], [".", 641], ["The", 643], ["mean", 647], ["interval", 652], ["between", 661], ["radiosurgery", 669], ["and", 682], ["removal", 686], ["was", 694], ["36", 698], ["Months", 701], [",", 707], ["from", 709], ["10", 714], ["to", 717], ["83", 720], ["Months", 723], [".", 729], ["The", 731], ["mean", 735], ["increase", 740], ["in", 749], ["Volume", 752], ["was", 759], ["559", 763], ["%", 766], ["(", 768], ["37", 769], ["to", 772], ["3036", 775], ["%", 779], [",", 780], ["median", 782], ["160", 789], ["%", 792], [")", 793], [".", 794], ["Evolution", 796], ["of", 806], ["the", 809], ["Koos", 813], ["grading", 818], ["was", 826], ["found", 830], ["from", 836], ["8", 841], ["grade", 843], ["II", 849], [",", 851], ["10", 853], ["grade", 856], ["III", 862], ["et", 866], ["2", 869], ["grade", 871], ["IV", 877], ["to", 880], ["10", 883], ["grade", 886], ["III", 892], ["and", 896], ["10", 900], ["grade", 903], ["IV", 909], [".", 911], ["Patients", 913], ["have", 922], ["been", 927], ["operated", 932], ["for", 941], ["radiological", 945], ["tumor", 958], ["growth", 964], ["in", 971], ["7", 974], ["cases", 976], ["and", 982], ["for", 986], ["clinico", 990], ["-", 997], ["radiological", 998], ["evolution", 1011], ["in", 1021], ["13", 1024], ["cases", 1027], [".", 1032], ["In", 1034], ["9", 1037], ["cases", 1039], [",", 1044], ["the", 1046], ["surgeon", 1050], ["considered", 1058], ["that", 1069], ["he", 1074], ["had", 1077], ["to", 1081], ["face", 1084], ["unusual", 1089], ["difficulties", 1097], ["mainly", 1110], ["because", 1117], ["of", 1125], ["adhesion", 1128], ["of", 1137], ["the", 1140], ["tumor", 1144], ["to", 1150], ["neurovascular", 1153], ["structures", 1167], [".", 1177], ["Tumor", 1179], ["removal", 1185], ["was", 1193], ["total", 1197], ["in", 1203], ["14", 1206], ["cases", 1209], [",", 1214], ["near", 1216], ["total", 1221], ["in", 1227], ["4", 1230], ["cases", 1232], ["and", 1238], ["subtotal", 1242], ["in", 1251], ["2", 1254], ["cases", 1256], [".", 1261], ["One", 1263], ["case", 1267], ["of", 1272], ["venous", 1275], ["infarction", 1282], ["was", 1293], ["noticed", 1297], ["at", 1305], ["the", 1308], ["second", 1312], ["day", 1319], ["following", 1323], ["surgery", 1333], ["responsible", 1341], ["of", 1353], ["hemiparesis", 1356], ["and", 1368], ["aphasia", 1372], ["that", 1380], ["gradually", 1385], ["recovered", 1395], [".", 1404], ["At", 1406], ["last", 1409], ["follow", 1414], ["-", 1420], ["up", 1421], ["examination", 1424], [",", 1435], ["facial", 1437], ["nerve", 1444], ["was", 1450], ["normal", 1454], ["(", 1461], ["House", 1462], ["and", 1468], ["Brackmann", 1472], ["grade", 1482], ["I", 1488], ["and", 1490], ["II", 1494], [")", 1496], ["in", 1498], ["10", 1501], ["cases", 1504], ["while", 1510], ["it", 1516], ["was", 1519], ["a", 1523], ["grade", 1525], ["III", 1531], ["in", 1535], ["7", 1538], ["cases", 1540], ["and", 1546], ["grade", 1550], ["IV", 1556], ["and", 1559], ["V", 1563], ["in", 1565], ["3", 1568], ["cases", 1570], [".", 1575], ["We", 1577], ["recommend", 1580], ["that", 1590], ["the", 1595], ["decision", 1599], ["for", 1608], ["surgical", 1612], ["removal", 1621], ["of", 1629], ["growing", 1632], ["vestibular", 1640], ["schwannoma", 1651], ["after", 1662], ["Gamma", 1668], ["Knife", 1674], ["treatment", 1680], ["should", 1690], ["be", 1697], ["done", 1700], ["after", 1705], ["a", 1711], ["sufficiently", 1713], ["long", 1726], ["follow", 1731], ["-", 1737], ["up", 1738], ["period", 1741], [".", 1747], ["Our", 1749], ["results", 1753], ["show", 1761], ["that", 1766], ["the", 1771], ["quality", 1775], ["of", 1783], ["removal", 1786], ["and", 1794], ["of", 1798], ["facial", 1801], ["nerve", 1808], ["preservation", 1814], ["might", 1827], ["be", 1833], ["impaired", 1836], ["by", 1845], ["radiosurgery", 1848], ["in", 1861], ["half", 1864], ["of", 1869], ["cases", 1872], [".", 1877], ["However", 1879], ["these", 1887], ["results", 1893], ["do", 1901], ["not", 1904], ["support", 1908], ["a", 1916], ["change", 1918], ["in", 1925], ["our", 1928], ["policy", 1932], ["of", 1939], ["radiosurgical", 1942], ["treatment", 1956], ["of", 1966], ["small", 1969], ["to", 1975], ["medium", 1978], ["size", 1985], ["vestibular", 1990], ["schwannoma", 2001], [".", 2011]]}
{"context": "The aim of the present study was to investigate the antibiotic susceptibility patterns and molecular epidemiology of clinical methicillin-resistant Staphylococcus aureus (MRSA) isolates recovered in 24 hospitals in 20 cities in Croatia from October to December 2004. A total of 1815 consecutive S. aureus isolates were recovered, 248 of which were MRSA. The MRSA isolates were analysed using spa typing, multilocus sequence typing and SCCmec typing. Furthermore, the presence of Panton-Valentine leukocidin (PVL) genes was determined as a genetic marker for community-associated MRSA. The MRSA prevalence was 14%. Ninety-six per cent of the MRSA isolates were resistant to ciprofloxacin, 95% to clindamycin and azithromycin, 94% to gentamicin, and 93% to erythromycin. The majority of the MRSA isolates (78%) was associated with the ST111-MRSA-I clone. In addition, various other endemic MRSA clones were observed, such as the ST247-MRSA-I (4%), the ST45-MRSA-IV (2%), the ST5-MRSA-I (2%), the ST239-MRSA-III (2%), the ST5-MRSA-II (1%), the ST8-MRSA-IV (1%) and the ST5-MRSA-IV (<1%) clones. Furthermore, we observed one PVL-negative ST80-MRSA-IV isolate. Four PVL-positive MRSA isolates were found, associated with ST8-MRSA-IV, ST80-MRSA-IV and ST80-MRSA-I. The ST111-MRSA-I clone was predominant in Croatia. Future surveillance studies of MRSA are important to elucidate whether changes in the clonal distribution of MRSA will occur, and if the minor endemic MRSA clones observed in the present study will replace the ST111-MRSA-I clone on a large scale.", "qas": [{"question": "What is MRSA?", "answers": ["methicillin-resistant S. aureus", "MRSA"], "qid": "d763f93b6e6f410da3bf3ba40aa856aa", "question_tokens": [["What", 0], ["is", 5], ["MRSA", 8], ["?", 12]], "detected_answers": [{"text": "MRSA", "token_spans": [[114, 114], [101, 101], [253, 253], [285, 285], [60, 60], [164, 164], [57, 57], [297, 297], [24, 24], [306, 306], [98, 98], [143, 143]], "char_spans": [[641, 644], [589, 592], [1174, 1177], [1341, 1344], [358, 361], [888, 891], [348, 351], [1419, 1422], [171, 174], [1461, 1464], [579, 582], [789, 792]]}]}], "context_tokens": [["The", 0], ["aim", 4], ["of", 8], ["the", 11], ["present", 15], ["study", 23], ["was", 29], ["to", 33], ["investigate", 36], ["the", 48], ["antibiotic", 52], ["susceptibility", 63], ["patterns", 78], ["and", 87], ["molecular", 91], ["epidemiology", 101], ["of", 114], ["clinical", 117], ["methicillin", 126], ["-", 137], ["resistant", 138], ["Staphylococcus", 148], ["aureus", 163], ["(", 170], ["MRSA", 171], [")", 175], ["isolates", 177], ["recovered", 186], ["in", 196], ["24", 199], ["hospitals", 202], ["in", 212], ["20", 215], ["cities", 218], ["in", 225], ["Croatia", 228], ["from", 236], ["October", 241], ["to", 249], ["December", 252], ["2004", 261], [".", 265], ["A", 267], ["total", 269], ["of", 275], ["1815", 278], ["consecutive", 283], ["S.", 295], ["aureus", 298], ["isolates", 305], ["were", 314], ["recovered", 319], [",", 328], ["248", 330], ["of", 334], ["which", 337], ["were", 343], ["MRSA", 348], [".", 352], ["The", 354], ["MRSA", 358], ["isolates", 363], ["were", 372], ["analysed", 377], ["using", 386], ["spa", 392], ["typing", 396], [",", 402], ["multilocus", 404], ["sequence", 415], ["typing", 424], ["and", 431], ["SCCmec", 435], ["typing", 442], [".", 448], ["Furthermore", 450], [",", 461], ["the", 463], ["presence", 467], ["of", 476], ["Panton", 479], ["-", 485], ["Valentine", 486], ["leukocidin", 496], ["(", 507], ["PVL", 508], [")", 511], ["genes", 513], ["was", 519], ["determined", 523], ["as", 534], ["a", 537], ["genetic", 539], ["marker", 547], ["for", 554], ["community", 558], ["-", 567], ["associated", 568], ["MRSA", 579], [".", 583], ["The", 585], ["MRSA", 589], ["prevalence", 594], ["was", 605], ["14", 609], ["%", 611], [".", 612], ["Ninety", 614], ["-", 620], ["six", 621], ["per", 625], ["cent", 629], ["of", 634], ["the", 637], ["MRSA", 641], ["isolates", 646], ["were", 655], ["resistant", 660], ["to", 670], ["ciprofloxacin", 673], [",", 686], ["95", 688], ["%", 690], ["to", 692], ["clindamycin", 695], ["and", 707], ["azithromycin", 711], [",", 723], ["94", 725], ["%", 727], ["to", 729], ["gentamicin", 732], [",", 742], ["and", 744], ["93", 748], ["%", 750], ["to", 752], ["erythromycin", 755], [".", 767], ["The", 769], ["majority", 773], ["of", 782], ["the", 785], ["MRSA", 789], ["isolates", 794], ["(", 803], ["78", 804], ["%", 806], [")", 807], ["was", 809], ["associated", 813], ["with", 824], ["the", 829], ["ST111-MRSA", 833], ["-", 843], ["I", 844], ["clone", 846], [".", 851], ["In", 853], ["addition", 856], [",", 864], ["various", 866], ["other", 874], ["endemic", 880], ["MRSA", 888], ["clones", 893], ["were", 900], ["observed", 905], [",", 913], ["such", 915], ["as", 920], ["the", 923], ["ST247-MRSA", 927], ["-", 937], ["I", 938], ["(", 940], ["4", 941], ["%", 942], [")", 943], [",", 944], ["the", 946], ["ST45-MRSA", 950], ["-", 959], ["IV", 960], ["(", 963], ["2", 964], ["%", 965], [")", 966], [",", 967], ["the", 969], ["ST5-MRSA", 973], ["-", 981], ["I", 982], ["(", 984], ["2", 985], ["%", 986], [")", 987], [",", 988], ["the", 990], ["ST239-MRSA", 994], ["-", 1004], ["III", 1005], ["(", 1009], ["2", 1010], ["%", 1011], [")", 1012], [",", 1013], ["the", 1015], ["ST5-MRSA", 1019], ["-", 1027], ["II", 1028], ["(", 1031], ["1", 1032], ["%", 1033], [")", 1034], [",", 1035], ["the", 1037], ["ST8-MRSA", 1041], ["-", 1049], ["IV", 1050], ["(", 1053], ["1", 1054], ["%", 1055], [")", 1056], ["and", 1058], ["the", 1062], ["ST5-MRSA", 1066], ["-", 1074], ["IV", 1075], ["(", 1078], ["<", 1079], ["1", 1080], ["%", 1081], [")", 1082], ["clones", 1084], [".", 1090], ["Furthermore", 1092], [",", 1103], ["we", 1105], ["observed", 1108], ["one", 1117], ["PVL", 1121], ["-", 1124], ["negative", 1125], ["ST80-MRSA", 1134], ["-", 1143], ["IV", 1144], ["isolate", 1147], [".", 1154], ["Four", 1156], ["PVL", 1161], ["-", 1164], ["positive", 1165], ["MRSA", 1174], ["isolates", 1179], ["were", 1188], ["found", 1193], [",", 1198], ["associated", 1200], ["with", 1211], ["ST8-MRSA", 1216], ["-", 1224], ["IV", 1225], [",", 1227], ["ST80-MRSA", 1229], ["-", 1238], ["IV", 1239], ["and", 1242], ["ST80-MRSA", 1246], ["-", 1255], ["I.", 1256], ["The", 1259], ["ST111-MRSA", 1263], ["-", 1273], ["I", 1274], ["clone", 1276], ["was", 1282], ["predominant", 1286], ["in", 1298], ["Croatia", 1301], [".", 1308], ["Future", 1310], ["surveillance", 1317], ["studies", 1330], ["of", 1338], ["MRSA", 1341], ["are", 1346], ["important", 1350], ["to", 1360], ["elucidate", 1363], ["whether", 1373], ["changes", 1381], ["in", 1389], ["the", 1392], ["clonal", 1396], ["distribution", 1403], ["of", 1416], ["MRSA", 1419], ["will", 1424], ["occur", 1429], [",", 1434], ["and", 1436], ["if", 1440], ["the", 1443], ["minor", 1447], ["endemic", 1453], ["MRSA", 1461], ["clones", 1466], ["observed", 1473], ["in", 1482], ["the", 1485], ["present", 1489], ["study", 1497], ["will", 1503], ["replace", 1508], ["the", 1516], ["ST111-MRSA", 1520], ["-", 1530], ["I", 1531], ["clone", 1533], ["on", 1539], ["a", 1542], ["large", 1544], ["scale", 1550], [".", 1555]]}
{"context": "RNA editing is proposed as a modulator of transcriptomes, but its biological impact has not been fully elucidated. In particular, its importance for transposable elements is controversial. We found RNA editing on antisense read-through transcripts of KP elements, one of the deletion derivatives of P transposable elements in Drosophila melanogaster. Three kinds of RNA editing were detected at 20 sites around the terminal inverted repeats (TIR); 15 A-to-G, four U-to-C, and one C-to-U conversions. A-to-G conversions are suggested to be attributed to A-to-I RNA editing on KP element RNAs, because inosine (I) in RNA is recognized as G by reverse transcriptase. TIRs were deduced to form dsRNAs as a putative target of ADAR. This is the first report of RNA editing on mobile elements of Drosophila.", "qas": [{"question": "Which is the major RNA editing enzyme in Drosophila melanogaster?", "answers": ["ADAR", "adenosine deaminase, RNA-specific"], "qid": "ed3c30f4b2954727ac67c7b6e40750c9", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["major", 13], ["RNA", 19], ["editing", 23], ["enzyme", 31], ["in", 38], ["Drosophila", 41], ["melanogaster", 52], ["?", 64]], "detected_answers": [{"text": "ADAR", "token_spans": [[150, 150]], "char_spans": [[721, 724]]}]}], "context_tokens": [["RNA", 0], ["editing", 4], ["is", 12], ["proposed", 15], ["as", 24], ["a", 27], ["modulator", 29], ["of", 39], ["transcriptomes", 42], [",", 56], ["but", 58], ["its", 62], ["biological", 66], ["impact", 77], ["has", 84], ["not", 88], ["been", 92], ["fully", 97], ["elucidated", 103], [".", 113], ["In", 115], ["particular", 118], [",", 128], ["its", 130], ["importance", 134], ["for", 145], ["transposable", 149], ["elements", 162], ["is", 171], ["controversial", 174], [".", 187], ["We", 189], ["found", 192], ["RNA", 198], ["editing", 202], ["on", 210], ["antisense", 213], ["read", 223], ["-", 227], ["through", 228], ["transcripts", 236], ["of", 248], ["KP", 251], ["elements", 254], [",", 262], ["one", 264], ["of", 268], ["the", 271], ["deletion", 275], ["derivatives", 284], ["of", 296], ["P", 299], ["transposable", 301], ["elements", 314], ["in", 323], ["Drosophila", 326], ["melanogaster", 337], [".", 349], ["Three", 351], ["kinds", 357], ["of", 363], ["RNA", 366], ["editing", 370], ["were", 378], ["detected", 383], ["at", 392], ["20", 395], ["sites", 398], ["around", 404], ["the", 411], ["terminal", 415], ["inverted", 424], ["repeats", 433], ["(", 441], ["TIR", 442], [")", 445], [";", 446], ["15", 448], ["A", 451], ["-", 452], ["to", 453], ["-", 455], ["G", 456], [",", 457], ["four", 459], ["U", 464], ["-", 465], ["to", 466], ["-", 468], ["C", 469], [",", 470], ["and", 472], ["one", 476], ["C", 480], ["-", 481], ["to", 482], ["-", 484], ["U", 485], ["conversions", 487], [".", 498], ["A", 500], ["-", 501], ["to", 502], ["-", 504], ["G", 505], ["conversions", 507], ["are", 519], ["suggested", 523], ["to", 533], ["be", 536], ["attributed", 539], ["to", 550], ["A", 553], ["-", 554], ["to", 555], ["-", 557], ["I", 558], ["RNA", 560], ["editing", 564], ["on", 572], ["KP", 575], ["element", 578], ["RNAs", 586], [",", 590], ["because", 592], ["inosine", 600], ["(", 608], ["I", 609], [")", 610], ["in", 612], ["RNA", 615], ["is", 619], ["recognized", 622], ["as", 633], ["G", 636], ["by", 638], ["reverse", 641], ["transcriptase", 649], [".", 662], ["TIRs", 664], ["were", 669], ["deduced", 674], ["to", 682], ["form", 685], ["dsRNAs", 690], ["as", 697], ["a", 700], ["putative", 702], ["target", 711], ["of", 718], ["ADAR", 721], [".", 725], ["This", 727], ["is", 732], ["the", 735], ["first", 739], ["report", 745], ["of", 752], ["RNA", 755], ["editing", 759], ["on", 767], ["mobile", 770], ["elements", 777], ["of", 786], ["Drosophila", 789], [".", 799]]}
{"context": "Interleukin-1\u03b2 (IL-1\u03b2) is a key orchestrator in inflammatory and several immune responses. IL-1\u03b2 exerts its effects through interleukin-1 receptor type I (IL-1RI) and interleukin-1 receptor accessory protein (IL-1RAcP), which together form a heterotrimeric signaling-competent complex. Canakinumab and gevokizumab are highly specific IL-1\u03b2 monoclonal antibodies. Canakinumab is known to neutralize IL-1\u03b2 by competing for binding to IL-1R and therefore blocking signaling by the antigen:antibody complex. Gevokizumab is claimed to be a regulatory therapeutic antibody that modulates IL-1\u03b2 bioactivity by reducing the affinity for its IL-1RI:IL-1RAcP signaling complex. How IL-1\u03b2 signaling is affected by both canakinumab and gevokizumab was not yet experimentally determined. We have analyzed the crystal structures of canakinumab and gevokizumab antibody binding fragment (Fab) as well as of their binary complexes with IL-1\u03b2. Furthermore, we characterized the epitopes on IL-1\u03b2 employed by the antibodies by NMR epitope mapping studies. The direct comparison of NMR and X-ray data shows that the epitope defined by the crystal structure encompasses predominantly those residues whose NMR resonances are severely perturbed upon complex formation. The antigen:Fab co-structures confirm the previously identified key contact residues on IL-1\u03b2 and provide insight into the mechanisms leading to their distinct modulation of IL-1\u03b2 signaling. A significant steric overlap of the binding interfaces of IL-1R and canakinumab on IL-1\u03b2 causes competitive inhibition of the association of IL-1\u03b2 and its receptor. In contrast, gevokizumab occupies an allosteric site on IL-1\u03b2 and complex formation results in a minor reduction of binding affinity to IL-1RI. This suggests two different mechanisms of IL-1\u03b2 pathway attenuation.", "qas": [{"question": "Which molecule is targeted by the drug Gevokizumab?", "answers": ["IL-1\u03b2"], "qid": "2f0cee196ddb4065924495ca24e444df", "question_tokens": [["Which", 0], ["molecule", 6], ["is", 15], ["targeted", 18], ["by", 27], ["the", 30], ["drug", 34], ["Gevokizumab", 39], ["?", 50]], "detected_answers": [{"text": "IL-1\u03b2", "token_spans": [[144, 144], [61, 61], [90, 90], [52, 52], [212, 212], [105, 105], [153, 153], [249, 249], [263, 263], [284, 284], [225, 225], [2, 2], [15, 15], [241, 241]], "char_spans": [[920, 924], [398, 402], [582, 586], [334, 338], [1335, 1339], [672, 676], [973, 977], [1579, 1583], [1659, 1663], [1789, 1793], [1421, 1425], [16, 20], [91, 95], [1521, 1525]]}]}], "context_tokens": [["Interleukin-1\u03b2", 0], ["(", 15], ["IL-1\u03b2", 16], [")", 21], ["is", 23], ["a", 26], ["key", 28], ["orchestrator", 32], ["in", 45], ["inflammatory", 48], ["and", 61], ["several", 65], ["immune", 73], ["responses", 80], [".", 89], ["IL-1\u03b2", 91], ["exerts", 97], ["its", 104], ["effects", 108], ["through", 116], ["interleukin-1", 124], ["receptor", 138], ["type", 147], ["I", 152], ["(", 154], ["IL-1RI", 155], [")", 161], ["and", 163], ["interleukin-1", 167], ["receptor", 181], ["accessory", 190], ["protein", 200], ["(", 208], ["IL-1RAcP", 209], [")", 217], [",", 218], ["which", 220], ["together", 226], ["form", 235], ["a", 240], ["heterotrimeric", 242], ["signaling", 257], ["-", 266], ["competent", 267], ["complex", 277], [".", 284], ["Canakinumab", 286], ["and", 298], ["gevokizumab", 302], ["are", 314], ["highly", 318], ["specific", 325], ["IL-1\u03b2", 334], ["monoclonal", 340], ["antibodies", 351], [".", 361], ["Canakinumab", 363], ["is", 375], ["known", 378], ["to", 384], ["neutralize", 387], ["IL-1\u03b2", 398], ["by", 404], ["competing", 407], ["for", 417], ["binding", 421], ["to", 429], ["IL-1R", 432], ["and", 438], ["therefore", 442], ["blocking", 452], ["signaling", 461], ["by", 471], ["the", 474], ["antigen", 478], [":", 485], ["antibody", 486], ["complex", 495], [".", 502], ["Gevokizumab", 504], ["is", 516], ["claimed", 519], ["to", 527], ["be", 530], ["a", 533], ["regulatory", 535], ["therapeutic", 546], ["antibody", 558], ["that", 567], ["modulates", 572], ["IL-1\u03b2", 582], ["bioactivity", 588], ["by", 600], ["reducing", 603], ["the", 612], ["affinity", 616], ["for", 625], ["its", 629], ["IL-1RI", 633], [":", 639], ["IL-1RAcP", 640], ["signaling", 649], ["complex", 659], [".", 666], ["How", 668], ["IL-1\u03b2", 672], ["signaling", 678], ["is", 688], ["affected", 691], ["by", 700], ["both", 703], ["canakinumab", 708], ["and", 720], ["gevokizumab", 724], ["was", 736], ["not", 740], ["yet", 744], ["experimentally", 748], ["determined", 763], [".", 773], ["We", 775], ["have", 778], ["analyzed", 783], ["the", 792], ["crystal", 796], ["structures", 804], ["of", 815], ["canakinumab", 818], ["and", 830], ["gevokizumab", 834], ["antibody", 846], ["binding", 855], ["fragment", 863], ["(", 872], ["Fab", 873], [")", 876], ["as", 878], ["well", 881], ["as", 886], ["of", 889], ["their", 892], ["binary", 898], ["complexes", 905], ["with", 915], ["IL-1\u03b2", 920], [".", 925], ["Furthermore", 927], [",", 938], ["we", 940], ["characterized", 943], ["the", 957], ["epitopes", 961], ["on", 970], ["IL-1\u03b2", 973], ["employed", 979], ["by", 988], ["the", 991], ["antibodies", 995], ["by", 1006], ["NMR", 1009], ["epitope", 1013], ["mapping", 1021], ["studies", 1029], [".", 1036], ["The", 1038], ["direct", 1042], ["comparison", 1049], ["of", 1060], ["NMR", 1063], ["and", 1067], ["X", 1071], ["-", 1072], ["ray", 1073], ["data", 1077], ["shows", 1082], ["that", 1088], ["the", 1093], ["epitope", 1097], ["defined", 1105], ["by", 1113], ["the", 1116], ["crystal", 1120], ["structure", 1128], ["encompasses", 1138], ["predominantly", 1150], ["those", 1164], ["residues", 1170], ["whose", 1179], ["NMR", 1185], ["resonances", 1189], ["are", 1200], ["severely", 1204], ["perturbed", 1213], ["upon", 1223], ["complex", 1228], ["formation", 1236], [".", 1245], ["The", 1247], ["antigen", 1251], [":", 1258], ["Fab", 1259], ["co", 1263], ["-", 1265], ["structures", 1266], ["confirm", 1277], ["the", 1285], ["previously", 1289], ["identified", 1300], ["key", 1311], ["contact", 1315], ["residues", 1323], ["on", 1332], ["IL-1\u03b2", 1335], ["and", 1341], ["provide", 1345], ["insight", 1353], ["into", 1361], ["the", 1366], ["mechanisms", 1370], ["leading", 1381], ["to", 1389], ["their", 1392], ["distinct", 1398], ["modulation", 1407], ["of", 1418], ["IL-1\u03b2", 1421], ["signaling", 1427], [".", 1436], ["A", 1438], ["significant", 1440], ["steric", 1452], ["overlap", 1459], ["of", 1467], ["the", 1470], ["binding", 1474], ["interfaces", 1482], ["of", 1493], ["IL-1R", 1496], ["and", 1502], ["canakinumab", 1506], ["on", 1518], ["IL-1\u03b2", 1521], ["causes", 1527], ["competitive", 1534], ["inhibition", 1546], ["of", 1557], ["the", 1560], ["association", 1564], ["of", 1576], ["IL-1\u03b2", 1579], ["and", 1585], ["its", 1589], ["receptor", 1593], [".", 1601], ["In", 1603], ["contrast", 1606], [",", 1614], ["gevokizumab", 1616], ["occupies", 1628], ["an", 1637], ["allosteric", 1640], ["site", 1651], ["on", 1656], ["IL-1\u03b2", 1659], ["and", 1665], ["complex", 1669], ["formation", 1677], ["results", 1687], ["in", 1695], ["a", 1698], ["minor", 1700], ["reduction", 1706], ["of", 1716], ["binding", 1719], ["affinity", 1727], ["to", 1736], ["IL-1RI", 1739], [".", 1745], ["This", 1747], ["suggests", 1752], ["two", 1761], ["different", 1765], ["mechanisms", 1775], ["of", 1786], ["IL-1\u03b2", 1789], ["pathway", 1795], ["attenuation", 1803], [".", 1814]]}
{"context": "Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, which causes progressive and eventually fatal loss of motor function. Here, we describe genetic and pathologic characterization of brain tissue banked from 19 ALS patients over nearly 20\u00a0years at the Department of Anatomy and the Centre for Brain Research, University of Auckland, New Zealand. We screened for mutations in SOD1, TARDBP, FUS, and C9ORF72 genes and for neuropathology caused by phosphorylated TDP-43, dipeptide repeats (DPRs), and ubiquilin. We identified 2 cases with C9ORF72 repeat expansions. Both harbored phosphorylated TDP-43 and DPR inclusions. We show that DPR inclusions can incorporate or occur independently of ubiquilin. We also identified 1 case with a UBQLN2 mutation, which showed phosphorylated TDP-43 and characteristic ubiquilin protein inclusions. This is the first study of ALS genetics in New Zealand, adding New Zealand to the growing list of countries in which C9ORF72 repeat expansion and UBQLN2 mutations are detected in ALS cases.", "qas": [{"question": "Which human disease is associated with mutated UBQLN2", "answers": ["ALS", "amyotrophic lateral sclerosis"], "qid": "56561ee2c5e6437da905d1d0cb1db046", "question_tokens": [["Which", 0], ["human", 6], ["disease", 12], ["is", 20], ["associated", 23], ["with", 34], ["mutated", 39], ["UBQLN2", 47]], "detected_answers": [{"text": "ALS", "token_spans": [[175, 175], [4, 4], [37, 37], [149, 149]], "char_spans": [[1041, 1043], [31, 33], [239, 241], [889, 891]]}, {"text": "amyotrophic lateral sclerosis", "token_spans": [[0, 2]], "char_spans": [[0, 28]]}]}], "context_tokens": [["Amyotrophic", 0], ["lateral", 12], ["sclerosis", 20], ["(", 30], ["ALS", 31], [")", 34], ["is", 36], ["a", 39], ["devastating", 41], ["neurodegenerative", 53], ["disease", 71], [",", 78], ["which", 80], ["causes", 86], ["progressive", 93], ["and", 105], ["eventually", 109], ["fatal", 120], ["loss", 126], ["of", 131], ["motor", 134], ["function", 140], [".", 148], ["Here", 150], [",", 154], ["we", 156], ["describe", 159], ["genetic", 168], ["and", 176], ["pathologic", 180], ["characterization", 191], ["of", 208], ["brain", 211], ["tissue", 217], ["banked", 224], ["from", 231], ["19", 236], ["ALS", 239], ["patients", 243], ["over", 252], ["nearly", 257], ["20", 264], ["years", 267], ["at", 273], ["the", 276], ["Department", 280], ["of", 291], ["Anatomy", 294], ["and", 302], ["the", 306], ["Centre", 310], ["for", 317], ["Brain", 321], ["Research", 327], [",", 335], ["University", 337], ["of", 348], ["Auckland", 351], [",", 359], ["New", 361], ["Zealand", 365], [".", 372], ["We", 374], ["screened", 377], ["for", 386], ["mutations", 390], ["in", 400], ["SOD1", 403], [",", 407], ["TARDBP", 409], [",", 415], ["FUS", 417], [",", 420], ["and", 422], ["C9ORF72", 426], ["genes", 434], ["and", 440], ["for", 444], ["neuropathology", 448], ["caused", 463], ["by", 470], ["phosphorylated", 473], ["TDP-43", 488], [",", 494], ["dipeptide", 496], ["repeats", 506], ["(", 514], ["DPRs", 515], [")", 519], [",", 520], ["and", 522], ["ubiquilin", 526], [".", 535], ["We", 537], ["identified", 540], ["2", 551], ["cases", 553], ["with", 559], ["C9ORF72", 564], ["repeat", 572], ["expansions", 579], [".", 589], ["Both", 591], ["harbored", 596], ["phosphorylated", 605], ["TDP-43", 620], ["and", 627], ["DPR", 631], ["inclusions", 635], [".", 645], ["We", 647], ["show", 650], ["that", 655], ["DPR", 660], ["inclusions", 664], ["can", 675], ["incorporate", 679], ["or", 691], ["occur", 694], ["independently", 700], ["of", 714], ["ubiquilin", 717], [".", 726], ["We", 728], ["also", 731], ["identified", 736], ["1", 747], ["case", 749], ["with", 754], ["a", 759], ["UBQLN2", 761], ["mutation", 768], [",", 776], ["which", 778], ["showed", 784], ["phosphorylated", 791], ["TDP-43", 806], ["and", 813], ["characteristic", 817], ["ubiquilin", 832], ["protein", 842], ["inclusions", 850], [".", 860], ["This", 862], ["is", 867], ["the", 870], ["first", 874], ["study", 880], ["of", 886], ["ALS", 889], ["genetics", 893], ["in", 902], ["New", 905], ["Zealand", 909], [",", 916], ["adding", 918], ["New", 925], ["Zealand", 929], ["to", 937], ["the", 940], ["growing", 944], ["list", 952], ["of", 957], ["countries", 960], ["in", 970], ["which", 973], ["C9ORF72", 979], ["repeat", 987], ["expansion", 994], ["and", 1004], ["UBQLN2", 1008], ["mutations", 1015], ["are", 1025], ["detected", 1029], ["in", 1038], ["ALS", 1041], ["cases", 1045], [".", 1050]]}
{"context": "Flumazenil is a benzodiazepine antagonist. It is widely used as an antidote in comatose patients suspected of having ingested a benzodiazepine overdose. Flumazenil is known to induce cardiac arythmias and seizures, in part because of drug interactions. We present a 75-year-old woman, who was brought to the Emergency Department with a drug overdose following a suicide attempt. She developed generalized seizures shortly after the administration of flumazenil.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "b31d0f65b3754a4091a4d59b39e2a6a4", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[24, 24], [0, 0], [74, 74]], "char_spans": [[153, 162], [0, 9], [450, 459]]}]}], "context_tokens": [["Flumazenil", 0], ["is", 11], ["a", 14], ["benzodiazepine", 16], ["antagonist", 31], [".", 41], ["It", 43], ["is", 46], ["widely", 49], ["used", 56], ["as", 61], ["an", 64], ["antidote", 67], ["in", 76], ["comatose", 79], ["patients", 88], ["suspected", 97], ["of", 107], ["having", 110], ["ingested", 117], ["a", 126], ["benzodiazepine", 128], ["overdose", 143], [".", 151], ["Flumazenil", 153], ["is", 164], ["known", 167], ["to", 173], ["induce", 176], ["cardiac", 183], ["arythmias", 191], ["and", 201], ["seizures", 205], [",", 213], ["in", 215], ["part", 218], ["because", 223], ["of", 231], ["drug", 234], ["interactions", 239], [".", 251], ["We", 253], ["present", 256], ["a", 264], ["75-year", 266], ["-", 273], ["old", 274], ["woman", 278], [",", 283], ["who", 285], ["was", 289], ["brought", 293], ["to", 301], ["the", 304], ["Emergency", 308], ["Department", 318], ["with", 329], ["a", 334], ["drug", 336], ["overdose", 341], ["following", 350], ["a", 360], ["suicide", 362], ["attempt", 370], [".", 377], ["She", 379], ["developed", 383], ["generalized", 393], ["seizures", 405], ["shortly", 414], ["after", 422], ["the", 428], ["administration", 432], ["of", 447], ["flumazenil", 450], [".", 460]]}
{"context": "In neurodegenerative diseases, it remains unclear why certain brain regions are selectively vulnerable to protein aggregation. In transgenic mice expressing human A53T \u03b1-synuclein, the brainstem and spinal cord develop the most prominent \u03b1-synuclein inclusions which correlate with age-dependent motor dysfunction. Herein we present the novel finding that this selective aggregation is in part dependent on the inability of chaperone-mediated autophagy (CMA) to effectively degrade \u03b1-synuclein in these brain regions. Lysosomal assays revealed that CMA activity was significantly decreased in aggregation-prone regions compared to the remainder of the brain. Previously, CMA activity has been shown to be proportional to levels of the CMA receptor Lamp-2a. Using antibodies, brain tissue from Lamp-2a null mice, enzymatic deglycosylation, and mass spectrometry, we identified Lamp2a as a novel 72kDa glycoprotein in the mouse brain. Examination of Lamp-2a levels revealed differences in expression across brain regions. The brainstem and the spinal cord had a more than three-fold greater levels of Lamp-2a as compared to regions less vulnerable to aggregation and exhibited a selective upregulation of Lamp-2a during development of \u03b1-synuclein inclusions. Despite this dynamic response of Lamp-2a, the levels of substrates bound to the brain lysosomes as well as the rates of substrate uptake and degradation were not proportional to the levels of Lamp-2a. These regional differences in CMA activity and Lamp-2a expression were found in both non-transgenic mice as well as A53T \u03b1-syn mice. Therefore, these are inherent variations and not a transgene-specific effect. However, differences in CMA activity may render select brain regions vulnerable to homeostatic dysfunction in the presence of stressors such as overexpression of human A53T \u03b1-syn. Collectively, the data provide a potential mechanism to explain the dichotomy of vulnerability or resistance that underlies brain regions during aggregate formation in neurodegenerative disease.", "qas": [{"question": "Which is the receptor for substrates of Chaperone Mediated Autophagy?", "answers": ["LAMP2A", "Lysosome-associated membrane protein 2 isoform A"], "qid": "fdc608c223704b0ca4a61d478dc8dbe2", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["receptor", 13], ["for", 22], ["substrates", 26], ["of", 37], ["Chaperone", 40], ["Mediated", 50], ["Autophagy", 59], ["?", 68]], "detected_answers": [{"text": "LAMP2A", "token_spans": [[146, 146]], "char_spans": [[876, 881]]}]}], "context_tokens": [["In", 0], ["neurodegenerative", 3], ["diseases", 21], [",", 29], ["it", 31], ["remains", 34], ["unclear", 42], ["why", 50], ["certain", 54], ["brain", 62], ["regions", 68], ["are", 76], ["selectively", 80], ["vulnerable", 92], ["to", 103], ["protein", 106], ["aggregation", 114], [".", 125], ["In", 127], ["transgenic", 130], ["mice", 141], ["expressing", 146], ["human", 157], ["A53", 163], ["T", 166], ["\u03b1", 168], ["-", 169], ["synuclein", 170], [",", 179], ["the", 181], ["brainstem", 185], ["and", 195], ["spinal", 199], ["cord", 206], ["develop", 211], ["the", 219], ["most", 223], ["prominent", 228], ["\u03b1", 238], ["-", 239], ["synuclein", 240], ["inclusions", 250], ["which", 261], ["correlate", 267], ["with", 277], ["age", 282], ["-", 285], ["dependent", 286], ["motor", 296], ["dysfunction", 302], [".", 313], ["Herein", 315], ["we", 322], ["present", 325], ["the", 333], ["novel", 337], ["finding", 343], ["that", 351], ["this", 356], ["selective", 361], ["aggregation", 371], ["is", 383], ["in", 386], ["part", 389], ["dependent", 394], ["on", 404], ["the", 407], ["inability", 411], ["of", 421], ["chaperone", 424], ["-", 433], ["mediated", 434], ["autophagy", 443], ["(", 453], ["CMA", 454], [")", 457], ["to", 459], ["effectively", 462], ["degrade", 474], ["\u03b1", 482], ["-", 483], ["synuclein", 484], ["in", 494], ["these", 497], ["brain", 503], ["regions", 509], [".", 516], ["Lysosomal", 518], ["assays", 528], ["revealed", 535], ["that", 544], ["CMA", 549], ["activity", 553], ["was", 562], ["significantly", 566], ["decreased", 580], ["in", 590], ["aggregation", 593], ["-", 604], ["prone", 605], ["regions", 611], ["compared", 619], ["to", 628], ["the", 631], ["remainder", 635], ["of", 645], ["the", 648], ["brain", 652], [".", 657], ["Previously", 659], [",", 669], ["CMA", 671], ["activity", 675], ["has", 684], ["been", 688], ["shown", 693], ["to", 699], ["be", 702], ["proportional", 705], ["to", 718], ["levels", 721], ["of", 728], ["the", 731], ["CMA", 735], ["receptor", 739], ["Lamp-2a", 748], [".", 755], ["Using", 757], ["antibodies", 763], [",", 773], ["brain", 775], ["tissue", 781], ["from", 788], ["Lamp-2a", 793], ["null", 801], ["mice", 806], [",", 810], ["enzymatic", 812], ["deglycosylation", 822], [",", 837], ["and", 839], ["mass", 843], ["spectrometry", 848], [",", 860], ["we", 862], ["identified", 865], ["Lamp2a", 876], ["as", 883], ["a", 886], ["novel", 888], ["72kDa", 894], ["glycoprotein", 900], ["in", 913], ["the", 916], ["mouse", 920], ["brain", 926], [".", 931], ["Examination", 933], ["of", 945], ["Lamp-2a", 948], ["levels", 956], ["revealed", 963], ["differences", 972], ["in", 984], ["expression", 987], ["across", 998], ["brain", 1005], ["regions", 1011], [".", 1018], ["The", 1020], ["brainstem", 1024], ["and", 1034], ["the", 1038], ["spinal", 1042], ["cord", 1049], ["had", 1054], ["a", 1058], ["more", 1060], ["than", 1065], ["three", 1070], ["-", 1075], ["fold", 1076], ["greater", 1081], ["levels", 1089], ["of", 1096], ["Lamp-2a", 1099], ["as", 1107], ["compared", 1110], ["to", 1119], ["regions", 1122], ["less", 1130], ["vulnerable", 1135], ["to", 1146], ["aggregation", 1149], ["and", 1161], ["exhibited", 1165], ["a", 1175], ["selective", 1177], ["upregulation", 1187], ["of", 1200], ["Lamp-2a", 1203], ["during", 1211], ["development", 1218], ["of", 1230], ["\u03b1", 1233], ["-", 1234], ["synuclein", 1235], ["inclusions", 1245], [".", 1255], ["Despite", 1257], ["this", 1265], ["dynamic", 1270], ["response", 1278], ["of", 1287], ["Lamp-2a", 1290], [",", 1297], ["the", 1299], ["levels", 1303], ["of", 1310], ["substrates", 1313], ["bound", 1324], ["to", 1330], ["the", 1333], ["brain", 1337], ["lysosomes", 1343], ["as", 1353], ["well", 1356], ["as", 1361], ["the", 1364], ["rates", 1368], ["of", 1374], ["substrate", 1377], ["uptake", 1387], ["and", 1394], ["degradation", 1398], ["were", 1410], ["not", 1415], ["proportional", 1419], ["to", 1432], ["the", 1435], ["levels", 1439], ["of", 1446], ["Lamp-2a", 1449], [".", 1456], ["These", 1458], ["regional", 1464], ["differences", 1473], ["in", 1485], ["CMA", 1488], ["activity", 1492], ["and", 1501], ["Lamp-2a", 1505], ["expression", 1513], ["were", 1524], ["found", 1529], ["in", 1535], ["both", 1538], ["non", 1543], ["-", 1546], ["transgenic", 1547], ["mice", 1558], ["as", 1563], ["well", 1566], ["as", 1571], ["A53", 1574], ["T", 1577], ["\u03b1", 1579], ["-", 1580], ["syn", 1581], ["mice", 1585], [".", 1589], ["Therefore", 1591], [",", 1600], ["these", 1602], ["are", 1608], ["inherent", 1612], ["variations", 1621], ["and", 1632], ["not", 1636], ["a", 1640], ["transgene", 1642], ["-", 1651], ["specific", 1652], ["effect", 1661], [".", 1667], ["However", 1669], [",", 1676], ["differences", 1678], ["in", 1690], ["CMA", 1693], ["activity", 1697], ["may", 1706], ["render", 1710], ["select", 1717], ["brain", 1724], ["regions", 1730], ["vulnerable", 1738], ["to", 1749], ["homeostatic", 1752], ["dysfunction", 1764], ["in", 1776], ["the", 1779], ["presence", 1783], ["of", 1792], ["stressors", 1795], ["such", 1805], ["as", 1810], ["overexpression", 1813], ["of", 1828], ["human", 1831], ["A53", 1837], ["T", 1840], ["\u03b1", 1842], ["-", 1843], ["syn", 1844], [".", 1847], ["Collectively", 1849], [",", 1861], ["the", 1863], ["data", 1867], ["provide", 1872], ["a", 1880], ["potential", 1882], ["mechanism", 1892], ["to", 1902], ["explain", 1905], ["the", 1913], ["dichotomy", 1917], ["of", 1927], ["vulnerability", 1930], ["or", 1944], ["resistance", 1947], ["that", 1958], ["underlies", 1963], ["brain", 1973], ["regions", 1979], ["during", 1987], ["aggregate", 1994], ["formation", 2004], ["in", 2014], ["neurodegenerative", 2017], ["disease", 2035], [".", 2042]]}
{"context": "Intravenous immunoglobulin (IVIG) has shown limited promise so far in human clinical studies on Alzheimer's disease (AD), yet overwhelmingly positive preclinical work in animals and human brain cultures support the notion that the therapy remains potentially efficacious. Here, we elaborate on IVIG neuropreservation by demonstrating that IVIG protects human primary neurons against oxidative stress in vitro and that IVIG preserves antioxidant defense mechanisms in vivo. Based on these results, we propose the following translational impact: If the dosage and treatment conditions are adequately optimized, then IVIG treatment could play a significant role in preventing and/or delaying the progression of neurodegenerative diseases, such as AD. We suggest that IVIG warrants further investigation to fully exploit its potential as an anti-oxidant, neuroprotective and synapto-protecting agent.", "qas": [{"question": "What is the administration route of IVIG in Alzheimer's disease patients?", "answers": ["Intravenous"], "qid": "b281754e18ae429e9ea7345319018381", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["administration", 12], ["route", 27], ["of", 33], ["IVIG", 36], ["in", 41], ["Alzheimer", 44], ["'s", 53], ["disease", 56], ["patients", 64], ["?", 72]], "detected_answers": [{"text": "Intravenous", "token_spans": [[0, 0]], "char_spans": [[0, 10]]}]}], "context_tokens": [["Intravenous", 0], ["immunoglobulin", 12], ["(", 27], ["IVIG", 28], [")", 32], ["has", 34], ["shown", 38], ["limited", 44], ["promise", 52], ["so", 60], ["far", 63], ["in", 67], ["human", 70], ["clinical", 76], ["studies", 85], ["on", 93], ["Alzheimer", 96], ["'s", 105], ["disease", 108], ["(", 116], ["AD", 117], [")", 119], [",", 120], ["yet", 122], ["overwhelmingly", 126], ["positive", 141], ["preclinical", 150], ["work", 162], ["in", 167], ["animals", 170], ["and", 178], ["human", 182], ["brain", 188], ["cultures", 194], ["support", 203], ["the", 211], ["notion", 215], ["that", 222], ["the", 227], ["therapy", 231], ["remains", 239], ["potentially", 247], ["efficacious", 259], [".", 270], ["Here", 272], [",", 276], ["we", 278], ["elaborate", 281], ["on", 291], ["IVIG", 294], ["neuropreservation", 299], ["by", 317], ["demonstrating", 320], ["that", 334], ["IVIG", 339], ["protects", 344], ["human", 353], ["primary", 359], ["neurons", 367], ["against", 375], ["oxidative", 383], ["stress", 393], ["in", 400], ["vitro", 403], ["and", 409], ["that", 413], ["IVIG", 418], ["preserves", 423], ["antioxidant", 433], ["defense", 445], ["mechanisms", 453], ["in", 464], ["vivo", 467], [".", 471], ["Based", 473], ["on", 479], ["these", 482], ["results", 488], [",", 495], ["we", 497], ["propose", 500], ["the", 508], ["following", 512], ["translational", 522], ["impact", 536], [":", 542], ["If", 544], ["the", 547], ["dosage", 551], ["and", 558], ["treatment", 562], ["conditions", 572], ["are", 583], ["adequately", 587], ["optimized", 598], [",", 607], ["then", 609], ["IVIG", 614], ["treatment", 619], ["could", 629], ["play", 635], ["a", 640], ["significant", 642], ["role", 654], ["in", 659], ["preventing", 662], ["and/or", 673], ["delaying", 680], ["the", 689], ["progression", 693], ["of", 705], ["neurodegenerative", 708], ["diseases", 726], [",", 734], ["such", 736], ["as", 741], ["AD", 744], [".", 746], ["We", 748], ["suggest", 751], ["that", 759], ["IVIG", 764], ["warrants", 769], ["further", 778], ["investigation", 786], ["to", 800], ["fully", 803], ["exploit", 809], ["its", 817], ["potential", 821], ["as", 831], ["an", 834], ["anti", 837], ["-", 841], ["oxidant", 842], [",", 849], ["neuroprotective", 851], ["and", 867], ["synapto", 871], ["-", 878], ["protecting", 879], ["agent", 890], [".", 895]]}
{"context": "Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are widely used to treat HIV-1-infected individuals; indeed most first-line antiretroviral therapies typically include one NNRTI in combination with two nucleoside analogs. In 2008, the next-generation NNRTI etravirine was approved for the treatment of HIV-infected antiretroviral therapy-experienced individuals, including those with prior NNRTI exposure. NNRTIs are also increasingly being included in strategies to prevent HIV-1 infection. For example: (1) nevirapine is used to prevent mother-to-child transmission; (2) the ASPIRE (MTN 020) study will test whether a vaginal ring containing dapivirine can prevent HIV-1 infection in women; (3) a microbicide gel formulation containing the urea-PETT derivative MIV-150 is in a phase I study to evaluate safety, pharmacokinetics, pharmacodynamics and acceptability; and (4) a long acting rilpivirine formulation is under-development for pre-exposure prophylaxis. Given their widespread use, particularly in resource-limited settings, as well as their low genetic barriers to resistance, there are concerns about overlapping resistance between the different NNRTIs. Consequently, a better understanding of the resistance and cross-resistance profiles among the NNRTI class is important for predicting response to treatment, and surveillance of transmitted drug-resistance.", "qas": [{"question": "Which infection can be prevented with Dapivirine?", "answers": ["HIV"], "qid": "f8585ae680a84b258cfa4b315d1378ba", "question_tokens": [["Which", 0], ["infection", 6], ["can", 16], ["be", 20], ["prevented", 23], ["with", 33], ["Dapivirine", 38], ["?", 48]], "detected_answers": [{"text": "HIV", "token_spans": [[48, 48]], "char_spans": [[309, 311]]}]}], "context_tokens": [["Nonnucleoside", 0], ["reverse", 14], ["transcriptase", 22], ["inhibitors", 36], ["(", 47], ["NNRTIs", 48], [")", 54], ["are", 56], ["widely", 60], ["used", 67], ["to", 72], ["treat", 75], ["HIV-1-infected", 81], ["individuals", 96], [";", 107], ["indeed", 109], ["most", 116], ["first", 121], ["-", 126], ["line", 127], ["antiretroviral", 132], ["therapies", 147], ["typically", 157], ["include", 167], ["one", 175], ["NNRTI", 179], ["in", 185], ["combination", 188], ["with", 200], ["two", 205], ["nucleoside", 209], ["analogs", 220], [".", 227], ["In", 229], ["2008", 232], [",", 236], ["the", 238], ["next", 242], ["-", 246], ["generation", 247], ["NNRTI", 258], ["etravirine", 264], ["was", 275], ["approved", 279], ["for", 288], ["the", 292], ["treatment", 296], ["of", 306], ["HIV", 309], ["-", 312], ["infected", 313], ["antiretroviral", 322], ["therapy", 337], ["-", 344], ["experienced", 345], ["individuals", 357], [",", 368], ["including", 370], ["those", 380], ["with", 386], ["prior", 391], ["NNRTI", 397], ["exposure", 403], [".", 411], ["NNRTIs", 413], ["are", 420], ["also", 424], ["increasingly", 429], ["being", 442], ["included", 448], ["in", 457], ["strategies", 460], ["to", 471], ["prevent", 474], ["HIV-1", 482], ["infection", 488], [".", 497], ["For", 499], ["example", 503], [":", 510], ["(", 512], ["1", 513], [")", 514], ["nevirapine", 516], ["is", 527], ["used", 530], ["to", 535], ["prevent", 538], ["mother", 546], ["-", 552], ["to", 553], ["-", 555], ["child", 556], ["transmission", 562], [";", 574], ["(", 576], ["2", 577], [")", 578], ["the", 580], ["ASPIRE", 584], ["(", 591], ["MTN", 592], ["020", 596], [")", 599], ["study", 601], ["will", 607], ["test", 612], ["whether", 617], ["a", 625], ["vaginal", 627], ["ring", 635], ["containing", 640], ["dapivirine", 651], ["can", 662], ["prevent", 666], ["HIV-1", 674], ["infection", 680], ["in", 690], ["women", 693], [";", 698], ["(", 700], ["3", 701], [")", 702], ["a", 704], ["microbicide", 706], ["gel", 718], ["formulation", 722], ["containing", 734], ["the", 745], ["urea", 749], ["-", 753], ["PETT", 754], ["derivative", 759], ["MIV-150", 770], ["is", 778], ["in", 781], ["a", 784], ["phase", 786], ["I", 792], ["study", 794], ["to", 800], ["evaluate", 803], ["safety", 812], [",", 818], ["pharmacokinetics", 820], [",", 836], ["pharmacodynamics", 838], ["and", 855], ["acceptability", 859], [";", 872], ["and", 874], ["(", 878], ["4", 879], [")", 880], ["a", 882], ["long", 884], ["acting", 889], ["rilpivirine", 896], ["formulation", 908], ["is", 920], ["under", 923], ["-", 928], ["development", 929], ["for", 941], ["pre", 945], ["-", 948], ["exposure", 949], ["prophylaxis", 958], [".", 969], ["Given", 971], ["their", 977], ["widespread", 983], ["use", 994], [",", 997], ["particularly", 999], ["in", 1012], ["resource", 1015], ["-", 1023], ["limited", 1024], ["settings", 1032], [",", 1040], ["as", 1042], ["well", 1045], ["as", 1050], ["their", 1053], ["low", 1059], ["genetic", 1063], ["barriers", 1071], ["to", 1080], ["resistance", 1083], [",", 1093], ["there", 1095], ["are", 1101], ["concerns", 1105], ["about", 1114], ["overlapping", 1120], ["resistance", 1132], ["between", 1143], ["the", 1151], ["different", 1155], ["NNRTIs", 1165], [".", 1171], ["Consequently", 1173], [",", 1185], ["a", 1187], ["better", 1189], ["understanding", 1196], ["of", 1210], ["the", 1213], ["resistance", 1217], ["and", 1228], ["cross", 1232], ["-", 1237], ["resistance", 1238], ["profiles", 1249], ["among", 1258], ["the", 1264], ["NNRTI", 1268], ["class", 1274], ["is", 1280], ["important", 1283], ["for", 1293], ["predicting", 1297], ["response", 1308], ["to", 1317], ["treatment", 1320], [",", 1329], ["and", 1331], ["surveillance", 1335], ["of", 1348], ["transmitted", 1351], ["drug", 1363], ["-", 1367], ["resistance", 1368], [".", 1378]]}
{"context": "Chronic myelogenous leukemia (CML) is characterized by Philadelphia (Ph) chromosome with a chimeric gene BCR-ABL created by reciprocal t(9:22) (q34;q11) translocation. Variant Ph chromosome translocations involving chromosomes other than 9 and 22 are found in 5-10% of CML cases. We here report a CML patient who carries a four-way Ph chromosome translocation, t(9;22;15;19) (q34;q11;q15;q13). The patient was diagnosed in 1997 and initially treated with hydroxyurea. In 2002, treatment with imatinib, a selective BCR-ABL tyrosine kinase inhibitor (TKI), was started but Ph-positive chromosomes remained at the levels of 42-65%, indicating imatinib failure. In 2006, the point mutations of F359I and L387M were detected in BCR/ABL gene, which may be related to imatinib failure. Treatment with nilotinib, a TKI with high target specificity, was then started which resulted in durable major molecular response. Administration of nilotinib offered an effective treatment in a CML patient with variant Ph chromosome translocations and BCR-ABL point mutations after imatinib failure.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "fdeaba7b6cb142ef8d135fd8ca5d8c0a", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[193, 195], [141, 143], [18, 20], [96, 98]], "char_spans": [[1032, 1038], [723, 729], [105, 111], [514, 520]]}]}], "context_tokens": [["Chronic", 0], ["myelogenous", 8], ["leukemia", 20], ["(", 29], ["CML", 30], [")", 33], ["is", 35], ["characterized", 38], ["by", 52], ["Philadelphia", 55], ["(", 68], ["Ph", 69], [")", 71], ["chromosome", 73], ["with", 84], ["a", 89], ["chimeric", 91], ["gene", 100], ["BCR", 105], ["-", 108], ["ABL", 109], ["created", 113], ["by", 121], ["reciprocal", 124], ["t(9:22", 135], [")", 141], ["(", 143], ["q34;q11", 144], [")", 151], ["translocation", 153], [".", 166], ["Variant", 168], ["Ph", 176], ["chromosome", 179], ["translocations", 190], ["involving", 205], ["chromosomes", 215], ["other", 227], ["than", 233], ["9", 238], ["and", 240], ["22", 244], ["are", 247], ["found", 251], ["in", 257], ["5", 260], ["-", 261], ["10", 262], ["%", 264], ["of", 266], ["CML", 269], ["cases", 273], [".", 278], ["We", 280], ["here", 283], ["report", 288], ["a", 295], ["CML", 297], ["patient", 301], ["who", 309], ["carries", 313], ["a", 321], ["four", 323], ["-", 327], ["way", 328], ["Ph", 332], ["chromosome", 335], ["translocation", 346], [",", 359], ["t(9;22;15;19", 361], [")", 373], ["(", 375], ["q34;q11;q15;q13", 376], [")", 391], [".", 392], ["The", 394], ["patient", 398], ["was", 406], ["diagnosed", 410], ["in", 420], ["1997", 423], ["and", 428], ["initially", 432], ["treated", 442], ["with", 450], ["hydroxyurea", 455], [".", 466], ["In", 468], ["2002", 471], [",", 475], ["treatment", 477], ["with", 487], ["imatinib", 492], [",", 500], ["a", 502], ["selective", 504], ["BCR", 514], ["-", 517], ["ABL", 518], ["tyrosine", 522], ["kinase", 531], ["inhibitor", 538], ["(", 548], ["TKI", 549], [")", 552], [",", 553], ["was", 555], ["started", 559], ["but", 567], ["Ph", 571], ["-", 573], ["positive", 574], ["chromosomes", 583], ["remained", 595], ["at", 604], ["the", 607], ["levels", 611], ["of", 618], ["42", 621], ["-", 623], ["65", 624], ["%", 626], [",", 627], ["indicating", 629], ["imatinib", 640], ["failure", 649], [".", 656], ["In", 658], ["2006", 661], [",", 665], ["the", 667], ["point", 671], ["mutations", 677], ["of", 687], ["F359I", 690], ["and", 696], ["L387", 700], ["M", 704], ["were", 706], ["detected", 711], ["in", 720], ["BCR", 723], ["/", 726], ["ABL", 727], ["gene", 731], [",", 735], ["which", 737], ["may", 743], ["be", 747], ["related", 750], ["to", 758], ["imatinib", 761], ["failure", 770], [".", 777], ["Treatment", 779], ["with", 789], ["nilotinib", 794], [",", 803], ["a", 805], ["TKI", 807], ["with", 811], ["high", 816], ["target", 821], ["specificity", 828], [",", 839], ["was", 841], ["then", 845], ["started", 850], ["which", 858], ["resulted", 864], ["in", 873], ["durable", 876], ["major", 884], ["molecular", 890], ["response", 900], [".", 908], ["Administration", 910], ["of", 925], ["nilotinib", 928], ["offered", 938], ["an", 946], ["effective", 949], ["treatment", 959], ["in", 969], ["a", 972], ["CML", 974], ["patient", 978], ["with", 986], ["variant", 991], ["Ph", 999], ["chromosome", 1002], ["translocations", 1013], ["and", 1028], ["BCR", 1032], ["-", 1035], ["ABL", 1036], ["point", 1040], ["mutations", 1046], ["after", 1056], ["imatinib", 1062], ["failure", 1071], [".", 1078]]}
{"context": "Ehlers-Danlos syndromes (EDS) are a heterogeneous group of heritable connective tissue disorders. Gastrointestinal manifestations in EDS have been described but their frequency, nature and impact are poorly known. We aimed to assess digestive features in a national cohort of EDS patients. A questionnaire has been sent to 212 EDS patients through the French patient support group, all of which had been formally diagnosed according to the Villefranche criteria. The questionnaire included questions about digestive functional symptoms, the GIQLI (Gastrointestinal Quality of Life Index), KESS scoring system and the Rome III criteria. Overall, 135 patients (64% response rate) completed the questionnaire and 134 were analyzable (123 women; 91%). Mean age and Body Mass Index were respectively 35\u00b114.7 years and 24.3\u00b16.1 kg/m(2). The most common EDS subtype was hypermobility form (n=108; 80.6%). GIQLI and KESS median values were respectively 63.5 (27-117) and 19 [13.5-22]. Eighty four percent of patients had functional bowel disorders (FBD) according to the Rome III criteria. An irritable bowel syndrome according to the same criteria was observed in 64 patients (48%) and 48 patients (36%) reported functional constipation. A gastro-esophageal reflux disease (GERD) was reported in 90 patients (68.7%), significantly associated with a poorer GIQLI (60.5\u00b116.8 versus 75.9\u00b120.3; p<0.0001). GIQLI was also negatively impacted by the presence of an irritable bowel syndrome or functional constipation (p=0.007). There was a significant correlation between FBD and GERD. Natural frequency of gastrointestinal manifestations in EDS seems higher than previously assessed. FBD and GERD are very common in our study population, the largest ever published until now. Their impact is herein shown to be important. A systematic clinical assessment of digestive features should be recommended in EDS.", "qas": [{"question": "What tissue is most affected in Ehlers-Danlos syndromes?", "answers": ["connective tissue"], "qid": "922ae9318d264f8ea1e929e98b4bbe0b", "question_tokens": [["What", 0], ["tissue", 5], ["is", 12], ["most", 15], ["affected", 20], ["in", 29], ["Ehlers", 32], ["-", 38], ["Danlos", 39], ["syndromes", 46], ["?", 55]], "detected_answers": [{"text": "connective tissue", "token_spans": [[13, 14]], "char_spans": [[69, 85]]}]}], "context_tokens": [["Ehlers", 0], ["-", 6], ["Danlos", 7], ["syndromes", 14], ["(", 24], ["EDS", 25], [")", 28], ["are", 30], ["a", 34], ["heterogeneous", 36], ["group", 50], ["of", 56], ["heritable", 59], ["connective", 69], ["tissue", 80], ["disorders", 87], [".", 96], ["Gastrointestinal", 98], ["manifestations", 115], ["in", 130], ["EDS", 133], ["have", 137], ["been", 142], ["described", 147], ["but", 157], ["their", 161], ["frequency", 167], [",", 176], ["nature", 178], ["and", 185], ["impact", 189], ["are", 196], ["poorly", 200], ["known", 207], [".", 212], ["We", 214], ["aimed", 217], ["to", 223], ["assess", 226], ["digestive", 233], ["features", 243], ["in", 252], ["a", 255], ["national", 257], ["cohort", 266], ["of", 273], ["EDS", 276], ["patients", 280], [".", 288], ["A", 290], ["questionnaire", 292], ["has", 306], ["been", 310], ["sent", 315], ["to", 320], ["212", 323], ["EDS", 327], ["patients", 331], ["through", 340], ["the", 348], ["French", 352], ["patient", 359], ["support", 367], ["group", 375], [",", 380], ["all", 382], ["of", 386], ["which", 389], ["had", 395], ["been", 399], ["formally", 404], ["diagnosed", 413], ["according", 423], ["to", 433], ["the", 436], ["Villefranche", 440], ["criteria", 453], [".", 461], ["The", 463], ["questionnaire", 467], ["included", 481], ["questions", 490], ["about", 500], ["digestive", 506], ["functional", 516], ["symptoms", 527], [",", 535], ["the", 537], ["GIQLI", 541], ["(", 547], ["Gastrointestinal", 548], ["Quality", 565], ["of", 573], ["Life", 576], ["Index", 581], [")", 586], [",", 587], ["KESS", 589], ["scoring", 594], ["system", 602], ["and", 609], ["the", 613], ["Rome", 617], ["III", 622], ["criteria", 626], [".", 634], ["Overall", 636], [",", 643], ["135", 645], ["patients", 649], ["(", 658], ["64", 659], ["%", 661], ["response", 663], ["rate", 672], [")", 676], ["completed", 678], ["the", 688], ["questionnaire", 692], ["and", 706], ["134", 710], ["were", 714], ["analyzable", 719], ["(", 730], ["123", 731], ["women", 735], [";", 740], ["91", 742], ["%", 744], [")", 745], [".", 746], ["Mean", 748], ["age", 753], ["and", 757], ["Body", 761], ["Mass", 766], ["Index", 771], ["were", 777], ["respectively", 782], ["35\u00b114.7", 795], ["years", 803], ["and", 809], ["24.3\u00b16.1", 813], ["kg", 822], ["/", 824], ["m(2", 825], [")", 828], [".", 829], ["The", 831], ["most", 835], ["common", 840], ["EDS", 847], ["subtype", 851], ["was", 859], ["hypermobility", 863], ["form", 877], ["(", 882], ["n=108", 883], [";", 888], ["80.6", 890], ["%", 894], [")", 895], [".", 896], ["GIQLI", 898], ["and", 904], ["KESS", 908], ["median", 913], ["values", 920], ["were", 927], ["respectively", 932], ["63.5", 945], ["(", 950], ["27", 951], ["-", 953], ["117", 954], [")", 957], ["and", 959], ["19", 963], ["[", 966], ["13.5", 967], ["-", 971], ["22].", 972], ["Eighty", 977], ["four", 984], ["percent", 989], ["of", 997], ["patients", 1000], ["had", 1009], ["functional", 1013], ["bowel", 1024], ["disorders", 1030], ["(", 1040], ["FBD", 1041], [")", 1044], ["according", 1046], ["to", 1056], ["the", 1059], ["Rome", 1063], ["III", 1068], ["criteria", 1072], [".", 1080], ["An", 1082], ["irritable", 1085], ["bowel", 1095], ["syndrome", 1101], ["according", 1110], ["to", 1120], ["the", 1123], ["same", 1127], ["criteria", 1132], ["was", 1141], ["observed", 1145], ["in", 1154], ["64", 1157], ["patients", 1160], ["(", 1169], ["48", 1170], ["%", 1172], [")", 1173], ["and", 1175], ["48", 1179], ["patients", 1182], ["(", 1191], ["36", 1192], ["%", 1194], [")", 1195], ["reported", 1197], ["functional", 1206], ["constipation", 1217], [".", 1229], ["A", 1231], ["gastro", 1233], ["-", 1239], ["esophageal", 1240], ["reflux", 1251], ["disease", 1258], ["(", 1266], ["GERD", 1267], [")", 1271], ["was", 1273], ["reported", 1277], ["in", 1286], ["90", 1289], ["patients", 1292], ["(", 1301], ["68.7", 1302], ["%", 1306], [")", 1307], [",", 1308], ["significantly", 1310], ["associated", 1324], ["with", 1335], ["a", 1340], ["poorer", 1342], ["GIQLI", 1349], ["(", 1355], ["60.5\u00b116.8", 1356], ["versus", 1366], ["75.9\u00b120.3", 1373], [";", 1382], ["p<0.0001", 1384], [")", 1392], [".", 1393], ["GIQLI", 1395], ["was", 1401], ["also", 1405], ["negatively", 1410], ["impacted", 1421], ["by", 1430], ["the", 1433], ["presence", 1437], ["of", 1446], ["an", 1449], ["irritable", 1452], ["bowel", 1462], ["syndrome", 1468], ["or", 1477], ["functional", 1480], ["constipation", 1491], ["(", 1504], ["p=0.007", 1505], [")", 1512], [".", 1513], ["There", 1515], ["was", 1521], ["a", 1525], ["significant", 1527], ["correlation", 1539], ["between", 1551], ["FBD", 1559], ["and", 1563], ["GERD", 1567], [".", 1571], ["Natural", 1573], ["frequency", 1581], ["of", 1591], ["gastrointestinal", 1594], ["manifestations", 1611], ["in", 1626], ["EDS", 1629], ["seems", 1633], ["higher", 1639], ["than", 1646], ["previously", 1651], ["assessed", 1662], [".", 1670], ["FBD", 1672], ["and", 1676], ["GERD", 1680], ["are", 1685], ["very", 1689], ["common", 1694], ["in", 1701], ["our", 1704], ["study", 1708], ["population", 1714], [",", 1724], ["the", 1726], ["largest", 1730], ["ever", 1738], ["published", 1743], ["until", 1753], ["now", 1759], [".", 1762], ["Their", 1764], ["impact", 1770], ["is", 1777], ["herein", 1780], ["shown", 1787], ["to", 1793], ["be", 1796], ["important", 1799], [".", 1808], ["A", 1810], ["systematic", 1812], ["clinical", 1823], ["assessment", 1832], ["of", 1843], ["digestive", 1846], ["features", 1856], ["should", 1865], ["be", 1872], ["recommended", 1875], ["in", 1887], ["EDS", 1890], [".", 1893]]}
{"context": "Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder, caused by an expansion of a CTG triplet repeat in the DMPK gene. The aims of the present study were to classify a cohort of children with DM1, to describe their neuropsychiatric problems and cognitive level, to estimate the size of the CTG expansion, and to correlate the molecular findings with the neuropsychiatric problems. Fifty-seven children and adolescents (26 females; 31 males) with DM1 (CTG repeats > 40) were included in the study. The following instruments were used: Autism Diagnostic Interview-Revised (ADI-R), 5-15, Griffiths Mental Development Scales, and the Wechsler Scales. Based on age at onset and presenting symptoms, the children were divided into four DM1 groups; severe congenital (n = 19), mild congenital (n = 18), childhood (n = 18), and classical DM1 (n = 2). Forty-nine percent had an autism spectrum disorder (ASD) and autistic disorder was the most common diagnosis present in 35% of the subjects. Eighty-six percent of the individuals with DM1 had mental retardation (MR), most of them moderate or severe MR. ASD was significantly correlated with the DM1 form; the more severe the form of DM1, the higher the frequency of ASD. The frequency of ASD increased with increasing CTG repeat expansions. ASD and/or other neuropsychiatric disorders such as attention deficit hyperactivity disorder, and Tourette's disorder were found in 54% of the total DM1 group. In conclusion, awareness of ASD comorbidity in DM1 is essential. Further studies are warranted to elucidate the molecular etiology causing neurodevelopmental symptoms such as ASD and MR in DM1.", "qas": [{"question": "How is myotonic dystrophy inherited?", "answers": ["autosomal dominant"], "qid": "d33ad3bcc29749269c3aa087a59610af", "question_tokens": [["How", 0], ["is", 4], ["myotonic", 7], ["dystrophy", 16], ["inherited", 26], ["?", 35]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[9, 10]], "char_spans": [[38, 55]]}]}], "context_tokens": [["Myotonic", 0], ["dystrophy", 9], ["type", 19], ["1", 24], ["(", 26], ["DM1", 27], [")", 30], ["is", 32], ["an", 35], ["autosomal", 38], ["dominant", 48], ["disorder", 57], [",", 65], ["caused", 67], ["by", 74], ["an", 77], ["expansion", 80], ["of", 90], ["a", 93], ["CTG", 95], ["triplet", 99], ["repeat", 107], ["in", 114], ["the", 117], ["DMPK", 121], ["gene", 126], [".", 130], ["The", 132], ["aims", 136], ["of", 141], ["the", 144], ["present", 148], ["study", 156], ["were", 162], ["to", 167], ["classify", 170], ["a", 179], ["cohort", 181], ["of", 188], ["children", 191], ["with", 200], ["DM1", 205], [",", 208], ["to", 210], ["describe", 213], ["their", 222], ["neuropsychiatric", 228], ["problems", 245], ["and", 254], ["cognitive", 258], ["level", 268], [",", 273], ["to", 275], ["estimate", 278], ["the", 287], ["size", 291], ["of", 296], ["the", 299], ["CTG", 303], ["expansion", 307], [",", 316], ["and", 318], ["to", 322], ["correlate", 325], ["the", 335], ["molecular", 339], ["findings", 349], ["with", 358], ["the", 363], ["neuropsychiatric", 367], ["problems", 384], [".", 392], ["Fifty", 394], ["-", 399], ["seven", 400], ["children", 406], ["and", 415], ["adolescents", 419], ["(", 431], ["26", 432], ["females", 435], [";", 442], ["31", 444], ["males", 447], [")", 452], ["with", 454], ["DM1", 459], ["(", 463], ["CTG", 464], ["repeats", 468], [">", 476], ["40", 478], [")", 480], ["were", 482], ["included", 487], ["in", 496], ["the", 499], ["study", 503], [".", 508], ["The", 510], ["following", 514], ["instruments", 524], ["were", 536], ["used", 541], [":", 545], ["Autism", 547], ["Diagnostic", 554], ["Interview", 565], ["-", 574], ["Revised", 575], ["(", 583], ["ADI", 584], ["-", 587], ["R", 588], [")", 589], [",", 590], ["5", 592], ["-", 593], ["15", 594], [",", 596], ["Griffiths", 598], ["Mental", 608], ["Development", 615], ["Scales", 627], [",", 633], ["and", 635], ["the", 639], ["Wechsler", 643], ["Scales", 652], [".", 658], ["Based", 660], ["on", 666], ["age", 669], ["at", 673], ["onset", 676], ["and", 682], ["presenting", 686], ["symptoms", 697], [",", 705], ["the", 707], ["children", 711], ["were", 720], ["divided", 725], ["into", 733], ["four", 738], ["DM1", 743], ["groups", 747], [";", 753], ["severe", 755], ["congenital", 762], ["(", 773], ["n", 774], ["=", 776], ["19", 778], [")", 780], [",", 781], ["mild", 783], ["congenital", 788], ["(", 799], ["n", 800], ["=", 802], ["18", 804], [")", 806], [",", 807], ["childhood", 809], ["(", 819], ["n", 820], ["=", 822], ["18", 824], [")", 826], [",", 827], ["and", 829], ["classical", 833], ["DM1", 843], ["(", 847], ["n", 848], ["=", 850], ["2", 852], [")", 853], [".", 854], ["Forty", 856], ["-", 861], ["nine", 862], ["percent", 867], ["had", 875], ["an", 879], ["autism", 882], ["spectrum", 889], ["disorder", 898], ["(", 907], ["ASD", 908], [")", 911], ["and", 913], ["autistic", 917], ["disorder", 926], ["was", 935], ["the", 939], ["most", 943], ["common", 948], ["diagnosis", 955], ["present", 965], ["in", 973], ["35", 976], ["%", 978], ["of", 980], ["the", 983], ["subjects", 987], [".", 995], ["Eighty", 997], ["-", 1003], ["six", 1004], ["percent", 1008], ["of", 1016], ["the", 1019], ["individuals", 1023], ["with", 1035], ["DM1", 1040], ["had", 1044], ["mental", 1048], ["retardation", 1055], ["(", 1067], ["MR", 1068], [")", 1070], [",", 1071], ["most", 1073], ["of", 1078], ["them", 1081], ["moderate", 1086], ["or", 1095], ["severe", 1098], ["MR", 1105], [".", 1107], ["ASD", 1109], ["was", 1113], ["significantly", 1117], ["correlated", 1131], ["with", 1142], ["the", 1147], ["DM1", 1151], ["form", 1155], [";", 1159], ["the", 1161], ["more", 1165], ["severe", 1170], ["the", 1177], ["form", 1181], ["of", 1186], ["DM1", 1189], [",", 1192], ["the", 1194], ["higher", 1198], ["the", 1205], ["frequency", 1209], ["of", 1219], ["ASD", 1222], [".", 1225], ["The", 1227], ["frequency", 1231], ["of", 1241], ["ASD", 1244], ["increased", 1248], ["with", 1258], ["increasing", 1263], ["CTG", 1274], ["repeat", 1278], ["expansions", 1285], [".", 1295], ["ASD", 1297], ["and/or", 1301], ["other", 1308], ["neuropsychiatric", 1314], ["disorders", 1331], ["such", 1341], ["as", 1346], ["attention", 1349], ["deficit", 1359], ["hyperactivity", 1367], ["disorder", 1381], [",", 1389], ["and", 1391], ["Tourette", 1395], ["'s", 1403], ["disorder", 1406], ["were", 1415], ["found", 1420], ["in", 1426], ["54", 1429], ["%", 1431], ["of", 1433], ["the", 1436], ["total", 1440], ["DM1", 1446], ["group", 1450], [".", 1455], ["In", 1457], ["conclusion", 1460], [",", 1470], ["awareness", 1472], ["of", 1482], ["ASD", 1485], ["comorbidity", 1489], ["in", 1501], ["DM1", 1504], ["is", 1508], ["essential", 1511], [".", 1520], ["Further", 1522], ["studies", 1530], ["are", 1538], ["warranted", 1542], ["to", 1552], ["elucidate", 1555], ["the", 1565], ["molecular", 1569], ["etiology", 1579], ["causing", 1588], ["neurodevelopmental", 1596], ["symptoms", 1615], ["such", 1624], ["as", 1629], ["ASD", 1632], ["and", 1636], ["MR", 1640], ["in", 1643], ["DM1", 1646], [".", 1649]]}
{"context": "Many neurodegenerative diseases are associated with the aggregation of misfolded proteins into amyloid oligomers or fibrils that are deposited as pathological lesions within areas of the brain. An attractive therapeutic strategy for preventing or ameliorating amyloid formation is to identify agents that inhibit the onset or propagation of protein aggregation. Here we demonstrate how solid-state nuclear magnetic resonance (ssNMR) may be used to identify key residues within amyloidogenic protein sequences that may be targeted to inhibit the aggregation of the host protein. For alpha-synuclein, the major protein component of Lewy bodies associated with Parkinson's disease, we have used a combination of ssNMR and biochemical data to identify the key region for self-aggregation of the protein as residues 77-82 (VAQKTV). We used our new structural information to design a peptide derived from residues 77 to 82 of alpha-synuclein with an N-methyl group at the C-terminal residue, which was able to disrupt the aggregation of alpha-synuclein. Thus, we have shown how structural data obtained from ssNMR can guide the design of modified peptides for use as amyloid inhibitors, as a primary step toward developing therapeutic compounds for prevention and/or treatment of amyloid diseases.", "qas": [{"question": "Which is the primary protein component of Lewy bodies?", "answers": ["alpha-synuclein", "\u03b1-synuclein", "\u03b1Syn"], "qid": "ec3fbfeea1b541fd86801d3f230fe7ac", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["primary", 13], ["protein", 21], ["component", 29], ["of", 39], ["Lewy", 42], ["bodies", 47], ["?", 53]], "detected_answers": [{"text": "alpha-synuclein", "token_spans": [[179, 181], [90, 92], [155, 157]], "char_spans": [[1031, 1045], [582, 596], [920, 934]]}]}], "context_tokens": [["Many", 0], ["neurodegenerative", 5], ["diseases", 23], ["are", 32], ["associated", 36], ["with", 47], ["the", 52], ["aggregation", 56], ["of", 68], ["misfolded", 71], ["proteins", 81], ["into", 90], ["amyloid", 95], ["oligomers", 103], ["or", 113], ["fibrils", 116], ["that", 124], ["are", 129], ["deposited", 133], ["as", 143], ["pathological", 146], ["lesions", 159], ["within", 167], ["areas", 174], ["of", 180], ["the", 183], ["brain", 187], [".", 192], ["An", 194], ["attractive", 197], ["therapeutic", 208], ["strategy", 220], ["for", 229], ["preventing", 233], ["or", 244], ["ameliorating", 247], ["amyloid", 260], ["formation", 268], ["is", 278], ["to", 281], ["identify", 284], ["agents", 293], ["that", 300], ["inhibit", 305], ["the", 313], ["onset", 317], ["or", 323], ["propagation", 326], ["of", 338], ["protein", 341], ["aggregation", 349], [".", 360], ["Here", 362], ["we", 367], ["demonstrate", 370], ["how", 382], ["solid", 386], ["-", 391], ["state", 392], ["nuclear", 398], ["magnetic", 406], ["resonance", 415], ["(", 425], ["ssNMR", 426], [")", 431], ["may", 433], ["be", 437], ["used", 440], ["to", 445], ["identify", 448], ["key", 457], ["residues", 461], ["within", 470], ["amyloidogenic", 477], ["protein", 491], ["sequences", 499], ["that", 509], ["may", 514], ["be", 518], ["targeted", 521], ["to", 530], ["inhibit", 533], ["the", 541], ["aggregation", 545], ["of", 557], ["the", 560], ["host", 564], ["protein", 569], [".", 576], ["For", 578], ["alpha", 582], ["-", 587], ["synuclein", 588], [",", 597], ["the", 599], ["major", 603], ["protein", 609], ["component", 617], ["of", 627], ["Lewy", 630], ["bodies", 635], ["associated", 642], ["with", 653], ["Parkinson", 658], ["'s", 667], ["disease", 670], [",", 677], ["we", 679], ["have", 682], ["used", 687], ["a", 692], ["combination", 694], ["of", 706], ["ssNMR", 709], ["and", 715], ["biochemical", 719], ["data", 731], ["to", 736], ["identify", 739], ["the", 748], ["key", 752], ["region", 756], ["for", 763], ["self", 767], ["-", 771], ["aggregation", 772], ["of", 784], ["the", 787], ["protein", 791], ["as", 799], ["residues", 802], ["77", 811], ["-", 813], ["82", 814], ["(", 817], ["VAQKTV", 818], [")", 824], [".", 825], ["We", 827], ["used", 830], ["our", 835], ["new", 839], ["structural", 843], ["information", 854], ["to", 866], ["design", 869], ["a", 876], ["peptide", 878], ["derived", 886], ["from", 894], ["residues", 899], ["77", 908], ["to", 911], ["82", 914], ["of", 917], ["alpha", 920], ["-", 925], ["synuclein", 926], ["with", 936], ["an", 941], ["N", 944], ["-", 945], ["methyl", 946], ["group", 953], ["at", 959], ["the", 962], ["C", 966], ["-", 967], ["terminal", 968], ["residue", 977], [",", 984], ["which", 986], ["was", 992], ["able", 996], ["to", 1001], ["disrupt", 1004], ["the", 1012], ["aggregation", 1016], ["of", 1028], ["alpha", 1031], ["-", 1036], ["synuclein", 1037], [".", 1046], ["Thus", 1048], [",", 1052], ["we", 1054], ["have", 1057], ["shown", 1062], ["how", 1068], ["structural", 1072], ["data", 1083], ["obtained", 1088], ["from", 1097], ["ssNMR", 1102], ["can", 1108], ["guide", 1112], ["the", 1118], ["design", 1122], ["of", 1129], ["modified", 1132], ["peptides", 1141], ["for", 1150], ["use", 1154], ["as", 1158], ["amyloid", 1161], ["inhibitors", 1169], [",", 1179], ["as", 1181], ["a", 1184], ["primary", 1186], ["step", 1194], ["toward", 1199], ["developing", 1206], ["therapeutic", 1217], ["compounds", 1229], ["for", 1239], ["prevention", 1243], ["and/or", 1254], ["treatment", 1261], ["of", 1271], ["amyloid", 1274], ["diseases", 1282], [".", 1290]]}
{"context": "Selenium (Se) is an essential trace element primarily found in selenoproteins as the 21st amino acid (selenocysteine, Sec, or U). Selenoproteins play an important role in growth and proliferation and are typically involved in cellular redox balance. Selenocysteine is encoded by an in-frame UGA codon specified by a stem-loop structure, the Sec insertion sequence element (SECIS), which, in eukaryotes, is located in the 3'-untranslated region (UTR). The availability of the Naegleria gruberi (ATCC 30224) genome sequence and the use of this organism as a model system for the pathogenic amoeba N. fowleri allowed us to investigate the Sec incorporation pathway in this primitive eukaryote. Using bioinformatics tools, we identified gene sequences encoding PSTK (O-phosphoseryl-tRNA(Sec) kinase), SepSecS (O-phosphoseryl-tRNA:selenocysteinyl-tRNA synthase), SelD/SPS2 (selenophosphate synthetase), EFSec (selenocysteine-specific elongation factor) and SBP (SECIS binding protein). These findings were confirmed by RT-PCR and by sequencing. A potential tRNA(Ser)Sec (SelC) gene and a putative selenoprotein with sequence similarity to a mitochondrial thioredoxin reductase (TR3) were also identified. Our results show that the selenocysteine incorporation machinery is indeed present in N. gruberi. Interestingly, the SelD/SPS2 gene is 2214 bp in length and contains two distinct domains. The N-terminal region shows sequence similarity to predicted methyltransferase proteins, and the C-terminal region is homologous to prokaryotic SelD/SPS2. Our results suggest the possibility of novel selenoproteins.", "qas": [{"question": "What is the name of the stem loop present in the 3' end of genes encoding for selenoproteins?", "answers": ["SECIS"], "qid": "0c52975c66384d66a1af964bd53fdfc5", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["name", 12], ["of", 17], ["the", 20], ["stem", 24], ["loop", 29], ["present", 34], ["in", 42], ["the", 45], ["3", 49], ["'", 50], ["end", 52], ["of", 56], ["genes", 59], ["encoding", 65], ["for", 74], ["selenoproteins", 78], ["?", 92]], "detected_answers": [{"text": "SECIS", "token_spans": [[181, 181], [69, 69]], "char_spans": [[957, 961], [373, 377]]}]}], "context_tokens": [["Selenium", 0], ["(", 9], ["Se", 10], [")", 12], ["is", 14], ["an", 17], ["essential", 20], ["trace", 30], ["element", 36], ["primarily", 44], ["found", 54], ["in", 60], ["selenoproteins", 63], ["as", 78], ["the", 81], ["21st", 85], ["amino", 90], ["acid", 96], ["(", 101], ["selenocysteine", 102], [",", 116], ["Sec", 118], [",", 121], ["or", 123], ["U", 126], [")", 127], [".", 128], ["Selenoproteins", 130], ["play", 145], ["an", 150], ["important", 153], ["role", 163], ["in", 168], ["growth", 171], ["and", 178], ["proliferation", 182], ["and", 196], ["are", 200], ["typically", 204], ["involved", 214], ["in", 223], ["cellular", 226], ["redox", 235], ["balance", 241], [".", 248], ["Selenocysteine", 250], ["is", 265], ["encoded", 268], ["by", 276], ["an", 279], ["in", 282], ["-", 284], ["frame", 285], ["UGA", 291], ["codon", 295], ["specified", 301], ["by", 311], ["a", 314], ["stem", 316], ["-", 320], ["loop", 321], ["structure", 326], [",", 335], ["the", 337], ["Sec", 341], ["insertion", 345], ["sequence", 355], ["element", 364], ["(", 372], ["SECIS", 373], [")", 378], [",", 379], ["which", 381], [",", 386], ["in", 388], ["eukaryotes", 391], [",", 401], ["is", 403], ["located", 406], ["in", 414], ["the", 417], ["3'-untranslated", 421], ["region", 437], ["(", 444], ["UTR", 445], [")", 448], [".", 449], ["The", 451], ["availability", 455], ["of", 468], ["the", 471], ["Naegleria", 475], ["gruberi", 485], ["(", 493], ["ATCC", 494], ["30224", 499], [")", 504], ["genome", 506], ["sequence", 513], ["and", 522], ["the", 526], ["use", 530], ["of", 534], ["this", 537], ["organism", 542], ["as", 551], ["a", 554], ["model", 556], ["system", 562], ["for", 569], ["the", 573], ["pathogenic", 577], ["amoeba", 588], ["N.", 595], ["fowleri", 598], ["allowed", 606], ["us", 614], ["to", 617], ["investigate", 620], ["the", 632], ["Sec", 636], ["incorporation", 640], ["pathway", 654], ["in", 662], ["this", 665], ["primitive", 670], ["eukaryote", 680], [".", 689], ["Using", 691], ["bioinformatics", 697], ["tools", 712], [",", 717], ["we", 719], ["identified", 722], ["gene", 733], ["sequences", 738], ["encoding", 748], ["PSTK", 757], ["(", 762], ["O", 763], ["-", 764], ["phosphoseryl", 765], ["-", 777], ["tRNA(Sec", 778], [")", 786], ["kinase", 788], [")", 794], [",", 795], ["SepSecS", 797], ["(", 805], ["O", 806], ["-", 807], ["phosphoseryl", 808], ["-", 820], ["tRNA", 821], [":", 825], ["selenocysteinyl", 826], ["-", 841], ["tRNA", 842], ["synthase", 847], [")", 855], [",", 856], ["SelD", 858], ["/", 862], ["SPS2", 863], ["(", 868], ["selenophosphate", 869], ["synthetase", 885], [")", 895], [",", 896], ["EFSec", 898], ["(", 904], ["selenocysteine", 905], ["-", 919], ["specific", 920], ["elongation", 929], ["factor", 940], [")", 946], ["and", 948], ["SBP", 952], ["(", 956], ["SECIS", 957], ["binding", 963], ["protein", 971], [")", 978], [".", 979], ["These", 981], ["findings", 987], ["were", 996], ["confirmed", 1001], ["by", 1011], ["RT", 1014], ["-", 1016], ["PCR", 1017], ["and", 1021], ["by", 1025], ["sequencing", 1028], [".", 1038], ["A", 1040], ["potential", 1042], ["tRNA(Ser)Sec", 1052], ["(", 1065], ["SelC", 1066], [")", 1070], ["gene", 1072], ["and", 1077], ["a", 1081], ["putative", 1083], ["selenoprotein", 1092], ["with", 1106], ["sequence", 1111], ["similarity", 1120], ["to", 1131], ["a", 1134], ["mitochondrial", 1136], ["thioredoxin", 1150], ["reductase", 1162], ["(", 1172], ["TR3", 1173], [")", 1176], ["were", 1178], ["also", 1183], ["identified", 1188], [".", 1198], ["Our", 1200], ["results", 1204], ["show", 1212], ["that", 1217], ["the", 1222], ["selenocysteine", 1226], ["incorporation", 1241], ["machinery", 1255], ["is", 1265], ["indeed", 1268], ["present", 1275], ["in", 1283], ["N.", 1286], ["gruberi", 1289], [".", 1296], ["Interestingly", 1298], [",", 1311], ["the", 1313], ["SelD", 1317], ["/", 1321], ["SPS2", 1322], ["gene", 1327], ["is", 1332], ["2214", 1335], ["bp", 1340], ["in", 1343], ["length", 1346], ["and", 1353], ["contains", 1357], ["two", 1366], ["distinct", 1370], ["domains", 1379], [".", 1386], ["The", 1388], ["N", 1392], ["-", 1393], ["terminal", 1394], ["region", 1403], ["shows", 1410], ["sequence", 1416], ["similarity", 1425], ["to", 1436], ["predicted", 1439], ["methyltransferase", 1449], ["proteins", 1467], [",", 1475], ["and", 1477], ["the", 1481], ["C", 1485], ["-", 1486], ["terminal", 1487], ["region", 1496], ["is", 1503], ["homologous", 1506], ["to", 1517], ["prokaryotic", 1520], ["SelD", 1532], ["/", 1536], ["SPS2", 1537], [".", 1541], ["Our", 1543], ["results", 1547], ["suggest", 1555], ["the", 1563], ["possibility", 1567], ["of", 1579], ["novel", 1582], ["selenoproteins", 1588], [".", 1602]]}
{"context": "The management of de Quervain's disease (DD) is nonoperative in the first instance, but surgery should be considered if conservative measures fail. We present the long-term results of operative treatment of DD. From July 1988 to July 1998, 94 consecutive patients with DD were treated operatively by a single surgeon. There were 80 women and 14 men. Average age at the time of operation was 47.4 years (range 22-76). The right wrist was involved in 43 cases, the left in 51 cases. All operations were done under tourniquet control with local infiltration anaesthesia using a longitudinal incision and partial resection of the extensor ligament. There were six perioperative complications, including one superficial wound infection, one delayed wound healing, and four transient lesions of the radial nerve. A successful outcome was achieved in all cases with negative Finkelstein's test. Simple decompression of both tendons and partial resection of the extensor ligament with a maximum of 3 mm can be recommended in operative treatment of DD with excellent long-term results.", "qas": [{"question": "Which disease is diagnosed using the Finkelstein's test?", "answers": ["de Quervain's disease"], "qid": "94956aa6f46c40d6942aab9ac607436f", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["diagnosed", 17], ["using", 27], ["the", 33], ["Finkelstein", 37], ["'s", 48], ["test", 51], ["?", 55]], "detected_answers": [{"text": "de Quervain's disease", "token_spans": [[3, 6]], "char_spans": [[18, 38]]}]}], "context_tokens": [["The", 0], ["management", 4], ["of", 15], ["de", 18], ["Quervain", 21], ["'s", 29], ["disease", 32], ["(", 40], ["DD", 41], [")", 43], ["is", 45], ["nonoperative", 48], ["in", 61], ["the", 64], ["first", 68], ["instance", 74], [",", 82], ["but", 84], ["surgery", 88], ["should", 96], ["be", 103], ["considered", 106], ["if", 117], ["conservative", 120], ["measures", 133], ["fail", 142], [".", 146], ["We", 148], ["present", 151], ["the", 159], ["long", 163], ["-", 167], ["term", 168], ["results", 173], ["of", 181], ["operative", 184], ["treatment", 194], ["of", 204], ["DD", 207], [".", 209], ["From", 211], ["July", 216], ["1988", 221], ["to", 226], ["July", 229], ["1998", 234], [",", 238], ["94", 240], ["consecutive", 243], ["patients", 255], ["with", 264], ["DD", 269], ["were", 272], ["treated", 277], ["operatively", 285], ["by", 297], ["a", 300], ["single", 302], ["surgeon", 309], [".", 316], ["There", 318], ["were", 324], ["80", 329], ["women", 332], ["and", 338], ["14", 342], ["men", 345], [".", 348], ["Average", 350], ["age", 358], ["at", 362], ["the", 365], ["time", 369], ["of", 374], ["operation", 377], ["was", 387], ["47.4", 391], ["years", 396], ["(", 402], ["range", 403], ["22", 409], ["-", 411], ["76", 412], [")", 414], [".", 415], ["The", 417], ["right", 421], ["wrist", 427], ["was", 433], ["involved", 437], ["in", 446], ["43", 449], ["cases", 452], [",", 457], ["the", 459], ["left", 463], ["in", 468], ["51", 471], ["cases", 474], [".", 479], ["All", 481], ["operations", 485], ["were", 496], ["done", 501], ["under", 506], ["tourniquet", 512], ["control", 523], ["with", 531], ["local", 536], ["infiltration", 542], ["anaesthesia", 555], ["using", 567], ["a", 573], ["longitudinal", 575], ["incision", 588], ["and", 597], ["partial", 601], ["resection", 609], ["of", 619], ["the", 622], ["extensor", 626], ["ligament", 635], [".", 643], ["There", 645], ["were", 651], ["six", 656], ["perioperative", 660], ["complications", 674], [",", 687], ["including", 689], ["one", 699], ["superficial", 703], ["wound", 715], ["infection", 721], [",", 730], ["one", 732], ["delayed", 736], ["wound", 744], ["healing", 750], [",", 757], ["and", 759], ["four", 763], ["transient", 768], ["lesions", 778], ["of", 786], ["the", 789], ["radial", 793], ["nerve", 800], [".", 805], ["A", 807], ["successful", 809], ["outcome", 820], ["was", 828], ["achieved", 832], ["in", 841], ["all", 844], ["cases", 848], ["with", 854], ["negative", 859], ["Finkelstein", 868], ["'s", 879], ["test", 882], [".", 886], ["Simple", 888], ["decompression", 895], ["of", 909], ["both", 912], ["tendons", 917], ["and", 925], ["partial", 929], ["resection", 937], ["of", 947], ["the", 950], ["extensor", 954], ["ligament", 963], ["with", 972], ["a", 977], ["maximum", 979], ["of", 987], ["3", 990], ["mm", 992], ["can", 995], ["be", 999], ["recommended", 1002], ["in", 1014], ["operative", 1017], ["treatment", 1027], ["of", 1037], ["DD", 1040], ["with", 1043], ["excellent", 1048], ["long", 1058], ["-", 1062], ["term", 1063], ["results", 1068], [".", 1075]]}
{"context": "Transcription-coupled repair (TCR) is a subpathway of nucleotide excision repair (NER) that acts specifically on lesions in the transcribed strand of expressed genes. First reported in mammalian cells, TCR was then documented in Escherichia coli. In this organism, an RNA polymerase arrested at a lesion is displaced by the transcription repair coupling factor, Mfd. This protein recruits the NER lesion-recognition factor UvrA, and then dissociates from the DNA. UvrA binds UvrB, and the assembled UvrAB* complex initiates repair. In mutants lacking active Mfd, TCR is absent. A gene transcribed by the bacteriophage T7 RNA polymerase in E. coli also requires Mfd for TCR. The CSB protein (missing or defective in cells of patients with Cockayne syndrome, complementation group B) is essential for TCR in humans. CSB and its homologs in higher eukaryotes are likely functional equivalents of Mfd.", "qas": [{"question": "Which gene strand is targeted by transcription-coupled repair (TCR)?", "answers": ["the transcribed strand"], "qid": "a9840cebbd6f4308916ff40aa8133f59", "question_tokens": [["Which", 0], ["gene", 6], ["strand", 11], ["is", 18], ["targeted", 21], ["by", 30], ["transcription", 33], ["-", 46], ["coupled", 47], ["repair", 55], ["(", 62], ["TCR", 63], [")", 66], ["?", 67]], "detected_answers": [{"text": "the transcribed strand", "token_spans": [[24, 25]], "char_spans": [[128, 145]]}]}], "context_tokens": [["Transcription", 0], ["-", 13], ["coupled", 14], ["repair", 22], ["(", 29], ["TCR", 30], [")", 33], ["is", 35], ["a", 38], ["subpathway", 40], ["of", 51], ["nucleotide", 54], ["excision", 65], ["repair", 74], ["(", 81], ["NER", 82], [")", 85], ["that", 87], ["acts", 92], ["specifically", 97], ["on", 110], ["lesions", 113], ["in", 121], ["the", 124], ["transcribed", 128], ["strand", 140], ["of", 147], ["expressed", 150], ["genes", 160], [".", 165], ["First", 167], ["reported", 173], ["in", 182], ["mammalian", 185], ["cells", 195], [",", 200], ["TCR", 202], ["was", 206], ["then", 210], ["documented", 215], ["in", 226], ["Escherichia", 229], ["coli", 241], [".", 245], ["In", 247], ["this", 250], ["organism", 255], [",", 263], ["an", 265], ["RNA", 268], ["polymerase", 272], ["arrested", 283], ["at", 292], ["a", 295], ["lesion", 297], ["is", 304], ["displaced", 307], ["by", 317], ["the", 320], ["transcription", 324], ["repair", 338], ["coupling", 345], ["factor", 354], [",", 360], ["Mfd", 362], [".", 365], ["This", 367], ["protein", 372], ["recruits", 380], ["the", 389], ["NER", 393], ["lesion", 397], ["-", 403], ["recognition", 404], ["factor", 416], ["UvrA", 423], [",", 427], ["and", 429], ["then", 433], ["dissociates", 438], ["from", 450], ["the", 455], ["DNA", 459], [".", 462], ["UvrA", 464], ["binds", 469], ["UvrB", 475], [",", 479], ["and", 481], ["the", 485], ["assembled", 489], ["UvrAB", 499], ["*", 504], ["complex", 506], ["initiates", 514], ["repair", 524], [".", 530], ["In", 532], ["mutants", 535], ["lacking", 543], ["active", 551], ["Mfd", 558], [",", 561], ["TCR", 563], ["is", 567], ["absent", 570], [".", 576], ["A", 578], ["gene", 580], ["transcribed", 585], ["by", 597], ["the", 600], ["bacteriophage", 604], ["T7", 618], ["RNA", 621], ["polymerase", 625], ["in", 636], ["E.", 639], ["coli", 642], ["also", 647], ["requires", 652], ["Mfd", 661], ["for", 665], ["TCR", 669], [".", 672], ["The", 674], ["CSB", 678], ["protein", 682], ["(", 690], ["missing", 691], ["or", 699], ["defective", 702], ["in", 712], ["cells", 715], ["of", 721], ["patients", 724], ["with", 733], ["Cockayne", 738], ["syndrome", 747], [",", 755], ["complementation", 757], ["group", 773], ["B", 779], [")", 780], ["is", 782], ["essential", 785], ["for", 795], ["TCR", 799], ["in", 803], ["humans", 806], [".", 812], ["CSB", 814], ["and", 818], ["its", 822], ["homologs", 826], ["in", 835], ["higher", 838], ["eukaryotes", 845], ["are", 856], ["likely", 860], ["functional", 867], ["equivalents", 878], ["of", 890], ["Mfd", 893], [".", 896]]}
{"context": "The actions of benzodiazepines are due to the potentiation of the neural inhibition that is mediated by gamma-aminobutyric acid (GABA). Practically all effects of the benzodiazepines result from their actions on the ionotropic GABA(A) receptors in the central nervous system. Benzodiazepines do not activate GABA(A) receptors directly but they require GABA. The main effects of benzodiazepines are sedation, hypnosis, decreased anxiety, anterograde amnesia, centrally mediated muscle relaxation and anti-convulsant activity. In addition to their action on the central nervous system, benzodiazepines have a dose-dependent ventilatory depressant effect and they also cause a modest reduction in arterial blood pressure and an increase in heart rate as a result of a decrease of systemic vascular resistance. The four benzodiazepines, widely used in clinical anaesthesia, are the agonists midazolam, diazepam and lorazepam and the antagonist flumazenil. Midazolam, diazepam and flumazenil are metabolized by cytochrome P450 (CYP) enzymes and by glucuronide conjugation whereas lorazepam directly undergoes glucuronide conjugation. CYP3A4 is important in the biotransformation of both midazolam and diazepam. CYP2C19 is important in the biotransformation of diazepam. Liver and renal dysfunction have only a minor effect on the pharmacokinetics of lorazepam but they slow down the elimination of the other benzodiazepines used in clinical anaesthesia. The duration of action of all benzodiazepines is strongly dependent on the duration of their administration. Based on clinical studies and computer simulations, midazolam has the shortest recovery profile followed by lorazepam and diazepam. Being metabolized by CYP enzymes, midazolam and diazepam have many clinically significant interactions with inhibitors and inducers of CYP3A4 and 2C19. In addition to pharmacokinetic interactions, benzodiazepines have synergistic interactions with other hypnotics and opioids. Midazolam, diazepam and lorazepam are widely used for sedation and to some extent also for induction and maintenance of anaesthesia. Flumazenil is very useful in reversing benzodiazepine-induced sedation as well as to diagnose or treat benzodiazepine overdose.", "qas": [{"question": "Which drug should be used as an antidote in benzodiazepine overdose?", "answers": ["flumazenil"], "qid": "0652e34262bc426d97340af838f8da7e", "question_tokens": [["Which", 0], ["drug", 6], ["should", 11], ["be", 18], ["used", 21], ["as", 26], ["an", 29], ["antidote", 32], ["in", 41], ["benzodiazepine", 44], ["overdose", 59], ["?", 67]], "detected_answers": [{"text": "flumazenil", "token_spans": [[161, 161], [155, 155], [330, 330]], "char_spans": [[976, 985], [940, 949], [2100, 2109]]}]}], "context_tokens": [["The", 0], ["actions", 4], ["of", 12], ["benzodiazepines", 15], ["are", 31], ["due", 35], ["to", 39], ["the", 42], ["potentiation", 46], ["of", 59], ["the", 62], ["neural", 66], ["inhibition", 73], ["that", 84], ["is", 89], ["mediated", 92], ["by", 101], ["gamma", 104], ["-", 109], ["aminobutyric", 110], ["acid", 123], ["(", 128], ["GABA", 129], [")", 133], [".", 134], ["Practically", 136], ["all", 148], ["effects", 152], ["of", 160], ["the", 163], ["benzodiazepines", 167], ["result", 183], ["from", 190], ["their", 195], ["actions", 201], ["on", 209], ["the", 212], ["ionotropic", 216], ["GABA(A", 227], [")", 233], ["receptors", 235], ["in", 245], ["the", 248], ["central", 252], ["nervous", 260], ["system", 268], [".", 274], ["Benzodiazepines", 276], ["do", 292], ["not", 295], ["activate", 299], ["GABA(A", 308], [")", 314], ["receptors", 316], ["directly", 326], ["but", 335], ["they", 339], ["require", 344], ["GABA", 352], [".", 356], ["The", 358], ["main", 362], ["effects", 367], ["of", 375], ["benzodiazepines", 378], ["are", 394], ["sedation", 398], [",", 406], ["hypnosis", 408], [",", 416], ["decreased", 418], ["anxiety", 428], [",", 435], ["anterograde", 437], ["amnesia", 449], [",", 456], ["centrally", 458], ["mediated", 468], ["muscle", 477], ["relaxation", 484], ["and", 495], ["anti", 499], ["-", 503], ["convulsant", 504], ["activity", 515], [".", 523], ["In", 525], ["addition", 528], ["to", 537], ["their", 540], ["action", 546], ["on", 553], ["the", 556], ["central", 560], ["nervous", 568], ["system", 576], [",", 582], ["benzodiazepines", 584], ["have", 600], ["a", 605], ["dose", 607], ["-", 611], ["dependent", 612], ["ventilatory", 622], ["depressant", 634], ["effect", 645], ["and", 652], ["they", 656], ["also", 661], ["cause", 666], ["a", 672], ["modest", 674], ["reduction", 681], ["in", 691], ["arterial", 694], ["blood", 703], ["pressure", 709], ["and", 718], ["an", 722], ["increase", 725], ["in", 734], ["heart", 737], ["rate", 743], ["as", 748], ["a", 751], ["result", 753], ["of", 760], ["a", 763], ["decrease", 765], ["of", 774], ["systemic", 777], ["vascular", 786], ["resistance", 795], [".", 805], ["The", 807], ["four", 811], ["benzodiazepines", 816], [",", 831], ["widely", 833], ["used", 840], ["in", 845], ["clinical", 848], ["anaesthesia", 857], [",", 868], ["are", 870], ["the", 874], ["agonists", 878], ["midazolam", 887], [",", 896], ["diazepam", 898], ["and", 907], ["lorazepam", 911], ["and", 921], ["the", 925], ["antagonist", 929], ["flumazenil", 940], [".", 950], ["Midazolam", 952], [",", 961], ["diazepam", 963], ["and", 972], ["flumazenil", 976], ["are", 987], ["metabolized", 991], ["by", 1003], ["cytochrome", 1006], ["P450", 1017], ["(", 1022], ["CYP", 1023], [")", 1026], ["enzymes", 1028], ["and", 1036], ["by", 1040], ["glucuronide", 1043], ["conjugation", 1055], ["whereas", 1067], ["lorazepam", 1075], ["directly", 1085], ["undergoes", 1094], ["glucuronide", 1104], ["conjugation", 1116], [".", 1127], ["CYP3A4", 1129], ["is", 1136], ["important", 1139], ["in", 1149], ["the", 1152], ["biotransformation", 1156], ["of", 1174], ["both", 1177], ["midazolam", 1182], ["and", 1192], ["diazepam", 1196], [".", 1204], ["CYP2C19", 1206], ["is", 1214], ["important", 1217], ["in", 1227], ["the", 1230], ["biotransformation", 1234], ["of", 1252], ["diazepam", 1255], [".", 1263], ["Liver", 1265], ["and", 1271], ["renal", 1275], ["dysfunction", 1281], ["have", 1293], ["only", 1298], ["a", 1303], ["minor", 1305], ["effect", 1311], ["on", 1318], ["the", 1321], ["pharmacokinetics", 1325], ["of", 1342], ["lorazepam", 1345], ["but", 1355], ["they", 1359], ["slow", 1364], ["down", 1369], ["the", 1374], ["elimination", 1378], ["of", 1390], ["the", 1393], ["other", 1397], ["benzodiazepines", 1403], ["used", 1419], ["in", 1424], ["clinical", 1427], ["anaesthesia", 1436], [".", 1447], ["The", 1449], ["duration", 1453], ["of", 1462], ["action", 1465], ["of", 1472], ["all", 1475], ["benzodiazepines", 1479], ["is", 1495], ["strongly", 1498], ["dependent", 1507], ["on", 1517], ["the", 1520], ["duration", 1524], ["of", 1533], ["their", 1536], ["administration", 1542], [".", 1556], ["Based", 1558], ["on", 1564], ["clinical", 1567], ["studies", 1576], ["and", 1584], ["computer", 1588], ["simulations", 1597], [",", 1608], ["midazolam", 1610], ["has", 1620], ["the", 1624], ["shortest", 1628], ["recovery", 1637], ["profile", 1646], ["followed", 1654], ["by", 1663], ["lorazepam", 1666], ["and", 1676], ["diazepam", 1680], [".", 1688], ["Being", 1690], ["metabolized", 1696], ["by", 1708], ["CYP", 1711], ["enzymes", 1715], [",", 1722], ["midazolam", 1724], ["and", 1734], ["diazepam", 1738], ["have", 1747], ["many", 1752], ["clinically", 1757], ["significant", 1768], ["interactions", 1780], ["with", 1793], ["inhibitors", 1798], ["and", 1809], ["inducers", 1813], ["of", 1822], ["CYP3A4", 1825], ["and", 1832], ["2C19", 1836], [".", 1840], ["In", 1842], ["addition", 1845], ["to", 1854], ["pharmacokinetic", 1857], ["interactions", 1873], [",", 1885], ["benzodiazepines", 1887], ["have", 1903], ["synergistic", 1908], ["interactions", 1920], ["with", 1933], ["other", 1938], ["hypnotics", 1944], ["and", 1954], ["opioids", 1958], [".", 1965], ["Midazolam", 1967], [",", 1976], ["diazepam", 1978], ["and", 1987], ["lorazepam", 1991], ["are", 2001], ["widely", 2005], ["used", 2012], ["for", 2017], ["sedation", 2021], ["and", 2030], ["to", 2034], ["some", 2037], ["extent", 2042], ["also", 2049], ["for", 2054], ["induction", 2058], ["and", 2068], ["maintenance", 2072], ["of", 2084], ["anaesthesia", 2087], [".", 2098], ["Flumazenil", 2100], ["is", 2111], ["very", 2114], ["useful", 2119], ["in", 2126], ["reversing", 2129], ["benzodiazepine", 2139], ["-", 2153], ["induced", 2154], ["sedation", 2162], ["as", 2171], ["well", 2174], ["as", 2179], ["to", 2182], ["diagnose", 2185], ["or", 2194], ["treat", 2197], ["benzodiazepine", 2203], ["overdose", 2218], [".", 2226]]}
{"context": "The cytogenetic characteristic of Chronic Myeloid Leukemia (CML) is the formation of the Philadelphia chromosome gene product, BCR-ABL. Given that BCR-ABL is the specific target of Gleevec in CML treatment, we investigated the regulation of the catalytic component of telomerase, hTERT, by BCR-ABL at multiple levels in K562 cells. Molecular techniques such as over expression, knockdown, real-time PCR, immunoprecipitation, western blotting, reporter assay, confocal microscopy, telomerase assays and microarray were used to suggest that hTERT expression and activity is modulated by BCR-ABL at multiple levels. Our results suggest that BCR-ABL plays an important role in regulating hTERT in K562 (BCR-ABL positive human leukemia) cells. When Gleevec inhibited the tyrosine kinase activity of BCR-ABL, phosphorylation of hTERT was downregulated, therefore suggesting a positive correlation between BCR-ABL and hTERT. Gleevec treatment inhibited hTERT at mRNA level and significantly reduced telomerase activity (TA) in K562 cells, but not in HL60 or Jurkat cells (BCR-ABL negative cells). We also demonstrated that the transcription factor STAT5a plays a critical role in hTERT gene regulation in K562 cells. Knockdown of STAT5a, but not STAT5b, resulted in a marked downregulation of hTERT mRNA level, TA and hTERT protein level in K562 cells. Furthermore, translocation of hTERT from nucleoli to nucleoplasm was observed in K562 cells induced by Gleevec. Our data reveal that BCR-ABL can regulate TA at multiple levels, including transcription, post-translational level, and proper localization. Thus, suppression of cell growth and induction of apoptosis by Gleevec treatment may be partially due to TA inhibition. Additionally, we have identified STAT5a as critical mediator of the hTERT gene expression in BCR-ABL positive CML cells, suggesting that targeting STAT5a may be a promising therapeutic strategy for BCR-ABL positive CML patients.", "qas": [{"question": "What tyrosine kinase, involved in a Philadelphia- chromosome positive chronic myelogenous leukemia, is the target of Imatinib (Gleevec)?", "answers": ["BCR-ABL"], "qid": "0641e4745b234652b621a99faaec9192", "question_tokens": [["What", 0], ["tyrosine", 5], ["kinase", 14], [",", 20], ["involved", 22], ["in", 31], ["a", 34], ["Philadelphia-", 36], ["chromosome", 50], ["positive", 61], ["chronic", 70], ["myelogenous", 78], ["leukemia", 90], [",", 98], ["is", 100], ["the", 103], ["target", 107], ["of", 114], ["Imatinib", 117], ["(", 126], ["Gleevec", 127], [")", 134], ["?", 135]], "detected_answers": [{"text": "BCR-ABL", "token_spans": [[145, 147], [161, 163], [20, 22], [270, 272], [53, 55], [26, 28], [104, 106], [328, 330], [346, 348], [194, 196], [128, 130], [115, 117]], "char_spans": [[794, 800], [899, 905], [127, 133], [1479, 1485], [290, 296], [147, 153], [585, 591], [1812, 1818], [1917, 1923], [1065, 1071], [699, 705], [638, 644]]}]}], "context_tokens": [["The", 0], ["cytogenetic", 4], ["characteristic", 16], ["of", 31], ["Chronic", 34], ["Myeloid", 42], ["Leukemia", 50], ["(", 59], ["CML", 60], [")", 63], ["is", 65], ["the", 68], ["formation", 72], ["of", 82], ["the", 85], ["Philadelphia", 89], ["chromosome", 102], ["gene", 113], ["product", 118], [",", 125], ["BCR", 127], ["-", 130], ["ABL", 131], [".", 134], ["Given", 136], ["that", 142], ["BCR", 147], ["-", 150], ["ABL", 151], ["is", 155], ["the", 158], ["specific", 162], ["target", 171], ["of", 178], ["Gleevec", 181], ["in", 189], ["CML", 192], ["treatment", 196], [",", 205], ["we", 207], ["investigated", 210], ["the", 223], ["regulation", 227], ["of", 238], ["the", 241], ["catalytic", 245], ["component", 255], ["of", 265], ["telomerase", 268], [",", 278], ["hTERT", 280], [",", 285], ["by", 287], ["BCR", 290], ["-", 293], ["ABL", 294], ["at", 298], ["multiple", 301], ["levels", 310], ["in", 317], ["K562", 320], ["cells", 325], [".", 330], ["Molecular", 332], ["techniques", 342], ["such", 353], ["as", 358], ["over", 361], ["expression", 366], [",", 376], ["knockdown", 378], [",", 387], ["real", 389], ["-", 393], ["time", 394], ["PCR", 399], [",", 402], ["immunoprecipitation", 404], [",", 423], ["western", 425], ["blotting", 433], [",", 441], ["reporter", 443], ["assay", 452], [",", 457], ["confocal", 459], ["microscopy", 468], [",", 478], ["telomerase", 480], ["assays", 491], ["and", 498], ["microarray", 502], ["were", 513], ["used", 518], ["to", 523], ["suggest", 526], ["that", 534], ["hTERT", 539], ["expression", 545], ["and", 556], ["activity", 560], ["is", 569], ["modulated", 572], ["by", 582], ["BCR", 585], ["-", 588], ["ABL", 589], ["at", 593], ["multiple", 596], ["levels", 605], [".", 611], ["Our", 613], ["results", 617], ["suggest", 625], ["that", 633], ["BCR", 638], ["-", 641], ["ABL", 642], ["plays", 646], ["an", 652], ["important", 655], ["role", 665], ["in", 670], ["regulating", 673], ["hTERT", 684], ["in", 690], ["K562", 693], ["(", 698], ["BCR", 699], ["-", 702], ["ABL", 703], ["positive", 707], ["human", 716], ["leukemia", 722], [")", 730], ["cells", 732], [".", 737], ["When", 739], ["Gleevec", 744], ["inhibited", 752], ["the", 762], ["tyrosine", 766], ["kinase", 775], ["activity", 782], ["of", 791], ["BCR", 794], ["-", 797], ["ABL", 798], [",", 801], ["phosphorylation", 803], ["of", 819], ["hTERT", 822], ["was", 828], ["downregulated", 832], [",", 845], ["therefore", 847], ["suggesting", 857], ["a", 868], ["positive", 870], ["correlation", 879], ["between", 891], ["BCR", 899], ["-", 902], ["ABL", 903], ["and", 907], ["hTERT", 911], [".", 916], ["Gleevec", 918], ["treatment", 926], ["inhibited", 936], ["hTERT", 946], ["at", 952], ["mRNA", 955], ["level", 960], ["and", 966], ["significantly", 970], ["reduced", 984], ["telomerase", 992], ["activity", 1003], ["(", 1012], ["TA", 1013], [")", 1015], ["in", 1017], ["K562", 1020], ["cells", 1025], [",", 1030], ["but", 1032], ["not", 1036], ["in", 1040], ["HL60", 1043], ["or", 1048], ["Jurkat", 1051], ["cells", 1058], ["(", 1064], ["BCR", 1065], ["-", 1068], ["ABL", 1069], ["negative", 1073], ["cells", 1082], [")", 1087], [".", 1088], ["We", 1090], ["also", 1093], ["demonstrated", 1098], ["that", 1111], ["the", 1116], ["transcription", 1120], ["factor", 1134], ["STAT5a", 1141], ["plays", 1148], ["a", 1154], ["critical", 1156], ["role", 1165], ["in", 1170], ["hTERT", 1173], ["gene", 1179], ["regulation", 1184], ["in", 1195], ["K562", 1198], ["cells", 1203], [".", 1208], ["Knockdown", 1210], ["of", 1220], ["STAT5a", 1223], [",", 1229], ["but", 1231], ["not", 1235], ["STAT5b", 1239], [",", 1245], ["resulted", 1247], ["in", 1256], ["a", 1259], ["marked", 1261], ["downregulation", 1268], ["of", 1283], ["hTERT", 1286], ["mRNA", 1292], ["level", 1297], [",", 1302], ["TA", 1304], ["and", 1307], ["hTERT", 1311], ["protein", 1317], ["level", 1325], ["in", 1331], ["K562", 1334], ["cells", 1339], [".", 1344], ["Furthermore", 1346], [",", 1357], ["translocation", 1359], ["of", 1373], ["hTERT", 1376], ["from", 1382], ["nucleoli", 1387], ["to", 1396], ["nucleoplasm", 1399], ["was", 1411], ["observed", 1415], ["in", 1424], ["K562", 1427], ["cells", 1432], ["induced", 1438], ["by", 1446], ["Gleevec", 1449], [".", 1456], ["Our", 1458], ["data", 1462], ["reveal", 1467], ["that", 1474], ["BCR", 1479], ["-", 1482], ["ABL", 1483], ["can", 1487], ["regulate", 1491], ["TA", 1500], ["at", 1503], ["multiple", 1506], ["levels", 1515], [",", 1521], ["including", 1523], ["transcription", 1533], [",", 1546], ["post", 1548], ["-", 1552], ["translational", 1553], ["level", 1567], [",", 1572], ["and", 1574], ["proper", 1578], ["localization", 1585], [".", 1597], ["Thus", 1599], [",", 1603], ["suppression", 1605], ["of", 1617], ["cell", 1620], ["growth", 1625], ["and", 1632], ["induction", 1636], ["of", 1646], ["apoptosis", 1649], ["by", 1659], ["Gleevec", 1662], ["treatment", 1670], ["may", 1680], ["be", 1684], ["partially", 1687], ["due", 1697], ["to", 1701], ["TA", 1704], ["inhibition", 1707], [".", 1717], ["Additionally", 1719], [",", 1731], ["we", 1733], ["have", 1736], ["identified", 1741], ["STAT5a", 1752], ["as", 1759], ["critical", 1762], ["mediator", 1771], ["of", 1780], ["the", 1783], ["hTERT", 1787], ["gene", 1793], ["expression", 1798], ["in", 1809], ["BCR", 1812], ["-", 1815], ["ABL", 1816], ["positive", 1820], ["CML", 1829], ["cells", 1833], [",", 1838], ["suggesting", 1840], ["that", 1851], ["targeting", 1856], ["STAT5a", 1866], ["may", 1873], ["be", 1877], ["a", 1880], ["promising", 1882], ["therapeutic", 1892], ["strategy", 1904], ["for", 1913], ["BCR", 1917], ["-", 1920], ["ABL", 1921], ["positive", 1925], ["CML", 1934], ["patients", 1938], [".", 1946]]}
{"context": "Neurological abnormalities associated with spiculated, \"acanthocytic\" red cells in blood have been described as neuroacanthocytosis. This is a heterogeneous group of conditions that can be clearly subdivided on the basis of recent genetic findings. The McLeod Syndrome, one of the core neuroacanthocytosis syndromes, is a rare X-linked disorder caused by mutations of the XK gene, an X-chromosomal gene of unknown function characterized by haemopoietic abnormalities and late-onset neurological and muscular defects. We report two Chilean brothers with the McLeod phenotype who showed important psychiatric features. The diagnosis may be elusive if the presence of acanthocytosis is not properly studied. We describe a method which allowed the diagnosis that unmasked acanthocytosis. Otherwise the condition could have remained undiagnosed as it had been for decades in this family. This syndrome must be considered when assessing a familial movement disorder, specially affecting males with relevant psychiatric features. A reliable test for acanthocytosis assessment is available.", "qas": [{"question": "Mutation of which gene is associated with McLeod syndrome?", "answers": ["XK"], "qid": "c79bc1f8f85548358708cf9eb729f140", "question_tokens": [["Mutation", 0], ["of", 9], ["which", 12], ["gene", 18], ["is", 23], ["associated", 26], ["with", 37], ["McLeod", 42], ["syndrome", 49], ["?", 57]], "detected_answers": [{"text": "XK", "token_spans": [[62, 62]], "char_spans": [[372, 373]]}]}], "context_tokens": [["Neurological", 0], ["abnormalities", 13], ["associated", 27], ["with", 38], ["spiculated", 43], [",", 53], ["\"", 55], ["acanthocytic", 56], ["\"", 68], ["red", 70], ["cells", 74], ["in", 80], ["blood", 83], ["have", 89], ["been", 94], ["described", 99], ["as", 109], ["neuroacanthocytosis", 112], [".", 131], ["This", 133], ["is", 138], ["a", 141], ["heterogeneous", 143], ["group", 157], ["of", 163], ["conditions", 166], ["that", 177], ["can", 182], ["be", 186], ["clearly", 189], ["subdivided", 197], ["on", 208], ["the", 211], ["basis", 215], ["of", 221], ["recent", 224], ["genetic", 231], ["findings", 239], [".", 247], ["The", 249], ["McLeod", 253], ["Syndrome", 260], [",", 268], ["one", 270], ["of", 274], ["the", 277], ["core", 281], ["neuroacanthocytosis", 286], ["syndromes", 306], [",", 315], ["is", 317], ["a", 320], ["rare", 322], ["X", 327], ["-", 328], ["linked", 329], ["disorder", 336], ["caused", 345], ["by", 352], ["mutations", 355], ["of", 365], ["the", 368], ["XK", 372], ["gene", 375], [",", 379], ["an", 381], ["X", 384], ["-", 385], ["chromosomal", 386], ["gene", 398], ["of", 403], ["unknown", 406], ["function", 414], ["characterized", 423], ["by", 437], ["haemopoietic", 440], ["abnormalities", 453], ["and", 467], ["late", 471], ["-", 475], ["onset", 476], ["neurological", 482], ["and", 495], ["muscular", 499], ["defects", 508], [".", 515], ["We", 517], ["report", 520], ["two", 527], ["Chilean", 531], ["brothers", 539], ["with", 548], ["the", 553], ["McLeod", 557], ["phenotype", 564], ["who", 574], ["showed", 578], ["important", 585], ["psychiatric", 595], ["features", 607], [".", 615], ["The", 617], ["diagnosis", 621], ["may", 631], ["be", 635], ["elusive", 638], ["if", 646], ["the", 649], ["presence", 653], ["of", 662], ["acanthocytosis", 665], ["is", 680], ["not", 683], ["properly", 687], ["studied", 696], [".", 703], ["We", 705], ["describe", 708], ["a", 717], ["method", 719], ["which", 726], ["allowed", 732], ["the", 740], ["diagnosis", 744], ["that", 754], ["unmasked", 759], ["acanthocytosis", 768], [".", 782], ["Otherwise", 784], ["the", 794], ["condition", 798], ["could", 808], ["have", 814], ["remained", 819], ["undiagnosed", 828], ["as", 840], ["it", 843], ["had", 846], ["been", 850], ["for", 855], ["decades", 859], ["in", 867], ["this", 870], ["family", 875], [".", 881], ["This", 883], ["syndrome", 888], ["must", 897], ["be", 902], ["considered", 905], ["when", 916], ["assessing", 921], ["a", 931], ["familial", 933], ["movement", 942], ["disorder", 951], [",", 959], ["specially", 961], ["affecting", 971], ["males", 981], ["with", 987], ["relevant", 992], ["psychiatric", 1001], ["features", 1013], [".", 1021], ["A", 1023], ["reliable", 1025], ["test", 1034], ["for", 1039], ["acanthocytosis", 1043], ["assessment", 1058], ["is", 1069], ["available", 1072], [".", 1081]]}
{"context": "High circulating levels of group IIA secretory phospholipase A2 (sPLA2-IIA) activity and mass are independent cardiovascular risk factors. Therefore, inhibition of sPLA2-IIA may be a target for the treatment of atherosclerotic cardiovascular disease. The present study evaluated the effects of sPLA2-IIA inhibition with varespladib acid in a novel mouse model, human apolipoprotein B (apoB)/human cholesteryl ester transfer protein (CETP)/human sPLA2-IIA triple transgenic mice (TTT) fed a Western-type diet. sPLA2-IIA expression increased atherosclerotic lesion formation in TTT compared with human apoB/human CETP double transgenic mice (P<0.01). Varespladib acid effectively inhibited plasma sPLA2-IIA activity. Surprisingly, however, administration of varespladib acid to TTT had no impact on atherosclerosis, which could be attributed to a proatherogenic plasma lipoprotein profile that appears in response to sPLA2-IIA inhibition because of increased plasma CETP activity. In the TTT model, sPLA2-IIA decreased CETP activity by reducing the acceptor properties of sPLA2-IIA-modified very low-density lipoproteins specifically because of a significantly lower apoE content. Increasing very low-density lipoprotein-apoE content by means of adenovirus-mediated gene transfer in sPLA2-IIA transgenic mice restored the acceptor properties for CETP. These data show that in a humanized triple transgenic mouse model with hypercholesterolemia, sPLA2-IIA inhibition increases CETP activity via increasing the very low-density lipoprotein-apoE content, resulting in a proatherogenic lipoprotein profile.", "qas": [{"question": "Which enzyme is inhibited by Varespladib?", "answers": ["secretory phospholipase A2"], "qid": "9f57803776af4b0bbe0deae68fbd40b0", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["Varespladib", 29], ["?", 40]], "detected_answers": [{"text": "secretory phospholipase A2", "token_spans": [[6, 8]], "char_spans": [[37, 62]]}]}], "context_tokens": [["High", 0], ["circulating", 5], ["levels", 17], ["of", 24], ["group", 27], ["IIA", 33], ["secretory", 37], ["phospholipase", 47], ["A2", 61], ["(", 64], ["sPLA2-IIA", 65], [")", 74], ["activity", 76], ["and", 85], ["mass", 89], ["are", 94], ["independent", 98], ["cardiovascular", 110], ["risk", 125], ["factors", 130], [".", 137], ["Therefore", 139], [",", 148], ["inhibition", 150], ["of", 161], ["sPLA2-IIA", 164], ["may", 174], ["be", 178], ["a", 181], ["target", 183], ["for", 190], ["the", 194], ["treatment", 198], ["of", 208], ["atherosclerotic", 211], ["cardiovascular", 227], ["disease", 242], [".", 249], ["The", 251], ["present", 255], ["study", 263], ["evaluated", 269], ["the", 279], ["effects", 283], ["of", 291], ["sPLA2-IIA", 294], ["inhibition", 304], ["with", 315], ["varespladib", 320], ["acid", 332], ["in", 337], ["a", 340], ["novel", 342], ["mouse", 348], ["model", 354], [",", 359], ["human", 361], ["apolipoprotein", 367], ["B", 382], ["(", 384], ["apoB)/human", 385], ["cholesteryl", 397], ["ester", 409], ["transfer", 415], ["protein", 424], ["(", 432], ["CETP)/human", 433], ["sPLA2-IIA", 445], ["triple", 455], ["transgenic", 462], ["mice", 473], ["(", 478], ["TTT", 479], [")", 482], ["fed", 484], ["a", 488], ["Western", 490], ["-", 497], ["type", 498], ["diet", 503], [".", 507], ["sPLA2-IIA", 509], ["expression", 519], ["increased", 530], ["atherosclerotic", 540], ["lesion", 556], ["formation", 563], ["in", 573], ["TTT", 576], ["compared", 580], ["with", 589], ["human", 594], ["apoB", 600], ["/", 604], ["human", 605], ["CETP", 611], ["double", 616], ["transgenic", 623], ["mice", 634], ["(", 639], ["P<0.01", 640], [")", 646], [".", 647], ["Varespladib", 649], ["acid", 661], ["effectively", 666], ["inhibited", 678], ["plasma", 688], ["sPLA2-IIA", 695], ["activity", 705], [".", 713], ["Surprisingly", 715], [",", 727], ["however", 729], [",", 736], ["administration", 738], ["of", 753], ["varespladib", 756], ["acid", 768], ["to", 773], ["TTT", 776], ["had", 780], ["no", 784], ["impact", 787], ["on", 794], ["atherosclerosis", 797], [",", 812], ["which", 814], ["could", 820], ["be", 826], ["attributed", 829], ["to", 840], ["a", 843], ["proatherogenic", 845], ["plasma", 860], ["lipoprotein", 867], ["profile", 879], ["that", 887], ["appears", 892], ["in", 900], ["response", 903], ["to", 912], ["sPLA2-IIA", 915], ["inhibition", 925], ["because", 936], ["of", 944], ["increased", 947], ["plasma", 957], ["CETP", 964], ["activity", 969], [".", 977], ["In", 979], ["the", 982], ["TTT", 986], ["model", 990], [",", 995], ["sPLA2-IIA", 997], ["decreased", 1007], ["CETP", 1017], ["activity", 1022], ["by", 1031], ["reducing", 1034], ["the", 1043], ["acceptor", 1047], ["properties", 1056], ["of", 1067], ["sPLA2-IIA", 1070], ["-", 1079], ["modified", 1080], ["very", 1089], ["low", 1094], ["-", 1097], ["density", 1098], ["lipoproteins", 1106], ["specifically", 1119], ["because", 1132], ["of", 1140], ["a", 1143], ["significantly", 1145], ["lower", 1159], ["apoE", 1165], ["content", 1170], [".", 1177], ["Increasing", 1179], ["very", 1190], ["low", 1195], ["-", 1198], ["density", 1199], ["lipoprotein", 1207], ["-", 1218], ["apoE", 1219], ["content", 1224], ["by", 1232], ["means", 1235], ["of", 1241], ["adenovirus", 1244], ["-", 1254], ["mediated", 1255], ["gene", 1264], ["transfer", 1269], ["in", 1278], ["sPLA2-IIA", 1281], ["transgenic", 1291], ["mice", 1302], ["restored", 1307], ["the", 1316], ["acceptor", 1320], ["properties", 1329], ["for", 1340], ["CETP", 1344], [".", 1348], ["These", 1350], ["data", 1356], ["show", 1361], ["that", 1366], ["in", 1371], ["a", 1374], ["humanized", 1376], ["triple", 1386], ["transgenic", 1393], ["mouse", 1404], ["model", 1410], ["with", 1416], ["hypercholesterolemia", 1421], [",", 1441], ["sPLA2-IIA", 1443], ["inhibition", 1453], ["increases", 1464], ["CETP", 1474], ["activity", 1479], ["via", 1488], ["increasing", 1492], ["the", 1503], ["very", 1507], ["low", 1512], ["-", 1515], ["density", 1516], ["lipoprotein", 1524], ["-", 1535], ["apoE", 1536], ["content", 1541], [",", 1548], ["resulting", 1550], ["in", 1560], ["a", 1563], ["proatherogenic", 1565], ["lipoprotein", 1580], ["profile", 1592], [".", 1599]]}
{"context": "Neurofibromatosis type 1 (NF1) is a common disorder of dysregulated tissue growth secondary to mutations in the tumor suppressor gene NF1. Pulmonary arterial hypertension (PAH) in patients with NF1 is hypothesized to be secondary to an underlying vasculopathy. We describe the entity we term NF1-associated PAH (NF1-PAH) in four new patients and update the data on four previously published reports of patients with PAH and NF1. We performed genetic testing of the bone morphogenic protein receptor 2 (BMPR2) gene, which mutated in 70% of patients with familial PAH and approximately 25% of patients with idiopathic PAH. We report, for the first time, pathologic findings in the autopsy-obtained lung of one patient with NF1-PAH. Patients with NF1-PAH have a generally poor long-term prognosis. In four patients, we observed the mosaic pattern of lung attenuation on a CT scan of the chest, a radiographic finding that can be consistent with an underlying vasculopathy. No mutations or rearrangements in the BMPR2 gene were found. We observed complex plexiform lesions in the one available autopsy specimen. Similar lesions are a hallmark of plexogenic pulmonary arteriopathy and are associated with several severe types of PAH. (Plexiform lesions should not be confused with plexiform neurofibromas, which are distinctive tumors seen in NF1.) Our findings suggest that NF1 should be considered as being \"associated with PAH as outlined in the Revised Clinical Classification of Pulmonary Hypertension. Understanding the mechanism of PAH in NF1 may inform the pathogenesis of PAH, NF1-PAH itself, and other NF1-associated vasculopathies. The pulmonary vasculature should now be included among the arterial beds affected by NF1 vasculopathy.", "qas": [{"question": "Which is the gene mutated in type 1 neurofibromatosis?", "answers": ["NF1"], "qid": "d0289ed00e594970840413f51ee34e30", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["gene", 13], ["mutated", 18], ["in", 26], ["type", 29], ["1", 34], ["neurofibromatosis", 36], ["?", 53]], "detected_answers": [{"text": "NF1", "token_spans": [[243, 243], [299, 299], [22, 22], [236, 236], [4, 4], [73, 73], [270, 270], [33, 33]], "char_spans": [[1370, 1372], [1723, 1725], [134, 136], [1338, 1340], [26, 28], [424, 426], [1541, 1543], [194, 196]]}]}], "context_tokens": [["Neurofibromatosis", 0], ["type", 18], ["1", 23], ["(", 25], ["NF1", 26], [")", 29], ["is", 31], ["a", 34], ["common", 36], ["disorder", 43], ["of", 52], ["dysregulated", 55], ["tissue", 68], ["growth", 75], ["secondary", 82], ["to", 92], ["mutations", 95], ["in", 105], ["the", 108], ["tumor", 112], ["suppressor", 118], ["gene", 129], ["NF1", 134], [".", 137], ["Pulmonary", 139], ["arterial", 149], ["hypertension", 158], ["(", 171], ["PAH", 172], [")", 175], ["in", 177], ["patients", 180], ["with", 189], ["NF1", 194], ["is", 198], ["hypothesized", 201], ["to", 214], ["be", 217], ["secondary", 220], ["to", 230], ["an", 233], ["underlying", 236], ["vasculopathy", 247], [".", 259], ["We", 261], ["describe", 264], ["the", 273], ["entity", 277], ["we", 284], ["term", 287], ["NF1-associated", 292], ["PAH", 307], ["(", 311], ["NF1-PAH", 312], [")", 319], ["in", 321], ["four", 324], ["new", 329], ["patients", 333], ["and", 342], ["update", 346], ["the", 353], ["data", 357], ["on", 362], ["four", 365], ["previously", 370], ["published", 381], ["reports", 391], ["of", 399], ["patients", 402], ["with", 411], ["PAH", 416], ["and", 420], ["NF1", 424], [".", 427], ["We", 429], ["performed", 432], ["genetic", 442], ["testing", 450], ["of", 458], ["the", 461], ["bone", 465], ["morphogenic", 470], ["protein", 482], ["receptor", 490], ["2", 499], ["(", 501], ["BMPR2", 502], [")", 507], ["gene", 509], [",", 513], ["which", 515], ["mutated", 521], ["in", 529], ["70", 532], ["%", 534], ["of", 536], ["patients", 539], ["with", 548], ["familial", 553], ["PAH", 562], ["and", 566], ["approximately", 570], ["25", 584], ["%", 586], ["of", 588], ["patients", 591], ["with", 600], ["idiopathic", 605], ["PAH", 616], [".", 619], ["We", 621], ["report", 624], [",", 630], ["for", 632], ["the", 636], ["first", 640], ["time", 646], [",", 650], ["pathologic", 652], ["findings", 663], ["in", 672], ["the", 675], ["autopsy", 679], ["-", 686], ["obtained", 687], ["lung", 696], ["of", 701], ["one", 704], ["patient", 708], ["with", 716], ["NF1-PAH", 721], [".", 728], ["Patients", 730], ["with", 739], ["NF1-PAH", 744], ["have", 752], ["a", 757], ["generally", 759], ["poor", 769], ["long", 774], ["-", 778], ["term", 779], ["prognosis", 784], [".", 793], ["In", 795], ["four", 798], ["patients", 803], [",", 811], ["we", 813], ["observed", 816], ["the", 825], ["mosaic", 829], ["pattern", 836], ["of", 844], ["lung", 847], ["attenuation", 852], ["on", 864], ["a", 867], ["CT", 869], ["scan", 872], ["of", 877], ["the", 880], ["chest", 884], [",", 889], ["a", 891], ["radiographic", 893], ["finding", 906], ["that", 914], ["can", 919], ["be", 923], ["consistent", 926], ["with", 937], ["an", 942], ["underlying", 945], ["vasculopathy", 956], [".", 968], ["No", 970], ["mutations", 973], ["or", 983], ["rearrangements", 986], ["in", 1001], ["the", 1004], ["BMPR2", 1008], ["gene", 1014], ["were", 1019], ["found", 1024], [".", 1029], ["We", 1031], ["observed", 1034], ["complex", 1043], ["plexiform", 1051], ["lesions", 1061], ["in", 1069], ["the", 1072], ["one", 1076], ["available", 1080], ["autopsy", 1090], ["specimen", 1098], [".", 1106], ["Similar", 1108], ["lesions", 1116], ["are", 1124], ["a", 1128], ["hallmark", 1130], ["of", 1139], ["plexogenic", 1142], ["pulmonary", 1153], ["arteriopathy", 1163], ["and", 1176], ["are", 1180], ["associated", 1184], ["with", 1195], ["several", 1200], ["severe", 1208], ["types", 1215], ["of", 1221], ["PAH", 1224], [".", 1227], ["(", 1229], ["Plexiform", 1230], ["lesions", 1240], ["should", 1248], ["not", 1255], ["be", 1259], ["confused", 1262], ["with", 1271], ["plexiform", 1276], ["neurofibromas", 1286], [",", 1299], ["which", 1301], ["are", 1307], ["distinctive", 1311], ["tumors", 1323], ["seen", 1330], ["in", 1335], ["NF1", 1338], [".", 1341], [")", 1342], ["Our", 1344], ["findings", 1348], ["suggest", 1357], ["that", 1365], ["NF1", 1370], ["should", 1374], ["be", 1381], ["considered", 1384], ["as", 1395], ["being", 1398], ["\"", 1404], ["associated", 1405], ["with", 1416], ["PAH", 1421], ["as", 1425], ["outlined", 1428], ["in", 1437], ["the", 1440], ["Revised", 1444], ["Clinical", 1452], ["Classification", 1461], ["of", 1476], ["Pulmonary", 1479], ["Hypertension", 1489], [".", 1501], ["Understanding", 1503], ["the", 1517], ["mechanism", 1521], ["of", 1531], ["PAH", 1534], ["in", 1538], ["NF1", 1541], ["may", 1545], ["inform", 1549], ["the", 1556], ["pathogenesis", 1560], ["of", 1573], ["PAH", 1576], [",", 1579], ["NF1-PAH", 1581], ["itself", 1589], [",", 1595], ["and", 1597], ["other", 1601], ["NF1-associated", 1607], ["vasculopathies", 1622], [".", 1636], ["The", 1638], ["pulmonary", 1642], ["vasculature", 1652], ["should", 1664], ["now", 1671], ["be", 1675], ["included", 1678], ["among", 1687], ["the", 1693], ["arterial", 1697], ["beds", 1706], ["affected", 1711], ["by", 1720], ["NF1", 1723], ["vasculopathy", 1727], [".", 1739]]}
{"context": "Reperfusion injury to tissue following an ischemic event occurs as a consequence of an acute inflammatory response that can cause significant morbidity and mortality. Components of both the innate (complement, immunoglobulin, monocytes, and neutrophils) and adaptive (B and T lymphocytes) immune systems have been demonstrated to mediate tissue injury. Spleen tyrosine kinase (Syk) is responsible for membrane-mediated signaling in various cell types including B lymphocytes, macrophages, and T cells. We investigated the ability of a small drug Syk inhibitor, R788, to protect mice against mesenteric ischemia-reperfusion (I/R)-induced local (intestine) and remote lung injury. Mice were fed with chow containing a Syk inhibitor for 6 days before the performance of intestinal I/R, which resulted in silencing of the expression of the active phosphorylated Syk. Syk inhibition significantly suppressed both local and remote lung injury. The beneficial effect was associated with reduced IgM and complement 3 deposition in the tissues and significant reduction of polymorphonuclear cell infiltration. Our data place Syk upstream of events leading to the binding of natural antibodies to the ischemia-conditioned tissues and urge the consideration of the use of Syk inhibitors in the prevention or improvement of tissue injury of organs exposed to ischemia or hypoperfusion.", "qas": [{"question": "Which enzyme is inhibited by a drug fostamatinib?", "answers": ["spleen tyrosine kinase"], "qid": "c39a985f3db547f193720f8ea9d1d8ff", "question_tokens": [["Which", 0], ["enzyme", 6], ["is", 13], ["inhibited", 16], ["by", 26], ["a", 29], ["drug", 31], ["fostamatinib", 36], ["?", 48]], "detected_answers": [{"text": "spleen tyrosine kinase", "token_spans": [[58, 60]], "char_spans": [[353, 374]]}]}], "context_tokens": [["Reperfusion", 0], ["injury", 12], ["to", 19], ["tissue", 22], ["following", 29], ["an", 39], ["ischemic", 42], ["event", 51], ["occurs", 57], ["as", 64], ["a", 67], ["consequence", 69], ["of", 81], ["an", 84], ["acute", 87], ["inflammatory", 93], ["response", 106], ["that", 115], ["can", 120], ["cause", 124], ["significant", 130], ["morbidity", 142], ["and", 152], ["mortality", 156], [".", 165], ["Components", 167], ["of", 178], ["both", 181], ["the", 186], ["innate", 190], ["(", 197], ["complement", 198], [",", 208], ["immunoglobulin", 210], [",", 224], ["monocytes", 226], [",", 235], ["and", 237], ["neutrophils", 241], [")", 252], ["and", 254], ["adaptive", 258], ["(", 267], ["B", 268], ["and", 270], ["T", 274], ["lymphocytes", 276], [")", 287], ["immune", 289], ["systems", 296], ["have", 304], ["been", 309], ["demonstrated", 314], ["to", 327], ["mediate", 330], ["tissue", 338], ["injury", 345], [".", 351], ["Spleen", 353], ["tyrosine", 360], ["kinase", 369], ["(", 376], ["Syk", 377], [")", 380], ["is", 382], ["responsible", 385], ["for", 397], ["membrane", 401], ["-", 409], ["mediated", 410], ["signaling", 419], ["in", 429], ["various", 432], ["cell", 440], ["types", 445], ["including", 451], ["B", 461], ["lymphocytes", 463], [",", 474], ["macrophages", 476], [",", 487], ["and", 489], ["T", 493], ["cells", 495], [".", 500], ["We", 502], ["investigated", 505], ["the", 518], ["ability", 522], ["of", 530], ["a", 533], ["small", 535], ["drug", 541], ["Syk", 546], ["inhibitor", 550], [",", 559], ["R788", 561], [",", 565], ["to", 567], ["protect", 570], ["mice", 578], ["against", 583], ["mesenteric", 591], ["ischemia", 602], ["-", 610], ["reperfusion", 611], ["(", 623], ["I", 624], ["/", 625], ["R)-induced", 626], ["local", 637], ["(", 643], ["intestine", 644], [")", 653], ["and", 655], ["remote", 659], ["lung", 666], ["injury", 671], [".", 677], ["Mice", 679], ["were", 684], ["fed", 689], ["with", 693], ["chow", 698], ["containing", 703], ["a", 714], ["Syk", 716], ["inhibitor", 720], ["for", 730], ["6", 734], ["days", 736], ["before", 741], ["the", 748], ["performance", 752], ["of", 764], ["intestinal", 767], ["I", 778], ["/", 779], ["R", 780], [",", 781], ["which", 783], ["resulted", 789], ["in", 798], ["silencing", 801], ["of", 811], ["the", 814], ["expression", 818], ["of", 829], ["the", 832], ["active", 836], ["phosphorylated", 843], ["Syk", 858], [".", 861], ["Syk", 863], ["inhibition", 867], ["significantly", 878], ["suppressed", 892], ["both", 903], ["local", 908], ["and", 914], ["remote", 918], ["lung", 925], ["injury", 930], [".", 936], ["The", 938], ["beneficial", 942], ["effect", 953], ["was", 960], ["associated", 964], ["with", 975], ["reduced", 980], ["IgM", 988], ["and", 992], ["complement", 996], ["3", 1007], ["deposition", 1009], ["in", 1020], ["the", 1023], ["tissues", 1027], ["and", 1035], ["significant", 1039], ["reduction", 1051], ["of", 1061], ["polymorphonuclear", 1064], ["cell", 1082], ["infiltration", 1087], [".", 1099], ["Our", 1101], ["data", 1105], ["place", 1110], ["Syk", 1116], ["upstream", 1120], ["of", 1129], ["events", 1132], ["leading", 1139], ["to", 1147], ["the", 1150], ["binding", 1154], ["of", 1162], ["natural", 1165], ["antibodies", 1173], ["to", 1184], ["the", 1187], ["ischemia", 1191], ["-", 1199], ["conditioned", 1200], ["tissues", 1212], ["and", 1220], ["urge", 1224], ["the", 1229], ["consideration", 1233], ["of", 1247], ["the", 1250], ["use", 1254], ["of", 1258], ["Syk", 1261], ["inhibitors", 1265], ["in", 1276], ["the", 1279], ["prevention", 1283], ["or", 1294], ["improvement", 1297], ["of", 1309], ["tissue", 1312], ["injury", 1319], ["of", 1326], ["organs", 1329], ["exposed", 1336], ["to", 1344], ["ischemia", 1347], ["or", 1356], ["hypoperfusion", 1359], [".", 1372]]}
{"context": "p73 is a p53 family transcription factor. Due to the presence in the 5' flanking region of two promoters, there are two N-terminal variants, TAp73, which retains a fully active transactivation domain (TA), and \u0394Np73, in which the N terminus is truncated. In addition, extensive 3' splicing gives rise to at least seven distinctive isoforms; TAp73-selective knockout highlights its role as a regulator of cell death, senescence and tumor suppressor. \u0394Np73-selective knockout, on the other hand, highlights anti-apoptotic function of \u0394Np73 and its involvement in DNA damage response. In this work, we investigated the expression pattern of murine p73 C-terminal isoforms. By using a RT-PCR approach, we were able to detect mRNAs of all the C-terminal isoforms described in humans. We characterized their in vivo expression profile in mouse organs and in different mouse developmental stages. Finally, we investigated p73 C-terminal expression profile following DNA damage, ex vivo after primary cultures treatment and in vivo after systemic administration of cytotoxic compounds. Overall, our study first elucidates spatio-temporal expression of mouse p73 isoforms and provides novel insights on their expression-switch under triggered conditions.", "qas": [{"question": "How many TAp73 isoforms have been identified in humans?", "answers": ["seven", "7"], "qid": "4d0d8f548cf94dc489db689b3aa53512", "question_tokens": [["How", 0], ["many", 4], ["TAp73", 9], ["isoforms", 15], ["have", 24], ["been", 29], ["identified", 34], ["in", 45], ["humans", 48], ["?", 54]], "detected_answers": [{"text": "seven", "token_spans": [[66, 66]], "char_spans": [[313, 317]]}]}], "context_tokens": [["p73", 0], ["is", 4], ["a", 7], ["p53", 9], ["family", 13], ["transcription", 20], ["factor", 34], [".", 40], ["Due", 42], ["to", 46], ["the", 49], ["presence", 53], ["in", 62], ["the", 65], ["5", 69], ["'", 70], ["flanking", 72], ["region", 81], ["of", 88], ["two", 91], ["promoters", 95], [",", 104], ["there", 106], ["are", 112], ["two", 116], ["N", 120], ["-", 121], ["terminal", 122], ["variants", 131], [",", 139], ["TAp73", 141], [",", 146], ["which", 148], ["retains", 154], ["a", 162], ["fully", 164], ["active", 170], ["transactivation", 177], ["domain", 193], ["(", 200], ["TA", 201], [")", 203], [",", 204], ["and", 206], ["\u0394Np73", 210], [",", 215], ["in", 217], ["which", 220], ["the", 226], ["N", 230], ["terminus", 232], ["is", 241], ["truncated", 244], [".", 253], ["In", 255], ["addition", 258], [",", 266], ["extensive", 268], ["3", 278], ["'", 279], ["splicing", 281], ["gives", 290], ["rise", 296], ["to", 301], ["at", 304], ["least", 307], ["seven", 313], ["distinctive", 319], ["isoforms", 331], [";", 339], ["TAp73-selective", 341], ["knockout", 357], ["highlights", 366], ["its", 377], ["role", 381], ["as", 386], ["a", 389], ["regulator", 391], ["of", 401], ["cell", 404], ["death", 409], [",", 414], ["senescence", 416], ["and", 427], ["tumor", 431], ["suppressor", 437], [".", 447], ["\u0394Np73-selective", 449], ["knockout", 465], [",", 473], ["on", 475], ["the", 478], ["other", 482], ["hand", 488], [",", 492], ["highlights", 494], ["anti", 505], ["-", 509], ["apoptotic", 510], ["function", 520], ["of", 529], ["\u0394Np73", 532], ["and", 538], ["its", 542], ["involvement", 546], ["in", 558], ["DNA", 561], ["damage", 565], ["response", 572], [".", 580], ["In", 582], ["this", 585], ["work", 590], [",", 594], ["we", 596], ["investigated", 599], ["the", 612], ["expression", 616], ["pattern", 627], ["of", 635], ["murine", 638], ["p73", 645], ["C", 649], ["-", 650], ["terminal", 651], ["isoforms", 660], [".", 668], ["By", 670], ["using", 673], ["a", 679], ["RT", 681], ["-", 683], ["PCR", 684], ["approach", 688], [",", 696], ["we", 698], ["were", 701], ["able", 706], ["to", 711], ["detect", 714], ["mRNAs", 721], ["of", 727], ["all", 730], ["the", 734], ["C", 738], ["-", 739], ["terminal", 740], ["isoforms", 749], ["described", 758], ["in", 768], ["humans", 771], [".", 777], ["We", 779], ["characterized", 782], ["their", 796], ["in", 802], ["vivo", 805], ["expression", 810], ["profile", 821], ["in", 829], ["mouse", 832], ["organs", 838], ["and", 845], ["in", 849], ["different", 852], ["mouse", 862], ["developmental", 868], ["stages", 882], [".", 888], ["Finally", 890], [",", 897], ["we", 899], ["investigated", 902], ["p73", 915], ["C", 919], ["-", 920], ["terminal", 921], ["expression", 930], ["profile", 941], ["following", 949], ["DNA", 959], ["damage", 963], [",", 969], ["ex", 971], ["vivo", 974], ["after", 979], ["primary", 985], ["cultures", 993], ["treatment", 1002], ["and", 1012], ["in", 1016], ["vivo", 1019], ["after", 1024], ["systemic", 1030], ["administration", 1039], ["of", 1054], ["cytotoxic", 1057], ["compounds", 1067], [".", 1076], ["Overall", 1078], [",", 1085], ["our", 1087], ["study", 1091], ["first", 1097], ["elucidates", 1103], ["spatio", 1114], ["-", 1120], ["temporal", 1121], ["expression", 1130], ["of", 1141], ["mouse", 1144], ["p73", 1150], ["isoforms", 1154], ["and", 1163], ["provides", 1167], ["novel", 1176], ["insights", 1182], ["on", 1191], ["their", 1194], ["expression", 1200], ["-", 1210], ["switch", 1211], ["under", 1218], ["triggered", 1224], ["conditions", 1234], [".", 1244]]}
{"context": "Histone variant H2A.Z-containing nucleosomes exist at most eukaryotic promoters and play important roles in gene transcription and genome stability. The multisubunit nucleosome-remodeling enzyme complex SWR1, conserved from yeast to mammals, catalyzes the ATP-dependent replacement of histone H2A in canonical nucleosomes with H2A.Z. How SWR1 catalyzes the replacement reaction is largely unknown. Here, we determined the crystal structure of the N-terminal region (599-627) of the catalytic subunit Swr1, termed Swr1-Z domain, in complex with the H2A.Z-H2B dimer at 1.78 \u00c5 resolution. The Swr1-Z domain forms a 310 helix and an irregular chain. A conserved LxxLF motif in the Swr1-Z 310 helix specifically recognizes the \u03b1C helix of H2A.Z. Our results show that the Swr1-Z domain can deliver the H2A.Z-H2B dimer to the DNA-(H3-H4)2 tetrasome to form the nucleosome by a histone chaperone mechanism.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "fd3253087bbd4003b295d765450a9097", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[83, 83], [52, 52], [29, 29]], "char_spans": [[500, 503], [338, 341], [203, 206]]}]}], "context_tokens": [["Histone", 0], ["variant", 8], ["H2A.Z", 16], ["-", 21], ["containing", 22], ["nucleosomes", 33], ["exist", 45], ["at", 51], ["most", 54], ["eukaryotic", 59], ["promoters", 70], ["and", 80], ["play", 84], ["important", 89], ["roles", 99], ["in", 105], ["gene", 108], ["transcription", 113], ["and", 127], ["genome", 131], ["stability", 138], [".", 147], ["The", 149], ["multisubunit", 153], ["nucleosome", 166], ["-", 176], ["remodeling", 177], ["enzyme", 188], ["complex", 195], ["SWR1", 203], [",", 207], ["conserved", 209], ["from", 219], ["yeast", 224], ["to", 230], ["mammals", 233], [",", 240], ["catalyzes", 242], ["the", 252], ["ATP", 256], ["-", 259], ["dependent", 260], ["replacement", 270], ["of", 282], ["histone", 285], ["H2A", 293], ["in", 297], ["canonical", 300], ["nucleosomes", 310], ["with", 322], ["H2A.Z.", 327], ["How", 334], ["SWR1", 338], ["catalyzes", 343], ["the", 353], ["replacement", 357], ["reaction", 369], ["is", 378], ["largely", 381], ["unknown", 389], [".", 396], ["Here", 398], [",", 402], ["we", 404], ["determined", 407], ["the", 418], ["crystal", 422], ["structure", 430], ["of", 440], ["the", 443], ["N", 447], ["-", 448], ["terminal", 449], ["region", 458], ["(", 465], ["599", 466], ["-", 469], ["627", 470], [")", 473], ["of", 475], ["the", 478], ["catalytic", 482], ["subunit", 492], ["Swr1", 500], [",", 504], ["termed", 506], ["Swr1-Z", 513], ["domain", 520], [",", 526], ["in", 528], ["complex", 531], ["with", 539], ["the", 544], ["H2A.Z", 548], ["-", 553], ["H2B", 554], ["dimer", 558], ["at", 564], ["1.78", 567], ["\u00c5", 572], ["resolution", 574], [".", 584], ["The", 586], ["Swr1-Z", 590], ["domain", 597], ["forms", 604], ["a", 610], ["310", 612], ["helix", 616], ["and", 622], ["an", 626], ["irregular", 629], ["chain", 639], [".", 644], ["A", 646], ["conserved", 648], ["LxxLF", 658], ["motif", 664], ["in", 670], ["the", 673], ["Swr1-Z", 677], ["310", 684], ["helix", 688], ["specifically", 694], ["recognizes", 707], ["the", 718], ["\u03b1C", 722], ["helix", 725], ["of", 731], ["H2A.Z.", 734], ["Our", 741], ["results", 745], ["show", 753], ["that", 758], ["the", 763], ["Swr1-Z", 767], ["domain", 774], ["can", 781], ["deliver", 785], ["the", 793], ["H2A.Z", 797], ["-", 802], ["H2B", 803], ["dimer", 807], ["to", 813], ["the", 816], ["DNA-(H3-H4)2", 820], ["tetrasome", 833], ["to", 843], ["form", 846], ["the", 851], ["nucleosome", 855], ["by", 866], ["a", 869], ["histone", 871], ["chaperone", 879], ["mechanism", 889], [".", 898]]}
{"context": "The completeness of meningioma resection depends on the resection of dura mater invaded by the tumor. The pathological changes of the dura around the tumor can be interpreted by evaluating the dural tail sign (DTS) on MRI studies. The goal of this study was to clarify the pathological characteristics of the DTSs, propose a classification based on the histopathological and radiological correlation, and identify the invasive range of tumor cells in different types of DTS. The authors retrospectively reviewed 179 patients with convexity meningiomas who underwent Simpson Grade I resection. All patients underwent an enhanced MRI examination preoperatively. The convexity meningiomas were dichotomized into various subtypes in accordance with the 2007 WHO classification of tumors of the CNS, and the DTS was identified based on the Goldsher criteria. The range of resection of the involved dura was 3 cm from the base of the tumor, which corresponded with the length of DTS on MRI studies. Histopathological examination of dura at 0.5, 1.0, 1.5, 2.0, 2.5, and 3.0 cm from the base of the tumor was conducted, and the findings were correlated with the preoperative MRI appearance of the DTS. A total of 154 (86%) of 179 convexity meningiomas were classified into WHO Grade I subtype, including transitional (44 [28.6%] of 154), meningothelial (36 [23.4%] of 154), fibrous (23 [14.9%] of 154), psammomatous (22 [14.3%] of 154), secretory (10 [6.5%] of 154), and angiomatous (19 [12.3%] of 154). The other 25 (14%) were non-Grade I (WHO) tumors, including atypical (12 [48%] of 25), anaplastic (5 [20%] of 25), and papillary (8 [32%] of 25). The DTS was classified into 5 types: smooth (16 [8.9%] of 179), nodular (36 [20.1%] of 179), mixed (57 [31.8%] of 179), symmetrical multipolar (15 [8.4%] of 179), and asymmetrical multipolar (55 [30.7%] of 179). There was a significant difference in distribution of DTS type between Grade I and non-Grade I tumors (p = 0.004), whereas the difference was not significant among Grade I tumors (0.841) or among non-Grade I tumors (p = 0.818). All smooth-type DTSs were encountered in Grade I tumors, and the mixed DTS (52 [33.8%] of 154) was the most common type in these tumors. Nodular-type DTS was more commonly seen in non-Grade I tumors (12 [48%] of 25). Tumor invasion was found in 88.3% (158 of 179) of convexity meningiomas, of which the range of invasion in 82.3% (130 of 158) was within 2 cm and that in 94.9% (150 of 158) was within 2.5 cm. The incidence of invasion and the range invaded by tumor cells varied in different types of DTS, and differences were statistically significant (p < 0.001). Nodular-type DTS on MRI studies might be associated with non-Grade I tumors. The range of dural resection for convexity meningiomas should be 2.5 cm from the tumor base, and if this extent of resection is not feasible, the type of DTS should be considered. However, for skull base meningiomas, in which mostly Simpson Grade II resection is achieved, the use of this classification should be further validated. The classification of DTS enables the surgeon to predict preoperatively and then to achieve the optimal range of dural resection that might significantly reduce the recurrence rate of meningiomas.", "qas": [{"question": "Simpson grading is used to describe resection of which brain tumor?", "answers": ["meningioma"], "qid": "dfc371178f7740ec80686c0baf2ecc3a", "question_tokens": [["Simpson", 0], ["grading", 8], ["is", 16], ["used", 19], ["to", 24], ["describe", 27], ["resection", 36], ["of", 46], ["which", 49], ["brain", 55], ["tumor", 61], ["?", 66]], "detected_answers": [{"text": "meningioma", "token_spans": [[3, 3]], "char_spans": [[20, 29]]}]}], "context_tokens": [["The", 0], ["completeness", 4], ["of", 17], ["meningioma", 20], ["resection", 31], ["depends", 41], ["on", 49], ["the", 52], ["resection", 56], ["of", 66], ["dura", 69], ["mater", 74], ["invaded", 80], ["by", 88], ["the", 91], ["tumor", 95], [".", 100], ["The", 102], ["pathological", 106], ["changes", 119], ["of", 127], ["the", 130], ["dura", 134], ["around", 139], ["the", 146], ["tumor", 150], ["can", 156], ["be", 160], ["interpreted", 163], ["by", 175], ["evaluating", 178], ["the", 189], ["dural", 193], ["tail", 199], ["sign", 204], ["(", 209], ["DTS", 210], [")", 213], ["on", 215], ["MRI", 218], ["studies", 222], [".", 229], ["The", 231], ["goal", 235], ["of", 240], ["this", 243], ["study", 248], ["was", 254], ["to", 258], ["clarify", 261], ["the", 269], ["pathological", 273], ["characteristics", 286], ["of", 302], ["the", 305], ["DTSs", 309], [",", 313], ["propose", 315], ["a", 323], ["classification", 325], ["based", 340], ["on", 346], ["the", 349], ["histopathological", 353], ["and", 371], ["radiological", 375], ["correlation", 388], [",", 399], ["and", 401], ["identify", 405], ["the", 414], ["invasive", 418], ["range", 427], ["of", 433], ["tumor", 436], ["cells", 442], ["in", 448], ["different", 451], ["types", 461], ["of", 467], ["DTS", 470], [".", 473], ["The", 475], ["authors", 479], ["retrospectively", 487], ["reviewed", 503], ["179", 512], ["patients", 516], ["with", 525], ["convexity", 530], ["meningiomas", 540], ["who", 552], ["underwent", 556], ["Simpson", 566], ["Grade", 574], ["I", 580], ["resection", 582], [".", 591], ["All", 593], ["patients", 597], ["underwent", 606], ["an", 616], ["enhanced", 619], ["MRI", 628], ["examination", 632], ["preoperatively", 644], [".", 658], ["The", 660], ["convexity", 664], ["meningiomas", 674], ["were", 686], ["dichotomized", 691], ["into", 704], ["various", 709], ["subtypes", 717], ["in", 726], ["accordance", 729], ["with", 740], ["the", 745], ["2007", 749], ["WHO", 754], ["classification", 758], ["of", 773], ["tumors", 776], ["of", 783], ["the", 786], ["CNS", 790], [",", 793], ["and", 795], ["the", 799], ["DTS", 803], ["was", 807], ["identified", 811], ["based", 822], ["on", 828], ["the", 831], ["Goldsher", 835], ["criteria", 844], [".", 852], ["The", 854], ["range", 858], ["of", 864], ["resection", 867], ["of", 877], ["the", 880], ["involved", 884], ["dura", 893], ["was", 898], ["3", 902], ["cm", 904], ["from", 907], ["the", 912], ["base", 916], ["of", 921], ["the", 924], ["tumor", 928], [",", 933], ["which", 935], ["corresponded", 941], ["with", 954], ["the", 959], ["length", 963], ["of", 970], ["DTS", 973], ["on", 977], ["MRI", 980], ["studies", 984], [".", 991], ["Histopathological", 993], ["examination", 1011], ["of", 1023], ["dura", 1026], ["at", 1031], ["0.5", 1034], [",", 1037], ["1.0", 1039], [",", 1042], ["1.5", 1044], [",", 1047], ["2.0", 1049], [",", 1052], ["2.5", 1054], [",", 1057], ["and", 1059], ["3.0", 1063], ["cm", 1067], ["from", 1070], ["the", 1075], ["base", 1079], ["of", 1084], ["the", 1087], ["tumor", 1091], ["was", 1097], ["conducted", 1101], [",", 1110], ["and", 1112], ["the", 1116], ["findings", 1120], ["were", 1129], ["correlated", 1134], ["with", 1145], ["the", 1150], ["preoperative", 1154], ["MRI", 1167], ["appearance", 1171], ["of", 1182], ["the", 1185], ["DTS", 1189], [".", 1192], ["A", 1194], ["total", 1196], ["of", 1202], ["154", 1205], ["(", 1209], ["86", 1210], ["%", 1212], [")", 1213], ["of", 1215], ["179", 1218], ["convexity", 1222], ["meningiomas", 1232], ["were", 1244], ["classified", 1249], ["into", 1260], ["WHO", 1265], ["Grade", 1269], ["I", 1275], ["subtype", 1277], [",", 1284], ["including", 1286], ["transitional", 1296], ["(", 1309], ["44", 1310], ["[", 1313], ["28.6", 1314], ["%", 1318], ["]", 1319], ["of", 1321], ["154", 1324], [")", 1327], [",", 1328], ["meningothelial", 1330], ["(", 1345], ["36", 1346], ["[", 1349], ["23.4", 1350], ["%", 1354], ["]", 1355], ["of", 1357], ["154", 1360], [")", 1363], [",", 1364], ["fibrous", 1366], ["(", 1374], ["23", 1375], ["[", 1378], ["14.9", 1379], ["%", 1383], ["]", 1384], ["of", 1386], ["154", 1389], [")", 1392], [",", 1393], ["psammomatous", 1395], ["(", 1408], ["22", 1409], ["[", 1412], ["14.3", 1413], ["%", 1417], ["]", 1418], ["of", 1420], ["154", 1423], [")", 1426], [",", 1427], ["secretory", 1429], ["(", 1439], ["10", 1440], ["[", 1443], ["6.5", 1444], ["%", 1447], ["]", 1448], ["of", 1450], ["154", 1453], [")", 1456], [",", 1457], ["and", 1459], ["angiomatous", 1463], ["(", 1475], ["19", 1476], ["[", 1479], ["12.3", 1480], ["%", 1484], ["]", 1485], ["of", 1487], ["154", 1490], [")", 1493], [".", 1494], ["The", 1496], ["other", 1500], ["25", 1506], ["(", 1509], ["14", 1510], ["%", 1512], [")", 1513], ["were", 1515], ["non", 1520], ["-", 1523], ["Grade", 1524], ["I", 1530], ["(", 1532], ["WHO", 1533], [")", 1536], ["tumors", 1538], [",", 1544], ["including", 1546], ["atypical", 1556], ["(", 1565], ["12", 1566], ["[", 1569], ["48", 1570], ["%", 1572], ["]", 1573], ["of", 1575], ["25", 1578], [")", 1580], [",", 1581], ["anaplastic", 1583], ["(", 1594], ["5", 1595], ["[", 1597], ["20", 1598], ["%", 1600], ["]", 1601], ["of", 1603], ["25", 1606], [")", 1608], [",", 1609], ["and", 1611], ["papillary", 1615], ["(", 1625], ["8", 1626], ["[", 1628], ["32", 1629], ["%", 1631], ["]", 1632], ["of", 1634], ["25", 1637], [")", 1639], [".", 1640], ["The", 1642], ["DTS", 1646], ["was", 1650], ["classified", 1654], ["into", 1665], ["5", 1670], ["types", 1672], [":", 1677], ["smooth", 1679], ["(", 1686], ["16", 1687], ["[", 1690], ["8.9", 1691], ["%", 1694], ["]", 1695], ["of", 1697], ["179", 1700], [")", 1703], [",", 1704], ["nodular", 1706], ["(", 1714], ["36", 1715], ["[", 1718], ["20.1", 1719], ["%", 1723], ["]", 1724], ["of", 1726], ["179", 1729], [")", 1732], [",", 1733], ["mixed", 1735], ["(", 1741], ["57", 1742], ["[", 1745], ["31.8", 1746], ["%", 1750], ["]", 1751], ["of", 1753], ["179", 1756], [")", 1759], [",", 1760], ["symmetrical", 1762], ["multipolar", 1774], ["(", 1785], ["15", 1786], ["[", 1789], ["8.4", 1790], ["%", 1793], ["]", 1794], ["of", 1796], ["179", 1799], [")", 1802], [",", 1803], ["and", 1805], ["asymmetrical", 1809], ["multipolar", 1822], ["(", 1833], ["55", 1834], ["[", 1837], ["30.7", 1838], ["%", 1842], ["]", 1843], ["of", 1845], ["179", 1848], [")", 1851], [".", 1852], ["There", 1854], ["was", 1860], ["a", 1864], ["significant", 1866], ["difference", 1878], ["in", 1889], ["distribution", 1892], ["of", 1905], ["DTS", 1908], ["type", 1912], ["between", 1917], ["Grade", 1925], ["I", 1931], ["and", 1933], ["non", 1937], ["-", 1940], ["Grade", 1941], ["I", 1947], ["tumors", 1949], ["(", 1956], ["p", 1957], ["=", 1959], ["0.004", 1961], [")", 1966], [",", 1967], ["whereas", 1969], ["the", 1977], ["difference", 1981], ["was", 1992], ["not", 1996], ["significant", 2000], ["among", 2012], ["Grade", 2018], ["I", 2024], ["tumors", 2026], ["(", 2033], ["0.841", 2034], [")", 2039], ["or", 2041], ["among", 2044], ["non", 2050], ["-", 2053], ["Grade", 2054], ["I", 2060], ["tumors", 2062], ["(", 2069], ["p", 2070], ["=", 2072], ["0.818", 2074], [")", 2079], [".", 2080], ["All", 2082], ["smooth", 2086], ["-", 2092], ["type", 2093], ["DTSs", 2098], ["were", 2103], ["encountered", 2108], ["in", 2120], ["Grade", 2123], ["I", 2129], ["tumors", 2131], [",", 2137], ["and", 2139], ["the", 2143], ["mixed", 2147], ["DTS", 2153], ["(", 2157], ["52", 2158], ["[", 2161], ["33.8", 2162], ["%", 2166], ["]", 2167], ["of", 2169], ["154", 2172], [")", 2175], ["was", 2177], ["the", 2181], ["most", 2185], ["common", 2190], ["type", 2197], ["in", 2202], ["these", 2205], ["tumors", 2211], [".", 2217], ["Nodular", 2219], ["-", 2226], ["type", 2227], ["DTS", 2232], ["was", 2236], ["more", 2240], ["commonly", 2245], ["seen", 2254], ["in", 2259], ["non", 2262], ["-", 2265], ["Grade", 2266], ["I", 2272], ["tumors", 2274], ["(", 2281], ["12", 2282], ["[", 2285], ["48", 2286], ["%", 2288], ["]", 2289], ["of", 2291], ["25", 2294], [")", 2296], [".", 2297], ["Tumor", 2299], ["invasion", 2305], ["was", 2314], ["found", 2318], ["in", 2324], ["88.3", 2327], ["%", 2331], ["(", 2333], ["158", 2334], ["of", 2338], ["179", 2341], [")", 2344], ["of", 2346], ["convexity", 2349], ["meningiomas", 2359], [",", 2370], ["of", 2372], ["which", 2375], ["the", 2381], ["range", 2385], ["of", 2391], ["invasion", 2394], ["in", 2403], ["82.3", 2406], ["%", 2410], ["(", 2412], ["130", 2413], ["of", 2417], ["158", 2420], [")", 2423], ["was", 2425], ["within", 2429], ["2", 2436], ["cm", 2438], ["and", 2441], ["that", 2445], ["in", 2450], ["94.9", 2453], ["%", 2457], ["(", 2459], ["150", 2460], ["of", 2464], ["158", 2467], [")", 2470], ["was", 2472], ["within", 2476], ["2.5", 2483], ["cm", 2487], [".", 2489], ["The", 2491], ["incidence", 2495], ["of", 2505], ["invasion", 2508], ["and", 2517], ["the", 2521], ["range", 2525], ["invaded", 2531], ["by", 2539], ["tumor", 2542], ["cells", 2548], ["varied", 2554], ["in", 2561], ["different", 2564], ["types", 2574], ["of", 2580], ["DTS", 2583], [",", 2586], ["and", 2588], ["differences", 2592], ["were", 2604], ["statistically", 2609], ["significant", 2623], ["(", 2635], ["p", 2636], ["<", 2638], ["0.001", 2640], [")", 2645], [".", 2646], ["Nodular", 2648], ["-", 2655], ["type", 2656], ["DTS", 2661], ["on", 2665], ["MRI", 2668], ["studies", 2672], ["might", 2680], ["be", 2686], ["associated", 2689], ["with", 2700], ["non", 2705], ["-", 2708], ["Grade", 2709], ["I", 2715], ["tumors", 2717], [".", 2723], ["The", 2725], ["range", 2729], ["of", 2735], ["dural", 2738], ["resection", 2744], ["for", 2754], ["convexity", 2758], ["meningiomas", 2768], ["should", 2780], ["be", 2787], ["2.5", 2790], ["cm", 2794], ["from", 2797], ["the", 2802], ["tumor", 2806], ["base", 2812], [",", 2816], ["and", 2818], ["if", 2822], ["this", 2825], ["extent", 2830], ["of", 2837], ["resection", 2840], ["is", 2850], ["not", 2853], ["feasible", 2857], [",", 2865], ["the", 2867], ["type", 2871], ["of", 2876], ["DTS", 2879], ["should", 2883], ["be", 2890], ["considered", 2893], [".", 2903], ["However", 2905], [",", 2912], ["for", 2914], ["skull", 2918], ["base", 2924], ["meningiomas", 2929], [",", 2940], ["in", 2942], ["which", 2945], ["mostly", 2951], ["Simpson", 2958], ["Grade", 2966], ["II", 2972], ["resection", 2975], ["is", 2985], ["achieved", 2988], [",", 2996], ["the", 2998], ["use", 3002], ["of", 3006], ["this", 3009], ["classification", 3014], ["should", 3029], ["be", 3036], ["further", 3039], ["validated", 3047], [".", 3056], ["The", 3058], ["classification", 3062], ["of", 3077], ["DTS", 3080], ["enables", 3084], ["the", 3092], ["surgeon", 3096], ["to", 3104], ["predict", 3107], ["preoperatively", 3115], ["and", 3130], ["then", 3134], ["to", 3139], ["achieve", 3142], ["the", 3150], ["optimal", 3154], ["range", 3162], ["of", 3168], ["dural", 3171], ["resection", 3177], ["that", 3187], ["might", 3192], ["significantly", 3198], ["reduce", 3212], ["the", 3219], ["recurrence", 3223], ["rate", 3234], ["of", 3239], ["meningiomas", 3242], [".", 3253]]}
{"context": "A family with the Romano-Ward syndrome is presented. This family showed typical features of this syndrome with QT prolongation, torsades de pointes ventricular tachycardia, sudden death and an autosomal dominant inheritance pattern. The index case presented with an exacerbation of torsades de pointes ventricular tachycardia from diuretic induced hypokalaemia, and responded to diuretic withdrawal and beta blocker therapy.", "qas": [{"question": "What is the mode of inheritance of Romano Ward long QT syndrome?", "answers": ["autosomal dominant"], "qid": "f3e0556321574bc9984f02992df32320", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["mode", 12], ["of", 17], ["inheritance", 20], ["of", 32], ["Romano", 35], ["Ward", 42], ["long", 47], ["QT", 52], ["syndrome", 55], ["?", 63]], "detected_answers": [{"text": "autosomal dominant", "token_spans": [[33, 34]], "char_spans": [[193, 210]]}]}], "context_tokens": [["A", 0], ["family", 2], ["with", 9], ["the", 14], ["Romano", 18], ["-", 24], ["Ward", 25], ["syndrome", 30], ["is", 39], ["presented", 42], [".", 51], ["This", 53], ["family", 58], ["showed", 65], ["typical", 72], ["features", 80], ["of", 89], ["this", 92], ["syndrome", 97], ["with", 106], ["QT", 111], ["prolongation", 114], [",", 126], ["torsades", 128], ["de", 137], ["pointes", 140], ["ventricular", 148], ["tachycardia", 160], [",", 171], ["sudden", 173], ["death", 180], ["and", 186], ["an", 190], ["autosomal", 193], ["dominant", 203], ["inheritance", 212], ["pattern", 224], [".", 231], ["The", 233], ["index", 237], ["case", 243], ["presented", 248], ["with", 258], ["an", 263], ["exacerbation", 266], ["of", 279], ["torsades", 282], ["de", 291], ["pointes", 294], ["ventricular", 302], ["tachycardia", 314], ["from", 326], ["diuretic", 331], ["induced", 340], ["hypokalaemia", 348], [",", 360], ["and", 362], ["responded", 366], ["to", 376], ["diuretic", 379], ["withdrawal", 388], ["and", 399], ["beta", 403], ["blocker", 408], ["therapy", 416], [".", 423]]}
{"context": "Nerve growth factor (NGF) is indispensable during normal embryonic development and critical for the amplification of pain signals in adults. Intervention in NGF signaling holds promise for the alleviation of pain resulting from human diseases such as osteoarthritis, cancer and chronic lower back disorders. We developed a fast, high-fidelity method to convert a hybridoma-derived NGF-targeted mouse antibody into a clinical candidate. This method, termed Library Scanning Mutagenesis (LSM), resulted in the ultra-high affinity antibody tanezumab, a first-in-class anti-hyperalgesic specific for an NGF epitope. Functional and structural comparisons between tanezumab and the mouse 911 precursor antibody using neurotrophin-specific cell survival assays and X-ray crystal structures of both Fab-antigen complexes illustrated high fidelity retention of the NGF epitope. These results suggest the potential for wide applicability of the LSM method for optimization of well-characterized antibodies during humanization.", "qas": [{"question": "What is the target of tanezumab?", "answers": ["nerve growth factor", "NGF"], "qid": "702ca078e3664e4f8f2e876395b0f7d4", "question_tokens": [["What", 0], ["is", 5], ["the", 8], ["target", 12], ["of", 19], ["tanezumab", 22], ["?", 31]], "detected_answers": [{"text": "nerve growth factor", "token_spans": [[0, 2]], "char_spans": [[0, 18]]}, {"text": "NGF", "token_spans": [[64, 64], [107, 107], [147, 147], [4, 4], [25, 25]], "char_spans": [[381, 383], [599, 601], [856, 858], [21, 23], [157, 159]]}]}], "context_tokens": [["Nerve", 0], ["growth", 6], ["factor", 13], ["(", 20], ["NGF", 21], [")", 24], ["is", 26], ["indispensable", 29], ["during", 43], ["normal", 50], ["embryonic", 57], ["development", 67], ["and", 79], ["critical", 83], ["for", 92], ["the", 96], ["amplification", 100], ["of", 114], ["pain", 117], ["signals", 122], ["in", 130], ["adults", 133], [".", 139], ["Intervention", 141], ["in", 154], ["NGF", 157], ["signaling", 161], ["holds", 171], ["promise", 177], ["for", 185], ["the", 189], ["alleviation", 193], ["of", 205], ["pain", 208], ["resulting", 213], ["from", 223], ["human", 228], ["diseases", 234], ["such", 243], ["as", 248], ["osteoarthritis", 251], [",", 265], ["cancer", 267], ["and", 274], ["chronic", 278], ["lower", 286], ["back", 292], ["disorders", 297], [".", 306], ["We", 308], ["developed", 311], ["a", 321], ["fast", 323], [",", 327], ["high", 329], ["-", 333], ["fidelity", 334], ["method", 343], ["to", 350], ["convert", 353], ["a", 361], ["hybridoma", 363], ["-", 372], ["derived", 373], ["NGF", 381], ["-", 384], ["targeted", 385], ["mouse", 394], ["antibody", 400], ["into", 409], ["a", 414], ["clinical", 416], ["candidate", 425], [".", 434], ["This", 436], ["method", 441], [",", 447], ["termed", 449], ["Library", 456], ["Scanning", 464], ["Mutagenesis", 473], ["(", 485], ["LSM", 486], [")", 489], [",", 490], ["resulted", 492], ["in", 501], ["the", 504], ["ultra", 508], ["-", 513], ["high", 514], ["affinity", 519], ["antibody", 528], ["tanezumab", 537], [",", 546], ["a", 548], ["first", 550], ["-", 555], ["in", 556], ["-", 558], ["class", 559], ["anti", 565], ["-", 569], ["hyperalgesic", 570], ["specific", 583], ["for", 592], ["an", 596], ["NGF", 599], ["epitope", 603], [".", 610], ["Functional", 612], ["and", 623], ["structural", 627], ["comparisons", 638], ["between", 650], ["tanezumab", 658], ["and", 668], ["the", 672], ["mouse", 676], ["911", 682], ["precursor", 686], ["antibody", 696], ["using", 705], ["neurotrophin", 711], ["-", 723], ["specific", 724], ["cell", 733], ["survival", 738], ["assays", 747], ["and", 754], ["X", 758], ["-", 759], ["ray", 760], ["crystal", 764], ["structures", 772], ["of", 783], ["both", 786], ["Fab", 791], ["-", 794], ["antigen", 795], ["complexes", 803], ["illustrated", 813], ["high", 825], ["fidelity", 830], ["retention", 839], ["of", 849], ["the", 852], ["NGF", 856], ["epitope", 860], [".", 867], ["These", 869], ["results", 875], ["suggest", 883], ["the", 891], ["potential", 895], ["for", 905], ["wide", 909], ["applicability", 914], ["of", 928], ["the", 931], ["LSM", 935], ["method", 939], ["for", 946], ["optimization", 950], ["of", 963], ["well", 966], ["-", 970], ["characterized", 971], ["antibodies", 985], ["during", 996], ["humanization", 1003], [".", 1015]]}
{"context": "To evaluate short- and mid-term level of imbalance after vestibular schwannoma (VS) microsurgery by the transpetrosal approach, to search for factors predictive of vestibular compensation, and to determine which patient categories need a postoperative vestibular rehabilitation program. Prospective cohort study at a tertiary referral center. Between 2010 and 2011, patients aged 18 to 75 operated on for VS by transpetrosal approaches were included. VS was characterized by its size (Koos classification) and the presence or not of a cystic component. Hearing was classified according to the Gardner Robertson grading. The preoperative workup included an audiogram, computerized video nystagmography (VNG) with caloric testing, gaze study, rotatory tests, click-evoked cervical vestibular evoked myogenic potential measurements (cVEMPs), and subjective visual vertical test. Patients were asked to complete a Dizziness Handicap Inventory (DHI). Postoperatively, patients were reevaluated on D7 (clinical status), D90 (VNG and DHI), and D180 (DHI). Timing and duration of vestibular rehabilitation were also recorded. Forty-eight patients were included. Preoperatively, 77% experienced mild instability problems with a mean DHI score of 14.1 (range 4-32). Postoperatively, 71% reported stable or even improved perceived stability. Mean DHI scores were 28.1 on D90 and 19.8 on D180. Serviceable hearing, cystic transformation, normal cVEMPs, diplopia, and vestibular syndrome on D7 were found to be predictive of worse equilibrium outcome than when absent. A preoperative caloric deficit greater than 75% seemed to be a good prognostic factor. Vestibular rehabilitation was conducted in 56% of patients. Starting it early (<1 mo) seemed to be beneficial for final equilibrium outcome. VS microsurgery provides good stability results. Some preoperative parameters may be predictive of worse or improved balance recovery, as is clinical status on D7.", "qas": [{"question": "Which disease can be categorized using the Koos grading system?", "answers": ["vestibular schwannoma"], "qid": "44cd890f1a1b4d6a9b055e363d1c3221", "question_tokens": [["Which", 0], ["disease", 6], ["can", 14], ["be", 18], ["categorized", 21], ["using", 33], ["the", 39], ["Koos", 43], ["grading", 48], ["system", 56], ["?", 62]], "detected_answers": [{"text": "vestibular schwannoma", "token_spans": [[11, 12]], "char_spans": [[57, 77]]}]}], "context_tokens": [["To", 0], ["evaluate", 3], ["short-", 12], ["and", 19], ["mid", 23], ["-", 26], ["term", 27], ["level", 32], ["of", 38], ["imbalance", 41], ["after", 51], ["vestibular", 57], ["schwannoma", 68], ["(", 79], ["VS", 80], [")", 82], ["microsurgery", 84], ["by", 97], ["the", 100], ["transpetrosal", 104], ["approach", 118], [",", 126], ["to", 128], ["search", 131], ["for", 138], ["factors", 142], ["predictive", 150], ["of", 161], ["vestibular", 164], ["compensation", 175], [",", 187], ["and", 189], ["to", 193], ["determine", 196], ["which", 206], ["patient", 212], ["categories", 220], ["need", 231], ["a", 236], ["postoperative", 238], ["vestibular", 252], ["rehabilitation", 263], ["program", 278], [".", 285], ["Prospective", 287], ["cohort", 299], ["study", 306], ["at", 312], ["a", 315], ["tertiary", 317], ["referral", 326], ["center", 335], [".", 341], ["Between", 343], ["2010", 351], ["and", 356], ["2011", 360], [",", 364], ["patients", 366], ["aged", 375], ["18", 380], ["to", 383], ["75", 386], ["operated", 389], ["on", 398], ["for", 401], ["VS", 405], ["by", 408], ["transpetrosal", 411], ["approaches", 425], ["were", 436], ["included", 441], [".", 449], ["VS", 451], ["was", 454], ["characterized", 458], ["by", 472], ["its", 475], ["size", 479], ["(", 484], ["Koos", 485], ["classification", 490], [")", 504], ["and", 506], ["the", 510], ["presence", 514], ["or", 523], ["not", 526], ["of", 530], ["a", 533], ["cystic", 535], ["component", 542], [".", 551], ["Hearing", 553], ["was", 561], ["classified", 565], ["according", 576], ["to", 586], ["the", 589], ["Gardner", 593], ["Robertson", 601], ["grading", 611], [".", 618], ["The", 620], ["preoperative", 624], ["workup", 637], ["included", 644], ["an", 653], ["audiogram", 656], [",", 665], ["computerized", 667], ["video", 680], ["nystagmography", 686], ["(", 701], ["VNG", 702], [")", 705], ["with", 707], ["caloric", 712], ["testing", 720], [",", 727], ["gaze", 729], ["study", 734], [",", 739], ["rotatory", 741], ["tests", 750], [",", 755], ["click", 757], ["-", 762], ["evoked", 763], ["cervical", 770], ["vestibular", 779], ["evoked", 790], ["myogenic", 797], ["potential", 806], ["measurements", 816], ["(", 829], ["cVEMPs", 830], [")", 836], [",", 837], ["and", 839], ["subjective", 843], ["visual", 854], ["vertical", 861], ["test", 870], [".", 874], ["Patients", 876], ["were", 885], ["asked", 890], ["to", 896], ["complete", 899], ["a", 908], ["Dizziness", 910], ["Handicap", 920], ["Inventory", 929], ["(", 939], ["DHI", 940], [")", 943], [".", 944], ["Postoperatively", 946], [",", 961], ["patients", 963], ["were", 972], ["reevaluated", 977], ["on", 989], ["D7", 992], ["(", 995], ["clinical", 996], ["status", 1005], [")", 1011], [",", 1012], ["D90", 1014], ["(", 1018], ["VNG", 1019], ["and", 1023], ["DHI", 1027], [")", 1030], [",", 1031], ["and", 1033], ["D180", 1037], ["(", 1042], ["DHI", 1043], [")", 1046], [".", 1047], ["Timing", 1049], ["and", 1056], ["duration", 1060], ["of", 1069], ["vestibular", 1072], ["rehabilitation", 1083], ["were", 1098], ["also", 1103], ["recorded", 1108], [".", 1116], ["Forty", 1118], ["-", 1123], ["eight", 1124], ["patients", 1130], ["were", 1139], ["included", 1144], [".", 1152], ["Preoperatively", 1154], [",", 1168], ["77", 1170], ["%", 1172], ["experienced", 1174], ["mild", 1186], ["instability", 1191], ["problems", 1203], ["with", 1212], ["a", 1217], ["mean", 1219], ["DHI", 1224], ["score", 1228], ["of", 1234], ["14.1", 1237], ["(", 1242], ["range", 1243], ["4", 1249], ["-", 1250], ["32", 1251], [")", 1253], [".", 1254], ["Postoperatively", 1256], [",", 1271], ["71", 1273], ["%", 1275], ["reported", 1277], ["stable", 1286], ["or", 1293], ["even", 1296], ["improved", 1301], ["perceived", 1310], ["stability", 1320], [".", 1329], ["Mean", 1331], ["DHI", 1336], ["scores", 1340], ["were", 1347], ["28.1", 1352], ["on", 1357], ["D90", 1360], ["and", 1364], ["19.8", 1368], ["on", 1373], ["D180", 1376], [".", 1380], ["Serviceable", 1382], ["hearing", 1394], [",", 1401], ["cystic", 1403], ["transformation", 1410], [",", 1424], ["normal", 1426], ["cVEMPs", 1433], [",", 1439], ["diplopia", 1441], [",", 1449], ["and", 1451], ["vestibular", 1455], ["syndrome", 1466], ["on", 1475], ["D7", 1478], ["were", 1481], ["found", 1486], ["to", 1492], ["be", 1495], ["predictive", 1498], ["of", 1509], ["worse", 1512], ["equilibrium", 1518], ["outcome", 1530], ["than", 1538], ["when", 1543], ["absent", 1548], [".", 1554], ["A", 1556], ["preoperative", 1558], ["caloric", 1571], ["deficit", 1579], ["greater", 1587], ["than", 1595], ["75", 1600], ["%", 1602], ["seemed", 1604], ["to", 1611], ["be", 1614], ["a", 1617], ["good", 1619], ["prognostic", 1624], ["factor", 1635], [".", 1641], ["Vestibular", 1643], ["rehabilitation", 1654], ["was", 1669], ["conducted", 1673], ["in", 1683], ["56", 1686], ["%", 1688], ["of", 1690], ["patients", 1693], [".", 1701], ["Starting", 1703], ["it", 1712], ["early", 1715], ["(", 1721], ["<", 1722], ["1", 1723], ["mo", 1725], [")", 1727], ["seemed", 1729], ["to", 1736], ["be", 1739], ["beneficial", 1742], ["for", 1753], ["final", 1757], ["equilibrium", 1763], ["outcome", 1775], [".", 1782], ["VS", 1784], ["microsurgery", 1787], ["provides", 1800], ["good", 1809], ["stability", 1814], ["results", 1824], [".", 1831], ["Some", 1833], ["preoperative", 1838], ["parameters", 1851], ["may", 1862], ["be", 1866], ["predictive", 1869], ["of", 1880], ["worse", 1883], ["or", 1889], ["improved", 1892], ["balance", 1901], ["recovery", 1909], [",", 1917], ["as", 1919], ["is", 1922], ["clinical", 1925], ["status", 1934], ["on", 1941], ["D7", 1944], [".", 1946]]}
{"context": "Turner syndrome (TS) is the most common genetic problem affecting women and occurs when an X chromosome is completely deleted, portions of an X chromosome are deleted, or chromosomal mosaicism occurs. Girls with TS may also have occult Y chromosome sequences. Whereas some girls with TS are identified in infancy or early childhood, many girls with TS are not detected until after 10 yr of age, resulting in delayed evaluation and treatment. To prevent the delayed recognition and treatment of TS, a quantitative method of genotyping that can be performed as part of newborn screening is needed. To screen for sex chromosome abnormalities, we assembled a panel of informative single nucleotide polymorphism (SNP) markers that span the X chromosome from the dbSNP database. Pyrosequencing assays suitable for quantitative assessment of signal strength from single nucleotides were designed and used to genotype 46,XX; 46,XY; 45,X; and TS mosaics, examining zygosity and signal strength for individual alleles. Pyrosequencing assays were also designed for the detection of Y chromosome material. With just four informative SNP markers for the X chromosome, all TS girls with 45,X, partial X chromosome deletions, or mosaicism were identified with 100% sensitivity. In mosaic individuals, Y chromosomal material was detected with 100% sensitivity. These results suggest that inexpensive high-throughput screening is possible for TS and other sex chromosome disorders using quantitative genotyping approaches.", "qas": [{"question": "What chromosome is affected in Turner's syndrome?", "answers": ["X"], "qid": "4d9adbc83c164890a231325d350c9a93", "question_tokens": [["What", 0], ["chromosome", 5], ["is", 16], ["affected", 19], ["in", 28], ["Turner", 31], ["'s", 37], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "X", "token_spans": [[131, 131], [26, 26], [196, 196], [206, 206], [17, 17]], "char_spans": [[735, 735], [142, 142], [1141, 1141], [1187, 1187], [91, 91]]}]}], "context_tokens": [["Turner", 0], ["syndrome", 7], ["(", 16], ["TS", 17], [")", 19], ["is", 21], ["the", 24], ["most", 28], ["common", 33], ["genetic", 40], ["problem", 48], ["affecting", 56], ["women", 66], ["and", 72], ["occurs", 76], ["when", 83], ["an", 88], ["X", 91], ["chromosome", 93], ["is", 104], ["completely", 107], ["deleted", 118], [",", 125], ["portions", 127], ["of", 136], ["an", 139], ["X", 142], ["chromosome", 144], ["are", 155], ["deleted", 159], [",", 166], ["or", 168], ["chromosomal", 171], ["mosaicism", 183], ["occurs", 193], [".", 199], ["Girls", 201], ["with", 207], ["TS", 212], ["may", 215], ["also", 219], ["have", 224], ["occult", 229], ["Y", 236], ["chromosome", 238], ["sequences", 249], [".", 258], ["Whereas", 260], ["some", 268], ["girls", 273], ["with", 279], ["TS", 284], ["are", 287], ["identified", 291], ["in", 302], ["infancy", 305], ["or", 313], ["early", 316], ["childhood", 322], [",", 331], ["many", 333], ["girls", 338], ["with", 344], ["TS", 349], ["are", 352], ["not", 356], ["detected", 360], ["until", 369], ["after", 375], ["10", 381], ["yr", 384], ["of", 387], ["age", 390], [",", 393], ["resulting", 395], ["in", 405], ["delayed", 408], ["evaluation", 416], ["and", 427], ["treatment", 431], [".", 440], ["To", 442], ["prevent", 445], ["the", 453], ["delayed", 457], ["recognition", 465], ["and", 477], ["treatment", 481], ["of", 491], ["TS", 494], [",", 496], ["a", 498], ["quantitative", 500], ["method", 513], ["of", 520], ["genotyping", 523], ["that", 534], ["can", 539], ["be", 543], ["performed", 546], ["as", 556], ["part", 559], ["of", 564], ["newborn", 567], ["screening", 575], ["is", 585], ["needed", 588], [".", 594], ["To", 596], ["screen", 599], ["for", 606], ["sex", 610], ["chromosome", 614], ["abnormalities", 625], [",", 638], ["we", 640], ["assembled", 643], ["a", 653], ["panel", 655], ["of", 661], ["informative", 664], ["single", 676], ["nucleotide", 683], ["polymorphism", 694], ["(", 707], ["SNP", 708], [")", 711], ["markers", 713], ["that", 721], ["span", 726], ["the", 731], ["X", 735], ["chromosome", 737], ["from", 748], ["the", 753], ["dbSNP", 757], ["database", 763], [".", 771], ["Pyrosequencing", 773], ["assays", 788], ["suitable", 795], ["for", 804], ["quantitative", 808], ["assessment", 821], ["of", 832], ["signal", 835], ["strength", 842], ["from", 851], ["single", 856], ["nucleotides", 863], ["were", 875], ["designed", 880], ["and", 889], ["used", 893], ["to", 898], ["genotype", 901], ["46,XX", 910], [";", 915], ["46,XY", 917], [";", 922], ["45,X", 924], [";", 928], ["and", 930], ["TS", 934], ["mosaics", 937], [",", 944], ["examining", 946], ["zygosity", 956], ["and", 965], ["signal", 969], ["strength", 976], ["for", 985], ["individual", 989], ["alleles", 1000], [".", 1007], ["Pyrosequencing", 1009], ["assays", 1024], ["were", 1031], ["also", 1036], ["designed", 1041], ["for", 1050], ["the", 1054], ["detection", 1058], ["of", 1068], ["Y", 1071], ["chromosome", 1073], ["material", 1084], [".", 1092], ["With", 1094], ["just", 1099], ["four", 1104], ["informative", 1109], ["SNP", 1121], ["markers", 1125], ["for", 1133], ["the", 1137], ["X", 1141], ["chromosome", 1143], [",", 1153], ["all", 1155], ["TS", 1159], ["girls", 1162], ["with", 1168], ["45,X", 1173], [",", 1177], ["partial", 1179], ["X", 1187], ["chromosome", 1189], ["deletions", 1200], [",", 1209], ["or", 1211], ["mosaicism", 1214], ["were", 1224], ["identified", 1229], ["with", 1240], ["100", 1245], ["%", 1248], ["sensitivity", 1250], [".", 1261], ["In", 1263], ["mosaic", 1266], ["individuals", 1273], [",", 1284], ["Y", 1286], ["chromosomal", 1288], ["material", 1300], ["was", 1309], ["detected", 1313], ["with", 1322], ["100", 1327], ["%", 1330], ["sensitivity", 1332], [".", 1343], ["These", 1345], ["results", 1351], ["suggest", 1359], ["that", 1367], ["inexpensive", 1372], ["high", 1384], ["-", 1388], ["throughput", 1389], ["screening", 1400], ["is", 1410], ["possible", 1413], ["for", 1422], ["TS", 1426], ["and", 1429], ["other", 1433], ["sex", 1439], ["chromosome", 1443], ["disorders", 1454], ["using", 1464], ["quantitative", 1470], ["genotyping", 1483], ["approaches", 1494], [".", 1504]]}
{"context": "Borderline oxacillin-resistant Staphylococcus aureus (BORSA) represents a quite poorly understood and inadequately defined phenotype of methicillin resistance. BORSA strains show low, borderline resistance to penicillinase-resistant penicillins (PRPs), with oxacillin MICs typically equal to 1-8\u2009\u00b5g\u2009ml", "qas": [{"question": "What is BORSA?", "answers": ["Borderline oxacillin-resistant Staphylococcus aureus"], "qid": "6bf60ce1cd73408f93464f39ccdb6be4", "question_tokens": [["What", 0], ["is", 5], ["BORSA", 8], ["?", 13]], "detected_answers": [{"text": "Borderline oxacillin-resistant Staphylococcus aureus", "token_spans": [[0, 5]], "char_spans": [[0, 51]]}]}], "context_tokens": [["Borderline", 0], ["oxacillin", 11], ["-", 20], ["resistant", 21], ["Staphylococcus", 31], ["aureus", 46], ["(", 53], ["BORSA", 54], [")", 59], ["represents", 61], ["a", 72], ["quite", 74], ["poorly", 80], ["understood", 87], ["and", 98], ["inadequately", 102], ["defined", 115], ["phenotype", 123], ["of", 133], ["methicillin", 136], ["resistance", 148], [".", 158], ["BORSA", 160], ["strains", 166], ["show", 174], ["low", 179], [",", 182], ["borderline", 184], ["resistance", 195], ["to", 206], ["penicillinase", 209], ["-", 222], ["resistant", 223], ["penicillins", 233], ["(", 245], ["PRPs", 246], [")", 250], [",", 251], ["with", 253], ["oxacillin", 258], ["MICs", 268], ["typically", 273], ["equal", 283], ["to", 289], ["1", 292], ["-", 293], ["8", 294], ["\u00b5g", 296], ["ml", 299]]}
{"context": "Here, we report the biochemical and genetic basis of the Vel blood group antigen, which has been a vexing mystery for decades, especially as anti-Vel regularly causes severe haemolytic transfusion reactions. The protein carrying the Vel blood group antigen was biochemically purified from red blood cell membranes. Mass spectrometry-based de novo peptide sequencing identified this protein to be small integral membrane protein 1 (SMIM1), a previously uncharacterized single-pass membrane protein. Expression of SMIM1 cDNA in Vel- cultured cells generated anti-Vel cell surface reactivity, confirming that SMIM1 encoded the Vel blood group antigen. A cohort of 70 Vel- individuals was found to be uniformly homozygous for a 17 nucleotide deletion in the coding sequence of SMIM1. The genetic homogeneity of the Vel- blood type, likely having a common origin, facilitated the development of two highly specific DNA-based tests for rapid Vel genotyping, which can be easily integrated into blood group genotyping platforms. These results answer a 60-year-old riddle and provide tools of immediate assistance to all clinicians involved in the care of Vel- patients.", "qas": [{"question": "Which gene-defect causes the Vel-blood type?", "answers": ["a 17 nucleotide deletion"], "qid": "1a0f88859ac041309e802081a92d69d7", "question_tokens": [["Which", 0], ["gene", 6], ["-", 10], ["defect", 11], ["causes", 18], ["the", 25], ["Vel", 29], ["-", 32], ["blood", 33], ["type", 39], ["?", 43]], "detected_answers": [{"text": "a 17 nucleotide deletion", "token_spans": [[125, 127]], "char_spans": [[724, 745]]}]}], "context_tokens": [["Here", 0], [",", 4], ["we", 6], ["report", 9], ["the", 16], ["biochemical", 20], ["and", 32], ["genetic", 36], ["basis", 44], ["of", 50], ["the", 53], ["Vel", 57], ["blood", 61], ["group", 67], ["antigen", 73], [",", 80], ["which", 82], ["has", 88], ["been", 92], ["a", 97], ["vexing", 99], ["mystery", 106], ["for", 114], ["decades", 118], [",", 125], ["especially", 127], ["as", 138], ["anti", 141], ["-", 145], ["Vel", 146], ["regularly", 150], ["causes", 160], ["severe", 167], ["haemolytic", 174], ["transfusion", 185], ["reactions", 197], [".", 206], ["The", 208], ["protein", 212], ["carrying", 220], ["the", 229], ["Vel", 233], ["blood", 237], ["group", 243], ["antigen", 249], ["was", 257], ["biochemically", 261], ["purified", 275], ["from", 284], ["red", 289], ["blood", 293], ["cell", 299], ["membranes", 304], [".", 313], ["Mass", 315], ["spectrometry", 320], ["-", 332], ["based", 333], ["de", 339], ["novo", 342], ["peptide", 347], ["sequencing", 355], ["identified", 366], ["this", 377], ["protein", 382], ["to", 390], ["be", 393], ["small", 396], ["integral", 402], ["membrane", 411], ["protein", 420], ["1", 428], ["(", 430], ["SMIM1", 431], [")", 436], [",", 437], ["a", 439], ["previously", 441], ["uncharacterized", 452], ["single", 468], ["-", 474], ["pass", 475], ["membrane", 480], ["protein", 489], [".", 496], ["Expression", 498], ["of", 509], ["SMIM1", 512], ["cDNA", 518], ["in", 523], ["Vel-", 526], ["cultured", 531], ["cells", 540], ["generated", 546], ["anti", 556], ["-", 560], ["Vel", 561], ["cell", 565], ["surface", 570], ["reactivity", 578], [",", 588], ["confirming", 590], ["that", 601], ["SMIM1", 606], ["encoded", 612], ["the", 620], ["Vel", 624], ["blood", 628], ["group", 634], ["antigen", 640], [".", 647], ["A", 649], ["cohort", 651], ["of", 658], ["70", 661], ["Vel-", 664], ["individuals", 669], ["was", 681], ["found", 685], ["to", 691], ["be", 694], ["uniformly", 697], ["homozygous", 707], ["for", 718], ["a", 722], ["17", 724], ["nucleotide", 727], ["deletion", 738], ["in", 747], ["the", 750], ["coding", 754], ["sequence", 761], ["of", 770], ["SMIM1", 773], [".", 778], ["The", 780], ["genetic", 784], ["homogeneity", 792], ["of", 804], ["the", 807], ["Vel-", 811], ["blood", 816], ["type", 822], [",", 826], ["likely", 828], ["having", 835], ["a", 842], ["common", 844], ["origin", 851], [",", 857], ["facilitated", 859], ["the", 871], ["development", 875], ["of", 887], ["two", 890], ["highly", 894], ["specific", 901], ["DNA", 910], ["-", 913], ["based", 914], ["tests", 920], ["for", 926], ["rapid", 930], ["Vel", 936], ["genotyping", 940], [",", 950], ["which", 952], ["can", 958], ["be", 962], ["easily", 965], ["integrated", 972], ["into", 983], ["blood", 988], ["group", 994], ["genotyping", 1000], ["platforms", 1011], [".", 1020], ["These", 1022], ["results", 1028], ["answer", 1036], ["a", 1043], ["60-year", 1045], ["-", 1052], ["old", 1053], ["riddle", 1057], ["and", 1064], ["provide", 1068], ["tools", 1076], ["of", 1082], ["immediate", 1085], ["assistance", 1095], ["to", 1106], ["all", 1109], ["clinicians", 1113], ["involved", 1124], ["in", 1133], ["the", 1136], ["care", 1140], ["of", 1145], ["Vel-", 1148], ["patients", 1153], [".", 1161]]}
{"context": "The dynamin-related protein Opa1 is localized to the mitochondrial intermembrane space, where it facilitates fusion between mitochondria. Apoptosis causes Opa1 release into the cytosol and causes mitochondria to fragment. Loss of mitochondrial membrane potential also causes mitochondrial fragmentation but not Opa1 release into the cytosol. Both conditions induce the proteolytic cleavage of Opa1, suggesting that mitochondrial fragmentation is triggered by Opa1 inactivation. The opposite effect was observed with knockdown of the mitochondrial intermembrane space protease Yme1. Knockdown of Yme1 prevents the constitutive cleavage of a subset of Opa1 splice variants but does not affect carbonyl cyanide m-chlorophenyl hydrazone or apoptosis-induced cleavage. Knockdown of Yme1 also increases mitochondrial connectivity, but this effect is independent of Opa1 because it also occurs in Opa1 knockdown cells. We conclude that Yme1 constitutively regulates a subset of Opa1 isoforms and an unknown mitochondrial morphology protein, whereas the loss of membrane potential induces the further proteolysis of Opa1.", "qas": [{"question": "Which is the cellular localization of the protein Opa1?", "answers": ["mitochondrial intermembrane space"], "qid": "06ee6c4a1f9d4cd19afcd49b8dd40d16", "question_tokens": [["Which", 0], ["is", 6], ["the", 9], ["cellular", 13], ["localization", 22], ["of", 35], ["the", 38], ["protein", 42], ["Opa1", 50], ["?", 54]], "detected_answers": [{"text": "mitochondrial intermembrane space", "token_spans": [[10, 12], [79, 81]], "char_spans": [[53, 85], [533, 565]]}]}], "context_tokens": [["The", 0], ["dynamin", 4], ["-", 11], ["related", 12], ["protein", 20], ["Opa1", 28], ["is", 33], ["localized", 36], ["to", 46], ["the", 49], ["mitochondrial", 53], ["intermembrane", 67], ["space", 81], [",", 86], ["where", 88], ["it", 94], ["facilitates", 97], ["fusion", 109], ["between", 116], ["mitochondria", 124], [".", 136], ["Apoptosis", 138], ["causes", 148], ["Opa1", 155], ["release", 160], ["into", 168], ["the", 173], ["cytosol", 177], ["and", 185], ["causes", 189], ["mitochondria", 196], ["to", 209], ["fragment", 212], [".", 220], ["Loss", 222], ["of", 227], ["mitochondrial", 230], ["membrane", 244], ["potential", 253], ["also", 263], ["causes", 268], ["mitochondrial", 275], ["fragmentation", 289], ["but", 303], ["not", 307], ["Opa1", 311], ["release", 316], ["into", 324], ["the", 329], ["cytosol", 333], [".", 340], ["Both", 342], ["conditions", 347], ["induce", 358], ["the", 365], ["proteolytic", 369], ["cleavage", 381], ["of", 390], ["Opa1", 393], [",", 397], ["suggesting", 399], ["that", 410], ["mitochondrial", 415], ["fragmentation", 429], ["is", 443], ["triggered", 446], ["by", 456], ["Opa1", 459], ["inactivation", 464], [".", 476], ["The", 478], ["opposite", 482], ["effect", 491], ["was", 498], ["observed", 502], ["with", 511], ["knockdown", 516], ["of", 526], ["the", 529], ["mitochondrial", 533], ["intermembrane", 547], ["space", 561], ["protease", 567], ["Yme1", 576], [".", 580], ["Knockdown", 582], ["of", 592], ["Yme1", 595], ["prevents", 600], ["the", 609], ["constitutive", 613], ["cleavage", 626], ["of", 635], ["a", 638], ["subset", 640], ["of", 647], ["Opa1", 650], ["splice", 655], ["variants", 662], ["but", 671], ["does", 675], ["not", 680], ["affect", 684], ["carbonyl", 691], ["cyanide", 700], ["m", 708], ["-", 709], ["chlorophenyl", 710], ["hydrazone", 723], ["or", 733], ["apoptosis", 736], ["-", 745], ["induced", 746], ["cleavage", 754], [".", 762], ["Knockdown", 764], ["of", 774], ["Yme1", 777], ["also", 782], ["increases", 787], ["mitochondrial", 797], ["connectivity", 811], [",", 823], ["but", 825], ["this", 829], ["effect", 834], ["is", 841], ["independent", 844], ["of", 856], ["Opa1", 859], ["because", 864], ["it", 872], ["also", 875], ["occurs", 880], ["in", 887], ["Opa1", 890], ["knockdown", 895], ["cells", 905], [".", 910], ["We", 912], ["conclude", 915], ["that", 924], ["Yme1", 929], ["constitutively", 934], ["regulates", 949], ["a", 959], ["subset", 961], ["of", 968], ["Opa1", 971], ["isoforms", 976], ["and", 985], ["an", 989], ["unknown", 992], ["mitochondrial", 1000], ["morphology", 1014], ["protein", 1025], [",", 1032], ["whereas", 1034], ["the", 1042], ["loss", 1046], ["of", 1051], ["membrane", 1054], ["potential", 1063], ["induces", 1073], ["the", 1081], ["further", 1085], ["proteolysis", 1093], ["of", 1105], ["Opa1", 1108], [".", 1112]]}
{"context": "To define the relationship between body indices of healthy adults and cross-sectional areas of the carpal tunnel and median nerve and to obtain the nerve/tunnel index, which represents a new standard for diagnosing carpal tunnel syndrome using sonography. Body indices (height, weight, and body mass index) were analyzed in 60 healthy adults, and electromyography and sonography were also performed. The cross-sectional areas of the proximal and distal median nerve and carpal tunnel were obtained by sonography. The proximal and distal nerve/tunnel indices were obtained by calculating the ratio between the proximal and distal cross-sectional areas of the median nerve to those of the carpal tunnel and multiplying the value by 100. Although the proximal cross-sectional areas of the median nerve and body indices showed statistically significant relationships with weak positive correlations, the proximal and distal areas of the carpal tunnel showed relatively stronger correlations with body indices. Between sexes, there were significant differences in the proximal median nerve cross-sectional area (mean \u00b1 SD: male, 10.48 \u00b1 3.21 mm(2); female, 8.81 \u00b1 3.21 mm(2); P < .05) and proximal carpal tunnel area (male, 182.50 \u00b1 21.15 mm(2); female, 151.23 \u00b1 21.14 mm(2); P < .05). There was no difference in the proximal nerve/tunnel index (male, 5.80% \u00b1 1.72%; female, 5.91% \u00b1 1.63%). There was a statistically significant difference in the distal carpal tunnel cross-sectional area (male, 138.90 \u00b1 20.95 mm(2); female, 121.50 \u00b1 18.99 mm(2); P < .05) between sexes, but the distal median area (male, 9.99 \u00b1 3.42 mm(2); female, 8.46 \u00b1 1.84 mm(2)) and distal nerve/tunnel index (male, 7.15% \u00b1 2.00%; female, 7.01% \u00b1 1.38%) showed no significant differences. The proximal index was significantly higher than the distal index (proximal, 5.85% \u00b1 1.66%; distal, 7.08% \u00b1 1.71%). The nerve/tunnel index is unaffected by body indices or sex and thus may be a useful and objective standard for diagnosing carpal tunnel syndrome.", "qas": [{"question": "What nerve is involved in carpal tunnel syndrome?", "answers": ["median"], "qid": "75f0878c248e4bbab73420d14772e958", "question_tokens": [["What", 0], ["nerve", 5], ["is", 11], ["involved", 14], ["in", 23], ["carpal", 26], ["tunnel", 33], ["syndrome", 40], ["?", 48]], "detected_answers": [{"text": "median", "token_spans": [[181, 181], [310, 310], [116, 116], [140, 140], [20, 20], [81, 81]], "char_spans": [[1072, 1077], [1582, 1587], [658, 663], [786, 791], [117, 122], [453, 458]]}]}], "context_tokens": [["To", 0], ["define", 3], ["the", 10], ["relationship", 14], ["between", 27], ["body", 35], ["indices", 40], ["of", 48], ["healthy", 51], ["adults", 59], ["and", 66], ["cross", 70], ["-", 75], ["sectional", 76], ["areas", 86], ["of", 92], ["the", 95], ["carpal", 99], ["tunnel", 106], ["and", 113], ["median", 117], ["nerve", 124], ["and", 130], ["to", 134], ["obtain", 137], ["the", 144], ["nerve", 148], ["/", 153], ["tunnel", 154], ["index", 161], [",", 166], ["which", 168], ["represents", 174], ["a", 185], ["new", 187], ["standard", 191], ["for", 200], ["diagnosing", 204], ["carpal", 215], ["tunnel", 222], ["syndrome", 229], ["using", 238], ["sonography", 244], [".", 254], ["Body", 256], ["indices", 261], ["(", 269], ["height", 270], [",", 276], ["weight", 278], [",", 284], ["and", 286], ["body", 290], ["mass", 295], ["index", 300], [")", 305], ["were", 307], ["analyzed", 312], ["in", 321], ["60", 324], ["healthy", 327], ["adults", 335], [",", 341], ["and", 343], ["electromyography", 347], ["and", 364], ["sonography", 368], ["were", 379], ["also", 384], ["performed", 389], [".", 398], ["The", 400], ["cross", 404], ["-", 409], ["sectional", 410], ["areas", 420], ["of", 426], ["the", 429], ["proximal", 433], ["and", 442], ["distal", 446], ["median", 453], ["nerve", 460], ["and", 466], ["carpal", 470], ["tunnel", 477], ["were", 484], ["obtained", 489], ["by", 498], ["sonography", 501], [".", 511], ["The", 513], ["proximal", 517], ["and", 526], ["distal", 530], ["nerve", 537], ["/", 542], ["tunnel", 543], ["indices", 550], ["were", 558], ["obtained", 563], ["by", 572], ["calculating", 575], ["the", 587], ["ratio", 591], ["between", 597], ["the", 605], ["proximal", 609], ["and", 618], ["distal", 622], ["cross", 629], ["-", 634], ["sectional", 635], ["areas", 645], ["of", 651], ["the", 654], ["median", 658], ["nerve", 665], ["to", 671], ["those", 674], ["of", 680], ["the", 683], ["carpal", 687], ["tunnel", 694], ["and", 701], ["multiplying", 705], ["the", 717], ["value", 721], ["by", 727], ["100", 730], [".", 733], ["Although", 735], ["the", 744], ["proximal", 748], ["cross", 757], ["-", 762], ["sectional", 763], ["areas", 773], ["of", 779], ["the", 782], ["median", 786], ["nerve", 793], ["and", 799], ["body", 803], ["indices", 808], ["showed", 816], ["statistically", 823], ["significant", 837], ["relationships", 849], ["with", 863], ["weak", 868], ["positive", 873], ["correlations", 882], [",", 894], ["the", 896], ["proximal", 900], ["and", 909], ["distal", 913], ["areas", 920], ["of", 926], ["the", 929], ["carpal", 933], ["tunnel", 940], ["showed", 947], ["relatively", 954], ["stronger", 965], ["correlations", 974], ["with", 987], ["body", 992], ["indices", 997], [".", 1004], ["Between", 1006], ["sexes", 1014], [",", 1019], ["there", 1021], ["were", 1027], ["significant", 1032], ["differences", 1044], ["in", 1056], ["the", 1059], ["proximal", 1063], ["median", 1072], ["nerve", 1079], ["cross", 1085], ["-", 1090], ["sectional", 1091], ["area", 1101], ["(", 1106], ["mean", 1107], ["\u00b1", 1112], ["SD", 1114], [":", 1116], ["male", 1118], [",", 1122], ["10.48", 1124], ["\u00b1", 1130], ["3.21", 1132], ["mm(2", 1137], [")", 1141], [";", 1142], ["female", 1144], [",", 1150], ["8.81", 1152], ["\u00b1", 1157], ["3.21", 1159], ["mm(2", 1164], [")", 1168], [";", 1169], ["P", 1171], ["<", 1173], [".05", 1175], [")", 1178], ["and", 1180], ["proximal", 1184], ["carpal", 1193], ["tunnel", 1200], ["area", 1207], ["(", 1212], ["male", 1213], [",", 1217], ["182.50", 1219], ["\u00b1", 1226], ["21.15", 1228], ["mm(2", 1234], [")", 1238], [";", 1239], ["female", 1241], [",", 1247], ["151.23", 1249], ["\u00b1", 1256], ["21.14", 1258], ["mm(2", 1264], [")", 1268], [";", 1269], ["P", 1271], ["<", 1273], [".05", 1275], [")", 1278], [".", 1279], ["There", 1281], ["was", 1287], ["no", 1291], ["difference", 1294], ["in", 1305], ["the", 1308], ["proximal", 1312], ["nerve", 1321], ["/", 1326], ["tunnel", 1327], ["index", 1334], ["(", 1340], ["male", 1341], [",", 1345], ["5.80", 1347], ["%", 1351], ["\u00b1", 1353], ["1.72", 1355], ["%", 1359], [";", 1360], ["female", 1362], [",", 1368], ["5.91", 1370], ["%", 1374], ["\u00b1", 1376], ["1.63", 1378], ["%", 1382], [")", 1383], [".", 1384], ["There", 1386], ["was", 1392], ["a", 1396], ["statistically", 1398], ["significant", 1412], ["difference", 1424], ["in", 1435], ["the", 1438], ["distal", 1442], ["carpal", 1449], ["tunnel", 1456], ["cross", 1463], ["-", 1468], ["sectional", 1469], ["area", 1479], ["(", 1484], ["male", 1485], [",", 1489], ["138.90", 1491], ["\u00b1", 1498], ["20.95", 1500], ["mm(2", 1506], [")", 1510], [";", 1511], ["female", 1513], [",", 1519], ["121.50", 1521], ["\u00b1", 1528], ["18.99", 1530], ["mm(2", 1536], [")", 1540], [";", 1541], ["P", 1543], ["<", 1545], [".05", 1547], [")", 1550], ["between", 1552], ["sexes", 1560], [",", 1565], ["but", 1567], ["the", 1571], ["distal", 1575], ["median", 1582], ["area", 1589], ["(", 1594], ["male", 1595], [",", 1599], ["9.99", 1601], ["\u00b1", 1606], ["3.42", 1608], ["mm(2", 1613], [")", 1617], [";", 1618], ["female", 1620], [",", 1626], ["8.46", 1628], ["\u00b1", 1633], ["1.84", 1635], ["mm(2", 1640], [")", 1644], [")", 1645], ["and", 1647], ["distal", 1651], ["nerve", 1658], ["/", 1663], ["tunnel", 1664], ["index", 1671], ["(", 1677], ["male", 1678], [",", 1682], ["7.15", 1684], ["%", 1688], ["\u00b1", 1690], ["2.00", 1692], ["%", 1696], [";", 1697], ["female", 1699], [",", 1705], ["7.01", 1707], ["%", 1711], ["\u00b1", 1713], ["1.38", 1715], ["%", 1719], [")", 1720], ["showed", 1722], ["no", 1729], ["significant", 1732], ["differences", 1744], [".", 1755], ["The", 1757], ["proximal", 1761], ["index", 1770], ["was", 1776], ["significantly", 1780], ["higher", 1794], ["than", 1801], ["the", 1806], ["distal", 1810], ["index", 1817], ["(", 1823], ["proximal", 1824], [",", 1832], ["5.85", 1834], ["%", 1838], ["\u00b1", 1840], ["1.66", 1842], ["%", 1846], [";", 1847], ["distal", 1849], [",", 1855], ["7.08", 1857], ["%", 1861], ["\u00b1", 1863], ["1.71", 1865], ["%", 1869], [")", 1870], [".", 1871], ["The", 1873], ["nerve", 1877], ["/", 1882], ["tunnel", 1883], ["index", 1890], ["is", 1896], ["unaffected", 1899], ["by", 1910], ["body", 1913], ["indices", 1918], ["or", 1926], ["sex", 1929], ["and", 1933], ["thus", 1937], ["may", 1942], ["be", 1946], ["a", 1949], ["useful", 1951], ["and", 1958], ["objective", 1962], ["standard", 1972], ["for", 1981], ["diagnosing", 1985], ["carpal", 1996], ["tunnel", 2003], ["syndrome", 2010], [".", 2018]]}
{"context": "Psychiatric disorders have a great impact on morbidity and mortality. Genotype-phenotype resources for psychiatric diseases are key to enable the translation of research findings to a better care of patients. PsyGeNET is a knowledge resource on psychiatric diseases and their genes, developed by text mining and curated by domain experts. We present psygenet2r, an R package that contains a variety of functions for leveraging PsyGeNET database and facilitating its analysis and interpretation. The package offers different types of queries to the database along with variety of analysis and visualization tools, including the study of the anatomical structures in which the genes are expressed and gaining insight of gene's molecular function. Psygenet2r is especially suited for network medicine analysis of psychiatric disorders. The package is implemented in R and is available under MIT license from Bioconductor (http://bioconductor.org/packages/release/bioc/html/psygenet2r.html). juanr.gonzalez@isglobal.org or laura.furlong@upf.edu. Supplementary data are available at Bioinformatics online.", "qas": [{"question": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?", "answers": ["Psygenet2r"], "qid": "4d4e76e2c6944123bd9d9709e0e9d250", "question_tokens": [["Which", 0], ["R", 6], ["/", 7], ["Bioconductor", 8], ["package", 21], ["has", 29], ["been", 33], ["developed", 38], ["for", 48], ["the", 52], ["analysis", 56], ["of", 65], ["psychiatric", 68], ["disease", 80], ["genes", 88], ["?", 93]], "detected_answers": [{"text": "Psygenet2r", "token_spans": [[121, 121], [58, 58]], "char_spans": [[745, 754], [350, 359]]}]}], "context_tokens": [["Psychiatric", 0], ["disorders", 12], ["have", 22], ["a", 27], ["great", 29], ["impact", 35], ["on", 42], ["morbidity", 45], ["and", 55], ["mortality", 59], [".", 68], ["Genotype", 70], ["-", 78], ["phenotype", 79], ["resources", 89], ["for", 99], ["psychiatric", 103], ["diseases", 115], ["are", 124], ["key", 128], ["to", 132], ["enable", 135], ["the", 142], ["translation", 146], ["of", 158], ["research", 161], ["findings", 170], ["to", 179], ["a", 182], ["better", 184], ["care", 191], ["of", 196], ["patients", 199], [".", 207], ["PsyGeNET", 209], ["is", 218], ["a", 221], ["knowledge", 223], ["resource", 233], ["on", 242], ["psychiatric", 245], ["diseases", 257], ["and", 266], ["their", 270], ["genes", 276], [",", 281], ["developed", 283], ["by", 293], ["text", 296], ["mining", 301], ["and", 308], ["curated", 312], ["by", 320], ["domain", 323], ["experts", 330], [".", 337], ["We", 339], ["present", 342], ["psygenet2r", 350], [",", 360], ["an", 362], ["R", 365], ["package", 367], ["that", 375], ["contains", 380], ["a", 389], ["variety", 391], ["of", 399], ["functions", 402], ["for", 412], ["leveraging", 416], ["PsyGeNET", 427], ["database", 436], ["and", 445], ["facilitating", 449], ["its", 462], ["analysis", 466], ["and", 475], ["interpretation", 479], [".", 493], ["The", 495], ["package", 499], ["offers", 507], ["different", 514], ["types", 524], ["of", 530], ["queries", 533], ["to", 541], ["the", 544], ["database", 548], ["along", 557], ["with", 563], ["variety", 568], ["of", 576], ["analysis", 579], ["and", 588], ["visualization", 592], ["tools", 606], [",", 611], ["including", 613], ["the", 623], ["study", 627], ["of", 633], ["the", 636], ["anatomical", 640], ["structures", 651], ["in", 662], ["which", 665], ["the", 671], ["genes", 675], ["are", 681], ["expressed", 685], ["and", 695], ["gaining", 699], ["insight", 707], ["of", 715], ["gene", 718], ["'s", 722], ["molecular", 725], ["function", 735], [".", 743], ["Psygenet2r", 745], ["is", 756], ["especially", 759], ["suited", 770], ["for", 777], ["network", 781], ["medicine", 789], ["analysis", 798], ["of", 807], ["psychiatric", 810], ["disorders", 822], [".", 831], ["The", 833], ["package", 837], ["is", 845], ["implemented", 848], ["in", 860], ["R", 863], ["and", 865], ["is", 869], ["available", 872], ["under", 882], ["MIT", 888], ["license", 892], ["from", 900], ["Bioconductor", 905], ["(", 918], ["http://bioconductor.org/packages/release/bioc/html/psygenet2r.html", 919], [")", 985], [".", 986], ["juanr.gonzalez@isglobal.org", 988], ["or", 1016], ["laura.furlong@upf.edu", 1019], [".", 1040], ["Supplementary", 1042], ["data", 1056], ["are", 1061], ["available", 1065], ["at", 1075], ["Bioinformatics", 1078], ["online", 1093], [".", 1099]]}
{"context": "Histone variant H2A.Z-containing nucleosomes are incorporated at most eukaryotic promoters. This incorporation is mediated by the conserved SWR1 complex, which replaces histone H2A in canonical nucleosomes with H2A.Z in an ATP-dependent manner. Here, we show that promoter-proximal nucleosomes are highly heterogeneous for H2A.Z in Saccharomyces cerevisiae, with substantial representation of nucleosomes containing one, two, or zero H2A.Z molecules. SWR1-catalyzed H2A.Z replacement in vitro occurs in a stepwise and unidirectional fashion, one H2A.Z-H2B dimer at a time, producing heterotypic nucleosomes as intermediates and homotypic H2A.Z nucleosomes as end products. The ATPase activity of SWR1 is specifically stimulated by H2A-containing nucleosomes without ensuing histone H2A eviction. Remarkably, further addition of free H2A.Z-H2B dimer leads to hyperstimulation of ATPase activity, eviction of nucleosomal H2A-H2B, and deposition of H2A.Z-H2B. These results suggest that the combination of H2A-containing nucleosome and free H2A.Z-H2B dimer acting as both effector and substrate for SWR1 governs the specificity and outcome of the replacement reaction.", "qas": [{"question": "Which protein mediates the replacement of H2A by H2A.Z in the yeast Saccharomyces cerevisiae?", "answers": ["SWR1"], "qid": "9473f38b4dee41f9afdbbe99bea8b018", "question_tokens": [["Which", 0], ["protein", 6], ["mediates", 14], ["the", 23], ["replacement", 27], ["of", 39], ["H2A", 42], ["by", 46], ["H2A.Z", 49], ["in", 55], ["the", 58], ["yeast", 62], ["Saccharomyces", 68], ["cerevisiae", 82], ["?", 92]], "detected_answers": [{"text": "SWR1", "token_spans": [[20, 20], [180, 180], [111, 111]], "char_spans": [[140, 143], [1096, 1099], [696, 699]]}]}], "context_tokens": [["Histone", 0], ["variant", 8], ["H2A.Z", 16], ["-", 21], ["containing", 22], ["nucleosomes", 33], ["are", 45], ["incorporated", 49], ["at", 62], ["most", 65], ["eukaryotic", 70], ["promoters", 81], [".", 90], ["This", 92], ["incorporation", 97], ["is", 111], ["mediated", 114], ["by", 123], ["the", 126], ["conserved", 130], ["SWR1", 140], ["complex", 145], [",", 152], ["which", 154], ["replaces", 160], ["histone", 169], ["H2A", 177], ["in", 181], ["canonical", 184], ["nucleosomes", 194], ["with", 206], ["H2A.Z", 211], ["in", 217], ["an", 220], ["ATP", 223], ["-", 226], ["dependent", 227], ["manner", 237], [".", 243], ["Here", 245], [",", 249], ["we", 251], ["show", 254], ["that", 259], ["promoter", 264], ["-", 272], ["proximal", 273], ["nucleosomes", 282], ["are", 294], ["highly", 298], ["heterogeneous", 305], ["for", 319], ["H2A.Z", 323], ["in", 329], ["Saccharomyces", 332], ["cerevisiae", 346], [",", 356], ["with", 358], ["substantial", 363], ["representation", 375], ["of", 390], ["nucleosomes", 393], ["containing", 405], ["one", 416], [",", 419], ["two", 421], [",", 424], ["or", 426], ["zero", 429], ["H2A.Z", 434], ["molecules", 440], [".", 449], ["SWR1-catalyzed", 451], ["H2A.Z", 466], ["replacement", 472], ["in", 484], ["vitro", 487], ["occurs", 493], ["in", 500], ["a", 503], ["stepwise", 505], ["and", 514], ["unidirectional", 518], ["fashion", 533], [",", 540], ["one", 542], ["H2A.Z", 546], ["-", 551], ["H2B", 552], ["dimer", 556], ["at", 562], ["a", 565], ["time", 567], [",", 571], ["producing", 573], ["heterotypic", 583], ["nucleosomes", 595], ["as", 607], ["intermediates", 610], ["and", 624], ["homotypic", 628], ["H2A.Z", 638], ["nucleosomes", 644], ["as", 656], ["end", 659], ["products", 663], [".", 671], ["The", 673], ["ATPase", 677], ["activity", 684], ["of", 693], ["SWR1", 696], ["is", 701], ["specifically", 704], ["stimulated", 717], ["by", 728], ["H2A", 731], ["-", 734], ["containing", 735], ["nucleosomes", 746], ["without", 758], ["ensuing", 766], ["histone", 774], ["H2A", 782], ["eviction", 786], [".", 794], ["Remarkably", 796], [",", 806], ["further", 808], ["addition", 816], ["of", 825], ["free", 828], ["H2A.Z", 833], ["-", 838], ["H2B", 839], ["dimer", 843], ["leads", 849], ["to", 855], ["hyperstimulation", 858], ["of", 875], ["ATPase", 878], ["activity", 885], [",", 893], ["eviction", 895], ["of", 904], ["nucleosomal", 907], ["H2A", 919], ["-", 922], ["H2B", 923], [",", 926], ["and", 928], ["deposition", 932], ["of", 943], ["H2A.Z", 946], ["-", 951], ["H2B.", 952], ["These", 957], ["results", 963], ["suggest", 971], ["that", 979], ["the", 984], ["combination", 988], ["of", 1000], ["H2A", 1003], ["-", 1006], ["containing", 1007], ["nucleosome", 1018], ["and", 1029], ["free", 1033], ["H2A.Z", 1038], ["-", 1043], ["H2B", 1044], ["dimer", 1048], ["acting", 1054], ["as", 1061], ["both", 1064], ["effector", 1069], ["and", 1078], ["substrate", 1082], ["for", 1092], ["SWR1", 1096], ["governs", 1101], ["the", 1109], ["specificity", 1113], ["and", 1125], ["outcome", 1129], ["of", 1137], ["the", 1140], ["replacement", 1144], ["reaction", 1156], [".", 1164]]}
{"context": "The purpose of this study was to describe the technique and usefulness of ultrasound-guided intrasheath injection of triamcinolone in the treatment of de Quervain's disease (dQD). Our study was retrospective in design. Seventy-one wrists of 62 patients who were treated with an ultrasound-guided triamcinolone injection for dQD were included. A literature search was performed to compare our results. In the literature we found supportive evidence that accurate injection of triamcinolone in the first dorsal compartment of the wrist is important for a good outcome. In this retrospective study we found that treatment with ultrasound-guided injections of triamcinolone is both safe and effective. After two injections, 91% of the patients had good long-term results, which is a higher cure rate than found in most other studies. Furthermore, we found that Finkelstein's test can give a false positive result. Therefore, ultrasound should not only be considered to improve the treatment outcome, but can also be useful as a diagnostic tool in the management of de Quervain's disease.", "qas": [{"question": "Which disease is diagnosed using the Finkelstein's test?", "answers": ["de Quervain's disease"], "qid": "28c063ee9b8f48c0a4043216a47ce037", "question_tokens": [["Which", 0], ["disease", 6], ["is", 14], ["diagnosed", 17], ["using", 27], ["the", 33], ["Finkelstein", 37], ["'s", 48], ["test", 51], ["?", 55]], "detected_answers": [{"text": "de Quervain's disease", "token_spans": [[190, 193], [24, 27]], "char_spans": [[1061, 1081], [151, 171]]}]}], "context_tokens": [["The", 0], ["purpose", 4], ["of", 12], ["this", 15], ["study", 20], ["was", 26], ["to", 30], ["describe", 33], ["the", 42], ["technique", 46], ["and", 56], ["usefulness", 60], ["of", 71], ["ultrasound", 74], ["-", 84], ["guided", 85], ["intrasheath", 92], ["injection", 104], ["of", 114], ["triamcinolone", 117], ["in", 131], ["the", 134], ["treatment", 138], ["of", 148], ["de", 151], ["Quervain", 154], ["'s", 162], ["disease", 165], ["(", 173], ["dQD", 174], [")", 177], [".", 178], ["Our", 180], ["study", 184], ["was", 190], ["retrospective", 194], ["in", 208], ["design", 211], [".", 217], ["Seventy", 219], ["-", 226], ["one", 227], ["wrists", 231], ["of", 238], ["62", 241], ["patients", 244], ["who", 253], ["were", 257], ["treated", 262], ["with", 270], ["an", 275], ["ultrasound", 278], ["-", 288], ["guided", 289], ["triamcinolone", 296], ["injection", 310], ["for", 320], ["dQD", 324], ["were", 328], ["included", 333], [".", 341], ["A", 343], ["literature", 345], ["search", 356], ["was", 363], ["performed", 367], ["to", 377], ["compare", 380], ["our", 388], ["results", 392], [".", 399], ["In", 401], ["the", 404], ["literature", 408], ["we", 419], ["found", 422], ["supportive", 428], ["evidence", 439], ["that", 448], ["accurate", 453], ["injection", 462], ["of", 472], ["triamcinolone", 475], ["in", 489], ["the", 492], ["first", 496], ["dorsal", 502], ["compartment", 509], ["of", 521], ["the", 524], ["wrist", 528], ["is", 534], ["important", 537], ["for", 547], ["a", 551], ["good", 553], ["outcome", 558], [".", 565], ["In", 567], ["this", 570], ["retrospective", 575], ["study", 589], ["we", 595], ["found", 598], ["that", 604], ["treatment", 609], ["with", 619], ["ultrasound", 624], ["-", 634], ["guided", 635], ["injections", 642], ["of", 653], ["triamcinolone", 656], ["is", 670], ["both", 673], ["safe", 678], ["and", 683], ["effective", 687], [".", 696], ["After", 698], ["two", 704], ["injections", 708], [",", 718], ["91", 720], ["%", 722], ["of", 724], ["the", 727], ["patients", 731], ["had", 740], ["good", 744], ["long", 749], ["-", 753], ["term", 754], ["results", 759], [",", 766], ["which", 768], ["is", 774], ["a", 777], ["higher", 779], ["cure", 786], ["rate", 791], ["than", 796], ["found", 801], ["in", 807], ["most", 810], ["other", 815], ["studies", 821], [".", 828], ["Furthermore", 830], [",", 841], ["we", 843], ["found", 846], ["that", 852], ["Finkelstein", 857], ["'s", 868], ["test", 871], ["can", 876], ["give", 880], ["a", 885], ["false", 887], ["positive", 893], ["result", 902], [".", 908], ["Therefore", 910], [",", 919], ["ultrasound", 921], ["should", 932], ["not", 939], ["only", 943], ["be", 948], ["considered", 951], ["to", 962], ["improve", 965], ["the", 973], ["treatment", 977], ["outcome", 987], [",", 994], ["but", 996], ["can", 1000], ["also", 1004], ["be", 1009], ["useful", 1012], ["as", 1019], ["a", 1022], ["diagnostic", 1024], ["tool", 1035], ["in", 1040], ["the", 1043], ["management", 1047], ["of", 1058], ["de", 1061], ["Quervain", 1064], ["'s", 1072], ["disease", 1075], [".", 1082]]}
{"context": "In cancer research, background models for mutation rates have been extensively calibrated in coding regions, leading to the identification of many driver genes, recurrently mutated more than expected. Noncoding regions are also associated with disease; however, background models for them have not been investigated in as much detail. This is partially due to limited noncoding functional annotation. Also, great mutation heterogeneity and potential correlations between neighboring sites give rise to substantial overdispersion in mutation count, resulting in problematic background rate estimation. Here, we address these issues with a new computational framework called LARVA. It integrates variants with a comprehensive set of noncoding functional elements, modeling the mutation counts of the elements with a \u03b2-binomial distribution to handle overdispersion. LARVA, moreover, uses regional genomic features such as replication timing to better estimate local mutation rates and mutational hotspots. We demonstrate LARVA's effectiveness on 760 whole-genome tumor sequences, showing that it identifies well-known noncoding drivers, such as mutations in the TERT promoter. Furthermore, LARVA highlights several novel highly mutated regulatory sites that could potentially be noncoding drivers. We make LARVA available as a software tool and release our highly mutated annotations as an online resource (larva.gersteinlab.org).", "qas": [{"question": "Which tool is used for the identification of recurrent variants in noncoding regions?", "answers": ["LARVA"], "qid": "b64f61ec5c4c4a3383e26a39db26cd14", "question_tokens": [["Which", 0], ["tool", 6], ["is", 11], ["used", 14], ["for", 19], ["the", 23], ["identification", 27], ["of", 42], ["recurrent", 45], ["variants", 55], ["in", 64], ["noncoding", 67], ["regions", 77], ["?", 84]], "detected_answers": [{"text": "LARVA", "token_spans": [[135, 135], [104, 104], [159, 159], [190, 190], [207, 207]], "char_spans": [[864, 868], [673, 677], [1019, 1023], [1188, 1192], [1304, 1308]]}]}], "context_tokens": [["In", 0], ["cancer", 3], ["research", 10], [",", 18], ["background", 20], ["models", 31], ["for", 38], ["mutation", 42], ["rates", 51], ["have", 57], ["been", 62], ["extensively", 67], ["calibrated", 79], ["in", 90], ["coding", 93], ["regions", 100], [",", 107], ["leading", 109], ["to", 117], ["the", 120], ["identification", 124], ["of", 139], ["many", 142], ["driver", 147], ["genes", 154], [",", 159], ["recurrently", 161], ["mutated", 173], ["more", 181], ["than", 186], ["expected", 191], [".", 199], ["Noncoding", 201], ["regions", 211], ["are", 219], ["also", 223], ["associated", 228], ["with", 239], ["disease", 244], [";", 251], ["however", 253], [",", 260], ["background", 262], ["models", 273], ["for", 280], ["them", 284], ["have", 289], ["not", 294], ["been", 298], ["investigated", 303], ["in", 316], ["as", 319], ["much", 322], ["detail", 327], [".", 333], ["This", 335], ["is", 340], ["partially", 343], ["due", 353], ["to", 357], ["limited", 360], ["noncoding", 368], ["functional", 378], ["annotation", 389], [".", 399], ["Also", 401], [",", 405], ["great", 407], ["mutation", 413], ["heterogeneity", 422], ["and", 436], ["potential", 440], ["correlations", 450], ["between", 463], ["neighboring", 471], ["sites", 483], ["give", 489], ["rise", 494], ["to", 499], ["substantial", 502], ["overdispersion", 514], ["in", 529], ["mutation", 532], ["count", 541], [",", 546], ["resulting", 548], ["in", 558], ["problematic", 561], ["background", 573], ["rate", 584], ["estimation", 589], [".", 599], ["Here", 601], [",", 605], ["we", 607], ["address", 610], ["these", 618], ["issues", 624], ["with", 631], ["a", 636], ["new", 638], ["computational", 642], ["framework", 656], ["called", 666], ["LARVA", 673], [".", 678], ["It", 680], ["integrates", 683], ["variants", 694], ["with", 703], ["a", 708], ["comprehensive", 710], ["set", 724], ["of", 728], ["noncoding", 731], ["functional", 741], ["elements", 752], [",", 760], ["modeling", 762], ["the", 771], ["mutation", 775], ["counts", 784], ["of", 791], ["the", 794], ["elements", 798], ["with", 807], ["a", 812], ["\u03b2", 814], ["-", 815], ["binomial", 816], ["distribution", 825], ["to", 838], ["handle", 841], ["overdispersion", 848], [".", 862], ["LARVA", 864], [",", 869], ["moreover", 871], [",", 879], ["uses", 881], ["regional", 886], ["genomic", 895], ["features", 903], ["such", 912], ["as", 917], ["replication", 920], ["timing", 932], ["to", 939], ["better", 942], ["estimate", 949], ["local", 958], ["mutation", 964], ["rates", 973], ["and", 979], ["mutational", 983], ["hotspots", 994], [".", 1002], ["We", 1004], ["demonstrate", 1007], ["LARVA", 1019], ["'s", 1024], ["effectiveness", 1027], ["on", 1041], ["760", 1044], ["whole", 1048], ["-", 1053], ["genome", 1054], ["tumor", 1061], ["sequences", 1067], [",", 1076], ["showing", 1078], ["that", 1086], ["it", 1091], ["identifies", 1094], ["well", 1105], ["-", 1109], ["known", 1110], ["noncoding", 1116], ["drivers", 1126], [",", 1133], ["such", 1135], ["as", 1140], ["mutations", 1143], ["in", 1153], ["the", 1156], ["TERT", 1160], ["promoter", 1165], [".", 1173], ["Furthermore", 1175], [",", 1186], ["LARVA", 1188], ["highlights", 1194], ["several", 1205], ["novel", 1213], ["highly", 1219], ["mutated", 1226], ["regulatory", 1234], ["sites", 1245], ["that", 1251], ["could", 1256], ["potentially", 1262], ["be", 1274], ["noncoding", 1277], ["drivers", 1287], [".", 1294], ["We", 1296], ["make", 1299], ["LARVA", 1304], ["available", 1310], ["as", 1320], ["a", 1323], ["software", 1325], ["tool", 1334], ["and", 1339], ["release", 1343], ["our", 1351], ["highly", 1355], ["mutated", 1362], ["annotations", 1370], ["as", 1382], ["an", 1385], ["online", 1388], ["resource", 1395], ["(", 1404], ["larva.gersteinlab.org", 1405], [")", 1426], [".", 1427]]}
